FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Carvalho, A
   Sales, HF
   Ventura, P
   Gnoatto-Medeiros, M
   Brites, C
   Lucena, R
AF Carvalho, Alessandra
   Sales, Henrique F.
   Ventura, Paloma
   Gnoatto-Medeiros, Marina
   Brites, Carlos
   Lucena, Rita
TI The neurodevelopmental spectrum of congenital Zika infection: a scoping
   review
SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
LA English
DT Review
ID VIRUS-INFECTION; CHILDREN; BORN
AB Aim To describe the standardized neurodevelopmental outcomes after the first year of life in children with congenital Zika syndrome (CZS) and those exposed to Zika virus (ZIKV) during fetal life, but without microcephaly at birth. Method This scoping review included observational studies about the standardized neurodevelopmental outcome in children with CZS or exposed to ZIKV, but without microcephaly, assessed after 12 months of age. The databases searched were MEDLINE/Pubmed, LILACS, Scielo, Scopus, PsycINFO, CINAHL, and Embase. Risk of bias was assessed with the Joanna Briggs Institute Critical Appraisal Checklists. Results Seventeen papers were included: 12 focused on children with CZS, four on children born without microcephaly, and one described both. Only one of the studies about CZS reported a child with microcephaly and typical development; the remainder described a severe pattern of global developmental delay and cerebral palsy. The prevalence of epilepsy was 74.6%. In the reports about children born without microcephaly, 6.9% to 8.7% had some domain with a score below -2 SD, and three children developed autism spectrum disorder. Interpretation CZS is associated with severe global developmental delay and cerebral palsy after 1 year of age. In children born without microcephaly, although most have typical development, some may be at risk for impairments.
C1 [Carvalho, Alessandra; Ventura, Paloma] SARAH Network Rehabil Hosp, Salvador, BA, Brazil.
   [Carvalho, Alessandra; Brites, Carlos; Lucena, Rita] Univ Fed Bahia, Bahia Med Sch, Post Grad Program Med & Hlth, Salvador, BA, Brazil.
   [Sales, Henrique F.] Univ Fed Bahia, Bahia Med Sch, Salvador, BA, Brazil.
   [Gnoatto-Medeiros, Marina] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil.
RP Carvalho, A (corresponding author), SARAH Salvador Hosp, 2782 Tancredo Neves Ave, BR-41820900 Salvador, BA, Brazil.
EM 13110@sarah.br
RI Lucena, Rita/L-9842-2013
OI Lucena, Rita/0000-0002-6190-9168; Ventura, Paloma A./0000-0002-7487-2958
FU Coordination for the Improvement of Higher Education Personnel (CAPES),
   BrazilCAPES
FX We thank Marilene da ConceicAo Felix da Silva for her contributions to
   the literature search. We also thank the Coordination for the
   Improvement of Higher Education Personnel (CAPES), Brazil, for
   supporting the Post Graduation Program in Medicine and Health, Bahia
   Medical School, Federal University of Bahia, Salvador, Bahia, Brazil.
   This institution had no role in the study design, data collection and
   analysis, decision to publish, or preparation of this manuscript. This
   research did not receive any specific grant from funding agencies in the
   public, commercial, or not-for-profit sectors. The authors have stated
   that they had no interests that might be perceived as posing conflict or
   bias.
CR Alves LV, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021304
   Besnard M, 2017, EMERG INFECT DIS, V23, P1421, DOI 10.3201/eid2308.170198
   Carvalho A, 2019, BRAIN DEV-JPN, V41, P587, DOI 10.1016/j.braindev.2019.03.005
   Ferreira HNC, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061107
   de Carvalho AL, 2018, EMERG INFECT DIS, V24, P2128, DOI 10.3201/eid2411.180883
   Vianna RAD, 2019, J TROP PEDIATRICS, V65, P592, DOI 10.1093/tropej/fmz019
   Faical Adriana Virginia, 2019, BMJ Paediatr Open, V3, pe000486, DOI 10.1136/bmjpo-2019-000486
   Franca TLB, 2018, INT J ENV RES PUB HE, V15, pE1990
   Lima Danielly Laís Pereira, 2019, Fisioter. Pesqui., V26, P145, DOI 10.1590/1809-2950/18001626022019
   Marques FJP, 2019, J CHILD NEUROL, V34, P81, DOI 10.1177/0883073818811234
   Melo A, 2020, DEV MED CHILD NEUROL, V62, P221, DOI 10.1111/dmcn.14227
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Nielsen-Saines K, 2019, NAT MED, V25, P1213, DOI 10.1038/s41591-019-0496-1
   Rice ME, 2018, MMWR-MORBID MORTAL W, V67, P858, DOI 10.15585/mmwr.mm6731e1
   Satterfield-Nash A, 2017, MMWR-MORBID MORTAL W, V66, P1347, DOI 10.15585/mmwr.mm6649a2
   Soares-Marangoni DD, 2019, DEV NEUROREHABIL, V22, P71, DOI 10.1080/17518423.2018.1437843
   Subissi L, 2018, EMERG INFECT DIS, V24, P1850, DOI 10.3201/eid2410.172079
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Ventura PA, 2020, J DEV BEHAV PEDIATR, V41, P134, DOI 10.1097/DBP.0000000000000722
   Wheeler AC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201495
NR 20
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1622
EI 1469-8749
J9 DEV MED CHILD NEUROL
JI Dev. Med. Child Neurol.
PD DEC
PY 2020
VL 62
IS 12
BP 1356
EP 1362
DI 10.1111/dmcn.14675
EA SEP 2020
PG 7
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA OK6PQ
UT WOS:000569156800001
PM 32931050
DA 2020-12-01
ER

PT J
AU Vaz, SN
   de Santana, DS
   Martins, E
   Pedroso, C
   Wang, WK
   Santos, FDA
   Brites, C
AF Vaz, Sara Nunes
   de Santana, Daniele Souza
   Martins Netto, Eduardo
   Pedroso, Celia
   Wang, Wei-Kung
   Alves Santos, Felice Deminco
   Brites, Carlos
TI Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; COVID-19 saliva; Diagnostics
ID RESPIRATORY SYNDROME CORONAVIRUS
AB Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Although Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) of respiratory specimens is the gold standard test for detection of SARS-CoV-2 infection, collecting nasopharyngeal swabs causes discomfort to patients and may represent considerable risk for healthcare workers. The use of saliva as a diagnostic sample has several advantages.
   Objectives: The aim of this study was to validate the use of saliva as a biological sample for diagnosis of COVID-19.
   Methods: This study was conducted at Infectious Diseases Research Laboratory (LAPI), in Salvador, Brazil. Participants presenting with signs/symptoms suggesting SARS-CoV-2 infection underwent a nasopharyngeal swab (NPS) and/or oropharyngeal swab (OPS), and saliva collection. Saliva samples were diluted in PBS, followed by RNA isolation and RT-Real Time PCR for SARS-CoV-2.
   Results of conventional vs saliva samples testing were compared. Statistical analyses were performed using Statistical Package for the Social Sciences software (SPSS) version 18.0. Results: One hundred fifty-five participants were recruited and samples pairs of NPS/OPS and saliva were collected. The sensitivity and specificity of RT-PCR using saliva samples were 94.4% (95% CI 86.4-97.8) and 97.62% (95% CI 91.7-99.3), respectively. There was an overall high agreement (96.1%) between the two tests.
   Conclusions: Use of self-collected saliva samples is an easy, convenient, and low-cost alternative to conventional NP swab-based molecular tests. These results may allow a broader use of molecular tests for management of COVID19 pandemic, especially in resources-limited settings. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Vaz, Sara Nunes; de Santana, Daniele Souza; Martins Netto, Eduardo; Pedroso, Celia; Alves Santos, Felice Deminco; Brites, Carlos] Univ Fed Bahia UFBA, Hosp Univ Prof Edgard Santos HUPES, Lab Pesquisa Infectol LAPI, Salvador, BA, Brazil.
   [Wang, Wei-Kung] Univ Hawaii Manoa UH Manoa, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA.
RP Brites, C (corresponding author), Univ Fed Bahia UFBA, Hosp Univ Prof Edgard Santos HUPES, Lab Pesquisa Infectol LAPI, Salvador, BA, Brazil.
EM saranunes02@hotmail.com; dnssan@hotmail.com; nettoeduardom@hotmail.com;
   cpedrodoj@gmail.com; wangwk@hawaii.edu; fdeminco@gmail.com;
   crbrites@gmail.com
RI ; Brites, Carlos/D-1353-2013
OI Wang, Wei-Kung/0000-0002-6670-4663; Brites, Carlos/0000-0002-4673-6991;
   De Santana, Daniele/0000-0002-0829-6817
CR Azzi L, 2020, J INFECTION, V81, pE45, DOI 10.1016/j.jinf.2020.04.005
   Centers for Disease Control and Prevention, INT GUID COLL HANDL
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chen L, 2020, SSRN, DOI [10.1007/s42532-020-00048-1, DOI 10.2139/SSRN.3557140, 10.2139/ssrn.3557140]
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Corman VM, 2020, EUROSURVEILLANCE, V25, P1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   McCormick-Baw C, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01109-20
   Ministerio da saude, PAIN COR
   Pasomsub E, 2020, CLIN MICROBIOL INFEC, DOI DOI 10.1016/J.CMI.7070.05.001
   Penarrubia L, 2020, INT J INFECT DIS, V97, P225, DOI 10.1016/j.ijid.2020.06.027
   Ramanathan K, 2020, LANCET MICROBE
   Sueki A, 2016, CLIN CHIM ACTA, V453, P71, DOI 10.1016/j.cca.2015.12.006
   To KKW, 2019, CLIN MICROBIOL INFEC, V25, P372, DOI 10.1016/j.cmi.2018.06.009
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   To KK, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.35
   Wang WK, 2004, EMERG INFECT DIS, V10, P1213, DOI 10.3201/eid1007.031113
   Wang YS, 2020, J MED VIROL, V92, P538, DOI 10.1002/jmv.25721
   Williams E, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00776-20
   World Health Organization, WHO COR DIS COVID 19
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wyllie AL, 2020, SALIVA IS MORE SENSI, DOI [DOI 10.1101/2020.04.16.20067835, 10.1101/2020.04.16.20067835]
NR 24
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2020
VL 24
IS 5
BP 422
EP 427
DI 10.1016/j.bjid.2020.08.001
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA OH5ID
UT WOS:000582615500007
PM 32888905
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Sousa, CP
   Brites, C
AF Sousa, Caciane Portela
   Brites, Carlos
TI Immune response in SARS-CoV-2 infection: the role of interferons type I
   and type III
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Review
DE IFN type I; IFN type III; SARS-CoV-2; Immune response
ID RESPIRATORY SYNDROME CORONAVIRUS; PLASMACYTOID DENDRITIC CELLS;
   IFN-LAMBDA; CYTOKINE/CHEMOKINE PROFILES; ALVEOLAR MACROPHAGES; ANTIVIRAL
   PROTECTION; SIGNAL-TRANSDUCTION; CYTOKINE RESPONSES; VIRUS-INFECTION;
   RIG-I
AB Background: There is scarce information on the human immune response to the SARS-CoV-2 infection, and on the exacerbated inflammatory reaction observed in severe COVID-19 cases. Objective: To review the available evidence on the role of interferons type I and type III to SARS-CoV-2 infection.
   Methods: We reviewed the available published evidence on the role of immune response to SARS-CoV-2 infection as well as recent publications on characteristics and outcomes of COVID-19, and their relationship with interferons type I and type III.
   Results: The available data indicates that immune response plays an important role in controlling SARS-CoV-2 infection and the immune dysregulation can significantly modify the clinical outcomes of affected patients. In addition, the evidence suggests that IFN type I and III can play an important role in controlling viremia and modulating the immune response in COVID-19.
   Conclusions: Due to their central role in immune response against SARS-CoV-2 infection, IFN type I and III could be considered for treatment of COVID-19. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Sousa, Caciane Portela] Univ Fed Piaui, Ctr Ciencias Saude, Dept Parasitol & Microbiol, Teresina, PI, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Fac Med, Lab Pesquisa Infectol LAPI, Salvador, BA, Brazil.
RP Sousa, CP (corresponding author), Univ Fed Piaui, Campus Univ Minist Petronio Portella, BR-64049550 Teresina, PI, Brazil.
EM portelasousa@ufpi.edu.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Andreakos E, 2019, CURR OPIN IMMUNOL, V56, P67, DOI 10.1016/j.coi.2018.10.007
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003
   Beachboard DC, 2016, CURR OPIN MICROBIOL, V32, P113, DOI 10.1016/j.mib.2016.05.015
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x
   Chow KT, 2018, ANNU REV IMMUNOL, V36, P667, DOI 10.1146/annurev-immunol-042617-053309
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888
   Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141
   Dickensheets H, 2013, J LEUKOCYTE BIOL, V93, P377, DOI 10.1189/jlb.0812395
   Galani IE, 2017, IMMUNITY, V46, P875, DOI 10.1016/j.immuni.2017.04.025
   Garcia-Sastre A, 2017, CELL HOST MICROBE, V22, P176, DOI 10.1016/j.chom.2017.07.012
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   ISAACS A, 1987, J INTERFERON RES, V7, P429, DOI 10.1089/jir.1987.7.429
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   Jewell NA, 2010, J VIROL, V84, P11515, DOI 10.1128/JVI.01703-09
   Jia DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013927
   Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC
   Kell AM, 2015, VIROLOGY, V479, P110, DOI 10.1016/j.virol.2015.02.017
   Kelly A, 2016, J INTERF CYTOK RES, V36, P671, DOI 10.1089/jir.2015.0169
   Kim S, 2017, AM J RESP CELL MOL, V56, P202, DOI 10.1165/rcmb.2016-0174OC
   King PH, 2014, J INTERF CYTOK RES, V34, P267, DOI 10.1089/jir.2013.0143
   Klinkhammer J, 2018, ELIFE, V7, DOI 10.7554/eLife.33354
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013
   Pirtle WNL, 2020, HEALTH EDUC BEHAV, V47, P504, DOI 10.1177/1090198120922942
   Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025
   Lazear HM, 2015, IMMUNITY, V43, P15, DOI 10.1016/j.immuni.2015.07.001
   Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9
   Marcello T, 2006, GASTROENTEROLOGY, V131, P1887, DOI 10.1053/j.gastro.2006.09.052
   Megjugorac NJ, 2009, J LEUKOCYTE BIOL, V86, P1359, DOI 10.1189/jlb.0509347
   Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105
   Mora AL, 2006, AM J RESP CELL MOL, V35, P466, DOI 10.1165/rcmb.2006-0121OC
   Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961
   Ng EKO, 2003, CLIN CHEM, V49, P1976, DOI 10.1373/clinchem.2003.024125
   Ng MHL, 2004, J INFECT DIS, V190, P515, DOI 10.1086/421523
   Odendall C, 2014, NAT IMMUNOL, V15, P717, DOI 10.1038/ni.2915
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   Page C, 2012, J VIROL, V86, P13334, DOI 10.1128/JVI.01689-12
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Pervolaraki K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00459
   Poissy J, 2014, J CLIN VIROL, V61, P275, DOI 10.1016/j.jcv.2014.07.002
   Robek MD, 2005, J VIROL, V79, P3851, DOI 10.1128/JVI.79.6.3851-3854.2005
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873
   Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017
   Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Thiel V, 2008, CYTOKINE GROWTH F R, V19, P121, DOI 10.1016/j.cytogfr.2008.01.001
   To KKW, 2010, CLIN INFECT DIS, V50, P850, DOI 10.1086/650581
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Tseng CTK, 2005, J IMMUNOL, V174, P7977, DOI 10.4049/jimmunol.174.12.7977
   van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X
   Wack A, 2015, NAT IMMUNOL, V16, P802, DOI 10.1038/ni.3212
   Wells AI, 2018, TRENDS IMMUNOL, V39, P848, DOI 10.1016/j.it.2018.08.008
   Wikstrom ME, 2013, J VIROL, V87, P7911, DOI 10.1128/JVI.00187-13
   World Health Organisation, 2020, NOV COR CHIN
   World Health Organization (WHO), NOV COR 2019 NCOV SI
   Wu Z., 2020, JAMA
   Ye L, 2019, NAT REV IMMUNOL, V19, P614, DOI 10.1038/s41577-019-0182-z
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 79
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2020
VL 24
IS 5
BP 428
EP 433
DI 10.1016/j.bjid.2020.07.011
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA OH5ID
UT WOS:000582615500008
PM 32866437
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Vargas, L
   Bastos, F
   Guimaraes, A
   Amaral, S
   Fausto, T
   Arriaga, M
   Sarno, M
   Brites, C
AF Vargas, Ludy
   Bastos, Fernanda
   Guimaraes, Andre
   Amaral, Savio
   Fausto, Tarcisio
   Arriaga, Maria
   Sarno, Manoel
   Brites, Carlos
TI Seroprevalence and factors associated with Human Immunodeficiency virus,
   Human T lymphotropic virus and Hepatitis B/C infections in parturient
   women of Salvador - Bahia, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Seroprevalence; Risk factors; Parturient; HIV; HTLV; Hepatitis B;
   Hepatitis C
ID PREGNANT-WOMEN; PREVALENCE; HIV; SYPHILIS; STATE; TOXOPLASMOSIS;
   RUBELLA; SEROPOSITIVITY; COINFECTIONS; REGION
AB Background: The heterogeneity in detection rates of Human immunodeficiency virus, (HIV), Human T lymphotropic virus (HTLV) and Hepatitis B and C infections among pregnant women and the continuous exposure to risk factors limits the adoption of preventive and control actions.
   Objective: To evaluate the HIV, HTLV, Hepatitis B and C seroprevalence rates, and associated risk factors in parturient women in Salvador, Brazil.
   Methods: This was a cross-sectional study in 2099 parturient women attended in two public maternity hospitals in Salvador, Brazil. One blood sample was drawn for serological screening and socio-demographic, obstetric and clinical data were collected.
   Results: HIV seroprevalence rate was 1.5% (of which 0.6% were new cases); seroprevalence rates for HTLV, HBV, and HCV were 0.4%, 0.4%, and 0.1%, respectively. Univariate analysis showed a significant association between socio-demographic and behavioral factors with retroviral infections, while viral hepatitis was mainly associated with parenteral exposure. In a multivariate analysis, multiple sexual partners (OR 3.3; 95% CI: 1.1-9.2), history of sexual/domestic violence (OR 2.8; 95% CI: 1.1-6.9), syphilis co-infection (OR 2.6; 95% CI: 1.0-6.9), use of alcohol or drugs (OR 2.5; 95% CI: 1.2-5.5), and low schooling level (OR 2.3; 95% CI: 1.1-4.9) were independent risk factors for HIV infection. History of stillbirth and low birth weight infants was significantly associated with HTLV positive status, showing a negative impact on gestation.
   Conclusions: The seroprevalence rates for HIV, HCV, HBV, and HTLV were similar to that found in previous studies in other Brazilian regions. The high individual, socioeconomic, and social vulnerability detected in seropositive parturient women indicates the need to improve coverage and effectiveveness of STDs control with prevention, detection and monitoring strategies, focusing in pregnant women exposed to high biopsychosocial risk. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Vargas, Ludy; Bastos, Fernanda; Guimaraes, Andre; Amaral, Savio; Fausto, Tarcisio; Arriaga, Maria; Sarno, Manoel; Brites, Carlos] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
   [Vargas, Ludy] Univ Pedag & Tecnol Colombia, Boyaca, Colombia.
   [Arriaga, Maria] Fundacao Goncalo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Arriaga, Maria] Fundacao Jose Silveira, Inst Brasileiro Invest TB, Salvador, BA, Brazil.
   [Sarno, Manoel] Univ Fed Bahia, Maternidade Climerio Oliveira, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Fac Med, Complexo Hosp Prof Edgard Santos, Salvador, BA, Brazil.
RP Vargas, L (corresponding author), Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.; Vargas, L (corresponding author), Univ Pedag & Tecnol Colombia, Boyaca, Colombia.
EM medalexa@hotmail.com
RI ; Brites, Carlos/D-1353-2013
OI Pessoa Bonfim Guimaraes, Andre/0000-0002-6405-9066; Brites,
   Carlos/0000-0002-4673-6991
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (Fapesb) [9620/2015];
   CAPESCAPES
FX The study was supported by the Fundacao de Amparo a Pesquisa do Estado
   da Bahia (Fapesb 9620/2015) and by the CAPES for the scholarship granted
   to the post-graduate student author.
CR Barmpas ELBS, 2014, REV HUPE RIO DE JANE, P1381
   Brasil. Ministerio da Sande. Secretariade Vigilancia em Sande, 2013, GUIA MAN CLIN INF PE
   Brasil Ministerio de Sande, 2014, PROT INV TRANSM VERT, P7014
   Brasil Ministerio de Sande Programa Humanizacao do part, 2002, PROGR HUM PART, P7007
   Brasil. Ministerio de Sande Secretaria de Vigilancia em Sande, 2017, B EPIDEMIOLOGICO HEP, V48
   Brasil. Ministerio de Sande Secretaria de Vigilancia em Sande Departamento de DST, 2016, B EPIDEINIOLEGICO AI
   Cardoso IM, 2011, REV SOC BRAS MED TRO, V44, P430, DOI 10.1590/s0037-86822011005000044
   Carvalho Rui Lara de, 2004, Rev. Bras. Ginecol. Obstet., V26, P325, DOI 10.1590/S0100-72032004000400010
   Fernandes CND, 2014, REV ESC ENFERM USP, V48, P89, DOI 10.1590/S0080-623420140000100011
   de Oliveira SR, 2006, REV BRAS GINECOL OBS, V28, P467, DOI 10.1590/S0100-72032006000800005
   Goncalves MAD, 2010, BRAZ J INFECT DIS, V14, P601, DOI 10.1590/S1413-86702010000600009
   Ferezin RI, 2013, REV BRAS GINECOL OBS, V35, P66, DOI 10.1590/S0100-72032013000200005
   Dal Fabbrol MMFJ, 2008, REV SOC BRAS MED TRO, V41, P148, DOI 10.1590/S0037-86822008000200003
   Ferrairo MM, 2008, REV SOC BRAS MED TRO, V41, P148
   Filho AM, 2010, REV RYAS GINECOL OBS, V32, P176
   Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
   Mello MAG, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-28
   Guerra AB, 2018, BMC PREGNANCY CHILDB, V18, P1
   Kiesslich D, 2003, EPIDEMIOL SERV SAUDE, V12, P155
   Liell Andressa Pilonetto, 2009, Arq. Gastroenterol., V46, P75, DOI 10.1590/S0004-28032009000100018
   Madi JM, 2010, BRAZ J INFECT DIS, V14, P24, DOI 10.1590/S1413-86702010000100006
   Magalhaes T, 2008, J MED VIROL, V80, P2040, DOI 10.1002/jmv.21278
   de Lima LHM, 2009, CAD SAUDE PUBLICA, V25, P668, DOI 10.1590/S0102-311X2009000300021
   Pereira GFM, 2016, REV BRAS GINECOL OBS, V38, P391, DOI 10.1055/s-0036-1592102
   Menezes LSH, 2012, J BRAS DOENCAS SEX T, V24, P250
   Ministerio de SaUde Secretaria Vigilancia em SaUde Departamento de DST AIDS Hepatitis Virais, IND DAD BAS IIIV AID
   Moreira M, 2013, BRAZ J INFECT DIS, V17, P661, DOI 10.1016/j.bjid.2013.04.009
   Moura AA, 2015, INT J INFECT DIS, V39, P10, DOI 10.1016/j.ijid.2015.07.022
   Nobrega I, 2013, BRAZ J INFECT DIS, V17, P184, DOI 10.1016/j.bjid.2012.10.018
   Pan American Health Organization, 2017, PAHOCHA17009
   Pinto CS, 2011, REV SAUDE PUBL, V45, P974, DOI 10.1590/s0034-89102011005000053
   Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6
   Sanson Marina Cordeiro Gomes, 2018, Rev. Bras. Saude Mater. Infant., V18, P711, DOI 10.1590/1806-93042018000400003
   Sbalqueiro RL, 2004, DST J BRAS DOENCAS S, V16, P40
   Domingues RMSM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0837-8
   Souza S, 2012, THESIS
   Squires JE, 2017, HEPATOL COMMUN, V1, P87, DOI 10.1002/hep4.1028
   Tavares LHL, 2013, DST J BRAS DOENCAS S, V25, P82
   UNAIDS, 2016, PREV GAP REP
   Vargas L, 2018, BJOG, DOI [10.1111/1471-0578.15304, DOI 10.1111/1471-0578.15304]
   Vilte RMCV, 2016, J BRAS DOENCAS SEX T, V28, P20, DOI [10.5533/DST-2177-8264-201628105, DOI 10.5533/DST-2177-8264-201628105]
NR 41
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2020
VL 24
IS 4
BP 279
EP 287
DI 10.1016/j.bjid.2020.05.001
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA NW2JT
UT WOS:000574836900002
PM 32464116
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Brites, C
   Miranda, F
   Luz, E
   Netto, EM
AF Brites, Carlos
   Miranda, Fernanda
   Luz, Estela
   Netto, Eduardo Martins
TI Early and Successful Combination Antiretroviral Therapy Normalizes
   Survival Time in Patients Coinfected With Human Immunodeficiency Virus
   and Human T-cell Lymphotrophic Virus Type 1
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; HTLV-1; coinfection; survival
ID IMMUNE ACTIVATION; HTLV-I; HIV; AIDS; PROGRESSION; IMPACT; CHILDREN;
   RISK; I/II
AB Background. Coinfection with human T-cell lymphotrophic virus type 1 (HTLV-1) is associated with shorter survival for adults and children infected with human immunodeficiency virus (HIV), although the reasons remain a matter of debate. We evaluated the factors associated with survival time in a large cohort of HIV/HTLV-1-coinfected and HIV-monoinfected individuals on combination antiretroviral therapy (cART).
   Methods. In a nested, retrospective case-control study (1:1), we reviewed medical records of people with HIV infection on cART in a referral AIDS center in Salvador, Brazil. We matched 149 patients coinfected with HTLV-1 (cases) by age at HIV diagnosis and sex, to an equal number of HTLV-uninfected persons (controls). Death rates, survival time, baseline and current CD4 cell count, last HIV-1 RNA plasma viral load (pVL), and causes of death were compared between groups.
   Results. The overall mortality rate was 2.1 person-years (76 deaths, 53 among coinfected patients). Survival time for cases (16.7 +/- 0.7 years) was significantly shorter than for controls (18.1 +/- 0.4 years; P =.001). Among patients with pVL >50 copies/mL, coinfected patients had a shorter survival time (8.4 +/- 0.8 years) than monoinfected ones (12.9 +/- 1.4 years; P =.02), regardless of pVL magnitude. However, survival time did not differ for HIV-monoinfected (19.0 +/- 0.4 years) or coinfected patients (20.2 +/- 0.6 years) presenting with pVL <50 copies/mL (P =.5). Deceased coinfected patients had higher initial CD4 count (417 +/- 219 cells) than monoinfected ones with the same outcome (177 +/- 160 cells; P =.004), while survivors had similar CD4 cell count at baseline, regardless of HTLV status.
   Conclusions. Successful cART is able to normalize survival for coinfected patients and should be introduced for all coinfected patients, regardless of CD4 cell count.
C1 [Brites, Carlos; Miranda, Fernanda; Luz, Estela; Netto, Eduardo Martins] Univ Fed Bahia, Fac Med, Lab Pesquisa Infectol, Complexo Hosp Prof Edgard Santos, Rua Augusto Viana SN, BR-40110060 Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Fac Med, Lab Pesquisa Infectol, Complexo Hosp Prof Edgard Santos, Rua Augusto Viana SN, BR-40110060 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR BARTHOLOMEW C, 1987, LANCET, V2, P1469
   Beilke MA, 2004, CLIN INFECT DIS, V39, P256, DOI 10.1086/422146
   Bhatt NB, 2009, INT J STD AIDS, V20, P863, DOI 10.1258/ijsa.2008.008401
   Brites C, 2005, CLIN INFECT DIS, V40, P329, DOI 10.1086/426690
   Brites C, 2011, BRAZ J INFECT DIS, V15, P6, DOI 10.1590/S1413-86702011000100002
   Brites C, 2001, AIDS, V15, P2053, DOI 10.1097/00002030-200110190-00023
   Brites C, 2009, AIDS REV, V11, P8
   Fox JM, 2016, TROP MED INT HEALTH, V21, P312, DOI 10.1111/tmi.12659
   Futsch N, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10010001
   Gudo ES, 2012, INT J STD AIDS, V23, P717, DOI 10.1258/ijsa.2012.011446
   Gudo ES, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-211
   Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006
   Hunt Peter W, 2007, Curr HIV/AIDS Rep, V4, P42, DOI 10.1007/s11904-007-0007-8
   KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Pedroso C, 2011, JAIDS-J ACQ IMM DEF, V57, pS208, DOI 10.1097/QAI.0b013e31821e9baf
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Rockwood N, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002275
   SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353
   Sobesky M, 2000, PRESSE MED, V29, P413
   Sodora DL, 2008, AIDS, V22, P439, DOI 10.1097/QAD.0b013e3282f2dbe7
   Vandormael A, 2017, CURR HIV RES, V15, P225, DOI [10.2174/1570162X15666170216114917, 10.2174/1570162x15666170216114917]
NR 22
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL 1
PY 2020
VL 71
IS 1
BP 196
EP 200
DI 10.1093/cid/ciz756
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MO4UU
UT WOS:000551523900031
PM 31406994
DA 2020-12-01
ER

PT J
AU Moreira-Soto, A
   Sampaio, GD
   Pedroso, C
   Postigo-Hidalgo, I
   Berneck, BS
   Ulbert, S
   Brites, C
   Netto, EM
   Drexler, JF
AF Moreira-Soto, Andres
   de Souza Sampaio, Gilmara
   Pedroso, Celia
   Postigo-Hidalgo, Ignacio
   Berneck, Beatrice Sarah
   Ulbert, Sebastian
   Brites, Carlos
   Netto, Eduardo Martins
   Drexler, Jan Felix
TI Rapid decline of Zika virus NS1 antigen-specific antibody responses,
   northeastern Brazil
SO VIRUS GENES
LA English
DT Article
DE Zika virus; Flavivirus; Serology; Antigens
ID OUTBREAK
AB Zika virus (ZIKV) is a positive-stranded RNA virus within theFlaviviridaefamily. After decades of circulation in Asia, ZIKV was introduced to Brazil in 2014-2015, associated with a rise in congenital malformations. Unlike the genetically related dengue virus (DENV), ZIKV constitutes only one serotype. Although assumed that ZIKV infection may engender lifelong immunity, the long-term kinetics of ZIKV antibody responses are unclear. We assessed long-term kinetics of ZIKV NS1-IgG response in 144 individuals from 3 different subpopulations: HIV patients, tuberculosis patients and healthy individuals first tested in 2016 and retested 1.5-2 years after the 2015-2016 ZIKV epidemic in Salvador de Bahia, Brazil, using a widely distributed NS1-based commercial ELISA. The seropositivity in 2016 reached 59.0% (85/144, 95% confidence interval (CI) 50.7-66.7%), and decreased to 38.6% (56/144, CI 31.3-47.0%) 1.5-2 years later. In addition, the median ZIKV NS1-ELISA reactivity for individuals that remained positive in both timepoints significantly decreased from a ratio of 4.4 (95% CI 3.8-5.0) to 1.6 (95% CI 1.6-1.9) over the 2-year interval (Z: - 6.1;p < 0.001) irrespective of the subpopulation analyzed. Initial 2016 DENV antibody response was non-significant between groups, suggesting comparable DENV background. The high 20.6% seroreversion suggest that widely used serologic tests may fail to account a considerable proportion of past ZIKV infections in flavivirus endemic countries. In addition, ZIKV immunity might be shorter-lived than previously thought, which may contribute to local ZIKV resurgence once individual immune responses wane sufficiently to reduce community protective immunity in addition to birth and migration.
C1 [Moreira-Soto, Andres; Postigo-Hidalgo, Ignacio; Drexler, Jan Felix] Humboldt Univ, Charite Univ Med Berlin, Berlin, Germany.
   [Moreira-Soto, Andres; Postigo-Hidalgo, Ignacio; Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [de Souza Sampaio, Gilmara; Pedroso, Celia; Brites, Carlos; Netto, Eduardo Martins] Univ Fed Bahia, Salvador, BA, Brazil.
   [Berneck, Beatrice Sarah; Ulbert, Sebastian] Fraunhofer Inst Cell Therapy & Immunol, Dept Immunol, Leipzig, Germany.
   [Netto, Eduardo Martins] Fundacao Jose Silveira, Salvador, BA, Brazil.
   [Drexler, Jan Felix] German Ctr Infect Res DZIF, Braunschweig, Germany.
   [Drexler, Jan Felix] Sechenov Univ, Martsinovsky Inst Med Parasitol Trop & Vector Bor, Moscow, Russia.
   [Drexler, Jan Felix] Campus Charite Mitte, Helmut Ruska Haus, Inst Virol, Charitepl 1, D-10098 Berlin, Germany.
RP Drexler, JF (corresponding author), Humboldt Univ, Charite Univ Med Berlin, Berlin, Germany.; Drexler, JF (corresponding author), Berlin Inst Hlth, Inst Virol, Berlin, Germany.; Drexler, JF (corresponding author), German Ctr Infect Res DZIF, Braunschweig, Germany.; Drexler, JF (corresponding author), Sechenov Univ, Martsinovsky Inst Med Parasitol Trop & Vector Bor, Moscow, Russia.; Drexler, JF (corresponding author), Campus Charite Mitte, Helmut Ruska Haus, Inst Virol, Charitepl 1, D-10098 Berlin, Germany.
EM felix.drexler@charite.de
OI Drexler, Jan Felix/0000-0002-3509-0232; Postigo-Hidalgo,
   Ignacio/0000-0001-9083-4102; Moreira-Soto, Andres/0000-0002-9224-5157
FU European UnionEuropean Union (EU) [734548, 721367]
FX This work was supported by the European Union's Horizon 2020 research
   and innovation program through the ZIKAlliance project (Grant No.
   734548) and the Innovative Training Networks HONOURs project (Grant No.
   721367) to Jan Felix Drexler.
CR Aubry M, 2017, EMERG INFECT DIS, V23, P669, DOI 10.3201/eid2304.161549
   Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114
   Bozza FA, 2019, EMERG INFECT DIS, V25, P311, DOI 10.3201/eid2502.180166
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Cleton NB, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003580
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Figueiredo LTM, 2000, MICROBES INFECT, V2, P1643, DOI 10.1016/S1286-4579(00)01320-4
   Fischer C, 2019, LANCET INFECT DIS, V19, P240, DOI 10.1016/S1473-3099(19)30049-0
   Gallian P, 2017, BLOOD, V129, P263, DOI 10.1182/blood-2016-09-737981
   Goo L, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006178
   Henderson AD, 2020, ELIFE, V9, DOI 10.7554/eLife.48460
   Hill SC, 2019, LANCET INFECT DIS, V19, P1138, DOI 10.1016/S1473-3099(19)30293-2
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Lustig Y, 2018, J CLIN VIROL, V99-100, P31, DOI 10.1016/j.jcv.2017.12.007
   Marques ETA, 2019, MBIO, V10, DOI 10.1128/mBio.01849-19
   Moureau G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117849
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Nascimento EJM, 2018, J VIROL METHODS, V257, P62, DOI 10.1016/j.jviromet.2018.04.009
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   Oliveira RAS, 2019, MEM I OSWALDO CRUZ, V114, DOI 10.1590/0074-02760190098
   Pedroso C, 2019, EMERG INFECT DIS, V25, P1485, DOI 10.3201/eid2508.190113
NR 25
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-8569
EI 1572-994X
J9 VIRUS GENES
JI Virus Genes
PD OCT
PY 2020
VL 56
IS 5
BP 632
EP 637
DI 10.1007/s11262-020-01772-2
EA JUN 2020
PG 6
WC Genetics & Heredity; Virology
SC Genetics & Heredity; Virology
GA NL8GH
UT WOS:000540418500001
PM 32542479
OA Green Published, Other Gold
DA 2020-12-01
ER

PT J
AU Boettiger, DC
   Escuder, MM
   Law, MG
   Veloso, V
   Souza, RA
   Ikeda, MLR
   de Alencastro, PR
   Tupinambas, U
   Brites, C
   Grinsztejn, B
   Ggomes, JO
   Ribeiro, S
   McGowan, CC
   Jayathilake, K
   Castilho, JL
   Grangeiro, A
AF Boettiger, David C.
   Escuder, Maria Mercedes
   Law, Matthew G.
   Veloso, Valdilea
   Souza, Rosa A.
   Ikeda, Maria L. R.
   de Alencastro, Paulo R.
   Tupinambas, Unai
   Brites, Carlos
   Grinsztejn, Beatriz
   Ggomes, Jackeline O.
   Ribeiro, Sayonara
   McGowan, Catherine C.
   Jayathilake, Karu
   Castilho, Jessica L.
   Grangeiro, Alexandre
CA HIV-Brazil Cohort Study
TI Cardiovascular disease among people living with HIV in Brazil
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE HIV; cardiovascular disease; mortality; Brazil; antiretroviral therapy
ID ACUTE MYOCARDIAL-INFARCTION; LONG-TERM SURVIVAL; NATIONAL-HEALTH SURVEY;
   ABACAVIR USE; ANTIRETROVIRAL THERAPIES; INCREASED RISK; POPULATION;
   MORTALITY; EVENTS; INDIVIDUALS
AB Objectives There is a paucity of data on cardiovascular disease (CVD) among people living with HIV (PLHIV) in resource-limited countries. We assessed factors associated with CVD and the impact of prevalent CVD on all-cause mortality in PLHIV on antiretroviral therapy in Brazil.
   Methods Competing risk regression to assess factors associated with CVD and all-cause mortality in the HIV-Brazil Cohort Study between 2003 and 2014.
   Results Among 5614 patients, the rate of CVD was 3.5 (95% confidence interval [95% CI] 2.9-4.3) per 1000 person-years. CVD was associated with older age (adjusted hazard ratio [aHR] 6.4 for >= 55 years vs. <35 years, 95% CI: 2.5-16.3, P < 0.01), black race (aHR 1.8 vs. white race, 95% CI: 1.0-3.1, P = 0.04), past CVD (aHR 3.0 vs. no past CVD, 95% CI: 1.4-6.2, P < 0.01), hypertension (aHR 1.8 vs. no hypertension, 95% CI: 1.0-3.1, P = 0.04), high-grade dyslipidemia (aHR 9.3 vs. no high-grade dyslipidemia, 95% CI: 6.0-14.6, P < 0.01), ever smoking (aHR 2.4 vs. never, 95% CI: 1.2-5.0, P = 0.02) and low nadir CD4 cell count (aHR 1.8 for 100-250 cells/mm(3) vs. >250 cells/mm(3), 95% CI: 1.0-3.2, P = 0.05). The rate of death was 16.6 (95% CI: 15.1-18.3) per 1000 person-years. Death was strongly associated with having had a past CVD event (aHR 1.7 vs. no past CVD event, 95% CI: 1.1-2.7, P = 0.01).
   Conclusions Traditional and HIV-specific factors associated with CVD among PLHIV in Brazil are similar to those identified among PLHIV in high-income countries. PLHIV in Brazil with a history of CVD have a high risk of death. CVD care and treatment remain priorities for PLHIV in Brazil as this population ages and antiretroviral therapy use expands.
C1 [Boettiger, David C.] Univ Calif San Francisco, Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94143 USA.
   [Boettiger, David C.; Law, Matthew G.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Escuder, Maria Mercedes; Ggomes, Jackeline O.] Inst Hlth, Sao Paulo State Dept Hlth, Sao Paulo, Brazil.
   [Veloso, Valdilea; Grinsztejn, Beatriz; Ribeiro, Sayonara] Fundacao Oswaldo Cruz, Natl Inst Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Souza, Rosa A.] AIDS Reference & Training Ctr, Sao Paulo State Dept Hlth, Sao Paulo, Brazil.
   [Ikeda, Maria L. R.] Univ Vale Rio dos Sinos, Sch Hlth, Porto Alegre, RS, Brazil.
   [de Alencastro, Paulo R.] Hosp Sanatorio Partenon, Rio Grande Sul State Dept Hlth, Care & Treatment Clin, Porto Alegre, RS, Brazil.
   [Tupinambas, Unai] Univ Fed Minas Gerais, Med Sch, Belo Horizonte, MG, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil.
   [McGowan, Catherine C.; Jayathilake, Karu; Castilho, Jessica L.] Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA.
   [Grangeiro, Alexandre] Univ Sao Paulo, Dept Prevent Med, Sch Med, Sao Paulo, Brazil.
RP Boettiger, DC (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94143 USA.
EM dboettiger@kirby.unsw.edu.au
FU Brazilian National Council for Scientific & Technological Development;
   Brazilian National Ministry of Health; Pan American Health Organization;
   U.S. National Institutes of Health (NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [K23AI1120875, P30AI110527]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [U01AI069923];
   Eunice Kennedy Shriver National Institute Of Child Health & Human
   Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Cancer Institute (NCI)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI); National Institute Of Allergy And Infectious
   Diseases (NIAID)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); National Institute Of Mental
   Health (NIMH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); Office Of The Director, National Institutes Of Health (OD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA
FX The HIV-Brazil Cohort Study was supported by the Brazilian National
   Council for Scientific & Technological Development, Brazilian National
   Ministry of Health, and Pan American Health Organization. The study was
   supported in part by the U.S. National Institutes of Health (NIH)
   (K23AI1120875 and P30AI110527) and the NIH-funded Caribbean, Central and
   South America network for HIV epidemiology (CCASAnet), a member cohort
   of the International epidemiology Databases to Evaluate AIDS (leDEA)
   (U01AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute Of Child Health & Human Development
   (NICHD), National Cancer Institute (NCI), National Institute Of Allergy
   And Infectious Diseases (NIAID), National Institute Of Mental Health
   (NIMH), and the Office Of The Director, National Institutes Of Health
   (OD).
CR Bedimo RJ, 2011, CLIN INFECT DIS, V53, P84, DOI 10.1093/cid/cir269
   Bijker R, 2019, HIV MED, V20, P183, DOI 10.1111/hiv.12687
   Bronnum-Hansen H, 2001, STROKE, V32, P2131, DOI 10.1161/hs0901.094253
   Brothers CH, 2009, JAIDS-J ACQ IMM DEF, V51, P20, DOI 10.1097/QAI.0b013e31819ff0e6
   Brouwer ES, 2014, EPIDEMIOLOGY, V25, P406, DOI 10.1097/EDE.0000000000000041
   Castilho JL, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25233
   Choi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16
   Cruciani M, 2011, AIDS, V25, P1993, DOI 10.1097/QAD.0b013e328349c6ee
   Desai M, 2015, CLIN INFECT DIS, V61, P445, DOI 10.1093/cid/civ316
   Diaz CM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1735-4
   Ding X, 2012, JAIDS-J ACQ IMM DEF, V61, P441, DOI 10.1097/QAI.0b013e31826f993c
   Drozd DR, 2017, JAIDS-J ACQ IMM DEF, V75, P568, DOI 10.1097/qai.0000000000001450
   Duncan Bruce Bartholow, 2017, Rev. bras. epidemiol., V20, P90, DOI 10.1590/1980-5497201700050008
   Elion RA, 2018, JAIDS-J ACQ IMM DEF, V78, P62, DOI [10.1097/QAI.0000000000001642, 10.1097/qai.0000000000001642]
   Friis-Moller N, 2016, EUR J PREV CARDIOL, V23, P214, DOI 10.1177/2047487315579291
   Grangeiro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095673
   Gupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730
   Lorgis L, 2013, CIRCULATION, V127, P1767, DOI 10.1161/CIRCULATIONAHA.113.001874
   Mahajan AP, 2008, AIDS, V22, pS67, DOI 10.1097/01.aids.0000327438.13291.62
   Malta DC, 2016, SAO PAULO MED J, V134, P163, DOI 10.1590/1516-3180.2015.02090911
   Malta DC, 2015, SAO PAULO MED J, V133, P286, DOI 10.1590/1516-3180.2015.13340308
   Nauta ST, 2012, DIABETES CARE, V35, P2043, DOI 10.2337/dc11-2462
   Obel N, 2010, HIV MED, V11, P130, DOI 10.1111/j.1468-1293.2009.00751.x
   Sabin CA, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0588-4
   Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9
   Schmidt M, 2016, CIRC-CARDIOVASC QUAL, V9, P523, DOI 10.1161/CIRCOUTCOMES.115.002661
   Schmidt M, 2014, NEUROLOGY, V82, P340, DOI 10.1212/WNL.0000000000000062
   Shah ASV, 2018, CIRCULATION, V138, P1100, DOI 10.1161/CIRCULATIONAHA.117.033369
   Smolina K, 2012, CIRC-CARDIOVASC QUAL, V5, P532, DOI 10.1161/CIRCOUTCOMES.111.964700
   Walker RW, 2013, LANCET GLOB HEALTH, V1, pE282, DOI 10.1016/S2214-109X(13)70068-8
   Zanni MV, 2012, CURR HIV-AIDS REP, V9, P200, DOI 10.1007/s11904-012-0123-y
NR 31
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 2020
VL 25
IS 7
BP 886
EP 896
DI 10.1111/tmi.13405
EA MAY 2020
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA MF1NP
UT WOS:000531433900001
PM 32306480
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Delagreverie, HM
   Bauduin, C
   De Castro, N
   Grinsztejn, B
   Chevrier, M
   Jouenne, F
   Mourah, S
   Kalidi, I
   Pilotto, JH
   Brites, C
   Barcellos, NT
   Amara, A
   Wittkop, L
   Molina, JM
   Delaugerre, C
AF Delagreverie, Heloise M.
   Bauduin, Claire
   De Castro, Nathalie
   Grinsztejn, Beatriz
   Chevrier, Marc
   Jouenne, Fanelie
   Mourah, Samia
   Kalidi, Issa
   Pilotto, Jose Henrique
   Brites, Carlos
   Barcellos, Nemora Tregnago
   Amara, Ali
   Wittkop, Linda
   Molina, Jean-Michel
   Delaugerre, Constance
TI Impact of Raltegravir or Efavirenz on Cell-Associated Human
   Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic
   Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating
   Antiretroviral Therapy
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1 DNA; HIV integrase inhibitors; inflammation; raltegravir;
   tuberculosis
ID IMMUNE ACTIVATION; PREDICT MORTALITY; DECAY DYNAMICS; REPEAT CIRCLES;
   DNA; PHARMACOKINETICS; INTENSIFICATION; INFECTION; RESERVOIR; BLOOD
AB Background. In view of the fast viremia decline obtained with integrase inhibitors, we studied the respective effects of initiating efavirenz (EFV) or raltegravir (RAL)-based antiretroviral therapy (ART) regimens on human immunodeficiency virus (HIV)-1 deoxyribonucleic acid (DNA) levels and inflammation biomarkers in the highly inflammatory setting of advanced HIV-1 disease with tuberculosis (TB) coinfection.
   Methods. We followed cell-associated HIV-1 DNA, high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), soluble CD14 and D-Dimer levels for 48 weeks after ART initiation in the participants to the ANRS12-180 REFLATE-TB study. This phase II open-label randomized study included ART-naive people with HIV and TB treated with rifampicin to receive RAL 400 mg twice daily (RAL400), RAL 800 mg twice daily (RAL800) or EFV 600 mg QD with tenofovir and lamivudine.
   Results. In 146 participants, the median (interquartile range [IQR]) week (W)0 HIV-1 DNA level was 4.7 (IQR, 4.3-5.1) log(10) copies/10(6) CD4(+), and the reduction by W48 was -0.8 log(10) copies/10(6) CD4(+) on EFV, -0.9 on RAL400, and -1.0 on RAL800 (P = .74). Baseline median (IQR) hsCRP, IL-6, sCD14, and D-Dimer levels were 6.9 (IQR, 3.3-15.6) mg/L, 7.3 (IQR, 3.5-12.3) pg/mL, 3221 (IQR, 2383-4130) ng/mL, and 975 (IQR, 535-1970) ng/mL. All biomarker levels decreased over the study: the overall W0-W48 mean (95% confidence interval) fold-change on ART was 0.37 (IQR, 0.28-0.48) for hsCRP, 0.42 (IQR, 0.35-0.51) for IL-6, 0.51 (IQR, 0.47-0.56) for sCD14, and 0.39 (IQR, 0.32-0.47) for D-Dimers. There were no differences in biomarker reduction across treatment arms.
   Conclusions. In participants with HIV and TB, EFV, RAL400, or RAL800 effectively and equally reduced inflammation and HIV-1 DNA levels.
C1 [Delagreverie, Heloise M.; Delaugerre, Constance] Hop St Louis, AP HP, Lab Virol, Paris, France.
   [Delagreverie, Heloise M.; Amara, Ali; Molina, Jean-Michel; Delaugerre, Constance] Univ Paris, INSERM, U944, Paris, France.
   [Bauduin, Claire; Wittkop, Linda] Bordeaux Univ, Bordeaux Populat Hlth Res Ctr, Team MORPH3EUS, ISPED,Inserm,UMR 1219,CIC,EC 1401, Bordeaux, France.
   [De Castro, Nathalie; Molina, Jean-Michel] Hop St Louis, AP HP, Malad Infect & Trop, Paris, France.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst, STD AIDS Clin Res Lab, Rio De Janeiro, Brazil.
   [Chevrier, Marc] Hop St Louis, AP HP, Lab Biochim, Paris, France.
   [Jouenne, Fanelie; Mourah, Samia] Hop St Louis, AP HP, Lab Pharmacol, Paris, France.
   [Kalidi, Issa] Hop St Louis, AP HP, Lab Hematol, Paris, France.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Dept DST AIDS, Rio De Janeiro, Brazil.
   [Brites, Carlos] Hosp Univ Profesor Edgar Santos, Lab Pesquisa Doencas Infecciosas, Salvador, BA, Brazil.
   [Barcellos, Nemora Tregnago] Hosp Sanatorio Partenon, Hlth State Secretariat RS, Porto Alegre, RS, Brazil.
   [Wittkop, Linda] CHU Bordeaux, Serv Informat Med, Pole Sante Publ, Bordeaux, France.
RP Delaugerre, C (corresponding author), Hop St Louis, Lab Virol, 1 Ave Claude Vellefaux, F-75010 Paris, France.
EM constance.delaugerre@aphp.fr
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; AMARA,
   Ali/0000-0002-0283-1815
FU French National Agency for Research on AIDS and Viral Hepatitis
   (ANRS)ANRSFrench National Research Agency (ANR); Brazilian National
   STD/AIDS Program of the Ministry of Health; MERCKMerck & Company [IISP
   50621]
FX This work was funded by the French National Agency for Research on AIDS
   and Viral Hepatitis (ANRS), the Brazilian National STD/AIDS Program of
   the Ministry of Health, and MERCK (Investigator Initiated Studies
   Program; IISP 50621).
CR Achhra AC, 2015, HIV MED, V16, P449, DOI 10.1111/hiv.12258
   Alteri C, 2019, J CLIN VIROL, V117, P61, DOI 10.1016/j.jcv.2019.06.004
   De Castro N, 2019, IAS 2019
   Avettand-Fenoel V, 2016, CLIN MICROBIOL REV, V29, P859, DOI 10.1128/CMR.00015-16
   Avettand-Fenol V, 2009, J MED VIROL, V81, P217, DOI 10.1002/jmv.21390
   Baker JV, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx262
   Besson GJ, 2014, CLIN INFECT DIS, V59, P1312, DOI 10.1093/cid/ciu585
   Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   Delaugerre C, 2010, AIDS, V24, P2391, DOI 10.1097/QAD.0b013e32833d214c
   Dooley KE, AIDS C 2018 AMST NET
   Dutertre M, 2017, INITIATION ART BASED
   Funderburg NT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083514
   Gandhi RT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006285
   Ghislain M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144317
   Gibb D, CROI 2018
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P459, DOI 10.1016/S1473-3099(14)70711-X
   Hatano H, 2013, J INFECT DIS, V208, P1436, DOI 10.1093/infdis/jit453
   Hileman CO, 2015, J INFECT DIS, V212, P345, DOI 10.1093/infdis/jiv004
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Kelesidis T, 2015, CLIN INFECT DIS, V61, P651, DOI 10.1093/cid/civ327
   Khoury G, 2017, J INFECT DIS, V215, P911, DOI 10.1093/infdis/jix039
   Koelsch KK, 2011, AIDS, V25, P2069, DOI 10.1097/QAD.0b013e32834b9658
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lam YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034233
   Lee S, 2017, J INFECT DIS, V215, P1270, DOI 10.1093/infdis/jix113
   Lelievre JD, CROI C 2018 BOST MA
   Manosuthi W, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0106-y
   Massanella M, 2016, CURR OPIN HIV AIDS, V11, P234, DOI 10.1097/COH.0000000000000230
   Olsson O, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz015
   Parisi SG, 2012, J CLIN MICROBIOL, V50, P258, DOI 10.1128/JCM.06022-11
   Reynolds HE, 2015, J ANTIMICROB CHEMOTH, V70, P550, DOI 10.1093/jac/dku376
   Rossetti B, 2017, J CLIN VIROL, V91, P18, DOI 10.1016/j.jcv.2017.03.018
   Sasindran SJ, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00002
   Sullivan ZA, 2015, EBIOMEDICINE, V2, P334, DOI 10.1016/j.ebiom.2015.03.005
   Taburet AM, 2015, CLIN INFECT DIS, V61, P1328, DOI 10.1093/cid/civ477
   Uprety P, 2015, CLIN INFECT DIS, V61, P1862, DOI 10.1093/cid/civ688
   Vallejo A, 2012, AIDS, V26, P1885, DOI 10.1097/QAD.0b013e3283584521
   Wada NI, 2016, CLIN INFECT DIS, V63, P984, DOI 10.1093/cid/ciw409
   Wenning LA, 2009, ANTIMICROB AGENTS CH, V53, P2852, DOI 10.1128/AAC.01468-08
   Wijting I, 2017, INTEGRASE INHIBITORS
NR 41
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD FEB
PY 2020
VL 7
IS 2
AR ofz549
DI 10.1093/ofid/ofz549
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA KY9BQ
UT WOS:000522870200029
PM 32083147
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Neto, MMD
   Brites, C
   Borges, AH
AF da Silva Neto, Marinho Marques
   Brites, Carlos
   Borges, Alvaro H.
TI Cancer during HIV infection
SO APMIS
LA English
DT Review
DE HIV; AIDS; cancer; screening; antiretroviral therapy
ID COMBINATION ANTIRETROVIRAL THERAPY; INCREASED RISK; LUNG-CANCER;
   MALIGNANCIES; PROTEIN; PEOPLE; COAGULATION; MARKERS; ADULTS; DEATH
AB HIV+ persons have a significantly increased risk of cancer when compared to the general population. The excess cancer risk observed during HIV infection is particularly higher for infection-related malignancies. Mechanisms underlying this remain unclear, but both HIV-related and HIV-unrelated factors have been postulated to play a role. Here, we (i) review newly published data on cancer burden in the setting of HIV infection with a focus on HIV-related risk factors for cancer; (ii) discuss emerging data on cancer among HIV+ persons living in low- and middle-income countries; and (iii) review guideline recommendations for cancer screening among HIV+ persons and discuss ongoing studies investigating strategies for cancer screening among HIV+ patients.
C1 [da Silva Neto, Marinho Marques] Bahia State Univ, Dept Life Sci, Salvador, BA, Brazil.
   [da Silva Neto, Marinho Marques] Univ Salvador, Laureate Int Univ, Sch Hlth Sci, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Fac Med, Complexo Hosp Prof Edgard Santos, LAPI Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Borges, Alvaro H.] Statens Serum Inst, Dept Infect Dis Immunol, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
RP Borges, AH (corresponding author), Statens Serum Inst, Dept Infect Dis Immunol, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM albs@ssi.dk
RI da Silva Neto, Marinho Marques/Q-9064-2019
OI da Silva Neto, Marinho Marques/0000-0002-9728-7268
FU LundbeckfondenLundbeckfonden [R219-2016-762]; Danish National Research
   FoundationDanmarks Grundforskningsfond [DNRF 126]
FX This work was supported by Lundbeckfonden (grant number R219-2016-762 to
   AHB) and the Danish National Research Foundation (grant DNRF 126).
CR Aboulafia DM, 2017, WOMENS HEALTH, V13, P68, DOI 10.1177/1745505717731970
   Althoff KN, 2019, LANCET HIV, V6, pE93, DOI 10.1016/S2352-3018(18)30295-9
   Ananworanich J, 2014, J ACQ IMMUN DEF SYND, V67, P99
   [Anonymous], GUID PREV TREATM OPP
   Barnell GM, 2019, JAIDS-J ACQ IMM DEF, V81, P292, DOI 10.1097/QAI.0000000000002040
   Borges AH, 2019, J INFECT DIS, V219, P254, DOI 10.1093/infdis/jiy442
   Borges AH, 2016, CLIN INFECT DIS, V63, P1668, DOI 10.1093/cid/ciw621
   Borges AH, 2017, CURR OPIN HIV AIDS, V12, P12, DOI 10.1097/COH.0000000000000334
   Borges AH, 2016, J INFECT DIS, V214, P408, DOI 10.1093/infdis/jiw173
   Borges AH, 2014, AIDS, V28, P2565, DOI 10.1097/QAD.0000000000000433
   Borges AH, 2014, CURR OPIN HIV AIDS, V9, P34, DOI 10.1097/COH.0000000000000025
   Borges AH, 2013, AIDS, V27, P1433, DOI 10.1097/QAD.0b013e32835f6b0c
   Brazilian Ministry of Health, 2018, PROT CLIN DIR TER MA
   British HIV Association, 2019, BHIVA GUID ROUT INV
   Brunetta E, 2010, AIDS, V24, P27, DOI 10.1097/QAD.0b013e3283328d1f
   Bruyand M, 2015, JAIDS-J ACQ IMM DEF, V68, P568, DOI 10.1097/QAI.0000000000000523
   Caccuri F, 2019, HEMATOL ONCOL, V37, P176, DOI 10.1002/hon.2562
   Castilho JL, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/1750-9378-10-4
   Chang E, 2018, JAIDS-J ACQ IMM DEF, V79, P141, DOI [10.1097/QAI.0000000000001798, 10.1097/qai.0000000000001798]
   Chao C, 2012, AIDS, V26, P2223, DOI 10.1097/QAD.0b013e32835935b3
   Chinula L, 2017, CURR OPIN HIV AIDS, V12, P89, DOI 10.1097/COH.0000000000000329
   Coghill AE, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2019.1742
   Coghill AE, 2019, CANCER-AM CANCER SOC, V125, P2868, DOI 10.1002/cncr.32158
   Colon-Lopez V, 2018, J CLIN ONCOL, V36, P68, DOI 10.1200/JCO.2017.74.9291
   Corrigan KL, 2019, CANCER-AM CANCER SOC, V125, P843, DOI 10.1002/cncr.31838
   de Martel C, 2015, AIDS, V29, P2173, DOI 10.1097/QAD.0000000000000808
   Dhokotera T, 2019, INFECT AGENTS CANCER, V14, DOI 10.1186/s13027-019-0228-7
   Dolcetti R, 2016, BLOOD, V127, P1403, DOI 10.1182/blood-2015-11-681411
   Dolcetti R, 2015, P NATL ACAD SCI USA, V112, P14331, DOI 10.1073/pnas.1514748112
   Dubrow R, 2017, JAIDS-J ACQ IMM DEF, V75, P382, DOI 10.1097/QAI.0000000000001394
   Dubrow R, 2012, CURR OPIN ONCOL, V24, P506, DOI 10.1097/CCO.0b013e328355e131
   Engels EA, 2019, AM J TRANSPLANT, V19, P3223, DOI 10.1111/ajt.15495
   Engels EA, 2017, CLIN INFECT DIS, V65, P636, DOI 10.1093/cid/cix392
   European AIDS Clinical Society, 2019, EUR GUID TREATM HIV
   Franzetti M, 2019, CURR HIV RES, V17, P1, DOI 10.2174/1570162X17666190327153038
   Godbole SV, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004850
   Goedert JJ, 2016, TRENDS CANCER, V2, P416, DOI 10.1016/j.trecan.2016.06.007
   Grinspoon SK, 2019, AM HEART J, V212, P23, DOI 10.1016/j.ahj.2018.12.016
   Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2
   Helleberg M, 2013, CLIN INFECT DIS, V57, P314, DOI 10.1093/cid/cit232
   Hernandez-Ramirez RU, 2020, CLIN INFECT DIS, V70, P1176, DOI 10.1093/cid/ciz329
   Hernandez-Ramirez RU, 2019, LANCET HIV, V6, pE240, DOI 10.1016/S2352-3018(18)30360-6
   Hernandez-Ramirez RU, 2017, LANCET HIV, V4, pE495, DOI 10.1016/S2352-3018(17)30125-X
   Hessol NA, 2015, AIDS, V29, P1183, DOI 10.1097/QAD.0000000000000690
   Horner MJ, 2019, CLIN INFECT DIS, V69, P829, DOI 10.1093/cid/ciy960
   Jiamsakul A, 2019, JAIDS-J ACQ IMM DEF, V80, P301, DOI 10.1097/QAI.0000000000001918
   Landgren O, 2010, J CLIN ONCOL, V28, P773, DOI 10.1200/JCO.2009.25.1322
   Lee CY, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3251-1
   Lucar O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01850
   Lundgren JD, 2018, CURR HIV-AIDS REP, V15, P162, DOI 10.1007/s11904-018-0387-y
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Marcus JL, 2017, AIDS, V31, P989, DOI [10.1097/qad.0000000000001434, 10.1097/QAD.0000000000001434]
   Marques M, 2018, CANCER EPIDEMIOL, V54, P133, DOI 10.1016/j.canep.2018.04.001
   Mbang PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142966
   Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749
   Nolting A, 2010, VIROLOGY, V406, P12, DOI 10.1016/j.virol.2010.05.014
   Omland SH, 2018, J AM ACAD DERMATOL, V79, P689, DOI 10.1016/j.jaad.2018.03.024
   Pacek LR, 2015, CURR HIV-AIDS REP, V12, P413, DOI 10.1007/s11904-015-0281-9
   Parkin DM, 2020, INT J CANCER, V146, P2089, DOI 10.1002/ijc.32538
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Petoumenos K, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-51
   Revollo B, 2020, CLIN INFECT DIS, V71, P390, DOI 10.1093/cid/ciz831
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X
   Rogena EA, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/s13027-015-0021-1
   Shepherd L, 2018, HIV MED, V19, P90, DOI 10.1111/hiv.12546
   Shepherd L, 2016, HIV MED, V17, P590, DOI 10.1111/hiv.12359
   Shepherd L, 2018, JNCI-J NATL CANCER I, V110, P598, DOI 10.1093/jnci/djx249
   Shepherd L, 2016, ANTIVIR THER, V21, P529, DOI 10.3851/IMP3026
   Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076
   Shiels MS, 2009, JAIDS-J ACQ IMM DEF, V52, P611, DOI 10.1097/QAI.0b013e3181b327ca
   Silverberg MJ, 2015, ANN INTERN MED, V163, P507, DOI 10.7326/M14-2768
   Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8
   Thrift AP, 2018, CURR INFECT DIS REP, V20, DOI 10.1007/s11908-018-0626-9
   Van't Klooster CC, 2019, EUR HEART J, V40, P3901, DOI 10.1093/eurheartj/ehz587
   Wareham NE, 2019, J CANCER RES CLIN, V145, P3125, DOI 10.1007/s00432-019-03039-2
   Wilkin Timothy J, 2018, Top Antivir Med, V26, P85
   World Health Organization, 2017, CONS GUID SEX REPR H
   Worm SW, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-471
NR 79
TC 1
Z9 1
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD FEB
PY 2020
VL 128
IS 2
BP 121
EP 128
DI 10.1111/apm.13020
EA JAN 2020
PG 8
WC Immunology; Microbiology; Pathology
SC Immunology; Microbiology; Pathology
GA LI5FL
UT WOS:000509591700001
PM 31990100
OA Bronze
DA 2020-12-01
ER

PT J
AU de Carvalho, AL
   Ventura, P
   Taguchi, T
   Brandi, I
   Brites, C
   Lucena, R
AF de Carvalho, Alessandra Lemos
   Ventura, Paloma
   Taguchi, Tania
   Brandi, Ivar
   Brites, Carlos
   Lucena, Rita
TI Cerebral Palsy in Children With Congenital Zika Syndrome: A 2-Year
   Neurodevelopmental Follow-up
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE Zika virus; congenital Zika; cerebral palsy; neurodevelopment
ID INFANT NEUROLOGICAL EXAMINATION; AGE
AB Objective: To describe the 2-year neurodevelopmental outcome in children with cerebral palsy associated with congenital Zika (CZ) and explore variables associated with a more severe presentation. Methods: Data on 69 children with cerebral palsy associated with CZ, followed in a neurorehabilitation hospital, who consecutively attended the neurodevelopmental assessment at 2 years of age, were collected. Bayley III Scales of Infant and Toddler Development, Hammersmith Infant Neurological Examination, and Gross Motor Function Classification System were used for the outcome evaluation. Descriptive and inferential statistical analysis were performed. Results: The median age at follow-up was of 24.0 (23-32) months. Only 3 (4.3%) children were not microcephalic. The majority presented with bilateral (94.2%), spastic (100.0%), Gross Motor Function Classification System grade IV or V (92.8%) cerebral palsy, epilepsy (73.1%), extremely low performances on cognitive (94.2%), language (95.7%), and motor (95.7%) Bayley-III Scales of Infant and Toddler Development Test scores. The median Hammersmith Infant Neurological Examination score was of 21.0 (range 9-75). There was a correlation between birth head circumference with the cognitive (r = 0.3, P < .01), language (r = 0.3, P < .01), and motor (r = 0.3, P < .01) Bayley-III Scales of Infant and Toddler Development Test scores, as well as with the Hammersmith Infant Neurological Examination score (r = 0.2, P < .03). An association was observed between an inferior median Hammersmith Infant Neurological Examination score with congenital microcephaly (P = .04), arthrogryposis (P = .02), and epilepsy in the first year (P < .01). Conclusion: Cerebral palsy related to CZ presents with a severe global impairment at a 2-year follow-up. Birth head circumference, arthrogryposis, and early epilepsy are associated with a worse outcome and may be considered as prognostic markers. These findings are important for the neurorehabilitation planning, parents' guiding, and future prognostic studies.
C1 [de Carvalho, Alessandra Lemos; Ventura, Paloma; Taguchi, Tania; Brandi, Ivar] SARAH Network Rehabil Hosp, Salvador, BA, Brazil.
   [Brites, Carlos; Lucena, Rita] Univ Fed Bahia, Salvador, BA, Brazil.
RP de Carvalho, AL (corresponding author), SARAH Salvador Hosp, Ave Tancredo Neves,2782 Caminho Arvores, BR-41820900 Salvador, BA, Brazil.
EM 13110@sarah.br
RI Lucena, Rita/L-9842-2013
OI Lucena, Rita/0000-0002-6190-9168
CR Alves LV, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021304
   Botelho Ana Carla Gomes, 2016, Rev. Bras. Saude Mater. Infant., V16, P39, DOI 10.1590/1806-9304201600s100004
   BRASIL, 2018, B EPIDEMIOLOGICO, V49, P1, DOI DOI 10.1111/are.13485
   Carvalho AL, 2019, CLIN MICROBIOL INFEC, V25, P524, DOI 10.1016/j.cmi.2018.12.021
   Carvalho A, 2019, BRAIN DEV-JPN, V41, P587, DOI 10.1016/j.braindev.2019.03.005
   Ferreira HNC, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061107
   de Carvalho AL, 2018, EMERG INFECT DIS, V24, P2128, DOI 10.3201/eid2411.180883
   Einspieler C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7235
   Moreira MEL, 2018, NEW ENGL J MED, V379, P2377, DOI 10.1056/NEJMc1800098
   Madaschi Vanessa, 2016, Paidéia (Ribeirão Preto), V26, P189, DOI 10.1590/1982-43272664201606
   Marques FJP, 2019, J CHILD NEUROL, V34, P81, DOI 10.1177/0883073818811234
   Melo A, 2020, DEV MED CHILD NEUROL, V62, P221, DOI 10.1111/dmcn.14227
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Novak I, 2017, JAMA PEDIATR, V171, P897, DOI 10.1001/jamapediatrics.2017.1689
   Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x
   Pan American Health Organization Organization PAHOWH, 2016, NEUR SYNDR CONG AN Z
   Pessoa A, 2018, PEDIATRICS, V141, pS167, DOI 10.1542/peds.2017-2038F
   Rice ME, 2018, MMWR-MORBID MORTAL W, V67, P858, DOI 10.15585/mmwr.mm6731e1
   Romeo DM, 2016, DEV MED CHILD NEUROL, V58, P240, DOI 10.1111/dmcn.12876
   Romeo DMM, 2008, EUR J PAEDIATR NEURO, V12, P24, DOI 10.1016/j.ejpn.2007.05.006
   Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x
   Satterfield-Nash A, 2017, MMWR-MORBID MORTAL W, V66, P1347, DOI 10.15585/mmwr.mm6649a2
   Soares-Marangoni D, 2018, DEV NEUROREHABIL, V16, P1
   Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6
   World Health Organization, 2017, ZIK VIR MICR GUILL B
NR 25
TC 4
Z9 4
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD MAR
PY 2020
VL 35
IS 3
BP 202
EP 207
AR UNSP 0883073819885724
DI 10.1177/0883073819885724
EA NOV 2019
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA KF9TL
UT WOS:000497623200001
PM 31718421
DA 2020-12-01
ER

PT J
AU Gomes, TV
   Brites, C
AF Gomes, Tacila Veras
   Brites, Carlos
TI Prevalence and risk factors for erectile dysfunction in HIV-infected
   patients in Salvador, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Erectile dysfunction; AIDS; Bahia; Risk factors
ID ANTIRETROVIRAL THERAPY; SEXUAL DYSFUNCTIONS; MEN; COHORT; AIDS; GAY
AB Background: Effective antiretroviral therapy (ART) has increased life expectancy for HIV patients to levels close to that observed for general population. Comorbidities are also increasing, due to ageing of such population. Erectile dysfunction (ED) has been a frequent finding in men living with HIV.
   Objectives: The goals of the present study were to define the prevalence of ED and associated factors in HIV-infected men, in a referral center of Salvador city, Brazil.
   Methods: HIV-infected men >= 18 years of age, receiving care at the AIDS Clinics of Complexo Hospitalar Professor Edgard Santos (C-HUPES), Universidade Federal da Bahia were consecutively included in the study until the estimated sample size (N = 134) was reached. Patients filled a structured questionnaire on clinical-epidemiological characteristics, as well as the International Index on Erectile Function to assess ED.
   Results: Most (55%) were black and single (79%), mean age 44.8 years. ED was detected in 29 (21.6%) patients; 86% of ED cases were classified as severe. The only factors associated with ED were low income (p = 0.02) and unemployment (p = 0.01). No association was found between ED and frequency of comorbidities, age, or ART used by patients.
   Conclusion: In a referral center in Salvador city, socio-economic problems were the main factors associated with ED. Psychological impact of poor social conditions should be routinely assessed in patients with ED to implement preventive measures for ED. (C) 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Gomes, Tacila Veras; Brites, Carlos] Univ Fed Bahia, Fac Med, Programa Posgrad Med & Saude, Salvador, BA, Brazil.
   [Gomes, Tacila Veras; Brites, Carlos] Univ Fed Bahia, Complexo Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectologia LAPI, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Fac Med, Programa Posgrad Med & Saude, Salvador, BA, Brazil.; Brites, C (corresponding author), Univ Fed Bahia, Complexo Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectologia LAPI, Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Catalan J, 2000, AIDS CARE, V12, P279, DOI 10.1080/09540120050042927
   Colson AE, 2002, J ACQ IMMUN DEF SYND, V30, P27
   De Ryck I, 2013, J SEX MED, V10, P1816, DOI 10.1111/jsm.12175
   Driemeier M, 2012, CLINICS, V67, P19, DOI 10.6061/clinics/2012(01)04
   Finotelli IJ, 2001, PSICO-USF, V16, P45
   Fumaz CR, 2017, AM J MENS HEALTH, V11, P647, DOI 10.1177/1557988316669041
   Guaraldi G, 2012, J SEX MED, V9, P1114, DOI 10.1111/j.1743-6109.2011.02243.x
   Hart TA, 2012, J SEX MED, V9, P1106, DOI 10.1111/j.1743-6109.2011.02648.x
   Perez I, 2013, INT J STD AIDS, V24, P712, DOI 10.1177/0956462413482423
   Romero-Velez G, 2014, SEX MED-UK, V2, P24, DOI 10.1002/sm2.25
   Scanavino MD, 2010, CLINICS, V65, P511, DOI 10.1590/S1807-59322010000500009
   Shindel AW, 2011, AIDS PATIENT CARE ST, V25, P341, DOI 10.1089/apc.2011.0059
   Sollima S, 2001, AIDS, V15, P2331, DOI 10.1097/00002030-200111230-00020
   Staiman Victoria R, 2004, ScientificWorldJournal, V4 Suppl 1, P427
   van Griensven F, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-13
   Vansintejan J, 2013, HIV AIDS-RES PALLIAT, V5, P89, DOI 10.2147/HIV.S43962
   Wang Q, 2013, ANTIVIR THER, V18, P337, DOI 10.3851/IMP2372
   Zona S, 2012, J SEX MED, V9, P1923, DOI 10.1111/j.1743-6109.2012.02750.x
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2019
VL 23
IS 6
BP 464
EP 467
DI 10.1016/j.bjid.2019.08.006
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA JW6UX
UT WOS:000503185600012
PM 31545951
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Kusterer, LEL
   Valdelamar, J
   Aguiar, CVN
   Menezes, MS
   Netto, EM
   Brites, C
AF Lins Kusterer, Liliane Elze
   Valdelamar, Juliet
   Nova Aguiar, Carolina Villa
   Menezes, Marta Silva
   Netto, Eduardo Martins
   Brites, Carlos
TI Validation of SF-36 version 2 in Brazilian people living with HIV
SO QUALITY OF LIFE RESEARCH
LA English
DT Meeting Abstract
C1 [Lins Kusterer, Liliane Elze] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Valdelamar, Juliet; Netto, Eduardo Martins; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
   [Nova Aguiar, Carolina Villa; Menezes, Marta Silva] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil.
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD OCT
PY 2019
VL 28
SU 1
SI SI
MA 1037
BP S81
EP S82
PG 2
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA IY6IM
UT WOS:000486499800186
DA 2020-12-01
ER

PT J
AU Brites, C
   Nogueira, RS
   Gosuen, GC
   Kalmar, EMC
   Leme, STS
   Martins, RT
   Oyama, T
   Bastos, FA
AF Brites, Carlos
   Nogueira, Roberta Schiavon
   Gosuen, Gisele C.
   Kalmar, Erica M. C.
   Leme, Susana T. S.
   Martins, Rafaela T.
   Oyama, Thiago
   Bastos, Fernanda A.
TI Getting Older with HIV: Increasing Frequency of Comorbidities and
   Polypharmacy in Brazilian HIV Patients
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE HIV; aging; Brazil; noncommunicable diseases
AB Life expectancy of HIV patients has increased over time. Older HIV patients have a higher frequency of noncommunicable diseases (NCD) than general population, and require multiple treatments. The main objective is to evaluate the changes in frequency of NCD and polypharmacy in HIV patients of three referral centers in Salvador and Sao Paulo. We compared the frequency of NCD and use of concomitant treatments in HIV patients, >50 years, in three Brazilian referral centers (Sao Paulo and Salvador). Data on sociodemographic characteristics, HIV therapy, CD4 count and viral load measurements, and frequency of NCD at baseline and last medical visit were recorded. We evaluated 451 patients, 128 in Salvador and 323 in Sao Paulo. Mean age was 57.9 +/- 6.9 years. Mean baseline CD4 count was 199 +/- 169. At baseline, dyslipidemia (4.0%) was the most frequent comorbidity, but at last visit we detected a high frequency of diabetes (14.9%), dyslipidemia (26.7%), osteoporosis (6.7%), stroke (4.4%), and malignancies (3.1%). Use of concomitant drugs for treatment of NCD increased significantly between first and last visit, especially antihypertensive, lipids lowering, and diabetes drugs. Aging in HIV patients in Brazil is characterized by an increasing incidence of NCD and polypharmacy.
C1 [Brites, Carlos; Martins, Rafaela T.; Bastos, Fernanda A.] Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, LAPI Lab Pesquisa Infectol, Augusto Viana Sn,6o Andar, BR-40110060 Salvador, BA, Brazil.
   [Nogueira, Roberta Schiavon] CRT Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Gosuen, Gisele C.; Kalmar, Erica M. C.; Leme, Susana T. S.; Oyama, Thiago] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, LAPI Lab Pesquisa Infectol, Augusto Viana Sn,6o Andar, BR-40110060 Salvador, BA, Brazil.
EM crbrites@gmail.com
CR Castilho JL, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25233
   Chary A, 2017, EXPERT REV CLIN PHAR, V10, P1329, DOI 10.1080/17512433.2017.1377610
   Cuzin L, 2007, CLIN INFECT DIS, V45, P654, DOI 10.1086/520652
   Maciel RA, 2018, INT J INFECT DIS, V70, P30, DOI 10.1016/j.ijid.2018.02.009
   Miranda Gabriella Morais Duarte, 2016, Rev. bras. geriatr. gerontol., V19, P507, DOI 10.1590/1809-98232016019.150140
   Sabin CA, 2017, AIDS, V31, pS121, DOI [10.1097/QAD.0000000000001374, 10.1097/qad.0000000000001374]
   Sabin CA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-251
   Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684
   Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0
NR 9
TC 1
Z9 1
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2019
VL 35
IS 11-12
BP 1103
EP 1105
DI 10.1089/aid.2019.0069
EA SEP 2019
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA JM7KZ
UT WOS:000488241100001
PM 31452382
DA 2020-12-01
ER

PT J
AU Zeballos, D
   Lins, L
   Brites, C
AF Zeballos, Diana
   Lins, Liliane
   Brites, Carlos
TI Frailty and Its Association with Health Related Quality of Life in Older
   HIV Patients, in Salvador, Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE frailty; HIV; aging; AIDS; health-related quality of life
ID INFECTED ADULTS; PREVALENCE; PHENOTYPE; AIDS; PAIN; AGE; INDIVIDUALS;
   IMPAIRMENT; HIV/AIDS; DISEASE
AB Frailty is a geriatric syndrome that may develop earlier in the presence of HIV. Frail individuals are more vulnerable to adverse health outcomes and poorer quality of life. This study aimed to determine the prevalence and factors associated with frailty and to define the impact of frailty on quality of life. A cross-sectional study was conducted with 201 adults living with HIV, aged 50 or older, receiving outpatient care between April and November of 2017 at a referral center in Salvador, Brazil. Frailty was assessed using Fried frailty phenotype. Factors related to frailty were identified using multinomial logistic regression. The association between frailty and quality of life was tested through multiple linear regression. All but one patient were on antiretroviral therapy. The median age was 55 years (range 50-83 years), 63.7% were males, and 91.6% self-identified as black or racially mixed. The median CD4 cell count was 673 cells/mm(3) (IQR 470-900), and 88.1% were virally suppressed. The prevalence of frailty and prefrailty was 19.4% and 49.3%, respectively. Female sex, unemployment, and pain were associated with frailty. Unemployment and the use of nucleoside reverse transcriptase inhibitors were associated with prefrailty. Frailty was associated with a decrease in health-related quality of life. The prevalence of frailty was higher than the prevalence found in general population which was at least 10 years older. Half of the participants were prefrail, indicating the need for improved long-term care. Pain management is a potential target for interventions to prevent frailty and to improve quality of life.
C1 [Zeballos, Diana; Lins, Liliane; Brites, Carlos] Univ Fed Bahia, Postgrad Program Med & Hlth, Rua Doutor Augusto Viana S-N, BR-40110060 Salvador, BA, Brazil.
   [Lins, Liliane; Brites, Carlos] Univ Hosp Prof Edgard Santos, Sch Med, LAPI Res Lab Infect Dis, Salvador, BA, Brazil.
RP Zeballos, D (corresponding author), Univ Fed Bahia, Postgrad Program Med & Hlth, Rua Doutor Augusto Viana S-N, BR-40110060 Salvador, BA, Brazil.
EM dianazeballos@gmail.com
RI Lins-Kusterer, Liliane/Q-5191-2019
OI Lins-Kusterer, Liliane/0000-0003-3736-0002
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil
   (CAPES)CAPES [001]
FX This study was financed, in part, by the Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior - Brazil (CAPES) - Finance Code 001,
   through a Master's fellowship granted to DZ.
CR Althoff KN, 2014, J GERONTOL A-BIOL, V69, P189, DOI 10.1093/gerona/glt148
   Branas F, 2017, AGE AGEING, V46, P522, DOI 10.1093/ageing/afx013
   Brothers TD, 2014, CURR OPIN HIV AIDS, V9, P412, DOI 10.1097/COH.0000000000000070
   Cardoso SW, 2013, BRAZ J INFECT DIS, V17, P464, DOI 10.1016/j.bjid.2012.11.007
   Chen C, 2018, P NATL ACAD SCI USA, V115, P9169, DOI 10.1073/pnas.1806260115
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Desquilbet L, 2007, J GERONTOL A-BIOL, V62, P1279, DOI 10.1093/gerona/62.11.1279
   Ding YY, 2017, J INFECT DIS, V215, P687, DOI 10.1093/infdis/jix032
   Erlandson KM, 2012, HIV CLIN TRIALS, V13, P324, DOI 10.1310/hct1306-324
   Fine PG, 2011, PAIN MED, V12, P996, DOI 10.1111/j.1526-4637.2011.01187.x
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Fumaz CR, 2015, AIDS CARE, V27, P1396, DOI 10.1080/09540121.2015.1114989
   Furr R.M., 2011, SCALE CONSTRUCTION P
   George S, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0517-4
   Greene M, 2015, JAIDS-J ACQ IMM DEF, V69, P161, DOI 10.1097/QAI.0000000000000556
   Gustafson DR, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013993
   Hawkins KL, 2018, AIDS, V32, P1257, DOI 10.1097/QAD.0000000000001829
   Hawkins KL, 2018, AIDS S2, V31, P1
   Horvath S, 2015, J INFECT DIS, V212, P1563, DOI 10.1093/infdis/jiv277
   Ianas Voichita, 2013, J Int Assoc Provid AIDS Care, V12, P62, DOI 10.1177/1545109712457241
   Jung YY, 2010, J GERONTOL B-PSYCHOL, V65, P256, DOI [10.1093/geronb/gbq005, 10.1093/geronb/gbp105]
   LAMPING DL, 1994, PSYCHOL HEALTH, V9, P31, DOI 10.1080/08870449408407458
   Levett TJ, 2016, J AM GERIATR SOC, V64, P1006, DOI 10.1111/jgs.14101
   Lustosa L, 2011, GERIATR GERONTOL INT, V5, P57
   Mahy M, 2014, AIDS, V28, pS453, DOI 10.1097/QAD.0000000000000479
   Martin GE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055279
   Masel MC, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-70
   Ministry of Health (Brazil): Secretariat of Health Surveillance, 2017, EP B AIDS STI
   Neri AL, 2013, CAD SAUDE PUBLICA, V29, P778, DOI [10.1590/S0102-311X2013000400015, 10.1590/S0102-311X2013000800015]
   Nessighaoui H, 2015, J FRALITY AGING, V4, P144, DOI 10.14283/jfa.2015.53
   Onen NF, 2009, J INFECTION, V59, P346, DOI 10.1016/j.jinf.2009.08.008
   Oguntibeju OO, 2012, HIV AIDS-RES PALLIAT, V4, P117, DOI 10.2147/HIV.S32321
   Okulicz JF, 2011, CURR OPIN HIV AIDS, V6, P163, DOI 10.1097/COH.0b013e328344f35e
   Pathai S, 2013, AIDS, V27, P2375, DOI 10.1097/QAD.0b013e328363bf7f
   Pathai S, 2013, JAIDS-J ACQ IMM DEF, V62, P43, DOI 10.1097/QAI.0b013e318273b631
   Sousa ACPD, 2012, ARCH GERONTOL GERIAT, V54, pE95, DOI 10.1016/j.archger.2011.08.010
   Petit N, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009852
   Piggott DA, 2017, J GERONTOL A-BIOL, V72, P389, DOI 10.1093/gerona/glw142
   Piggott DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054910
   Rueda S, 2011, AIDS CARE, V23, P435, DOI 10.1080/09540121.2010.507952
   Skevington SM, 2012, AIDS CARE, V24, P1219, DOI 10.1080/09540121.2012.661838
   Tamez-Rivera O, 2014, J FRALITY AGING, V3, P89, DOI 10.14283/jfa.2014.7
   Terzian AS, 2009, J WOMENS HEALTH, V18, P1965, DOI 10.1089/jwh.2008.1090
   United Nations Department of Economic and Social Affairs Population Division, 2015, STESASERA390 UN DEP
   United Nations Department of Economic and Social Affairs Population Division, 2017, STESASERA408 UN DEP
   Walston J, 1999, MED CLIN N AM, V83, P1173, DOI 10.1016/S0025-7125(05)70157-7
   Ware JE, 1993, SF 36 HLTH SURVEY MA
   Yeoh HL, 2018, ANTIVIR THER, V23, P117, DOI 10.3851/IMP3185
   Zamudio-Rodriguez A, 2017, GAC MED MEX, V153, P598, DOI 10.24875/GMM.17002875
NR 50
TC 2
Z9 2
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2019
VL 35
IS 11-12
BP 1074
EP 1081
DI 10.1089/aid.2019.0103
EA SEP 2019
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA JM7KZ
UT WOS:000485521500001
PM 31373215
DA 2020-12-01
ER

PT J
AU Lins-Kusterer, L
   Valdelamar, J
   Aguiar, CVN
   Menezes, MS
   Netto, EM
   Brites, C
AF Lins-Kusterer, Liliane
   Valdelamar, Juliet
   Nova Aguiar, Carolina Villa
   Menezes, Marta Silva
   Martins Netto, Eduardo
   Brites, Carlos
TI Validity and reliability of the 36-Item Short Form Health Survey
   questionnaire version 2 among people living with HIV in Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Health-related quality of life; Factor analysis; Validation studies
ID QUALITY-OF-LIFE; SF-36; HIV/AIDS
AB Background: The 36-Item Short Form Health Survey questionnaire (SF-36) is a widely used instrument for evaluating health-related quality-of-life (HRQoL). The psychometric validation of the SF-36 version 2.0 (SF-36v2) in HIV-infected patients had not yet conducted in Brazil.
   Aim: To test data quality, reliability and validity of the SF-36v2 as a measure of HRQoL among Brazilian individuals living with HIV.
   Methods: A cross-sectional study included 393 HIV-infected patients in whom HRQoL was assessed by using the SF-36v2 questionnaire. Demographic characteristics, socioeconomic status and clinical data were also collected. The SF-36 version 1 translated into Brazilian-Portuguese was adapted and introduced version 2 improvements according to the instrument developers. SPSS version 21 was used for data analyses. Confirmatory factor analysis (CFA) and structural equation modelling were performed using AMOS SPSS version 18. T-test for independent samples was used to compare differences between mean levels of HRQoL components in different groups. Linear multiple regression techniques were used to analyze the relationship between Physical Component Summary (PCS), Mental Component Summary (MCS) and independent variables.
   Results: We performed the CFA and tested the hypothetical measurement model. We included five parameters to improve the adherence of data to the model. All indicators met the requirement suggested by specialized literature (chi(2) (gl): 980.7 (527); CFI: 0.949; GFI: 0.873; TLI: 0.943; RMSEA: 0.047; 90% IC: 0.042-0.051). Multiple regression analyses revealed that depression (p = 0.001), family income (p = 0.007), sex (p = 0.001) and age (p < 0.021) were associated with MCS. Comorbidities (p =0.001), health self-perception (p = 0.001), age (p = 0.001), and sex (p =0.025) were associated with PCS.
   Conclusions: A consistent validation of the SF-36v2 in Brazilian HIV patients were shown. Further studies with SF-36v2 psychometric analyses would be required in other populations to establish Brazilian normative data. (C) 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Lins-Kusterer, Liliane; Valdelamar, Juliet; Martins Netto, Eduardo; Brites, Carlos] Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Nova Aguiar, Carolina Villa; Menezes, Marta Silva] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
RP Lins-Kusterer, L; Valdelamar, J (corresponding author), Univ Fed Bahia, Edgard Santos Fed Univ Hosp, LAPI Res Lab Infect Dis, Rua Augusto Viana S-N, Salvador, BA, Brazil.
EM liliane.lins@ufba.br; okyuyi@gmail.com; carolinaaguiar@bahiana.edu.br;
   martamenezes@bahiana.edu.br; nettoeduardom@hotmail.com;
   crbrites@gmail.com
RI Lins-Kusterer, Liliane/Q-5191-2019; Netto, Eduardo/D-1432-2013; Brites,
   Carlos/D-1353-2013
OI Lins-Kusterer, Liliane/0000-0003-3736-0002; Netto,
   Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991;
   Valdelamar, Juliet/0000-0001-8323-7473
CR [Anonymous], 2018, OPTUM PROCORE 1 3 SM
   Baumgartner H., 1996, INT J RES, V13, P139, DOI DOI 10.1016/0167-8116(95)00038-0
   Betancur MN, 2017, BRAZ J INFECT DIS, V21, P507, DOI 10.1016/j.bjid.2017.04.004
   Byrne BM, 2010, BASICS CONCEPTS APPL
   Castillo-Carandang NT, 2013, PLOS ONE, V8, P1
   Ciconelli R. M., 1997, THESIS
   Clayson DJ, 2006, PHARMACOECONOMICS, V24, P751, DOI 10.2165/00019053-200624080-00003
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Doll W.J., 1994, MIS Q, V18, P357, DOI DOI 10.2307/249524
   Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1037, DOI 10.1016/S0895-4356(98)00095-X
   Furr R.M., 2011, SCALE CONSTRUCTION P
   Hosiner DW, 2000, APPL LOGISTIC REGRES
   Laguardia Josué, 2013, Rev. bras. epidemiol., V16, P889, DOI 10.1590/S1415-790X2013000400009
   Ledo Ana Paula, 2018, Open AIDS J, V12, P117, DOI 10.2174/1874613601812010117
   Lins L, 2016, SAGE OPEN MED, V4, DOI 10.1177/2050312116671725
   Nakao M, 2016, SPRINGERPLUS, V5, P1
   Peterson RA, 2013, J APPL PSYCHOL, V98, P194, DOI 10.1037/a0030767
   Thumboo J, 2001, QUAL LIFE RES, V10, P175, DOI 10.1023/A:1016701514299
   Vieira VC, 2018, BMC ORAL HEALTH, V18, P1
   Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008
   Ware JE, 2000, SCORE VERSION 2 SF 3
NR 21
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2019
VL 23
IS 5
BP 313
EP 321
DI 10.1016/j.bjid.2019.08.001
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA JW6UT
UT WOS:000503185200005
PM 31491370
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Vieira, VD
   Sarmento, VA
   Ribeiro, PML
   Netto, EM
   Brites, C
   Lins-Kusterer, L
AF Vieira, Vinicius da Costa
   Sarmento, Viviane Almeida
   Leite Ribeiro, Patricia Miranda
   Martins Netto, Eduardo
   Brites, Carlos
   Lins-Kusterer, Liliane
TI Unusual oral findings of the toxic epidermal necrolysis in an
   HIV-infected patient: a case report
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Toxic epidermal necrolysis; Stevens Johnson syndrome; Antiretroviral
   therapy; HIV
ID STEVENS-JOHNSON-SYNDROME; MORTALITY; THERAPY
AB Erythema multiforme (EM), Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (TEN) have been reported as possible adverse effects of some classes of first-line antiretroviral drugs (ART) for HIV treatment. Herein we report an unusual presentation of TEN lesions associated with ART in an HIV-infected patient. The patient presented disseminated cutaneous eruption and oral lesions from the lips to the oropharynx region, causing odynophagia and dysphagia. In the tongue, circular, atypical erythematous lesions appeared, increasing in diameter over seven days and coalescing since then to complete remission. TEN treatment included efavirenz interruption, use of methylprednisolone, prophylactic antibiotic, and daily laser therapy with low-intensity red light. The circular oral lesions have not been described yet. Reporting our findings and clinical management may help diagnosing other similar cases and guide the clinical conduct. Analgesia and acceleration of oral ulcer repair with red laser therapy are recommended. (C) 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Vieira, Vinicius da Costa] Complexo Hosp Univ Prof Edgard Santos, Serv Estomatol, Salvador, BA, Brazil.
   [Sarmento, Viviane Almeida; Leite Ribeiro, Patricia Miranda] Univ Fed Bahia, Sch Dent, Salvador, BA, Brazil.
   [Martins Netto, Eduardo; Brites, Carlos; Lins-Kusterer, Liliane] Complexo Hosp Univ Prof Edgard Santos, Lab Invest Doencas Infecciosas, Salvador, BA, Brazil.
RP Lins-Kusterer, L (corresponding author), Univ Fed Bahia, Edgard Santos Fed Univ Hosp, Res Lab Infect Dis, Lab Pesquisa Infectol, Rua Augusto Viana S-N, BR-40110060 Salvador, BA, Brazil.
EM viniciusvieiraoh@hotmail.com; viviane.sarmento@gmail.com;
   nettoeduardom@hotmail.com; crbrites@gmail.com; liliane.lins@ufba.br
RI Lins-Kusterer, Liliane/Q-5191-2019; Netto, Eduardo/D-1432-2013; Brites,
   Carlos/D-1353-2013; Sarmento, Viviane/F-9837-2014
OI Lins-Kusterer, Liliane/0000-0003-3736-0002; Netto,
   Eduardo/0000-0003-1691-6761; Leite-Ribeiro,
   Patricia/0000-0002-4243-6887; Brites, Carlos/0000-0002-4673-6991;
   Sarmento, Viviane/0000-0003-4403-3659
CR Aggarwal H, 2014, J CLIN DIAGN RES, V8, P218, DOI 10.7860/JCDR/2014/7639.4064
   Al-Johani KA, 2007, ORAL SURG ORAL MED O, V103, P642, DOI 10.1016/j.tripleo.2006.12.008
   BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92
   Borchers AT, 2008, AUTOIMMUN REV, V7, P598, DOI 10.1016/j.autrev.2008.06.004
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departmento de DST Aids e Hepatites Virais, 2015, PROT CLIN DIR TER AT, P120
   Choonhakarn C, 2016, J DERMATOL, V43, P156, DOI 10.1111/1346-8138.13040
   Churchill D, 2016, HIV MED, V17, pS2, DOI 10.1111/hiv.12426
   Kakande Betty, 2015, F1000Res, V4, P175, DOI 10.12688/f1000research.6715.1
   Mehmood K, 2014, J CLIN DIAGN RES, V8, DOI 10.7860/JCDR/2014/8184.5161
   Paik Sabyasachi, 2015, Drug Saf Case Rep, V2, P15
   Paik S, 2016, J CLIN DIAGN RES, V10, pFD3, DOI 10.7860/JCDR/2016/16360.7415
   Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG AD AD
   Reddy Ramana Bv, 2013, J Oral Maxillofac Pathol, V17, P431, DOI 10.4103/0973-029X.125214
   Saka B, 2015, MED SANTE TROP, V25, P446, DOI 10.1684/mst.2014.0422
   Schneck J, 2008, J AM ACAD DERMATOL, V58, P33, DOI 10.1016/j.jaad.2007.08.039
   Shubber Z, 2013, AIDS, V27, P1403, DOI 10.1097/QAD.0b013e32835f1db0
   Siedner-Weintraub Y, 2016, ACTA DERM VENEREOL
   Stewart A, 2016, PHARMACOEPIDEM DR S, V25, P1313, DOI 10.1002/pds.4067
   Suarez-Lorenzo I, 2016, CONTACT DERMATITIS, V74, P253, DOI 10.1111/cod.12508
   Tseng Jossy, 2017, J Int Assoc Provid AIDS Care, V16, P37, DOI 10.1177/2325957415614651
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2019
VL 23
IS 5
BP 363
EP 367
DI 10.1016/j.bjid.2019.08.003
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA JW6UT
UT WOS:000503185200012
PM 31562853
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Souza, JSM
   Silva, JJ
   Brites, C
   Monteiro-Cunha, JP
AF Souza, Juliana Sacramento M.
   Silva Junior, Jailton J.
   Brites, Carlos
   Monteiro-Cunha, Joana P.
TI Molecular and geographic characterization of hiv-1 bf recombinant
   viruses
SO VIRUS RESEARCH
LA English
DT Article
DE HIV; BF; Recombination; CRF; Genome
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SAO-PAULO; SUBTYPE-B; HOT-SPOT; FREQUENCY;
   VARIABILITY; RESISTANCE; MUTATIONS; DIVERSITY; NORTHEAST
AB The Human Immunodeficiency Virus Type 1 (HIV-1) presents a wide genetic variability, which is represented by four groups, nine subtypes of group M and several recombinant forms. Among these, the BF recombinants have been distinguished by a high global dispersion and an increase in number and diversity. To date, 15 BF Circulating Recombinant Forms (CRFs) and diverse BF Unique Recombinant Forms (URFs) have been described. In Brazil, nine CRF_BF have been identified. The aim of this work was to perform molecular and geographic characterization of HIV-1 BF recombinant strains. Near full-length genomes of 265 BF recombinant viruses were collected from public databases and molecular analyses were performed. These sequences were originally retrieved between 1993-2006 and isolated from 16 countries (51.3% from Brazil). Diagnostic's year analysis showed that BF recombinants circulate in Brazil since at least 1985. Most sequences displayed recombination in the pol (84.9%), gag (69.3%) and env (51.4%) regions. The subtype B predominated in all accessory and regulatory genes, except in vif, in which the F subtype was predominant (40.4%). Twelve regions with a recombination rate higher than 10% were identified, especially one region inside p24 gene (1359-1397) whose recombination was present in more than 30% of the sequences. Coreceptor usage prediction during viral entry showed that BF recombinants preferentially use CCR5 (67.2%) and the most frequent tetrapeptides found in the V3 loop were GPGR (47.9%) and GPGQ (21.1%). The frequency of X4/dual viruses was lower amongst F subtype (25.8%) V3 sequences, compared with B subtype (43%). In addition, mutations associated with intermediate or high resistance levels to PI (10.6%), NRTI (15.0%), NNRTI (14.0%) and INSTI (2.6%) were identified. The great diversity of the recombination patterns evidences that the recombination between the subtypes B and F is frequent, reflecting a probable high rate of dual infection and the acquisition of advantageous characteristics for viral fitness.
C1 [Souza, Juliana Sacramento M.; Silva Junior, Jailton J.; Monteiro-Cunha, Joana P.] Univ Fed Bahia, Inst Ciencias Saude, Dept Bioquim & Biofis, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Lab Pesquisa Infectol, Complex Hosp Prof Edgard Santos, Salvador, BA, Brazil.
RP Monteiro-Cunha, JP (corresponding author), Univ Fed Bahia, Dept Bioquim & Biofis, Av Reitor Miguel Calmon S-N, Salvador, BA, Brazil.
EM joana.monteiro@ufba.br
OI sacramento mota de souza, Juliana/0000-0002-7378-2029
FU Fundacao de Amparo a Pesquisa do Estado da Bahia
FX Fundacao de Amparo a Pesquisa do Estado da Bahia.
CR An WF, 2002, J VIROL, V76, P7897, DOI 10.1128/JVI.76.15.7897-7902.2002
   Aulicino PC, 2007, J VIROL, V81, P427, DOI 10.1128/JVI.01403-06
   Bello G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-22
   Binka M, 2012, J VIROL, V86, P49, DOI 10.1128/JVI.06082-11
   Bruselles A, 2009, AIDS RES HUM RETROV, V25, P937, DOI 10.1089/aid.2009.0083
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Cuevas MT, 2010, AIDS RES HUM RETROV, V26, P1019, DOI 10.1089/aid.2010.0018
   da Costa C. M, 2016, AIDS RES HUM RETROV, DOI [10.1089/aid.2016.0044.00, DOI 10.1089/AID.2016.0044.00]
   Reis MND, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178578
   De Candia C, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-259
   de Oliveira CM, 2008, ARCH VIROL, V153, P1799, DOI 10.1007/s00705-008-0178-7
   Dykes C, 2004, VIROLOGY, V326, P262, DOI 10.1016/j.virol.2004.02.033
   Ferraro GA, 2001, AIDS RES HUM RETROV, V17, P1241, DOI 10.1089/088922201750461294
   Galetto R, 2006, J BIOL CHEM, V281, P2711, DOI 10.1074/jbc.M505457200
   Galetto R, 2004, J BIOL CHEM, V279, P36625, DOI 10.1074/jbc.M405476200
   Guimara M. L, 2007, INFECT GENET EVOL, V7, P263, DOI [10.1016/j.meegid.2006.11.002, DOI 10.1016/J.MEEGID.2006.11.002]
   Guimaraes ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141372
   Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc
   Huang W, 2007, J VIROL, V81, P7885, DOI 10.1128/JVI.00218-07
   Iglesias-Sanchez MJ, 2002, VIROLOGY, V304, P392, DOI 10.1006/viro.2002.1657
   Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000
   Jia L, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0616-1
   Jiang XQ, 2010, NAT STRUCT MOL BIOL, V17, P955, DOI 10.1038/nsmb.1861
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   KELLAM P, 1995, J VIROL, V69, P669, DOI 10.1128/JVI.69.2.669-674.1995
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lau KA, 2013, INFECT DIS REP, V5, P15, DOI 10.4081/idr.2013.s1.e4
   Leal E, 2008, VIROLOGY, V381, P222, DOI 10.1016/j.virol.2008.08.029
   Leal E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011833
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   Delicado TL, 2016, J ANTIMICROB CHEMOTH, V71, P362, DOI 10.1093/jac/dkv333
   Melo FL, 2012, AIDS RES HUM RETROV, V28, P882, DOI 10.1089/aid.2011.0123
   Minin VN, 2007, GENETICS, V175, P1773, DOI 10.1534/genetics.106.066258
   Monteiro JP, 2009, J MED VIROL, V81, P391, DOI 10.1002/jmv.21414
   Monteiro-Cunha JP, 2011, AIDS RES HUM RETROV, V27, P623, DOI [10.1089/AID.2010.0126, 10.1089/aid.2010.0126]
   Moutouh L, 1996, P NATL ACAD SCI USA, V93, P6106, DOI 10.1073/pnas.93.12.6106
   Onafuwa-Nuga A, 2009, MICROBIOL MOL BIOL R, V73, P451, DOI 10.1128/MMBR.00012-09
   Pessoa R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152499
   Pessoa R, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00386-14
   Raffi F, 2015, AIDS, V29, P167, DOI 10.1097/QAD.0000000000000519
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Sanabani SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062552
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Sanjuan R, 2016, CELL MOL LIFE SCI, V73, P4433, DOI 10.1007/s00018-016-2299-6
   Santoro Maria Mercedes, 2013, ISRN Microbiol, V2013, P481314, DOI 10.1155/2013/481314
   Streeck H, 2008, J EXP MED, V205, P1789, DOI 10.1084/jem.20080281
   Thomson MM, 2002, J GEN VIROL, V83, P107, DOI 10.1099/0022-1317-83-1-107
   Tongo M, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey015
   Trifinopoulos J, 2016, NUCLEIC ACIDS RES, V44, pW232, DOI 10.1093/nar/gkw256
   Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541
   Wensing AM, 2017, TOP ANTIVIR MED, V24, P132
   Zhang ZL, 2016, J VIROL, V90, P10193, DOI 10.1128/JVI.01497-16
NR 52
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD SEP
PY 2019
VL 270
AR 197650
DI 10.1016/j.virusres.2019.197650
PG 10
WC Virology
SC Virology
GA IU5TL
UT WOS:000483650100002
PM 31279829
DA 2020-12-01
ER

PT J
AU Carvalho, A
   Brites, C
   Mochida, G
   Ventura, P
   Fernandes, A
   Lage, ML
   Taguchi, T
   Brandi, I
   Silva, A
   Franceschi, G
   Lucena, P
   Lucena, R
AF Carvalho, Alessandra
   Brites, Carlos
   Mochida, Ganeshwaran
   Ventura, Paloma
   Fernandes, Adriana
   Lage, Maria Lucia
   Taguchi, Thnia
   Brandi, Ivar
   Silva, Alfredo
   Franceschi, Giulia
   Lucena, Pedro
   Lucena, Rita
TI Clinical and neurodevelopmental features in children with cerebral palsy
   and probable congenital Zika
SO BRAIN & DEVELOPMENT
LA English
DT Article
DE Zika virus; Cerebral palsy; Neurodevelopment
ID VIRUS-INFECTION; INFANTS; BRAZIL; OUTCOMES; GROWTH; BORN; AGE
AB Objective: To describe the neurological and neurodevelopmental features at 1 year of age in children with cerebral palsy (CP) related to probable congenital Zika (CZ), followed in a referral neurorehabilitation hospital.
   Methods. - Data on 82 children with CP associated with probable CZ, who consecutively attended the neurodevelopmental and neurological assessment around one year of age, were collected. For neurodevelopmental evaluation, Bayley-III Scales of Infant and Toddler Development was used. Descriptive statistical analysis was performed.
   Results: The children were admitted into the rehabilitation program at a young age (mean age: 4.8 months, SD 3.1), followed beyond the first year of life (mean age of follow up: 13.2 months, SD 2.1), born to young mothers (mean age: 28.1 years, SD 5.9), in their first pregnancy (62.2%). The majority had severe congenital microcephaly (62.0%), spastic CP (96.3%), epilepsy (63.4%), absent expected postural reactions (93.2%), abnormal persistence of primitive reflexes (94.7%), and severe neuroimaging abnormalities, predominantly calcifications (97.6%). Extremely low performances on cognitive (95.1%), language (97.6%) and motor (97.6%) developmental composite scores were observed. There was a correlation between the cognitive score with the birth head circumference (HC) (r = 0.3, p = 0.01) and with the follow up HC (r = 0.4, p < 0.01), as well as between the follow up HC with the motor score (r = 0.2, p = 0.03).
   Conclusion: Congenital Zika may be associated with a severe form of CP, mainly bilateral spastic, with a severe global neurodevelopmental impairment and early signs of a poor prognosis for independent walking. Head circumference may be a prognostic marker among those children. These results may help establish goals for the rehabilitation program and identify priority health services. (C) 2019 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
C1 [Carvalho, Alessandra; Ventura, Paloma; Fernandes, Adriana; Taguchi, Thnia; Brandi, Ivar; Silva, Alfredo] SARAH Network Rehabil Hosp, Salvador, BA, Brazil.
   [Brites, Carlos; Lage, Maria Lucia; Franceschi, Giulia; Lucena, Rita] Univ Fed Bahia, Salvador, BA, Brazil.
   [Mochida, Ganeshwaran] Boston Childrens Hosp, Boston, MA USA.
   [Mochida, Ganeshwaran] Harvard Med Sch, Boston, MA 02115 USA.
   [Mochida, Ganeshwaran] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Lucena, Pedro] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil.
RP Carvalho, A (corresponding author), SARAH Salvador Hosp, Av Tancredo Neves 2782, BR-41820900 Salvador, BA, Brazil.
EM 13110@sarah.br
RI Lucena, Rita/L-9842-2013
OI Lucena, Rita/0000-0002-6190-9168; Mochida,
   Ganeshwaran/0000-0001-7912-4097; Lucena, Pedro/0000-0003-1148-7806
CR Abramov DM, 2018, NEUROLOGY, V90, pE606, DOI 10.1212/WNL.0000000000004974
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   BLECK EE, 1975, DEV MED CHILD NEUROL, V17, P18
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Carvalho AL, 2019, CLIN MICROBIOL INFEC, V25, P524, DOI 10.1016/j.cmi.2018.12.021
   Cortes MS, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2018.01.012
   Petribu NCD, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4188
   Melo ASD, 2016, JAMA NEUROL, V73, P1407, DOI 10.1001/jamaneurol.2016.3720
   del Campo M, 2017, AM J MED GENET A, V173, P841, DOI 10.1002/ajmg.a.38170
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Granild-Jensen JB, 2015, DEV MED CHILD NEUROL, V57, P931, DOI 10.1111/dmcn.12760
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Kadkhoda K, 2017, DIAGN MICR INFEC DIS, V88, P233, DOI 10.1016/j.diagmicrobio.2017.04.002
   Leal MC, 2016, MMWR-MORBID MORTAL W, V65, P917, DOI 10.15585/mmwr.mm6534e3
   Lustig Y, 2018, J CLIN VIROL, V99-100, P31, DOI 10.1016/j.jcv.2017.12.007
   Madaschi Vanessa, 2016, Paidéia (Ribeirão Preto), V26, P189, DOI 10.1590/1982-43272664201606
   Meneses JD, 2017, CLIN INFECT DIS, V64, P1302, DOI 10.1093/cid/cix166
   Ministerio da Saude Monitoramento dos casos de dengue, 2018, B EPIDEMIOLOGICO, V49, P1
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   da Silva AAM, 2016, EMERG INFECT DIS, V22, P1953, DOI 10.3201/eid2211.160956
   Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x
   Pan American Health Organization World Health Organization, 2016, NEUR SYNDR CONG AN Z, V8
   Pessoa A, 2018, PEDIATRICS, V141, pS167, DOI 10.1542/peds.2017-2038F
   Rice ME, 2018, MMWR-MORBID MORTAL W, V67, P858, DOI 10.15585/mmwr.mm6731e1
   Rodo C, 2017, CLIN MICROBIOL INFEC, V24, P2017
   Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x
   Rosman NP, 2011, PEDIATRICS, V127, P665, DOI 10.1542/peds.2010-1576
   Satterfield-Nash A, 2017, MMWR-MORBID MORTAL W, V66, P1347, DOI 10.15585/mmwr.mm6649a2
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
   Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6
NR 35
TC 12
Z9 12
U1 2
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0387-7604
EI 1872-7131
J9 BRAIN DEV-JPN
JI Brain Dev.
PD AUG
PY 2019
VL 41
IS 7
BP 587
EP 594
DI 10.1016/j.braindev.2019.03.005
PG 8
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA IY1EA
UT WOS:000486133200003
PM 30914212
DA 2020-12-01
ER

PT J
AU Pedroso, C
   Fischer, C
   Feldmann, M
   Sarno, M
   Luz, E
   Moreira-Soto, A
   Cabral, R
   Netto, EM
   Brites, C
   Kummerer, BM
   Drexler, JF
AF Pedroso, Celia
   Fischer, Carlo
   Feldmann, Marie
   Sarno, Manoel
   Luz, Estela
   Moreira-Soto, Andres
   Cabral, Renata
   Netto, Eduardo Martins
   Brites, Carlos
   Kummerer, Beate M.
   Drexler, Jan Felix
TI Cross-Protection of Dengue Virus Infection against Congenital Zika
   Syndrome, Northeastern Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID ANTIBODY-DEPENDENT ENHANCEMENT; RIO-DE-JANEIRO; DISEASE; TYPE-3; STATE
AB The Zika virus outbreak in Latin America resulted in congenital malformations, called congenital Zika syndrome (CZS). For unknown reasons, CZS incidence was highest in northeastern Brazil; one potential explanation is that dengue virus (DENV)-mediated immune enhancement may promote CZS development. In contrast, our analyses of historical DENV genomic data refuted the hypothesis that unique genome signatures for northeastern Brazil explain the uneven dispersion of CZS cases. To confirm our findings, we performed serotype-specific DENV neutralization tests in a case-control framework in northeastern Brazil among 29 Zika virus-seropositive mothers of neonates with CZS and 108 Zika virus-seropositive control mothers. Neutralization titers did not differ significantly between groups. In contrast, DENV seroprevalence and median number of neutralized serotypes were significantly lower among the mothers of neonates with CZS. Supported by model analyses, our results suggest that multitypic DENV infection may protect from, rather than enhance, development of CZS.
C1 [Pedroso, Celia; Sarno, Manoel; Luz, Estela; Cabral, Renata; Netto, Eduardo Martins; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
   [Fischer, Carlo; Moreira-Soto, Andres; Drexler, Jan Felix] Charite Univ Med Berlin, Berlin, Germany.
   [Fischer, Carlo; Moreira-Soto, Andres; Drexler, Jan Felix] Free Univ Berlin, Berlin, Germany.
   [Fischer, Carlo; Moreira-Soto, Andres; Drexler, Jan Felix] Humbolt Univ Berlin, Berlin, Germany.
   [Fischer, Carlo; Moreira-Soto, Andres; Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [Feldmann, Marie; Kummerer, Beate M.] Univ Bonn, Med Ctr, Bonn, Germany.
   [Kummerer, Beate M.; Drexler, Jan Felix] Sechenov Univ, German Ctr Infect Res, Moscow, Russia.
   [Drexler, Jan Felix] Sechenov Univ, Martsinovsky Inst Med Parasitol Trop & Vector Bor, Moscow, Russia.
RP Drexler, JF (corresponding author), Charite Univ Med Berlin, Inst Virol, Helmut Ruska Haus Charite Pl 1, D-10098 Berlin, Germany.
EM felix.drexler@charite.de
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; Fischer, Carlo/0000-0001-9163-2406;
   Moreira-Soto, Andres/0000-0002-9224-5157
FU German Centre for Infection Research through the ZIKApath project, an
   intramural funding program at the University of Bonn; European Union's
   Horizon 2020 research and innovation program through the ZIKAlliance
   project [734548]
FX This work was supported by the German Centre for Infection Research
   through the ZIKApath project, an intramural funding program at the
   University of Bonn, and the European Union's Horizon 2020 research and
   innovation program through the ZIKAlliance project (grant agreement no.
   734548). The data used are part of the thesis of M.F.
CR Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   [Anonymous], 1997, Rev Panam Salud Publica, V1, P68
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Butler D, 2016, NATURE, V530, P399, DOI 10.1038/530398a
   Campos MC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201452
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Collins M, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.82
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   Delgado FG, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090480
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Gordon A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002726
   Grifoni A, 2017, J VIROL, V91, DOI [10.1128/JVI.01469-17, 10.1128/jvi.01469-17]
   Gu LJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191681
   Guzman MG, 2012, INT J INFECT DIS, V16, pE198, DOI 10.1016/j.ijid.2011.09.026
   Halstead SB, 2010, LANCET INFECT DIS, V10, P712, DOI 10.1016/S1473-3099(10)70166-3
   Hermanns K, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0199-6
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Katzelnick LC, 2017, VACCINE, V35, P4659, DOI 10.1016/j.vaccine.2017.07.045
   Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Kurolt IC, 2013, CLIN MICROBIOL INFEC, V19, pE163, DOI 10.1111/1469-0691.12104
   Mayor S, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3492
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Moreira-Soto A, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2018.01.026
   Moreira-Soto A, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00278-18
   Moreira-Soto Andres, 2017, J Infect Dis, V216, P1501, DOI 10.1093/infdis/jix539
   Moureau G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117849
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   NOGUEIRA RMR, 1993, EPIDEMIOL INFECT, V111, P163, DOI 10.1017/S0950268800056788
   Nogueira RMR, 2001, MEM I OSWALDO CRUZ, V96, P925, DOI 10.1590/S0074-02762001000700007
   OhAinle M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003084
   Olkowski S, 2013, J INFECT DIS, V208, P1026, DOI 10.1093/infdis/jit273
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Pettersson JHO, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0082-5
   de Figueiredo RMP, 2008, EMERG INFECT DIS, V14, P667, DOI 10.3201/eid1404.071185
   Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42
   Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0
   Ribeiro GS, 2018, LANCET GLOB HEALTH, V6, pE140, DOI 10.1016/S2214-109X(17)30496-5
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Salles TS, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2830-8
   Saron WAA, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar4297
   SCHATZMAYR H G, 1986, Memorias do Instituto Oswaldo Cruz, V81, P245, DOI 10.1590/S0074-02761986000200019
   Sullivan KM, 2009, PUBLIC HEALTH REP, V124, P471, DOI 10.1177/003335490912400320
   Uno N, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0168-0
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
NR 50
TC 18
Z9 18
U1 0
U2 5
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2019
VL 25
IS 8
BP 1485
EP 1493
DI 10.3201/eid2508.190113
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IJ5MF
UT WOS:000475946500006
PM 31075077
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Dutra, BS
   Ledo, AP
   Lins-Kusterer, L
   Luz, E
   Prieto, IR
   Brites, C
AF Dutra, Brenda Soares
   Ledo, Ana Paula
   Lins-Kusterer, Liliane
   Luz, Estela
   Prieto, Indira Rodriguez
   Brites, Carlos
TI Changes health-related quality of life in HIV-infected patients
   following initiation of antiretroviral therapy: a longitudinal study
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Health-related quality of life; Antiretroviral Therapy; HIV; Patient
   Reported Outcome Measures
ID PEOPLE; RELIABILITY; COEFFICIENT; ERA
AB Background: Several tools have been developed to evaluate HIV health-related quality of life (HRQoL) during and after antiretroviral therapy (ART). Few longitudinal studies evaluated the effect of ART on the quality of life of HIV patients.
   Objective: To evaluate changes in HRQoL in HIV-infected individuals one year after initiating ART.
   Methods: A prospective study was conducted from May 2016 to July 2018. Data on clinical and sociodemographic characteristics of 91 HIV-infected patients were collected prior to initiation of ART and one year thereafter. Demographic and clinical data were collected and the questionnaires 36-item Short Form Health Survey (SF-36) and HIV/AIDS-targeted quality of life (HAT-QoL) were administered in both periods. Asymptomatic individuals, aged >= 18 years, were included in the study. Patients who discontinued treatment were excluded. The association between predictors of physical and mental HRQoL was analyzed by multiple linear regression analysis.
   Results: Patients were predominantly male (78.0%), mean age 35.3 +/- 10.7 years, with no stable relationship (80.2%), and no comorbidities (73.6%). Most of the SF-36 domains improved after one year, particularly Physical Function (p = 0.0001), General Health (p = 0.0001), Social Functioning (p = 0.0001), Mental Health (p = 0.001), and Mental Component Summary (p = 0.004). HAT-QoL domains improved in the Overall Function (p = 0.0001), Life Satisfaction (p = 0.0001), Provider Trust (p = 0.001), and Sexual Function (p = 0.0001) domains. Sex (p = 0.032), age (p = 0.001), income (p = 0.007), and stable relationship (p = 0.004) were good predictors of the Physical Component Summary. Sex (p = 0.002) and stable relationship (p = 0.038) were good predictors of the Mental Component Summary. SF-36 and HAT-QoL scales presented strong correlations, except for Medication Concerns (0.15-0.37), HIV Mastery (0.18-0.38), Disclosure Worries (-0.15 to 0.07), and Provider Trust (-0.07 to 0.15).
   Conclusions: ART improved HRQoL after one year of use. The HAT-QoL and SF-36 correlated well and are good tools to evaluate HRQoL in HIV-infected patients on ART. (C) 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Dutra, Brenda Soares; Ledo, Ana Paula; Prieto, Indira Rodriguez] Univ Fed Bahia, Escola Med, Salvador, BA, Brazil.
   [Lins-Kusterer, Liliane; Luz, Estela; Brites, Carlos] Complexo Hosp Univ Prof Edgard Santos, Lab Invest Doencas Infecciosas, Salvador, BA, Brazil.
RP Lins-Kusterer, L (corresponding author), Univ Fed Bahia, Edgard Santos Fed Univ Hosp, LAPI Res Lab Infect Dis, Rua Augusto Viana S-N, BR-40110060 Salvador, BA, Brazil.
EM brendasdutra@hotmail.com; anapaulaledo3@gmail.com; liliane.lins@ufba.br;
   eluz5@yahoo.com.br; indira.rodriguez70@gmail.com; crbrites@gmail.com
RI Lins-Kusterer, Liliane/Q-5191-2019
OI Lins-Kusterer, Liliane/0000-0003-3736-0002
CR Bhatia M S, 2014, J Clin Diagn Res, V8, pWC01, DOI 10.7860/JCDR/2014/7725.4927
   BOZZETTE SA, 1994, MED CARE, V32, P716, DOI 10.1097/00005650-199407000-00005
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Clayson DJ, 2006, PHARMACOECONOMICS, V24, P751, DOI 10.2165/00019053-200624080-00003
   Cooper V, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0778-6
   den Daas C, 2019, QUAL LIFE RES, V28, P2685, DOI 10.1007/s11136-019-02203-y
   EBRAHIM S, 1995, SOC SCI MED, V41, P1383, DOI 10.1016/0277-9536(95)00116-O
   Emuren L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178953
   GRAU JM, 1993, ANN NEUROL, V34, P206, DOI 10.1002/ana.410340217
   Hays RD, 2000, AM J MED, V108, P714, DOI 10.1016/S0002-9343(00)00387-9
   Hays RD, 2008, EPIDEMIOLOGY AND DEM, P195
   Holmes WC, 1998, MED CARE, V36, P138, DOI 10.1097/00005650-199802000-00004
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Janssen MAM, 2015, AIDS, V29, P2139, DOI 10.1097/QAD.0000000000000824
   Karimi M, 2016, PHARMACOECONOMICS, V34, P645, DOI 10.1007/s40273-016-0389-9
   Langebeek N, 2017, AIDS, V31, P1471, DOI 10.1097/QAD.0000000000001511
   Lins L, 2016, SAGE OPEN MED, V4, DOI 10.1177/2050312116671725
   Liu CL, 2006, QUAL LIFE RES, V15, P941, DOI 10.1007/s11136-005-5913-x
   Liu CL, 2006, JAIDS-J ACQ IMM DEF, V42, P470, DOI 10.1097/01.qai.0000225730.79610.61
   Mahy M, 2010, SEX TRANSM INFECT, V86, pI67, DOI 10.1136/sti.2010.046060
   Miller J, 2003, HIV Med, V4, P293
   Miners A, 2014, LANCET HIV, V1, pE32, DOI 10.1016/S2352-3018(14)70018-9
   Ming ZQ, 2014, J ASSOC NURSE AIDS C, V25, P603, DOI 10.1016/j.jana.2014.04.003
   Mrus JM, 2005, QUAL LIFE RES, V14, P479, DOI 10.1007/s11136-004-4693-z
   Mukaka MM, 2012, MALAWI MED J, V24, P69
   Nakagawa F, 2012, AIDS, V26, P335, DOI 10.1097/QAD.0b013e32834dcec9
   Nunnally JC, 1994, PSYCHOMETRIC THEORY
   Onyebuchi-Iwudibia O, 2014, AIDS CARE, V26, P653, DOI 10.1080/09540121.2013.844761
   Oparah Azuka C, 2013, Value Health Reg Issues, V2, P254, DOI 10.1016/j.vhri.2013.07.004
   Ostrow DE, 2002, AIDS, V16, P775, DOI 10.1097/00002030-200203290-00013
   Reis RK, 2011, TEXTO CONTEXTO ENFER, V20, P365
   Shahriar Jim, 2003, Health Qual Life Outcomes, V1, P25, DOI 10.1186/1477-7525-1-25
   Simpson D, 2004, AIDS, V18, P1403, DOI 10.1097/01.aids.0000131309.70451.fe
   Simpson KN, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-164
   Streiner DL, 2003, J PERS ASSESS, V80, P217, DOI 10.1207/S15327752JPA8003_01
   Tesfay A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/516369
   Viswanathan H, 2005, QUAL LIFE RES, V14, P935, DOI 10.1007/s11136-004-3507-7
   Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008
   Wu AW, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-42
   Wu AW, 1991, INT C AIDS, V7, P348
NR 40
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2019
VL 23
IS 4
BP 211
EP 217
DI 10.1016/j.bjid.2019.06.005
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA JA4SR
UT WOS:000487823900001
PM 31344351
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Barreto, RG
   Brites, C
AF Barreto, Raphael Gusmao
   Brites, Carlos
TI Low frequency of hypersensitivity reactions to abacavir in HIV infected
   patients in a referral center in Bahia, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Hypersensitivity; Antiretroviral; HIV; Abacavir
ID HLA-B-ASTERISK-5701
AB Abacavir can cause a multi-systemic hypersensitivity reaction (HSR) in 5-8% of the patients, which is related to HLA-B*57-01 allele. In Brazil, the HLA-B*57-01 screening test became available only in March 2018, several years after abacavir was in use. In this retrospective study we reviewed medical charts of all patients receiving an abacavir-containing regimen to evaluate the frequency of HSR in patients followed at a referral center in Salvador, Brazil. A total of 192 patients who received abacavir were identified, most male (67.1%), black or racially mixed (77.8%), and having diagnosis of a previous AIDS defining conditions (83.7%). Only one patient developed HSR (incidence: 0.52%). The main reasons for abacavir-containing antiretroviral therapy discontinuation were virological failure (28%), adverse effects to other components of the regimen (25%), and simplification of therapy (16%). The low incidence of HSR to abacavir does not support the use of HLA-B*57-01 screening test, in Salvador, Brazil. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Sociedade Brasileira de Infectologia.
C1 [Barreto, Raphael Gusmao; Brites, Carlos] Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR [Anonymous], 1998, ZIAGEN BUL
   Crovella S, 2011, CLINICS, V66, P1485, DOI 10.1590/S1807-59322011000800030
   European Medicines Agency, 2016, EUR PUBL ASS REP EPA
   Hetherington S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6
   Instituto Brasileiro de Geografia e Estatistica (IBGE), 2007, EST SOC AN ESP REF M
   Kapoor R, 2015, PHARMACOGENET GENOM, V25, P60, DOI 10.1097/FPC.0000000000000107
   Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X
   Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135
   Ministerio da Sande, 2018, 52018COVIGCGVPDIAHVS
   Ministerio da Satide, 2017, PROT CLIN DIR TER MA
   Rodriguez-Novoa S, 2008, PHARMACOGENOMICS, V9, P1531, DOI 10.2217/14622416.9.10.1531
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2019
VL 23
IS 4
BP 268
EP 270
DI 10.1016/j.bjid.2019.06.003
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA JA4SR
UT WOS:000487823900008
PM 31374183
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Brazier, E
   Maruri, F
   Duda, SN
   Tymejczyk, O
   Wester, CW
   Somi, G
   Ross, J
   Freeman, A
   Cornell, M
   Poda, A
   Musick, BS
   Zhang, F
   Althoff, KN
   Mugglin, C
   Kimmel, AD
   Yotebieng, M
   Nash, D
   Karminia, A
   Sohn, AH
   Allen, D
   Bloch, M
   Boyd, S
   Brown, K
   Costa, J
   Donohue, W
   Gunathilake, M
   Hoy, J
   MacRae, K
   Moore, R
   Roth, N
   Rowling, D
   Silvers, J
   Smith, DJ
   Sowden, D
   Templeton, D
   Varma, R
   Woolley, I
   Youds, D
   Meng, SC
   Vannary, B
   Chan, YT
   Lam, W
   Lee, MP
   Ning, H
   Pansy, YPC
   Zhang, FJ
   Kumarasamy, N
   Pujari, S
   Kurniati, N
   Merati, TP
   Muktiarti, D
   Parwata, WS
   Ratni, M
   Sukmawati, NMDD
   Vedaswari, DSPD
   Wati, KDK
   Yunihastuty, E
   Tanuma, J
   Mills, G
   Raymond, N
   Ditangco, R
   Papa, OS
   Tek, NO
   Ah-neez
   Azwa, R
   Dato
   Daud, F
   Juin, WK
   Kamarulzaman, AB
   Khairulddin, N
   Li, CM
   Moy, FS
   Shah, RI
   Shyan, WP
   Sim, B
   Thahira, JM
   Tuang, KM
   Yusoff, N
   Choi, JY
   Chan, YJ
   Huang, CS
   Wong, WW
   Avihingsanon, A
   Chokephaibulkit, K
   Hansudewechakul, R
   Khumcha, B
   Khusuwan, S
   Kiertiburanakul, S
   Lumbiganon, P
   Maleesatharn, A
   Praparattanapan, J
   Puthanakit, T
   Sricharoenchai, S
   Sudjaritruk, T
   Watanaporn, S
   An, VT
   Cuong, DD
   Hang, BT
   Huy, BV
   Quy, DT
   Van, LN
   Baragunzwa, A
   Gakima, D
   Ingabire, G
   Kankinoi, F
   Manyundo, RS
   Misago, C
   Nahimana, T
   Nimbona, P
   Ntirampeba, F
   Twizere, C
   Ajeh, R
   Djenabou, A
   Dzudie, A
   Ewanoge, AN
   Tchassem, E
   Bampapa, T
   Lelo, P
   Kitetele, F
   Paul, M
   Tytyna, A
   Akolbout, M
   Bitsindou, P
   Diafouka, M
   Mafoua, A
   Mahinga, N
   Moudila, E
   Moutoula, A
   Ndala, U
   Nsonde, DM
   Ayinkamiye, J
   Dusabe, C
   Hakizimana, T
   Mbaraga, G
   Mukamana, J
   Mukantwali, S
   Munyaneza, A
   Murangwa, A
   Musenguwera, JC
   Ngutegure, MI
   Ntarambirwa, F
   Nyiransabimana, D
   Sinayobye, JD
   Tuyishimire, Y
   Uwamahoro, O
   Uwamahoro, O
   Viateur, H
   Vincent, S
   Kuhn, YY
   Musick, B
   Rodriguez, I
   Wools-Kaloustian, K
   Yiannoutsos, C
   Akajoroit, E
   Ariya, P
   Atsimale, M
   Barua, Z
   Busaka, O
   Bukusi, E
   Chebor, V
   Chemweno, T
   Chirchir, J
   Esendi, LDS
   Fwamba, A
   Mmella, A
   Githumbi, E
   Hussein, MN
   Kandie, X
   Kemunto, M
   Khaemba, E
   Kipchumba, M
   Koech, E
   Kosgei, C
   Laundrick, B
   Merongo, R
   Mochotto, P
   Munyisi, C
   Ndakalu, L
   Ochieng, WO
   Odalo, P
   Okumu, W
   Omari, L
   Omondi, A
   Osia, L
   Owino, M
   Oyoo, M
   Pepela, D
   Rono, M
   Simon, O
   Tenge, A
   Too, M
   Toto, M
   Towett, C
   Wawire, K
   Kimambo, M
   Kinyota, E
   Lyamuya, R
   Mathias, J
   Mfuko, AR
   Michael, D
   Ngonyani, KZ
   Nyaga, C
   Somi, GR
   Urassa, MS
   Batte, J
   Bwana, MB
   Castelnuovo, B
   Kanyesigye, M
   Kisakye, A
   Nalugoda, F
   Semuwemba, H
   Ssali, J
   Ssemakadde, M
   Castilho, J
   Cesar, C
   de Alencastro, PR
   Barbosa, EL
   Brites, C
   Caricol, R
   do Carmo, FB
   Coelho, LE
   Escuder, MM
   Estevam, DL
   Ferreira, FGF
   Goncalves, A
   Gouvea, ADB
   Ikeda, MLR
   Kalichman, AO
   Machado, DM
   Queiroz, S
   Souza, RD
   Succi, RC
   Trindade, KV
   Tupinambas, U
   Wolff, M
   Rouzier, V
   Padgett, D
   Crabtree, B
   Martin, CEV
   Mejia, F
   Chang, B
   Done, B
   Gabe, L
   Gill, J
   Gough, K
   Howlett, G
   Klein, M
   Latendre-Paquette, J
   Leung, V
   MacPhee, P
   MacPherson, P
   Maharaj, R
   Medina, LC
   Page, S
   Pexos, C
   Rachlis, A
   Salters, K
   Sterling, S
   Boswell, S
   Burkholder, G
   Cesteros, G
   Chagaris, K
   Franklin, R
   Freeman, A
   Fuhrer, J
   Gilbert, CL
   Goetz, M
   Grasso, C
   Horberg, M
   Hunter-Mellado, RF
   Kell, R
   Kitahata, M
   Klein, D
   Levine, K
   Marconi, V
   Mathews, C
   Mayor, AM
   McGowan, C
   Moore, R
   Napravnik, S
   Novak, R
   Oursler, KA
   Ramos, S
   Rodriguez, B
   Rodriguez, MC
   Silverberg, M
   Simberkoff, MS
   Varshney, M
   Ward, D
   Widick, B
   Yangco, BG
   Cornell, M
   Davies, MA
   Smith, L
   von Groote, PM
   Muhairwe, J
   Balakasi, S
   Banda, Q
   Kalepa, G
   Bello, A
   Bulla, JW
   Chigeda, M
   Chikaphupha, J
   Chikwekwere, F
   Kachoka, J
   Kapito, A
   Katondo, AN
   Kumwenda, M
   Labein, FP
   Magombo, R
   Malumbe, B
   Makuwira, I
   Marico, P
   Masangale, B
   Mchiela, A
   Midian, D
   Phiri, K
   Tambe, M
   Thomas, B
   Thomson, C
   Hector, J
   Cross, A
   Dlamini, S
   Eley, B
   Euvrard, J
   Fatti, G
   Hilderbrand, K
   Hsiao, M
   Mpye, M
   Prozesky, H
   Reubenson, G
   Rose, L
   Sawry, S
   Sibambo, N
   Technau, K
   Vinikoor, M
   Chimbetete, C
   Kamenova, K
   Balestre, E
   Leroy, V
   Malasteste, K
   Djimon, MZ
   D'Almeida, M
   Hounhoui, G
   Assogba, M
   Poda, A
   Zoungrana, J
   Yameogo, I
   Tapsoba, A
   Abdelh, S
   Bosse, CA
   Diabate, M
   Eboua, TKF
   Folquet, MA
   Hawelander, D
   Konate, M
   Kouakou, K
   Lambert, D
   Minga, AK
   N'gbeche, MS
   Tanon, A
   Yao, A
   Renner, L
   N'Diaye, C
   Berthe, MA
   Seydi, M
   Tine, J
   Elom, TO
   Kariylare, B
   Patassi, A
AF Brazier, Ellen
   Maruri, Fernanda
   Duda, Stephany N.
   Tymejczyk, Olga
   Wester, C. William
   Somi, Geoffrey
   Ross, Jeremy
   Freeman, Aimee
   Cornell, Morna
   Poda, Armel
   Musick, Beverly S.
   Zhang, Fujie
   Althoff, Keri N.
   Mugglin, Catrina
   Kimmel, April D.
   Yotebieng, Marcel
   Nash, Denis
   Karminia, Azar
   Sohn, Annette H.
   Allen, Debbie
   Bloch, Mark
   Boyd, Susan
   Brown, Katherine
   Costa, Jess
   Donohue, William
   Gunathilake, Manoji
   Hoy, Jennifer
   MacRae, Karen
   Moore, Richard
   Roth, Norman
   Rowling, Diane
   Silvers, Julie
   Smith, David J.
   Sowden, David
   Templeton, David
   Varma, Rick
   Woolley, Ian
   Youds, David
   Meng, Somanithd Chhay
   Vannary, Bun
   Chan, Yun Ting
   Lam, Wilson
   Lee, Man Po
   Ning, Han
   Pansy, Yu Po Chu
   Zhang, Fujie
   Kumarasamy, N.
   Pujari, Sanjay
   Kurniati, Nia
   Merati, Tuti Parwati
   Muktiarti, Dina
   Parwata, Wayan Sandhi
   Ratni, Made
   Sukmawati, Ni Made Dewi Dian
   Vedaswari, Dian Sulistya Putu Diah
   Wati, Ketut Dewi Kumara
   Yunihastuty, Evy
   Tanuma, Junko
   Mills, Graham
   Raymond, Nigel
   Ditangco, Rossana
   Papa, Ohnmar Seinn
   Tek, Ng Oon
   Dr Ah-neez
   Azwa, Raja
   Dato
   Daud, Fauziah
   Juin, Wong Ke
   Kamarulzaman, Adeeba Binti
   Khairulddin, Nik
   Li, Chong Meng
   Moy, Fong Siew
   Shah, Raja Iskandar
   Shyan, Wong Peng
   Sim, Benedict
   Thahira, Jamal Mohamed
   Tuang, Koh Mia
   Yusoff, Nik
   Choi, Jun Yong
   Chan, Yu-Jiun
   Huang, Chih-Sheng
   Wong Wing-Wai
   Avihingsanon, Anchalee
   Chokephaibulkit, Kulkanya
   Hansudewechakul, Rawiwan
   Khumcha, Benjhawan
   Khusuwan, Suwimon
   Kiertiburanakul, Sasisopin
   Lumbiganon, Pagakrong
   Maleesatharn, Alan
   Praparattanapan, Jutarat
   Puthanakit, Thanyawee
   Sricharoenchai, Sirintip
   Sudjaritruk, Tavitiya
   Watanaporn, Suporn
   Vu Thien An
   Do Duy Cuong
   Bui Thu Hang
   Bui Vu Huy
   Du Tuan Quy
   Lam Nguyen Van
   Baragunzwa, Agathomfue
   Gakima, Devote
   Ingabire, Gloria
   Kankinoi, Floride
   Manyundo, Risase Scholastique
   Misago, Celestin
   Nahimana, Thierry
   Nimbona, Pelagie
   Ntirampeba, Felicite
   Twizere, Christella
   Ajeh, Rogers
   Djenabou, Amadou
   Dzudie, Anastase
   Ewanoge, Alice Ndelle
   Tchassem, Edmond
   Bampapa, Therese
   Lelo, Patricia
   Kitetele, Faustin
   Paul, Marie
   Tytyna, Amida
   Akolbout, Maryse
   Bitsindou, Parfait
   Diafouka, Merlin
   Mafoua, Adolphe
   Mahinga, Nadine
   Moudila, Ella
   Moutoula, Antoinette
   Ndala, Ulrich
   Nsonde, Dominique Mahambou
   Ayinkamiye, Josephine
   Dusabe, Chantal
   Hakizimana, Theogene
   Mbaraga, Gilbert
   Mukamana, Joyce
   Mukantwali, Sandrine
   Munyaneza, Athanase
   Murangwa, Anthere
   Musenguwera, J. Claude
   Ngutegure, Marie Immanculee
   Ntarambirwa, Fidele
   Nyiransabimana, Diane
   Sinayobye, Jean d'Amour
   Tuyishimire, Yvonne
   Uwamahoro, Olive
   Uwamahoro, Olive
   Viateur, Habumuremyi
   Vincent, Sugira
   Kuhn, Yee Yee
   Musick, Beverly
   Rodriguez, Israel
   Wools-Kaloustian, Kara
   Yiannoutsos, Constantin
   Akajoroit, Esinasi
   Ariya, Peter
   Atsimale, Meshack
   Barua, Zeruya
   Busaka, Oscar
   Bukusi, Elizabeth
   Chebor, Valentine
   Chemweno, Timothy
   Chirchir, John
   Esendi, Lameck Diero Sagida
   Fwamba, Aisha
   Mmella, Anne
   Githumbi, Eunice
   Hussein, Marcia Nasimiyu
   Kandie, Xavier
   Kemunto, Martha
   Khaemba, Elizabeth
   Kipchumba, Mary
   Koech, Emily
   Kosgei, Caroline
   Laundrick, Barasa
   Merongo, Ruth
   Mochotto, Patricia
   Munyisi, Consolata
   Ndakalu, Lilian
   Ochieng, William Okoth
   Odalo, Paul
   Okumu, Wicklife
   Omari, Lilian
   Omondi, Alphoce
   Osia, Lydia
   Owino, Magret
   Oyoo, Maureen
   Pepela, Doris
   Rono, Millicent
   Simon, Omar
   Tenge, Angie
   Too, Mary
   Toto, Modesta
   Towett, Cathrine
   Wawire, Kennedy
   Kimambo, Mensaria
   Kinyota, Ester
   Lyamuya, Rita
   Mathias, Julia
   Mfuko, Athuman Ramadhan
   Michael, Denna
   Ngonyani, Kapella Zacharia
   Nyaga, Charles
   Somi, G. R.
   Urassa, Mark S.
   Batte, James
   Bwana, Mwebesa Bosco
   Castelnuovo, Barbara
   Kanyesigye, Michael
   Kisakye, Alice
   Nalugoda, Fred
   Semuwemba, Haruna
   Ssali, John
   Ssemakadde, Matthew
   Castilho, Jessica
   Cesar, Carina
   de Alencastro, Paulo Ricardo
   Barbosa, Eduardo Luiz
   Brites, Carlos
   Caricol, Renata
   do Carmo, Fabiana Bononi
   Coelho, Lara Esteves
   Escuder, Maria Mercedes
   Estevam, Denize Lotufo
   Faleiro Ferreira, Flavia Gomes
   Goncalves, Alexandre
   Barbosa Gouvea, Aida de Fatima
   Rodrigues Ikeda, Maria Leticia
   Kalichman, Artur O.
   Machado, Daisy Maria
   Queiroz, Simone
   Souza, Rosa de Alencar
   Succi, Regina Celia
   Trindade, Katia Valeska
   Tupinambas, Unai
   Wolff, Marcelo
   Rouzier, Vanessa
   Padgett, Denis
   Crabtree, Brenda
   Verne Martin, Carlos Eduardo
   Mejia, Fernando
   Chang, Benny
   Done, Brenda
   Gabe, Larry
   Gill, John
   Gough, Kevin
   Howlett, Gail
   Klein, Marin
   Latendre-Paquette, Judy
   Leung, Victor
   MacPhee, Paul
   MacPherson, P.
   Maharaj, Raj
   Medina, Lorna Carrasco
   Page, Suzanne
   Pexos, Costas
   Rachlis, Anita
   Salters, Kate
   Sterling, Sherine
   Boswell, Stephen
   Burkholder, Greer
   Cesteros, Gisela
   Chagaris, Kalliope
   Franklin, Rosa
   Freeman, Aimee
   Fuhrer, Jack
   Gilbert, Cynthia L.
   Goetz, Matthew
   Grasso, Chris
   Horberg, Michael
   Hunter-Mellado, Robert F.
   Kell, Rita
   Kitahata, Mari
   Klein, Daniel
   Levine, Ken
   Marconi, Vincent
   Mathews, Christopher
   Mayor, Angel M.
   McGowan, Catherine
   Moore, Richard
   Napravnik, Sonia
   Novak, Richard
   Oursler, Kris Ann
   Ramos, Shellier
   Rodriguez, Benigno
   Rodriguez, Maria C.
   Silverberg, Michael
   Simberkoff, Michael S.
   Varshney, Mohit
   Ward, Douglas
   Widick, Barb
   Yangco, Bienvenido G.
   Cornell, Morna
   Davies, Mary-Ann
   Smith, Lilian
   von Groote, Per Maximilian
   Muhairwe, Josephine
   Balakasi, Steve
   Banda, Quietus
   Kalepa, Getrude
   Bello, Andrew
   Bulla, J. W.
   Chigeda, Maria
   Chikaphupha, Joyce
   Chikwekwere, Flora
   Kachoka, Jack
   Kapito, Allan
   Katondo, Alinafe Nathan
   Kumwenda, Molly
   Labein, Felix Phewa
   Magombo, Ronald
   Malumbe, Bridget
   Makuwira, I.
   Marico, Patricia
   Masangale, Betha
   Mchiela, Angella
   Midian, Dan
   Phiri, Kezia
   Tambe, Mary
   Thomas, Baid
   Thomson, Charles
   Hector, Jonas
   Cross, Anna
   Dlamini, Siphephelo
   Eley, Brian
   Euvrard, Jonathan
   Fatti, Geoffrey
   Hilderbrand, Katherine
   Hsiao, Marvin
   Mpye, Michael
   Prozesky, Hans
   Reubenson, Gary
   Rose, Lesley
   Sawry, Shobna
   Sibambo, Nosisa
   Technau, Karl
   Vinikoor, Michael
   Chimbetete, Cleophas
   Kamenova, Kamelia
   Balestre, Eric
   Leroy, Valeriane
   Malasteste, Karen
   Djimon, Marcel Zannou
   D'Almeida, Marcelline
   Hounhoui, Ghislaine
   Assogba, Michee
   Poda, Armel
   Zoungrana, Jacques
   Yameogo, Issouf
   Tapsoba, Achille
   Abdelh, Sidibe
   Bosse, Clarisse Amani
   Diabate, Mamoudou
   Eboua, Tanoh Kassi Francois
   Folquet, Madeleine Amorissani
   Hawelander, Denise
   Konate, Mamadou
   Kouakou, Kouadio
   Lambert, Dohoun
   Minga, Albert Kla
   N'gbeche, Marie Sylvie
   Tanon, Aristophane
   Yao, Abo
   Renner, Lorna
   N'Diaye, Clementine
   Berthe, Mme Alima
   Seydi, Moussa
   Tine, Judicael
   Elom, Takassi Ounoo
   Kariylare, Benjamin
   Patassi, Akessiwe
CA IeDEA Consortium
TI Implementation of "Treat-all" at adult HIV care and treatment sites in
   the Global IeDEA Consortium: results from the Site Assessment Survey
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; "Treat all"; antiretroviral treatment; HIV care; guideline
   implementation
ID ANTIRETROVIRAL THERAPY; RAPID INITIATION; PREVENTION; POLICY; DIAGNOSIS
AB Introduction Since 2015, the World Health Organization (WHO) has recommended that all people living with HIV (PLHIV) initiate antiretroviral treatment (ART), irrespective of CD4+ count or clinical stage. National adoption of universal treatment has accelerated since WHO's 2015 "Treat All" recommendation; however, little is known about the translation of this guidance into practice. This study aimed to assess the status of Treat All implementation across regions, countries, and levels of the health care delivery system. Methods Between June and December 2017, 201/221 (91%) adult HIV treatment sites that participate in the global IeDEA research consortium completed a survey on capacity and practices related to HIV care. Located in 41 countries across seven geographic regions, sites provided information on the status and timing of site-level introduction of Treat All, as well as site-level practices related to ART initiation. Results Almost all sites (93%) reported that they had begun implementing Treat All, and there were no statistically significant differences in site-level Treat All introduction by health facility type, urban/rural location, sector (public/private) or country income level. The median time between national policy adoption and site-level introduction was one month. In countries where Treat All was not yet adopted in national guidelines, 69% of sites reported initiating all patients on ART, regardless of clinical criteria, and these sites had been implementing Treat All for a median period of seven months at the time of the survey. The majority of sites (77%) reported typically initiating patients on ART within 14 days of confirming diagnosis, with 60% to 62% of sites implementing Treat All in East, Southern and West Africa reporting same-day ART initiation for most patients. Conclusions By mid- to late-2017, the Treat All strategy was the standard of care at almost all IeDEA sites, including rural, primary-level health facilities in low-resource settings. While further assessments of site-level capacity to provide high-quality HIV care under Treat All and to support sustained viral suppression after ART initiation are needed, the widespread introduction of Treat All at the service delivery level is a critical step towards global targets for ending the HIV epidemic as a public health threat.
C1 [Brazier, Ellen; Tymejczyk, Olga; Nash, Denis] CUNY, Inst Implementat Sci Populat Hlth, New York, NY 10021 USA.
   [Brazier, Ellen; Tymejczyk, Olga; Nash, Denis] CUNY, GSPHHP, New York, NY 10021 USA.
   [Maruri, Fernanda; Wester, C. William] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA.
   [Duda, Stephany N.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA.
   [Wester, C. William] VIGH, Nashville, TN USA.
   [Somi, Geoffrey] Natl AIDS Control Programme, Dar Es Salaam, Tanzania.
   [Ross, Jeremy] Fdn AIDS Res, TREAT Asia, AmfAR, Bangkok, Thailand.
   [Freeman, Aimee; Althoff, Keri N.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Cornell, Morna] Univ Cape Town, Sch Publ Hlth & Family Med, Fac Hlth Sci, Cape Town, South Africa.
   [Poda, Armel] CHU Souro Sanou, Hop Jour, Serv Malad Infect, Bobo Dioulasso, Burkina Faso.
   [Poda, Armel] Univ Nazi Boni, Inst Super Sci Sante INSSA, Bobo Dioulasso, Burkina Faso.
   [Musick, Beverly S.] Indiana Univ, Sch Med, Indianapolis, IN USA.
   [Zhang, Fujie] Capital Med Univ, Beijing Ditan Hosp, Clin & Res Ctr Infect Dis, Beijing, Peoples R China.
   [Mugglin, Catrina] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.
   [Kimmel, April D.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA.
   [Yotebieng, Marcel] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA.
RP Brazier, E (corresponding author), 55,West 125th St,6th Floor, New York, NY 10027 USA.
EM ellen.brazier@sph.cuny.edu
RI Tanuma, Junko/AAE-5395-2020; , Leroy/F-8129-2013; Hoy,
   Jennifer/AAK-7968-2020; Leroy, Valeriane/AAO-5175-2020; Prozesky,
   Hans/ABE-6956-2020; Fatti, Geoffrey/AAA-9217-2019; Wester, C.
   William/G-3695-2014
OI , Leroy/0000-0003-3542-8616; Leroy, Valeriane/0000-0003-3542-8616;
   Prozesky, Hans/0000-0001-9715-3449; Fatti, Geoffrey/0000-0002-6467-662X;
   Cornell, Morna/0000-0001-7149-8799; Woolley, Ian
   John/0000-0003-2928-1291; Wester, C. William/0000-0002-8375-3926;
   Castelnuovo, Barbara/0000-0001-7756-5032
FU U.S. National Institutes of Health's National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); Eunice Kennedy Shriver
   National Institute of Child Health and Human DevelopmentUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD); National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); National Institute of Mental
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); National Institute on Drug Abuse: Asia-Pacific [U01AI069907];
   National Institute on Drug Abuse: CCASAnet [U01AI069923]; National
   Institute on Drug Abuse: Central Africa [U01AI096299]; National
   Institute on Drug Abuse: East Africa [U01AI069911]; National Institute
   on Drug Abuse: NA-ACCORD [U01AI069918]; National Institute on Drug
   Abuse: Southern Africa [U01AI069924]; National Institute on Drug Abuse:
   West Africa [U01AI069919]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI027757, P30AI027757, U01AI069907,
   U01AI069918, P30AI027757, P30AI027757, P30AI027757, P30AI027757,
   P30AI027757, P30AI027757, U01AI069924, P30AI027757, U01AI069907,
   P30AI027757, P30AI027757, P30AI027757, P30AI027757, U01AI069918,
   U01AI069911, P30AI027757, U01AI069919, U01AI069918, U01AI069923,
   P30AI027757, P30AI027757, P30AI027757, P30AI027757, P30AI027757,
   P30AI027757, U01AI069911, U01AI096299, U01AI069918, P30AI027757,
   U01AI096299, P30AI027757, P30AI027757, P30AI027757, U01AI096299,
   U01AI069918, P30AI027757, P30AI027757, U01AI096299, U01AI069924,
   U01AI069911, U01AI069907, U01AI069923, U01AI069919, P30AI027757,
   U01AI069911, P30AI027757, P30AI027757, U01AI069907, P30AI027757,
   P30AI027757, P30AI027757, P30AI027757, U01AI069911, P30AI027757,
   P30AI027757, P30AI027757, U01AI069918, U01AI069924, P30AI027757,
   P30AI027757, U01AI069923, P30AI027757, P30AI027757, U01AI069924,
   P30AI027757, P30AI027757, P30AI027757, P30AI027757, U01AI069919,
   U01AI069924, P30AI027757, P30AI027757, P30AI027757, P30AI027757,
   P30AI027757, U01AI096299, P30AI027757, P30AI027757, P30AI027757,
   U01AI069923, P30AI027757] Funding Source: NIH RePORTER
FX The International Epidemiology Databases to Evaluate AIDS (IeDEA) is
   supported by the U.S. National Institutes of Health's National Institute
   of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development, the National Cancer
   Institute, the National Institute of Mental Health, and the National
   Institute on Drug Abuse: Asia-Pacific, U01AI069907; CCASAnet,
   U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911;
   NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa,
   U01AI069919. This work is solely the responsibility of the authors and
   does not necessarily represent the official views of any of the
   institutions mentioned above.
CR Alemnji G, 2018, AIDS RES HUM RETROV, V34, P132, DOI [10.1089/AID.2017.0158, 10.1089/aid.2017.0158]
   Ambia J, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2678-1
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Beer Linda, 2015, J Int Assoc Provid AIDS Care, V14, P245, DOI 10.1177/2325957414557267
   Bigna JJR, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0179-9
   Boyd MA, 2019, HIV MED, V20, P3, DOI 10.1111/hiv.12708
   Buchacz Kate, 2017, J Int Assoc Provid AIDS Care, V16, P81, DOI 10.1177/2325957416671410
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Duda SN, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19045
   Evans C, 2015, AIDS CARE, V27, P753, DOI 10.1080/09540121.2014.1002826
   Ford N, 2018, LANCET INFECT DIS, V18, pE76, DOI 10.1016/S1473-3099(17)30482-6
   Ford N, 2018, AIDS, V32, P17, DOI [10.1097/qad.0000000000001671, 10.1097/QAD.0000000000001671]
   Fritz CQ, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.20933
   Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9
   Gupta S, 2016, S AFR J HIV MED, V17, DOI 10.4102/sajhivmed.v17i1.459
   Gupta S, 2013, JAIDS-J ACQ IMM DEF, V62, pE87, DOI 10.1097/QAI.0b013e31827e4992
   Hanna DB, 2013, CLIN INFECT DIS, V56, P1174, DOI 10.1093/cid/cit003
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   IeDEA, INT EP DAT EV AIDS B
   International Association of Providers of AIDS Care (IAPAC), 2017, GLOB HIV POL WATCH
   Krakower DS, 2016, CLIN INFECT DIS, V62, P99, DOI 10.1093/cid/civ736
   Krakower DS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132398
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Mgbere O, 2018, J INT ASS PROVID AID, V17, P1
   Mwangome MN, 2017, HEALTH POLICY PLANN, V32, P825, DOI 10.1093/heapol/czx023
   Peter T, 2017, J INT AIDS SOC, V20, P9, DOI 10.1002/jia2.25008
   Pham MD, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0131-5
   Rosen S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002015
   The Global Fund to Fight AIDS Tuberculosis and Malaria, GLOB FUND DAT SERV G
   Tlhajoane M, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0358-1
   U. S. President's Emergency Plan for AIDS Relief (PEPFAR), PEPFAR BIL COUNTR OF
   UNAIDS, END AIDS PROGR 90 90
   UNAIDS, 2014, FAST TRACK END AIDS
   UNAIDS, 2014, 90 90 90 AMB TREATM
   World Bank, 2017, WORLD BANK LIST EC
   World Health Organization, 2015, GUID START ANT THER
   World Health Organization (WHO), 2017, TREAT ALL POL AD IMP
NR 38
TC 5
Z9 5
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
IS 7
AR e25331
DI 10.1002/jia2.25331
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IN3UW
UT WOS:000478602900009
PM 31623428
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Da Silva, EM
   Kay, A
   Lobato, C
   Muwonge, R
   Zoulim, F
   Brites, C
   Parana, R
   Trepo, C
AF Da Silva, Edinete Melo
   Kay, Alan
   Lobato, Cirley
   Muwonge, Richard
   Zoulim, Fabien
   Brites, Carlos
   Parana, Raymundo
   Trepo, Christian
TI Non-F HBV/HDV-3 coinfection is associated with severe liver disease in
   Western Brazilian Amazon
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE endemic infection; hepatitis B virus; hepatitis D virus
ID HEPATITIS-B-VIRUS; GENOTYPE-III; DELTA; OUTBREAKS; BASIN
AB The clinical outcome of hepatitis B virus (HBV) infection may be related to host and viral genetic factors, as well as to the type of infection (monoinfection and coinfection). To analyze the distribution/combination of HBV/hepatitis D virus (HDV) genotypes and the associated clinical characteristics, 409 serum samples from patients with chronic HBV (94 of them coinfected by HDV) followed at the Viral Hepatitis Referral Center of Rio Branco, Brazil were enrolled. HBV DNA and HDV RNA were amplified, respectively, by polymerase chain reaction (PCR) and nested PCR using specific primers in the PreC/C region and the S gene, and by reverse-transcription PCR and seminested PCR using specific primers in the delta antigen region and sequenced. The proportion of women (56.1%) was significantly higher than males in this cohort (P < 0.01). Women were significantly younger (39.8 years; 8-77 years) than males (44.7 years; 12-79 years; P < 0.01). Sixty-eight (18%) patients were infected with HBV-F genotype and 264 (69.8%) with HBV/non-F genotypes. Coinfection by HDV was detected in 23.9% (94 of 409) of this population and was more frequent in male (54.2%, 51 of 94) than in female patients (44.7%, 42 of 94; P = 0.015). HDV-3 was the most prevalent (88.9%) genotype. Almost 70% of HDV-3 coinfected patients were infected with HBV/non-F genotypes. Severe liver disease was diagnosed in 41 patients, 60.9% (25 of 41) of them coinfected with HDV. HBV/HDV coinfection was associated with male sex, age above 30 years, severe liver disease, and increased alanine aminotransferase levels. HBV/HDV-3 coinfection is associated with severe liver disease, in Rio Branco, Brazil.
C1 [Da Silva, Edinete Melo; Kay, Alan; Zoulim, Fabien; Trepo, Christian] INSERM, U1052, 151 Cours Albert Thomas, F-69003 Lyon, France.
   [Lobato, Cirley] Univ Fed Acre, UFAC, Rio Branco, Brazil.
   [Muwonge, Richard] WHO, IARC, Lyon, France.
   [Zoulim, Fabien; Trepo, Christian] Hosp Civils Lyon, Croix Rousse Hosp, Dept Hepatol, Lyon, France.
   [Da Silva, Edinete Melo; Brites, Carlos] Univ Fed Bahia, HUPES, Infectol Res Lab, Salvador, BA, Brazil.
   [Parana, Raymundo] Univ Fed Bahia, HUPES, Sch Med, Hepatol Unit, Salvador, BA, Brazil.
RP Trepo, C (corresponding author), INSERM, U1052, 151 Cours Albert Thomas, F-69003 Lyon, France.
EM Christian.trepo@inserm.fr
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Zoulim, Fabien/0000-0002-2245-0083
FU Agence Nationale de Recherche sur le SIDA et les Hepatites Virales and
   Institute Nationale de la Sante et de la Recherche Medicale
   (ANRS/INSERM); Fundacao de Amparo a Pesquisa da Bahia (Fapesb); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; INSERM)
FX Agence Nationale de Recherche sur le SIDA et les Hepatites Virales and
   Institute Nationale de la Sante et de la Recherche Medicale
   (ANRS/INSERM); Fundacao de Amparo a Pesquisa da Bahia (Fapesb); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; INSERM
CR Alvarado-Mora MV, 2011, INFECT GENET EVOL, V11, P1462, DOI 10.1016/j.meegid.2011.05.020
   Braga W S, 2001, Rev Soc Bras Med Trop, V34, P349, DOI 10.1590/S0037-86822001000400007
   Casey JL, 1996, J INFECT DIS, V174, P920, DOI 10.1093/infdis/174.5.920
   Couto I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174453
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   Gomes-Gouvea MS, 2008, ACTA TROP, V106, P149, DOI 10.1016/j.actatropica.2008.02.009
   Kay A, 2014, J VIRAL HEPATITIS, V21, P921, DOI 10.1111/jvh.12267
   Manock SR, 2000, AM J TROP MED HYG, V63, P209, DOI 10.4269/ajtmh.2000.63.209
   Braga WSM, 2014, J HEPATOL, V61, P1205, DOI 10.1016/j.jhep.2014.05.041
   Niro GA, 2010, J HEPATOL, V53, P834, DOI 10.1016/j.jhep.2010.06.008
   Quintero A, 2001, J MED VIROL, V64, P356, DOI 10.1002/jmv.1058
   Romeo R, 2009, GASTROENTEROLOGY, V136, P1629, DOI 10.1053/j.gastro.2009.01.052
   Su CW, 2006, GASTROENTEROLOGY, V130, P1625, DOI 10.1053/j.gastro.2006.01.035
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   World Health Organization, 2018, HEP D
NR 15
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUN
PY 2019
VL 91
IS 6
BP 1081
EP 1086
DI 10.1002/jmv.25411
PG 6
WC Virology
SC Virology
GA HU2FP
UT WOS:000465087100024
PM 30695106
DA 2020-12-01
ER

PT J
AU Haguihara, T
   Silva, MD
   Reboucas, MC
   Netto, EM
   Brites, C
AF Haguihara, Tatiana
   Silva, Marcio da Oliveira
   Reboucas, Monaliza Cardozo
   Netto, Eduardo Martins
   Brites, Carlos
TI Factors associated with mortality in HIV patients failing antiretroviral
   therapy, in Salvador, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Virologic failure; Mortality; HIV
ID VIROLOGICAL FAILURE; PREDICTORS; SWITCH
AB Highly active antiretroviral therapy (HAART) has significantly improved survival of people living with HIV/Aids (PLWHA). However, poor treatment adherence to HAART and other problems, still cause therapy failure and contribute to increased morbidity and mortality of PLWHA. In this retrospective cohort study (2013-2015), we sought to evaluate the factors associated with mortality of PLWHA failing HAART in 2013, who were receiving care at a reference center for sexually transmitted diseases (STD) and HIV/AIDS. A total of 165 individuals over 18 years of age who were failing antiretroviral therapy were evaluated. In two-year follow-up, 19 (11.5%) deaths were documented. There were a significant association between mortality and report of illicit drug use (53%, p < 0.01), being attended by a larger number of medical professionals (6.3 +/- 3.2, p = 0.02), use of firstline non-nucleoside reverse transcriptase inhibitor (74%, p = 0.01), and history of interrupting HAART >= 3 months (90%), p = 0.02). Patients who died had a significantly higher viral load (mean 49,192.4 +/- 35,783.6 copies/mL) than survivors (26,389.2 +/- 27,416 copies/mm(3), p < 0.01), lower mean CD4 cell counts (127.8 +/- 145.6 cells/mm(3) vs. 303.3 +/- 202.4 cells/mm(3), p < 0.01), and higher frequency of previous virologic failure (89% vs. 74.7%, p < 0.01). Our results reinforce the importance of early detection and prevention of virologic failure, to reduce the mortality associated with this event. (C) 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Haguihara, Tatiana; Silva, Marcio da Oliveira; Reboucas, Monaliza Cardozo] Specialized Ctr Diag Assistance & Res, Dept Hlth State Bahia, Salvador, BA, Brazil.
   [Netto, Eduardo Martins; Brites, Carlos] Univ Fed Bahia, Postgrad Program Med & Hlth, Salvador, BA, Brazil.
RP Haguihara, T (corresponding author), Specialized Ctr Diag Assistance & Res, Dept Hlth State Bahia, Salvador, BA, Brazil.
EM tatyha@gmail.com
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
CR [Anonymous], 2018, JOINT UN PROGR HIV A
   Brasil. Ministerio da Sande, 2013, PROT INT PROGR NAC, P1
   Brasil. Ministerio da Sande, 2016, B EP HIV AIDS, V64
   Deeks SG, 2009, CLIN INFECT DIS, V49, P1582, DOI 10.1086/644768
   IBDGEE, 2015, CENS 2015
   Bello EJM, 2011, DRUG TARGET INSIGHT, V5, P33, DOI 10.4137/DTI.S7527
   Palombi L, 2009, CLIN INFECT DIS, V48, P115, DOI 10.1086/593312
   Petersen ML, 2014, AIDS, V28, P2097, DOI 10.1097/QAD.0000000000000349
   Rodrigues CS, 2003, REV SAUDE PUBL, V37, P183, DOI 10.1590/S0034-89102003000200004
   Srasuebkul P, 2009, CLIN INFECT DIS, V48, P940, DOI 10.1086/597354
NR 10
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2019
VL 23
IS 3
BP 160
EP 163
DI 10.1016/j.bjid.2019.06.001
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA IY0BP
UT WOS:000486056200003
PM 31301280
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Angulo, JMC
   Cuesta, TAC
   Menezes, EP
   Pedroso, C
   Brites, C
AF Cubillos Angulo, Juan Manuel
   Castro Cuesta, Taryn Ariadna
   Menezes, Eliane Pereira
   Pedroso, Celia
   Brites, Carlos
TI HLA-B*14 allele predicts HIV-1 mother-to-child-transmission, in
   Salvador, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Mother to child transmission; HIV; HLA-B
ID CLASS-I; VIRAL CONTROL; HLA-B; RESTRICTION; INHERITANCE; ASSOCIATION;
   CONCORDANCE; HLA-B57; IMPACT; RISK
AB Background: Class I human leukocyte antigens, especially the molecules encoded at the B locus (HLA-B), are associated with AIDS progression risk. Different groups of HLA-B alleles have been associated to a protective effect or increasing susceptibility to HIV infection and are expressed from the earliest stages of gestation.
   Objective: The aim of this study was to evaluate which variants of HLA-B are associated with the risk of HIV vertical transmission in infected pregnant women and in their offspring, in a referral center in Salvador Bahia.
   Methods: We performed HLA-B genotyping in 52 HIV-infected mothers and their children exposed to HIV-1 during pregnancy (N=65) in Salvador, Brazil. We compared the HLA-B alleles frequency in mothers, uninfected and infected children, according to the use of antiretroviral prophylaxis.
   Results: Absence of antiretroviral antenatal and postnatal prophylaxis was significantly associated with vertical transmission of HIV-1 (p = <0.01, and p = <0.01 respectively). Frequency of HLA-B*14 (29.2%,p = 0.002), HLA-B*18 (16.7%, p = 0.04) or HLA-B*14:1 (20.8%, p = 0.01) alleles subgroups were significantly higher in HIV-1 infected children and persisted (HLA-B*14, p = 0.04) even after adjusting for use of antiretroviral prophylaxis. No significant difference in expression of HLA-B alleles was observed among mothers who transmitted the virus compared to those who did not.
   Conclusions: Expression of HLA-B*14 allele in children exposed to HIV-1 is predictive of vertical transmission and reinforces the important role of genetics in mother-to-child transmission. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Sociedade Brasileira de Infectologia. This is an open access article under the CC BY-NC-ND license
C1 [Cubillos Angulo, Juan Manuel; Pedroso, Celia; Brites, Carlos] Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Cubillos Angulo, Juan Manuel; Castro Cuesta, Taryn Ariadna; Menezes, Eliane Pereira] Univ Fed Bahia, Escola Med Salvador, Complexo Hosp Prof Edgard Santos, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Lab Pesquisa Infectol, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Cubillos Angulo, Juan
   Manuel/0000-0002-3877-5077
FU Fundacao Bahiana de infectologia
FX We thank Marcos Neri and Augusto Hora for blood collection and Maria
   Belen Arriaga for her support in statistical analyses. This study was
   supported by a grant from Fundacao Bahiana de infectologia.
CR Adland E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004954
   Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005
   Arnaiz-Villena A, 2009, CURR HIV RES, V7, P314, DOI 10.2174/157016209788348029
   Farquhar C, 2004, AIDS RES HUM RETROVI
   Gao XJ, 2005, NAT MED, V11, P1290, DOI 10.1038/nm1333
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2017, UNAIDS DAT 2017, P1
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006
   Kuhn L, 2004, AIDS, V18, P1281, DOI 10.1097/00002030-200406180-00006
   MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243
   Mackelprang RD, 2010, J INFECT DIS, V202, P1273, DOI 10.1086/656318
   Martin MP, 2013, IMMUNOL REV, V254, P245, DOI 10.1111/imr.12071
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Paximadis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016541
   Polycarpou A, 2002, AIDS RES HUM RETROV, V18, P741, DOI 10.1089/08892220260139477
   Prendergast AJ, 2012, NAT REV IMMUNOL, V12, P636, DOI 10.1038/nri3277
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Rene C, 2016, HLA, V87, P338, DOI 10.1111/tan.12787
   Schneidewind A, 2009, J VIROL, V83, P8616, DOI 10.1128/JVI.00730-09
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Thobakgale CF, 2009, J VIROL, V83, P10234, DOI 10.1128/JVI.00921-09
   Winchester R, 2004, JAIDS-J ACQ IMM DEF, V36, P659, DOI 10.1097/00126334-200406010-00002
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2019
VL 23
IS 2
BP 71
EP 78
DI 10.1016/j.bjid.2019.04.009
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA IY0BE
UT WOS:000486055000001
PM 31112676
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bandeira, ID
   Guimaraes-Silva, P
   Cedro, RL
   de Almeida, VRP
   Bittencourt, AL
   Brites, C
AF Bandeira, Igor Dorea
   Guimaraes-Silva, Pedro
   Cedro-Filho, Robson Logrado
   Pedreira de Almeida, Vitoria Regina
   Bittencourt, Achilea L.
   Brites, Carlos
TI Primary cutaneous nocardiosis
SO JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
LA English
DT Letter
C1 [Bandeira, Igor Dorea; Guimaraes-Silva, Pedro; Cedro-Filho, Robson Logrado] Univ Fed Bahia, Med Sch Bahia, Praca 15 Novembro S-N Largo Terreiro Jesus, BR-40025010 Salvador, BA, Brazil.
   [Pedreira de Almeida, Vitoria Regina] Univ Fed Bahia, Prof Edgard Santos Univ Teaching Hosp, Div Dermatol, Salvador, BA, Brazil.
   [Bittencourt, Achilea L.] Univ Fed Bahia, Med Sch Bahia, Lab Pathol, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Prof Edgard Santos Univ Teaching Hosp, Infect Dis Res Lab, Salvador, BA, Brazil.
RP Bandeira, ID (corresponding author), Univ Fed Bahia, Med Sch Bahia, Praca 15 Novembro S-N Largo Terreiro Jesus, BR-40025010 Salvador, BA, Brazil.
EM igordbandeira@gmail.com
RI Bandeira, Igor Dorea/J-8835-2015; Pincelli, Carlo/A-7288-2012
OI Bandeira, Igor Dorea/0000-0002-6714-2658; Pincelli,
   Carlo/0000-0003-4416-2637
CR Bittencourt AL, 1995, TROPICAL PATHOLOGY, P705
   Bonifaz A, 2010, J DTSCH DERMATOL GES, V8, P619, DOI 10.1111/j.1610-0387.2010.07453.x
   MCNEILL MM, 1994, CLIN MICROBIOL REV, V7, P357, DOI 10.1128/CMR.7.3.357-417.1994
   Oda R, 2017, INTERNAL MED, V56, P469, DOI 10.2169/internalmedicine.56.7810
   Pai S, 2015, BMJ CASE REP, V2015
   Schwarzkopf A, 2015, J DTSCH DERMATOL GES, V13, P203, DOI [10.1111/ddg.12611_suppl, 10.1111/ddg.12611]
   Sousa JMP, 2014, J DTSCH DERMATOL GES, V12, P903, DOI 10.1111/ddg.12331
   Wilson JW, 2012, MAYO CLIN PROC, V87, P403, DOI 10.1016/j.mayocp.2011.11.016
NR 8
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1610-0379
EI 1610-0387
J9 J DTSCH DERMATOL GES
JI J. Dtsch. Dermatol. Ges.
PD MAR
PY 2019
VL 17
IS 3
BP 327
EP 329
DI 10.1111/ddg.13770
PG 3
WC Dermatology
SC Dermatology
GA HQ7PL
UT WOS:000462613000010
PM 30883034
DA 2020-12-01
ER

PT J
AU Aboud, M
   Kaplan, R
   Lombaard, J
   Zhang, F
   Hidalgo, JA
   Mamedova, E
   Losso, MH
   Chetchotisakd, P
   Brites, C
   Sievers, J
   Brown, D
   Hopking, J
   Underwood, M
   Nascimento, MC
   Punekar, Y
   Gartland, M
   Smith, K
AF Aboud, Michael
   Kaplan, Richard
   Lombaard, Johannes
   Zhang, Fujie
   Hidalgo, Jose A.
   Mamedova, Elmira
   Losso, Marcelo H.
   Chetchotisakd, Ploenchan
   Brites, Carlos
   Sievers, Jorg
   Brown, Dannae
   Hopking, Judy
   Underwood, Mark
   Nascimento, Maria Claudia
   Punekar, Yogesh
   Gartland, Martin
   Smith, Kimberly
TI Dolutegravir versus ritonavir-boosted lopinavir both with dual
   nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1
   infection in whom first-line therapy has failed (DAWNING): an
   open-label, non-inferiority, phase 3b trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID 2ND-LINE ANTIRETROVIRAL THERAPY; ONCE-DAILY DOLUTEGRAVIR; NAIVE ADULTS;
   DOUBLE-BLIND; RALTEGRAVIR; LAMIVUDINE; ABACAVIR
AB Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected patients in resource-limited settings. We assessed safety and efficacy of dolutegravir compared with ritonavir-boosted lopinavir, plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults in whom previous first-line antiretroviral therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two NRTIs has failed.
   Methods DAWNING is a phase 3b, open-label, parallel-group, non-inferiority, active-controlled trial done at 58 sites in 13 countries. Eligible adults were aged at least 18 years and, during at least 6 months of treatment with a first-line treatment containing an NNRTI and two NRTIs, had virological failure (confirmed HIV-1 RNA >= 400 copies per mL). Participants were randomly assigned by a central randomisation system to receive oral dolutegravir (50 mg once daily) or ritonavir-boosted lopinavir (800 mg lopinavir plus 200 mg ritonavir once daily or 400 mg plus 100 mg twice daily), plus two investigator-selected NRTIs (at least one fully active based on resistance testing at screening). The primary outcome was the proportion of participants achieving viral suppression (defined as plasma HIV-1 RNA <50 copies per mL) at week 48 using the snapshot algorithm and a non-inferiority margin of -12%. The primary analysis was done in an intention-to-treat-exposed (ITT-E) population of participants who received at least one dose of study medication, according to original group assignment. Safety was analysed in all participants who received at least one dose of study drug, according to which drug was received. The study was registered at ClinicalTrials.gov, number NCT02227238, and viiv-studyregister.com, number 200304.
   Findings Between Dec 11, 2014, and June 27, 2016, 968 adults were screened and 627 were randomly assigned to the dolutegravir group (n=312) or the ritonavir-boosted lopinavir group (n=315). Three patients in the ritonavir-boosted lopinavir group did not receive study medication and so 624 were included in the ITT-E population. At week 48, 261 (84%) of 312 participants in the dolutegravir group achieved viral suppression compared with 219 (70%) of 312 in the ritonavir-boosted lopinavir group (adjusted difference 13.8%; 95% CI 7.3-20.3). Non-inferiority was achieved on the basis of the 95% CI of the adjusted treatment difference having a lower bound greater than -12% (prespecified non-inferiority margin). Because the lower bound of the 95% CI is greater than zero (7.3%), superiority of dolutegravir was also concluded (p<0.0001). The safety profile for dolutegravir was favourable compared with that of ritonavir-boosted lopinavir. More grade 2-4 drug-related adverse events occurred with ritonavir-boosted lopinavir than dolutegravir (44 [14%] of 310 with ritonavir-boosted lopinavir vs 11 [4%] of 314 with dolutegravir), mainly driven by gastrointestinal disorders.
   Interpretation When administered with two NRTIs, dolutegravir was superior to ritonavir-boosted lopinavir at 48 weeks and can be considered a suitable option for second-line treatment. Copyright (c) 2019 Elsevier Ltd. All rights reserved.
C1 [Aboud, Michael; Sievers, Jorg; Nascimento, Maria Claudia; Punekar, Yogesh] ViiV Healthcare, Brentford TW8 9GS, England.
   [Kaplan, Richard] Desmond Tutu HIV Fdn, Cape Town, South Africa.
   [Lombaard, Johannes] Josha Res, Bloemfontein, South Africa.
   [Zhang, Fujie] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China.
   [Hidalgo, Jose A.] Via Libre, Lima, Peru.
   [Mamedova, Elmira] Kiev City AIDS Ctr, Kiev, Ukraine.
   [Losso, Marcelo H.] Hosp JM Ramos Mejia, Buenos Aires, DF, Argentina.
   [Chetchotisakd, Ploenchan] Khon Kaen Univ, Srinagarind Hosp, Khon Kaen, Thailand.
   [Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
   [Brown, Dannae] ViiV Healthcare, Abbotsford, Australia.
   [Hopking, Judy] GlaxoSmithKline, Stockley Pk, England.
   [Underwood, Mark; Gartland, Martin; Smith, Kimberly] ViiV Healthcare, Res Triangle Pk, NC USA.
RP Sievers, J (corresponding author), ViiV Healthcare, Brentford TW8 9GS, England.
EM jorg.x.sievers@viivhealthcare.com
OI Kaplan, Richard/0000-0003-1565-4704; Hidalgo, Jose/0000-0002-5789-3263
FU ViiV Healthcare
FX ViiV Healthcare.
CR [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   Boyd MA, 2013, LANCET, V381, P2091, DOI 10.1016/S0140-6736(13)61164-2
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Cahn P, 2013, LANCET, V382, P700, DOI 10.1016/S0140-6736(13)61221-0
   Clotet B, 2014, LANCET, V383, P2222, DOI 10.1016/S0140-6736(14)60084-2
   Demarest J, 2018, AIDS RES HUM RETROV, V34, P343, DOI [10.1089/aid.2017.0184, 10.1089/AID.2017.0184]
   Estill J, 2016, LANCET HIV, V3, pE132, DOI 10.1016/S2352-3018(16)00016-3
   Fettiplace A, 2017, JAIDS-J ACQ IMM DEF, V74, P423, DOI [10.1097/QAI.0000000000001269, 10.1097/qai.0000000000001269]
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Kanters S, 2017, LANCET HIV, V4, pE433, DOI 10.1016/S2352-3018(17)30109-1
   La Rosa AM, 2016, LANCET HIV, V3, pE247, DOI 10.1016/S2352-3018(16)30011-X
   Marcelin A-G, 2006, ANTIRETROVIRAL RESIS, P2006
   Orkin C, 2013, HIV MED, V14, P49, DOI 10.1111/j.1468-1293.2012.01060.x
   Orrell C, 2017, LANCET HIV, V4, pE536, DOI 10.1016/S2352-3018(17)30095-4
   Paton NI, 2017, LANCET HIV, V4, pE341, DOI 10.1016/S2352-3018(17)30065-6
   Paton NI, 2014, NEW ENGL J MED, V371, P234, DOI 10.1056/NEJMoa1311274
   Quashie PK, 2013, ANTIMICROB AGENTS CH, V57, P6223, DOI 10.1128/AAC.01835-13
   Raffi F, 2013, LANCET, V381, P735, DOI 10.1016/S0140-6736(12)61853-4
   Ryom L, 2013, J INFECT DIS, V207, P1359, DOI 10.1093/infdis/jit043
   U. S. Department of Health and Human Services NIoH National Institute of Allergy and Infectious Disease, 2009, DIV AIDS DAIDS TABL
   UNAIDS, 2017 GLOB HIV STAT
   US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, 2015, HUM IMM VIR 1 INF DE
   Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541
   WHO, 2017, TRANS US DOL WHAT IS
   WHO, 2018, UPD REC 1 LIN 2 LIN
   World Health Organization, 2016, CONS GUID US ANT DRU
   Zash R, 2018, NEW ENGL J MED, V379, P979, DOI 10.1056/NEJMc1807653
NR 27
TC 29
Z9 29
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD MAR
PY 2019
VL 19
IS 3
BP 253
EP 264
DI 10.1016/S1473-3099(19)30036-2
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA HN1AM
UT WOS:000459919500035
PM 30732940
DA 2020-12-01
ER

PT J
AU Tyson, J
   Tsai, WY
   Tsai, JJ
   Brites, C
   Massgard, L
   Youn, HH
   Pedroso, C
   Drexler, JF
   Stramer, SL
   Balmaseda, A
   Harris, E
   Wang, WK
AF Tyson, Jasmine
   Tsai, Wen-Yang
   Tsai, Jih-Jin
   Brites, Carlos
   Massgard, Ludvig
   Youn, Han Ha
   Pedroso, Celia
   Drexler, Jan Felix
   Stramer, Susan L.
   Balmaseda, Angel
   Harris, Eva
   Wang, Wei-Kung
TI Combination of Nonstructural Protein 1-Based Enzyme-Linked Immunosorbent
   Assays Can Detect and Distinguish Various Dengue Virus and Zika Virus
   Infections
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE Zika virus; dengue virus; nonstructural protein 1; serodiagnosis
ID WEST-NILE-VIRUS; CROSS-REACTIVITY; NEUTRALIZING ANTIBODIES;
   TRANSMISSION; ENHANCEMENT; DIAGNOSIS; TRAVELERS; KINETICS; INFANTS;
   SAFETY
AB The recent outbreaks of Zika virus (ZIKV) and associated birth defects in regions of dengue virus (DENV) endemicity emphasize the need for sensitive and specific serodiagnostic tests. We reported previously that enzyme-linked immunosor- bent assays (ELISAs) based on the nonstructural protein 1 (NS1) of DENV serotype 1 (DENV1) and ZIKV can distinguish primary DENV1, secondary DENV, and ZIKV infections. Whether ELISAs based on NS1 proteins of other DENV serotypes can discriminate various DENV and ZIKV infections remains unknown. We herein developed DENV2, DENV3, and DENV4 NS1 IgG ELISAs to test convalescent- and postconvalescent-phase samples from reverse transcription-PCR-confirmed cases, including 25 primary DENV1, 24 primary DENV2, 10 primary DENV3, 67 secondary DENV, 36 primary West Nile virus, 38 primary ZIKV, and 35 ZIKV with previous DENV infections as well as 55 flavivirus-naive samples. Each ELISA detected primary DENV infection with a sensitivity of 100% for the same serotype and 23.8% to 100% for different serotypes. IgG ELISA using a mixture of DENV1-4 NS1 proteins detected different primary and secondary DENV infections with a sensitivity of 95.6% and specificity of 89.5%. The ZIKV NS1 IgG ELISA detected ZIKV infection with a sensitivity of 100% and specificity of 82.9%. On the basis of the relative optical density ratio, the combination of DENV1-4 and ZIKV NS1 IgG ELISAs distinguished ZIKV with previous DENV and secondary DENV infections with a sensitivity of 91.7% to 94.1% and specificity of 87.0% to 95.0%. These findings have important applications to serodiagnosis, serosurveillance, and monitoring of both DENV and ZIKV infections in regions of endemicity.
C1 [Tyson, Jasmine; Tsai, Wen-Yang; Youn, Han Ha; Wang, Wei-Kung] Univ Hawaii Manoa, Dept Trop Med Med Microbiol & Pharmacol, John A Burns Sch Med, Honolulu, HI 96822 USA.
   [Tsai, Jih-Jin] Kaohsiung Med Univ Hosp, Trop Med Ctr, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univ Hosp, Div Infect Dis, Dept Internal Med, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univ, Ctr Dengue Fever Control & Res, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung, Taiwan.
   [Brites, Carlos; Pedroso, Celia] Univ Fed Bahia, Sch Med, LAPI Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Massgard, Ludvig] Linkoping Univ, Fac Med & Hlth Sci, Linkoping, Sweden.
   [Drexler, Jan Felix] Charite Univ Med Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Free Univ Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Humboldt Univ, Berlin, Germany.
   [Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [Drexler, Jan Felix] German Ctr Infect Res, Munich, Germany.
   [Stramer, Susan L.] Amer Red Cross Sci Support Off, Gaithersburg, MD USA.
   [Balmaseda, Angel] Minist Hlth, Natl Virol Lab, Natl Ctr Diag & Reference, Managua, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
RP Wang, WK (corresponding author), Univ Hawaii Manoa, Dept Trop Med Med Microbiol & Pharmacol, John A Burns Sch Med, Honolulu, HI 96822 USA.
EM wangwk@hawaii.edu
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Drexler, Jan
   Felix/0000-0002-3509-0232; TSAI, JIH-JIN/0000-0003-2226-8916
FU National Institute of Allergy and Infectious Diseases, NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI110769-01, R21AI135292-01A1, R01 AI099631, U54 AI065359, P01
   AI106695, U19 AI118610]; National Institute of General Medical Sciences,
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P30GM114737]; Ministry of Health and Welfare,
   Taiwan [MOHW107-TDU-B-212-123006]; National Health Research Institute,
   TaiwanNational Health Research Institutes - Taiwan [NHRI-MR-107-PP-38];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI118610, P01AI106695, U19AI118610, U19AI118610, U19AI118610,
   P01AI106695, U19AI118610, P01AI106695, U19AI118610, R21AI135292,
   P01AI106695, U19AI118610, U19AI118610, R01AI110769, P01AI106695,
   R01AI099631, P01AI106695, R21AI135292, P01AI106695, U19AI118610,
   U19AI118610, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   R01AI099631, U19AI118610, U19AI118610, P01AI106695, P01AI106695,
   P01AI106695, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   U19AI118610, P01AI106695, P01AI106695, R01AI099631, U19AI118610,
   U19AI118610, P01AI106695, U19AI118610, U19AI118610, R01AI110769,
   U19AI118610, U19AI118610, U19AI118610, U19AI118610, P01AI106695,
   U19AI118610, U19AI118610, P01AI106695, P01AI106695, U19AI118610,
   R01AI099631, U19AI118610, U19AI118610, R01AI110769, U19AI118610,
   P01AI106695, U19AI118610, P01AI106695, U19AI118610, P01AI106695,
   U19AI118610, U19AI118610, U19AI118610, P01AI106695, U19AI118610,
   P01AI106695, P01AI106695, P01AI106695, U19AI118610, U19AI118610,
   P01AI106695, P01AI106695, U19AI118610, P01AI106695, U19AI118610,
   U19AI118610, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, U19AI118610] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [P30GM114737, P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737,
   P30GM114737] Funding Source: NIH RePORTER
FX This work was supported by grants R01AI110769-01 (W.-K.W.),
   R21AI135292-01A1 (W.-K.W.), R01 AI099631 (A.B.), U54 AI065359 (A.B.),
   P01 AI106695 (E.H.), and U19 AI118610 (E.H.) from the National Institute
   of Allergy and Infectious Diseases, NIH, P30GM114737 from the National
   Institute of General Medical Sciences, NIH, MOHW107-TDU-B-212-123006
   (J.-J.-T.) from the Ministry of Health and Welfare, Taiwan,
   NHRI-MR-107-PP-38 (J.-J.-T.) from the National Health Research
   Institute, Taiwan, and in part by a gift from the Outpatient Parenteral
   Antimicrobial Therapy Outcomes Registry in honor of the late Alan Tice.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Balmaseda A, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/JCM.01785-17, 10.1128/jcm.01785-17]
   Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Brooks RB, 2016, MMWR-MORBID MORTAL W, V65, P915, DOI 10.15585/mmwr.mm6534e2
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   CDC, 2017, GUID US LAB TEST ZIK
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   Halstead SB, 2017, VACCINE, V35, P6355, DOI 10.1016/j.vaccine.2017.09.089
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Iacobucci G, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1765
   Johnson AJ, 2000, J CLIN MICROBIOL, V38, P1827, DOI 10.1128/JCM.38.5.1827-1831.2000
   Johnson BW, 2005, VECTOR-BORNE ZOONOT, V5, P137, DOI 10.1089/vbz.2005.5.137
   Krauer F, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002203
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Lai CY, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002451
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Lustig Y, 2017, J CLIN MICROBIOL, V55, P1894, DOI 10.1128/JCM.00346-17
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   Montoya M, 2018, J INFECT DIS, V218, P536, DOI 10.1093/infdis/jiy164
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Munoz-Jordan JL, 2017, J INFECT DIS, V216, pS951, DOI 10.1093/infdis/jix502
   Narvaez F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001397
   Nascimento EJM, 2018, J VIROL METHODS, V257, P48, DOI 10.1016/j.jviromet.2018.03.007
   Normile D, 2017, SCIENCE, V358, P1514, DOI 10.1126/science.358.6370.1514
   Paldanius M, 2003, CLIN DIAGN LAB IMMUN, V10, P8, DOI 10.1128/CDLI.10.1.8-12.2003
   Pasquier C, 2018, DIAGN MICR INFEC DIS, V90, P26, DOI 10.1016/j.diagmicrobio.2017.09.001
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Pierson T.C., 2013, FIELDS VIROLOGY, V6, P747
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Safronetz D, 2017, EMERG INFECT DIS, V23, P1577, DOI 10.3201/eid2309.162043
   Simmons G, 2018, CLIN INFECT DIS, V66, P1181, DOI 10.1093/cid/cix972
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Steinhagen K, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Stramer SL, 2005, NEW ENGL J MED, V353, P451, DOI 10.1056/NEJMoa044333
   Tsai JJ, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006879
   Tsai WY, 2017, CLIN INFECT DIS, V65, P1829, DOI 10.1093/cid/cix672
   Tsai WY, 2015, J VIROL, V89, P7348, DOI 10.1128/JVI.00273-15
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   van Meer MPA, 2017, J CLIN VIROL, V92, P25, DOI 10.1016/j.jcv.2017.05.001
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
NR 51
TC 4
Z9 4
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD FEB
PY 2019
VL 57
IS 2
AR e01464-18
DI 10.1128/JCM.01464-18
PG 13
WC Microbiology
SC Microbiology
GA HK0MA
UT WOS:000457592200019
PM 30429254
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Driesse, K
   Tsai, WY
   Brites, C
   Pedroso, C
   Wang, WK
AF Driesse, Kaitlin
   Tsai, Wen-Yang
   Brites, Carlos
   Pedroso, Celia
   Wang, Wei-Kung
TI DENGUE VIRUS IMMUNE STATUS AND ANTIBODY TITERS AMONG ASYMPTOMATIC
   PREGNANT WOMEN DURING THE ZIKA OUTBREAK IN SALVADOR, BRAZIL
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Society-for-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 20-24, 2019
CL National Harbor, MD
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Bavarian Nord, GSK, Takeda, Integrum Sci, Celgene, Vulcan, Plos Neglected Trop Dis, Elsevier
C1 [Driesse, Kaitlin; Tsai, Wen-Yang; Wang, Wei-Kung] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA.
   [Brites, Carlos; Pedroso, Celia] Univ Fed Bahia, LAPI Lab Pesquisa Infectol, Sch Med, Salvador, BA, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2019
VL 101
SU 5
MA 1497
BP 460
EP 460
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA KC7PF
UT WOS:000507364504207
DA 2020-12-01
ER

PT J
AU Sampaio, GD
   Brites, C
   Drexler, JF
   Moreira-Soto, A
   Miranda, F
   Netto, EM
AF Sampaio, Gilmara de Souza
   Brites, Carlos
   Drexler, Jan Felix
   Moreira-Soto, Andres
   Miranda, Fernanda
   Netto, Eduardo Martins
TI Expansion of Zika virus circulation from Africa to the Americas,
   1947-2018: a literature review
SO EPIDEMIOLOGIA E SERVICOS DE SAUDE
LA English
DT Review
DE Zika Virus; Flavivirus; Epidemiology; Epidemics; Congenital
   Abnormalities; Review Literature as Topic
ID YELLOW-FEVER; SEROLOGICAL SURVEY; ARBOVIRUS INFECTIONS; CHIKUNGUNYA
   VIRUSES; BORNE TRANSMISSION; AEDES-ALBOPICTUS; DENGUE; ANTIBODIES;
   NIGERIA; EPIDEMIC
AB Objective: to describe the temporal and geographical expansion of Zika virus (ZIKV) circulation in countries and territories, from the time it was first isolated until 2018. Methods: This was a non-systematic literature review covering the period from 1947 to 2018 using the MEDLINE database and World Health Organization estimates. Results: Since its isolation in 1947, ZIKV circulation spread through Africa, Asia and the Pacific before reaching the Americas in 2013, causing serious clinical manifestations; the highest seroprevalence rates were recorded in Yap (74%) and in Brazil (63%); genetic mutations, absence of immunity and high vector susceptibility may have influenced ZIKV transmissibility and help to explain the magnitude of its expansion. Conclusion: The spread of ZIKV circulation in the Americas was the most extensive recorded thus far, possibly as a result of population and geographical characteristics of the sites where the virus circulated.
C1 [Sampaio, Gilmara de Souza; Brites, Carlos; Miranda, Fernanda; Netto, Eduardo Martins] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Drexler, Jan Felix; Moreira-Soto, Andres] Charite Univ Med Berlin, Inst Virol, Berlim, Germany.
RP Sampaio, GD (corresponding author), Univ Fed Bahia, Hosp Univ Edgard Santos, Lab Pesquisa Infectol, Rua Joao Botas 157b, BR-40110160 Salvador, BA, Brazil.
EM gilmara.s.sampaio@hotmail.com
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; Moreira-Soto,
   Andres/0000-0002-9224-5157
FU Brazilian Hospital Services Company (EBSERH)
FX We thank the Brazilian Hospital Services Company (EBSERH), for its
   support in the development of this study.
CR ADEKOLUJOHN EO, 1983, T ROY SOC TROP MED H, V77, P149, DOI 10.1016/0035-9203(83)90053-6
   Akoua-Koffi C, 2001, B SOC PATHOL EXOT, V94, P227
   Alera MT, 2015, EMERG INFECT DIS, V21, P722, DOI 10.3201/eid2104.141707
   Malta JMAS, 2017, EPIDEMIOL SERV SAUDE, V26, P9, DOI [10.5123/s1679-49742017000100002, 10.5123/S1679-49742017000100002]
   Anglero-Rodriguez YI, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02050
   Arauz D, 2016, EMERG INFECT DIS, V22, P1515, DOI 10.3201/eid2208.160292
   Aubry F, 2018, BIORXIV, DOI DOI 10.1101/342741
   Aubry M, 2015, INT J INFECT DIS, V41, P11, DOI 10.1016/j.ijid.2015.10.005
   Azar SR, 2017, AM J TROP MED HYG, V97, P330, DOI 10.4269/ajtmh.16-0969
   BABANIYI OA, 2015, INT J PUBLIC HLTH EP, V4, P110
   Babaniyi OA, 2015, J GLOB INFECT DIS, V7, P11, DOI 10.4103/0974-777X.150884
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Barzon L, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.10.30159
   BOORMAN J. P. T., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Bozza FA, 2019, EMERG INFECT DIS, V25, P311, DOI 10.3201/eid2502.180166
   da Nobrega MEB, 2018, EPIDEMIOL SERV SAUDE, V27, DOI 10.5123/S1679-49742018000200016
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   BRES P., 1963, BULL SOC PATHOL EXOTIQUE, V56, P384
   BRES P, 1970, B WORLD HEALTH ORGAN, V43, P223
   Buathong R, 2015, AM J TROP MED HYG, V93, P380, DOI 10.4269/ajtmh.15-0022
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Campos MC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201452
   Campos TDL, 2018, INT J GENOMICS, V2018, P1
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Centers for Disease Control and Prevention, 2016, REV DIAGN TEST ZIK C
   Chammard TB, 2017, EMERG INFECT DIS, V23, P696, DOI 10.3201/eid2304.161967
   CHIPPAUX.C, 1966, B WORLD HEALTH ORGAN, V34, P105
   Chippaux-Hyppolite C, 1965, Bull Soc Pathol Exot Filiales, V58, P812
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Ciota AT, 2017, EMERG INFECT DIS, V23, P1110, DOI 10.3201/eid2307.161633
   Codrington J, 2018, PLOS CURR, V10
   Costello A, 2016, B WORLD HEALTH ORGAN, V94, P406, DOI 10.2471/BLT.16.176990
   DARWISH MA, 1983, T ROY SOC TROP MED H, V77, P442, DOI 10.1016/0035-9203(83)90106-2
   Daudens-Vaysse E, 2016, EUROSURVEILLANCE, V21, P11, DOI 10.2807/1560-7917.ES.2016.21.28.30285
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Caires LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02790-9
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   Di Luca M, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.18.30223
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   DICK GWA, 1953, T ROY SOC TROP MED H, V47, P13, DOI 10.1016/0035-9203(53)90021-2
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   FAGBAMI AH, 1979, J HYG-CAMBRIDGE, V83, P213, DOI 10.1017/S0022172400025997
   FAGBAMI AH, 1977, T ROY SOC TROP MED H, V71, P60, DOI 10.1016/0035-9203(77)90210-3
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   FILIPE AR, 1975, AM J TROP MED HYG, V24, P516, DOI 10.4269/ajtmh.1975.24.516
   Fokam E B, 2010, East Afr Med J, V87, P262
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frank C, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.23.30252
   GESER A, 1970, Bulletin of the World Health Organization, V43, P539
   GONZALEZ JP, 1979, B SOC PATHOL EXOT, V72, P416
   Gordon A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002726
   Guerbois M, 2016, J INFECT DIS, V214, P1349, DOI 10.1093/infdis/jiw302
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Hall-Mendelin S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004959
   HAMMON WM, 1958, AM J TROP MED HYG, V7, P323, DOI 10.4269/ajtmh.1958.7.323
   Heang V, 2012, EMERG INFECT DIS, V18, P349, DOI 10.3201/eid1802.111224
   HENDERSON BE, 1968, B WORLD HEALTH ORGAN, V38, P229
   HENDERSON BE, 1970, B WORLD HEALTH ORGAN, V42, P787
   Ikejezie J, 2017, MMWR-MORBID MORTAL W, V66, P329, DOI 10.15585/mmwr.mm6612a4
   KOKERNOT R. H., 1960, AN INST MED TROP, V17, P201
   KOKERNOT RH, 1965, T ROY SOC TROP MED H, V59, P563, DOI 10.1016/0035-9203(65)90159-8
   Korhonen EM, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.2.30107
   Krauer F, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002203
   Kwong JC, 2013, AM J TROP MED HYG, V89, P516, DOI 10.4269/ajtmh.13-0029
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065
   Lednicky J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004687
   Li JD, 2016, EMERG INFECT DIS, V22, P1133, DOI 10.3201/eid2206.160273
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   LOURENCO M, 2018, PLOS CURR, V10, DOI DOI 10.3390/V10060327
   MACNAMARA F. N., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P202, DOI 10.1016/0035-9203(59)90072-0
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Ministerio da Saude (BR), 2015, MIN SAUD CONF REL EN
   Ministerio da Saude (BR), 2017, 57 MIN SAUD BRAS
   Ministerio da Saude (BR), 2018, B EPIDEMIOL, V49
   Ministerio da Saude (BR), 2018, B EPIDEMIOL, V49, P1
   MONATH TP, 1973, B WORLD HEALTH ORGAN, V49, P235
   MONLUN E, 1993, B SOC PATHOL EXOT, V86, P21
   MOORE DL, 1975, ANN TROP MED PARASIT, V69, P49, DOI 10.1080/00034983.1975.11686983
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2015, LANCET, V386, P243, DOI 10.1016/S0140-6736(15)61273-9
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Naccache SN, 2016, EMERG INFECT DIS, V22, P1788, DOI 10.3201/eid2210.160663
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   Nogueira ML, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14047
   Oehler E., 2014, Eurosurveillance, V19, P20720
   OLSON JG, 1983, ANN TROP MED PARASIT, V77, P131, DOI 10.1080/00034983.1983.11811687
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   OMER AHS, 1981, J TROP MED HYG, V84, P63
   Organization W. H., 2016, WHO DIR GEN SUMM OUT
   Pacheco O, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMoa1604037
   Pan American Health Organization, 2016, ZIK EP UPD 22 SEPT 2
   Pan American Health Organization, 2015, IMPL PUBL HLTH AM
   Pan American Health Organization, 2015, EP AL INCR MICR NE B
   Pan American Health Organization, 2016, ZIKA EP UPD 29 DEC 2
   Pan American Health Organization/World Health Organization, 2017, ZIK SUSP CONF CAS RE
   Pan American Health Organization World Health Organization, 2016, ZIK SUSP CONF CAS RE
   PELLISSIER AIME, 1954, BULL SOC PATHOL EXOT, V47, P223
   Perkasa A, 2016, EMERG INFECT DIS, V22, P924, DOI 10.3201/eid2205.151915
   Pettersson JHO, 2016, MBIO, V7, DOI [10.1128/mBio.01239-16, 10.1128/mbio.01239-16]
   Pettersson JHO, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0082-5
   PINTO MR, 1967, B WORLD HEALTH ORGAN, V37, P101
   Pompon J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01282-6
   POND WILLIAM L., 1963, TRANS ROY SOC TROP MED AND HYG, V57, P364, DOI 10.1016/0035-9203(63)90100-7
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   REAGAN RL, 1953, TEX REP BIOL MED, V11, P347
   Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0
   RENAUDET J, 1978, B SOC PATHOL EXOT, V71, P131
   Reusken C, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.23.30251
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   Ritchie SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105846
   ROBIN Y, 1968, Bulletin de la Societe de Pathologie Exotique, V61, P833
   Robin Y., 1975, Bulletin Soc Path Exot, V68, P249
   RODHAIN F, 1989, T ROY SOC TROP MED H, V83, P851, DOI 10.1016/0035-9203(89)90352-0
   Rodier GR, 1996, T ROY SOC TROP MED H, V90, P237, DOI 10.1016/S0035-9203(96)90228-X
   Rodrigues LC, 2017, LANCET, V390, P824, DOI 10.1016/S0140-6736(17)31478-2
   Roth A, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.41.20929
   Ryan SJ, 2017, EMERG INFECT DIS, V23, P1926, DOI 10.3201/eid2311.171140
   SALAUN JJ, 1967, B WORLD HEALTH ORGAN, V37, P343
   Sanchez-Carbonel Jose, 2018, BMC Res Notes, V11, P175, DOI 10.1186/s13104-018-3290-0
   SERIE C, 1968, B WORLD HEALTH ORGAN, V38, P843
   Sheridan MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200086
   SMITHBURN KC, 1954, J IMMUNOL, V72, P248
   SMITHBURN KC, 1954, AM J HYG, V59, P157, DOI 10.1093/oxfordjournals.aje.a119630
   SMITHBURN KC, 1952, J IMMUNOL, V69, P223
   Sun JM, 2017, SCI REP-UK, V7, DOI 10.1038/srep43527
   Fantinato FFST, 2016, EPIDEMIOL SERV SAUDE, V25, P683, DOI [10.5123/s1679-49742016000400002, 10.5123/S1679-49742016000400002]
   Tappe D, 2014, EUROSURVEILLANCE, V19, P12, DOI 10.2807/1560-7917.ES2014.19.4.20685
   Tappe D, 2015, EMERG INFECT DIS, V21, P911, DOI 10.3201/eid2105.141960
   Theze J, 2018, CELL HOST MICROBE, V23, P855, DOI [10.1016/j.chom.2018.04.017, 10.101]
   Thomas DL, 2016, MMWR-MORBID MORTAL W, V65, P154, DOI 10.15585/mmwr.mm6506e2
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
   Vargas A, 2016, EPIDEMIOL SERV SAUDE, V25, P691, DOI [10.5123/S1679-49742016000400003, 10.5123/s1679-49742016000400003]
   Villamil-Gomez WE, 2016, INT J INFECT DIS, V51, P135, DOI 10.1016/j.ijid.2016.07.017
   Villarroel PMS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006239
   Waggoner JJ, 2016, CLIN INFECT DIS, V63, P1584, DOI 10.1093/cid/ciw589
   Waggoner JJ, 2016, J CLIN MICROBIOL, V54, P860, DOI 10.1128/JCM.00279-16
   Wang L, 2016, CELL HOST MICROBE, V19, P561, DOI 10.1016/j.chom.2016.04.006
   Weger-Lucarelli J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005101
   WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P263, DOI 10.1016/0035-9203(58)90085-3
   Wolfe ND, 2001, AM J TROP MED HYG, V64, P310, DOI 10.4269/ajtmh.2001.64.310
   Xia HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02816-2
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Yun SI, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00800-16
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 157
TC 1
Z9 1
U1 0
U2 2
PU MINISTERIO DA SAUDE
PI BRASILIA
PA ESPLANADA MINISTERIOS, BLOCO G, BRASILIA, DF 70058-900, BRAZIL
SN 1679-4974
EI 2237-9622
J9 EPIDEMIOL SERV SAUDE
JI Epidemiol. Serv. Saude
PY 2019
VL 28
IS 2
AR UNSP e2018411
DI 10.5123/S1679-49742019000200022
PG 23
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA IY7XJ
UT WOS:000486608200012
PM 31460659
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Angulo, JMC
   Cuesta, TAC
   Menezes, EP
   Pedroso, C
   Brites, C
AF Cubillos Angulo, Juan Manuel
   Castro Cuesta, Taryn Ariadna
   Menezes, Eliane Pereira
   Pedroso, Celia
   Brites, Carlos
TI A SYSTEMATIC REVIEW ON THE INFLUENCE OF HLA-B POLYMORPHISMS ON HIV-1
   MOTHER-TO-CHILD-TRANSMISSION
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Review
DE Mother to child transmission; HIV; HLA-B
ID CLASS-I; ESCAPE MUTATIONS; VIRAL LOAD; VIRUS; INHERITANCE; PROGRESSION;
   ALLELES; IMPACT; RISK; SLOW
AB Background: Mother-to-child-transmission (MTCT) is the main route of HIV-1 infection in children. Genetic studies suggest HLA-B alleles play an important role on HIV-1 transmission, progression, and control of HIV-1 infection. Objective: To evaluate which polymorphisms of HLA-B are involved in HIV-1 MTCT.
   Methods: Two independent reviewers performed a systematic review on search engines PubMed, Europe PMC, Cochrane, Scientific Electronic Library Online (SciELO), and Literatura Latino-americana e do Caribe em Ciencias da SaUde (Lilacs), using the following key terms: "HIV infection", "HIV newborn", "HLA polymorphisms", "HLA-B", and "Mother to child transmission". All studies focusing on evaluation of HIV-1 MTCT, HIV infection evolution, and molecular analyses of HLA-B in children were selected.
   Results: Nine studies fulfilled the inclusion criteria. Sixteen HLA-B alleles groups were associated with HIV-1 infection; seven of them (43.8%) were related to slow disease progression or reduced risk of MTCT, while six (37.5%) alleles groups were linked to a faster progression of HIV infection in children and to increased risk of MTCT. The available evidence suggest that HLA-B*57 group allele is associated with slow disease progression, while HLA-B*35 group allele is associated to increased risk of MTCT and rapid disease progression in infected children. The role of HLA-B*18, B*58 and B*44 are still controversial because they were associated to both, protection against MTCT, and to higher HIV replicative capacity, in different studies.
   Conclusion: HLA-B*57 group allele can be protective against MTCT while HLA-B*35 groups alleles are consistently associated with HIV-1 MTCT. (C) 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Cubillos Angulo, Juan Manuel; Pedroso, Celia; Brites, Carlos] Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Cubillos Angulo, Juan Manuel; Castro Cuesta, Taryn Ariadna] Univ Fed Bahia, Programa Posgrad Med & Saude, Salvador, BA, Brazil.
   [Menezes, Eliane Pereira; Brites, Carlos] Univ Fed Bahia, Fac Med, Dept Med, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.; Brites, C (corresponding author), Univ Fed Bahia, Fac Med, Dept Med, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Cubillos Angulo, Juan
   Manuel/0000-0002-3877-5077
CR Adland E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004954
   Arnaiz-Villena A, 2009, CURR HIV RES, V7, P314, DOI 10.2174/157016209788348029
   Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346
   Carrington M, 2012, ANNU REV MED, V63, P131, DOI 10.1146/annurev-med-062909-130018
   Child L, 2004, J VIROL, V78, P8927
   Farquhar C, 2004, AIDS RES HUM RETROV, V20, P692, DOI 10.1089/0889222041524616
   Feeney ME, 2006, J ALLERGY CLIN IMMUN, V118, P324, DOI 10.1016/j.jaci.2006.05.016
   Fouda GG, 2015, CURR OPIN VIH SIDA, V2, P177
   Gao XJ, 2005, NAT MED, V11, P1290, DOI 10.1038/nm1333
   Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203
   Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357
   Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2017, UNAIDS DAT 2017, P1
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Kaur G, 2009, TISSUE ANTIGENS, V74, P373, DOI 10.1111/j.1399-0039.2009.01337.x
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006
   Kloverpris HN, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00665
   Kosmrlj A, 2010, NATURE, V465, P350, DOI 10.1038/nature08997
   Kuhn L, 2004, AIDS, V18, P1281, DOI 10.1097/00002030-200406180-00006
   Levy JA, 2007, HIV AND THE PATHOGENESIS OF AIDS, 3RD EDITION, P1
   Li XL, 2014, HUM GENET, V133, P1187, DOI 10.1007/s00439-014-1465-x
   LIBERATI A, 2009, PLOS MED, V339, DOI [DOI 10.1136/BMJ.B2700, 10.1136/bmj.b2700]
   Mackelprang RD, 2008, J INFECT DIS, V197, P1156, DOI 10.1086/529528
   Mackelprang RD, 2010, J INFECT DIS, V202, P1273, DOI 10.1086/656318
   Mekue L, 2015, J AIDS CLIN RES, V06
   Meuleman T, 2015, HUM IMMUNOL, V76, P362, DOI 10.1016/j.humimm.2015.02.004
   Milligan C, 2014, J INFECT DIS, V210, pS631, DOI 10.1093/infdis/jiu344
   O'Brien SJ, 2001, TRENDS MOL MED, V7, P379, DOI 10.1016/S1471-4914(01)02131-1
   Paximadis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016541
   Prentice HA, 2013, J VIROL, V87, P4043, DOI 10.1128/JVI.03302-12
   Raghavan M, 2015, MOL IMMUNOL, V68, P89, DOI 10.1016/j.molimm.2015.07.007
   Rajapaksa US, 2012, P NATL ACAD SCI USA, V109, P13353, DOI 10.1073/pnas.1204199109
   Schneidewind A, 2009, J VIROL, V83, P8616, DOI 10.1128/JVI.00730-09
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Coloccini RS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113146
   Thobakgale CF, 2009, J VIROL, V83, P10234, DOI 10.1128/JVI.00921-09
   Winchester R, 2004, JAIDS-J ACQ IMM DEF, V36, P659, DOI 10.1097/00126334-200406010-00002
   Zhang X, 2013, CLIN VACCINE IMMUNOL, V20, P1048, DOI 10.1128/CVI.00015-13
NR 40
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2019
VL 23
IS 1
BP 53
EP 59
DI 10.1016/j.bjid.2018.12.002
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA IY0AR
UT WOS:000486053500009
PM 30772367
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Castilho, JL
   Escuder, MM
   Veloso, V
   Gomes, JO
   Jayathilake, K
   Ribeiro, S
   Souza, RA
   Ikeda, ML
   de Alencastro, PR
   Tupinanbas, U
   Brites, C
   McGowan, CC
   Grangeiro, A
   Grinsztejn, B
AF Castilho, Jessica L.
   Escuder, Maria M.
   Veloso, Valdilea
   Gomes, Jackeline O.
   Jayathilake, Karu
   Ribeiro, Sayonara
   Souza, Rosa A.
   Ikeda, Maria L.
   de Alencastro, Paulo R.
   Tupinanbas, Unai
   Brites, Carlos
   McGowan, Catherine C.
   Grangeiro, Alexandre
   Grinsztejn, Beatriz
TI Trends and predictors of non-communicable disease multimorbidity among
   adults living with HIV and receiving antiretroviral therapy in Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; ART; multimorbidity; non-communicable diseases; ageing; Brazil
ID T-CELL-ACTIVATION; NATIONAL-HEALTH SURVEY; CO-MORBIDITIES; AGE;
   COMORBIDITIES; POPULATION; ERA; INFLAMMATION; INDIVIDUALS; PREVALENCE
AB IntroductionPeople living with HIV (PLHIV) on antiretroviral therapy (ART) experience high rates of non-communicable diseases (NCDs). These co-morbidities often accumulate and older adults may suffer from multimorbidity. Multimorbidity has been associated with loss of quality of life, polypharmacy, and increased risk of frailty and mortality. Little is known of the trends or predictors NCD multimorbidity in PLHIV in low- and middle-income countries.
   MethodsWe examined NCD multimorbidity in adult PLHIV initiating ART between 2003 and 2014 using a multi-site, observational cohort in Brazil. NCDs included cardiovascular artery disease, hyperlipidemia (HLD), diabetes, chronic kidney disease, cirrhosis, osteoporosis, osteonecrosis, venous thromboembolism and non-AIDS-defining cancers. Multimorbidity was defined as the incident accumulation of two or more unique NCDs. We used Poisson regression to examine trends and Cox proportional hazard models to examine predictors of multimorbidity.
   ResultsOf the 6206 adults, 332 (5%) developed multimorbidity during the study period. Parallel to the ageing of the cohort, the prevalence of multimorbidity rose from 3% to 11% during the study period. Older age, female sex (adjusted hazard ratio (aHR)=1.30 (95% confidence interval (CI) 1.03 to 1.65)) and low CD4 nadir (<100 vs. 200cells/mm(3) aHR=1.52 (95% CI: 1.15 to 2.01)) at cohort entry were significantly associated with increased risk of multimorbidity. Among patients with incident multimorbidity, the most common NCDs were HLD and diabetes; however, osteoporosis was also frequent in women (16 vs. 35% of men and women with multimorbidity respectively).
   ConclusionsAmong adult PLHIV in Brazil, NCD multimorbidity increased from 2003 to 2014. Females and adults with low CD4 nadir were at increased risk in adjusted analyses. Further studies examining prevention, screening and management of NCDs in PLHIV in low- and middle-income countries are needed.
C1 [Castilho, Jessica L.; Jayathilake, Karu; McGowan, Catherine C.] Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA.
   [Escuder, Maria M.; Gomes, Jackeline O.] Inst Hlth, Sao Paulo State Dept Hlth, Sao Paulo, Brazil.
   [Veloso, Valdilea; Ribeiro, Sayonara; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Natl Inst Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Souza, Rosa A.] AIDS Reference & Training Ctr, Sao Paulo State Dept Hlth, Sao Paulo, Brazil.
   [Ikeda, Maria L.] Univ Vale Rio dos Sinos, Sch Hlth, Porto Alegre, RS, Brazil.
   [de Alencastro, Paulo R.] Care & Treatment Clin Partenon Sanat, Rio Grande Do Sul State Dept Hlth, Porto Alegre, RS, Brazil.
   [Tupinanbas, Unai] Univ Fed Minas Gerais, Med Sch, Belo Horizonte, MG, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil.
   [Grangeiro, Alexandre] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
RP Castilho, JL (corresponding author), Vanderbilt Univ, Med Ctr, A2200 Med Ctr North,1161 21st Ave South, Nashville, TN 37232 USA.
EM jessica.castilho@vanderbilt.edu
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01AI69923,
   K23AI1120875, P30AI110527]; Brazilian National Council for Scientific &
   Technological Development; Brazilian National Ministry of Health; Pan
   American Health Organization; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI069923, U01AI069923,
   U01AI069923, U01AI069923] Funding Source: NIH RePORTER
FX National Institutes of Health: U01AI69923 (J.L.C., M.M.E., V.G.V.,
   J.O.G., K.J., C.M., A.G., B.G.), K23AI1120875 (J.L.C.), P30AI110527
   (J.L.C.). Brazilian National Council for Scientific & Technological
   Development. Brazilian National Ministry of Health. Pan American Health
   Organization.
CR Balderson BH, 2013, AIDS CARE, V25, P451, DOI 10.1080/09540121.2012.712669
   Bertoldi AD, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-62
   Borges AH, 2015, J INFECT DIS, V212, P585, DOI 10.1093/infdis/jiv123
   Crabtree-Ramirez B, 2014, JAIDS-J ACQ IMM DEF, V67, pS96, DOI 10.1097/QAI.0000000000000261
   Duncan Bruce Bartholow, 2017, Rev. bras. epidemiol., V20, P90, DOI 10.1590/1980-5497201700050008
   Goulet JL, 2007, CLIN INFECT DIS, V45, P1593, DOI 10.1086/523577
   Grangeiro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095673
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Hearps AC, 2014, CURR HIV-AIDS REP, V11, P20, DOI 10.1007/s11904-013-0190-8
   Hentzien M, 2016, J NUTR HEALTH AGING, V20, P408, DOI 10.1007/s12603-015-0608-7
   Kaplan RC, 2011, ATHEROSCLEROSIS, V217, P207, DOI 10.1016/j.atherosclerosis.2011.03.011
   Kendall CE, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-161
   Kowal P, 2010, GLOBAL HEALTH ACTION, V3, P11, DOI 10.3402/gha.v3i0.5302
   Longenecker CT, 2013, HIV MED, V14, P385, DOI 10.1111/hiv.12013
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Mallon PWG, 2010, CURR OPIN INFECT DIS, V23, P1, DOI 10.1097/QCO.0b013e328334fe9a
   Malta DC, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0427-4
   Malta DC, 2016, SAO PAULO MED J, V134, P163, DOI 10.1590/1516-3180.2015.02090911
   Malta DC, 2015, SAO PAULO MED J, V133, P286, DOI 10.1590/1516-3180.2015.13340308
   Manner IW, 2013, J CLIN HYPERTENS, V15, P101, DOI 10.1111/jch.12029
   Moran Caitlin A, 2017, Curr Treat Options Infect Dis, V9, P52, DOI 10.1007/s40506-017-0109-9
   Narayan KMV, 2014, JAIDS-J ACQ IMM DEF, V67, pS2, DOI 10.1097/QAI.0000000000000267
   Oursler KK, 2006, AIDS PATIENT CARE ST, V20, P782, DOI 10.1089/apc.2006.20.782
   Pacheco YM, 2015, ANTIVIR RES, V117, P69, DOI 10.1016/j.antiviral.2015.03.002
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Rodriguez-Penney AT, 2013, AIDS PATIENT CARE ST, V27, P5, DOI 10.1089/apc.2012.0329
   Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9
   Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701
   Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0
   Tenorio AR, 2014, J INFECT DIS, V210, P1248, DOI 10.1093/infdis/jiu254
   Torres TS, 2013, BRAZ J INFECT DIS, V17, P324, DOI 10.1016/j.bjid.2012.10.024
   Vance DE, 2014, J NEUROSCI NURS, V46, P292, DOI 10.1097/JNN.0000000000000074
   Wong C, 2018, CLIN INFECT DIS, V66, P1230, DOI 10.1093/cid/cix998
NR 35
TC 5
Z9 5
U1 1
U2 6
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JAN
PY 2019
VL 22
IS 1
AR e25233
DI 10.1002/jia2.25233
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HK1ZI
UT WOS:000457705500011
PM 30697950
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Gomes-Neto, M
   Rodriguez, I
   Ledo, AP
   Vieira, JPB
   Brites, C
AF Gomes-Neto, Mansueto
   Rodriguez, Indira
   Ledo, Ana P.
   Vieira, Joao P. B.
   Brites, Carlos
TI Muscle Strength and Aerobic Capacity in HIV-Infected Patients: A
   Systematic Review and Meta-Analysis
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Review
DE HIV; muscle strength; physical activity; meta-analysis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; QUALITY-OF-LIFE; FUNCTIONAL IMPAIRMENT;
   EXERCISE CAPACITY; PHYSICAL FUNCTION; GRIP STRENGTH; YOUNG-ADULTS;
   CHILDREN; INDIVIDUALS; FITNESS
AB Background: Physical impairment is highly prevalent in HIV-infected patients. We conducted a systematic review of published studies that included studies comparing muscle function in HIV-infected patients to matched healthy controls, and studies comparing aerobic capacity in HIV-infected patients with that observed in matched healthy controls.
   Design: Systematic review and meta-analysis.
   Methods: We searched for references on MEDLINE, SciELO, Cumulative Index to Nursing and Allied Health (CINAHL), and Scopus up to December 2017. Weighted mean differences and 95% confidence intervals (CIs) were calculated, and heterogeneity was assessed using the I-2 test.
   Results: A total of 30 studies, covering 2148 healthy controls and 2161 HIV-infected patients, fulfilled the inclusion criteria. The average muscle strength and aerobic capacity were significantly lower in HIV-infected patients. Meta-analysis revealed moderate-quality evidence of weaker muscle strength and aerobic capacity in HIV-infected patients. A significant difference in lower-body strength of 1.07 (95% CI: 0.29 to 1.84) was found for participants in the healthy control group compared with HIV group. A significant difference in aerobic capacity (peak VO2) of 8.4 (95% CI: 4.8 to 12.0) was found for participants in the healthy control group compared with HIV group.
   Conclusions: Muscle strength and aerobic capacity of HIV-infected patients are reduced in comparison with healthy controls. Additional studies are needed to define the best interventions to improve the physical function in HIVinfected patients.
C1 [Gomes-Neto, Mansueto; Rodriguez, Indira; Ledo, Ana P.; Brites, Carlos] Univ Fed Bahia UFBA, Programa Posgrad Med & Saude, Salvador, BA, Brazil.
   [Gomes-Neto, Mansueto; Vieira, Joao P. B.] Univ Fed Bahia UFBA, Curso Fisioterapia, Dept Fisioterapia, Salvador, BA, Brazil.
RP Gomes-Neto, M (corresponding author), Univ Fed Bahia UFBA, Inst Ciencias Saude, Dept Fisioterapia, Ave Reitor Miguel Calmon S-N, BR-40110100 Salvador, BA, Brazil.
EM mansueto.neto@ufba.br
RI Brites, Carlos/D-1353-2013; Gomes-NETO, Mansueto MGN/I-5235-2014
OI Brites, Carlos/0000-0002-4673-6991; Gomes-NETO, Mansueto
   MGN/0000-0002-0717-9694
CR Armstrong N, 2009, PEDIATR EXERC SCI, V21, P130, DOI 10.1123/pes.21.2.130
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   de Lima LRA, 2017, PEDIATR EXERC SCI, V29, P377, DOI 10.1123/pes.2017-0036
   Baranoski AS, 2014, J WOMENS HEALTH, V23, P69, DOI 10.1089/jwh.2013.4367
   Bernard C, 2017, TROP MED INT HEALTH, V22, P516, DOI 10.1111/tmi.12852
   Cade WT, 2007, AM J PHYSIOL-ENDOC M, V292, pE812, DOI 10.1152/ajpendo.00300.2006
   Cade W Todd, 2002, Pediatr Rehabil, V5, P161
   Cade WT, 2003, ARCH PHYS MED REHAB, V84, P1831, DOI 10.1016/j.apmr.2003.03.004
   Cade WT, 2003, ARCH PHYS MED REHAB, V84, P1595, DOI 10.1053/S0003-9993(03)00275-2
   Cade WT, 2003, MED SCI SPORT EXER, V35, P1108, DOI 10.1249/01.MSS.0000074567.61400.93
   Cade WT, 2004, PHYS THER, V84, P655, DOI 10.1093/ptj/84.7.655
   Campo M, 2014, JAIDS-J ACQ IMM DEF, V65, P557, DOI 10.1097/QAI.0000000000000086
   Chisati EM, 2015, MALAWI MED J, V27, P5, DOI 10.4314/mmj.v27i1.2
   Cohen J, 1988, STAT POWER ANAL BEHA
   Crawford KW, 2013, AIDS RES HUM RETROV, V29, P1138, DOI [10.1089/aid.2013.0020, 10.1089/AID.2013.0020]
   da Silva GP, 2015, J ELECTROMYOGR KINES, V25, P515, DOI 10.1016/j.jelekin.2015.02.008
   DELAMARCHE P, 1992, EUR J APPL PHYSIOL, V65, P66, DOI 10.1007/BF01466276
   Diller GP, 2005, CIRCULATION, V112, P828, DOI 10.1161/CIRCULATIONAHA.104.529800
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erlandson KM, 2014, CURR HIV-AIDS REP, V11, P279, DOI 10.1007/s11904-014-0215-y
   Erlandson KM, 2013, JAIDS-J ACQ IMM DEF, V63, P209, DOI 10.1097/QAI.0b013e318289bb7e
   Frankenstein L, 2007, INT J CARDIOL, V122, P125, DOI 10.1016/j.ijcard.2006.11.038
   Githinji LN, 2017, ANN AM THORAC SOC, V14, P722, DOI [10.1513/annalsats.201612-1018oc, 10.1513/AnnalsATS.201612-1018OC]
   Gomes M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138066
   GRAU JM, 1993, ANN NEUROL, V34, P206, DOI 10.1002/ana.410340217
   Halin R, 2003, MED SCI SPORT EXER, V35, P1042, DOI 10.1249/01.MSS.0000069407.02648.47
   Higgins JP, 2016, COCHRANE LIB, V2006, P4, DOI DOI 10.1097/PEP.0000000000000505
   JOHNSON JE, 1990, AM REV RESPIR DIS, V141, P618, DOI 10.1164/ajrccm/141.3.618
   Laird RA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-229
   Lambertz D, 2003, J APPL PHYSIOL, V95, P64, DOI 10.1152/japplphysiol.00885.2002
   de Souza PML, 2011, CLINICS, V66, P261, DOI 10.1590/S1807-59322011000200014
   Macdonald HM, 2017, J MUSCULOSKEL NEURON, V17, P27
   Mbada CE, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-106
   Mhariwa P., 2015, MASTER SCI PHYSIOTHE, P1
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097]
   MORGELLO S, 1995, ACTA NEUROPATHOL, V90, P366, DOI 10.1007/BF00315010
   Neto MG, 2016, BRAZ J INFECT DIS, V20, P76, DOI 10.1016/j.bjid.2015.11.001
   da Silva AMO, 2014, TRANSPL P, V46, P3039, DOI 10.1016/j.transproceed.2014.07.015
   Oliveira VH, 2017, AGING CELL, V16, P461
   Olsen MF, 2015, EPIDEMIOL INFECT, V143, P1048, DOI 10.1017/S0950268814001502
   Ortmeyer HK, 2016, PHYSL REP, V4, P1
   Oursler KK, 2006, AIDS RES HUM RETROV, V22, P1113, DOI 10.1089/aid.2006.22.1113
   Pasanen T, 2017, BRIT J SPORT MED, V51, P1459, DOI 10.1136/bjsports-2016-097132
   Patil R, 2017, INDIAN J SEX TRANSM, V38, P47, DOI 10.4103/0253-7184.196886
   POTHOFF G, 1994, RESPIRATION, V61, P80
   Ramirez-Marrero FA, 2014, P R HEALTH SCI J, V33, P163
   Ramos E, 2012, PM&R, V4, P171, DOI 10.1016/j.pmrj.2011.11.009
   Raso V, 2014, J SPORT MED PHYS FIT, V54, P100
   Raso V, 2013, CLINICS, V68, P359, DOI 10.6061/clinics/2013(03)OA12
   Richert L, 2011, AIDS, V25, P797, DOI 10.1097/QAD.0b013e3283455dff
   Roge BT, 2002, AIDS, V16, P973, DOI 10.1097/00002030-200205030-00003
   Rusch Melanie, 2004, Health Qual Life Outcomes, V2, P46, DOI 10.1186/1477-7525-2-46
   Rylance J, 2016, AIDS, V30, P2795, DOI 10.1097/QAD.0000000000001249
   Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001
   Simpson D, 2004, AIDS, V18, P1403, DOI 10.1097/01.aids.0000131309.70451.fe
   SIMPSON DM, 1994, ANN INTERN MED, V121, P769, DOI 10.7326/0003-4819-121-10-199411150-00008
   Somarriba G, 2013, AIDS RES HUM RETROV, V29, P112, DOI [10.1089/aid.2012.0047, 10.1089/AID.2012.0047]
   Wallet MA, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0106-z
NR 58
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2018
VL 79
IS 4
BP 491
EP 500
DI 10.1097/QAI.0000000000001835
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HK4GE
UT WOS:000457879400014
PM 30371532
DA 2020-12-01
ER

PT J
AU de Carvalho, AL
   Brites, C
   Taguchi, TB
   Pinho, SF
   Campos, G
   Lucena, R
AF de Carvalho, Alessandra Lemos
   Brites, Carlos
   Taguchi, Tania Barreto
   Pinho, Suely Fernandes
   Campos, Gubio
   Lucena, Rita
TI Congenital Zika Virus Infection with Normal Neurodevelopmental Outcome,
   Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
AB We describe a case of a 20-month-old girl with probable congenital Zika virus infection and normal neurodevelopment, despite microcephaly and abnormal neuroimaging. This case raises questions about early prognostic markers and draws attention to the need for investigation in suspected Zika cases, even if the child's early neurodevelopment is normal.
C1 [de Carvalho, Alessandra Lemos] SARAH Network Rehabil Hosp, Child Rehabil Ctr, Salvador Unit, Salvador, BA, Brazil.
   [Taguchi, Tania Barreto; Pinho, Suely Fernandes] SARAH Network Rehabil Hosp, Salvador, BA, Brazil.
   [Brites, Carlos; Campos, Gubio; Lucena, Rita] Univ Fed Bahia, Salvador, BA, Brazil.
RP de Carvalho, AL (corresponding author), SARAH Salvador Hosp, Av Tancredo Neves 2782, BR-41820900 Salvador, BA, Brazil.
EM alessandracarvalhoped@gmail.com
RI Brites, Carlos/D-1353-2013; Lucena, Rita/L-9842-2013
OI Brites, Carlos/0000-0002-4673-6991; Lucena, Rita/0000-0002-6190-9168
FU Coordination for the Improvement of Higher Education Personnel (CAPES),
   BrazilCAPES
FX No external funding was used for this study. G.C. received a "Zika fast
   track grant" provided by Coordination for the Improvement of Higher
   Education Personnel (CAPES), Brazil, to perform ELISA testing for Zika
   virus in the neonatal period. This institution had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of this manuscript. The other authors have no financial
   disclosures relevant to this article.
CR de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Bayley N., 2005, BAYLEY SCALES INFANT
   del Campo M, 2017, AM J MED GENET A, V173, P841, DOI 10.1002/ajmg.a.38170
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097]
   da Silva AAM, 2016, EMERG INFECT DIS, V22, P1953, DOI 10.3201/eid2211.160956
   Pan American Health Organization, 2016, EP UPD NEUR SYNDR CO
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6
   World Health Organization Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA
NR 10
TC 2
Z9 2
U1 0
U2 5
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD NOV
PY 2018
VL 24
IS 11
BP 2128
EP 2130
DI 10.3201/eid2411.180883
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GX4UO
UT WOS:000447732600037
PM 30334734
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Lins, L
   Ledo, A
   Luz, E
   Dutra, BS
   Prieto, IR
   Brites, C
AF Lins, L.
   Ledo, A.
   Luz, E.
   Soares Dutra, B.
   Rodriguez Prieto, I.
   Brites, C.
TI ART improves most domains of HRQoL by both SF-36 and HAT-QoL scales
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Lins, L.; Ledo, A.; Luz, E.; Soares Dutra, B.; Rodriguez Prieto, I.; Brites, C.] Edgard Santos Fed Univ Hosp, Res Lab Infect Dis, Salvador, BA, Brazil.
RI Lins-Kusterer, Liliane/Q-5191-2019
OI Lins-Kusterer, Liliane/0000-0003-3736-0002
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2018
VL 21
SU 8
SI SI
MA P133
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GY3UU
UT WOS:000448482200170
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Herrera, BB
   Tsai, WY
   Brites, C
   Luz, E
   Pedroso, C
   Drexler, JF
   Wang, WK
   Kanki, PJ
AF Herrera, Bobby Brooke
   Tsai, Wen-Yang
   Brites, Carlos
   Luz, Estela
   Pedroso, Celia
   Drexler, Jan Felix
   Wang, Wei-Kung
   Kanki, Phyllis J.
TI T Cell Responses to Nonstructural Protein 3 Distinguish Infections by
   Dengue and Zika Viruses (vol 9, e00755-18, 2018)
SO MBIO
LA English
DT Correction
C1 [Herrera, Bobby Brooke; Kanki, Phyllis J.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Tsai, Wen-Yang; Wang, Wei-Kung] Univ Hawaii Manoa, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA.
   [Brites, Carlos; Luz, Estela; Pedroso, Celia] Univ Fed Bahia, Sch Med, Lab Infect Res, Salvador, BA, Brazil.
   [Drexler, Jan Felix] Humboldt Univ, Freie Univ Berlin, Charite Univ Med Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Inst Virol, Berlin Inst Hlth, Berlin, Germany.
   [Drexler, Jan Felix] German Ctr Infect Res, Bonn, Germany.
RP Herrera, BB (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Herrera BB, 2018, MBIO, V9, DOI [10.1128/mBio.00755-18, 10.1128/mbio.00755-18]
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2018
VL 9
IS 5
AR e01995-18
DI 10.1128/mBio.01995-18
PG 1
WC Microbiology
SC Microbiology
GA GZ5NY
UT WOS:000449472200097
PM 30352936
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Vargas, L
   Amaral, S
   Arriaga, M
   Sarno, M
   Brites, C
AF Vargas, L.
   Amaral, S.
   Arriaga, M.
   Sarno, M.
   Brites, C.
TI High prevalence of syphilis in parturient women and congenital syphilis
   cases in public maternities in Salvador-Bahia, Brazil
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Editorial Material
C1 [Vargas, L.; Amaral, S.; Arriaga, M.; Brites, C.] Univ Fed Bahia, Lab Pesquisa Infectol, Complexo Hosp Prof Edgard Santos, LAPI, Salvador, BA, Brazil.
   [Sarno, M.] Univ Fed Bahia, Dept Obstet & Gynecol, Sch Med, Salvador, BA, Brazil.
RP Vargas, L (corresponding author), Rua Augusto Viana Sn,6 Andar, BR-40110060 Salvador, BA, Brazil.
EM medalexa@hotmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Almeida MFG, 2007, BAHIA DST J BRAS DOE, V19, P144
   Brasil Ministerio de Sande, 2014, PROT INV TRANSM VERT, P7014
   Griemberg G, 2000, MEDICINA-BUENOS AIRE, V60, P343
   Ministerio da Saude, 2017, B EPIDEMIOLOGICO, V48
   Moura AA, 2015, INT J INFECT DIS, V39, P10, DOI 10.1016/j.ijid.2015.07.022
   Nobrega I, 2013, BRAZ J INFECT DIS, V17, P184, DOI 10.1016/j.bjid.2012.10.018
   Oliveira A, 2016, INICIACAO CIENTIFICA, V18, P15
   Oliveira TA, 2016, REV BRAS GINECOL OBS, V38, P183, DOI 10.1055/s-0036-1580710
   Domingues RMSM, 2014, REV SAUDE PUBL, V48, P766, DOI 10.1590/S0034-8910.2014048005114
NR 9
TC 2
Z9 3
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-0328
EI 1471-0528
J9 BJOG-INT J OBSTET GY
JI BJOG
PD SEP
PY 2018
VL 125
IS 10
SI SI
BP 1212
EP 1214
DI 10.1111/1471-0528.15304
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA GP6JF
UT WOS:000440985300002
PM 29802689
OA Bronze
DA 2020-12-01
ER

PT J
AU Vieira, VD
   Lins, L
   Sarmento, VA
   Netto, EM
   Brites, C
AF Vieira, Vinicius da Costa
   Lins, Liliane
   Sarmento, Viviane Almeida
   Netto, Eduardo Martins
   Brites, Carlos
TI Oral health and health-related quality of life in HIV patients
SO BMC ORAL HEALTH
LA English
DT Article
DE Health-related quality of life; Oral health; Depression; HIV
ID ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; HIV/AIDS PATIENTS;
   DEPRESSION; BRAZIL; METAANALYSIS; ADHERENCE; VARIABLES; ANXIETY; LESIONS
AB Background: Oral health care may improve the health-related quality of life (HRQoL) of HIV/AIDS patients. We aimed to evaluate oral health and HRQoL of HIV/AIDS patients using antiretroviral therapy.
   Methods: A cross-sectional study included 120 HIV-infected patients, aged >= 18 years, from February, 2016 to September, 2017. The 36-Item Short Form Health Survey (SF-36) was used to evaluate the HRQoL. We assessed dental caries status using the Decayed, Missing and Filled Teeth (DMFT) index. Information about demographic, socioeconomic status, depression, and other comorbidities were collected. All patients with depression had a medical diagnosis. Comorbidities were defined as medical diagnoses of arterial hypertension, type-2 diabetes, tuberculosis, syphilis, cardiopathy, chronic renal failure, lymphoma, HCV infection, HBV infection and fatty liver disease. Independent t-tests were used to compare differences between mean levels of HRQoL, age, and DMFT and its components according to groups of sex, comorbidities and depression. Simple linear regression was used to analyze the relationship between the Mental Component Summary (MCS) and DMFT, and a multiple regression equation investigated depression, age, MCS, and comorbidities as predictors of DMFT.
   Results: The mean DMFT index was 12.4 +/- 8.2. A linear regression equation estimated a significant (p = 0.022) decrease of 0.25 unit (%) in MCS for each unit increase in DMFT. Among depressed patients, a significant (p = 0.008) decrease of 0.67% in MCS for each unity increase in DMFT was estimated. Depressed patients showed worse oral health indicators (DFMT index; p <= 0.001; and mean Missing Teeth; p <= 0.052) and lower HRQoL domains than non-depressed patients. DMFT remained associated with depression (P < 0.005) after controlling for age, MCS, and comorbidities.
   Conclusions: We found association between poorer oral health (higher DMFT index) and lower Mental Health Component Summary in HIV-infected patients with depression. Patients with depression deserve especial attention to their HRQoL and oral care.
C1 [Vieira, Vinicius da Costa; Lins, Liliane] Univ Fed Bahia, Sch Med, Praca 15 Novembro,Largo Terreiro Jesus S-N, BR-40026010 Salvador, BA, Brazil.
   [Sarmento, Viviane Almeida] Univ Fed Bahia, Sch Dent, Salvador, BA, Brazil.
   [Netto, Eduardo Martins; Brites, Carlos] Edgard Santos Fed Univ Hosp, Res Lab Infect Dis, Salvador, BA, Brazil.
RP Lins, L (corresponding author), Univ Fed Bahia, Sch Med, Praca 15 Novembro,Largo Terreiro Jesus S-N, BR-40026010 Salvador, BA, Brazil.
EM liliane.lins@ufba.br
RI Lins-Kusterer, Liliane/Q-5191-2019; Brites, Carlos/D-1353-2013; Netto,
   Eduardo/D-1432-2013; Sarmento, Viviane/F-9837-2014
OI Lins-Kusterer, Liliane/0000-0003-3736-0002; Brites,
   Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761;
   Sarmento, Viviane/0000-0003-4403-3659
CR Aleixo RQ, 2010, BRAZ J INFECT DIS, V14, P449, DOI 10.1590/S1413-86702010000500005
   Batavia AS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150656
   Betancur MN, 2017, BRAZ J INFECT DIS, V21, P507, DOI 10.1016/j.bjid.2017.04.004
   Bretz WA, 2000, AIDS PATIENT CARE ST, V14, P549, DOI 10.1089/108729100750018317
   Brites-Alves C, 2015, BRAZIL J IMMUNOL RES, V2015
   Campos LN, 2010, AIDS BEHAV, V14, P289, DOI 10.1007/s10461-008-9435-8
   Degroote S, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-40
   Fleming CA, 2004, CLIN INFECT DIS, V38, P572, DOI 10.1086/381263
   Jaquet A, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18867
   Jia HG, 2007, QUAL LIFE RES, V16, P961, DOI 10.1007/s11136-007-9214-4
   Khazaei S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/786462
   Krasse B., 1985, CARIES RISK PRACTICA
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Leroy R, 2010, BMC ORAL HEALTH, V10, DOI 10.1186/1472-6831-10-8
   Liberali SA, 2013, AUST DENT J, V58, P18, DOI 10.1111/adj.12031
   Lins L, 2017, J MED VIROL, V89, P1782, DOI 10.1002/jmv.24852
   Liu CL, 2006, QUAL LIFE RES, V15, P941, DOI 10.1007/s11136-005-5913-x
   McGavin G, 1998, J DENT RES, V77, P781
   Mohamed N, 2017, BMC ORAL HEALTH, V17, DOI 10.1186/s12903-017-0409-y
   Navazesh M, 2003, ORAL SURG ORAL MED O, V95, P693, DOI 10.1067/moe.2003.230
   Ngum PA, 2017, NEUROL THER, V6, P103, DOI 10.1007/s40120-017-0065-9
   Okoro CA, 2012, COMMUNITY DENT ORAL, V40, P134, DOI 10.1111/j.1600-0528.2011.00637.x
   Pinheiro A, 2004, INT DENT J, V54, P131, DOI 10.1111/j.1875-595X.2004.tb00268.x
   Rodriguez-Penney AT, 2013, AIDS PATIENT CARE ST, V27, P5, DOI 10.1089/apc.2012.0329
   Santo AE, 2010, ORAL DIS, V16, P176, DOI 10.1111/j.1601-0825.2009.01622.x
   Saravani S, 2016, INT J HIGH RISK BEHA, V5
   Schwendicke F, 2015, J DENT RES, V94, P10, DOI 10.1177/0022034514557546
   Soares GB, 2014, SPEC CARE DENT, V34, P176, DOI 10.1111/scd.12056
   Uthman OA, 2014, CURR HIV-AIDS REP, V11, P291, DOI 10.1007/s11904-014-0220-1
   Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008
   WHO, 1997, ORAL HLTH SURVEYS BA
   Wu PY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104945
NR 32
TC 3
Z9 3
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD AUG 29
PY 2018
VL 18
AR 151
DI 10.1186/s12903-018-0605-4
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA GS4SY
UT WOS:000443641900001
PM 30157834
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Tsai, WY
   Youn, HH
   Tyson, J
   Brites, C
   Tsai, JJ
   Pedroso, C
   Drexler, JF
   Balmaseda, A
   Harris, E
   Wang, WK
AF Tsai, Wen-Yang
   Youn, Han Ha
   Tyson, Jasmine
   Brites, Carlos
   Tsai, Jih-Jin
   Pedroso, Celia
   Drexler, Jan Felix
   Balmaseda, Angel
   Harris, Eva
   Wang, Wei-Kung
TI Use of Urea Wash ELISA to Distinguish Zika and Dengue Virus Infections
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID NEUTRALIZING ANTIBODIES; CROSS-REACTIVITY; ENHANCEMENT
AB Serologic testing remains crucial for Zika virus diagnosis. We found that urea wash in a Zika virus nonstructural protein 1 IgG ELISA distinguishes secondary dengue from Zika virus infection with previous dengue (sensitivity 87.5%, specificity 93.8%). This test will aid serodiagnosis, serosurveillance, and monitoring of Zika complications in dengue-endemic regions.
C1 [Tsai, Wen-Yang] Univ Hawaii Manoa, Dept Trop Med Med Microbiol & Pharmacol, John A Burns Sch Med, 651 Ilalo St,BSB 325E, Honolulu, HI 96822 USA.
   [Youn, Han Ha; Tyson, Jasmine; Wang, Wei-Kung] Univ Hawaii Manoa, Honolulu, HI 96822 USA.
   [Brites, Carlos; Pedroso, Celia] Univ Fed Bahia, Salvador, BA, Brazil.
   [Tsai, Jih-Jin] Kaohsiung Med Univ, Kaohsiung, Taiwan.
   [Drexler, Jan Felix] Univ Bonn, Med Ctr, Bonn, Germany.
   [Balmaseda, Angel] Minist Hlth, Natl Ctr Diag & Reference, Managua, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Berkeley, CA 94720 USA.
RP Wang, WK (corresponding author), Univ Hawaii Manoa, Dept Trop Med Med Microbiol & Pharmacol, John A Burns Sch Med, 651 Ilalo St,BSB 325E, Honolulu, HI 96822 USA.
EM wangwk@hawaii.edu
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Drexler, Jan
   Felix/0000-0002-3509-0232
FU National Institutes of Health, National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI110769-01, R01 AI099631,
   U54AI065359, P01AI106695, U19 AI118610]; Molecular and Cellular
   Immunology Core from the National Institute of General Medical Sciences
   [5P30GM114737]; National Health Research Institutes, TaiwanNational
   Health Research Institutes - Taiwan [NHRI-106A1-MRCO-1017178]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U54AI065359, U19AI118610, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U19AI118610, U19AI118610, R01AI110769, U54AI065359,
   U54AI065359, U19AI118610, U54AI065359, U19AI118610, U54AI065359,
   U54AI065359, U19AI118610, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, P01AI106695, P01AI106695, U54AI065359,
   U54AI065359, P01AI106695, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, P01AI106695, U54AI065359, R01AI099631, U54AI065359,
   U19AI118610, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U19AI118610, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U19AI118610,
   U54AI065359, U54AI065359, U19AI118610, P01AI106695, U54AI065359,
   U54AI065359, U19AI118610, U54AI065359, U19AI118610, P01AI106695,
   U54AI065359, U54AI065359, U54AI065359, P01AI106695, U54AI065359,
   U54AI065359, U54AI065359, P01AI106695, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, P01AI106695, U54AI065359, U54AI065359,
   U19AI118610, U54AI065359, U54AI065359, U19AI118610, P01AI106695,
   U54AI065359, U54AI065359, U54AI065359, R01AI099631, U54AI065359,
   U54AI065359, P01AI106695, U54AI065359, U54AI065359, U19AI118610,
   U54AI065359, U19AI118610, U54AI065359, P01AI106695, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, P01AI106695, U19AI118610,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, R01AI099631, R01AI099631, U54AI065359, U19AI118610,
   P01AI106695, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U19AI118610, U54AI065359, U54AI065359, U54AI065359, U19AI118610,
   U19AI118610, U54AI065359, U19AI118610, U54AI065359, U54AI065359,
   U19AI118610, U54AI065359, R01AI099631, U54AI065359, U19AI118610,
   U54AI065359, U54AI065359, U54AI065359, U19AI118610, R01AI099631,
   U54AI065359, U54AI065359, U54AI065359, U19AI118610, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U19AI118610,
   U54AI065359, U19AI118610, U54AI065359, P01AI106695, U19AI118610,
   U54AI065359, U19AI118610, P01AI106695, P01AI106695, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U19AI118610, U54AI065359, U54AI065359, U19AI118610, U19AI118610,
   U54AI065359, U19AI118610, U54AI065359, R01AI110769, U54AI065359,
   U19AI118610, U19AI118610, U54AI065359, U54AI065359, U54AI065359,
   P01AI106695, U54AI065359, U54AI065359, U54AI065359, P01AI106695,
   U54AI065359, U54AI065359, U54AI065359, U19AI118610, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U19AI118610, U54AI065359,
   U19AI118610, U54AI065359, U54AI065359, U54AI065359, P01AI106695,
   U54AI065359, U54AI065359, U54AI065359, U19AI118610, P01AI106695,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U19AI118610, U19AI118610, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, P01AI106695, R01AI110769,
   R01AI099631, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   P01AI106695, U54AI065359, P01AI106695, P01AI106695, U54AI065359,
   U19AI118610, U19AI118610, R01AI110769, U54AI065359, U54AI065359,
   U54AI065359, U19AI118610, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U19AI118610, U54AI065359, P01AI106695, U19AI118610,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, P01AI106695,
   P01AI106695, U54AI065359, U54AI065359, U19AI118610, U19AI118610,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U19AI118610,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U19AI118610, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, P01AI106695, P01AI106695, U54AI065359, P01AI106695,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, P01AI106695, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U19AI118610,
   U54AI065359, U19AI118610, R01AI110769, P01AI106695, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, P01AI106695, U54AI065359,
   U54AI065359, U54AI065359, R01AI099631, U54AI065359, U54AI065359,
   U19AI118610, U19AI118610, U54AI065359, U54AI065359, U19AI118610,
   U54AI065359, U54AI065359, U19AI118610, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, P01AI106695, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U19AI118610, U54AI065359, U54AI065359,
   P01AI106695, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U19AI118610, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U19AI118610, P01AI106695, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U19AI118610, U54AI065359,
   U54AI065359, U19AI118610, U54AI065359, U54AI065359, U19AI118610,
   U54AI065359, U19AI118610, U54AI065359, U19AI118610, U54AI065359,
   U54AI065359, U54AI065359, R01AI099631, U54AI065359, U54AI065359,
   U54AI065359, P01AI106695, P01AI106695, P01AI106695, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, P01AI106695,
   U54AI065359, U19AI118610, U54AI065359, U19AI118610, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   U54AI065359, U54AI065359, U54AI065359, U54AI065359, U54AI065359,
   R01AI099631, P01AI106695, U54AI065359, U19AI118610, P01AI106695,
   U54AI065359, U19AI118610, U54AI065359] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737,
   P30GM114737, P30GM114737, P30GM114737, P30GM114737, P30GM114737] Funding
   Source: NIH RePORTER
FX This work was supported by grants R01AI110769-01 (W.-K.W.), R01 AI099631
   and U54AI065359 (A.B.), and P01AI106695 and U19 AI118610 (E.H.) from the
   National Institutes of Health, National Institute of Allergy and
   Infectious Diseases; Molecular and Cellular Immunology Core through
   grant 5P30GM114737 from the National Institute of General Medical
   Sciences; and grant NHRI-106A1-MRCO-1017178 (J.-J.T., W.-K.W.) from the
   National Health Research Institutes, Taiwan. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aliota MT, 2017, ANTIVIR RES, V144, P223, DOI 10.1016/j.antiviral.2017.06.001
   Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Centers for Disease Control and Prevention, GUID US LAB TEST ZIK
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Puschnik A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002274
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tsai WY, 2017, CLIN INFECT DIS, V65, P1829, DOI 10.1093/cid/cix672
   Tsai WY, 2015, J VIROL, V89, P7348, DOI 10.1128/JVI.00273-15
NR 15
TC 5
Z9 7
U1 0
U2 7
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUL
PY 2018
VL 24
IS 7
BP 1355
EP 1359
DI 10.3201/eid2407.171170
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GJ8JP
UT WOS:000435635900025
PM 29912689
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Herrera, BB
   Tsai, WY
   Brites, C
   Luz, E
   Pedroso, C
   Drexler, JF
   Wang, WK
   Kanki, PJ
AF Herrera, Bobby Brooke
   Tsai, Wen-Yang
   Brites, Carlos
   Luz, Estela
   Pedroso, Celia
   Drexler, Jan Felix
   Wang, Wei-Kung
   Kanki, Phyllis J.
TI T Cell Responses to Nonstructural Protein 3 Distinguish Infections by
   Dengue and Zika Viruses
SO MBIO
LA English
DT Article
DE Brazil; dengue virus; T cell immunity; Zika virus; nonstructural protein
   3
ID MHC CLASS-I; ANTIBODY-DEPENDENT ENHANCEMENT; ORIGINAL ANTIGENIC SIN;
   CROSS-REACTIVITY; PEPTIDE; CYTOSOL; PATHOGENESIS; EPITOPES; IMMUNITY;
   BINDING
AB The 2015-2016 Zika virus (ZIKV) epidemic in the Americas and the Caribbean demonstrated that clinical assays to detect, distinguish, and characterize immune responses to flaviviral infections are needed. ZIKV and dengue virus (DENV) are mosquito-transmitted flaviviruses sharing overlapping geographic distributions and have significant sequence similarities that can increase the potential for antibody and T cell cross-reaction. Using nonstructural protein 1-based enzyme-linked immunosorbent assays (ELISA5), we determined the serostatus of individuals living in a region of DENV and ZIKV endemicity in Brazil, identifying individuals with primary DENV (pDENV) and primary ZIKV (pZIKV), ZIKV with primary DENV (ZIKVwpDENV), and secondary DENV (sDENV) infections; the presence of pDENV and pZIKV was further confirmed by neutralization tests. Development of an enzyme-linked immunosorbent spot (ELISPOT) assay for DENV and ZIKV structural and nonstructural (NS) protein antigens enabled us to distinguish infections by these viruses based on T cell responses and to characterize those responses. We found that gamma interferon (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) T cell responses to NS3 differentiated DENV and ZIKV infections with 94% sensitivity and 92% specificity. In general, we also showed that pDENV and sDENV cases and pZIKV and ZIKVwpDENV cases elicit similar T cell response patterns and that HIV-infected individuals show T cell responses that are lower than those shown by HIV-negative individuals. These results have important implications for DENV and ZIKV diagnostic and vaccine development and provide critical insights into the T cell response in individuals with multiple flaviviral infections.
   IMPORTANCE The potential for antibody and T cell cross-reactions to DENV and ZIKV, flaviviruses that cocirculate and can sequentially infect individuals, has complicated diagnostic and vaccine development. Our serological data show that antibodies to nonstructural protein 1 can distinguish sequential human infections by DENV and ZIKV. The development of a simple and inexpensive assay also enables the differentiation of DENV and ZIKV infections based on characterization of T cell responses. Our T cell data reveal strong response patterns that are similar in nature to those seen with individuals with one or multiple DENV infections and with individuals with only primary ZIKV infection and ZIKV-infected individuals with previous DENV exposure. The characterization of T cell responses in a serologically validated group of individuals is of relevance to the development of vaccines and immunotherapeutics against these global threats.
C1 [Herrera, Bobby Brooke; Kanki, Phyllis J.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Tsai, Wen-Yang; Wang, Wei-Kung] Univ Hawaii Manoa, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA.
   [Brites, Carlos; Luz, Estela; Pedroso, Celia] Univ Fed Bahia, Sch Med, Lab Infect Res, Salvador, BA, Brazil.
   [Drexler, Jan Felix] Charite Univ Med Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Free Univ Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Humboldt Univ, Berlin, Germany.
   [Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [Drexler, Jan Felix] German Ctr Infect Res, Braunschweig, Germany.
RP Kanki, PJ (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.; Wang, WK (corresponding author), Univ Hawaii Manoa, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA.
EM wkwang@hawaii.edu; pkanki@hsph.harvard.edu
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Drexler, Jan
   Felix/0000-0002-3509-0232
FU Harvard University David Rockefeller Center for Latin American Studies;
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI110769-01]; National Institute of General Medical Sciences,
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P20GM103516]; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI110769, R01AI110769,
   R01AI110769, R01AI110769, R01AI110769] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [P20GM103516,
   P20GM103516, P20GM103516] Funding Source: NIH RePORTER
FX This work was funded by a Harvard University David Rockefeller Center
   for Latin American Studies grant to B.B.H. and by grants R01AI110769-01
   from the National Institute of Allergy and Infectious Diseases and
   P20GM103516 from the National Institute of General Medical Sciences,
   NIH, to W.-K.W. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Armstrong P, 2016, MMWR-MORBID MORTAL W, V65, P286, DOI 10.15585/mmwr.mm6511e1
   Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Cao HY, 2002, J INFECT DIS, V185, P244, DOI 10.1086/338448
   Castanha PMS, 2016, J INFECT DIS, V214, P265, DOI 10.1093/infdis/jiw143
   Centers for Disease Control and Prevention, GUID US LAB TEST ZIK
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Govindarajan D, 2015, VACCINE, V33, P4105, DOI 10.1016/j.vaccine.2015.06.067
   Grifoni A, 2017, J VIROL, V91, DOI [10.1128/JVI.01469-17, 10.1128/jvi.01469-17]
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Herrera BB, 2018, J VIROL, V92, DOI 10.1128/JVI.01992-17
   Herrera BB, 2017, J INFECT DIS, V215, P1546, DOI 10.1093/infdis/jix182
   Horig H, 1999, J IMMUNOL, V163, P4434
   Johnson BW, 2005, VECTOR-BORNE ZOONOT, V5, P137, DOI 10.1089/vbz.2005.5.137
   Karlsson RK, 2004, J IMMUNOL METHODS, V285, P89, DOI 10.1016/j.jim.2003.11.013
   Krauer F, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002203
   Kushner N, 2003, P NATL ACAD SCI USA, V100, P6652, DOI 10.1073/pnas.1131930100
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Liao Q, 2012, VACCINE, V30, P1601, DOI 10.1016/j.vaccine.2011.12.117
   Lu YC, 2000, P NATL ACAD SCI USA, V97, P8027, DOI 10.1073/pnas.97.14.8027
   MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103
   McEvers K, 2005, VACCINE, V23, P4128, DOI 10.1016/j.vaccine.2005.03.022
   McLinden JH, 2008, J INFECT DIS, V198, P860, DOI 10.1086/591254
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Moreira-Soto Andres, 2017, J Infect Dis, V216, P1501, DOI 10.1093/infdis/jix539
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   Organization W. H., 2016, WHO DIR GEN SUMM OUT
   Peirson TC, 2013, FIELDS VIROLOGY
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Sarr AD, 2001, AIDS RES HUM RETROV, V17, P1257, DOI 10.1089/088922201750461311
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Steinhagen K, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Stryhn A, 2000, EUR J IMMUNOL, V30, P3089, DOI 10.1002/1521-4141(200011)30:11<3089::AID-IMMU3089>3.0.CO;2-5
   Tsai WY, 2017, CLIN INFECT DIS, V65, P1829, DOI 10.1093/cid/cix672
   Tsai WY, 2013, J VIROL, V87, P12562, DOI 10.1128/JVI.00871-13
   Waggoner JJ, 2016, CLIN INFECT DIS, V63, P1584, DOI 10.1093/cid/ciw589
   Watt G, 2003, CLIN INFECT DIS, V36, P1067, DOI 10.1086/374600
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
NR 48
TC 4
Z9 4
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD JUL-AUG
PY 2018
VL 9
IS 4
AR e00755-18
DI 10.1128/mBio.00755-18
PG 15
WC Microbiology
SC Microbiology
GA GS7MC
UT WOS:000443884300010
PM 30087165
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Moreira-Soto, A
   Cabral, R
   Pedroso, C
   Eschbach-Bludau, M
   Rockstroh, A
   Vargas, LA
   Postigo-Hidalgo, I
   Luz, E
   Sampaio, GS
   Drosten, C
   Netto, EM
   Jaenisch, T
   Ulbert, S
   Sarno, M
   Brites, C
   Drexler, JF
AF Moreira-Soto, Andres
   Cabral, Renata
   Pedroso, Celia
   Eschbach-Bludau, Monika
   Rockstroh, Alexandra
   Vargas, Ludy Alexandra
   Postigo-Hidalgo, Ignacio
   Luz, Estela
   Sampaio, Gilmara Souza
   Drosten, Christian
   Netto, Eduardo Martins
   Jaenisch, Thomas
   Ulbert, Sebastian
   Sarno, Manoel
   Brites, Carlos
   Drexler, Jan Felix
TI Exhaustive TORCH Pathogen Diagnostics Corroborate Zika Virus Etiology of
   Congenital Malformations in Northeastern Brazil
SO MSPHERE
LA English
DT Article
DE Brazil; TORCH; Zika virus; microcephaly; parturient
ID INFECTION; RISK
AB The Latin American 2015-2016 Zika virus (ZIKV) outbreak was associ- ated with an increase in microcephaly predominantly in northeastern Brazil. To comparatively investigate infectious causes of congenital malformations, we performed a nested case-control study in 32 mothers of cases of suspected congenital Zika syndrome (CZS) and 160 age-matched controls from Bahia, northeastern Brazil. We collected clinical and imaging data and assessed past exposure to ZIKV, Chikungunya virus (CHIKV), dengue virus, and 8 established TORCH (Toxoplasma gondii, Treponema pallidum, rubella virus, cytomegalovirus, herpes simplex virus 1 [HSV-1] and HSV-2, varicella-zoster virus, parvovirus B19) pathogens using multiple serological tests. Heterogeneous symptoms prevented unequivocal diagnosis of CZS on clinical grounds. Only ZIKV and CHIKV seroprevalence rates differed significantly between cases and controls (93.8% versus 67.8% for ZIKV [Fisher's exact text, P = 0.0021 and 20.7% versus 8.2% for CHIKV [chi(2), P = 0.0391]). High ZIKV seroprevalence rates in cases could not be explained by previous dengue virus infections potentially eliciting cross-reactive antibody responses affecting ZIKV serological tests. In conditional logistic regression analyses, only ZIKV was significantly associated with congenital malformations (P = 0.030; odds ratio, 4.0 [95% confidence interval, 1.1 to 14.1]). Our data support an association between maternal ZIKV exposure and congenital malformations. Parallels between the discrepant ZIKV and CHIKV seroprevalence rates between cases and controls and similar seroprevalence rates between cases and controls for the sexually transmitted T. pallidum and HSV-2 may suggest the occurrence of predominantly vector-borne transmission in our study population. High seroprevalence of TORCH pathogens suggests that exhaustive diagnostics will be necessary in the aftermath of the ZIKV outbreak and provides baseline data for longitudinal studies on ZIKV pathogenesis.
   IMPORTANCE The Latin American Zika virus (ZIKV) outbreak had a major impact on reproductive health worldwide. The reasons for the massively increased reports of neonatal microcephaly in northeastern Brazil are still unclear. Beyond the technical limitations of laboratory diagnostics, unambiguous diagnosis of ZIKV as the cause of congenital malformations is hampered by similar clinical pictures elicited by other pathogens known as TORCH pathogens. We performed a case-control study comparing mothers of children with congenital malformations to age-matched controls from Salvador, Brazil, one of the areas most extensively affected by the ZIKV outbreak. The ZIKV and Chikungunya virus seroprevalence rates differed significantly, whereas the levels of maternal exposure to TORCH pathogens were similar between cases and controls. Our data support a link between maternal ZIKV infection and congenital malformations and suggest the occurrence of predominantly vector-borne ZIKV transmission in these cases. In addition, some highly prevalent TORCH pathogens may be misinterpreted as representative of ongoing ZIKV activity in the absence of exhaustive diagnostics in northeastern Brazil.
C1 [Moreira-Soto, Andres; Eschbach-Bludau, Monika] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Moreira-Soto, Andres; Postigo-Hidalgo, Ignacio; Drosten, Christian; Drexler, Jan Felix] Charite Univ Med Berlin, Berlin, Germany.
   [Moreira-Soto, Andres; Postigo-Hidalgo, Ignacio; Drosten, Christian; Drexler, Jan Felix] Free Univ Berlin, Berlin, Germany.
   [Moreira-Soto, Andres; Postigo-Hidalgo, Ignacio; Drosten, Christian; Drexler, Jan Felix] Humboldt Univ, Berlin, Germany.
   [Moreira-Soto, Andres; Postigo-Hidalgo, Ignacio; Drosten, Christian; Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [Cabral, Renata; Sarno, Manoel] Univ Fed Bahia, Maternidade Climerio de Oliveira, Salvador, BA, Brazil.
   [Pedroso, Celia; Vargas, Ludy Alexandra; Luz, Estela; Sampaio, Gilmara Souza; Netto, Eduardo Martins; Sarno, Manoel; Brites, Carlos] Univ Fed Bahia, Complexo Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Rockstroh, Alexandra; Ulbert, Sebastian] Fraunhofer Inst Cell Therapy & Immunol, Dept Immunol, Leipzig, Germany.
   [Drosten, Christian; Jaenisch, Thomas; Drexler, Jan Felix] German Ctr Infect Res DZIF, Braunschweig, Germany.
   [Jaenisch, Thomas] Heidelberg Univ Hosp, Dept Infect Dis, Sect Clin Trop Med, Heidelberg, Germany.
RP Drexler, JF (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; Drexler, JF (corresponding author), Free Univ Berlin, Berlin, Germany.; Drexler, JF (corresponding author), Humboldt Univ, Berlin, Germany.; Drexler, JF (corresponding author), Berlin Inst Hlth, Inst Virol, Berlin, Germany.; Drexler, JF (corresponding author), German Ctr Infect Res DZIF, Braunschweig, Germany.
EM felix.drexler@charite.de
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991;
   Drexler, Jan Felix/0000-0002-3509-0232; Postigo-Hidalgo,
   Ignacio/0000-0001-9083-4102; Moreira-Soto, Andres/0000-0002-9224-5157
FU German Centre for Infection Research (DZIF) through the ZIKApath
   project; European Union's Horizon 2020 research and innovation program
   through the ZIKAlliance project [734548]; German Research Foundation
   (DFG)German Research Foundation (DFG); Charite-Universitatsmedizin
   Berlin
FX This work was supported by the German Centre for Infection Research
   (DZIF) through the ZIKApath project, the European Union's Horizon 2020
   research and innovation program through the ZIKAlliance project (grant
   agreement no. 734548), the German Research Foundation (DFG), and the
   Open Access Publication Fund of Charite-Universitatsmedizin Berlin. We
   declare that we have no competing financial interests.
CR Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Clemens S A, 1999, J Pediatr (Rio J), V75, P433
   Coyne CB, 2016, NAT REV MICROBIOL, V14, P707, DOI 10.1038/nrmicro.2016.125
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Jaenisch T, 2017, B WORLD HEALTH ORGAN, V95, P191, DOI [10.2471/BLT.16.178608, 10.2471/blt.16.178608]
   Levine D, 2017, RADIOLOGY, V285, P744, DOI 10.1148/radiol.2017171238
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Mitsuka-Bregano R, 2010, EPIDEMIOLOGIA IMPACT, P5
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Moreira-Soto Andres, 2017, J Infect Dis, V216, P1501, DOI 10.1093/infdis/jix539
   Moura AA, 2015, INT J INFECT DIS, V39, P10, DOI 10.1016/j.ijid.2015.07.022
   Mower WR, 1999, ANN EMERG MED, V33, P85, DOI 10.1016/S0196-0644(99)70422-1
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   Nogueira ML, 2018, CLIN MICROBIOL INFEC, V24, P646, DOI 10.1016/j.cmi.2017.11.004
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Rockstroh A, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.87
   Rodrigues LC, 2017, LANCET, V390, P824, DOI 10.1016/S0140-6736(17)31478-2
   Schaub B, 2017, LANCET CHILD ADOLESC, V1, P45, DOI 10.1016/S2352-4642(17)30001-9
   Secretaria-de-Vigilancia-em-Saude, 2015, B EP PROGR NAC IM AS, P46
   SHEPARD TH, 1982, J PEDIATR-US, V101, P810, DOI 10.1016/S0022-3476(82)80338-7
   Souza AI, 2018, PUBLIC HEALTH REP, V133, P461, DOI 10.1177/0033354918777256
   Victora CG, 2016, LANCET, V387, P621, DOI 10.1016/S0140-6736(16)00273-7
NR 25
TC 2
Z9 2
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD JUL-AUG
PY 2018
VL 3
IS 4
AR e00278-18
DI 10.1128/mSphere.00278-18
PG 6
WC Microbiology
SC Microbiology
GA GP7FE
UT WOS:000441058200023
PM 30089647
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Brites-Alves, C
   Luz, E
   Netto, EM
   Ferreira, T
   Diaz, RS
   Pedroso, C
   Page, K
   Brites, C
AF Brites-Alves, Clara
   Luz, Estela
   Netto, Eduardo M.
   Ferreira, Thalis
   Diaz, Ricardo Sohbie
   Pedroso, Celia
   Page, Kimberly
   Brites, Carlos
TI Immune Activation, Proinflammatory Cytokines, and Conventional Risks for
   Cardiovascular Disease in HIV Patients: A Case-Control Study in Bahia,
   Brazil
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE HIV; cytokines; cardiovascular; immune activation; dyslipidemia
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; LIFE EXPECTANCY;
   UNITED-STATES; INFECTION; ERA; MORTALITY
AB Background: Cardiovascular events (CVE) are an increasing cause of morbi-mortality for HIV patients. The antiretroviral therapy (ART), persistent immune activation, and life style are factors that can increase CVE for such patients. We performed a case-control study to evaluate the role of coinfections and immune markers associated with CVE.
   Methods: We included patients under ART, with undetectable plasma viral load >= 12 months. Patients presenting any condition of risk for CVE were considered cases, and those without CVE risk conditions were controls. History of viral infections (Epstein-Barr virus, hepatitis C virus, hepatitis B virus, and cytomegalovirus), exposure to antiretroviral drugs, time since HIV diagnosis/under ART, and life style (demographics, weight, smoking, alcohol, and illicit drug use) were assessed. CD4/CD8 nadir and current counts, nadir and current CD4/CD8 ratio, immune activation markers (CD4CD38HLADR, CD8CD38HLADR), and serum levels of eight cytokines [IL-2, IL-4, IL-6, IL-10, tumoral necrosis factor-alpha (TNF-alpha), interferon gamma, macrophage inflammatory proteins 1 alpha, and interferon-inducing protein (IP-10)] were measured.
   Results: Two-thirds of patients were males. Cases (N = 106) were older (52.8 vs 49.5 years, p = 0.002), had higher levels of creatinine (0.97 vs 0.87 mg/dL, p = 0.002) and IL-6 (0.67 vs 0.52 pg/mL, p = 0.04) than controls (N = 114). There was no difference between groups regarding frequency of CD4CD39HLADR+ or CD8CD38HLADR+ cells. We found a significant correlation (all patients) between increased frequency of CD4CD38HLADR+ cells and levels of IP-10 (r = 0.171, p = 0.02) and TNF-a (r = 0.187, p = 0.01). Levels of IL-6 (r = 0.235, p = 0.02), TNF-alpha (r = 0.267, p = 0.01), and IP-10 (r = 0.205, p = 0.04) were correlated with CD4CD38HLADR+ cells, in controls. Higher frequency of CD4CD38HLADR+ cells was also correlated with levels of IP-10 (r = 0.271, p = 0.04) in patients presenting with arterial hypertension. Frequency of CD4CD38HLADR+ cells was negatively correlated with levels of IL-2 (r = -0.639, p = 0.01) and IL-6 (r = -0.0561, p = 0.03) in patients with hypercholesterolemia. No association was detected between viral infections or smoking/alcohol use and immune activation markers.
   Conclusion: Our results indicate IL-6 levels are associated with increased CV risk. Activated CD4+ T cells were associated with increased levels of proinflammatory cytokines.
C1 [Brites-Alves, Clara; Luz, Estela; Netto, Eduardo M.; Ferreira, Thalis; Pedroso, Celia; Brites, Carlos] Univ Fed Bahia, Lab Pesquisa Infectol, LAPI, Complexo Hosp Prof Edgard Santos, Salvador, BA, Brazil.
   [Diaz, Ricardo Sohbie] Univ Fed Sao Paulo, Lab Retrovirol, Sao Paulo, Brazil.
   [Page, Kimberly] Univ New Mexico, Albuquerque, NM 87131 USA.
RP Brites, C (corresponding author), Univ Fed Bahia, Lab Pesquisa Infectol, LAPI, Complexo Hosp Prof Edgard Santos, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DA03105603]; CNPQ (Brazil)National
   Council for Scientific and Technological Development (CNPq)
   [470087/2014-5]
FX The study was supported by a grant from NIH (R01DA03105603) and CNPQ
   (Brazil, 470087/2014-5).
CR Berenguer J, 2012, CYTOKINE, V57, P25, DOI 10.1016/j.cyto.2011.10.020
   Brooks JT, 2012, AM J PUBLIC HEALTH, V102, P1516, DOI 10.2105/AJPH.2012.300844
   Clark IA, 2007, CYTOKINE GROWTH F R, V18, P335, DOI 10.1016/j.cytogfr.2007.04.002
   Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195
   FEINGOLD KR, 1992, DIABETES, V41, P97, DOI 10.2337/diab.41.2.S97
   FEINGOLD KR, 1989, ENDOCRINOLOGY, V125, P267, DOI 10.1210/endo-125-1-267
   Feinstein MJ, 2016, AM J CARDIOL, V117, P214, DOI 10.1016/j.amjcard.2015.10.030
   Gallant J, 2017, J INFECT DIS, V216, P1525, DOI 10.1093/infdis/jix518
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Guaraldi G, 2014, JAIDS-J ACQ IMM DEF, V65, P175, DOI 10.1097/QAI.0000000000000018
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Jellinger PS, 2017, ENDOCR PRACT, V23, P1, DOI 10.4158/EP171764.APPGL
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Ledru E, 2000, BLOOD, V95, P3191, DOI 10.1182/blood.V95.10.3191.010k10_3191_3198
   Liovat AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046143
   McLaren JE, 2011, PROG LIPID RES, V50, P331, DOI 10.1016/j.plipres.2011.04.002
   Miller CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095061
   Ministerio da Saude Brasil, 2017, B EP AIDS IST AN 5
   Mooney S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144312
   Naeger DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008886
   NUNEZ EA, 1994, BAILLIERE CLIN ENDOC, V8, P803, DOI 10.1016/S0950-351X(05)80302-7
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Sabin CA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-251
   Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Triant VA, 2010, JAIDS-J ACQ IMM DEF, V55, P615, DOI 10.1097/QAI.0b013e3181f4b752
   Wong C, 2018, CLIN INFECT DIS, V66, P1230, DOI 10.1093/cid/cix998
   Zhang X, 2014, J HEPATOL, V61, P1365, DOI 10.1016/j.jhep.2014.07.006
NR 28
TC 4
Z9 4
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 26
PY 2018
VL 9
AR 1469
DI 10.3389/fimmu.2018.01469
PG 6
WC Immunology
SC Immunology
GA GK6LS
UT WOS:000436297500001
PM 29997625
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Marques, M
   Luz, E
   Leal, M
   Oliveira, JV
   Patricio, R
   Netto, EM
   Brites, C
AF Marques, Marinho
   Luz, Estela
   Leal, Mateus
   Oliveira, Joao Vitor
   Patricio, Rejane
   Martins Netto, Eduardo
   Brites, Carlos
TI Neoplasms-associated deaths in HIV-1 infected and non-infected patients
   in Bahia, Brazil
SO CANCER EPIDEMIOLOGY
LA English
DT Article
DE HIV/Aids; Malignancies; Mortality; CD4+T lymphocytes
ID AIDS-RELATED MALIGNANCIES; HIV-INFECTED PATIENTS; HODGKIN-LYMPHOMA;
   CANCER-RISK; HAART ERA; IMMUNODEFICIENCY; SURVIVAL; HIV/AIDS; OUTCOMES;
   PEOPLE
AB Background: HIV-infected patients are at a higher risk to develop malignancies than general population. Although AIDS-related malignancies are a common feature of late-stage disease, patients under successful antiretroviral therapy also have an increased risk for development of non-AIDS malignancies.
   Objective: To compare the frequency and characteristics of adults HIV-infected patients and general population who died of malignancies in Bahia, Brazil from January 2000 to December 2010.
   Methods: National Information System on Mortality (SIM) was searched to identify all deaths in the study period caused by malignancies in general population and in HIV patients. The frequency of malignancies in these two groups was compared. For HIV patients we also recorded the last HIV-1 RNA plasma viral load and CD4 + cells count, retrieved from oficial databases on laboratory monitoring for HIV patients.
   Results: In the study period 733,645 deaths were reported, 677,427 (92.3%) of them in individual older than 13 years. Malignancies were the cause of death in 77,174 (11.4%) of them, and 5156 (0.8%) were associated to HIV/Aids.
   Among deaths of HIV/Aids patients, Kaposi's sarcoma was the most prevalent malignancy (OR: 309.7; 95% CI: 177-544), followed by non-Hodgkin lymphoma (OR: 10.1; 95% CI: 5.3-19.3), Hodgkin's lymphoma (OR: 4.3; 95% CI: 2.2-8.4), and cranial nervous malignancies (OR: 3.3; 95% CI:1.6-7.0). HIV patients died at a significantly lower age (43.7 years), than general population (64.5 years, p < 0.0001). Patients who had a diagnosis of Aids-related malignancies had lower CD4 + cells count than those with non-AIDS relates malignancies (p = 0.04).
   Conclusion: HIV infection is a clear risk fator for development of some malignancies, and is associated with early mortality, compared to general population. The level of CD4 + cells count predicts the type of malignancies causing death in this population.
C1 [Marques, Marinho; Leal, Mateus; Oliveira, Joao Vitor] Univ Estado Bahia, Salvador, Ba, Brazil.
   [Luz, Estela; Martins Netto, Eduardo; Brites, Carlos] Univ Fed Bahia, Salvador, Ba, Brazil.
   [Patricio, Rejane] Secretaria Saude Estado Bahia, Salvador, Ba, Brazil.
RP Marques, M (corresponding author), Univ Estado Bahia, Dept Cienc Vida, Colegiado Med, Rua Silveira Martins,2555 Cabula, BR-41150000 Salvador, Ba, Brazil.
EM mmsneto@uneb.br
RI da Silva Neto, Marinho Marques/Q-9064-2019; Netto, Eduardo/D-1432-2013;
   Brites, Carlos/D-1353-2013
OI da Silva Neto, Marinho Marques/0000-0002-9728-7268; Netto,
   Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Albini L, 2013, AIDS RES HUM RETROV, V29, P1097, DOI [10.1089/aid.2012.0321, 10.1089/AID.2012.0321]
   Bedimo RJ, 2009, JAIDS-J ACQ IMM DEF, V52, P203, DOI 10.1097/QAI.0b013e3181b033ab
   Biggar RJ, 2006, BLOOD, V108, P3786, DOI 10.1182/blood-2006-05-024109
   Carroll V, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv044
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Neto LFDP, 2012, REV SOC BRAS MED TRO, V45, P687, DOI 10.1590/S0037-86822012000600006
   Dal Maso L, 2014, JAIDS-J ACQ IMM DEF, V66, P428, DOI 10.1097/QAI.0000000000000184
   Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59
   Grulich AE, 1999, AIDS, V13, P839, DOI 10.1097/00002030-199905070-00014
   Guiguet M, 2009, LANCET ONCOL, V10, P1152, DOI 10.1016/S1470-2045(09)70282-7
   Hema MN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161594
   Hleyhel M., CLIN INFECT DIS, V57
   Hleyhel M, 2014, AIDS, V28, P2109, DOI 10.1097/QAD.0000000000000382
   Hoffmann C, 2015, HIV MED, V16, P261, DOI 10.1111/hiv.12200
   Kowalkowski MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077409
   LEVINE AM, 1993, JNCI-J NATL CANCER I, V85, P1382, DOI 10.1093/jnci/85.17.1382
   Long JL, 2008, AIDS, V22, P489, DOI 10.1097/QAD.0b013e3282f47082
   Luz Estela, 2013, ISRN Hematol, V2013, P904201, DOI 10.1155/2013/904201
   Ministerio da Saude, 2016, B EP AIDS IST
   Cobucci RNO, 2015, J INFECT PUBLIC HEAL, V8, P1, DOI 10.1016/j.jiph.2014.08.003
   Riedel DJ, 2017, AIDS RES HUM RETROV, V33, P482, DOI [10.1089/aid.2016.0181, 10.1089/AID.2016.0181]
   Rubinstein PG, 2014, AIDS, V28, P453, DOI 10.1097/QAD.0000000000000071
   Sampaio J, 2007, CURR OPIN ONCOL, V19, P476, DOI 10.1097/CCO.0b013e3282c8c8eb
   Schommers P, 2015, BRIT J HAEMATOL, V168, P806, DOI 10.1111/bjh.13221
   Smith C, 1998, ANN MED, V30, P323, DOI 10.3109/07853899809029932
   Wiggill TM, 2011, JAIDS-J ACQ IMM DEF, V56, P460, DOI 10.1097/QAI.0b013e31820bb06a
   Wood C, 2005, CELL RES, V15, P947, DOI 10.1038/sj.cr.7290372
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1877-7821
EI 1877-783X
J9 CANCER EPIDEMIOL
JI Cancer Epidemiol.
PD JUN
PY 2018
VL 54
BP 133
EP 136
DI 10.1016/j.canep.2018.04.001
PG 4
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA GG6RF
UT WOS:000432825000021
PM 29727806
DA 2020-12-01
ER

PT J
AU Pereira, MF
   Luz, E
   Netto, EM
   Barbosa, MHF
   Brites, C
AF Pereira, Marcela Fonseca
   Luz, Estela
   Netto, Eduardo Martins
   Fonseca Barbosa, Manoel Henrique
   Brites, Carlos
TI Low variation in initial CD4 cell count in a HIV Chock for referral
   center, in Salvador, Brazil, from 2002 to updates 2015
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV/AIDS; CD4; Antiretroviral therapy
ID ANTIRETROVIRAL THERAPY; CARE; HIV/AIDS; PREVENTION; DIAGNOSES; COHORT;
   DELAY
AB Early initiation of antiretroviral therapy increases the likelihood of effective immune restoration, quality of life, and greater life expectancy for HIV-infected individuals. We evaluated the evolution of mean CD4+ cells count at diagnosis of HIV/AIDS in Salvador, Brazil from 2002 to 2015. We identified HIV/AIDS patients older than 18 years with diagnosis of HIV infection from 2002 to 2015, who had their first laboratory evaluation at Complexo Hospitalar Prof. Edgard Santos, Federal University of Bahia. Initial mean CD4+ cells count and age, over time were evaluated. A total of 1801 patients randomly selected individuals were included in the analysis. Overall mean CD4+ count at diagnosis in the whole period was 279 +/- 265, varying from 191 in 2015 to 334 in 2011. There was no improvement in the immunological status at diagnosis from 2002 to 2015. In addition, a higher frequency of CD4+ cells count < 200 cells/mL in the last two years was observed. This suggests that the adopted strategies for early diagnosis of HIV/AIDS in Salvador, Brazil, are still ineffective. (C) 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [Pereira, Marcela Fonseca; Luz, Estela; Netto, Eduardo Martins; Fonseca Barbosa, Manoel Henrique; Brites, Carlos] Univ Fed Bahia, Fac Med, Complexo Hosp Prof Edgard Santos, LAPI Lab Pesquisa Infectol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Fac Med, Complexo Hosp Prof Edgard Santos, LAPI Lab Pesquisa Infectol, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
CR Khoury Z, 2015, AIDS BEHAV, V19, P679, DOI 10.1007/s10461-014-0885-x
   Kiertiburanakul S, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18804
   Kittner JM, 2015, INFECTION, V43, P299, DOI 10.1007/s15010-014-0719-9
   Komninakis SV, 2018, AIDS RES HUM RETROV, V34, P129, DOI [10.1089/aid.2015.0379, 10.1089/AID.2015.0379]
   Lesko CR, 2013, CLIN INFECT DIS, V57, P1027, DOI 10.1093/cid/cit421
   Ministerio da Saticle Secretaria de Vigilancia em Departamento de DST AIDS e Hepatites Virais, 2013, PROT CLIN DIR TER AD
   Ministerio da Saude do Brasil, 2015, B EP HIV AIDS
   Monforte AD, 2011, ANTIVIR THER, V16, P1103, DOI 10.3851/IMP1883
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Organizacao Mundial de Saiicle, 2014, CONS GUID HIV PREV D
   Owen SM, 2012, CURR OPIN HIV AIDS, V7, P125, DOI 10.1097/COH.0b013e3283506613
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Pineirua A, 2015, LANCET INFECT DIS, V15, P833, DOI 10.1016/S1473-3099(15)00108-5
   Ransome Y, 2015, AIDS, V29, P1369, DOI 10.1097/QAD.0000000000000684
   Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5
   Souza PRB, 2007, CLINICS, V62, P579, DOI 10.1590/S1807-59322007000500008
   Valentini MB, 2015, BRAZ J INFECT DIS, V19, P253, DOI 10.1016/j.bjid.2015.01.005
   Zoufaly A, 2012, HIV MED, V13, P172, DOI 10.1111/j.1468-1293.2011.00958.x
NR 18
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2018
VL 22
IS 3
BP 245
EP 247
DI 10.1016/j.bjid.2018.05.005
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA GS0PP
UT WOS:000443207000014
PM 29883585
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Fischer, C
   Pedroso, C
   Mendrone, A
   de Filippis, AMB
   Vallinoto, ACR
   Ribeiro, BM
   Durigon, EL
   Marques, ETA
   Campos, GS
   Viana, IFT
   Levi, JE
   Scarpelli, LC
   Nogueira, ML
   Bastos, MD
   Souza, NCS
   Khouri, R
   Lira, SMC
   Komninakis, SV
   Baronti, C
   Charrel, RN
   Kummerer, BM
   Drosten, C
   Brites, C
   de Lamballerie, X
   Niedrig, M
   Netto, EM
   Drexler, JF
AF Fischer, Carlo
   Pedroso, Celia
   Mendrone, Alfredo, Jr.
   Bispo de Filippis, Ana Maria
   Rosario Vallinoto, Antonio Carlos
   Ribeiro, Bergmann Morais
   Durigon, Edison Luiz
   Marques, Ernesto T. A., Jr.
   Campos, Gubio S.
   Viana, Isabelle F. T.
   Levi, Jose Eduardo
   Scarpelli, Luciano Cesar
   Nogueira, Mauricio Lacerda
   Bastos, Michele de Souza
   Santiago Souza, Nathalia C.
   Khouri, Ricardo
   Costa Lira, Sanny M.
   Komninakis, Shirley Vasconcelos
   Baronti, Cecile
   Charrel, Remi N.
   Kuemmerer, Beate M.
   Drosten, Christian
   Brites, Carlos
   de lamballerie, Xavier
   Niedrig, Matthias
   Netto, Eduardo Martins
   Drexler, Jan Felix
TI External Quality Assessment for Zika Virus Molecular Diagnostic Testing,
   Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID INFECTION; LOAD
AB We conducted an external quality assessment of Zika virus molecular diagnostic tests in Brazil using a new Zika virus standard. Of 15 laboratories, 73% showed limited sensitivity and specificity. Viral load estimates varied significantly. Continuous quality assurance is required for adequate estimates of Zika virus-associated disease and determination of patient care.
C1 [Fischer, Carlo; Drosten, Christian; Drexler, Jan Felix] Charite, German Ctr Infect Res, Berlin, Germany.
   [Pedroso, Celia; Brites, Carlos; Netto, Eduardo Martins] Hosp Univ Prof Edgard Santos, LAPI, Salvador, BA, Brazil.
   [Mendrone, Alfredo, Jr.; Levi, Jose Eduardo] Fdn Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Bispo de Filippis, Ana Maria] Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Rosario Vallinoto, Antonio Carlos] Fed Univ Para, Belem, Para, Brazil.
   [Ribeiro, Bergmann Morais] Univ Brasilia, Brasilia, DF, Brazil.
   [Durigon, Edison Luiz; Levi, Jose Eduardo; Santiago Souza, Nathalia C.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Marques, Ernesto T. A., Jr.; Viana, Isabelle F. T.] Fundacao Oswaldo Cruz, Pernambuco, Brazil.
   [Campos, Gubio S.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Levi, Jose Eduardo; Scarpelli, Luciano Cesar] Diagnost Amer DASA, Sao Paulo, Brazil.
   [Levi, Jose Eduardo; Costa Lira, Sanny M.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Nogueira, Mauricio Lacerda] Fac Med Sao Jose do Rio Preto, Sao Jose De Rio Preto, Brazil.
   [Bastos, Michele de Souza] Fdn Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Khouri, Ricardo] Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Komninakis, Shirley Vasconcelos] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Baronti, Cecile; Charrel, Remi N.; de lamballerie, Xavier] Aix Marseille Univ, Marseille, France.
   [Baronti, Cecile; Charrel, Remi N.; de lamballerie, Xavier] Assistance Publ Hop Marseille, Marseille, France.
   [Kuemmerer, Beate M.] Univ Bonn, Med Ctr, Bonn, Germany.
   [Niedrig, Matthias] Robert Koch Inst, Berlin, Germany.
RP Drexler, JF (corresponding author), Inst Virol, Helmut Ruska Haus, Campus Charite Mitte,Charitepl 1, D-10098 Berlin, Germany.
EM felix.drexler@charite.de
RI Khouri, Ricardo/M-3184-2018; Vallinoto, Antonio Carlos/AAL-9501-2020;
   Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013; Komninakis,
   Shirley V/B-2915-2010; Marques, Ernesto T. A/L-4967-2013; Ribeiro,
   Bergmann Morais/C-7114-2015; Bastos, Michele/AAS-7386-2020; Nogueira,
   Mauricio L/B-7599-2012; Viana, Isabelle/M-4435-2017
OI Khouri, Ricardo/0000-0001-5664-4436; Vallinoto, Antonio
   Carlos/0000-0003-1135-6507; Brites, Carlos/0000-0002-4673-6991; Netto,
   Eduardo/0000-0003-1691-6761; Komninakis, Shirley V/0000-0001-7784-3418;
   Marques, Ernesto T. A/0000-0003-3826-9358; Ribeiro, Bergmann
   Morais/0000-0002-1061-196X; Bastos, Michele/0000-0003-3450-666X;
   Nogueira, Mauricio L/0000-0003-1102-2419; Drexler, Jan
   Felix/0000-0002-3509-0232; Fischer, Carlo/0000-0001-9163-2406; Viana,
   Isabelle/0000-0003-4648-6635
FU German Centre for Infection Research; European Union's Horizon research
   and innovation program (ZIKAlliance) [734548]; EVAg [653316]
FX This work was supported by the German Centre for Infection Research
   through a fast-track program for Zika virus outbreak response to J.F.D.
   and is partially supported by the European Union's Horizon 2020 research
   and innovation program (ZIKAlliance, grant agreement no. 734548 to
   X.d.L. and EVAg, grant agreement no. 653316 to C.D.).
CR Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   Baylis SA, 2017, TRANSFUSION, V57, P748, DOI 10.1111/trf.14026
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Charrel R, 2017, J CLIN MICROBIOL, V55, P3219, DOI 10.1128/JCM.00987-17
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   Domingo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036291
   Domingo C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000833
   Drexler JF, 2009, PLOS MED, V6, P210, DOI 10.1371/journal.pmed.1000031
   Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Moreira-Soto Andres, 2017, J Infect Dis, V216, P1501, DOI 10.1093/infdis/jix539
   Niedrig M, 2006, CLIN CHEM, V52, P1851, DOI 10.1373/clinchem.2005.064451
NR 15
TC 11
Z9 11
U1 0
U2 8
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAY
PY 2018
VL 24
IS 5
BP 888
EP 892
DI 10.3201/eid2405.171747
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GD2TP
UT WOS:000430355500012
PM 29470164
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Brites, C
   Abrahao, M
   Bozza, P
   Netto, EM
   Lyra, A
   Bahia, F
AF Brites, Carlos
   Abrahao, Marcos
   Bozza, Patricia
   Netto, Eduardo M.
   Lyra, Andre
   Bahia, Fabianna
TI Infection by HTLV-1 Is Associated With High Levels of Proinflammatory
   Cytokines in HIV-HCV-Coinfected Patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; HTLV-1; HCV; coinfection; cytokines
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; SPASTIC PARAPARESIS
   HAM/TSP; PROVIRAL LOAD; TYPE-1; INDIVIDUALS; DISEASE; CLEARANCE;
   SURVIVAL; BURDEN
AB Objectives: HIV, hepatitis C virus (HCV), and human T-cell lymphotropic virus type 1 (HTLV-1) share the same routes of infection, making coinfection by these viruses a frequent finding in endemic areas. However, there is scarce information on the clinical/immunological consequences of triple infection. Coinfection by HTLV-1 is able to modulate cytokine's production in patients with HIV, but there are no data on the immune response of HIV-HCV-HTLV-1-infected patients.
   Methods: We compared the plasma levels of 25 different cytokines in patients with HIV-HCV, according to their serostatus to HTLV-1 infection. Eligible patients should be on stable highly active antiretroviral therapy and have undetectable HIV-1 plasma viral load for, at least, 12 months. Cytokines levels were also evaluated by CD4(+) cells count, rates of sustained virological response (SVR) to previous HCV treatment, frequency of spontaneous HCV clearance, and HCV/IFN-lambda 3 genotypes.
   Results: Twenty-five patients (15 coinfected by HIV and HCV, 10 coinfected by HIV, HCV, and HTLV-1) were evaluated. Among the triply infected group, 3 had undetectable HCV viremia (spontaneous clearance). All but one remaining patients were previously treated for HCV, with similar SVR rates (similar to 29%). Cytokines levels did not differ per HCV/IFN-lambda 3 genotypes, mean CD4(+) cells count, age, sex, or SVR. However, patients coinfected by HTLV-1 showed significantly higher levels of IL-1b, IL-2, TNF-alpha, IFN-gamma, MIP-1 alpha, RANTES, and interferon-induced protein 10 (IP-10) than HIV-HCV-coinfected ones. Patients presenting HCV spontaneous clearance had the highest levels of cytokines.
   Conclusions: Coinfection by HTLV-1 increases the plasma levels of proinflammatory cytokines of patients with HIV-HCV and can influence the outcomes of coinfected patients.
C1 [Brites, Carlos; Netto, Eduardo M.; Lyra, Andre; Bahia, Fabianna] Univ Fed Bahia, Complexo Hosp Univ Prof Edgard Santos, Dept Med, Lab Pesquisa Infectol,LAPI, Salvador, BA, Brazil.
   [Abrahao, Marcos] Univ Fed Bahia, Complexo Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectol, LAPI, Salvador, BA, Brazil.
   [Bozza, Patricia] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Complexo Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectol, LAPI, Augusto Viana SN,6o Andar, BR-40110060 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; Bozza, Patricia/0000-0001-8349-9529
FU Brazilian Research Council (CNPq) Grant [470087/2014-5]
FX Supported in part by a Brazilian Research Council (CNPq) Grant
   (470087/2014-5).
CR Abrahao MHN, 2012, AIDS RES HUM RETROV, V28, P806, DOI [10.1089/aid.2011.0192, 10.1089/AID.2011.0192]
   Alejos B, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004727
   Bahia F, 2011, JAIDS-J ACQ IMM DEF, V57, pS202, DOI 10.1097/QAI.0b013e31821e9a1e
   Bangham CRM, 2000, J CLIN PATHOL, V53, P581, DOI 10.1136/jcp.53.8.581
   Beilke MA, 2007, CLIN INFECT DIS, V44, P1229, DOI 10.1086/513428
   Best I, 2006, CLIN EXP IMMUNOL, V146, P226, DOI 10.1111/j.1365-2249.2006.03208.x
   Starling ALB, 2013, ACTA TROP, V125, P75, DOI 10.1016/j.actatropica.2012.09.012
   Boschi-Pinto C, 2000, J INFECT DIS, V181, P35, DOI 10.1086/315177
   Brites C, 2001, AIDS, V15, P2053, DOI 10.1097/00002030-200110190-00023
   Brites C, 2009, AIDS REV, V11, P8
   Carvalho EM, 2001, J ACQ IMMUN DEF SYND, V27, P1, DOI 10.1097/00126334-200105010-00001
   Chen JY, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.17
   Down C, 2016, AIDS RES HUM RETROV, V32, P868, DOI [10.1089/AID.2016.0051, 10.1089/aid.2016.0051]
   Feld JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080003
   Flynn JK, 2012, J INFECT DIS, V206, P1568, DOI 10.1093/infdis/jis544
   Hisada M, 1998, J ACQ IMMUN DEF SYND, V19, P421, DOI 10.1097/00042560-199812010-00015
   Hisada M, 2003, J INFECT DIS, V188, P891, DOI 10.1086/377585
   Keane C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066831
   Kishihara Y, 2001, J INFECT DIS, V184, P1114, DOI 10.1086/323890
   Klein MB, 2016, CURR OPIN HIV AIDS, V11, P521, DOI 10.1097/COH.0000000000000292
   Klenerman P, 2007, PLOS MED, V4, P1608, DOI 10.1371/journal.pmed.0040240
   Le Marchand C, 2015, BRAZ J INFECT DIS, V19, P486, DOI 10.1016/j.bjid.2015.06.007
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Rockstroh JK, 2004, EUR J MED RES, V9, P304
   Thomson EC, 2011, GUT, V60, P837, DOI 10.1136/gut.2010.217166
   Voigt E, 2006, J INFECTION, V53, P36, DOI 10.1016/j.jinf.2005.09.007
   Watanabe T, 1997, INT J HEMATOL, V66, P257
   Zhang XZ, 2012, J MED VIROL, V84, P1344, DOI 10.1002/jmv.23315
NR 28
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD FEB 1
PY 2018
VL 77
IS 2
BP 230
EP 234
DI 10.1097/QAI.0000000000001576
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GB5QW
UT WOS:000429122000021
PM 29084047
DA 2020-12-01
ER

PT J
AU Brites, C
   Nobrega, I
   Luz, E
   Travassos, AG
   Lorenzo, C
   Netto, EM
AF Brites, Carlos
   Nobrega, Isabella
   Luz, Estela
   Travassos, Ana Gabriela
   Lorenzo, Cynthia
   Netto, Eduardo M.
TI Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected
   late-presenting pregnant women
SO HIV CLINICAL TRIALS
LA English
DT Article
DE Raltegravir; Lopinavir/ritonavir; HIV-1; Pregnant women;
   Mother-to-child-transmission
ID TO-CHILD-TRANSMISSION; VIRAL LOAD; ANTIRETROVIRAL THERAPY; SOUTH-AFRICA;
   EFFICACY; SAFETY; PHARMACOKINETICS; BRAZIL; METAANALYSIS; PREVENTION
AB Background: Late-presenting pregnant women pose a challenge in the prevention of HIV-1 mother-to-child-transmission. We compared the safety and efficacy of raltegravir and lopinavir/ritonavir for this population.
   Methods: We did a single-center, pilot, open-label, randomized trial in Brazil (N=44). We randomly allocated late-presenting HIV-infected pregnant women (older than 18 years with a plasma HIV-1 RNA >1000 copies/mL) to receive raltegravir 400 mg twice a day or lopinavir/ritonavir 400/100 mg twice a day plus zidovudine and lamivudine (1:1). The primary endpoint was virological suppression at delivery (HIV-1 RNA <50 copies per mL), in all patients who received at least one dose of study drugs (modified intention-to-treat analysis). Missing information was treated as failure. We assessed safety in all patients.
   Results We enrolled and randomly assigned treatment to 33 patients (17 in raltegravir group) between June 2015 and June 2017. The study was interrupted by the IRB because a significant difference between arms was detected in an interim analysis. All patients completed follow up at delivery. At delivery, virological suppression was achieved by 13/17 (76.5%) of patients in raltegravir group, versus 4/16 (25.0%) in lopinavir/ritonavir group (RR 3.1, 95% CI: 1.3-7.4). Patients in raltegravir group had significantly higher proportion of virological suppression at 2, 4, and 6 weeks than lopinavir/ritonavir group. Adverse events were most of mild intensity, but patients in lopinavir/ritonavir group had significantly more gastrointestinal adverse events. There was neither discontinuation nor deaths in this trial.
   Conclusion: Raltegravir might be a first-line option for treatment of HIV-infected late-presenting pregnant women.
C1 [Brites, Carlos; Nobrega, Isabella; Luz, Estela; Lorenzo, Cynthia; Netto, Eduardo M.] Univ Fed Bahia, LAPI Lab Pesquisa Infectol, Comlexo Hosp Prof Edgard Santos, Rua Augusto Viana Sn,6o Andar, BR-40110060 Salvador, BA, Brazil.
   [Nobrega, Isabella; Travassos, Ana Gabriela; Lorenzo, Cynthia] CEDAP Ctr Estadual Especializado Diagnost Assiste, Secretaria Saude Estado Bahia, Salvador, BA, Brazil.
   [Travassos, Ana Gabriela] UNEB Univ Estado Bahia, Sch Med, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, LAPI Lab Pesquisa Infectol, Comlexo Hosp Prof Edgard Santos, Rua Augusto Viana Sn,6o Andar, BR-40110060 Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Netto, Eduardo/D-1432-2013; Travassos, Ana Gabriela A/E-6809-2016;
   Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Travassos, Ana Gabriela
   A/0000-0001-9242-828X; Brites, Carlos/0000-0002-4673-6991; Luz,
   Estela/0000-0002-1062-7179
CR Blonk MI, 2015, CLIN INFECT DIS, V61, P809, DOI 10.1093/cid/civ366
   Boucoiran I, 2015, CAN J INFECT DIS MED, V26, P145, DOI 10.1155/2015/731043
   Brasil. Ministerio da Saude (MS), 2016, B EP HIV AIDS
   Clarke DF, 2014, JAIDS-J ACQ IMM DEF, V67, P310, DOI 10.1097/QAI.0000000000000316
   European AIDS Clinical Society, 2017, EACS GUIDELINES VERS
   Hegazi A, 2012, AIDS, V26, P2421, DOI 10.1097/QAD.0b013e32835a9aeb
   Hermes A, 2012, HIV CLIN TRIALS, V13, P308, DOI 10.1310/hct1306-308
   Joao EC, 2012, INT J STD AIDS, V23, P44, DOI 10.1258/ijsa.2011.010545
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Maliakkal A, 2016, JAIDS-J ACQ IMM DEF, V72, P153, DOI 10.1097/QAI.0000000000000932
   Myer L, 2017, HIV MED, V18, P80, DOI 10.1111/hiv.12397
   Myer L, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20045
   Nobrega I, 2013, AIDS RES HUM RETROV, V29, P1451, DOI [10.1089/aid.2013.0059, 10.1089/AID.2013.0059]
   Nobrega I, 2012, AIDS RES HUM RETROV, V28, P233, DOI 10.1089/aid.2011.0165
   Pasley MV, 2013, AIDS REV, V15, P38
   Rahangdale L, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.052
   Senise J.F., 2006, Braz J Infect Dis, V10, P259, DOI 10.1590/S1413-86702006000400009
   Smith F, 2011, DRUG INF J, V45, P291, DOI 10.1177/009286151104500309
   Sturt AS, 2010, COCHRANE DB SYST REV, V17
   Tookey PA, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1400-y
   Tornatore M, 2010, INT J STD AIDS, V21, P351, DOI 10.1258/ijsa.2009.009033
   Tubiana R, 2010, CLIN INFECT DIS, V50, P585, DOI 10.1086/650005
   Wensing AM, 2017, TOP ANTIVIR MED, V24, P132
   Westling K, 2012, AIDS PATIENT CARE ST, V26, P714, DOI 10.1089/apc.2012.0283
NR 24
TC 5
Z9 6
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1528-4336
EI 1945-5771
J9 HIV CLIN TRIALS
JI HIV Clin. Trials
PY 2018
VL 19
IS 3
BP 94
EP 100
DI 10.1080/15284336.2018.1459343
PG 7
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA GG2TG
UT WOS:000432545000002
PM 29629852
DA 2020-12-01
ER

PT J
AU Sarno, M
   Aquino, M
   Pimentel, K
   Cabral, R
   Costa, G
   Bastos, F
   Brites, C
AF Sarno, M.
   Aquino, M.
   Pimentel, K.
   Cabral, R.
   Costa, G.
   Bastos, F.
   Brites, C.
TI Progressive lesions of central nervous system in microcephalic fetuses
   with suspected congenital Zika virus syndrome
SO ULTRASOUND IN OBSTETRICS & GYNECOLOGY
LA English
DT Article
DE Brazil; congenital Zika virus syndrome; fetal defects; microcephaly;
   ultrasound; Zika virus
AB Objective To describe the pattern and progression of central nervous system (CNS) lesions in microcephalic fetuses with suspected Zika virus (ZIKV) infection.
   Methods In this prospective study in Salvador, Brazil, we analyzed fetuses diagnosed with microcephaly and suspected ZIKV infection after a routine primary care ultrasound scan between July 2015 and February 2016 raised suspicion of fetal microcephaly. The pregnancies were followed with serial ultrasound scans until delivery at one of the three main referral centers for fetal abnormalities in Salvador, Brazil. Microcephaly was diagnosed when the head circumference was two or more SDs below the mean for gestational age and its relationship with ZIKV infection was defined according to the World Health Organization's criteria. All women were interviewed, to assess potential factors associated with fetal microcephaly. Serology test results for toxoplasmosis, cytomegalovirus, rubella, syphilis and human immunodeficiency virus (HIV) were recorded, as were previous routine ultrasound results. Signs/symptoms of infection during the pregnancy were noted.
   Results Of 60 cases of suspected ZIKV-related fetal microcephaly seen during the study period, eight were excluded due to serological evidence of other congenital infections or major ultrasound chromosomal markers. In the remaining 52 fetuses, microcephaly was diagnosed between 19 and 40 (median, 27.7; interquartile range, 23.4-32.0) weeks of gestation. The main ultrasound findings were: ventriculomegaly (65.4% of cases), cerebral calcifications (44.2%) and posterior fossa abnormalities (32.7%). 9.6% presented with arthrogryposis as an associated finding. Microcephaly was an isolated finding in four cases (7.7%). While ventriculomegaly was progressive in 41.2% of cases with this finding, the velocity of head circumference increase decreased progressively in almost all cases. Exanthematic disease was present in the majority (86.5%) of the women, 67.3% presenting in the first trimester of pregnancy. Additional lesions were detected after birth in 71.4% of the 35 cases with neonatal follow-up.
   Conclusions The majority of cases of congenital ZIKV syndrome have other ultrasonographic findings in addition to microcephaly. ZIKV-related CNS anomalies present mainly as progressive CNS lesions and slowing rate of growth of the fetal head, and this seems to be evident only in the late second trimester, even when maternal infection occurs in the first trimester. Other ultrasound findings, such as ventriculomegaly, brain calcifications and posterior fossa destruction lesions, are also common in this congenital syndrome. Posterior fossa destruction lesions and arthrogryposis are an uncommon finding in other congenital infections, perhaps suggesting a novel severe congenital syndrome associated with fetal ZIKV. Copyright (C) 2016 ISUOG. Published by John Wiley & Sons Ltd.
C1 [Sarno, M.; Aquino, M.; Pimentel, K.; Cabral, R.] Univ Fed Bahia, Maternidade Climerio Oliveira, Rua Limoeiro 137, BR-40055150 Salvador, BA, Brazil.
   [Sarno, M.; Aquino, M.; Pimentel, K.] Caliper Escola Imagem, Ultrasound Training Ctr, Salvador, BA, Brazil.
   [Sarno, M.; Pimentel, K.] Hosp Geral Roberto Santos, Secretaria Estadual Saude Bahia, Salvador, BA, Brazil.
   [Costa, G.; Bastos, F.; Brites, C.] Univ Fed Bahia, Salvador, BA, Brazil.
RP Sarno, M (corresponding author), Univ Fed Bahia, Maternidade Climerio Oliveira, Rua Limoeiro 137, BR-40055150 Salvador, BA, Brazil.
EM manoelsarno@ufba.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Alcantara D, 2014, AM J MED GENET C, V166, P124, DOI 10.1002/ajmg.c.31397
   [Anonymous], 2016, PROT VIG RESP OC MIC, P17
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Cauchemez S, 2016, LANCET
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   HADLOCK FP, 1991, J ULTRAS MED, V10, P557
   Javanbakht Javad, 2014, Diagn Pathol, V9, P223, DOI 10.1186/s13000-014-0223-7
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   MILLER E, 1982, LANCET, V2, P781
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Salvador FS, 2016, TRAVEL MED INFECT DI, V14, P49, DOI 10.1016/j.tmaid.2015.10.004
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Teissier N, 2014, J NEUROPATH EXP NEUR, V73, P143, DOI 10.1097/NEN.0000000000000038
   Thiebaut R, 2007, LANCET, V369, P115
   Villar J, 2014, LANCET DIABETES ENDO, V2, P781, DOI 10.1016/S2213-8587(14)70121-4
   World Health Organization, 2016, PREGN MAN CONT ZIK V
NR 17
TC 18
Z9 19
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7692
EI 1469-0705
J9 ULTRASOUND OBST GYN
JI Ultrasound Obstet. Gynecol.
PD DEC
PY 2017
VL 50
IS 6
BP 717
EP 722
DI 10.1002/uog.17303
PG 6
WC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine &
   Medical Imaging
SC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine &
   Medical Imaging
GA FP0AM
UT WOS:000417260500007
PM 27644020
OA Bronze
DA 2020-12-01
ER

PT J
AU Tsai, WY
   Youn, HH
   Brites, C
   Tsai, JJ
   Tyson, J
   Pedroso, C
   Drexler, JF
   Stone, M
   Simmons, G
   Busch, MP
   Lanteri, M
   Stramer, SL
   Balmaseda, A
   Harris, E
   Wang, WK
AF Tsai, Wen-Yang
   Youn, Han Ha
   Brites, Carlos
   Tsai, Jih-Jin
   Tyson, Jasmine
   Pedroso, Celia
   Drexler, Jan Felix
   Stone, Mars
   Simmons, Graham
   Busch, Michael P.
   Lanteri, Marion
   Stramer, Susan L.
   Balmaseda, Angel
   Harris, Eva
   Wang, Wei-Kung
TI Distinguishing Secondary Dengue Virus Infection From Zika Virus
   Infection With Previous Dengue by a Combination of 3 Simple Serological
   Tests
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; dengue virus; non-structural protein 1; serological test;
   cross-reactivity
ID HUMAN-ANTIBODY RESPONSES; CROSS-REACTIVITY; TRANSMISSION; DIAGNOSIS;
   SPECIFICITY; CHIKUNGUNYA; TECHNOLOGY; INFANTS; ASSAYS; ELISA
AB An algorithm is proposed to distinguish primary Zika virus (ZIKV), ZIKV with previous dengue virus (DENV), and secondary DENV infections, which is critical for understanding the epidemiology, pathogenesis, and complications of ZIKV in dengue-endemic regions.The explosive spread of Zika virus (ZIKV) and associated microcephaly present an urgent need for sensitive and specific serodiagnostic tests, particularly for pregnant women in dengue virus (DENV)-endemic regions. Recent reports of enhanced ZIKV replication by dengue-immune sera have raised concerns about the role of previous DENV infection on the risk and severity of microcephaly and other ZIKV complications.
   Enzyme-linked immunosorbent assays (ELISAs) based on ZIKV and DENV nonstructural protein 1 (NS1) were established to test acute, convalescent phase, and post-convalescent phase serum/plasma samples from reverse-transcription polymerase chain reaction-confirmed cases including 20 primary ZIKV, 25 ZIKV with previous DENV, 58 secondary DENV, and 16 primary DENV1 infections.
   ZIKV-NS1 immunoglobulin M (IgM) and immunoglobulin G (IgG) ELISAs combined can detect ZIKV infection with a sensitivity of 95% and specificity of 66.7%. The ZIKV-NS1 IgG cross-reactivity by samples from secondary DENV infection cases ranged from 66.7% to 28.1% (within 1 month to 1-2 years post-illness, respectively). Addition of DENV1-NS1 IgG ELISA can distinguish primary ZIKV infection; the ratio of absorbance of ZIKV-NS1 to DENV1-NS1 IgG ELISA can distinguish ZIKV with previous DENV and secondary DENV infections with a sensitivity of 87.5% and specificity of 81.3%. These findings were supported by analysis of sequential samples.
   An algorithm for ZIKV serodiagnosis based on 3 simple ELISAs is proposed to distinguish primary ZIKV, ZIKV with previous DENV, and secondary DENV infections; this could be applied to serodiagnosis for ZIKV, serosurveillance, and monitoring ZIKV infection during pregnancy to understand the epidemiology, pathogenesis, and complications of ZIKV in dengue-endemic regions.
C1 [Tsai, Wen-Yang; Youn, Han Ha; Tyson, Jasmine; Wang, Wei-Kung] Univ Hawaii Manoa, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA.
   [Brites, Carlos; Pedroso, Celia] Univ Fed Bahia, Sch Med, Lab Infect Res, Salvador, BA, Brazil.
   [Tsai, Jih-Jin] Kaohsiung Med Univ Hosp, Div Infect Dis, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univ Hosp, Trop Med Ctr, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univ, Coll Med, Dept Med, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univ, Ctr Dengue Fever Control & Res, Kaohsiung, Taiwan.
   [Drexler, Jan Felix] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Drexler, Jan Felix] German Ctr Infect Res, Bonn Cologne, Germany.
   [Stone, Mars; Simmons, Graham; Busch, Michael P.; Lanteri, Marion] Blood Syst Res Inst, San Francisco, CA USA.
   [Simmons, Graham; Busch, Michael P.; Lanteri, Marion] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Stramer, Susan L.] Amer Red Cross, Sci Support Off, Gaithersburg, MD USA.
   [Balmaseda, Angel] Minist Hlth, Natl Ctr Diag & Reference, Natl Virol Lab, Managua, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
RP Wang, WK (corresponding author), Univ Hawaii Manoa, John A Burns Sch Med, 651 Ilalo St,BSB 325E, Honolulu, HI 96813 USA.
EM wangwk@hawaii.edu
RI amsalu, ribka/G-8780-2019; Simmons, Graham/G-3523-2012
OI Simmons, Graham/0000-0002-9615-7023; Drexler, Jan
   Felix/0000-0002-3509-0232
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI110769-01, R01 AI099631,
   P01AI106695, U19 AI118610]; National Institute of General Medical
   Sciences, NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P20GM103516]; National Heart, Lung, and Blood
   Institute, NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [RC2HL101632, HHSN268201100001I]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI118610, U19AI118610, U19AI118610, P01AI106695, P01AI106695,
   U19AI118610, R01AI099631, P01AI106695, U19AI118610, R01AI099631,
   U19AI118610, P01AI106695, U19AI118610, U19AI118610, P01AI106695,
   P01AI106695, P01AI106695, U19AI118610, P01AI106695, P01AI106695,
   U19AI118610, R01AI099631, U19AI118610, U19AI118610, U19AI118610,
   R01AI110769, P01AI106695, U19AI118610, P01AI106695, P01AI106695,
   P01AI106695, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   U19AI118610, R01AI099631, U19AI118610, U19AI118610, P01AI106695,
   R01AI099631, U19AI118610, P01AI106695, U19AI118610, U19AI118610,
   P01AI106695, U19AI118610, U19AI118610, U19AI118610, P01AI106695,
   R01AI110769, U19AI118610, U19AI118610, U19AI118610, R01AI099631,
   U19AI118610, P01AI106695, U19AI118610, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, U19AI118610, U19AI118610, U19AI118610,
   P01AI106695, U19AI118610, P01AI106695, P01AI106695, U19AI118610,
   U19AI118610, U19AI118610, P01AI106695, U19AI118610, P01AI106695,
   P01AI106695, U19AI118610, U19AI118610, R01AI110769, U19AI118610,
   R01AI099631, P01AI106695, P01AI106695, U19AI118610, P01AI106695,
   P01AI106695, R01AI110769, U19AI118610, U19AI118610, P01AI106695,
   U19AI118610, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   U19AI118610, U19AI118610, U19AI118610, R01AI099631, U19AI118610,
   P01AI106695, P01AI106695, P01AI106695, U19AI118610, R01AI110769,
   P01AI106695, U19AI118610, U19AI118610, U19AI118610, P01AI106695,
   U19AI118610, U19AI118610, U19AI118610, U19AI118610, U19AI118610,
   U19AI118610, U19AI118610, U19AI118610, R01AI099631, U19AI118610,
   P01AI106695, U19AI118610, U19AI118610, P01AI106695, P01AI106695,
   R01AI099631, P01AI106695] Funding Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health (NIH) (grant numbers
   R01AI110769-01 to W. K. W., R01 AI099631 to A. B., P01AI106695 and U19
   AI118610 to E. H.); the National Institute of General Medical Sciences,
   NIH (grant number P20GM103516 to R.Y.); and the National Heart, Lung,
   and Blood Institute, NIH (award number RC2HL101632 and contract number
   HHSN268201100001I).
CR Balmaseda A, 2006, TROP MED INT HEALTH, V11, P935, DOI 10.1111/j.1365-3156.2006.01641.x
   Brooks RB, 2016, MMWR-MORBID MORTAL W, V65, P915, DOI 10.15585/mmwr.mm6534e2
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Centers for Disease Control and Prevention, GUID US LAB TEST ZIK
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   FERNANDEZ RJ, 1990, MEM I OSWALDO CRUZ, V85, P347, DOI 10.1590/S0074-02761990000300012
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7
   Galel SA, 2017, TRANSFUSION, V57, P762, DOI 10.1111/trf.14029
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Jarmer J, 2014, J VIROL, V88, P13845, DOI 10.1128/JVI.02086-14
   Johnson AJ, 2000, J CLIN MICROBIOL, V38, P1827, DOI 10.1128/JCM.38.5.1827-1831.2000
   Johnson BW, 2005, VECTOR-BORNE ZOONOT, V5, P137, DOI 10.1089/vbz.2005.5.137
   Krauer F, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002203
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Lai CY, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002451
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Paldanius M, 2003, CLIN DIAGN LAB IMMUN, V10, P8, DOI 10.1128/CDLI.10.1.8-12.2003
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Pierson T.C., 2013, FIELDS VIROLOGY, V6, P747
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Steinhagen K., 2015, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Stone M, 2017, TRANSFUSION, V57, P734, DOI 10.1111/trf.14031
   Tsai WY, 2015, J VIROL, V89, P7348, DOI 10.1128/JVI.00273-15
   US Food and Drug Administration, 2016, ZIK VIR EM US AUTH S
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Vaughn DW, 1999, AM J TROP MED HYG, V60, P693, DOI 10.4269/ajtmh.1999.60.693
   Waggoner JJ, 2016, CLIN INFECT DIS, V63, P1584, DOI 10.1093/cid/ciw589
   Waggoner JJ, 2016, EMERG INFECT DIS, V22, P1295, DOI 10.3201/eid2207.160326
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
NR 40
TC 31
Z9 33
U1 1
U2 16
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 1
PY 2017
VL 65
IS 11
BP 1829
EP 1836
DI 10.1093/cid/cix672
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FM5NA
UT WOS:000415081300013
PM 29020159
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Rockstroh, A
   Moges, B
   Barzon, L
   Sinigaglia, A
   Palu, G
   Kumbukgolla, W
   Schmidt-Chanasit, J
   Sarno, M
   Brites, C
   Moreira-Soto, A
   Drexler, JF
   Ferreira, OC
   Ulbert, S
AF Rockstroh, Alexandra
   Moges, Beyene
   Barzon, Luisa
   Sinigaglia, Alessandro
   Palu, Giorgio
   Kumbukgolla, Widuranga
   Schmidt-Chanasit, Jonas
   Sarno, Manoel
   Brites, Carlos
   Moreira-Soto, Andres
   Drexler, Jan Felix
   Ferreira, Orlando C.
   Ulbert, Sebastian
TI Specific detection of dengue and Zika virus antibodies using envelope
   proteins with mutations in the conserved fusion loop
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE dengue virus; Zika virus; diagnosis; cross-reactivity; ELISA; envelope
   proteins
ID LINKED IMMUNOSORBENT ASSAYS; CROSS-REACTIVE EPITOPES; WEST-NILE;
   FLAVIVIRUS INFECTION; DIAGNOSIS; ELISA; NEUTRALIZATION; GLYCOPROTEIN;
   ENHANCEMENT; CHALLENGES
AB Detection of antibodies is widely used for the diagnosis of infections with arthropod-borne flaviviruses including dengue (DENV) and Zika virus (ZIKV). Due to the emergence of ZIKV in areas endemic for DENV, massive co-circulation is observed and methods to specifically diagnose these infections and differentiate them from each other are mandatory. However, serological assays for flaviviruses in general, and for DENV and ZIKV in particular, are compromised by the high degree of similarities in their proteins which can lead to cross-reacting antibodies and false-positive test results. Cross-reacting flavivirus antibodies mainly target the highly conserved fusion loop (FL) domain in the viral envelope (E-) protein, and we and others have shown previously that recombinant E-proteins bearing FL-mutations strongly reduce cross-reactivity. Here we investigate whether such mutant E-proteins can be used to specifically detect antibodies against DENV and ZIKV in an ELISA-format. IgM antibodies against DENV and ZIKV virus were detected with 100% and 94.2% specificity and 90.7% and 87.5% sensitivity, respectively. For IgG the mutant E-proteins showed cross-reactivity, which was overcome by pre-incubation of the sera with the heterologous antigen. This resulted in specificities of 97.1% and 97.9% and in sensitivities of 100% and 100% for the DENV and ZIKV antigens, respectively. Our results suggest that E-proteins bearing mutations in the FL-domain have a high potential for the development of serological DENV and ZIKV tests with high specificity.
C1 [Rockstroh, Alexandra; Moges, Beyene; Ulbert, Sebastian] Fraunhofer Inst Cell Therapy & Immunol, Dept Immunol, Perlickstr 1, D-04103 Leipzig, Germany.
   [Barzon, Luisa; Sinigaglia, Alessandro; Palu, Giorgio] Univ Padua, Dept Mol Med, Via A Gabelli 63, I-35121 Padua, Italy.
   [Kumbukgolla, Widuranga] Rajarata Univ Sri Lanka, Fac Med & Allied Sci, Mihinthale 50008, Sri Lanka.
   [Schmidt-Chanasit, Jonas] Bernhard Nocht Inst Trop Med, WHO Collaborating Ctr Arbovirus & Haemorrhag Feve, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
   [Schmidt-Chanasit, Jonas; Drexler, Jan Felix] Univ Fed Bahia, German Ctr Infect Res DZIF, BR-40110060 Salvador, BA, Brazil.
   [Sarno, Manoel; Brites, Carlos] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, BR-40110060 Salvador, BA, Brazil.
   [Sarno, Manoel] Univ Fed Bahia, Maternidade Climerio de Oliveira, BR-40005150 Salvador, BA, Brazil.
   [Moreira-Soto, Andres] Univ Bonn, Med Ctr, Inst Virol, D-53127 Bonn, Germany.
   [Moreira-Soto, Andres; Drexler, Jan Felix] Charite Univ Med Berlin, D-10117 Berlin, Germany.
   [Moreira-Soto, Andres; Drexler, Jan Felix] Free Univ Berlin, D-10117 Berlin, Germany.
   [Moreira-Soto, Andres; Drexler, Jan Felix] Humboldt Univ, D-10117 Berlin, Germany.
   [Moreira-Soto, Andres; Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, D-10117 Berlin, Germany.
   [Ferreira, Orlando C.] Univ Fed Rio de Janeiro, Dept Genet, Lab Mol Virol, BR-21941901 Rio de Janeiro, Brazil.
RP Ulbert, S (corresponding author), Fraunhofer Inst Cell Therapy & Immunol, Dept Immunol, Perlickstr 1, D-04103 Leipzig, Germany.
EM sebastian.ulbert@izi.fraunhofer.de
RI Brites, Carlos/D-1353-2013; Barzon, Luisa/K-7961-2016
OI Brites, Carlos/0000-0002-4673-6991; Barzon, Luisa/0000-0003-0720-8456;
   sinigaglia, alessandro/0000-0002-2386-1757; Ulbert,
   Sebastian/0000-0001-5910-3643; Drexler, Jan Felix/0000-0002-3509-0232;
   Moreira-Soto, Andres/0000-0002-9224-5157
FU European Union (EFRE grant) [100216415]; German Academic Exchange
   Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD)
FX We thank Ulrike Ehlert and Frederik von Daak for technical assistance
   and Dr Rolf Fendel (Fraunhofer IME, Aachen, Germany) and Professor
   Matthias Niedrig (Robert-Koch Institute, Berlin, Germany) for supplying
   serum samples. Parts of the work were supported by the European Union
   (EFRE grant NO 100216415). BM was supported by a personal fellowship
   from the German Academic Exchange Service (DAAD).
CR Alagarasu K, 2016, VACCINE, V34, P2759, DOI 10.1016/j.vaccine.2016.04.070
   Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Barzon L, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw202
   Barzon L, 2015, EXPERT REV ANTI-INFE, V13, P327, DOI 10.1586/14787210.2015.1007044
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Chabierski S, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-246
   Charrel RN, 2016, B WORLD HEALTH ORGAN, V94, P574, DOI 10.2471/BLT.16.171207
   Chiou SS, 2008, CLIN VACCINE IMMUNOL, V15, P825, DOI 10.1128/CVI.00004-08
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   Crill WD, 2007, J GEN VIROL, V88, P1169, DOI 10.1099/vir.0.82640-0
   Crill WD, 2004, J VIROL, V78, P13975, DOI 10.1128/JVI.78.24.13975-13986.2004
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Domingo C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0877-0
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Gubler DJ, 2007, FIELDS VIROLOGY, P1153
   Guy B, 2016, NAT REV MICROBIOL, V14, P45, DOI 10.1038/nrmicro.2015.2
   Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003
   Gyurech D, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14296
   Heinz FX, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/mmbr.00055-16, 10.1128/MMBR.00055-16]
   Hunsperger EA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003171
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Koraka P, 2002, MICROBES INFECT, V4, P1209, DOI 10.1016/S1286-4579(02)01647-7
   L'Huillier AG, 2017, J CLIN MICROBIOL, V55, P2462, DOI 10.1128/JCM.00442-17
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Lustig Y, 2017, J CLIN MICROBIOL, V55, P1894, DOI 10.1128/JCM.00346-17
   Maeda A, 2013, VET J, V195, P33, DOI 10.1016/j.tvjl.2012.08.019
   Mansfield KL, 2011, J GEN VIROL, V92, P2821, DOI 10.1099/vir.0.031641-0
   Pessoa R, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003201
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Roberson JA, 2007, J CLIN MICROBIOL, V45, P3167, DOI 10.1128/JCM.01143-07
   Rockstroh A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004218
   Sanchini A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002184
   Schwarz NG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176708
   Seligman SJ, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-27
   Steinhagen K., 2015, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tang KF, 2012, EXPERT REV ANTI-INFE, V10, P895, DOI [10.1586/eri.12.76, 10.1586/ERI.12.76]
   Van Esbroeck M, 2016, EUROSURVEILLANCE, V21, P32, DOI 10.2807/1560-7917.ES.2016.21.21.30237
   van Meer MPA, 2017, J CLIN VIROL, V92, P25, DOI 10.1016/j.jcv.2017.05.001
   Vannice KS, 2016, VACCINE, V34, P2934, DOI 10.1016/j.vaccine.2015.12.073
   Vogt MR, 2011, J VIROL, V85, P11567, DOI 10.1128/JVI.05859-11
   Zhang B, 2017, NAT MED, V23, P548, DOI 10.1038/nm.4302
NR 48
TC 14
Z9 15
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD NOV 8
PY 2017
VL 6
AR e99
DI 10.1038/emi.2017.87
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA FM4TR
UT WOS:000415015700004
PM 29116222
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Netto, EM
   Moreira-Soto, A
   Pedroso, C
   Hoser, C
   Funk, S
   Kucharski, AJ
   Rockstroh, A
   Kummerer, BM
   Sampaio, GS
   Luz, E
   Vaz, SN
   Dias, JP
   Bastos, FA
   Cabral, R
   Kistemann, T
   Ulbert, S
   de Lamballerie, X
   Jaenisch, T
   Brady, OJ
   Drosten, C
   Sarno, M
   Brites, C
   Drexler, JF
AF Netto, Eduardo Martins
   Moreira-Soto, Andres
   Pedroso, Celia
   Hoser, Christoph
   Funk, Sebastian
   Kucharski, Adam J.
   Rockstroh, Alexandra
   Kuemmerer, Beate M.
   Sampaio, Gilmara Souza
   Luz, Estela
   Vaz, Sara Nunes
   Dias, Juarez Pereira
   Bastos, Fernanda Anjos
   Cabral, Renata
   Kistemann, Thomas
   Ulbert, Sebastian
   de lamballerie, Xavier
   Jaenisch, Thomas
   Brady, Oliver J.
   Drosten, Christian
   Sarno, Manoel
   Brites, Carlos
   Drexler, Jan Felix
TI High Zika Virus Seroprevalence in Salvador, Northeastern Brazil Limits
   the Potential for Further Outbreaks
SO MBIO
LA English
DT Article
DE Zika virus; microcephaly; risk factors; serology; socioeconomic status
ID INFECTION; DENGUE; TRANSMISSION; ASSOCIATION; EPIDEMIC; RISK
AB During 2015 to 2016, Brazil reported more Zika virus (ZIKV) cases than any other country, yet population exposure remains unknown. Serological studies of ZIKV are hampered by cross-reactive immune responses against heterologous viruses. We conducted serosurveys for ZIKV, dengue virus (DENV), and Chikungunya virus (CHIKV) in 633 individuals prospectively sampled during 2015 to 2016, including microcephaly and non-microcephaly pregnancies, HIV-infected patients, tuberculosis patients, and university staff in Salvador in northeastern Brazil using enzyme-linked immunosorbent assays (ELISAs) and plaque reduction neutralization tests. Sera sampled retrospectively during 2013 to 2015 from 277 HIV-infected patients were used to assess the spread of ZIKV over time. Individuals were georeferenced, and sociodemographic indicators were compared between ZIKV-positive and -negative areas and areas with and without microcephaly cases. Epidemiological key parameters were modeled in a Bayesian framework. ZIKV seroprevalence increased rapidly during 2015 to 2016, reaching 63.3% by 2016 (95% confidence interval [CI], 59.4 to 66.8%), comparable to the seroprevalence of DENV (75.7%; CI, 69.4 to 81.1%) and higher than that of CHIKV (7.4%; CI, 5.6 to 9.8%). Of 19 microcephaly pregnancies, 94.7% showed ZIKV IgG antibodies, compared to 69.3% of 257 non-microcephaly pregnancies (P = 0.017). Analyses of sociodemographic data revealed a higher ZIKV burden in low socioeconomic status (SES) areas. High seroprevalence, combined with case data dynamics allowed estimates of the basic reproduction number R-0 of 2.1 (CI, 1.8 to 2.5) at the onset of the outbreak and an effective reproductive number R-eff of <1 in subsequent years. Our data corroborate ZIKV-associated congenital disease and an association of low SES and ZIKV infection and suggest that population immunity caused cessation of the outbreak. Similar studies from other areas will be required to determine the fate of the American ZIKV outbreak.
   IMPORTANCE The ongoing American Zika virus (ZIKV) outbreak involves millions of cases and has a major impact on maternal and child health. Knowledge of infection rates is crucial to project future epidemic patterns and determine the absolute risk of microcephaly upon maternal ZIKV infection during pregnancy. For unknown reasons, the vast majority of ZIKV-associated microcephaly cases are concentrated in northeastern Brazil. We analyzed different subpopulations from Salvador, a Brazilian metropolis representing one of the most affected areas during the American ZIKV outbreak. We demonstrate rapid spread of ZIKV in Salvador, Brazil, and infection rates exceeding 60%. We provide evidence for the link between ZIKV and microcephaly, report that ZIKV predominantly affects geographic areas with low socioeconomic status, and show that population immunity likely caused cessation of the outbreak. Our results enable stakeholders to identify target populations for vaccination and for trials on vaccine efficacy and allow refocusing of research efforts and intervention strategies.
C1 [Netto, Eduardo Martins; Pedroso, Celia; Sampaio, Gilmara Souza; Luz, Estela; Vaz, Sara Nunes; Dias, Juarez Pereira; Sarno, Manoel; Brites, Carlos] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Netto, Eduardo Martins] IBIT FJS, Salvador, BA, Brazil.
   [Moreira-Soto, Andres; Kuemmerer, Beate M.; Drexler, Jan Felix] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Hoser, Christoph; Kistemann, Thomas] Univ Bonn, Inst Hyg & Publ Hlth, GeoHlth Ctr, WHO Collaborating Ctr Hlth Promoting Water Manage, Bonn, Germany.
   [Funk, Sebastian; Kucharski, Adam J.; Brady, Oliver J.] London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, London, England.
   [Rockstroh, Alexandra; Ulbert, Sebastian] Fraunhofer Inst Cell Therapy & Immunol, Dept Immunol, Leipzig, Germany.
   [Kuemmerer, Beate M.; Jaenisch, Thomas; Drosten, Christian; Drexler, Jan Felix] German Ctr Infect Res DZIF, Munich, Germany.
   [Bastos, Fernanda Anjos; Cabral, Renata; Sarno, Manoel] Univ Fed Bahia, Maternidade Climerio de Oliveira, Salvador, BA, Brazil.
   [de lamballerie, Xavier] Aix Marseille Univ, IRD French Inst Res Dev, EHESP French Sch Publ Hlth 19, EPV UMR D Emergence Pathol Virales 190, Marseille, France.
   [de lamballerie, Xavier] Publ Hosp Marseille 21, AP HM, IHU Inst Hosp Univ Mediterranee Infect, Marseille, France.
   [Jaenisch, Thomas] Heidelberg Univ Hosp, INF 324, Dept Infect Dis, Sect Clin Trop Med, Heidelberg, Germany.
   [Drosten, Christian; Drexler, Jan Felix] Charite, Berlin, Germany.
   [de lamballerie, Xavier; Drexler, Jan Felix] Free Univ Berlin, Berlin, Germany.
   [de lamballerie, Xavier; Drexler, Jan Felix] Humboldt Univ, Berlin, Germany.
   [de lamballerie, Xavier; Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
RP Brites, C (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.; Drexler, JF (corresponding author), Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.; Drexler, JF (corresponding author), German Ctr Infect Res DZIF, Munich, Germany.; Drexler, JF (corresponding author), Charite, Berlin, Germany.; Drexler, JF (corresponding author), Free Univ Berlin, Berlin, Germany.; Drexler, JF (corresponding author), Humboldt Univ, Berlin, Germany.; Drexler, JF (corresponding author), Berlin Inst Hlth, Inst Virol, Berlin, Germany.
EM crbrites@ufba.br; felix.drexler@charite.de
RI Brites, Carlos/D-1353-2013; Brady, Oliver/P-9421-2019; Netto,
   Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Brady, Oliver/0000-0002-3235-2129;
   Netto, Eduardo/0000-0003-1691-6761; Moreira-Soto,
   Andres/0000-0002-9224-5157; Funk, Sebastian/0000-0002-2842-3406;
   Drexler, Jan Felix/0000-0002-3509-0232
FU German Centre for Infection Research (DZIF) through the ZIKApath
   project; European Union's Horizon 2020 research and innovation program
   through the ZIKAlliance project [734548]
FX This work was supported by the German Centre for Infection Research
   (DZIF) through the ZIKApath project to J.F.D. and T.J., and the European
   Union's Horizon 2020 research and innovation program through the
   ZIKAlliance project (grant agreement 734548) to J.FD., T.J., B.M.K.,
   O.J.B., and X.D.L.
CR Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   Ashwal S, 2009, NEUROLOGY, V73, P887, DOI 10.1212/WNL.0b013e3181b783f7
   Atieh T, 2016, SCI REP-UK, V6, DOI 10.1038/srep39384
   Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Butler D, 2016, NATURE, V535, P475, DOI 10.1038/nature.2016.20309
   CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37
   Cardoso CW, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005334
   Cauchemez S, 2016, LANCET, V388, P338, DOI 10.1016/S0140-6736(16)31017-0
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   Ximenes RAD, 2009, INT J EPIDEMIOL, V38, P1285, DOI 10.1093/ije/dyp224
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Diario Oficial da Uniao, 2016, DIARIO OFICIAL UNIAO
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Funk S., 2016, RBI HELPERS RBI HELP
   Gake B, 2017, BRAZ J INFECT DIS, V21, P481, DOI 10.1016/j.bjid.2017.03.018
   Gallian P, 2017, BLOOD, V129, P263, DOI 10.1182/blood-2016-09-737981
   Granger D, 2017, J CLIN MICROBIOL, V55, P2127, DOI [10.1128/JCM.00580-17, 10.1128/jcm.00580-17]
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Jacob PE, 2017, RBI R INTERFACE LIBB
   Jaenisch T, 2017, B WORLD HEALTH ORGAN, V95, P191, DOI [10.2471/BLT.16.178608, 10.2471/blt.16.178608]
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Kucharski AJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004726
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Landry ML, 2017, ARCH PATHOL LAB MED, V141, P60, DOI 10.5858/arpa.2016-0406-SA
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Lourenco-de-Oliveira R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005698
   Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Ministerio do Planejamento, 2010, 12 CENS DEM
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Murray L.M., 2013, ARXIV13063277
   Musso D, 2015, LANCET, V386, P243, DOI 10.1016/S0140-6736(15)61273-9
   Perkins TA, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.126, 10.1038/nmicrobiol.2016.126]
   Petersen Lyle R, 2016, F1000Res, V5, DOI 10.12688/f1000research.7171.1
   Pomar L, 2017, ULTRASOUND OBST GYN, V49, P729, DOI 10.1002/uog.17404
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rockstroh A, EMERG MICROBES INFEC
   Rockstroh A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004218
   Rodrigues Faria N, 2016, PLOS CURR OUTBREAKS
   Steinhagen K., 2015, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Towers S, 2016, EPIDEMICS-NETH, V17, P50, DOI 10.1016/j.epidem.2016.10.003
   Vega-Rua A, 2015, VIRUSES-BASEL, V7, P5902, DOI 10.3390/v7112917
   Victora CG, 2016, LANCET, V387, P621, DOI 10.1016/S0140-6736(16)00273-7
   WHO, 2016, WHO STAT 1 M INT HLT
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zinszer K, 2017, EMERG INFECT DIS, V23, P92, DOI 10.3201/eid2301.161274
NR 56
TC 74
Z9 75
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2017
VL 8
IS 6
AR e01390-17
DI 10.1128/mBio.01390-17
PG 14
WC Microbiology
SC Microbiology
GA FR2IC
UT WOS:000418889500015
PM 29138300
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Travassos, AG
   Netto, E
   Xavier-Souza, E
   Nobrega, I
   Adami, K
   Timbo, M
   Abbehusen, K
   Fernandes, S
   Duran, C
   Haguihara, T
   Ferreira, F
   Brites, C
AF Travassos, Ana Gabriela
   Netto, Eduardo
   Xavier-Souza, Eveline
   Nobrega, Isabella
   Adami, Karina
   Timbo, Maiara
   Abbehusen, Karen
   Fernandes, Sheyla
   Duran, Camila
   Haguihara, Tatiana
   Ferreira, Fabio
   Brites, Carlos
TI Predictors of HPV incidence and clearance in a cohort of Brazilian
   HIV-infected women
SO PLOS ONE
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS INFECTION; RISK HUMAN-PAPILLOMAVIRUS;
   RIO-DE-JANEIRO; ANTIRETROVIRAL THERAPY; VIRAL SUPPRESSION;
   CERVICAL-CANCER; PERSISTENCE; INTEGRATION; PREVALENCE; RESPONSES
AB Persistent infection with high-risk human papillomavirus (HR-HPV) is necessary for the development of precursor lesions and cervical cancer. HPV infection among women living with HIV/AIDS (WLHA) occurs more frequently, presents a higher rate of persistent infections and an earlier progression to cancer. We aimed to evaluate HR-HPV prevalence, incidence and clearance, and its association with HIV viral suppression, immunological response and other risk factors among WLHA followed at an STD/HIV reference center. This was a cohort study conducted at a reference center for STD/AIDS in Northeastern Brazil from September 2013 to September 2015. Follow-up visits were conducted at 6 and 12 months after enrolment, where socio-epidemiological data were obtained. Cervical samples were collected for conventional cytology and HPV DNA research (PCR COBAS (R) Roche) in addition to blood samples for CD4+ T lymphocyte count and HIV viral load. We prospectively evaluated 333 women. HR-HPV DNA prevalence was 33.3% at baseline. HPV-16 was present in 5.1%, HPV-18 in 3.9% and 29.4% WLHA had other HR-HPV (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The HR-HPV incidence during the follow-up was 10.8%, at the 6-month visit was 7.7% and at the 12-month visit was 3.7%. Variables associated with HRHPV incidence were: nulliparity, combined oral contraceptive use and detectable HIV viral load. The HR-HPV clearance rate was 41.7% and was associated with age > 30 years and lymphocyte T CD4 count >500 cells/mm3 at enrolment. These findings contribute to the knowledge about a group of women that need more careful HPV screening and describe the association between an efficient immunological response and HIV viral suppression with lower incidence and increased clearance of HR-HPV.
C1 [Travassos, Ana Gabriela; Nobrega, Isabella; Adami, Karina; Abbehusen, Karen; Fernandes, Sheyla; Haguihara, Tatiana] Secretaria Saude Estado Bahia, CEDAP, Salvador, BA, Brazil.
   [Travassos, Ana Gabriela] Univ Estadual Bahia, Colegiado Med, Dept Ciencias Vida, Salvador, BA, Brazil.
   [Netto, Eduardo; Xavier-Souza, Eveline; Timbo, Maiara; Brites, Carlos] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
   [Duran, Camila] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   [Ferreira, Fabio] Lab Cent Saude Publ Prof Goncalo Moniz, Salvador, BA, Brazil.
RP Travassos, AG (corresponding author), Secretaria Saude Estado Bahia, CEDAP, Salvador, BA, Brazil.; Travassos, AG (corresponding author), Univ Estadual Bahia, Colegiado Med, Dept Ciencias Vida, Salvador, BA, Brazil.
EM atravassos@uneb.br
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013; Travassos, Ana
   Gabriela A/E-6809-2016
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761;
   Travassos, Ana Gabriela A/0000-0001-9242-828X
CR ACOG, 2014, AM COLL OBSTET GYNEC, V123, P1118
   Adler DH, 2010, CURR HIV RES, V8, P493, DOI 10.2174/157016210793499240
   [Anonymous], 2014, MANUAL TECNICO DIAGN
   Blitz S, 2013, J INFECT DIS, V208, P454, DOI 10.1093/infdis/jit181
   Bornstein J, 2012, OBSTET GYNECOL, V120, P166, DOI 10.1097/AOG.0b013e318254f90c
   Branca M, 2003, INT J STD AIDS, V14, P417, DOI 10.1258/095646203765371321
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de DST Aids e Hepatites Virais., 2015, PROT CLIN DIR TER AT, P120
   Brickman C, 2015, CURR HIV-AIDS REP, V12, P6, DOI 10.1007/s11904-014-0254-4
   Cambou MC, 2015, INT J INFECT DIS, V41, P17, DOI 10.1016/j.ijid.2015.10.017
   Castellsague A X, 2003, J NATL CANC I MONOGR, P20
   Castilho JL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1486-4
   Centers for Disease Control and Prevention (CDC), 1993, MMWR REC REP MORB MO
   da Silva L, 2015, BRAZ J INFECT DIS, V19, P557, DOI 10.1016/j.bjid.2015.07.001
   de Abreu ALP, 2016, AM J CANCER RES, V6, P1371
   Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083
   Geraets DT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080382
   Heard I, 2009, CURR OPIN HIV AIDS, V4, P68, DOI 10.1097/COH.0b013e328319bcbe
   Instituto Nacional de ca A ncer (INCA), 2011, DIR RASTR CANC COL U
   Jaisamrarn U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079260
   Keller MJ, 2015, CLIN INFECT DIS, V61, P1573, DOI 10.1093/cid/civ569
   Kitchener HC, 2006, VACCINE, V24, P63, DOI 10.1016/j.vaccine.2006.05.113
   Konopnicki D, 2013, J INFECT DIS, V207, P1723, DOI 10.1093/infdis/jit090
   Ministry of Land Infrastructure transport and tourism and Ministry of economy trade and industry of Japan, 2006, IN LAT CAR DES SOST, P1
   Minkoff H, 2010, J INFECT DIS, V201, P681, DOI 10.1086/650467
   Money DM, 2016, VACCINE, V34, P4799, DOI 10.1016/j.vaccine.2016.08.016
   Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115
   Nayar Ritu, 2004, Cytojournal, V1, P4, DOI 10.1186/1742-6413-1-4
   Palefsky JM, 2016, CURR OPIN HIV AIDS, V1
   Palefsky J, 2009, CURR OPIN HIV AIDS, V4, P52, DOI 10.1097/COH.0b013e32831a7246
   Ramanakumar AV, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011371
   Rosa MI, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.033
   Rositch AF, 2013, INT J CANCER, V133, P1271, DOI 10.1002/ijc.27828
   Roura E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147029
   Secretaria de Vigilancia em Saude, 2013, PROT CLIN DIR TER MA
   Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076
   Shrestha S, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-295
   Martins AES, 2014, MEM I OSWALDO CRUZ, V109, P738, DOI 10.1590/0074-0276140070
   Stanley M, 2006, VACCINE, V24, P16, DOI 10.1016/j.vaccine.2005.09.002
   Strickler HD, 2003, JNCI-J NATL CANCER I, V95, P1062, DOI 10.1093/jnci/95.14.1062
   Sudenga SL, 2013, INT J INFECT DIS, V17, pE216, DOI 10.1016/j.ijid.2012.12.027
   Thorsteinsson K, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2881-1
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Vaccarella S, 2008, INT J EPIDEMIOL, V37, P536, DOI 10.1093/ije/dyn033
   Ceccato BPV, 2015, REV BRAS GINECOL OBS, V37, P178, DOI 10.1590/SO100-720320150005184
   von Karsa L, 2015, EUROPEAN GUIDELINES
   Vriend HJ, 2015, CANCER MED-US, V4, P1589, DOI 10.1002/cam4.496
   WHO, 2012, WHOHIV201212, V1
   Williams VM, 2011, FUTURE VIROL, V6, P45, DOI 10.2217/FVL.10.73
   Wongworawat YC, 2016, AM J CANCER RES, V6, P764
   Workowski KA, 2015, MMWR RECOMM REP, V64, P1
   Zhu HY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003077
NR 51
TC 8
Z9 8
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 5
PY 2017
VL 12
IS 10
AR e0185423
DI 10.1371/journal.pone.0185423
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FI9WM
UT WOS:000412360300038
PM 28981551
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Lins, L
   Farias, E
   Brites-Alves, C
   Torres, A
   Netto, EM
   Brites, C
AF Lins, Liliane
   Farias, Erica
   Brites-Alves, Clara
   Torres, Alex
   Netto, Eduardo M.
   Brites, Carlos
TI Increased expression of CD38 and HLADR in HIV-infected patients with
   oral lesion
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE activation; human immunodeficiency virus; infection
ID ANTIRETROVIRAL THERAPY; CELLS; DISEASES; NUMBERS
AB Persistent immune actiation is associated with innadequate immune recovery in HIV-patients. This study assessed the relationship between frequency of expression of cell activation markers (CD38 and HLADR) and presence of oral lesions in HIV-1 infected patients. Fifty-seven HIV-infected persons, undergoing antiretroviral treatment, were divided into three groups, according to the number of CD4(+) T cells and CD4(+)/CD8(+) ratio: adequate, partial, and inadequate immune restauration. All patients underwent full mouth assessments for saliva flow measurement, oral mucosal lesion, periodontal disease, and severity of periodontitis. Immune activation markers levels were compared according to three groups of periodontal disease ("No periodontal disease," "gingivitis," and "periodontitis"). Oral mucosal lesions (P = 0.03) and peridodontal disease (P = 0.03) were associated with lower CD4(+)/CD8(+) ratio. Patients with oral mucosal lesions had significantly higher median levels of HLADR and CD38 markers in all T-lymphocytes populations than patients without oral lesions. Patients with gingivitis and with periodontitis presented significantly higher median levels of CD3(+) HLADR(+), CD4(+) HLADR(+), CD8(+) HLADR(+), and CD3(+) CD38(+) and significantly lower CD4(+)/CD8(+) ratio than patients with no periodontal disease. Increased levels of HLADR and CD38 expressions in peripheral blood were associated with oral lesions in HIV-positive patients. Periodontal disease was associated with HLADR expression.
C1 [Lins, Liliane; Brites, Carlos] Univ Fed Bahia, Sch Med, Praca 15 Novembro,Largo Terreiro Jesus S-N, BR-40026010 Salvador, BA, Brazil.
   [Farias, Erica; Brites-Alves, Clara; Torres, Alex; Netto, Eduardo M.; Brites, Carlos] Edgard Santos Fed Univ Hosp, Res Lab Infect Dis, Salvador, BA, Brazil.
RP Lins, L (corresponding author), Univ Fed Bahia, Sch Med, Praca 15 Novembro,Largo Terreiro Jesus S-N, BR-40026010 Salvador, BA, Brazil.
EM liliane.lins@ufba.br
RI Torres, Alex JL/Q-6186-2018; Brites, Carlos/D-1353-2013; Netto,
   Eduardo/D-1432-2013; Lins-Kusterer, Liliane/Q-5191-2019
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761;
   Lins-Kusterer, Liliane/0000-0003-3736-0002
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [306885/2011-5]
FX Brazilian National Research Council (CNPq), Grant number: 306885/2011-5
CR Benito DM, 2005, JAIDS-J ACQ IMM DEF, V38, P373, DOI 10.1097/01.qai.0000153105.42455.c2
   Berberi Antoine, 2015, J Int Oral Health, V7, P18
   Brites-Alves C, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/174215
   Cao W, 2009, AIDS RES HUM RETROV, V25, P183, DOI 10.1089/aid.2008.0140
   Corbeau P, 2011, BLOOD, V117, P5582, DOI 10.1182/blood-2010-12-322453
   Falasca K, 2008, EUR J MED RES, V13, P163
   Fauci AS, 2007, CLIN INFECT DIS, V45, pS206, DOI 10.1086/522540
   Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957
   Gonzalez OA, 2009, ORAL DIS, V15, P313, DOI 10.1111/j.1601-0825.2009.01533.x
   Guihot A, 2011, TRENDS IMMUNOL, V32, P131, DOI 10.1016/j.it.2010.12.002
   Huang CB, 2011, CELL IMMUNOL, V268, P105, DOI 10.1016/j.cellimm.2011.02.003
   Imai K, 2012, CURR HIV RES, V10, P238, DOI 10.2174/157016212800618183
   John CN, 2013, BMC ORAL HEALTH, V13, DOI 10.1186/1472-6831-13-69
   Jordan Laura, 2013, J Dent Hyg, V87, P59
   Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093
   Krasse B., 1988, RISCO CARIE GUIA PRA
   Leroy R, 2010, BMC ORAL HEALTH, V10, DOI 10.1186/1472-6831-10-8
   da Silva CAL, 2008, J PUBLIC HEALTH DENT, V68, P178, DOI 10.1111/j.1752-7325.2007.00071.x
   Liu XA, 2003, J VIROL, V77, P3470, DOI 10.1128/JVI.77.6.3470-3476.2003
   Lou LX, 2014, AM J INFECT CONTROL, V42, P1044, DOI 10.1016/j.ajic.2014.06.029
   Mattila R, 2011, ORAL SURG ORAL MED O, V111, P211, DOI 10.1016/j.tripleo.2010.09.075
   Myint M, 2000, J CLIN PERIODONTOL, V27, P513, DOI 10.1034/j.1600-051x.2000.027007513.x
   ODDEN K, 1995, J ORAL PATHOL MED, V24, P413, DOI 10.1111/j.1600-0714.1995.tb01211.x
   Page RC, 2007, J PERIODONTOL, V78, P1387, DOI 10.1902/jop.2007.060264
   Petersen PE, 1997, ORAL HLTH SURVEYS BA
   POULTER LW, 1989, CLIN EXP IMMUNOL, V78, P189
NR 26
TC 4
Z9 5
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2017
VL 89
IS 10
BP 1782
EP 1787
DI 10.1002/jmv.24852
PG 6
WC Virology
SC Virology
GA FF7YA
UT WOS:000409231100014
PM 28500735
DA 2020-12-01
ER

PT J
AU Reboucas, MC
   da Silva, MO
   Haguihara, T
   Brites, C
   Netto, EM
AF Reboucas, Monaliza Cardozo
   da Silva, Marcio Oliveira
   Haguihara, Tatiana
   Brites, Carlos
   Netto, Eduardo Martins
TI Tuberculosis incidence among people living with HIV/AIDS with
   virological failure of antiretroviral therapy in Salvador, Bahia, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Tuberculosis; Virological failure; HIV infection
ID ADULTS
AB Antiretroviral therapy for HIV has led to increased survival of HIV-infected patients. How ever, tuberculosis remains the leading opportunistic infection and cause of death among people living with HIV/AIDS. Tuberculosis has been shown to be a good predictor of virological failure in this group. This study aimed to evaluate the incidence of tuberculosis and its consequences among individuals diagnosed with virological failure of HIV. This was a retrospective cohort study involving people living with HIV/AIDS being followed-up in an AIDS reference center in Salvador, Bahia, Brazil. Individuals older than 18 years with HIV infection on antiretroviral therapy for at least six months, diagnosed with virological failure (HIV-RNA greater than or equal to 1000copies/mL), from January to December 2013 were included. Tuberculosis was diagnosed according to the criteria of the Brazilian Society of Pneumology. Fourteen out of 165 (8.5%) patients developed tuberculosis within two years of follow-up (incidence density=4.1 patient-years). Death was directly related to tuber culosis in 6/14 (42.9%). A high incidence and tuberculosis-related mortality was observed among patients with virological failure. Diagnosis of and prophylaxis for tuberculosis in high-incidence countries such as Brazil is critical to decrease morbidity and mortality in people living with HIV/AIDS. (C) 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [Reboucas, Monaliza Cardozo; da Silva, Marcio Oliveira; Haguihara, Tatiana] CEDAP, Secretaria Saude Estado Bahia SESAB, Salvador, BA, Brazil.
   [Brites, Carlos; Netto, Eduardo Martins] Univ Fed Bahia UFBA, PPGMS, Salvador, BA, Brazil.
RP Reboucas, MC (corresponding author), CEDAP, Secretaria Saude Estado Bahia SESAB, Salvador, BA, Brazil.
EM monaenf@hotmail.com
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Ahoua L, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-81
   Badri M, 2001, INT J TUBERC LUNG D, V5, P225
   Cohen K, 2008, J ANTIMICROB CHEMOTH, V61, P389, DOI 10.1093/jac/dkm484
   Conde MB, 2009, J BRAS PNEUMOL, V35, P1018, DOI 10.1590/S1806-37132009001000011
   Tran DA, 2014, SEX TRANSM INFECT, V90, P538, DOI 10.1136/sextrans-2013-051353
   Datay MI, 2010, JAIDS-J ACQ IMM DEF, V54, P489, DOI 10.1097/QAI.0b013e3181d91788
   [DIVEP (Diretoria de Vigilancia Epidemiologica) SESAB (Secretaria de Saude do Estado da Bahia)], 2015, B EP TUB, V1, P1
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   El-Khatib Z, 2010, AIDS, V24, P1679, DOI 10.1097/QAD.0b013e32833a097b
   [Joint United Nations Programme on HIV/AIDS UNAIDS], 2016, AIDS S4, V17
   Lawn SD, 2011, LANCET, V378, P57, DOI 10.1016/S0140-6736(10)62173-3
   Luebbert J, 2012, CLIN INFECT DIS, V55, P441, DOI 10.1093/cid/cis438
   McIlleron H, 2007, J INFECT DIS, V196, pS63, DOI 10.1086/518655
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   Ministerio da Saude, 2015, BOL EP SIF, P1
   [Secretaria de vigilancia em saude Ministerio da Satide], 2015, B EP IL, V46
   Singh A, 2013, J AIDS CLIN RES, V4
   Srasuebkul P, 2007, HIV MED, V8, P46, DOI 10.1111/j.1468-1293.2007.00427.x
   WHO, 2014, GLOB TUB REP 2014, P171
   WHO World Health Organization, 2016, HIV DRUG GLOB REP EA
NR 20
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2017
VL 21
IS 5
BP 562
EP 566
DI 10.1016/j.bjid.2017.05.005
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA FL5KS
UT WOS:000414276300014
PM 28628760
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Betancur, MN
   Lins, L
   de Oliveira, IR
   Brites, C
AF Betancur, Monica Narvaez
   Lins, Liliane
   de Oliveira, Irismar Reis
   Brites, Carlos
TI Quality of life, anxiety and depression in patients with HIV/AIDS who
   present poor adherence to antiretroviral therapy: a cross-sectional
   study in Salvador, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Highly active antiretroviral therapy; HIV/AIDS; Adherence; Nonadherence;
   Anxiety; Depression; Quality of life
ID HIV-INFECTED PATIENTS; SOUTHERN BRAZIL; NONADHERENCE; DETERMINANTS;
   VALIDATION; INVENTORY; DISTRICT; REGIMENS; ADULTS; HAART
AB The introduction of highly active antiretroviral therapy marked a major gain in efficacy of HIV/AIDS treatment and a reduction in morbidity and mortality of the infected patients. However, high levels of adherence are required to obtain virologie suppression. In Brazil, the policy of free and universal access to antiretroviral therapy has been in place since 1996, although there are reports of poor adherence.& para;& para;Objective: To define the clinical, demographic and psychological characteristics, and quality of life of patients with HIV/AIDS who present poor adherence to highly active antiretroviral therapy.& para;& para;Methods: This was a cross-sectional study. To be included in the study patients had to be 18 through 65 years old, diagnosed with HIV/AIDS, having the two previous viral loads above 500 copies, a surrogate for poor adherence to antiretrovirals. The following instruments were applied to all eligible patients: the sociodemographic questionnaire "Adherence Follow-up Questionnaire", the Beck Depression Inventory (BDI-II), the Beck Anxiety Inventory (BAI), and the 36-Item Short Form Survey.& para;& para;Results: 47 patients were evaluated, 70.2% were female, mean age of 41.9 years (+/- 10.5), 46.8% were single, 51.1% self-reported adherence >= 95%, 46.8% mentioned depression as the main reason for not taking the medication, 59.5% presented symptoms of moderate to severe depression, and 44.7% presented symptoms of moderate to severe anxiety. Finally, regarding health-related quality of life these patients obtained low scores in all dimensions, physical component summary of 43.96 (+/- 9.64) and mental component summary of 33.19 (+/- 13.35).& para;& para;Conclusion: The psychological component is considered to be fundamental in the management of HIV/AIDS patients. Psychoeducation should be conducted at the initial evaluation to reduce negative beliefs regarding antiretroviral therapy Assessment of anxiety and depression symptoms should be done throughout therapy as both psycological conditions are associated with patient adherence, success of treatment, and ultimately with patients' quality of life. (C) 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [Betancur, Monica Narvaez; Brites, Carlos] Univ Fed Bahia UFBA, Programa Posgrad Med & Saude, Salvador, BA, Brazil.
   [Lins, Liliane; de Oliveira, Irismar Reis; Brites, Carlos] Univ Fed Bahia UFBA, Fac Med, Dept Med, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia UFBA, Programa Posgrad Med & Saude, Salvador, BA, Brazil.; Brites, C (corresponding author), Univ Fed Bahia UFBA, Fac Med, Dept Med, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; Lins-Kusterer, Liliane/Q-5191-2019
OI Brites, Carlos/0000-0002-4673-6991; Lins-Kusterer,
   Liliane/0000-0003-3736-0002
CR Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015
   Beer L, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003171
   Bonolo PD, 2008, CAD SAUDE PUBLICA, V24, P2603, DOI 10.1590/S0102-311X2008001100015
   Bonolo PD, 2005, AIDS, V19, pS5
   Brigido LFM, 2001, AIDS PATIENT CARE ST, V15, P587, DOI 10.1089/108729101753287685
   Campos LN, 2010, AIDS BEHAV, V14, P289, DOI 10.1007/s10461-008-9435-8
   Campos LN, 2009, CLINICS, V64, P867, DOI 10.1590/S1807-59322009000900007
   Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773
   Ciconelli R. M., 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005
   Collier AC, 2005, J INFECT DIS, V192, P1398, DOI 10.1086/466526
   Guimaraes MDC, 2008, CLINICS, V63, P165, DOI 10.1590/S1807-59322008000200003
   Cunha J., 2001, MANUAL VERSA PORTUGU
   de Carvalho CV, 2007, REV SOC BRAS MED TRO, V40, P555, DOI 10.1590/S0037-86822007000500013
   de Soarez PC, 2009, REV PANAM SALUD PUBL, V25, P69, DOI 10.1590/S1020-49892009000100011
   Do AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092842
   Dozois DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83
   EZEAMAMA AE, 2016, MEDICINE, V95
   Feuillet P, 2016, HIV MED
   Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1
   Silva JAG, 2015, CAD SAUDE PUBLICA, V31, P1188, DOI 10.1590/0102-311X00106914
   Gomes-Oliveira MH, 2012, REV BRAS PSIQUIATR, V34, P389, DOI 10.1016/j.rbp.2012.03.005
   Gunthard HF, 2016, JAMA-J AM MED ASSOC, V316, P191, DOI 10.1001/jama.2016.8900
   Ickovics JR, 2002, AIDS CARE, V14, P309, DOI 10.1080/09540120220123685
   Passos SMK, 2015, CAD SAUDE PUBLICA, V31, P800, DOI 10.1590/0102-311X00000514
   Krumme AA, 2015, J EPIDEMIOL COMMUN H, V69, P284, DOI 10.1136/jech-2014-204494
   Mannheimer SB, 2005, AIDS CARE, V17, P10, DOI 10.1080/09540120412331305098
   McCoy Katryna, 2016, J Int Assoc Provid AIDS Care, V15, P248, DOI 10.1177/2325957416642019
   Ministerio da Saude, 2013, SECR VIG SAUD PROT C, P216
   Ortego C, 2012, AIDS CARE, V24, P1519, DOI 10.1080/09540121.2012.672722
   Peltzer K, 2012, SAHARA J-J SOC ASP H, V9, P218, DOI 10.1080/17290376.2012.745640
   Peter E, 2014, INT J PREVENTIVE MED, V5, P203
   Prasithsirikul W, 2016, AIDS CARE, P1
   Remien RH, 2007, AIDS CARE, V19, P740, DOI 10.1080/09540120600842516
   Ricci G, 2016, BRAZ J INFECT DIS, V20, P429, DOI 10.1016/j.bjid.2016.05.009
   Sampaio-Sa M, 2008, AIDS BEHAV, V12, pS54, DOI 10.1007/s10461-008-9414-0
   Silveira MPT, 2012, REV BRAS PSIQUIATR, V34, P162, DOI 10.1590/S1516-44462012000200008
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Tostes MA, 2004, AIDS CARE, V16, P177, DOI 10.1080/09540120410001641020
   Zubaran C, 2014, AIDS CARE, V26, P619, DOI 10.1080/09540121.2013.841838
NR 39
TC 17
Z9 18
U1 0
U2 9
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2017
VL 21
IS 5
BP 507
EP 514
DI 10.1016/j.bjid.2017.04.004
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA FL5KS
UT WOS:000414276300003
PM 28535397
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Castilho, J
   Escuder, MM
   Veloso, V
   Gomes, JO
   Jayathilake, K
   Ribeiro, S
   Souza, RA
   Ikeda, ML
   de Alencastro, PR
   Tupinanba, U
   Brites, C
   McGowan, C
   Grangeiro, A
   Grinsztejn, B
AF Castilho, J.
   Escuder, M. M.
   Veloso, V.
   Gomes, J. O.
   Jayathilake, K.
   Ribeiro, S.
   Souza, R. A.
   Ikeda, M. L.
   de Alencastro, P. R.
   Tupinanba, U.
   Brites, C.
   McGowan, C.
   Grangeiro, A.
   Grinsztejn, B.
TI Trends and predictors of non-communicable disease multi-morbidity among
   HIV-infected adults initiating ART in Brazil, 2003-2014
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Castilho, J.; Jayathilake, K.; McGowan, C.] Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA.
   [Escuder, M. M.; Gomes, J. O.] Sao Paulo State Dept Hlth, Hlth Inst, Sao Paulo, Brazil.
   [Veloso, V.; Ribeiro, S.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Souza, R. A.] Sao Paulo State Dept Hlth, AIDS Reference & Training Ctr, Sao Paulo, Brazil.
   [Ikeda, M. L.; de Alencastro, P. R.] Rio Grande do Sul State Dept Hlth, Care & Treatment Clin Partenon Sanatorium, Porto Alegre, RS, Brazil.
   [Tupinanba, U.] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil.
   [Brites, C.] 7Federal Univ Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil.
   [Grangeiro, A.] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
EM jessica.castilho@vanderbilt.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2017
VL 20
SU 5
MA WEAB0101
BP 52
EP 53
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FB8ZQ
UT WOS:000406429800104
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Brites, C
   Nobrega, I
   Travassos, AG
   Luz, E
   Stelitano, C
   Fernandes, S
   Figueredo, C
   Lorenzo, C
   Netto, EM
AF Brites, C.
   Nobrega, I.
   Travassos, A. G.
   Luz, E.
   Stelitano, C.
   Fernandes, S.
   Figueredo, C.
   Lorenzo, C.
   Martins Netto, E.
TI Raltegravir vs. lopinavir/r for late-presenter pregnant women
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Brites, C.; Martins Netto, E.] Univ Fed Bahia, Med, Salvador, BA, Brazil.
   [Brites, C.; Luz, E.; Stelitano, C.; Martins Netto, E.] Fundacao Bahiana Infectol, Clin Res, Salvador, BA, Brazil.
   [Nobrega, I.; Travassos, A. G.; Fernandes, S.; Figueredo, C.; Lorenzo, C.] Ctr Especializado Diagnost Assistencia & Pesquisa, Salvador, BA, Brazil.
EM crbritesl@gmail.com
RI Netto, Eduardo/D-1432-2013; Travassos, Ana Gabriela A/E-6809-2016
OI Netto, Eduardo/0000-0003-1691-6761; Travassos, Ana Gabriela
   A/0000-0001-9242-828X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2017
VL 20
SU 5
MA WEAC0201
BP 58
EP 59
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FB8ZQ
UT WOS:000406429800114
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU de Abreu, JC
   Vaz, SN
   Netto, EM
   Brites, C
AF de Abreu, Juliana Costa
   Vaz, Sara Nunes
   Netto, Eduardo Martins
   Brites, Carlos
TI Virological suppression in children and adolescents is not influenced by
   genotyping, but depends on optimal adherence to antiretroviral therapy
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Children; Virological suppression; Genotyping; Adherence
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DRUG-RESISTANCE; BRAZILIAN CHILDREN;
   INFECTED CHILDREN; PREVALENCE; MUTATIONS; PATTERNS; SUBTYPES; NETWORK;
   IMPACT
AB Objective: To evaluate the virological outcomes in children and adolescents infected with HIV-1 in Salvador, Bahia according to genotyping results.
   Methods: We retrospectively evaluated the rates of virological suppression of children and adolescents submitted to HIV-1 genotyping test from January/2008 to December/2012. The participants were followed in the two referral centers for pediatric AIDS care, in Salvador, Brazil. Resistance mutations, drug sensitivity profiles, and viral subtypes were analyzed using the Stanford HIV-1 Drug Resistance Database. Adherence was estimated by drugs withdrawal at pharmacies of the two sites.
   Results: 101 subjects were included: 35 (34.6%) were drug-naive, and the remaining 66 were failing ART. In drug-naive group, 3 (8.6%), presented with NNRTIs resistance mutations, along with polymorphic mutations to PIs in most (82.8%) of them. Among the failing therapy group, we detected a high frequency (89.4%) of resistance mutations to PIs, NRTI (84.8%), and NNRTI (59.1%). Virological suppression after introduction/modification of genotyping-guided ART was achieved only for patients (53.1%) with drug withdrawal over 95%. Main detected HIV-1 subtypes were B (67.3%), F (7.9), C (1.9%), and recombinant forms (22.9%).
   Conclusions: Despite the use of genotyping tests in guidance of a more effective antiretroviral regimen, poor adherence to ART seems to be the main determinant of low virological suppression rate for children and adolescents, in Salvador, Brazil. (C) 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [de Abreu, Juliana Costa; Vaz, Sara Nunes; Netto, Eduardo Martins; Brites, Carlos] Univ Fed Bahia, Lab Retrovirol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Lab Retrovirol, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Almeida FJ, 2011, ARCH PEDIATR URUG, V82, P247
   de Angelis DSA, 2011, BRAZ J INFECT DIS, V15, P60, DOI 10.1590/S1413-86702011000100011
   Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001
   Brindeiro PA, 2002, J CLIN MICROBIOL, V40, P4512, DOI 10.1128/JCM.40.12.4512-4519.2002
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Brito A M, 2001, Rev Soc Bras Med Trop, V34, P207, DOI 10.1590/S0037-86822001000200010
   Caride E, 2001, VIRUS GENES, V23, P193, DOI 10.1023/A:1011812810397
   Colombrini MRC, 2008, REV ESC ENFERM USP, V42, P487, DOI 10.1590/S0080-62342008000300011
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   Cohen NJ, 2002, PEDIATR INFECT DIS J, V21, P647, DOI 10.1097/00006454-200207000-00009
   Colombrini Maria Rosa Ceccato, 2006, Rev. esc. enferm. USP, V40, P576, DOI 10.1590/S0080-62342006000400018
   Cornelissen M, 1997, J VIROL, V71, P6348, DOI 10.1128/JVI.71.9.6348-6358.1997
   de Oliveira CM, 2008, ARCH VIROL, V153, P1799, DOI 10.1007/s00705-008-0178-7
   De Toni Elisa Cristina, 2012, Revista de Ciencias Farmaceuticas Basica e Aplicada, V33, P147
   Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2
   Ferreira FGF, 2010, AIDS RES HUM RETROV, V26, P229, DOI 10.1089/aid.2009.0146
   Frater AJ, 2001, AIDS, V15, P1493, DOI 10.1097/00002030-200108170-00006
   Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680
   Hirsch MS, 2008, CLIN INFECT DIS, V47, P266, DOI 10.1086/589297
   Johann-Liang R, 2000, PEDIATR INFECT DIS J, V19, P363, DOI 10.1097/00006454-200004000-00025
   Kantor Rami, 2003, AIDS Reviews, V5, P25
   Machado Daisy Maria, 2005, Rev. Inst. Med. trop. S. Paulo, V47, P1, DOI 10.1590/S0036-46652005000100001
   Machado ES, 2004, AN ACAD BRAS CIENC, V76, P727, DOI 10.1590/S0001-37652004000400008
   Machado ES, 2004, J CLIN VIROL, V30, P24, DOI 10.1016/j.jcv.2003.08.001
   Machtinger EL, HIV SITE KNOWLEDGE B
   Ministere de l'agriculture, 2015, ENV SOUND MAT CYCL S, P1
   Ministry of Health (BR), 2009, MIN HLTH BR MAN SER
   Mullen J, 2002, J MED VIROL, V68, P299, DOI 10.1002/jmv.10203
   Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004
   Palella FJ, 2002, AIDS, V16, P1617, DOI 10.1097/00002030-200208160-00007
   Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
   Pillay D, 2002, J INFECT DIS, V186, P617, DOI 10.1086/342680
   Ramos AN, 2011, PEDIATR INFECT DIS J, V30, P1
   Sanabani SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062552
   Sharland M, 1998, LANCET, V352, P577, DOI 10.1016/S0140-6736(05)79289-8
   Simonetti SRR, 2003, MEM I OSWALDO CRUZ, V98, P831, DOI 10.1590/S0074-02762003000600021
   Vaz SN, 2015, AIDS RES HUM RETROV, V31, P1046, DOI [10.1089/aid.2015.0166, 10.1089/AID.2015.0166]
   Villada EP, 2011, PEDIATRICS, V197, P423
   Walsh JC, 2002, J ACQ IMMUN DEF SYND, V30, P278, DOI [10.1097/00126334-200207010-00003, 10.1097/01.QAI.0000018000.56638.43]
   Wensing Annemarie M, 2014, Top Antivir Med, V22, P642
   Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6
NR 41
TC 5
Z9 7
U1 0
U2 4
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2017
VL 21
IS 3
BP 219
EP 225
DI 10.1016/j.bjid.2017.02.001
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA EZ1ET
UT WOS:000404453600002
PM 28253476
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU de Oliveira, AW
   Brites, C
AF de Oliveira Filho, Antonio Walter
   Brites, Carlos
TI Geolocalization of HIV-1 subtypes and resistance mutations of patients
   failing antiretroviral therapy in Salvador - Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; Resistance mutations; Brazil; Geolocalization
ID INFECTIONS; PREVALENCE; DIVERSITY; NORTHEAST; HISTORY; POVERTY; GENDER;
   SPREAD; AIDS
AB Background: Geographical distribution of HIV variants is an important way to understand the circulation and spread of such viral strains. Objectives: To evaluate the spatial distribution of HIV-1 variants in patients failing antiretroviral therapy, in Salvador, Brazil.
   Methods: We performed a cross-sectional evaluation of HIV resistance test reports of patients who underwent genotyping tests in a referral center in Salvador, Brazil, for the years 2008-2014. The laboratory database contains around 2500 resistance reports of patients failing antiretroviral therapy. Genotypic tests were performed by sequencing of HIV-1 POL region (TrueGene, Siemens). We assessed HIV-1 resistance mutations and subtype, as well as residential address, age, and gender of patients.
   Results: We evaluated 1300 reports, 772 (59.4%) of them from male patients. As expected, subtype B predominated (79%) followed by subtypes F1 (6.7%) and BF (6.5%). The most frequent mutations in HIV-1 reverse transcriptase were 184V (79.1%), 41L (33.5%), 67N (30.4%), 103N (42.4%), and 108I (11.1%). Most frequent mutations in HIV-1 protease were 63P (52.4%), 36I (47.9%), 15 V (33.0%), 62 V (28.1%) and 13 V (25.8%). Some mutations (41L, 215Y, 210W) were significantly more frequent among men. We detected a significantly higher accumulation of 103N mutation in specific areas of Salvador. We identified a more restricted circulation pattern for subtype FB (more frequent in some regions), and F1 (almost absent in a specific region).
   Conclusion: Our results suggest that specific subtypes/resistance mutations present a distinct frequency rate in specific areas of Salvador, probably due to a restricted circulation pattern. This trend to clustering was observed in regions covered by AIDS referral centers, suggesting that pattern of care for such patients can interfere in virological outcomes. (C) 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [de Oliveira Filho, Antonio Walter; Brites, Carlos] Univ Fed Bahia, Fac Med, LAPI Lab Pesquisa Infectol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Fac Med, LAPI Lab Pesquisa Infectol, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Santos ASED, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164774
   Beer L, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003171
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brito Ana Maria de, 2005, Braz J Infect Dis, V9, P9, DOI 10.1590/S1413-86702005000100004
   Davanos N, 2015, HIV AIDS-RES PALLIAT, V7, P277, DOI 10.2147/HIV.S90755
   Ferreira JLD, 2008, MEM I OSWALDO CRUZ, V103, P800, DOI 10.1590/S0074-02762008000800010
   Esparza J, 2013, VACCINE, V31, P3502, DOI 10.1016/j.vaccine.2013.05.018
   Gray RR, 2009, AIDS, V23, pF9, DOI 10.1097/QAD.0b013e32832faf61
   Kalichman SC, 2016, J CLIN PSYCHOL MED S, V23, P420, DOI 10.1007/s10880-016-9481-8
   Kalichman SC, 2015, J COMMUN HEALTH, V40, P702, DOI 10.1007/s10900-014-9988-6
   Lynch RM, 2009, AIDS RES HUM RETROV, V25, P237, DOI 10.1089/aid.2008.0219
   MANN JM, 1992, J INFECT DIS, V165, P245, DOI 10.1093/infdis/165.2.245
   Ministerio da Saude, 2016, B EP AID DST AN V N
   Monteiro JP, 2009, J MED VIROL, V81, P391, DOI 10.1002/jmv.21414
   OSMANOV S, 1994, AIDS RES HUM RETROV, V10, P1327, DOI 10.1089/aid.1994.10.1327
   Parker R, 2000, Cad Saude Publica, V16, P89
   Pinto Mônica Edelenyi, 2006, Cad. Saúde Pública, V22, P473, DOI 10.1590/S0102-311X2006000300002
   Poon AFY, 2015, J INFECT DIS, V211, P926, DOI 10.1093/infdis/jiu560
   Santos LA, 2011, J MED VIROL, V83, P2066, DOI 10.1002/jmv.22170
   Schultze A, 2015, AIDS, V29, P1379, DOI 10.1097/QAD.0000000000000708
   Sey K, 2014, J MED VIROL, V86, P1639, DOI 10.1002/jmv.23989
   Smith RJ, 2010, SCIENCE, V327, P697, DOI 10.1126/science.1180556
   Tanser F, 2009, INT J EPIDEMIOL, V38, P1008, DOI 10.1093/ije/dyp148
   Tatem AJ, 2012, AIDS, V26, P2351, DOI 10.1097/QAD.0b013e328359a904
   Tedaldi EM, 2008, JAIDS-J ACQ IMM DEF, V47, P441, DOI 10.1097/QAI.0b013e3181609da8
   Toinazelli J, 2003, CAD SAUDE PUBLICA, V19, P1049
   Trepka MJ, 2015, PUBLIC HEALTH REP, V130, P505, DOI 10.1177/003335491513000513
   Wensing Annemarie M, 2015, Top Antivir Med, V23, P132
   Yebra G, 2015, J GEN VIROL, V96, P1890, DOI 10.1099/vir.0.000107
NR 29
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2017
VL 21
IS 3
BP 234
EP 239
DI 10.1016/j.bjid.2017.02.006
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA EZ1ET
UT WOS:000404453600004
PM 28363087
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Lorenzo, CRS
   Netto, EM
   Patricio, FRL
   Brites, C
AF Lorenzo, Cynthia R. S.
   Netto, Eduardo M.
   Patricio, Fatima R. L.
   Brites, Carlos
TI Survival Estimates and Mortality Risk Factors in a Cohort of HIV
   Vertically Infected Individuals in Salvador, Brazil
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE children; HIV; survival; Brazil
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-1-INFECTED CHILDREN; GROWING-UP;
   FOLLOW-UP; ADOLESCENTS; IMPACT; PREDICTORS; INITIATION; MORBIDITY;
   OUTCOMES
AB Background: There are few data on long-term survival of Brazilian children with vertically acquired HIV infection. We assessed survival, mortality risk factors and response to antiretroviral therapy (ART). We compared children with early and late access to care.
   Methods: We used Kaplan-Meier survival curves with Log-rank tests to compare survival time and mortality rates of 245 HIV vertically infected children admitted for care during 2002-2014.
   Results: Total follow-up sum was 1584.4 person-years. Overall survival was 83.9%. Median age at start of ART was 51.6 (18.0-94.2) months, and median age at death was 8.2 (1.7-10.1) years (mortality rate: 1.7/100 person-years). Pneumonia and sepsis were the main causes of death. Male gender, viral load (VL) >= 100,000 copies, severe immunosuppression, moderate/severe symptoms and history of opportunistic infection were associated with higher mortality in bivariate analysis. Only severe symptoms remained associated in multivariate analysis (P = 0.03). There was no difference in mortality in early compared to late access group. Overall, 217 patients received ART; 192 had a recent VL, of which 116 (59.8%) had <= 400 copies. Variables associated with therapeutic failure were as follows: VL >= 100,000 copies, less immune suppression, age <12 months at admission and age <3 years at ART start.
   Conclusions: We have a high mortality rate in comparison with developed countries. Although early access did not impact mortality, we detected a trend in favor of early treatment as a protecting factor against mortality. We need to increase adherence to care and treatment, and better drugs to optimize outcomes.
C1 [Lorenzo, Cynthia R. S.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Netto, Eduardo M.] Univ Fed Bahia, Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Patricio, Fatima R. L.] Univ Fed Bahia, Specialized Ctr Diag Assistance & Res CEDAP, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Sch Med, Dept Med, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Alvarez-Uria G, 2014, INFECT DIS REP, V6, P13, DOI 10.4081/idr.2014.5167
   Cardoso CAA, 2012, MEM I OSWALDO CRUZ, V107, P532, DOI 10.1590/S0074-02762012000400014
   Bamford A, 2018, HIV MED, V19, pe1, DOI 10.1111/hiv.12217
   Bernays S, 2014, LANCET, V383, P1355, DOI 10.1016/S0140-6736(13)62328-4
   Brady MT, 2010, JAIDS-J ACQ IMM DEF, V53, P86, DOI 10.1097/QAI.0b013e3181b9869f
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de DST Aids e Hepatites Virais, 2014, PROT CLIN DIR TER MA
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1
   Chakraborty R, 2013, PEDIATRICS, V132, P192, DOI 10.1542/peds.2013-1073
   Collins IJ, 2010, CLIN INFECT DIS, V51, P1449, DOI 10.1086/657401
   Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009
   Cruz Maria L.S., 2014, J. Pediatr. (Rio J.), V90, P563, DOI 10.1016/j.jped.2014.04.007
   de Lemos LMD, 2014, BRAZ J INFECT DIS, V18, P104, DOI 10.1016/j.bjid.2013.09.003
   Dollfus C, 2010, CLIN INFECT DIS, V51, P214, DOI 10.1086/653674
   Edmonds A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001044
   Gebremedhin A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1047
   Gonçalves Vera Lúcia Maria Alves, 2011, Rev. Soc. Bras. Med. Trop., V44, P4, DOI 10.1590/S0037-86822011000100002
   Hazra R, 2010, ANNU REV MED, V61, P169, DOI 10.1146/annurev.med.050108.151127
   Judd A, 2007, CLIN INFECT DIS, V45, P918, DOI 10.1086/521167
   Kabue MM, 2012, PEDIATRICS, V130, pE591, DOI 10.1542/peds.2011-1187
   Kapogiannis BG, 2011, CLIN INFECT DIS, V53, P1024, DOI 10.1093/cid/cir641
   Massavon W, 2014, ISRN AIDS, V2014, P852489, DOI 10.1155/2014/852489
   Ministerio da Saude (Brasil), 2014, B EP AIDS DST AN 3
   Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7
   Diniz LMO, 2011, J PEDIAT-BRAZIL, V87, P131, DOI [10.2223/JPED.2064, 10.1590/S0021-75572011000200008]
   Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, GUID US ANT AG PED H
   Patel K, 2008, CLIN INFECT DIS, V46, P507, DOI 10.1086/526524
   Puthanakit T, 2012, LANCET INFECT DIS, V12, P933, DOI 10.1016/S1473-3099(12)70242-6
   Ramos AN, 2011, PEDIATR INFECT DIS J, V30, P773, DOI 10.1097/INF.0b013e31821b11ab
   Cruz MLS, 2011, J TROP PEDIATRICS, V57, P165, DOI 10.1093/tropej/fmq068
   SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604
   Siberry GK, 2014, PEDIATR REV, V35, P268, DOI 10.1542/pir.35-7-268
   Souza ES, 2011, J TROP PEDIATRICS, V57, P197, DOI 10.1093/tropej/fmq082
   Sturt AS, 2012, PEDIATR INFECT DIS J, V31, P53, DOI 10.1097/INF.0b013e31823515a2
   Sutcliffe CG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029294
   Taye Bineyam, 2010, Ethiop Med J, V48, P1
   UNAIDS, 2014, THE GAP REP
   Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971
   WHO, 2006, WHO CHILD GROWTH STA
   Yin DE, 2014, PEDIATRICS, V134, pE1104, DOI 10.1542/peds.2014-0527
   Zanoni BC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022706
NR 40
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 2017
VL 36
IS 3
BP E62
EP E68
DI 10.1097/INF.0000000000001439
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA EL1CE
UT WOS:000394357300003
PM 27902650
DA 2020-12-01
ER

PT J
AU Tsai, WY
   Ha, HHH
   Brites, C
   Tsai, JJ
   Tyson, J
   Pedroso, C
   Drexler, JF
   Balmaseda, A
   Harris, E
   Wang, WK
AF Tsai, Wen-Yang
   Ha, Han Ha Han
   Brites, Carlos
   Tsai, Jih-Jin
   Tyson, Jasmine
   Pedroso, Celia
   Drexler, Jan Felix
   Balmaseda, Angel
   Harris, Eva
   Wang, Wei-Kung
TI DISTINGUISHING SECONDARY DENGUE VIRUS INFECTION FROM ZIKA VIRUS
   INFECTION WITH PREVIOUS DENGUE BY A COMBINATION OF THREE SEROLOGICAL
   TESTS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 05-09, 2017
CL Baltimore, MD
SP Amer Soc Trop Med & Hyg
C1 [Tsai, Wen-Yang; Ha, Han Ha Han; Tyson, Jasmine; Wang, Wei-Kung] Univ Hawaii Manoa, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96822 USA.
   [Brites, Carlos; Pedroso, Celia] Univ Fed Bahia, Sch Med, LAPI Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Tsai, Jih-Jin] Kaohsiung Med Univer, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univer, Kaohsiung Med Univ Hosp, Trop Med Ctr, Dept Med,Coll Med, Kaohsiung, Taiwan.
   [Tsai, Jih-Jin] Kaohsiung Med Univer, Ctr Dengue Fever Control & Res, Kaohsiung, Taiwan.
   [Drexler, Jan Felix] Univ Bonn, Med Ctr, Inst Virol, German Ctr Infect Res, Bonn, Germany.
   [Balmaseda, Angel] Minist Hlth, Natl Ctr Diag & Reference, Natl Virol Lab, Managua, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
SU S
MA 147
BP 47
EP 47
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5TD
UT WOS:000423215202147
DA 2020-12-01
ER

PT J
AU Phillips, A
   Fields, P
   Hermine, O
   Ramos, JC
   Beltran, BE
   Pereira, J
   Brites, C
   Wandroo, FA
   Lill, M
   Feldman, TA
   Casanova, L
   Janakiram, M
   Meniane, JC
   Sawas, A
   Cook, LB
   Kurman, MR
   George, J
   Dwyer, K
   Leoni, M
   Conlon, K
   Taylor, GP
   Gonsky, J
   Horwitz, SM
AF Phillips, Adrienne
   Fields, Paul
   Hermine, Olivier
   Ramos, Juan Carlos
   Beltran, Brady E.
   Pereira, Juliana
   Brites, Carlos
   Wandroo, Farooq Ahmad
   Lill, Michael
   Feldman, Tatyana A.
   Casanova, Luis
   Janakiram, Murali
   Meniane, Jean-Come
   Sawas, Ahmed
   Cook, Lucy B.
   Kurman, Michael R.
   George, Joyce
   Dwyer, Karen
   Leoni, Mollie
   Conlon, Kevin
   Taylor, Graham P.
   Gonsky, Jason
   Horwitz, Steven M.
TI A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal
   Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of
   Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma:
   Overall Response Rate, Progression-Free Survival, and Overall Survival
SO BLOOD
LA English
DT Meeting Abstract
CT 58th Annual Meeting and Exposition of the American-Society-of-Hematology
   (ASH)
CY DEC 03-06, 2016
CL San Diego, CA
SP Amer Soc Hematol
C1 [Phillips, Adrienne] Weill Cornell Med Coll, New York Presbyterian Hosp, Div Hematol & Med Oncol, New York, NY 10065 USA.
   [Fields, Paul] Guys & St Thomas Hosp NHS Trust, Dept Haematol, London, England.
   [Hermine, Olivier] Necker Univ Hosp, AP HP, Dept Hematol, Paris, France.
   [Ramos, Juan Carlos] Univ Miami Miller, Sch Med, Div Hematol Oncol, Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Beltran, Brady E.] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru.
   [Pereira, Juliana] Univ Sao Paulo, Med Sch, Dept Hematol, Sao Paulo, Brazil.
   [Brites, Carlos] Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Wandroo, Farooq Ahmad] Sandwell W Birmingham Hosp, NHS Trust, West Bromwich, England.
   [Lill, Michael] Cedars Sinai Med Ctr, Med, Los Angeles, CA 90048 USA.
   [Feldman, Tatyana A.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ 07604 USA.
   [Casanova, Luis] Inst Oncol Miraflores, Miraflores, Peru.
   [Janakiram, Murali] Albert Einstein Coll Med Montefiore Med Ctr, Dept Oncol, Bronx, NY 10467 USA.
   [Meniane, Jean-Come] CHU Ft France, Fort De France, Martinique, France.
   [Sawas, Ahmed] Columbia Univ, Med Ctr, Ctr Lymphoid Malignancies, New York, NY 10017 USA.
   [Cook, Lucy B.] Imperial Coll London, London, England.
   [Kurman, Michael R.] Michael Kurman Consulting LLC, Upper Saddle River, NJ USA.
   [George, Joyce; Dwyer, Karen; Leoni, Mollie] Kyowa Kirin Pharmaceut Dev Inc, Princeton, NJ USA.
   [Conlon, Kevin] NCI, Bethesda, MD 20892 USA.
   [Taylor, Graham P.] Imperial Coll, London, England.
   [Gonsky, Jason] Suny Downstate Med Ctr, Div Hematol Oncol, Dept Med, Brooklyn, NY 11203 USA.
   [Horwitz, Steven M.] Mem Sloan Kettering Canc Ctr, Hematol Oncol, New York, NY 10021 USA.
RI PEREIRA, JULIANA/C-2742-2014; Beltran, Brady/P-8655-2019
OI PEREIRA, JULIANA/0000-0002-0655-2821; Beltran, Brady/0000-0003-4469-3817
FU Kyowa Kirin; AB science; Celgene; NovartisNovartis; Alexion; Lill: Kite;
   Seattle Genetics; Infinity Pharmaceuticals; Spectrum Pharmaceuticals;
   Kyowa Kirin Pharmaceutical; Millennium PharmaceuticalsTakeda
   Pharmaceutical Company Ltd
FX Phillips: Takeda: Speakers Bureau; Kyowa Kirin: Research Funding;
   Celgene: Speakers Bureau. Hermine: AB science: Consultancy, Equity
   Ownership, Membership on an entity's Board of Directors or advisory
   committees, Patents & Royalties, Research Funding, Speakers Bureau;
   Celgene: Research Funding; Novartis: Research Funding; Alexion: Research
   Funding. Lill: Kite: Research Funding; California Cord Blood Services:
   Consultancy; Sanofi: Speakers Bureau. Feldman: Seattle Genetics:
   Consultancy, Research Funding, Speakers Bureau;
   Abbvie/Pharmacyclics/Janssen: Speakers Bureau; Celgene: Consultancy,
   Speakers Bureau. Sawas: Gilead Sciences: Speakers Bureau; Seattle
   Genetics: Honoraria. Cook: Kyowa Kirin Pharmaceutical Development, Inc.:
   Consultancy. Kurman: Kyowa Kirin Pharmaceutical Development, Inc:
   Consultancy. George: Kyowa Kirin Pharmaceutical Development: Employment.
   Dwyer: Kyowa Kirin Pharmaceutical Development, Inc.: Employment. Leoni:
   Kyowa Kirin Pharmaceutical Development, Inc.: Employment. Gonsky:
   Bioclinica: Other: Compensation for independent review of trial data.
   Horwitz: Infinity Pharmaceuticals: Research Funding; Celgene:
   Consultancy, Honoraria, Research Funding; Spectrum Pharmaceuticals:
   Consultancy, Honoraria, Research Funding; Kyowa Kirin Pharmaceutical:
   Research Funding; Millennium Pharmaceuticals: Consultancy, Honoraria,
   Research Funding; Seattle Genetics: Consultancy, Honoraria, Research
   Funding; Huya Bioscience International: Consultancy, Honoraria; Forty
   Seven, Inc.: Consultancy, Honoraria; ADC Therapeutics: Other: Travel.
NR 0
TC 3
Z9 3
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 2
PY 2016
VL 128
IS 22
MA 4159
DI 10.1182/blood.V128.22.4159.4159
PG 8
WC Hematology
SC Hematology
GA EL2LX
UT WOS:000394452308057
DA 2020-12-01
ER

PT J
AU Travassos, AG
   Xavier-Souza, E
   Netto, E
   Dantas, EV
   Timbo, M
   Nobrega, I
   Haguihara, T
   Neumayer, J
   Lisboa, N
   Soidan, MA
   Ferreira, F
   Brites, C
AF Travassos, Ana Gabriela
   Xavier-Souza, Eveline
   Netto, Eduardo
   Dantas, Eda Vinhaes
   Timbo, Maiara
   Nobrega, Isabella
   Haguihara, Tatiana
   Neumayer, Julia
   Lisboa, Nathalia
   Soidan, Maria Angela
   Ferreira, Fabio
   Brites, Carlos
TI Anogenital infection by Chlamydia trachomatis and Neisseria gonorrhoeae
   in HIV-infected men and women in Salvador, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Chlamydia trachomatis; Neisseria gonorrhoeae; Sexually transmitted
   infections; Anogenital infections
ID SEXUALLY-TRANSMITTED INFECTIONS; ANAL INTERCOURSE; ANORECTAL CHLAMYDIA;
   PREGNANT-WOMEN; PREVALENCE; METAANALYSIS; SEX; TRANSMISSION; PREVENTION;
   RISK
AB Background: Infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae are the most common bacterial sexually transmitted infections throughout the world. These sexually transmitted infections are a growing problem in people living with HIV/AIDS. However, the presence of these agents in extra genital sites, remains poorly studied in our country. The objective of this study was to estimate the prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae anal and genital infection in people living with HIV/AIDS followed in a reference center in Salvador, Brazil.
   Methods: Cross-sectional study, from June 2013 to June 2015. Proven HIV-infected people attending this reference center were invited. Clinical and epidemiological data were obtained through interview with standardized form. Chlamydia trachomatis and Neisseria gonorrhoeae screening was performed using qPCR (COBAS 4800 (R) Roche).
   Results: The frequency of positive cases of Chlamydia trachomatis and Neisseria gonorrhoeae was 12.3% in total, 9.2% cases amongst women and 17.1% amongst men. We found 14.0% of positive cases in anus and 3.1% in genital region in men, while 5.6% and 3.6%, in women, respectively. Among men, anal infection was associated with age <29 years (p = 0.033), report of anal intercourse (p = 0.029), pain during anal intercourse (p = 0.028). On the other hand, no association between genital infection and other variables were detected in bivariate analysis. Among women, we detected an association between Chlamydia trachomatis genital infection and age <29 years (p < 0.001), younger age at first sexual intercourse (p = 0.048), pregnancy (p < 0.001), viral load >50 copies/mL (p = 0.020), and no antiretroviral use (p = 0.008).Anal infection in women was associated with age <29 years old (p < 0.001) and pregnancy (p = 0.023), and was not associated with report of anal intercourse (p = 0.485).
   Conclusion: Missed opportunities for diagnosis in extra genital sites could impact on HIV transmission. The extra genital sites need to be considered to break the HIV and bacterial sexually transmitted infections chain-of-transmission. (C) 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license.
C1 [Travassos, Ana Gabriela] Univ Estadual Bahia UNEB, Salvador, BA, Brazil.
   [Travassos, Ana Gabriela; Dantas, Eda Vinhaes; Nobrega, Isabella; Haguihara, Tatiana; Soidan, Maria Angela] Ctr Estadual Especializado Diagnost Assistencia &, Salvador, BA, Brazil.
   [Xavier-Souza, Eveline; Netto, Eduardo; Timbo, Maiara; Neumayer, Julia; Lisboa, Nathalia; Brites, Carlos] Univ Fed Bahia UFBA, Salvador, BA, Brazil.
   [Ferreira, Fabio] Lab Cent Saude Publ Prof Goncalo Moniz LACEN BA, Salvador, BA, Brazil.
RP Travassos, AG (corresponding author), Univ Estadual Bahia UNEB, Salvador, BA, Brazil.; Travassos, AG (corresponding author), Ctr Estadual Especializado Diagnost Assistencia &, Salvador, BA, Brazil.
EM atravassos@uneb.br
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013; Travassos, Ana
   Gabriela A/E-6809-2016
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991;
   Travassos, Ana Gabriela A/0000-0001-9242-828X; Xavier-Souza,
   Eveline/0000-0001-9396-3487
FU Brazilian Department of STD, HIV and Viral Hepatitis, Brazilian Ministry
   of Health [BRA/K57]
FX The authors are grateful to the Brazilian Department of STD, HIV and
   Viral Hepatitis, Brazilian Ministry of Health for the financial support
   (Project BRA/K57).
CR Adachi K, 2015, SEX TRANSM DIS, V42, P554, DOI 10.1097/OLQ.0000000000000340
   Travassos AGA, 2012, BRAZ J INFECT DIS, V16, P581, DOI 10.1016/j.bjid.2012.08.016
   Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057
   Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0
   Brasil, 2013, PROT CLIN DIR TER MA
   Cunha CB, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2002-0
   Garner AL, 2015, INT J STD AIDS, V26, P462, DOI 10.1177/0956462414543120
   Jalil EM, 2008, REV BRAS GINECOL OBS, V30, P614, DOI 10.1590/S0100-72032008001200005
   Jarvis GA, 2012, CURR HIV RES, V29, P997
   Javanbakht M, 2012, SEX TRANSM DIS, V39, P917, DOI 10.1097/OLQ.0b013e31826ae9a2
   Johnson LF, 2008, SEX TRANSM DIS, V35, P946, DOI 10.1097/OLQ.0b013e3181812d15
   Kent CK, 2005, CLIN INFECT DIS, V41, P67, DOI 10.1086/430704
   Koedijk FDH, 2012, INT J STD AIDS, V23, P626, DOI 10.1258/ijsa.2012.011378
   Kong FYS, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1030-9
   Ladd J, 2014, SEX TRANSM INFECT, V90, P485, DOI 10.1136/sextrans-2013-051167
   Landes M, 2007, EUR J EPIDEMIOL, V22, P925, DOI 10.1007/s10654-007-9188-0
   Lanjouw E, 2010, INT J STD AIDS, V21, P729, DOI 10.1258/ijsa.2010.010302
   Mestecky J, 2009, J REPROD IMMUNOL, V83, P196, DOI 10.1016/j.jri.2009.07.005
   Miller WC, 2004, JAMA-J AM MED ASSOC, V292, P801, DOI 10.1001/jama.292.7.801-b
   Owen BN, 2015, AIDS BEHAV, V19, P1338, DOI 10.1007/s10461-015-0997-y
   Pace CA, 2012, INT J STD AIDS, V23, P853, DOI 10.1258/ijsa.2012.012004
   Rieg G, 2008, AIDS PATIENT CARE ST, V22, P947, DOI 10.1089/apc.2007.0240
   Stahlman S, 2015, SEX TRANSM DIS, V42, P364, DOI 10.1097/OLQ.0000000000000303
   Tanton C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017480
   Trebach JD, 2015, SEX TRANSM DIS, V42, P233, DOI 10.1097/OLQ.0000000000000248
   van Liere GAFS, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-274
   van Liere GAFS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134991
   Vogler Mary A, 2011, Curr HIV/AIDS Rep, V8, P122, DOI 10.1007/s11904-011-0077-5
   Workowski KA, 2015, SEXUALLY TRANSMITTED, V64
   World Health Organization, 2012, GLOB INC PREV SEL CU
NR 30
TC 3
Z9 6
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2016
VL 20
IS 6
BP 569
EP 575
DI 10.1016/j.bjid.2016.09.004
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA EE9SF
UT WOS:000389965800007
PM 27765581
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Paradella, AC
   Musegante, AFD
   Brites, C
AF Paradella, Ana Claudia
   de Arruda Musegante, Andre Ferraz
   Brites, Carlos
TI Comparison of different antibiotic protocols for asymptomatic
   bacteriuria in patients with neurogenic bladder treated with botulinum
   toxin A
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Botulinum toxin, type A; Urinary tract infections; Bacteriuria;
   Antibiotic prophylaxis
ID DETRUSOR OVERACTIVITY; PROPHYLAXIS; GUIDELINES; INFECTION; URINARY;
   TRACT
AB Intravesical botulinum toxin A (BoNTA) injection has been widely used for the treatment of detrusor overactivity in patients with neurogenic bladder due to spinal cord injury who do not respond to conventional treatment. There is no consensus about antibiotic prophylaxis for this procedure. We conducted a retrospective analysis of medical records of adult patients with spinal cord injury who underwent detrusor BoNTA injection between January of 2007 and December of 2013 in a rehabilitation hospital. Occurrence of symptomatic urinary tract infection (UTI) was assessed in 3 groups in accordance with their use of antibiotics (prophylactic dosage, 3 days, more than 3 days) for the treatment of asymptomatic bacteriuria. All patients were performing self or assisted clean intermittent bladder catheterization and underwent a rigid cystoscopy, under general or regional anesthesia with sedation, and the drug used was Botox (R). A total of 616 procedures were performed during the study period. There were 11 identified cases of UTI (1.8%) with a trend to a higher rate in the group that used antibiotics for longer time. This report shows that a single dose of antibiotics before the detrusor BoNTA injection is enough to prevent UTI. Randomized clinical trial should be conducted for definitive conclusions. (C) 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [Paradella, Ana Claudia; de Arruda Musegante, Andre Ferraz] SARAH Network Rehabil Hosp, Salvador, BA, Brazil.
   [Brites, Carlos] Complexo Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Complexo Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Alsaywid BS, 2013, UROL ANNALS, V5, P61, DOI 10.4103/0974-7796.109993
   Bennett JE, 2015, MANDELL DOUGLAS BENN
   Bootsma AMJ, 2008, EUR UROL, V54, P1270, DOI 10.1016/j.eururo.2008.03.033
   Cameron AP, 2012, J UROLOGY, V187, P391, DOI 10.1016/j.juro.2011.10.020
   Neto JAC, 2014, REV SOC BRAS MED TRO, V47, P528, DOI 10.1590/0037-8682-0029-2014
   Cek M, 2013, EUR UROL, V63, P386, DOI 10.1016/j.eururo.2012.09.038
   Grabe M., 2013, GUIDELINES UROLOGICA
   Jimenez-Cidre M A, 2015, ACTAS UROL ESP
   Linsenmeyer TA, 2013, J SPINAL CORD MED, V36, P402, DOI 10.1179/2045772313Y.0000000116
   Mouttalib S, 2010, BJU INT, V106, P1677, DOI 10.1111/j.1464-410X.2010.09435.x
   Naber KG, 2001, INT J ANTIMICROB AG, V17, P321, DOI 10.1016/S0924-8579(00)00361-7
   Nicolle LE, 2005, CLIN INFECT DIS, V40, P643, DOI 10.1086/427507
   Nicolle LE, 2006, INT J ANTIMICROB AG, V28, pS42, DOI 10.1016/j.ijantimicag.2006.05.010
   Rovner E, 2014, NEUROUROL URODYNAM, V33, pS32, DOI 10.1002/nau.22637
   Togan T, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.8905
   Togo Y, 2013, J INFECT CHEMOTHER, V19, P1093, DOI 10.1007/s10156-013-0631-8
NR 16
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2016
VL 20
IS 6
BP 623
EP 626
DI 10.1016/j.bjid.2016.08.012
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA EE9SF
UT WOS:000389965800015
PM 27765580
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Ricci, G
   Netto, EM
   Luz, E
   Rodamilans, C
   Brites, C
AF Ricci, Gabriela
   Netto, Eduardo Martins
   Luz, Estela
   Rodamilans, Cynthia
   Brites, Carlos
TI Adherence to antiretroviral therapy of Brazilian HIV-infected children
   and their caregivers
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Adherence; Antiretroviral therapy; Children; Caregivers
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PEDIATRIC ADHERENCE; DETERMINANTS;
   ADOLESCENTS; COUNTRIES
AB Background: Successful treatment of HIV-positive children requires a high level of adherence (at least 95%) to highly active antiretroviral therapy. Adherence is influenced by factors related to the child and caregivers.
   Objectives: To evaluate children and caregivers characteristics associated to children's adherence.
   Methods: Cross-sectional study, from September 2013 to June 2015, comprising a sample of caregivers of perinatally HIV-infected children, in the age group of 1-12 years, under antiretroviral therapy for at least 6 months and on follow-up in two AIDS reference centers in Salvador, Bahia. Caregiver self-reports were the sole source of 4 days adherence and sociodemographic information. Study participants who reported an intake >95% of prescribed medication were considered adherents. A variable, ("Composed Adherence"), was created to better evaluate adherence.
   Results: We included 77 children and their caregivers. 88.3% of the caregivers were female, the median age was 38.0 years (IQR 33.5-47.5), 48.1% were white or mixed, 72.7% lived in Salvador and 53.2% had no fixed income. The 4 days child's adherence was associated only to caregivers that received less than a minimum salary (p < 0.05), 70.1% of the caregivers had less than four years of formal education, 81.8% were children's relative and 53.2% of the caregivers were HIV positive. The caregiver's pharmacy refill, long-term adherence and 4 days adherence, were significantly associated with composed adherence (p < 0.05). Child's long-term adherence was strongly associated to the 4 days child's adherence referred by caregiver (p < 0.001).
   Conclusions: Our results suggest the need of improvement in HIV-infected children adherence, through reinforcement of the caregivers own adherence. (C) 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [Ricci, Gabriela; Brites, Carlos] Univ Fed Bahia UFBA, Programa Posgrad Med & Saude, Salvador, BA, Brazil.
   [Netto, Eduardo Martins; Luz, Estela; Brites, Carlos] Univ Fed Bahia UFBA, Fac Med, Dept Med, Salvador, BA, Brazil.
   [Rodamilans, Cynthia] CEDAP, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia UFBA, Programa Posgrad Med & Saude, Salvador, BA, Brazil.; Brites, C (corresponding author), Univ Fed Bahia UFBA, Fac Med, Dept Med, Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
CR Attaran A, 2007, PLOS MED, V4, P390, DOI 10.1371/journal.pmed.0040083
   Biadgilign S, 2011, PATIENT EDUC COUNS, V85, pE89, DOI 10.1016/j.pec.2011.02.008
   Boni S, 2000, INT J ANTIMICROB AG, V16, P371, DOI 10.1016/S0924-8579(00)00256-9
   Cupsa A, 2000, ANN NY ACAD SCI, V918, P351
   de Martino M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/jama.284.2.190
   Dionisio D, 2007, CURR HIV RES, V5, P155, DOI 10.2174/157016207780077075
   Duarte HA, 2015, BRAZ J INFECT DIS, V19, P263, DOI 10.1016/j.bjid.2015.01.004
   Ernesto AS, 2012, BRAZ J INFECT DIS, V16, P315, DOI 10.1016/j.bjid.2012.06.006
   Flynn PM, 2004, J INFECT DIS, V190, P271, DOI 10.1086/421521
   Giacomet V, 2003, ACTA PAEDIATR, V92, P1398, DOI 10.1080/08035250310006737
   Gibb DM, 2003, PEDIATR INFECT DIS J, V22, P56, DOI 10.1097/00006454-200301000-00015
   Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157
   Haberer Jessica, 2009, Curr HIV/AIDS Rep, V6, P194, DOI 10.1007/s11904-009-0026-8
   Hammami N, 2004, PEDIATRICS, V114, pE591, DOI 10.1542/peds.2004-0085
   Katko E, 2001, PEDIATR INFECT DIS J, V20, P1174, DOI 10.1097/00006454-200112000-00017
   Kip E, 2009, J NURS SCHOLARSHIP, V41, P149, DOI 10.1111/j.1547-5069.2009.01266.x
   Mellins CA, 2004, PEDIATR INFECT DIS J, V23, P1035, DOI 10.1097/01.inf.0000143646.15240.ac
   Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, pS127, DOI 10.1097/01.qai.0000248349.25630.3d
   Nash D, 2011, AIDS, V25, P1523, DOI 10.1097/QAD.0b013e32834811b2
   Pontali E, 2001, HIV Clin Trials, V2, P466
   Rachlis BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018948
   Wachholz NIR, 2007, CAD SAUDE PUBLICA, V23, pS424, DOI 10.1590/S0102-311X2007001500010
   Reddington C, 2000, PEDIATR INFECT DIS J, V19, P1148, DOI 10.1097/00006454-200012000-00005
   Sanjobo N, 2008, SAHARA J-J SOC ASP H, V5, P136, DOI 10.1080/17290376.2008.9724912
   Simoni JM, 2007, PEDIATRICS, V119, pE1371, DOI 10.1542/peds.2006-1232
   Skovdal M, 2011, INT J HEALTH PLAN M, V26, P296, DOI 10.1002/hpm.1082
   Van Dyke RB, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e61
   Vreeman RC, 2008, PEDIATR INFECT DIS J, V27, P686, DOI 10.1097/INF.0b013e31816dd325
   Watson DC, 1999, PEDIATR INFECT DIS J, V18, P682, DOI 10.1097/00006454-199908000-00006
   Wrubel J, 2005, SOC SCI MED, V61, P2423, DOI 10.1016/j.socscimed.2005.04.034
NR 30
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2016
VL 20
IS 5
BP 429
EP 436
DI 10.1016/j.bjid.2016.05.009
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA EA8HG
UT WOS:000386875300003
PM 27471126
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Brites, C
   Pinto-Neto, L
   Medeiros, M
   Nunes, E
   Sprinz, E
   Carvalho, M
AF Brites, Carlos
   Pinto-Neto, Lauro
   Medeiros, Melissa
   Nunes, Estevao
   Sprinz, Eduardo
   Carvalho, Mariana
TI Extensive variation in drug-resistance mutational profile of Brazilian
   patients failing antiretroviral therapy in five large Brazilian cities
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Resistance; Brazil; Mutations
ID HIV-1 SUBTYPE-C; REVERSE-TRANSCRIPTASE INHIBITORS; RESOURCE-LIMITED
   SETTINGS; RIO-DE-JANEIRO; EXPERIENCED PATIENTS; VIROLOGICAL FAILURE;
   SAO-PAULO; PREVALENCE; TYPE-1; HAART
AB Background: Development of drug-resistance mutations is the main cause of failure in antiretroviral therapy. In Brazil, there is scarce information on resistance pattern for patients failing antiretroviral therapy.
   Objectives: To define the HIV mutational profile associated with drug resistance in Brazilian patients from 5 large cities, after first, second or further failures to antiretroviral therapy.
   Methods: We reviewed genotyping results of 1520 patients failing therapy in five Brazilian cities. Frequency of mutations, mean number of active drugs, viral susceptibility to each antiretrovirals drug, and regional differences were assessed.
   Results: Mean time of antiretrovirals use was 22.7 +/- 41.1 months. Mean pre-genotyping viral load was 4.2 +/- 0.8 log (2.1 +/- 2.0 after switching antiretrovirals). Mean number of remaining active drugs was 9.4, 9.0, and 7.9 after 1st, 2nd, and 3rd failure, respectively. We detected regional variations in drug susceptibility: while BA and RS showed the highest (similar to 40%) resistance level to ATV/r, FPV/r and LPV/r, in the remaining cities it was around half of this rate. We detected 90% efavirenz/nevirapine resistance in SP, only 45% in RS, and levels between 25% and 30% in the other cities. Regarding NRTI, we found a similar pattern, with RJ presenting the highest, and CE the lowest susceptibility rates for all NRTI. Zidovudine resistance was detected in only 3% of patients in RJ, against 45-65% in the other cities. RJ and RS showed 3% resistance to tenofovir, while in CE it reached 55%. DRV/r (89-97%) and etravirine (61-85%) were the most active drugs, but again, with a wide variation across cities.
   Conclusions: The resistance mutational profile of Brazilian patients failing antiretroviral therapy is quite variable, depending on the city where patients were tested. This variation likely reflects distinctive choice of antiretrovirals drugs to initiate therapy, adherence to specific drugs, or circulating HIV-1 strains. Overall, etravirine and DRV/r remain as the most active drugs. (C) 2016 Elsevier Editora Ltda.
C1 [Brites, Carlos] Fundacao Bahiana Infectol FBaI, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia UFBA, Lab Pesquisa Infectol LAPI, Salvador, BA, Brazil.
   [Pinto-Neto, Lauro] Escola Ciencias Saude Santa Casa Vitoria, Vitoria, ES, Brazil.
   [Medeiros, Melissa] Unichristus, Fortaleza, Ceara, Brazil.
   [Nunes, Estevao] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Sprinz, Eduardo] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   [Carvalho, Mariana] Univ Estadual Campinas, UNICAMP, Campinas, SP, Brazil.
RP Brites, C (corresponding author), Fundacao Bahiana Infectol FBaI, Salvador, BA, Brazil.; Brites, C (corresponding author), Univ Fed Bahia UFBA, Lab Pesquisa Infectol LAPI, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; sprinz, eduardo/V-7961-2019
OI Brites, Carlos/0000-0002-4673-6991; sprinz, eduardo/0000-0003-4343-8304
FU Investigator's Initiative Grant - Janssen-Cilag Farmaceutica Ltda
FX This work was supported by an Investigator's Initiative Grant, funded by
   Janssen-Cilag Farmaceutica Ltda.
CR Alcalde R, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-156
   Basson AE, 2015, ANTIMICROB AGENTS CH, V59, P960, DOI 10.1128/AAC.04215-14
   Biscione Fernando Martin, 2014, J Int Assoc Provid AIDS Care, V13, P63, DOI 10.1177/2325957413502542
   Brenner B, 2003, AIDS, V17, pF1, DOI 10.1097/00002030-200301030-00001
   Brites C, 2015, BRAZ J INFECT DIS
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   de Medeiros RM, 2011, J MED VIROL, V83, P1682, DOI 10.1002/jmv.22188
   Nunes ERD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084066
   Delviks-Frankenberry KA, 2013, VIROLOGY, V435, P433, DOI 10.1016/j.virol.2012.09.021
   Eyer-Silva WA, 2008, MEM I OSWALDO CRUZ, V103, P143, DOI 10.1590/S0074-02762008000200004
   Gagliani LH, 2011, AIDS RES HUM RETROV, V27, P251, DOI 10.1089/aid.2010.0150
   Graf T, 2013, VIROLOGY, V435, P170, DOI 10.1016/j.virol.2012.08.048
   Kantor R, 2015, CLIN INFECT DIS, V60, P1541, DOI 10.1093/cid/civ102
   Llibre JM, 2008, J ANTIMICROB CHEMOTH, V62, P909, DOI 10.1093/jac/dkn297
   Medeiros MS, 2007, BRAZ J INFECT DIS, V11, P528
   Medeiros MS, 2007, BRAZ J INFECT DIS, V11, P390, DOI 10.1590/S1413-86702007000400003
   Toledo PV, 2010, BRAZ J INFECT DIS, V14, P360, DOI 10.1590/S1413-86702010000400009
   Ministerio da Saude, BRAZIL PROTOCOLO CLI
   Nunes CC, 2014, REV INST MED TROP SP, V56, P205, DOI 10.1590/S0036-46652014000300005
   Pennings PS, 2013, INFECT DIS REP, V5, P21, DOI 10.4081/idr.2013.s1.e5
   Ribeiro KM, 2014, BRAZ J INFECT DIS, V18, P1, DOI 10.1016/j.bjid.2013.04.001
   Salustiano Cavalcanti AM, 2007, MEM I OSWALDO CRUZ, V102, P785
   Stadeli KM, 2013, ANTIVIR THER, V18, P115, DOI 10.3851/IMP2437
   Varella RB, 2008, BRAZ J INFECT DIS, V12, P380, DOI 10.1590/S1413-86702008000500007
   Cardoso LPV, 2010, J MED VIROL, V82, P351, DOI 10.1002/jmv.21722
   Velasco-de-Castro CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087622
   Vidal JE, 2013, BRAZ J INFECT DIS, V17, P41, DOI 10.1016/j.bjid.2012.08.022
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   Westin MR, 2011, AIDS RES HUM RETROV, V27, P981, DOI 10.1089/aid.2010.0260
NR 29
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2016
VL 20
IS 4
BP 323
EP 329
DI 10.1016/j.bjid.2016.03.010
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA DS2AC
UT WOS:000380514100001
PM 27291892
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Phillips, AA
   Fields, P
   Hermine, O
   Ramos, JC
   Beltran, BE
   Pereira, J
   Brites, C
   Kurman, MR
   George, J
   Dwyer, KM
   Conlon, K
   Taylor, GP
   Gonsky, JP
   Horwitz, SM
AF Phillips, Adrienne Alise
   Fields, Paul
   Hermine, Olivier
   Ramos, Juan Carlos
   Beltran, Brady Ernesto
   Pereira, Juliana
   Brites, Carlos
   Kurman, Michael R.
   George, Joyce
   Dwyer, Karen M.
   Conlon, Kevin
   Taylor, Graham P.
   Gonsky, Jason Parker
   Horwitz, Steven M.
TI A prospective, multicenter, randomized study of anti-CCR4 monoclonal
   antibody mogamulizumab (moga) vs investigator's choice (IC) in the
   treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell
   leukemia-lymphoma (ATL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 03-07, 2016
CL Chicago, IL
SP Amer Soc Clin Oncol
RI PEREIRA, JULIANA/C-2742-2014; Beltran, Brady/P-8655-2019
OI PEREIRA, JULIANA/0000-0002-0655-2821; Beltran, Brady/0000-0003-4469-3817
NR 0
TC 8
Z9 8
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2016
VL 34
IS 15
SU S
MA 7501
DI 10.1200/JCO.2016.34.15_suppl.7501
PG 2
WC Oncology
SC Oncology
GA EZ4VV
UT WOS:000404711505015
DA 2020-12-01
ER

PT J
AU Campos, GC
   Sardi, SI
   Sarno, M
   Brites, C
AF Campos, Gubio C.
   Sardi, Silvia I.
   Sarno, Manoel
   Brites, Carlos
TI Zika virus infection, a new public health challenge
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
ID OUTBREAK
C1 [Campos, Gubio C.; Sardi, Silvia I.] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil.
   [Sarno, Manoel; Brites, Carlos] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; sardi, silvia ines/P-9349-2016
OI Brites, Carlos/0000-0002-4673-6991; sardi, silvia
   ines/0000-0002-2002-8436
CR [Anonymous], 2016, B EP, V47, P3
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   WHO/CDC/ICBDSR, 2016, ASS INF MICR CONT ZI
NR 7
TC 5
Z9 5
U1 0
U2 16
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2016
VL 20
IS 3
BP 227
EP 228
DI 10.1016/j.bjid.2016.05.001
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA DM6ER
UT WOS:000376443900001
PM 27215946
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Neto, MG
   Conceicao, CS
   Ogalha, C
   Brites, C
AF Neto, Mansueto Gomes
   Conceicao, Cristiano Sena
   Ogalha, Cecilia
   Brites, Carlos
TI Aerobic capacity and health-related quality of life in adults
   HIV-infected patients with and without lipodystrophy
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Antiretroviral therapy; HIV infection; Quality of life; Disability
ID HUMAN-IMMUNODEFICIENCY-VIRUS; EXERCISE DYSFUNCTION; PHYSICAL-DISABILITY;
   MUSCLE STRENGTH; INDIVIDUALS; MEN; ASSOCIATION; PERFORMANCE; HIV/AIDS;
   COHORT
AB Introduction: HIV infection and its therapy which can affect their aerobic capacity and health related quality of life of patients.
   Objective: We conducted a cross-sectional study to determine if aerobic capacity and health related quality of life was decreased in HIV-infected patients receiving highly active antiretroviral therapy and comparing patients with and without lipodystrophy.
   Research design and methods: HIV-infected patients older than 18 years, and in current use of highly active antiretroviral therapy drugs, were evaluated for blood count, fasting total cholesterol, high density lipoprotein, triglycerides, glucose, HIV viral load and CD4/CD8 counts, body composition, peak oxygen consumption (peak VO2) and metabolic equivalent. Health related quality of life was assessed by using Short Form-36 (SF-36). Statistical analysis was carried out using SPSS version 20.0.
   Results: A total of 63 patients with mean age of 43.1 +/- 6.4 years were evaluated, of these 34 (54%) had lipodystrophy. The average peak VO2 (31.4 +/- 7.6 mL kg(-1) min(-1)) was significantly lower (p < 0.01) than expected values (37.9 +/- 5.6 mL kg(-1) min(-1)) according to the characteristics of the patients. The lipodystrophy group presented with a significant difference in muscle mass, body fat, peak VO2 and metabolic equivalent and in functional capacity domains of SF-36.
   Conclusion: Aerobic capacity values were reduced in HIV-infected patients under highly active antiretroviral therapy when compared to predicted values. Lipodystrophy was associated with reduced aerobic capacity and higher frequency of metabolic syndrome. Lifestyle modification should be a priority in the management of chronic HIV disease. (C) 2015 Elsevier Editora Ltda. All rights reserved.
C1 [Neto, Mansueto Gomes; Conceicao, Cristiano Sena] Univ Fed Bahia UFBA, Curso Fisioterapia, Dept Biofuncao, BR-40110100 Salvador, BA, Brazil.
   [Neto, Mansueto Gomes; Ogalha, Cecilia; Brites, Carlos] Univ Fed Bahia UFBA, Programa Posgrad Med & Saude, BR-40110100 Salvador, BA, Brazil.
RP Neto, MG (corresponding author), Univ Fed Bahia UFBA, Inst Cienciasda Saude, Curso Fisioterapia, Dept Biofuncao, Av Reitor Miguel Calmon S-N, BR-40110100 Salvador, BA, Brazil.
EM mansueto.neto@ufba.br
RI Gomes-NETO, Mansueto MGN/I-5235-2014; Brites, Carlos/D-1353-2013
OI Gomes-NETO, Mansueto MGN/0000-0002-0717-9694; Brites,
   Carlos/0000-0002-4673-6991
CR American College of Sports Medicine, 2006, ACSMS GUIDELINES EXE
   BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395
   Blanch J, 2002, JAIDS, V31, P404, DOI 10.1097/00126334-200212010-00006
   Cade W Todd, 2002, Pediatr Rehabil, V5, P161
   Cade WT, 2004, PHYS THER, V84, P655, DOI 10.1093/ptj/84.7.655
   Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003
   Centers for Disease Control and Prevention, 2010, STAT IND REP PHYS AC
   Ciconelli R. M., 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005
   Crystal S, 2000, MED CARE, V38, P1210, DOI 10.1097/00005650-200012000-00008
   da Silva J, 2013, AIDS CARE, V25, P71, DOI 10.1080/09540121.2012.686594
   De Rose EH, 1984, CINEANTROPOMETRU PHY, P80
   Della Justina LB, 2014, REV SOC BRAS MED TRO, V47, P30, DOI 10.1590/0037-8682-0240-2013
   Erlandson KM, 2014, AIDS, P2
   Geocze L, 2010, REV SAUDE PUBL, V44, P743, DOI 10.1590/s0034-89102010000400019
   Neto MG, 2013, BRAZ J INFECT DIS, V17, P691, DOI 10.1016/j.bjid.2013.05.004
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Hsue PY, 2008, CIRCULATION, V118, pe41
   JACKSON AS, 1978, BRIT J NUTR, V40, P497, DOI 10.1079/BJN19780152
   JOHNSON JE, 1990, AM REV RESPIR DIS, V141, P618, DOI 10.1164/ajrccm/141.3.618
   NOVITSKY S, 1995, EUR J APPL PHYSIOL O, V70, P462, DOI 10.1007/BF00618499
   ODell MW, 1996, AIDS, V10, P667, DOI 10.1097/00002030-199606000-00013
   Oursler KK, 2011, AIDS PATIENT CARE ST, V25, P13, DOI 10.1089/apc.2010.0242
   Pollock ML, 1993, EXERCISE HLTH DIS AS
   POTHOFF G, 1994, RESPIRATION, V61, P80
   Preau M, 2007, AIDS CARE, V19, P449, DOI 10.1080/09540120601017464
   Raso V, 2014, J SPORT MED PHYS FIT, V54, P100
   Raso V, 2013, CLINICS, V68, P359, DOI 10.6061/clinics/2013(03)OA12
   Roge BT, 2002, AIDS, V16, P973, DOI 10.1097/00002030-200205030-00003
   Roubenoff R, 2000, AM J MANAG CARE, V6, P1003
   Scott WB, 2007, MUSCLE NERVE, V36, P374, DOI 10.1002/mus.20832
   Singhania R, 2011, HIV AIDS-RES PALLIAT, V3, P135, DOI 10.2147/HIV.S14562
   Somarriba G, 2010, HIV AIDS-RES PALLIAT, V2, P191, DOI 10.2147/HIV.S9069
   Stringer WW, 2000, MED SCI SPORT EXER, V32, pS412, DOI 10.1097/00005768-200007001-00006
   Zonta Marise Bueno, 2005, Braz J Infect Dis, V9, P479, DOI 10.1590/S1413-86702005000600005
   Zonta Marise Bueno, 2003, Braz J Infect Dis, V7, P301, DOI 10.1590/S1413-86702003000500004
NR 35
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2016
VL 20
IS 1
BP 76
EP 80
DI 10.1016/j.bjid.2015.11.001
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA DB5SO
UT WOS:000368574100012
PM 26707972
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Brites, C
   Salgado-Azoni, CA
   Ferreira, TL
   Lima, RF
   Ciasca, SM
AF Brites, C.
   Salgado-Azoni, C. A.
   Ferreira, T. L.
   Lima, R. F.
   Ciasca, S. M.
TI Development and applications of the SWAN rating scale for assessment of
   attention deficit hyperactivity disorder: a literature review
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Review
DE SWAN rating scale; Behavioral scale; Attention; Attention deficit
   hyperactivity disorder; Neuropsychology; Hyperactivity
ID DEFICIT/HYPERACTIVITY-DISORDER; ADHD-SYMPTOMS; RESPONSE-INHIBITION;
   GENERAL-POPULATION; COPY NUMBER; HONG-KONG; METHYLPHENIDATE;
   PRESCHOOLERS; PREVALENCE; WEAKNESSES
AB This study reviewed the use of the Strengths and Weaknesses of Attention-Deficit/Hyperactivity-symptoms and Normal-behaviors (SWAN) rating scale in diagnostic and evolutive approaches to attention deficit hyperactivity disorder (ADHD) and in correlational studies of the disorder. A review of articles published in indexed journals from electronic databases was conducted and 61 articles on the SWAN scale were analyzed. From these, 27 were selected to a) examine use of SWAN in research on attention disorders and b) verify evidence of its usefulness in the areas of genetics, neuropsychology, diagnostics, psychiatric comorbidities, neuroimaging, pharmacotherapy, and to examine its statistical reliability and validity in studies of diverse populations. This review of articles indicated a growing use of the SWAN scale for diagnostic purposes, for therapy, and in research on areas other than ADHD, especially when compared with other reliable scales. Use of the scale in ADHD diagnosis requires further statistical testing to define its psychometric properties.
C1 [Brites, C.] Univ Estadual Campinas, Lab Dificuldades & Disturbios Aprendizagem & Tran, Campinas, SP, Brazil.
   [Salgado-Azoni, C. A.] Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, Dept Fonoaudiol & Patol Linguagem, BR-59072970 Natal, RN, Brazil.
   [Ferreira, T. L.; Lima, R. F.; Ciasca, S. M.] Univ Estadual Campinas, Fac Ciencias Med, Dept Neurol, Campinas, SP, Brazil.
RP Brites, C (corresponding author), Univ Estadual Campinas, Lab Dificuldades & Disturbios Aprendizagem & Tran, Campinas, SP, Brazil.
EM drclayneuroped@yahoo.com.br
RI Brites, Carlos/D-1353-2013; Salgado-Azoni, Cintia Alves/I-3878-2013; de
   Lima, Ricardo Franco/C-6459-2011
OI Brites, Carlos/0000-0002-4673-6991; de Lima, Ricardo
   Franco/0000-0003-1022-2849
CR Abikoff HB, 2007, J CHILD ADOL PSYCHOP, V17, P581, DOI 10.1089/cap.2007.0068
   Arcos-Burgos M, 2010, MOL PSYCHIATR, V15, P1053, DOI 10.1038/mp.2010.6
   Arnett AB, 2013, J ATTEN DISORD, V17, P152, DOI 10.1177/1087054711427399
   Benczik EBP, 2010, PSYCHOL BULL, V131, P137
   Brock S. E., 2009, IDENTIFYING ASSESSIN
   Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896
   Coghill David, 2008, Child Adolesc Psychiatry Ment Health, V2, P31, DOI 10.1186/1753-2000-2-31
   Cornish KM, 2008, NEUROPSYCHOLOGY, V22, P217, DOI 10.1037/0894-4105.22.2.217
   Cornish KM, 2005, MOL PSYCHIATR, V10, P686, DOI 10.1038/sj.mp.4001641
   Crosbie J, 2013, J ABNORM CHILD PSYCH, V41, P497, DOI 10.1007/s10802-012-9693-9
   EISENBERG L, 1962, AM J PUBLIC HEALTH N, V52, P18, DOI 10.2105/AJPH.52.1.18
   Figueroa-Varela M, 2012, THESIS
   Hay DA, 2007, BIOL PSYCHIAT, V61, P700, DOI 10.1016/j.biopsych.2006.04.040
   Jacob CP, 2013, J PSYCHIATR RES, V47, P1902, DOI 10.1016/j.jpsychires.2013.08.006
   Kollins S, 2010, GUIDE ASSESSMENT SCA
   Kudo M, 2012, INT J ED PSYCHOL ASS, V10, P139
   Lai KYC, 2013, J ATTEN DISORD, V17, P194, DOI 10.1177/1087054711430711
   Lakatos Krisztina, 2010, Psychiatr Hung, V25, P493
   Lakes KD, 2012, J ATTEN DISORD, V16, P510, DOI 10.1177/1087054711413550
   Leung PWL, 2008, EUR CHILD ADOLES PSY, V17, P452, DOI 10.1007/s00787-008-0687-7
   Lubke GH, 2007, J AM ACAD CHILD PSY, V46, P1584, DOI 10.1097/chi.0b013e31815750dd
   Lui M, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-12
   Martin J, 2014, BIOL PSYCHIAT, V76, P664, DOI 10.1016/j.biopsych.2014.02.013
   Martin NC, 2006, HUM MOVEMENT SCI, V25, P110, DOI 10.1016/j.humov.2005.10.006
   Mattos P, 2008, PRINCIPLES PRACTICES
   Mattos P., 2006, REV PSIQUIATRIA CLIN, V33, P188, DOI DOI 10.1590/S0101-60832006000
   Normand S, 2012, J ABNORM CHILD PSYCH, V40, P555, DOI 10.1007/s10802-011-9584-5
   Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942
   Polderman TJC, 2007, J CHILD PSYCHOL PSYC, V48, P1080, DOI 10.1111/j.1469-7610.2007.01783.x
   Ramos-Quiroga JA, 2014, J PSYCHIATR RES, V49, P60, DOI 10.1016/j.jpsychires.2013.10.022
   Robaey P, 2007, J CAN ACAD CHILD ADO, V16, P80
   Rubia K, 2014, BIOL PSYCHIAT, V76, P616, DOI 10.1016/j.biopsych.2013.10.016
   Scheres A, 2003, J ABNORM CHILD PSYCH, V31, P105, DOI 10.1023/A:1021729501230
   Schmitz M, 2007, J BRAS PSIQ S1, V56, P25, DOI DOI 10.1590/S0047-20852007000500006
   Serrien DJ, 2014, DEV PSYCHOL, V50, P316, DOI 10.1037/a0032996
   Sims DM, 2013, J CLIN CHILD ADOLESC, V42, P208, DOI 10.1080/15374416.2012.738453
   Smalley SL, 2007, J AM ACAD CHILD PSY, V46, P1575, DOI 10.1097/chi.0b013e3181573137
   So CYC, 2008, BEHAV RES THER, V46, P983, DOI 10.1016/j.brat.2008.06.007
   Swanson J, OVER IDENTIFICATION
   Swanson JM, 2009, CURR PSYCHIAT REP, V11, P399, DOI 10.1007/s11920-009-0060-7
   van der Sluis S, 2013, MOL PSYCHIATR, V18, P2, DOI 10.1038/mp.2012.65
   Vitiello B, 2007, J CHILD ADOL PSYCHOP, V17, P593, DOI 10.1089/cap.2007.0058
   Volkow ND, 2009, JAMA-J AM MED ASSOC, V302, P1084, DOI 10.1001/jama.2009.1308
   Waschbusch DA, 2003, J PSYCHOEDUC ASSESS, V21, P261, DOI 10.1177/073428290302100303
   Young DJ, 2009, CHILD PSYCHIAT HUM D, V40, P543, DOI 10.1007/s10578-009-0143-z
NR 45
TC 6
Z9 7
U1 0
U2 8
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD NOV
PY 2015
VL 48
IS 11
BP 965
EP 972
DI 10.1590/1414-431X20154528
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA CV6YO
UT WOS:000364418500002
PM 26313140
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Vaz, SN
   Giovanetti, M
   Rego, FFD
   de Oliveira, T
   Danaviah, S
   Goncalves, MLF
   Alcantara, LC
   Brites, C
AF Vaz, Sara Nunes
   Giovanetti, Marta
   de Almeida Rego, Filipe Ferreira
   de Oliveira, Tulio
   Danaviah, Siva
   Freire Goncalves, Maria Luiza
   Junior Alcantara, Luiz Carlos
   Brites, Carlos
TI Molecular Characterization of the Human Immunodeficiency Virus Type 1 in
   Women and Their Vertically Infected Children
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HIV-1; RESISTANCE; POLYMORPHISMS; TRANSMISSION; PREVALENCE
AB Approximately 35 million people worldwide are infected with human immunodeficiency virus (HIV) around 3.2 million of whom are children under 15 years. Mother-to-child-transmission (MTCT) of HIV-1 accounts for 90% of all infections in children. Despite great advances in the prevention of MTCT in Brazil, children are still becoming infected. Samples from 19 HIV-1-infected families were collected. DNA was extracted and fragments from gag, pol, and env were amplified and sequenced directly. Phylogenetic reconstruction was performed. Drug resistance analyses were performed in pol and env sequences. We found 82.1% of subtype B and 17.9% of BF recombinants. A prevalence of 43.9% drug resistance-associated mutations in pol sequences was identified. Of the drug-naive children 33.3% presented at least one mutation related to protease inhibitor/nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor (PI/NRTI/NNRTI) resistance. The prevalence of transmitted drug resistance mutations was 4.9%. On env we found a low prevalence of HR1 (4.9%) and HR2 (14.6%) mutations.
C1 [Vaz, Sara Nunes; Brites, Carlos] Univ Fed Bahia, Retrovirol Lab, Salvador, BA, Brazil.
   [Vaz, Sara Nunes; Giovanetti, Marta; de Almeida Rego, Filipe Ferreira; Junior Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Lab Hematol Genet & Computat Biol, Salvador, BA, Brazil.
   [Giovanetti, Marta] Natl Inst Hlth, Dept Infect Parasit & Immunomediated Dis, Rome, Italy.
   [de Oliveira, Tulio; Danaviah, Siva] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Durban, South Africa.
   [Freire Goncalves, Maria Luiza] Specialized Ctr Diag Care & Res, Salvador, BA, Brazil.
RP Brites, C (corresponding author), HUPES UFBA, Rua Augusto Viana Sn, BR-40110060 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Giovanetti, Marta/AAK-7408-2020; Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Giovanetti,
   Marta/0000-0002-5849-7326; Alcantara, Luiz/0000-0002-6769-9931
FU Wellcome TrustWellcome Trust [097410] Funding Source: Medline
CR Ahmad N, 2008, ADV PHARMACOL, V56, P453, DOI 10.1016/S1054-3589(07)56015-1
   Alencar CS, 2010, AIDS RES HUM RETROV, V26, P1267, DOI 10.1089/aid.2010.0057
   Araujo AF, 2010, AIDS RES HUM RETROV, V26, P1249, DOI 10.1089/aid.2010.0068
   Brazil Ministry of Health, 2014, B EP AIDS E DST, VIII, P1
   Reis MND, 2014, J MED VIROL, V86, P8, DOI 10.1002/jmv.23738
   da Silveira AA, 2012, AIDS RES HUM RETROV, V28, P304, DOI 10.1089/aid.2011.0128
   de Oliveira CM, 2008, ARCH VIROL, V153, P1799, DOI 10.1007/s00705-008-0178-7
   Gifford RJ, 2009, BIOINFORMATICS, V25, P1197, DOI 10.1093/bioinformatics/btp134
   Guimaraes PM, 2015, AIDS RES HUM RETROV, V31, P1
   Monteiro-Cunha JP, 2011, AIDS RES HUM RETROV, V27, P623, DOI [10.1089/AID.2010.0126, 10.1089/aid.2010.0126]
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Moutouh L, 1996, P NATL ACAD SCI USA, V93, P6106, DOI 10.1073/pnas.93.12.6106
   Salminen MO, 1997, J VIROL, V71, P2647, DOI 10.1128/JVI.71.4.2647-2655.1997
   Sanabani SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062552
   Santos LA, 2011, J MED VIROL, V83, P2066, DOI 10.1002/jmv.22170
   Wensing Annemarie M, 2014, Top Antivir Med, V22, P642
   World Health Organization, AIDS EP 2013
NR 17
TC 5
Z9 5
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT 1
PY 2015
VL 31
IS 10
BP 1046
EP 1051
DI 10.1089/aid.2015.0166
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA CR5PL
UT WOS:000361395500015
PM 26200738
OA Green Published
DA 2020-12-01
ER

PT J
AU Gomes, M
   Conceicao, CS
   Carvalhom, VO
   Brites, C
AF Gomes Neto, Mansueto
   Conceicao, Cristiano Sena
   Carvalhom, Vitor Oliveira
   Brites, Carlos
TI Effects of Combined Aerobic and Resistance Exercise on Exercise
   Capacity, Muscle Strength and Quality of Life in HIV-Infected Patients:
   A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BODY-COMPOSITION; HEART-DISEASE;
   IMPAIRMENT; HIV/AIDS; REHABILITATION; GUIDELINES; FITNESS; IMPACT;
   TRIALS
AB Background
   Many HIV-infected patients demonstrate disability and lower aerobic capacity. The inclusion of resistance training combined with aerobic exercise in a single program is known as combined aerobic and resistance exercise (CARE) and seems to be an effective strategy to improve muscle weakness, as well as aerobic capacity in HIV-infected patients. We performed a meta-analysis to investigate the effects of CARE in HIV-infected patients.
   Methods
   We searched MEDLINE, Cochrane Controlled Trials Register, EMBASE, CINAHL (from the earliest date available to august 2014) for controlled trials that evaluated the effects of CARE in HIV-infected patients. Weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated, and heterogeneity was assessed using the I-2 test.
   Results
   Seven studies met the study criteria. CARE resulted in improvement in Peak VO2 WMD (4.48 mL.kg(-1).min(-1) 95% CI: 2.95 to 6.0), muscle strength of the knee extensors WMD (25.06 Kg 95% CI: 10.46 to 39.66) and elbow flexors WMD (4.44 Kg 95% CI: 1.22 to 7.67) compared with no exercise group. The meta-analyses also showed significant improvement in Health status, Energy/Vitality and physical function domains of quality of life for participants in the CARE group compared with no exercise group. A nonsignificant improvement in social function domain of quality of life was found for participants in the CARE group compared with no exercise group.
   Conclusions
   Combined aerobic and resistance exercise may improve peak VO2, muscle strength and health status, energy and physical function domains of quality of life and should be considered as a component of care of HIV-infected individuals.
C1 [Gomes Neto, Mansueto; Conceicao, Cristiano Sena] Univ Fed Bahia, UFBA, Curso Fisioterapia, Dept Biofunc O, Salvador, BA, Brazil.
   [Gomes Neto, Mansueto; Brites, Carlos] Univ Fed Bahia, Programa Pos Grad Med & Saude, Salvador, BA, Brazil.
   [Gomes Neto, Mansueto; Carvalhom, Vitor Oliveira] Univ Fed Sergipe, GREAT Grp, GRp Estudos ATividade Fis, Aracaju, SE, Brazil.
   [Carvalhom, Vitor Oliveira] Univ Fed Sergipe, Dept Fisioterapia, Aracaju, SE, Brazil.
RP Gomes, M (corresponding author), Univ Fed Bahia, UFBA, Curso Fisioterapia, Dept Biofunc O, Salvador, BA, Brazil.
EM mansueto.neto@ufba.br
RI Brites, Carlos/D-1353-2013; Gomes-NETO, Mansueto MGN/I-5235-2014
OI Brites, Carlos/0000-0002-4673-6991; Gomes-NETO, Mansueto
   MGN/0000-0002-0717-9694; carvalho, vitor/0000-0003-0007-2541
CR Achttien RJ, 2013, NETH HEART J, V21, P429, DOI 10.1007/s12471-013-0467-y
   Bopp Christopher M, 2003, J Assoc Nurses AIDS Care, V14, P73, DOI 10.1177/1055329002239192
   Cade WT, 2003, ARCH PHYS MED REHAB, V84, P1831, DOI 10.1016/j.apmr.2003.03.004
   Ciccolo JT, 2004, SPORTS MED, V34, P487, DOI 10.2165/00007256-200434080-00001
   Crystal S, 2000, MED CARE, V38, P1210, DOI 10.1097/00005650-200012000-00008
   Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309
   Diller GP, 2005, CIRCULATION, V112, P828, DOI 10.1161/CIRCULATIONAHA.104.529800
   Dolan SE, 2006, ARCH INTERN MED, V166, P1225, DOI 10.1001/archinte.166.11.1225
   Driscoll SD, 2004, AIDS, V18, P465, DOI 10.1097/00002030-200402200-00013
   Dudgeon WD, 2004, AIDS PATIENT CARE ST, V18, P81, DOI 10.1089/108729104322802515
   Erlandson KM, 2014, CURR HIV-AIDS REP, V11, P279, DOI 10.1007/s11904-014-0215-y
   Fillipas S, 2006, AUST J PHYSIOTHER, V52, P185, DOI 10.1016/S0004-9514(06)70027-7
   Frankenstein L, 2007, INT J CARDIOL, V122, P125, DOI 10.1016/j.ijcard.2006.11.038
   Garvey C, 2013, J CARDIOPULM REHABIL, V33, P314, DOI 10.1097/HCR.0b013e318297fea4
   Neto MG, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/319524
   Gomes-Neto M, 2013, CLINICS, V68, P1157, DOI 10.6061/clinics/2013(08)16
   GRAU JM, 1993, ANN NEUROL, V34, P206, DOI 10.1002/ana.410340217
   Grinspoon S, 2000, ANN INTERN MED, V133, P348, DOI 10.7326/0003-4819-133-5-200009050-00010
   Hand GA, 2008, AIDS CARE, V20, P1066, DOI 10.1080/09540120701796900
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jin Y, 2014, INT J STD AIDS, V5
   JOHNSON JE, 1990, AM REV RESPIR DIS, V141, P618, DOI 10.1164/ajrccm/141.3.618
   de Souza PML, 2008, CLINICS, V63, P619, DOI 10.1590/S1807-59322008000500009
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713
   McCarthy JP, 2002, MED SCI SPORT EXER, V34, P511, DOI 10.1097/00005768-200203000-00019
   Mendes EL, 2013, REV BRAS MED ESPORTE, V19, P16, DOI 10.1590/S1517-86922013000100003
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097]
   Mutimura E, 2008, QUAL LIFE RES, V17, P377, DOI 10.1007/s11136-008-9319-4
   O'Brien K, 2008, AIDS CARE, V20, P631, DOI 10.1080/09540120701661708
   O'Brien K, 2004, MED SCI SPORT EXER, V36, P1659, DOI 10.1249/01.MSS.0000142404.28165.9B
   O'Brien K, 2004, COCHRANE DB SYST REV, V18
   O'Brien K, 2010, COCHRANE COLLABORATO, V4, P1
   Ogalha C, 2011, JAIDS-J ACQ IMM DEF, V57, pS179, DOI 10.1097/QAI.0b013e31821e9bca
   Oguntibeju OO, 2012, HIV AIDS-RES PALLIAT, V4, P117, DOI 10.2147/HIV.S32321
   Olivo SA, 2008, PHYS THER, V88, P156, DOI 10.2522/ptj.20070147
   Perez-Moreno F, 2007, INT J SPORTS MED, V28, P1046, DOI 10.1055/s-2007-965129
   POTHOFF G, 1994, RESPIRATION, V61, P80
   Raso V, 2013, CLINICS, V68, P359, DOI 10.6061/clinics/2013(03)OA12
   RIGSBY LW, 1992, MED SCI SPORT EXER, V24, P6
   Rojas R, 2003, J SPORT EXERCISE PSY, V25, P440, DOI 10.1123/jsep.25.4.440
   Sillanpaa E, 2009, EUR J APPL PHYSIOL, V106, P285, DOI 10.1007/s00421-009-1013-x
   Stringer WW, 2000, MED SCI SPORT EXER, V32, pS412, DOI 10.1097/00005768-200007001-00006
   Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0
   Warburton DER, 2006, CAN MED ASSOC J, V174, P961, DOI 10.1503/cmaj.1040750
   Zonta Marise Bueno, 2003, Braz J Infect Dis, V7, P301, DOI 10.1590/S1413-86702003000500004
NR 46
TC 38
Z9 39
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 17
PY 2015
VL 10
IS 9
AR e0138066
DI 10.1371/journal.pone.0138066
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS0RH
UT WOS:000361769400049
PM 26378794
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Le Marchand, C
   Bahia, F
   Page, K
   Brites, C
AF Le Marchand, Chloe
   Bahia, Fabianna
   Page, Kimberly
   Brites, Carlos
TI Hepatitis C virus infection and spontaneous clearance in HTLV-1 and HIV
   co-infected patients in Salvador, Bahia, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HTLV-1; HIV; Hepatitis C; Brazil; Spontaneous HCV clearance
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTION-DRUG USERS; VIRAL CLEARANCE;
   GENERAL-POPULATION; HCV INFECTION; COINFECTION; EPIDEMIOLOGY;
   REINFECTION; IMMUNITY; DISEASE
AB Background: While 20-40% of patients with hepatitis C virus (HCV) monoinfection will spontaneously clear the virus, less is known regarding clearance with coinfections. HCV, human immunodeficiency virus (HIV), and human T-cell lymphotrophic virus 1 and 2 (HTLV-1/2) coinfection occurs due to shared routes of transmission and is prevalent in Brazil.
   Objectives: To compare the proportion of patients who have spontaneously cleared HCV in patients with HCV monoinfection to patients coinfected by HCV/HIV, or HCV/HIV/HTLV-1. Methods: Using medical records from two clinics in Salvador, Brazil, including demographic data and serological markers of HCV, HIV and HTLV-I/II, cross-sectional data was obtained from 197 patients. Patients who were anti-HCV positive and HCV RNA negative, and who did not receive HCV treatment were defined as having cleared infection.
   Results: Nineteen patients (9.5%) showed evidence of spontaneous HCV clearance; with clearance in 9 of 108 (8.3%) patients in the HCV monoinfected group, 5 of 68 (7.4%) patients with HCV/HIV, and 5 of 21 (23.8%) patients with HCV/HIV/HTLV. Demographic data were not associated with HCV clearance status. Patients coinfected with both HIV and HTLV-1 had increased odds (5.50; 95% CI 1.00, 30.17) of spontaneous clearance of HCV compared with patients who were HIV negative or of unknown HIV status.
   Conclusion: Our study found that patients coinfected with HIV and HTLV-1 were more likely to spontaneously clear hepatitis C virus than patients with HIV/HCV or HCV alone. The effects of HTLV coinfection on the immune response of such patients may be associated with these findings. (C) 2015 Elsevier Editora Ltda. All rights reserved.
C1 [Le Marchand, Chloe] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
   [Bahia, Fabianna; Brites, Carlos] Univ Fed Bahia UFBA, Dept Infect Dis, BR-40110160 Salvador, BA, Brazil.
   [Page, Kimberly] Univ New Mexico, Div Epidemiol Biostat & Prevent Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
RP Brites, C (corresponding author), Univ Fed Bahia UFBA, Dept Infect Dis, Rua Augusto Viana SN,6 Andar, BR-40110160 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Page, Kimberly/0000-0002-7120-1673
FU NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001449, UL1TR001449, UL1TR001449, UL1TR001449, UL1TR001449,
   UL1TR001449, UL1TR001449, UL1TR001449, UL1TR001449] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [R25MH064712, R25MH064712,
   R25MH064712, R25MH064712, R25MH064712, R25MH064712, R25MH064712,
   R25MH064712, R25MH064712, R25MH064712, R25MH064712, R25MH064712,
   R25MH064712, R25MH064712, R25MH064712] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017] Funding
   Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1 TR001449]
   Funding Source: Medline; NIDA NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [R01 DA016017] Funding Source: Medline;
   NIMH NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R25 MH064712] Funding Source: Medline
CR Abrahao MHN, 2012, AIDS RES HUM RETROV, V28, P806, DOI [10.1089/aid.2011.0192, 10.1089/AID.2011.0192]
   Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004
   AZEVEDO ES, 1982, HUM BIOL, V54, P329
   Bahia F, 2013, 16 INT C HUM RETR HT
   Bahia F, 2011, JAIDS-J ACQ IMM DEF, V57, pS202, DOI 10.1097/QAI.0b013e31821e9a1e
   Bentrem David J., 1994, Journal of Emergency Medicine, V12, P825
   Booth D, 2013, NAT GENET, V45, P119, DOI 10.1038/ng.2537
   Boschi-Pinto C, 2000, J INFECT DIS, V181, P35, DOI 10.1086/315177
   Cox AL, 2005, HEPATOLOGY, V42, P104, DOI 10.1002/hep.20749
   Cursino-Santos JR, 2007, LIVER INT, V27, P1371, DOI 10.1111/j.1478-3231.2007.01600.x
   Daar ES, 2001, J ACQ IMMUN DEF SYND, V26, P466, DOI 10.1097/00126334-200104150-00011
   Dourado I, 2007, CAD SAUDE PUBLICA, V23, P25, DOI 10.1590/S0102-311X2007000100004
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Eckels DD, 2000, IMMUNOL REV, V174, P90, DOI 10.1034/j.1600-0528.2002.017403.x
   Elliott LN, 2006, IMMUNOL CELL BIOL, V84, P239, DOI 10.1111/j.1440-1711.2006.01427.x
   Folgori A, 2006, GUT, V55, P1012, DOI 10.1136/gut.2005.080077
   Grebely J, 2013, HEPATOLOGY, DOI 10.1002/hep.26263
   Grebely J, 2007, CAN J GASTROENTEROL, V21, P447, DOI 10.1155/2007/796325
   Grebely J, 2012, LANCET INFECT DIS, V12, P408, DOI 10.1016/S1473-3099(12)70010-5
   Hajarizadeh B, 2015, PLOS ONE IN PRESS
   Hisada M, 2003, J INFECT DIS, V188, P891, DOI 10.1086/377585
   Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669
   Lavanchy D., 2009, LIVER INT S1, V29, P74
   Liu L, 2012, HEPATOLOGY, V55, P1684, DOI 10.1002/hep.25575
   Matthews GV, 2008, J GASTROEN HEPATOL, V23, P1000, DOI 10.1111/j.1440-1746.2008.05489.x
   Matthews-Greer JM, 2001, CLIN DIAGN LAB IMMUN, V8, P690, DOI 10.1128/CDLI.8.4.690-694.2001
   Micallef JM, 2006, J VIRAL HEPATITIS, V13, P34, DOI 10.1111/j.1365-2893.2005.00651.x
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Moreira ED, 2003, UROLOGY, V61, P431, DOI 10.1016/S0090-4295(02)02158-1
   Moxoto I, 2007, REV SOC BRAS MED TRO, V40, P37, DOI 10.1590/S0037-86822007000100007
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P1107, DOI 10.1590/S0100-879X1999000900009
   Page K, 2009, J INFECT DIS, V200, P1216, DOI 10.1086/605947
   Perz JF, 2006, J HEPATOL, V44, P441, DOI 10.1016/j.jhep.2005.12.007
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Shores NJ, 2008, J HEPATOL, V49, P323, DOI 10.1016/j.jhep.2008.04.010
   Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836
   Spada E, 2004, GUT, V53, P1673, DOI 10.1136/gut.2003.037788
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450
   Toro C, 2005, J CLIN VIROL, V32, P338, DOI 10.1016/j.jcv.2004.08.013
   Wang CC, 2007, J INFECT DIS, V196, P1474, DOI 10.1086/522608
   Yoshida M, 1984, Princess Takamatsu Symp, V15, P39
NR 42
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2015
VL 19
IS 5
BP 486
EP 491
DI 10.1016/j.bjid.2015.06.007
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA CS5FY
UT WOS:000362104000006
PM 26254690
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-01
ER

PT J
AU Brites, C
   Nobrega, I
   Netto, EM
AF Brites, Carlos
   Nobrega, Isabella
   Netto, Eduardo Martins
TI Use of new antiretroviral drugs and classes in Bahia, Brazil: a real
   life experience on salvage therapy of AIDS patients
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Antiretroviral; Salvage therapy
ID HIV-INFECTED PATIENTS; VIROLOGICAL SUPPRESSION; PROTEASE INHIBITORS;
   CLINICAL-TRIALS; EFFICACY; SAFETY; DARUNAVIR/RITONAVIR; ETRAVIRINE;
   ENFUVIRTIDE; RALTEGRAVIR
AB Antiretroviral therapy has significantly evolved in the last decade, with an increasing number of new drugs and classes. Currently, even heavily experienced patients can be successfully treated with new regimens. In Brazil, the recent incorporation of some new antiretroviral drugs made it possible to suppress HIV plasma viremia in most treated patients, with significant benefits in terms of quality of life and survival. However, little has been published on outcomes of patients under new drugs-based regimens. We reviewed the safety and efficacy of antiretroviral regimens using recently introduced drugs in Bahia. Our results confirm that patients using darunavir, raltegravir, enfuvirtide, or etravirine presented with a high rate of virological suppression without significant adverse events, after one year of follow-up. (C) 2015 Elsevier Editora Ltda. All rights reserved.
C1 [Brites, Carlos; Nobrega, Isabella; Netto, Eduardo Martins] Univ Fed Bahia UFBA, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Complexo Hosp Prof Edgard Santos, Rua Augusto Vianna SN, BR-40140480 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
FU Departamento de DST/AIDS e Hepatites Virais, Ministerio da Saude,
   Brasil/UNESCO
FX This study was supported by a grant from Departamento de DST/AIDS e
   Hepatites Virais, Ministerio da Saude, Brasil/UNESCO.
CR Arasteh K, 2009, ANTIVIR THER, V14, P859, DOI 10.3851/IMP1301
   Biscione Fernando Martin, 2014, J Int Assoc Provid AIDS Care, V13, P63, DOI 10.1177/2325957413502542
   Cahn P, 2006, CLIN INFECT DIS, V43, P1347, DOI 10.1086/508352
   Eron JJ, 2013, LANCET INFECT DIS, V13, P587, DOI 10.1016/S1473-3099(13)70093-8
   Fagard C, 2012, JAIDS-J ACQ IMM DEF, V59, P489, DOI 10.1097/QAI.0b013e31824bb720
   Gazzola L, 2014, HIV CLIN TRIALS, V15, P140, DOI 10.1310/hct1504-140
   Girard PM, 2012, HIV MED, V13, P427, DOI 10.1111/j.1468-1293.2012.00994.x
   Imaz A, 2011, AIDS REV, V13, P180
   Makinson A, 2009, CURR OPIN HIV AIDS, V4, P150, DOI 10.1097/COH.0b013e32832498d8
   McKinnell JA, 2009, AIDS, V23, P1539, DOI 10.1097/QAD.0b013e32832c7b5c
   Pennings PS, 2013, INFECT DIS REP, V5, P21, DOI 10.4081/idr.2013.s1.e5
   Reynes J, 2007, AIDS PATIENT CARE ST, V21, P533, DOI 10.1089/apc.2006.0174
   Ribeiro KM, 2014, BRAZ J INFECT DIS, V18, P1, DOI 10.1016/j.bjid.2013.04.001
   Fernandez-Montero JV, 2009, EXPERT OPIN PHARMACO, V10, P1615, DOI 10.1517/14656560902980202
   Vidal JE, 2013, BRAZ J INFECT DIS, V17, P41, DOI 10.1016/j.bjid.2012.08.022
NR 15
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2015
VL 19
IS 5
BP 529
EP 532
DI 10.1016/j.bjid.2015.03.005
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA CS5FY
UT WOS:000362104000013
PM 25997781
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Phillips, A
   Fields, P
   Hermine, O
   Taylor, GP
   Delioukina, M
   Horwitz, S
   Ramos, JC
   Meniane, JC
   Barta, SK
   Brites, C
   Pereria, J
   Beltran, B
   Casanova, L
   Wandroo, F
   Feldman, T
   Dwyer, K
   Kurman, M
   Conlon, K
AF Phillips, Adrienne
   Fields, Paul
   Hermine, Olivier
   Taylor, Graham P.
   Delioukina, Maria
   Horwitz, Steven
   Ramos, Juan C.
   Meniane, Jean-Come
   Barta, Stefan K.
   Brites, Carlos
   Pereria, Juliana
   Beltran, Brady
   Casanova, Luis
   Wandroo, Farooq
   Feldman, Tatyana
   Dwyer, Karen
   Kurman, Michael
   Conlon, Kevin
TI Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's
   choice in subjects with relapsed or refractory adult T-cell
   leukemia-lymphoma (ATL)
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Phillips, Adrienne] Weill Cornell Med Coll, New York, NY USA.
   [Fields, Paul] Guys Hosp, London SE1 9RT, England.
   [Hermine, Olivier] Hop Necker Enfants Malad, Paris, France.
   [Taylor, Graham P.] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Delioukina, Maria] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Horwitz, Steven] Mem Sloan Kettering Canc Ctr, New York, NY USA.
   [Ramos, Juan C.] Univ Miami, Sylvester Canc Ctr, Miami, FL USA.
   [Meniane, Jean-Come] CHU Ft France, Fort De France, Martinique, France.
   [Barta, Stefan K.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   [Brites, Carlos] Hosp Univ Prof Edgard Santos UFBA, Salvador, BA, Brazil.
   [Pereria, Juliana] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
   [Beltran, Brady] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru.
   [Casanova, Luis] Inst Oncol Miraflores, Lima, Peru.
   [Wandroo, Farooq] Sandwell & West Birmingham Hosp, Birmingham, W Midlands, England.
   [Feldman, Tatyana] John Theurer Canc Ctr Hackensack UMC, Hackensack, NJ USA.
   [Dwyer, Karen; Kurman, Michael] Inc Princeton, Kyowa Hakko Kirin Pharma, Princeton, NJ USA.
   [Conlon, Kevin] NCI, Bethesda, MD 20892 USA.
RI Beltran, Brady/P-8655-2019; Barta, Stefan/AAR-1309-2020
OI Beltran, Brady/0000-0003-4469-3817; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD AUG 28
PY 2015
VL 12
SU 1
DI 10.1186/1742-4690-12-S1-P31
PG 2
WC Virology
SC Virology
GA DA0EC
UT WOS:000367468500072
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-01
ER

PT J
AU Torres, AJL
   Cisneiros, P
   Guedes, R
   Grassi, MFR
   Meyer, R
   Bendicho, MT
   Lopes, TGSL
   Felix, G
   Netto, EM
   Brites, C
   Abe-Sandes, K
   Brandao, C
   Alcantara-Neves, N
   Freire, SM
AF Torres, Alex J. L.
   Cisneiros, Patricia
   Guedes, Rosa
   Grassi, Maria Fernanda R.
   Meyer, Roberto
   Bendicho, Maria T.
   Lopes, Tais G. S. L.
   Felix, Gabriela
   Netto, Eduardo M.
   Brites, Carlos
   Abe-Sandes, Kiyoko
   Brandao, Claudio
   Alcantara-Neves, Neuza
   Freire, Songeli M.
TI Lymphocyte subset reference intervals in blood donors from northeastern
   Brazil
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE lymphocyte subsets; reference values; flow cytometry; Brazil; blood
   donors
ID REGULATORY T-CELLS; RURAL NORTHERN TANZANIA; REFERENCE VALUES; REFERENCE
   RANGES; PULMONARY TUBERCULOSIS; HEALTHY-ADULTS; POPULATION; LEUKOPENIA;
   INFECTION; DISEASES
AB The reference intervals for leukocytes and lymphocytes currently used by most clinical laboratories present limitations as they are primarily derived from individuals of North American and European origin. The objective this study was to determine reference values for peripheral blood B lymphocytes, T lymphocyte subsets (CD4+, CD8+, naive, memory, regulatory, TCR alpha beta and TCR gamma delta+) and NK cells from blood donors in Salvador-Bahia, Brazil. Results: The proportion of included male subjects was 73.7% and the median ages of males (34) and females (35) were found to be similar. Absolute counts total lymphocytes subsets to both gender was 1,956 (1,060-4,186) cells and relative values 34%. The T CD4+ and T CD8+ lymphocytes relative values was 51% (20-62) and 24% (9-28), respectively. The most statistically significant finding observed was a higher percentage of B lymphocytes (p=0.03) in females. Commonly cited subset reference intervals were found to be consistent with values in several populations from different geographic areas.
C1 [Torres, Alex J. L.; Lopes, Tais G. S. L.; Felix, Gabriela; Abe-Sandes, Kiyoko] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectol, BR-40110160 Salvador, BA, Brazil.
   [Cisneiros, Patricia; Guedes, Rosa; Meyer, Roberto; Bendicho, Maria T.; Netto, Eduardo M.; Brites, Carlos; Freire, Songeli M.] Univ Fed Bahia, Inst Ciencias Saude, Lab Imunol & Biol Mol, BR-40110903 Salvador, BA, Brazil.
   [Brandao, Claudio] Hosp Geral, Fundacao Hematol & Hemoterapia Bahia HEMOBA, BR-40286240 Salvador, BA, Brazil.
   [Grassi, Maria Fernanda R.; Bendicho, Maria T.; Freire, Songeli M.] EBMSP, BR-40285000 Salvador, BA, Brazil.
   [Bendicho, Maria T.] Univ Estado Bahia UNEB, Dept Ciencias Vida, BR-41150000 Salvador, BA, Brazil.
   [Meyer, Roberto; Netto, Eduardo M.; Brites, Carlos; Alcantara-Neves, Neuza; Freire, Songeli M.] Univ Fed Bahia UFBA, Inst Ciencias Saude, BR-40110903 Salvador, BA, Brazil.
   [Meyer, Roberto; Brites, Carlos; Freire, Songeli M.] Minist Ciencia Tecnol & Inovacao, INCT DT, Serv Imunol, BR-40110160 Salvador, BA, Brazil.
   [Grassi, Maria Fernanda R.; Meyer, Roberto] Fundacao Oswaldo Cruz, Minist Saude, Lab Avancado Saude Publ, BR-40296710 Salvador, BA, Brazil.
   [Torres, Alex J. L.; Cisneiros, Patricia; Brandao, Claudio] ICS UFBA, Programa Posgrad Imunol, BR-40110903 Salvador, BA, Brazil.
   [Lopes, Tais G. S. L.; Freire, Songeli M.] ICS UFBA, Programa Posgrad Proc Interat Orgaos & Sistemas, BR-40110903 Salvador, BA, Brazil.
RP Freire, SM (corresponding author), Univ Fed Bahia, Inst Ciencias Saude, Lab Imunol & Biol Mol, Ave Reitor Miguel Calmon S-N, BR-40110903 Salvador, BA, Brazil.
EM songeli@ufba.br
RI Torres, Alex JL/Q-6186-2018; Netto, Eduardo/D-1432-2013; Grassi,
   Fernanda/X-7360-2019; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Grassi,
   Fernanda/0000-0002-7356-5569; Brites, Carlos/0000-0002-4673-6991
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB); Laboratory of
   Immunology and Molecular Biology-Health Sciences Institute (UFBA);
   Scientific Initiation Program and UFBA Post-Graduate Program; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq); Fundacao de
   Hematologia e Hemoterapia da Bahia (HEMOBA)
FX Financial support was provided by the Fundacao de Amparo a Pesquisa do
   Estado da Bahia (FAPESB), the Laboratory of Immunology and Molecular
   Biology-Health Sciences Institute (UFBA); Grants from the Scientific
   Initiation Program and UFBA Post-Graduate Program, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Hematologia
   e Hemoterapia da Bahia (HEMOBA). The authors would like to thank all
   volunteer blood donors, the staff and technicians from UFBA and HEMOBA,
   as well as Andris K. Walter for English revision and consultation
   services.
CR Bain BJ, 1996, J CLIN PATHOL, V49, P664, DOI 10.1136/jcp.49.8.664
   BARNES PF, 1992, J INFECT DIS, V165, P506, DOI 10.1093/infdis/165.3.506
   Belkaid Y, 2007, NAT REV IMMUNOL, V7, P875, DOI 10.1038/nri2189
   Bisset LR, 2004, EUR J HAEMATOL, V72, P203, DOI 10.1046/j.0902-4441.2003.00199.x
   Borrego Luis Miguel, 2007, Rev Port Pneumol, V13, P365
   BOTTINO C, 1988, J EXP MED, V168, P491, DOI 10.1084/jem.168.2.491
   Buclin T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018578
   Dattoli VCC, 2011, TROP MED INT HEALTH, V16, P514, DOI 10.1111/j.1365-3156.2010.02719.x
   Failace R., 2003, HEMOGRAMA MANUAL INT
   Felix Gabriela E. S., 2010, Rev. Bras. Hematol. Hemoter., V32, P282
   Ferreira MU, 2000, REV SAUDE PUBL, V34, P73, DOI 10.1590/S0034-89102000000700010
   Forbes WH, 1941, AM J MED SCI, V201, P407, DOI 10.1097/00000441-194103000-00013
   Han X, 1997, GYNECOL ONCOL, V65, P391, DOI 10.1006/gyno.1997.4668
   Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488
   IBGE-INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATISTICA, 2010, PAIN CENS 2010
   Lee BW, 1996, CYTOMETRY, V26, P8, DOI 10.1002/(SICI)1097-0320(19960315)26:1<8::AID-CYTO2>3.0.CO;2-E
   Lugada ES, 2004, CLIN DIAGN LAB IMMUN, V11, P29, DOI 10.1128/CDLI.11.1.29-34.2004
   MAGALHAES M, 2011, REV CIENCIAS MED PER, V7, P19
   Ngowi BJ, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-341
   Ngowi BJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-1
   Ochs HD, 2007, IMMUNOL RES, V38, P112, DOI 10.1007/s12026-007-0022-2
   PANCHAM SP, 1999, POSTGRAD DOCT CARIB, V18, P146
   RIPPEY JJ, 1967, LANCET, V2, P44
   Sachdeva M, 2010, JAIDS-J ACQ IMM DEF, V54, P447, DOI 10.1097/QAI.0b013e3181e0c7d0
   Santagostino A, 1999, HAEMATOLOGICA, V84, P499
   SHAHGHASEMPOUR S, 2001, ARCH IRAN MED, V4, P80
   Torgerson TR, 2007, CURR OPIN ALLERGY CL, V7, P515, DOI 10.1097/ACI.0b013e3282f1a27a
   Tsegaye A, 1999, CLIN DIAGN LAB IMMUN, V6, P410, DOI 10.1128/CDLI.6.3.410-414.1999
   Urquhart NE, 2008, W INDIAN MED J, V57, P147
   Wakeman L, 2007, INT J LAB HEMATOL, V29, P279, DOI 10.1111/j.1365-2257.2006.00883.x
   Yeh JJ, 2010, EUR RADIOL, V20, P2135, DOI 10.1007/s00330-010-1796-5
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD JUN
PY 2015
VL 87
IS 2
BP 1019
EP 1025
DI 10.1590/0001-3765201520130114
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CM2OH
UT WOS:000357520300038
PM 25923166
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Camargo, LFA
   Marra, AR
   Pignatari, ACC
   Sukiennik, T
   Behar, PPP
   Medeiros, EAS
   Ribeiro, J
   Girao, E
   Correa, L
   Guerra, C
   Brites, C
   Pereira, CAP
   Carneiro, I
   Reis, M
   Souza, MA
   Barata, CU
   Edmond, MB
AF Camargo, L. F. A.
   Marra, A. R.
   Pignatari, A. C. C.
   Sukiennik, T.
   Behar, P. P. P.
   Medeiros, E. A. S.
   Ribeiro, J.
   Girao, E.
   Correa, L.
   Guerra, C.
   Brites, C.
   Pereira, C. A. P.
   Carneiro, I.
   Reis, M.
   Souza, M. A.
   Barata, C. U.
   Edmond, M. B.
CA Brazilian SCOPE Study Grp
TI Nosocomial bloodstream infections in a nationwide study: comparison
   between solid organ transplant patients and the general population
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE bloodstream infection; hospital; transplantation; epidemiology;
   surveillance
ID RISK-FACTORS; RECIPIENTS; SURVEILLANCE; RESISTANT; HOSPITALS; MORTALITY;
   IMPACT
AB BackgroundThe incidence of bloodstream infection (BSI) varies according to the transplanted organ. Mortality can be as high as 24%, with a significant impact on graft survival. Transplantation is a risk factor for multidrug-resistant (MDR) organisms, but comparison with a non-transplanted population in a single large cohort has not been described.
   MethodsThis is a prospective nationwide study (16 centers) reporting data on 2364 monomicrobial nosocomial BSIs, comparing 83 episodes in solid organ transplant patients with 2447 BSIs occurring in the general hospital population.
   ResultsThe prevalence of groups of infecting organisms (gram-positive, gram-negative, and fungi) was similar between transplant patients and the general population and a similar crude mortality rate was observed (34.9% in transplant vs. 43.3% in non-transplant patients). Staphylococcus aureus was the single most frequently isolated organism in both groups, and Acinetobacter species was more frequently isolated in the general population. Regarding MDR organisms, Klebsiella species, and Enterobacter species resistant to cefepime, as well as Acinetobacter species resistant to meropenem, were significantly more frequent in transplant patients.
   ConclusionAntimicrobial resistance is higher, particularly among gram-negative bacteria in the transplant population, although the overall mortality rate between transplant and non-transplant patients with nosocomial BSI is similar.
C1 [Camargo, L. F. A.; Marra, A. R.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Camargo, L. F. A.; Marra, A. R.; Pignatari, A. C. C.; Medeiros, E. A. S.] Univ Fed Sao Paulo UNIFESP, Sao Paulo, Brazil.
   [Pignatari, A. C. C.] Hosp 9 Julho, Sao Paulo, Brazil.
   [Sukiennik, T.] Santa Casa Porto Alegre, Porto Alegre, RS, Brazil.
   [Behar, P. P. P.] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Ribeiro, J.] Hosp Base, Brasilia, DF, Brazil.
   [Girao, E.] Hosp Walter Cantidio, Fortaleza, Ceara, Brazil.
   [Correa, L.] Hosp Rim & Hipertensao, Sao Paulo, Brazil.
   [Guerra, C.] Hosp Diadema, Sao Paulo, Brazil.
   [Brites, C.] Hosp Espanhol, Salvador, BA, Brazil.
   [Pereira, C. A. P.] Inst Oncol Pediat IOP GRAAC, Sao Paulo, Brazil.
   [Reis, M.] Hosp Coracao, Natal, RN, Brazil.
   [Reis, M.] Hosp UNIMED, Natal, RN, Brazil.
   [Souza, M. A.] Hosp Clin Goiania, Goiania, Go, Brazil.
   [Barata, C. U.] Univ Fed Triangulo Mineiro, Uberaba, MG, Brazil.
   [Edmond, M. B.] Virginia Commonwealth Univ, Richmond, VA USA.
RP Camargo, LFA (corresponding author), Inst Israelita Ensino & Pesquisa, Av Albert Einstein 627-701,2nd S Floor, BR-05651901 Sao Paulo, Brazil.
EM luis_camargo@einstein.br
RI Brites, Carlos/D-1353-2013; Pignatari, Antonio CC/C-8427-2012; Medeiros,
   Eduardo A/B-9825-2012
OI Brites, Carlos/0000-0002-4673-6991; Medeiros, Eduardo
   A/0000-0002-6205-259X; Edmond, Michael/0000-0002-4144-8974; Pignatari,
   Antonio/0000-0002-2146-8476; Camargo, Luis Fernando
   Aranha/0000-0002-3888-8661; Bispo, Paulo/0000-0002-2867-1450
FU Pfizer Laboratories; FAPESP (Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Financial support (for data collection only) by Pfizer Laboratories and
   FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo).
CR Abbott KC, 2001, AM J NEPHROL, V21, P120, DOI 10.1159/000046234
   Al-Hasan MN, 2009, AM J TRANSPLANT, V9, P835, DOI 10.1111/j.1600-6143.2009.02559.x
   Al-Hasan MN, 2011, TRANSPLANTATION, V91, P1206, DOI 10.1097/TP.0b013e3182180535
   Berger N, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-127
   Candel FJ, 2005, TRANSPL P, V37, P4097, DOI 10.1016/j.transproceed.2005.09.181
   Clinical and Laboratory Standards Institute Wayne PA, 2010, M100S20 CLSI
   Dantas SRPE, 2006, J HOSP INFECT, V63, P117, DOI 10.1016/j.jhin.2005.10.018
   Garzoni C, 2009, AM J TRANSPLANT, V9, pS41, DOI 10.1111/j.1600-6143.2009.02892.x
   Hsu RB, 2011, EUR J CARDIO-THORAC, V40, P1362, DOI 10.1016/j.ejcts.2011.02.033
   Hussein K, 2009, INFECT CONT HOSP EP, V30, P666, DOI 10.1086/598244
   Lee SO, 2011, LIVER TRANSPLANT, V17, P733, DOI 10.1002/lt.22296
   Marra AR, 2011, J CLIN MICROBIOL, V49, P1866, DOI 10.1128/JCM.00376-11
   Moreno A, 2007, AM J TRANSPLANT, V7, P2579, DOI 10.1111/j.1600-6143.2007.01964.x
   Nunley DR, 2010, LUNG, V188, P381, DOI 10.1007/s00408-010-9250-7
   Palmer SM, 2000, TRANSPLANTATION, V69, P2360, DOI 10.1097/00007890-200006150-00025
   Pappas PG, 2010, CLIN INFECT DIS, V50, P1101, DOI 10.1086/651262
   Patel G, 2010, CURR OPIN ORGAN TRAN, V15, P676, DOI 10.1097/MOT.0b013e3283404373
   Schwaber MJ, 2008, ANTIMICROB AGENTS CH, V52, P1028, DOI 10.1128/AAC.01020-07
   Shi SH, 2009, TRANSPL INFECT DIS, V11, P405, DOI 10.1111/j.1399-3062.2009.00421.x
   Silva M, 2010, TRANSPLANTATION, V90, P581, DOI 10.1097/TP.0b013e3181e8a680
   vansDelden C, 2009, AM J TRANSPLANT, V9, pS27
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754
   Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946
NR 23
TC 22
Z9 23
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD APR
PY 2015
VL 17
IS 2
BP 308
EP 313
DI 10.1111/tid.12356
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA CF0FV
UT WOS:000352219400019
PM 25726707
DA 2020-12-01
ER

PT J
AU Quiros, RE
   Vilches, V
   Korman, TM
   Miyakis, S
   Boutlis, CS
   Reid, AB
   Gales, AC
   Schandert, L
   Affini, R
   Oliveira, AM
   Marra, AR
   Camargo, LFA
   Edmond, MB
   Correa, L
   Sukiennik, TCT
   Behar, PRP
   Girao, E
   Guerra, C
   Brites, C
   de Souza, MA
   McGeer, AJ
   Smith, S
   El Kholy, AA
   Plakias, G
   Tacconelli, E
   Honda, H
   Kluytmans, J
   Apisarnthanarak, A
   Fakih, MG
   Marschall, J
   Russo, AJ
AF Quiros, Rodolfo E.
   Vilches, Viviana
   Korman, Tony M.
   Miyakis, Spyros
   Boutlis, Craig S.
   Reid, Alistair B.
   Gales, Ana Cristina
   Schandert, Lygia
   Affini, Rafael
   Oliveira, Antonia Machado
   Marra, Alexandre R.
   Aranha Camargo, Luis Fernando
   Edmond, Michael B.
   Correa, Luci
   Teixeira Sukiennik, Teresa Cristina
   Petersen Behar, Paulo Renato
   Girao, Evelyne
   Guerra, Carla
   Brites, Carlos
   de Souza, Marta Antunes
   McGeer, Allison J.
   Smith, Stephanie
   El Kholy, Amani A.
   Plakias, George
   Tacconelli, Evelina
   Honda, Hitoshi
   Kluytmans, Jan
   Apisarnthanarak, Anucha
   Fakih, Mohamad G.
   Marschall, Jonas
   Russo, Anthony J.
TI Geographical Variability in the Likelihood of Bloodstream Infections Due
   to Gram-Negative Bacteria: Correlation with Proximity to the Equator and
   Health Care Expenditure (vol 9, e114548, 2014)
SO PLOS ONE
LA English
DT Correction
C1 [Quiros, Rodolfo E.] Hosp Univ Austral, Div Infect Dis Prevent & Infect Control Serv, Buenos Aires, DF, Argentina.
   [Vilches, Viviana] Hosp Univ Austral, Microbiol Lab, Buenos Aires, DF, Argentina.
   [Korman, Tony M.] Monash Hlth, Monash Infect Dis, Clayton, Vic, Australia.
   [Miyakis, Spyros; Boutlis, Craig S.; Reid, Alistair B.] Wollongong Hosp, Wollongong, NSW, Australia.
   [Gales, Ana Cristina; Schandert, Lygia; Affini, Rafael; Oliveira, Antonia Machado] Univ Fed Sao Paulo, Div Infect Dis, Lab Especial Microbiol Clin, Sao Paulo, Brazil.
   [Marra, Alexandre R.; Aranha Camargo, Luis Fernando; Correa, Luci] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Edmond, Michael B.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA.
   [Correa, Luci] Hosp Rim & Hipertensao, Sao Paulo, Brazil.
   [Teixeira Sukiennik, Teresa Cristina] Hosp Santa Casa Porto Alegre, Porto Alegre, RS, Brazil.
   [Petersen Behar, Paulo Renato] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Girao, Evelyne] Hosp Walter Cantidio, Fortaleza, Ceara, Brazil.
   [Guerra, Carla] Hosp Diadema, Sao Paulo, Brazil.
   [Brites, Carlos] Hosp Espanhol, Salvador, BA, Brazil.
   [de Souza, Marta Antunes] Hosp Clin Goiania, Goiania, Go, Brazil.
   [McGeer, Allison J.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
   [Smith, Stephanie] Univ Alberta, Div Infect Dis, Edmonton, AB, Canada.
   [El Kholy, Amani A.] Cairo Univ Kasr Ainy, Dar Al Fouad Hosp, Fac Med, Dept Clin Pathol, Cairo, Egypt.
   [Plakias, George] Hygeia Gen Hosp, Athens, Greece.
   [Tacconelli, Evelina] Univ Tubingen Hosp, Internal Med, Div Infect Dis, Tubingen, Germany.
   [Honda, Hitoshi] Tokyo Metropolitan Tama Med Ctr, Dept Infect Prevent, Tokyo, Japan.
   [Kluytmans, Jan] Amphia Hosp Breda, Lab Microbiol & Infect Control, Breda, Netherlands.
   [Apisarnthanarak, Anucha] Thammasat Univ Hosp, Div Infect Dis, Pathum Thani, Thailand.
   [Fakih, Mohamad G.] St John Hosp & Med Ctr, Infect Prevent & Control Dept, Grosse Pointe Woods, MI USA.
   [Marschall, Jonas] Univ Hosp Bern, Dept Infect Dis, CH-3010 Bern, Switzerland.
   [Marschall, Jonas] Univ Bern, Bern, Switzerland.
   [Russo, Anthony J.] Barnes Jewish Hosp, St Louis, MO 63110 USA.
RP Quiros, RE (corresponding author), Hosp Univ Austral, Div Infect Dis Prevent & Infect Control Serv, Buenos Aires, DF, Argentina.
RI Kholy, Amani El/ABA-4759-2020; Marschall, Jonas/AAF-6425-2019; mcgeer,
   allison/H-7747-2014; McGeer, Allison/AAB-6885-2020; Korman, Tony
   M/I-3099-2013; Gales, Ana Cristina/C-8280-2013; Tacconelli,
   Evelina/AAC-8200-2019
OI Marschall, Jonas/0000-0002-0052-3210; mcgeer,
   allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137;
   Korman, Tony M/0000-0002-6155-8353; Gales, Ana
   Cristina/0000-0003-0913-768X; 
CR Fisman D, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0114548, 10.1371/currents.outbreaks.89c0d3783f36958d96ebbae97348d571]
NR 1
TC 0
Z9 0
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 23
PY 2015
VL 10
IS 3
AR e0122435
DI 10.1371/journal.pone.0122435
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE6ZS
UT WOS:000351987300333
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Torres, AJL
   Brigido, LFD
   Abrahao, MHN
   Angelo, ALD
   Ferreira, GD
   Coelho, LP
   Ferreira, JL
   Jorge, CRMP
   Netto, EM
   Brites, C
AF Leite Torres, Alex Jose
   de Macedo Brigido, Luis Fernando
   Nunes Abrahao, Marcos Herculano
   Dias Angelo, Ana Luiza
   Ferreira, Gilcivaldo de Jesus
   Coelho, Luana Portes
   Ferreira, Joao Leandro
   Mayoral Pedroso Jorge, Celia Regina
   Netto, Eduardo Martins
   Brites, Carlos
TI High degree of concordance between flow cytometry and geno2pheno methods
   for HIV-1 tropism determination in proviral DNA
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; Tropism; Flow cytometry; Geno2pheno
ID MOLECULAR-INTERACTIONS; CORECEPTOR TROPISM; CCR5 ANTAGONISTS; ENTRY;
   INHIBITOR; MECHANISM; ASSAY; BINDING
AB Use of CCR5 antagonists requires previous viral tropism determination. The available methods have high cost, are time-consuming, or require highly trained personnel, and sophisticated equipment. We compared a flow cytometry-based tropism assay with geno2pheno method to determine HIV-1 tropism in AIDS patients, in Bahia, Brazil. We tested peripheral blood mononuclear cells of 102 AIDS patients under antiretroviral therapy by using a cytometry-based tropism assay and geno2pheno assay. Cellular membrane receptors were identified by using CXCR4, CCR5 and CD4 monoclonal antibodies, while detection of cytoplasmic mRNAs for gag and pol HIV regions was achieved by using a labeled probe. Genotypic identification of X4 and R5 tropic viruses was attempted by geno2pheno algorithm. There was a high degree of concordance between cytometry-based tropism assay and geno2pheno algorithm in determination of HIV-1 tropism. Cytometry-based tropism assay demonstrated higher sensitivity and specificity in comparison to geno2pheno, which was used as a gold-standard. One sample could not be amplified by geno2pheno method, but was classified as duotropic by cytometry-based tropism assay. We did not find any association between CD4+ count or plasma HIV-1 RNA viral load and tropism results. The overall performances of cytometry-based tropism assay and geno2pheno assay were almost identical in determination of HIV-1 tropism. (C) 2015 Elsevier Editora Ltda. All rights reserved.
C1 [Leite Torres, Alex Jose; Nunes Abrahao, Marcos Herculano; Dias Angelo, Ana Luiza; Ferreira, Gilcivaldo de Jesus; Mayoral Pedroso Jorge, Celia Regina; Netto, Eduardo Martins; Brites, Carlos] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [de Macedo Brigido, Luis Fernando; Coelho, Luana Portes; Ferreira, Joao Leandro] Adolfo Lutz Inst, Grp Pesquisa Caracterizacao Retrovirus Humanos, Sao Paulo, SP, Brazil.
RP Torres, AJL (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
EM ajltorres@gmail.com
RI Brites, Carlos/D-1353-2013; Torres, Alex JL/Q-6186-2018; Netto,
   Eduardo/D-1432-2013; Brigido, Luis F M/C-2155-2011
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761;
   Brigido, Luis F M/0000-0002-1022-7837
CR Archer J, 2009, AIDS, V23, P1209, DOI 10.1097/QAD.0b013e32832b4399
   Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   de Mendoza C, 2008, JAIDS-J ACQ IMM DEF, V48, P241, DOI 10.1097/QAI.0b013e3181734f0e
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697
   Gonzalez-Serna A, 2010, J CLIN MICROBIOL, V48, P4453, DOI 10.1128/JCM.00953-10
   Huang W, 2008, J VIROL, V82, P5584, DOI 10.1128/JVI.02676-07
   Kondru R, 2008, MOL PHARMACOL, V73, P789, DOI 10.1124/mol.107.042101
   Low AJ, 2008, AIDS REV, V10, P143
   Low AJ, 2007, AIDS, V21, pF19, DOI 10.1097/QAD.0b013e3282ef81ea
   Maeda K, 2006, J BIOL CHEM, V281, P12688, DOI 10.1074/jbc.M512688200
   Maeda K, 2008, J MOL BIOL, V381, P956, DOI 10.1016/j.jmb.2008.06.041
   MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x
   Patterson BK, 1998, CYTOMETRY, V31, P265, DOI 10.1002/(SICI)1097-0320(19980401)31:4&lt;265::AID-CYTO6&gt;3.0.CO;2-I
   Raymond S, 2011, J ANTIMICROB CHEMOTH, V66, P1972, DOI 10.1093/jac/dkr224
   Regoes RR, 2005, TRENDS MICROBIOL, V13, P269, DOI 10.1016/j.tim.2005.04.005
   Sanchez V, 2010, J CLIN MICROBIOL, V48, P4135, DOI 10.1128/JCM.01204-10
   Seibert C, 2006, VIROLOGY, V349, P41, DOI 10.1016/j.virol.2006.01.018
   Tsamis F, 2003, J VIROL, V77, P5201, DOI 10.1128/JVI.77.9.5201-5208.2003
   Vilchez R, 2009, 16 C RETR OPP INF CR
   Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565
   Whitcomb JM, 2007, ANTIMICROB AGENTS CH, V51, P566, DOI 10.1128/AAC.00853-06
   WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316
NR 24
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2015
VL 19
IS 2
BP 163
EP 169
DI 10.1016/j.bjid.2014.11.007
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA CG8SM
UT WOS:000353582600008
PM 25701547
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Brites-Alves, C
   Netto, EM
   Brites, C
AF Brites-Alves, Clara
   Netto, Eduardo Martins
   Brites, Carlos
TI Coinfection by Hepatitis C Is Strongly Associated with Abnormal CD4/CD8
   Ratio in HIV Patients under Stable ART in Salvador, Brazil
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; IMMUNE RESTORATION;
   VIRUS COINFECTION; IMPACT; INFLAMMATION; INITIATION; MORTALITY;
   RECOVERY; CD4(+)
AB Proper immune restoration (CD4 count >500 and normal CD4/8 ratio) is reached only by a fraction of HIV patients, despite stable viral suppression. Methods. We present a case-control study to compare HIV patients with viral suppression >1 year, according to immune restoration pattern: adequate response (AR) defined by CD4 > 500 cells/mm(3) and CD4/8 ratio > 1; partial response (PR = patients with CD4 > 500, but CD4/8 ratio <1); inadequate response (IR = CD4 < 500 cells). Results. We evaluated 293 consecutive patients (89 AR, 112 PR, and 92 IR), 70% males. Male gender (p < 0.01), lower mean CD4 nadir (p < 0.001), higher baseline VL (p = 0.01), previous diagnosis of Tb (p = 0.03), or HCV (p < 0.01) was associated with IR. Likelihood of AR/PR was similar regardless of gender, after adjusting for nadir CD4+ cells count. Longer time under suppressive ART was also associated with a greater chance of AR, but logistic regression identified coinfection by HCV as the main factor associated with abnormal CD4/CD8 ratio. Conclusion. Early initiation of ART and longer time since first undetectable PVL were predictors of AR. Previous HCV diagnosis significantly increases the risk of abnormal CD4/CD8 ratio.
C1 [Brites-Alves, Clara; Netto, Eduardo Martins; Brites, Carlos] Univ Fed Bahia, Complexo Hosp Univ Prof Edgard Santos, Lab Pesquisas Infectol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Complexo Hosp Univ Prof Edgard Santos, Lab Pesquisas Infectol, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
FU Conselho Nacional de Pesquisas, Brazil (CNPQ)National Council for
   Scientific and Technological Development (CNPq) [306885/2011-5]
FX This work was supported by a Conselho Nacional de Pesquisas, Brazil
   (CNPQ), Grant 306885/2011-5.
CR Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276
   Bhaskaran K, 2008, JAMA-J AM MED ASSOC, V300, P51, DOI 10.1001/jama.300.1.51
   Corbeau P, 2011, BLOOD, V117, P5582, DOI 10.1182/blood-2010-12-322453
   Costagliola D., 2014, J INT AIDS SOC S3, V17
   Deeks SG, 2012, CURR OPIN IMMUNOL, V24, P501, DOI 10.1016/j.coi.2012.05.004
   Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957
   Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627
   Guihot A, 2011, TRENDS IMMUNOL, V32, P131, DOI 10.1016/j.it.2010.12.002
   Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093
   Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003
   Miller MF, 2005, CLIN INFECT DIS, V41, P713, DOI 10.1086/432618
   Mussini C., 2014, P 2014 C RETR OPP IN
   Naftalin C. M., 2014, INT J STD AIDS
   Phillips AN, 2008, AIDS, V22, P2409, DOI 10.1097/QAD.0b013e3283174636
   Santin M, 2008, EUR J CLIN MICROBIOL, V27, P65, DOI 10.1007/s10096-007-0384-3
   Saracino A, 2014, AIDS RES HUM RETROV, V30, P1178, DOI 10.1089/aid.2014.0080
   Seminari E, 2010, CURR HIV RES, V8, P186, DOI 10.2174/157016210791111070
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Serrano-Villar S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085798
   Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882
   Taye S, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-23
   Vinikoor MJ, 2014, AIDS RES HUM RETROV, V30, P949, DOI [10.1089/aid.2014.0046, 10.1089/AID.2014.0046]
   Wilson EMP, 2013, IMMUNOL REV, V254, P343, DOI 10.1111/imr.12064
   Yacisin K, 2008, AIDS RES HUM RETROV, V24, P935, DOI 10.1089/aid.2008.0069
   Zwahlen M, 2009, INT J EPIDEMIOL, V38, P1624, DOI 10.1093/ije/dyp306
NR 25
TC 8
Z9 8
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2015
VL 2015
AR 174215
DI 10.1155/2015/174215
PG 6
WC Immunology
SC Immunology
GA CQ3FJ
UT WOS:000360487000001
PM 26355305
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Vendruscolo, O
   Majdalani, M
   Mota, R
   Luz, E
   Brites, C
AF Vendruscolo, Ornela
   Majdalani, Mateus
   Mota, Rafael
   Luz, Estela
   Brites, Carlos
TI Frequency of adverse events associated to antiretroviral drugs in
   patients starting therapy in Salvador, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
C1 [Vendruscolo, Ornela; Majdalani, Mateus; Mota, Rafael] Univ Fed Bahia, Fac Med, UFBA, BR-41170290 Salvador, BA, Brazil.
   [Luz, Estela; Brites, Carlos] Clin Hosp Salvador, Infect Dis Res Lab, Salvador, BA, Brazil.
RP Vendruscolo, O (corresponding author), Univ Fed Bahia, Infectol, Praca 15 Novembro S-N, BR-40025010 Salvador, BA, Brazil.
EM ornelacamille@hotmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Elzi L, 2010, ARCH INTERN MED, V170, P57, DOI 10.1001/archinternmed.2009.432
   Hanif H, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-574
   Prosperi MCF, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-296
NR 3
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2015
VL 19
IS 1
BP 108
EP 109
DI 10.1016/j.bjid.2014.09.008
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE9MS
UT WOS:000352168700023
PM 25527110
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Pimentel, A
   O'Hara, A
   de Lima, R
   Xu, SY
   Toomey, N
   Brites, C
   Fan, YS
   Ramos, JC
AF Pimentel, Agustin
   O'Hara, Andrea
   de Lima, Rosangela
   Xu, Suying
   Toomey, Ngoc
   Brites, Carlos
   Fan, Yao-Shan
   Ramos, Juan Carlos
TI Distinct Patterns of Genomic Alterations in Adult T-Cell
   Leukemia-Lymphoma Endemic in the Western World
SO BLOOD
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2014
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Pimentel, Agustin] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [O'Hara, Andrea] BioDiscovery Inc, Hawthorne, CA USA.
   [de Lima, Rosangela; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
   [Xu, Suying; Fan, Yao-Shan] Univ Miami, Miami, FL USA.
   [Toomey, Ngoc; Ramos, Juan Carlos] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 6
PY 2014
VL 124
IS 21
PG 3
WC Hematology
SC Hematology
GA CA9HU
UT WOS:000349233801030
DA 2020-12-01
ER

PT J
AU Soares, CMPD
   Vergara, TRC
   Brites, C
   Brito, JDU
   Grinberg, G
   Caseiro, MM
   Correa, C
   Suffert, TA
   Pereira, FR
   Camargo, M
   Janini, LM
   Komninakis, S
   Sucupira, MCA
   Diaz, RS
AF de Moraes Soares, Celina M. P.
   Vergara, Tania R. C.
   Brites, Carlos
   Brito, Jose D. U.
   Grinberg, Gorki
   Caseiro, Marcos M.
   Correa, Carlos
   Suffert, Theodoro A.
   Pereira, Flavio R.
   Camargo, Michelle
   Janini, Luiz M.
   Komninakis, Shirley
   Sucupira, Maria C. A.
   Diaz, Ricardo S.
TI Prevalence of transmitted HIV-1 antiretroviral resistance among patients
   initiating antiretroviral therapy in Brazil: a surveillance study using
   dried blood spots
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE transmitted drug resistance; dried blood spots; Brazil; genotyping;
   antiretroviral therapy; HIV subtype
ID RIO-DE-JANEIRO; IMMUNODEFICIENCY-VIRUS TYPE-1; TREATMENT-NAIVE PATIENTS;
   PRIMARY DRUG-RESISTANCE; SAO-PAULO; INFECTED INDIVIDUALS; MODERATE
   PREVALENCE; GENETIC DIVERSITY; SUBTYPES B; MUTATIONS
AB Introduction: In Brazil, the use of antiretrovirals is widespread: more than 260,000 individuals are currently undergoing treatment. We conducted a survey targeting antiretroviral-naive individuals who were initiating antiretroviral therapy (ART) according to local guidelines. This survey covered five Brazilian regions.
   Methods: The HIV Threshold Survey methodology (HIV-THS) of the World Health Organization was utilized, and subjects were selected from seven highly populated cities representative of all Brazilian macro-regions. Dried blood spots (DBS) were collected on SS903 collection cards and were transported by regular mail at room temperature to a single central laboratory for genotyping.
   Results: We analysed samples from 329 individuals initiating highly active antiretroviral therapy (HAART), 39 (11.8%) of whom were harbouring transmitted drug resistance (TDR). The mean CD4+ T cell count was 253 cells/mu L, and the mean viral load was 142,044 copies/mL. The regional prevalence of resistance was 17.0% in the Northeast, 12.8% in the Southeast, 10.6% in the Central region, 8.5% in the North and 8.5% in the South. The inhibitor-specific TDR prevalence was 6.9% for nucleoside reverse transcriptase inhibitors, 4.9% for non-nucleoside reverse transcriptase inhibitors and 3.9% for protease inhibitors; 3.6% of individuals presented resistance to more than one class of inhibitors. Overall, there were trends towards higher prevalences of subtype C towards the South and subtype F towards the North. Of the DBS samples collected, 9.3% failed to provide reliable results.
   Discussion: We identified variable TDR prevalence, ranging from intermediate to high levels, among individuals in whom HIV disease progressed, thus implying that resistance testing before initiating ART could be effective in Brazil. Our results also indicate that the use of DBS might be especially valuable for providing access to testing in resource-limited and remote settings.
C1 [de Moraes Soares, Celina M. P.; Vergara, Tania R. C.; Grinberg, Gorki; Caseiro, Marcos M.; Camargo, Michelle; Janini, Luiz M.; Komninakis, Shirley; Sucupira, Maria C. A.; Diaz, Ricardo S.] Univ Fed Sao Paulo, Infect Dis Unit, Sao Paulo, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Virol Res Lab, Salvador, BA, Brazil.
   [Brito, Jose D. U.] Fed Dist Hosp Fdn, Brasilia, DF, Brazil.
   [Caseiro, Marcos M.; Komninakis, Shirley] Lusiada Univ, Mol Biol Lab, Santos, SP, Brazil.
   [Correa, Carlos] Municipal Itajai, Itajai, Brazil.
   [Suffert, Theodoro A.] Municipal Porto Alegre, Porto Alegre, RS, Brazil.
   [Pereira, Flavio R.] State Univ Amazonas, Div Infect Dis, Manaus, Amazonas, Brazil.
RP Diaz, RS (corresponding author), Univ Fed Sao Paulo, EPM, Retrovirol Lab, R Pedro De Toledo 669,6 Andar, BR-04039032 Sao Paulo, Brazil.
EM rsdiaz@catg.com.br
RI Komninakis, Shirley V/B-2915-2010; Brites, Carlos/D-1353-2013
OI Komninakis, Shirley V/0000-0001-7784-3418; Brites,
   Carlos/0000-0002-4673-6991; Janini, Luiz Mario/0000-0002-6186-6284
FU Abbott Brazil; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2007/54923-1]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [479957/2010-0]; PNPD/CAPESCAPES
   [2496/08]
FX This project has been funded in part with funds from Abbott Brazil,
   FAPESP (2007/54923-1), CNPq (479957/2010-0) and PNPD/CAPES (2496/08).
   The authors thank Jean Paulo Lopes Zukurov, MSc, for sequence
   phylogenetic analyses, and Luiz Henrique Gagliani, PhD, for organizing
   biological material from the city of Santos.
CR Alencar CS, 2013, JAIDS-J ACQ IMM DEF, V63, P387, DOI 10.1097/QAI.0b013e31828ff979
   Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079
   Arruda E, 2011, AIDS RES HUM RETROV, V27, P153, DOI 10.1089/aid.2010.0028
   Barbour JD, 2004, AIDS, V18, P1683, DOI 10.1097/01.aids.0000131391.91468.ff
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
   Bermudez-Aza EH, 2011, JAIDS-J ACQ IMM DEF, V57, pS186, DOI 10.1097/QAI.0b013e31821e9c36
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Calazans A, 2005, J INFECT DIS, V191, P1961, DOI 10.1086/430002
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   da Costa ZB, 2013, AIDS PATIENT CARE ST, V27, P439, DOI 10.1089/apc.2012.0448
   de Medeiros LB, 2006, MEM I OSWALDO CRUZ, V101, P845, DOI 10.1590/S0074-02762006000800004
   de Medeiros RM, 2011, J MED VIROL, V83, P1682, DOI 10.1002/jmv.22188
   Ferreira JLD, 2008, MEM I OSWALDO CRUZ, V103, P800, DOI 10.1590/S0074-02762008000800010
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   de Sa DJ, 2009, AIDS RES HUM RETROV, V25, P925, DOI 10.1089/aid.2009.0073
   Diaz RS, 2008, 17 INT AIDS C MEX AU
   Felsenstein J, 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Ferreira FGF, 2010, AIDS RES HUM RETROV, V26, P229, DOI 10.1089/aid.2009.0146
   Gagliani LH, 2011, AIDS RES HUM RETROV, V27, P251, DOI 10.1089/aid.2010.0150
   Garcia-Lerma JG, 2001, P NATL ACAD SCI USA, V98, P13907, DOI 10.1073/pnas.241300698
   Gaspareto KV, 2012, REV INST MED TROP SP, V54, P207, DOI 10.1590/S0036-46652012000400005
   Gonsalez CR, 2007, VIRUS RES, V129, P87, DOI 10.1016/j.virusres.2007.06.021
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Jain V, 2011, J INFECT DIS, V203, P1174, DOI 10.1093/infdis/jiq167
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Little SJ, 2008, J VIROL, V82, P5510, DOI 10.1128/JVI.02579-07
   LONGINI IM, 1991, J ACQ IMMUN DEF SYND, V4, P1141
   Munerato P, 2010, AIDS RES HUM RETROV, V26, P265, DOI 10.1089/aid.2009.0288
   Ocfemia MC, 2012, 19 C RETR OPP INF CR
   Parkin N, 2012, CLIN INFECT DIS, V54, pS273, DOI 10.1093/cid/cir982
   Ferreira JLP, 2013, ADV VIROL, V2013, DOI 10.1155/2013/878237
   Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
   Pfrimer IAH, 2013, AIDS RES HUM RETROV, V29, P205, DOI [10.1089/aid.2012.0012, 10.1089/AID.2012.0012]
   Pilotto JH, 2013, AIDS RES HUM RETROV, V29, P681, DOI [10.1089/aid.2011.0333, 10.1089/AID.2011.0333]
   Pires IL, 2004, J CLIN MICROBIOL, V42, P426, DOI 10.1128/JCM.42.1.426-430.2004
   Cavalcanti AMS, 2012, MEM I OSWALDO CRUZ, V107, P450, DOI 10.1590/S0074-02762012000400002
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Souza DCF, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-45
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Sucupira MCA, 2013, AIDS RES HUM RETROV, V29, P880, DOI [10.1089/AID.2012.0259, 10.1089/aid.2012.0259]
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Tupinambas U, 2013, MEM I O CRUZ, V108, P470
   Varella RB, 2007, J MED VIROL, V79, P1033, DOI 10.1002/jmv.20845
   Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009
   Violin M, 2004, AIDS, V18, P227, DOI 10.1097/00002030-200401230-00012
NR 49
TC 17
Z9 18
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD SEP 22
PY 2014
VL 17
AR 19042
DI 10.7448/IAS.17.1.19042
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AP4PL
UT WOS:000342060100001
PM 25249214
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Travassos, AG
   Xavier-Souza, E
   Neumayer, J
   Timbo, M
   Almeida, PM
   Pires, M
   Brites, C
AF Travassos, Ana Gabriela
   Xavier-Souza, Eveline
   Neumayer, Julia
   Timbo, Maiara
   Almeida, Patricia Maria
   Pires, Marcio
   Brites, Carlos
TI CERVICAL CELL CHANGES IN WOMEN LIVING WITH HIV IN THE NORTHEAST OF
   BRAZIL - IDENTIFYING THE TARGET GROUP FOR HPV
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Travassos, Ana Gabriela; Almeida, Patricia Maria; Pires, Marcio] CEDAP Reference Ctr IST HIV AIDS, Salvador, BA, Brazil.
   [Xavier-Souza, Eveline; Neumayer, Julia; Timbo, Maiara; Brites, Carlos] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   [Brites, Carlos] CNPq, Brasilia, DF, Brazil.
EM agtravassos@yahoo.com.br
RI Travassos, Ana Gabriela A/E-6809-2016
OI Travassos, Ana Gabriela A/0000-0001-9242-828X
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 166
BP S140
EP S140
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500499
DA 2020-12-01
ER

PT J
AU Grinsztejn, B
   De Castro, N
   Arnold, V
   Veloso, VG
   Morgado, M
   Pilotto, JH
   Brites, C
   Madruga, JV
   Barcellos, NT
   Santos, BR
   Vorsatz, C
   Fagard, C
   Santini-Oliveira, M
   Patey, O
   Delaugerre, C
   Chene, G
   Molina, JM
AF Grinsztejn, Beatriz
   De Castro, Nathalie
   Arnold, Vincent
   Veloso, Valdilea G.
   Morgado, Mariza
   Pilotto, Jose Henrique
   Brites, Carlos
   Madruga, Jose Valdez
   Barcellos, Nemora Tregnago
   Santos, Breno Riegel
   Vorsatz, Carla
   Fagard, Catherine
   Santini-Oliveira, Marina
   Patey, Olivier
   Delaugerre, Constance
   Chene, Genevieve
   Molina, Jean-Michel
CA ANRS 12 180 Reflate TB Study Grp
TI Raltegravir for the treatment of patients co-infected with HIV and
   tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2,
   non-comparative, open-label, randomised trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; ACTIVE TUBERCULOSIS; EFAVIRENZ; SAFETY;
   PHARMACOKINETICS; METAANALYSIS; INDIVIDUALS; PREVENTION; SETTINGS;
   EFFICACY
AB Background Concurrent treatment of HIV and tuberculosis is complicated by drug interactions. We explored the safety and efficacy of raltegravir as an alternative to efavirenz for patients co-infected with HIV and tuberculosis.
   Methods We did a multicentre, phase 2, non-comparative, open-label, randomised trial at eight sites in Brazil and France. Using a computer-generated randomisation sequence, we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis (aged >= 18 years with a plasma HIV RNA concentration of >1000 copies per mL) to receive raltegravir 400 mg twice a day, raltegravir 800 mg twice daily, or efavirenz 600 mg once daily plus tenofovir and lamivudine (1:1:1; stratified by country). Patients began study treatment after the start of tuberculosis treatment. The primary endpoint was virological suppression at 24 weeks (HIV RNA <50 copies per mL) in all patients who received at least one dose of study drug (modified intention-to-treat analysis). We recorded death, study drug discontinuation, and loss to follow-up as failures to achieve the primary endpoint. We assessed safety in all patients who received study drugs. This study is registered in ClinicalTrials.gov, number NCT00822315.
   Findings Between July 3, 2009, and June 6, 2011, we enrolled and randomly assigned treatment to 155 individuals; 153 (51 in each group) received at least one dose of the study drug and were included in the primary analysis. 133 patients (87%) completed follow-up at week 48. At week 24, virological suppression was achieved in 39 patients (76%, 95% CI 65-88) in the raltegravir 400 mg group, 40 patients (78%, 67-90) in the raltegravir 800 mg group, and 32 patients (63%, 49-76) in the efavirenz group. The adverse-event profile was much the same across the three groups. Three (6%) patients allocated to efavirenz and three (6%) patients allocated to raltegravir 800 mg twice daily discontinued the study drugs due to adverse events. Seven patients died during the study (one in the raltegravir 400 mg group, four in the raltegravir 800 mg group, and two in the efavirenz group): none of the deaths was deemed related to study treatment.
   Interpretation Raltegravir 400 mg twice daily might be an alternative to efavirenz for the treatment of patients co-infected with HIV and tuberculosis.
C1 [Grinsztejn, Beatriz; Veloso, Valdilea G.; Vorsatz, Carla; Santini-Oliveira, Marina] Fiocruz MS, Evandro Chagas Clin Res Inst, STD AIDS Clin Res Lab, Paris, France.
   [De Castro, Nathalie; Molina, Jean-Michel] Univ Paris 07, Sorbonne Paris Cite, INSERM, Dept Infect Dis,U941, F-75221 Paris 05, France.
   [Delaugerre, Constance] Hop St Louis, AP HP, Dept Virol, Paris, France.
   [Arnold, Vincent; Fagard, Catherine; Chene, Genevieve] Univ Bordeaux, ISPED, INSERM U897, Bordeaux, France.
   [Morgado, Mariza] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Dept DST AIDS, Rio De Janeiro, Brazil.
   [Brites, Carlos] Hosp Univ Prof Edgar Santos, Lab Pesquisa Doencas Infecciosas, Salvador, BA, Brazil.
   [Madruga, Jose Valdez] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Barcellos, Nemora Tregnago] Hosp Sanatorio Partenon, Hlth State Secretariat RS, Porto Alegre, RS, Brazil.
   [Santos, Breno Riegel] Hosp Nossa Senhora Conceicao, Serv Infectiol, Porto Alegre, RS, Brazil.
   [Patey, Olivier] Dept Internal & Trop Med, Villeneuve St Georges, France.
   [Chene, Genevieve] CHU Bordeaux, Pole Sante Publ, Serv Informat Med, Bordeaux, France.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin DST AIDS, Av Brasil,4365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI chene, genevieve/H-8665-2014; Pilotto, Jose Henrique/AAD-9773-2019;
   Anglaret, Xavier/F-7333-2013; Brites, Carlos/D-1353-2013
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Brites,
   Carlos/0000-0002-4673-6991; Anglaret, Xavier/0000-0003-3319-8423
FU ANRSANRSFrench National Research Agency (ANR); Brazilian HIV/AIDS
   Program-Ministry of Health
FX Findings from this study were presented at the XIX International AIDS
   Conference, (Washington USA; July 22-27, 2012) and at the 20th
   Conference on Retroviruses and Opportunistic Infections (Atlanta, GA,
   USA; March 3-6, 2013). This trial was funded by ANRS and the Brazilian
   HIV/AIDS Program-Ministry of Health. We thank the members of the
   independent data and safety monitoring committee (F Raffi [chair], J P
   Aboulker, D Descamps, B Durovni) and members of the events validation
   committee (G Breton, B Denis, S Wagner). We thank Merck Sharp
   Dohme-Chibret who donated raltegravir (F Durand, A De Jacquelot), and
   Gilead Sciences who donated tenofovir (A Jacob, P Petour, V Tilliet).
CR A'Hern RP, 2001, STAT MED, V20, P859, DOI 10.1002/sim.721
   Agence Francaise de Recherche sur le SIDA et les Hepatites Virales, 2008, 2008 ANRS SCAL GRAD
   Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Bonnet M, 2013, LANCET INFECT DIS, V13, P303, DOI 10.1016/S1473-3099(13)70007-0
   Burger DM, 2010, AIDS, V24, P328, DOI 10.1097/QAD.0b013e3283350f08
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Ford N, 2010, AIDS, V24, P1461, DOI 10.1097/QAD.0b013e32833a2a14
   Gervasoni C, 2013, CLIN INFECT DIS, V57, P480, DOI 10.1093/cid/cit258
   Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   Khan FA, 2012, CLIN INFECT DIS, V55, P1154, DOI 10.1093/cid/cis630
   Lawn SD, 2010, LANCET INFECT DIS, V10, P489, DOI 10.1016/S1473-3099(10)70078-5
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1
   Mena A, 2011, J ANTIMICROB CHEMOTH, V66, P951, DOI 10.1093/jac/dkq540
   Rockstroh JK, 2013, JAIDS-J ACQ IMM DEF, V63, P77, DOI 10.1097/QAI.0b013e31828ace69
   Sauvageon H, 2013, 20 C RETR OPP INF AT
   Scourfield A, 2012, AIDS, V26, P1399, DOI 10.1097/QAD.0b013e328353b047
   Sibiude J, 2013, C RETR OPP INF ATL G
   Wenning LA, 2009, ANTIMICROB AGENTS CH, V53, P2852, DOI 10.1128/AAC.01468-08
   WHO, TUB CAR TB HIV COM I
   World Health Organization, HIV AIDS PROGR CONS
NR 23
TC 53
Z9 53
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUN
PY 2014
VL 14
IS 6
BP 459
EP 467
DI 10.1016/S1473-3099(14)70711-X
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA AH8UW
UT WOS:000336414700017
PM 24726095
DA 2020-12-01
ER

PT J
AU Grangeiro, A
   Escuder, MM
   Cassanote, AJF
   Souza, RA
   Kalichman, AO
   Veloso, V
   Ikeda, MLR
   Barcellos, NT
   Brites, C
   Tupinanbas, U
   Lucena, NO
   da Silva, CL
   Lacerda, HR
   Grinsztejn, B
   Castilho, EA
AF Grangeiro, Alexandre
   Escuder, Maria Mercedes
   Flores Cassanote, Alex Jones
   Souza, Rosa Alencar
   Kalichman, Artur O.
   Veloso, Valdilea
   Rodrigues Ikeda, Maria Leticia
   Barcellos, Nemora Tregnago
   Brites, Carlos
   Tupinanbas, Unai
   Lucena, Noaldo O.
   da Silva, Carlos Lima
   Lacerda, Heloisa Ramos
   Grinsztejn, Beatriz
   Castilho, Euclides Ayres
TI The HIV-Brazil Cohort Study: Design, Methods and Participant
   Characteristics
SO PLOS ONE
LA English
DT Article
ID RIO-DE-JANEIRO; ANTIRETROVIRAL TREATMENT; UNIVERSAL ACCESS;
   DRUG-RESISTANCE; AIDS TREATMENT; SURVIVAL; HIV/AIDS; INDIVIDUALS;
   CHALLENGES; DEATH
AB Background: The HIV-Brazil Cohort Study was established to analyze the effectiveness of combination antiretroviral therapy (cART) and the impact of this treatment on morbidity, quality of life (QOL) and mortality. The study design, patients' profiles and characteristics of cART initiation between 2003 and 2010 were described.
   Methodology/Principal Findings: Since 2003, the HIV-Brazil Cohort has been following HIV-infected adults receiving cART at 26 public health care facilities, using routine clinical care data and self-reported QOL questionnaires. When not otherwise available, data are obtained from national information systems. The main outcomes of interest are diseases related or unrelated to HIV; suppression of viral replication; adverse events; virological, clinical and immunological failures; changes in the cART; and mortality. For the 5,061 patients who started cART between 2003 and 2010, the median follow-up time was 4.1 years (IQR 2.2-5.9 years) with an 83.4% retention rate. Patient profiles were characterized by a predominance of men (male/female ratio 1.7:1), with a mean age of 36.9 years (SD 9.9 years); 55.2% had been infected with HIV via heterosexual contact. The majority of patients (53.4%) initiated cART with a CD4(+) T-cell count <= 200 cells/mm(3). The medications most often used in the various treatment regimens were efavirenz (59.7%) and lopinavir/ritonavir (18.2%). The proportion of individuals achieving viral suppression within the first 12 months of cART use was 77.4% (95% CI 76.1-78.6). Nearly half (45.4%) of the patients presented HIV-related clinical manifestations after starting cART, and the AIDS mortality rate was 13.9 per 1,000 person-years.
   Conclusions/Significance: Results from cART use in the daily practice of health services remain relatively unknown in low- and middle-income countries, and studies with the characteristics of the HIV-Brazil Cohort contribute to minimizing these shortcomings, given its scope and patient profile, which is similar to that of the AIDS epidemic in the country.
C1 [Grangeiro, Alexandre; Castilho, Euclides Ayres] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
   [Escuder, Maria Mercedes] Sao Paulo State Dept Hlth, Hlth Inst, Sao Paulo, Brazil.
   [Flores Cassanote, Alex Jones] Univ Sao Paulo, Sch Med, Postgrad Program Infect & Parasit Dis, Sao Paulo, Brazil.
   [Souza, Rosa Alencar; Kalichman, Artur O.] Sao Paulo State Dept Hlth, STD AIDS Referral & Training Ctr, Sao Paulo, Brazil.
   [Veloso, Valdilea; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Rodrigues Ikeda, Maria Leticia; Barcellos, Nemora Tregnago] Rio Grande do Sul State Dept Hlth, Care & Treatment Clin Partenon Sanat, Porto Alegre, RS, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil.
   [Tupinanbas, Unai] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil.
   [Lucena, Noaldo O.] Amazonas State Dept Hlth, Trop Med Fdn, Manaus, Amazonas, Brazil.
   [da Silva, Carlos Lima] Bahia State Dept Hlth, State Ctr Diag Treatment & Res, Salvador, BA, Brazil.
   [Lacerda, Heloisa Ramos] Univ Fed Pernambuco, Recife, PE, Brazil.
RP Grangeiro, A (corresponding author), Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
EM ale.grangeiro@gmail.com
RI Brites, Carlos/D-1353-2013; DE CASTILHO, EUCLIDES AYRES/K-7906-2016
OI Brites, Carlos/0000-0002-4673-6991; ikeda, maria
   leticia/0000-0002-2727-2298; Castilho, Euclides/0000-0002-7352-8784
FU Brazilian National Council for Scientific and Technological
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq); Brazilian National Ministry of Health; Pan American Health
   Organization; STD/AIDS Referral and Training Centre of the Sao Paulo
   State Department of Health; Evandro Chagas Clinical Research Institute
   of the Oswaldo Cruz Foundation
FX The study is funded by the Brazilian National Council for Scientific and
   Technological Development, the Brazilian National Ministry of Health,
   the Pan American Health Organization, the STD/AIDS Referral and Training
   Centre of the Sao Paulo State Department of Health and the Evandro
   Chagas Clinical Research Institute of the Oswaldo Cruz Foundation. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alencastro PR, 2011, AIDS PATIENT CARE ST, V25, P627, DOI 10.1089/apc.2010.0360
   Silva ACAL, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/186850
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   Veras MADM, 2011, CAD SAUDE PUBLICA, V27, pS104, DOI 10.1590/S0102-311X2011001300011
   Grangeiro A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014585
   Greco DB, 2007, AIDS, V21, pS37, DOI 10.1097/01.aids.0000279705.24428.a3
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Guibu IA, 2011, CAD SAUDE PUBLICA, V27, pS79, DOI 10.1590/S0102-311X2011001300009
   Hacker MA, 2007, CAD SAUDE PUBLICA, V23, pS345, DOI 10.1590/S0102-311X2007001500003
   Hofer CB, 2004, JAIDS-J ACQ IMM DEF, V36, P967, DOI 10.1097/00126334-200408010-00011
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Rezende ELLF, 2010, BRAZ J INFECT DIS, V14, P558, DOI [10.1590/S1413-86702010000600003, 10.1016/S1413-8670(10)70112-4]
   Malta M, 2009, JAIDS-J ACQ IMM DEF, V52, P629, DOI 10.1097/QAI.0b013e3181b31b8a
   Maruza M, 2012, INT J TUBERC LUNG D, V16, P618, DOI 10.5588/ijtld.11.0110
   Medeiros Roseane, 2002, Braz J Infect Dis, V6, P298, DOI 10.1590/S1413-86702002000600005
   Miranda A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000826
   Nunn AS, 2009, HEALTH AFFAIR, V28, P1103, DOI 10.1377/hlthaff.28.4.1103
   Okie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Portela MC, 2006, REV SAUDE PUBL, V40, P70, DOI 10.1590/S0034-89102006000800010
   Ribeiro FA, 2012, BRAZ J INFECT DIS, V16, P27, DOI 10.1590/S1413-86702012000100005
   Soares MA, 2004, AIDS, V18, pS9, DOI 10.1097/00002030-200406003-00003
   Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002
   Torres TS, 2013, BRAZ J INFECT DIS, V17, P324, DOI 10.1016/j.bjid.2012.10.024
NR 24
TC 21
Z9 21
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2014
VL 9
IS 5
AR e95673
DI 10.1371/journal.pone.0095673
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG6EE
UT WOS:000335510600046
PM 24789106
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Silva, RD
   Siqueira, MAM
   Netto, EM
   Bastos, JS
   Nascimento-Carvalho, CM
   Vilas-Boas, AL
   Bouzas, ML
   Motta, FD
   Brites, C
AF Silva, Rosangela de Castro
   Mendonca Siqueira, Marilda Agudo
   Netto, Eduardo Martins
   Bastos, Jacione Silva
   Nascimento-Carvalho, Cristiana Maria
   Vilas-Boas, Ana Luisa
   Bouzas, Maiara Lana
   Motta, Fernando do Couto
   Brites, Carlos
TI Epidemiological aspects of influenza A related to climatic conditions
   during and after a pandemic period in the city of Salvador, northeastern
   Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE influenza; A(H1N1)pdm09; children; epidemiology; seasonality; climate
ID VITAMIN-D; TRANSMISSION; H1N1; SEASONALITY; INFECTIONS; EPIDEMICS;
   VIRUS; WAVE
AB During the influenza pandemic of 2009, the A(H1N1)pdm09, A/H3N2 seasonal and influenza B viruses were observed to be co-circulating with other respiratory viruses. To observe the epidemiological pattern of the influenza virus between May 2009-August 2011, 467 nasopharyngeal aspirates were collected from children less than five years of age in the city of Salvador. In addition, data on weather conditions were obtained. Indirect immunofluorescence, real-time transcription reverse polymerase chain reaction (RT-PCR), and sequencing assays were performed for influenza virus detection. Of all 467 samples, 34 (7%) specimens were positive for influenza A and of these, viral characterisation identified Flu A/H3N2 in 25/34 (74%) and A(H1N1) pdm09 in 9/34 (26%). Influenza B accounted for a small proportion (0.8%) and the other respiratory viruses for 27.2% (127/467). No deaths were registered and no pattern of seasonality or expected climatic conditions could be established. These observations are important for predicting the evolution of epidemics and in implementing future anti-pandemic measures.
C1 [Silva, Rosangela de Castro; Netto, Eduardo Martins; Bastos, Jacione Silva; Brites, Carlos] Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Fac Med Bahia, Dept Pediat, Salvador, BA, Brazil.
   [Vilas-Boas, Ana Luisa; Bouzas, Maiara Lana] Univ Fed Bahia, Programa Posgrad Ciencias Saude, Salvador, BA, Brazil.
   [Mendonca Siqueira, Marilda Agudo; Motta, Fernando do Couto] Fiocruz MS, Inst Oswaldo Cruz, Lab Virus Resp & Influenza, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Silva, RD (corresponding author), Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
EM rosangel@ufba.br
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
FU FAPESB [159/2007]
FX Financial support: FAPESB (159/2007)
CR Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716
   Alonso WJ, 2007, AM J EPIDEMIOL, V165, P1434, DOI 10.1093/aje/kwm012
   Amato-Gauci A, 2011, EURO SURVEILL, V16, P19903
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P481
   Watanabe ASA, 2011, BRAZ J INFECT DIS, V15, P220, DOI [10.1590/S1413-86702011000300007, 10.1016/S1413-8670(11)70179-9]
   Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
   Bellei N, 2007, BRAZ J INFECT DIS, V11, P399, DOI 10.1590/S1413-86702007000400005
   Brankston G, 2007, LANCET INFECT DIS, V7, P257, DOI 10.1016/S1473-3099(07)70029-4
   Chowell G, 2010, P ROY SOC B-BIOL SCI, V277, P1857, DOI 10.1098/rspb.2009.1897
   Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Dowse GK, 2011, MED J AUSTRALIA, V194, P68, DOI 10.5694/j.1326-5377.2011.tb04170.x
   Peters BSE, 2009, ANN NUTR METAB, V54, P15, DOI 10.1159/000199454
   Iskander M, 2007, CURR OPIN INFECT DIS, V20, P259, DOI 10.1097/QCO.0b013e3280ad4687
   Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673
   Mello WA, 2009, PLOS ONE, V4, P1
   Moura FEA, 2009, AM J TROP MED HYG, V81, P180, DOI 10.4269/ajtmh.2009.81.180
   MS - Ministerio da Saude-Brasil, 2012, INF TECN INFL 2012
   Neuzil KM, 2002, ARCH PEDIAT ADOL MED, V156, P986, DOI 10.1001/archpedi.156.10.986
   OLIVEIRA WK, 2009, EURO SURVEILL, V14
   Sagripanti JL, 2007, PHOTOCHEM PHOTOBIOL, V83, P1278, DOI 10.1111/j.1751-1097.2007.00177.x
   Schout D, 2009, CLINICS, V64, P1025, DOI 10.1590/S1807-59322009001000014
   Shaman J, 2009, P NATL ACAD SCI USA, V106, P3243, DOI 10.1073/pnas.0806852106
   Simonsen L, 2011, BIRKHAUSER ADV INFEC, P27, DOI 10.1007/978-3-0346-0279-2_2
   Steel J, 2011, J VIROL, V85, P1400, DOI 10.1128/JVI.02186-10
   Straliotto Selir M., 2002, Rev. Soc. Bras. Med. Trop., V35, P283, DOI 10.1590/S0037-86822002000400002
   SUVISA/DIVEP - Superintendencia de Vigilancia e Protecao da Saude/Secretaria de Saude do Estado da Bahia, 2012, B INFL BAH 2012
   Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426
   Viboud C, 2004, EUR J EPIDEMIOL, V19, P1055, DOI 10.1007/s10654-004-2450-9
   Viboud C, 2006, PLOS MED, V3, P468, DOI 10.1371/journal.pmed.0030089
   Vidal LRR, 2008, MEM I OSWALDO CRUZ, V103, P180, DOI 10.1590/S0074-02762008000200009
   WHO/CDC - World Health Organization/Center for Disease Control and Prevention, 2009, CDC PROT REAL TIM RT
   WHO - World Health Organization, 2011, STAND TERM PAND H1N1
   WHO - World Health Organization, 2009, GLOB INFL SURV NETW
   World Health Organization, 2009, CLIN MAN HUM INF PAN
   World Health Organization Global Influenza Surveillance Network-WHO GISN, 2011, MAN LAB DIAGN VIR SU
   World Health Organization (WHO), 2009, SEQ PRIM PROT
NR 36
TC 6
Z9 6
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD APR
PY 2014
VL 109
IS 2
BP 229
EP 235
DI 10.1590/0074-0276140273
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AJ7VQ
UT WOS:000337908500014
PM 24714967
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Alves, MD
   Brites, C
   Sprinz, E
AF Alves, Marcelle D.
   Brites, Carlos
   Sprinz, Eduardo
TI HIV-associated lipodystrophy: a review from a Brazilian perspective
SO THERAPEUTICS AND CLINICAL RISK MANAGEMENT
LA English
DT Review
DE lipoatrophy; lipodystrophy; lipohypertrophy; HAART; dyslipidemia; Brazil
ID PLACEBO-CONTROLLED TRIAL; ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED
   CONTROLLED-TRIAL; ABDOMINAL FAT ACCUMULATION; HORMONE-RELEASING FACTOR;
   WOMENS INTERAGENCY HIV; INFECTED PATIENTS; GROWTH-HORMONE;
   MYOCARDIAL-INFARCTION; PROTEASE INHIBITORS
AB The prognosis of human immunodeficiency virus (HIV)-infected individuals has dramatically improved worldwide since the introduction of highly antiretroviral therapy. -Nevertheless, along with the decrease in mortality, several body modifications not initially related to HIV infection have been reported. Disorders in lipid and glucose metabolism, accompanied by body shape abnormalities and alterations in fat distribution, began to be described. A syndrome, named "HIV-associated lipodystrophy syndrome", was coined to classify these clinical spectrum aspects. This syndrome involves not only metabolic alterations but also fat redistribution, with lipoatrophy due to subcutaneous fat loss (predominantly in the face and lower limbs) and lipohypertrophy related to central fat gain. These changes in body shape are very important to be recognized, as they are associated with worse morbidity and mortality. Self-esteem difficulties related to body alterations might lead to treatment failures due to medication adherence problems. Moreover, these alterations have been associated with an increased risk of cardiovascular events. Therefore, it is extremely important to identify this syndrome early in order to provide an even better quality of life for this population, as the clinical approach is not easy. Treatment change, medications to treat dyslipidemia, and surgical intervention are instruments to be used to try to correct these abnormalities. The aim of this study is to review clinical presentation, diagnosis, and management of body shape and metabolic complications of HIV infection from a Brazilian perspective, a medium income country with a large number of patients on antiretroviral therapy.
C1 [Alves, Marcelle D.; Sprinz, Eduardo] Hosp Clin Porto Alegre, Dept Infect Dis, BR-90035003 Porto Alegre, RS, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Sprinz, Eduardo] Univ Fed Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil.
RP Sprinz, E (corresponding author), Hosp Clin Porto Alegre, Rua Ramiro Barcelos 2350,Sala 700, BR-90035003 Porto Alegre, RS, Brazil.
EM eduardo.sprinz@gmail.com
RI sprinz, eduardo/V-7961-2019; Brites, Carlos/D-1353-2013
OI sprinz, eduardo/0000-0003-4343-8304; Brites, Carlos/0000-0002-4673-6991
CR [Anonymous], 2011, SINDR LIP HIV
   Bacchetti P, 2005, JAIDS-J ACQ IMM DEF, V40, P121
   Bacchetti P, 2006, JAIDS-J ACQ IMM DEF, V42, P562
   Bhasin S, 2007, J CLIN ENDOCR METAB, V92, P1049, DOI 10.1210/jc.2006-2060
   Brown TT, 2007, AIDS, V21, P1731, DOI 10.1097/QAD.0b013e328270356a
   Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207
   Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6
   Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003
   Carr A, 2004, LANCET, V363, P429, DOI 10.1016/S0140-6736(04)15489-5
   Ceccato MGB, 2011, BRAZ J MED BIOL RES, V44, P1177, DOI [10.1590/S0100-879X2011007500129, 10.1590/S0100-879X2011001100015]
   Currier JS, 2003, JAIDS-J ACQ IMM DEF, V33, P506, DOI 10.1097/00126334-200308010-00012
   Currier Judith S, 2008, Circulation, V118, pe29, DOI 10.1161/CIRCULATIONAHA.107.189624
   de Waal R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063623
   dos Anjos EM, 2011, CLINICS, V66, P407, DOI 10.1590/S1807-59322011000300007
   Drechsler H, 2002, CLIN INFECT DIS, V35, P1219, DOI 10.1086/343050
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Falutz J, 2007, NEW ENGL J MED, V357, P2359, DOI 10.1056/NEJMoa072375
   Falutz J, 2010, JAIDS-J ACQ IMM DEF, V53, P311, DOI 10.1097/QAI.0b013e3181cbdaff
   Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Galescu O, 2013, REV ENDOCR METAB DIS, V14, P133, DOI 10.1007/s11154-013-9247-7
   Gomes-Neto M, 2013, CLINICS, V68, P1157, DOI 10.6061/clinics/2013(08)16
   Gosuen GC, 2012, AIDS RES HUM RETROV, V28, P747, DOI [10.1089/aid.2011.0292, 10.1089/AID.2011.0292]
   Grunfeld C, 2007, JAIDS-J ACQ IMM DEF, V45, P286
   Guaraldi G, 2013, JAIDS-J ACQ IMM DEF, V64, P360, DOI 10.1097/QAI.0000000000000001
   Hadigan C, 2004, ANN INTERN MED, V140, P786, DOI 10.7326/0003-4819-140-10-200405180-00008
   Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472
   Haubrich RH, 2009, AIDS, V23, P1109, DOI 10.1097/QAD.0b013e32832b4377
   Heath KV, 2001, AIDS, V15, P231, DOI 10.1097/00002030-200101260-00013
   Hendricks KM, 2003, AM J CLIN NUTR, V78, P790
   Jacobson DL, 2005, CLIN INFECT DIS, V40, P1837, DOI 10.1086/430379
   Joly V, 2002, AIDS, V16, P2447, DOI 10.1097/00002030-200212060-00010
   Justman JE, 2008, JAIDS-J ACQ IMM DEF, V47, P312, DOI 10.1097/QAI.0b013e318162f597
   Kotler Donald P, 2003, AIDS Read, V13, pS5
   Kroll AF, 2012, ARQ BRAS ENDOCRINOL, V56, P137, DOI 10.1590/S0004-27302012000200007
   Lazzaretti RK, 2013, SCI WORLD J, DOI 10.1155/2013/608415
   Lazzaretti RK, 2012, J AM COLL CARDIOL, V59, P979, DOI 10.1016/j.jacc.2011.11.038
   Leitz G, 2000, AIDS, V14, P468, DOI 10.1097/00002030-200003100-00026
   Lo J, 2008, JAMA-J AM MED ASSOC, V300, P509, DOI 10.1001/jama.300.5.509
   Lohse N, 2007, J ANTIMICROB CHEMOTH, V60, P461, DOI 10.1093/jac/dkm241
   Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030-200305020-00005
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011
   Ministry of Health-Bureau of Health Surveillance-Department of STD, 2013, B EP AIDS DST AN 2
   Monnerat BZ, 2008, BRAZ J INFECT DIS, V12, P264, DOI 10.1590/S1413-86702008000400002
   Moyle GJ, 2006, AIDS, V20, P2043, DOI 10.1097/01.aids.0000247574.33998.03
   Mulligan K, 2006, JAIDS-J ACQ IMM DEF, V41, P590, DOI 10.1097/01.qai.0000214811.72916.67
   Mulligan K, 2005, JAIDS-J ACQ IMM DEF, V38, P18, DOI 10.1097/00126334-200501010-00004
   Mulligan K, 2007, P C RETR OPP INF FEB
   Nadarajah JT, 2012, CLIN INFECT DIS, V55, P1568, DOI 10.1093/cid/cis745
   Nagy GS, 2003, CLIN INFECT DIS, V36, P795, DOI 10.1086/367859
   Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761
   Ofotokun I, 2014, P C RETR OPP INF MAR
   Ogalha C, 2011, JAIDS-J ACQ IMM DEF, V57, pS179, DOI 10.1097/QAI.0b013e31821e9bca
   Orsi AT, 2011, INT J DERMATOL, V50, P1255, DOI 10.1111/j.1365-4632.2011.04926.x
   Palella FJ, 2004, CLIN INFECT DIS, V38, P903
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Roubenoff R, 1999, AIDS, V13, P1373, DOI 10.1097/00002030-199907300-00015
   Santos CP, 2005, AIDS, V19, pS14, DOI 10.1097/01.aids.0000191485.92285.c7
   Sax PE, 2004, JAIDS-J ACQ IMM DEF, V37, P1111, DOI 10.1097/01.qai.0000138420.38995.86
   Shikuma CM, 2007, JAIDS-J ACQ IMM DEF, V44, P540, DOI 10.1097/QAI.0b013e318031d5a0
   Slama L, 2008, ANTIVIR THER, V13, P67
   Sprinz E, 2010, BRAZ J INFECT DIS, V14, P575, DOI [10.1590/S1413-86702010000600006, 10.1016/S1413-8670(10)70115-X]
   Stanley TL, 2009, AIDS, V23, P1349, DOI 10.1097/QAD.0b013e32832ba904
   Sutinen J, 2005, CURR OPIN INFECT DIS, V18, P25, DOI 10.1097/00001432-200502000-00005
   Thoni GJ, 2002, DIABETES METAB, V28, P397
   Tien PC, 2003, JAIDS-J ACQ IMM DEF, V34, P461, DOI 10.1097/00126334-200312150-00003
   Tuboi SH, 2007, JAIDS-J ACQ IMM DEF, V45, P52, DOI 10.1097/QAI.0b013e318042e1c3
   Tungsiripat M, 2010, AIDS, V24, P1291, DOI 10.1097/QAD.0b013e328339e274
   Valantin MA, 2003, AIDS, V17, P2471, DOI 10.1097/00002030-200311210-00009
   Wohl DA, 2006, CLIN INFECT DIS, V43, P645, DOI 10.1086/507333
NR 71
TC 14
Z9 14
U1 0
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-203X
J9 THER CLIN RISK MANAG
JI Therap. Clin. Risk Manag.
PY 2014
VL 10
BP 559
EP 566
DI 10.2147/TCRM.S35075
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AM6SU
UT WOS:000339996000001
PM 25083134
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Timerman, A
   Brites, C
   Bicudo, E
   Grinbaum, RS
   Filho, RC
   Carrilho, CDM
   Bichels, A
   Barreto, T
AF Timerman, Artur
   Brites, Carlos
   Bicudo, Eliana
   Grinbaum, Renato S.
   Filho, Rubens Costa
   Carrilho, Claudia D. M.
   Bichels, Andre
   Barreto, Tania
TI Brazilian experience in EU-CORE: daptomycin registry and treatment of
   serious Gram-positive infections
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Daptomycin; Methicillin-resistant; Staphylococcus aureus; Bacteremia;
   Endocarditis; Skin diseases; Infectious
ID RESISTANT STAPHYLOCOCCUS-AUREUS; CLINICAL-EXPERIENCE; VANCOMYCIN;
   THERAPY; SAFETY; OSTEOMYELITIS; EFFICACY; EUROPE; AGENTS
AB Objectives: To collect data about non-controlled prescribing use of daptomycin and its impact among Brazilian patients with serious Gram positive bacterial infection, as well as the efficacy and safety outcomes.
   Materials and methods: This is a multi-center, retrospective, non-interventional registry (August 01, 2009 to June 30, 2011) to collect data on 120 patients (44 patients in the first year and 76 patients in the second year) who had received at least one dose of commercial daptomycin in Brazil for the treatment of serious Gram-positive bacterial infection.
   Results: Right-sided endocarditis (15.8%), complicated skin and soft tissue infections (cSSTI)wound (15.0%) and bacteremia-catheter-related (14.2%) were the most frequent primary infections; lung (21.7%) was the most common site for infection. Daptomycin was used empirically in 76 (63.3%) patients, and methicillin-resistant Staphylococcus aureus (MRSA) was the most common suspected pathogen (86.1%). 82.5% of the cultures were obtained prior to or shortly after initiation of daptomycin therapy. Staphylococcus spp. -coagulase negative, MRSA, and methicillin-susceptible S. aureus were the most frequently identified pathogens (23.8%, 23.8% and 12.5%, respectively). The most common daptomycin dose administered for bacteremia and cSSTI was 6 mg/kg (30.6%) and 4 mg/kg (51.7%), respectively. The median duration of inpatient daptomycin therapy was 14 days. Most patients (57.1%) did not receive daptomycin while in intensive care unit. Carbapenem (22.5%) was the most commonly used antibiotic concomitantly. The patients showed clinical improvement after two days (median) following the start of daptomycin therapy. The clinical success rate was 80.8% and the overall rate of treatment failure was 10.8%. The main reasons for daptomycin discontinuation were successful end of therapy (75.8%), switched therapy (11.7%), and treatment failure (4.2%). Daptomycin demonstrated a favorable safety and tolerability profile regardless of treatment duration.
   Conclusions: Daptomycin had a relevant role in the treatment of Gram-positive infections in the clinical practice setting in Brazil. (C) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Timerman, Artur] Hosp Edmundo Vasconcelos, Sao Paulo, Brazil.
   [Brites, Carlos] Hosp Espanhol, Salvador, BA, Brazil.
   [Bicudo, Eliana] Hosp Santa Lucia, Brasilia, DF, Brazil.
   [Grinbaum, Renato S.] Hosp Beneficiencia Portuguesa Sao Paulo, Sao Paulo, Brazil.
   [Filho, Rubens Costa] Pro Cardiaco Pronto Socorro Cardiol, Rio De Janeiro, Brazil.
   [Carrilho, Claudia D. M.] Univ Estadual Londrina, Univ Hosp, Londrina, PR USA.
   [Bichels, Andre; Barreto, Tania] Novartis Brasil, Sao Paulo, Brazil.
RP Timerman, A (corresponding author), Rua Borges Lagoa 1450, BR-04038905 Sao Paulo, Brazil.
EM artur.timerman@globo.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; COSTA FILHO,
   RUBENS/0000-0002-9725-3762
FU NovartisNovartis
FX This study was supported by a grant from Novartis.
CR Appleman MD, 2010, DIAGN MICR INFEC DIS, V66, P441, DOI 10.1016/j.diagmicrobio.2009.11.008
   Arbeit RD, 2004, CLIN INFECT DIS, V38, P1673, DOI 10.1086/420818
   Brown JE, 2012, ANN PHARMACOTHER, V46, P495, DOI 10.1345/aph.1Q490
   Byren I, 2012, ANTIMICROB AGENTS CH, V56, P5626, DOI 10.1128/AAC.00038-12
   Calfee DP, 2012, CURR OPIN INFECT DIS, V25, P385, DOI 10.1097/QCO.0b013e3283553441
   Cardone KE, 2011, CLIN J AM SOC NEPHRO, V6, P1081, DOI 10.2215/CJN.08510910
   Carratala Jordi, 2012, Enferm Infecc Microbiol Clin, V30 Suppl 1, P43, DOI 10.1016/S0213-005X(12)70071-X
   Chamberlain RS, 2009, SURGERY, V146, P316, DOI 10.1016/j.surg.2009.03.037
   DePestel DD, 2010, AM J GERIATR PHARMAC, V8, P551, DOI 10.1016/S1543-5946(10)80004-2
   Falcone M, 2009, EUR J INTERN MED, V20, P343, DOI 10.1016/j.ejim.2008.08.016
   Fowler VG, 2006, NEW ENGL J MED, V355, P653, DOI 10.1056/NEJMoa053783
   Gales AC, 2009, BRAZ J INFECT DIS, V13, P90, DOI 10.1590/S1413-86702009000200004
   Gallagher JC, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-133
   Gonzalez-Ruiz A, 2008, J CHEMOTHERAPY, V20, P531, DOI 10.1179/joc.2008.20.5.531
   Gonzalez-Ruiz A, 2011, J ANTIMICROB CHEMOTH, V66, P912, DOI 10.1093/jac/dkq528
   Larioza J, 2011, AM J MED SCI, V342, P486, DOI 10.1097/MAJ.0b013e31821e1e6b
   Moenster RP, 2012, CLIN THER, V34, P1521, DOI 10.1016/j.clinthera.2012.06.013
   Montejo Miguel, 2012, Enferm Infecc Microbiol Clin, V30 Suppl 1, P54, DOI 10.1016/S0213-005X(12)70073-3
   Mueller BA, 2011, PHARMACOTHERAPY, V31, P665, DOI 10.1592/phco.31.7.665
   Parra-Ruiz J, 2011, ENFERM INFEC MICR CL, V29, P425, DOI 10.1016/j.eimc.2011.02.012
   Picazo JJ, 2011, DIAGN MICR INFEC DIS, V70, P373, DOI 10.1016/j.diagmicrobio.2011.02.009
   Rolston Kenneth V I, 2010, Clin Adv Hematol Oncol, V8, P249
   Salavert Miguel, 2010, Med Clin (Barc), V135 Suppl 3, P36, DOI 10.1016/S0025-7753(10)70039-7
   Sarria Cepeda Cristina, 2012, Enferm Infecc Microbiol Clin, V30 Suppl 1, P38, DOI 10.1016/S0213-005X(12)70070-8
   Tiemersma EW, 2004, EMERG INFECT DIS, V10, P1627, DOI 10.3201/eid1009.040069
   Trampuz A, 2006, DRUGS, V66, P1089, DOI 10.2165/00003495-200666080-00005
   Utili R, 2012, J CHEMOTHERAPY, V24, P113, DOI 10.1179/1120009X12Z.00000000023
   White Beth, 2011, Infect Drug Resist, V4, P115, DOI 10.2147/IDR.S13808
NR 28
TC 3
Z9 6
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2013
VL 17
IS 6
BP 647
EP 653
DI 10.1016/j.bjid.2013.03.005
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 280QJ
UT WOS:000329045500004
PM 23916455
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Moreira, M
   Ramos, A
   Netto, EM
   Brites, C
AF Moreira, Marcia
   Ramos, Andre
   Netto, Eduardo M.
   Brites, Carlos
TI Characteristics of co-infections by HCV and HBV among Brazilian patients
   infected by HIV-1 and/or HTLV-1
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; HTLV-1; Coinfection; HCV; HBV; Brazil
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL LYMPHOTROPIC VIRUS; BLOOD-BORNE
   INFECTIONS; HEPATITIS-C; RISK; PREVALENCE; EPIDEMIOLOGY; TRENDS; IMPACT;
   WOMEN
AB Background: The human retroviruses HIV-1 and HTLV-1 share the routes of infection with hepatitis viruses B and C. Co-infection by these agents are a common event, but we have scarce knowledge on co-infection by two or more of these agents.
   Objective: To evaluate the characteristics and risk factors for co-infections by HBV and HCV in patients infected by HIV-1 or/and HTLV-1, in Salvador, Brazil.
   Methods: In a case-control study we evaluated patients followed in the AIDS and HTLV clinics of Federal University of Bahia Hospital. Clinical and epidemiological characteristics were reviewed, and patients were tested for the presence of serological markers of HBV and HCV infections. HCV-infected patients were tested by PCR to evaluate the presence of viremia.
   Results: A total of 200 HIV-1, 213 HTLV-1-infected, and 38 HIV-HTLV-co-infected individuals were included. HIV-infected patients were more likely to have had more sexual partners in the lifetime than other patients' groups. HIV-HTLV-co-infected subjects were predominantly male. Patients infected by HTLV or co-infected had a significantly higher frequency of previous syphilis or gonorrhea, while HIV infection was mainly associated with HPV infection. Co-infection was significantly associated to intravenous drug use (IVDU). HBV and/ or HCV markers were more frequently found among co-infected patients. HBV markers were more frequently detected among HIV-infected patients, while HCV was clearly associated with IVDU across all groups. AgHBs was strongly associated with co-infection by HIV-HTLV (OR = 22.03, 95% CI: 2.69-469.7), as well as confirmed HCV infection (p = 0.001). Concomitant HCV and HBV infection was also associated with retroviral co-infection. Patients infected by HTLV-1 had a lower chance of detectable HCV viremia (OR = 0.04, 95% CI: 0.002-0.85).
   Conclusions: Infection by HCV and/ or HBV is frequent among patients presenting retroviral infection, but risk factors and prevalence for each infection are distinct for each agent. Retroviral co-infection increases the risk of a positive AgHBs, but HTLV-1 infection seems to increase the likelihood of HCV spontaneous clearance. (C) 2013 Published by Elsevier Editora Ltda.
C1 [Moreira, Marcia; Ramos, Andre; Netto, Eduardo M.; Brites, Carlos] Univ Fed Bahia UFBA, Complexo Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Rua Augusto Viana,Sn 6 Andar, BR-40140480 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Abrahao MHN, 2012, AIDS RES HUM RETROV, V28, P806, DOI [10.1089/aid.2011.0192, 10.1089/AID.2011.0192]
   Bahia F, 2011, JAIDS-J ACQ IMM DEF, V57, pS202, DOI 10.1097/QAI.0b013e31821e9a1e
   Barth RE, 2010, INT J INFECT DIS, V14, pE1024, DOI 10.1016/j.ijid.2010.06.013
   Blattner W A, 1984, Princess Takamatsu Symp, V15, P93
   Brites C, 2011, BRAZ J INFECT DIS, V15, P6, DOI 10.1590/S1413-86702011000100002
   Brites C, 2009, AIDS REV, V11, P8
   Buskin SE, 2011, WORLD J GASTROENTERO, V17, P1807, DOI 10.3748/wjg.v17.i14.1807
   Chacko EC, 2010, POSTGRAD MED J, V86, P486, DOI 10.1136/pgmj.2009.092775
   ICHIMURA H, 1995, JPN INT J STD AIDS, V6, P441
   Kershenobich D, 2011, LIVER INT, V31, P18, DOI 10.1111/j.1478-3231.2011.02538.x
   Martins T, 2011, REV ASSOC MED BRAS, V57, P107, DOI 10.1590/S0104-42302011000100024
   de Lima LHM, 2009, CAD SAUDE PUBLICA, V25, P668, DOI 10.1590/S0102-311X2009000300021
   Miranda AE, 2008, AIDS BEHAV, V12, pS25, DOI 10.1007/s10461-008-9378-0
   Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0
   Nunes CLX, 2007, BRAZ J INFECT DIS, V11, P561, DOI 10.1590/S1413-86702007000600007
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Puoti Massimo, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P30, DOI 10.1177/1545109708330906
   RICO MJA, 1994, MED CLIN-BARCELONA, V102, P369
   Sobesky M, 2000, PRESSE MED, V29, P413
   Soriano V, 2011, ENFERM INFEC MICR CL, V29, P691, DOI 10.1016/j.eimc.2011.07.003
   Trenchi A, 2007, J MED VIROL, V79, P1974, DOI 10.1002/jmv.21027
   Zou SM, 2010, TRANSFUSION, V50, P1487, DOI 10.1111/j.1537-2995.2010.02621.x
NR 22
TC 12
Z9 12
U1 0
U2 5
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2013
VL 17
IS 6
BP 661
EP 666
DI 10.1016/j.bjid.2013.04.009
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 280QJ
UT WOS:000329045500007
PM 24029434
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Nobrega, I
   Travassos, AG
   Haguihara, T
   Amorim, F
   Brites, C
AF Nobrega, Isabella
   Travassos, Ana Gabriela
   Haguihara, Tatiana
   Amorim, Fabio
   Brites, Carlos
TI Short Communication: Use of Raltegravir in Late-Presenting HIV-Infected
   Pregnant Women
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID TO-CHILD-TRANSMISSION; VIRAL LOAD; TRANSPLACENTAL TRANSFER;
   ANTIRETROVIRAL THERAPY; PREVENTION; DECLINE
AB The risk of HIV-1 mother-to-child transmission (MTCT) is clearly correlated with the maternal HIV cell-free viral load (VL) at delivery. Preventing MTCT in late-presenting (after 28 weeks) HIV-infected pregnant women remains a clinical challenge, and ensuring a rapid decrease of maternal VL is an important preventive strategy. Raltegravir (RGV) has a higher first and second phase viral decay rate, has a high placental transfer, with a potential preloading effect for neonate, and demonstrates effective accumulation in cervicovaginal secretions. We report 14 cases in which RGV was used late in pregnancy for HIV-1 MTCT prophylaxis. All women were RGV naive and the prophylaxis regimens included RGV plus at least two other antiretroviral agents. At RGV initiation, the median gestational age was 36 weeks (range 34-38) and the median maternal plasma HIV-1 RNA viral load was 35,364 copies/ml (range 636-391,535). At delivery, the median gestational age was 38 weeks (range 37-40). The median exposure time to RGV was 17 days (range 7-32), with a mean maternal VL decay of 2.6 log. At delivery, seven women had undetectable (<50 copies/ml) VL, four had between 64 and 457 copies/ml, and in three VL was not available. All but one infant's HIV-RNA tests were negative at 1 and 3 months (one case of in utero MTCT). Raltegravir-containing antiretroviral regimens induced a rapid HIV-RNA decline in maternal VL at delivery, and were safe and effective in preventing MTCT for late-presenting, HIV-infected women.
C1 [Nobrega, Isabella; Travassos, Ana Gabriela; Haguihara, Tatiana] Ctr Estadual Especializado Diagnost Assistencia &, Salvador, BA, Brazil.
   [Amorim, Fabio] Maternidade Referencia Prof Jose Maria de Magalha, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Lab Pesquisas Infectol, Salvador, BA, Brazil.
RP Nobrega, I (corresponding author), Av Prof Sabino Silva,862,Jd Apipema, BR-40155250 Salvador, BA, Brazil.
EM isabellasal@gmail.com
RI Travassos, Ana Gabriela A/E-6809-2016; Brites, Carlos/D-1353-2013
OI Travassos, Ana Gabriela A/0000-0001-9242-828X; Brites,
   Carlos/0000-0002-4673-6991
CR Adams JL, 2012, CURR OPIN HIV AIDS, V7, P390, DOI 10.1097/COH.0b013e328356e91c
   Bailey A, 1999, AIDS, V13, P1377
   BRASIL. Ministerio da Saude, 2012, REC TER ANT AD VIV H
   BRASIL. Ministerio da Saude, 2010, REC PROF TRANSM VERT
   Gouveia PAD, 2013, TROP MED INT HEALTH, V18, P276, DOI 10.1111/tmi.12042
   de Lemos LMD, 2012, REV SOC BRAS MED TRO, V45, P682, DOI 10.1590/S0037-86822012000600005
   Else LJ, 2011, ANTIVIR THER, V16, P1149, DOI 10.3851/IMP1919
   European AIDS Clinical Society (EACS), GUID CLIN MAN TREATM
   Hegazi A, 2012, AIDS, V26, P2421, DOI 10.1097/QAD.0b013e32835a9aeb
   Jaworsky D, 2010, ANTIVIR THER, V15, P677, DOI 10.3851/IMP1558
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Mckeown DA, 2010, AIDS, V24, P2416, DOI 10.1097/QAD.0b013e32833d8a50
   Ministerio da Saude, 2012, B EP AIDS DST
   Nobrega I, 2012, AIDS RES HUM RETROV, V28, P233, DOI 10.1089/aid.2011.0165
   Pinnetti C, 2010, J ANTIMICROB CHEMOTH, V65, P2050, DOI 10.1093/jac/dkq264
   Read PJ, 2012, AIDS, V26, P1095, DOI 10.1097/QAD.0b013e3283536a6c
   Senise J.F., 2006, Braz J Infect Dis, V10, P259, DOI 10.1590/S1413-86702006000400009
   Taylor N, 2011, INT J STD AIDS, V22, P358, DOI 10.1258/ijsa.2011.010469
   Tubiana R, 2010, CLIN INFECT DIS, V50, P585, DOI 10.1086/650005
   Warszawski J, 2008, AIDS, V22, P289, DOI 10.1097/QAD.0b013e3282f3d63c
   Westling K, 2012, AIDS PATIENT CARE ST, V26, P714, DOI 10.1089/apc.2012.0283
NR 21
TC 19
Z9 19
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2013
VL 29
IS 11
SI SI
BP 1451
EP 1454
DI 10.1089/aid.2013.0059
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 239PI
UT WOS:000326037500506
PM 23731224
OA Green Published
DA 2020-12-01
ER

PT J
AU Neto, MG
   Zwirtes, R
   Brites, C
AF Gomes Neto, Mansueto
   Zwirtes, Ricardo
   Brites, Carlos
TI A literature review on cardiovascular risk in human immunodeficiency
   virus-infected patients: implications for clinical management
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Review
DE AIDS; Therapeutics; Highly active antiretroviral therapy; Cardiovascular
   diseases
ID INDIVIDUAL ANTIRETROVIRAL DRUGS; ACUTE MYOCARDIAL-INFARCTION;
   INTIMA-MEDIA THICKNESS; HIV-INFECTION; ENDOTHELIAL FUNCTION; ARTERIAL
   STIFFNESS; METABOLIC SYNDROME; THERAPY; DISEASE; ABACAVIR
AB Introduction: In recent years, there has been growing concern about an increasing rate of cardiovascular diseases in human immunodeficiency virus-infected patients, which could be associated with side effects of highly active antiretroviral therapy. It is likely that the metabolic disorders related to anti-human immunodeficiency virus treatment will eventually translate into a increased cardiovascular risk in patients submitted to such regimens. Objective: To evaluate if human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy are at higher risk of cardiovascular diseases than human immunodeficiency virus infected patients not receiving highly active antiretroviral therapy, or the general population.
   Research design and methods: We conducted a computer-based search in representative databases, and also performed manual tracking of citations in selected articles.
   Result: The available evidence suggests an excess risk of cardiovascular events in human immunodeficiency virus-infected persons compared to non-human immunodeficiency virus infected individuals. The use of highly active antiretroviral therapy is associated with increased levels of total cholesterol, triglycerides, low-density lipoprotein and morphological signs of cardiovascular diseases. Some evidence suggested that human immunodeficiency virus-infected individuals on highly active antiretroviral therapy regimens are at increased risk of dyslipidemia, ischemic heart disease, and myocardial infarction, particularly if the highly active antiretroviral therapy regimen contains a protease inhibitor.
   Conclusion: Physicians must weigh the cardiovascular risk against potential benefits when prescribing highly active antiretroviral therapy. Careful cardiac screening is warranted for patients who are being evaluated for, or who are receiving highly active antiretroviral therapy regimens, particularly for those with known underlying cardiovascular risk factors. A better understanding of the molecular mechanisms responsible for increased risk of cardiovascular diseases in human immunodeficiency virus-infected patients will lead to the discovery of new drugs that will reduce cardiovascular risk in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. (C) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Gomes Neto, Mansueto; Zwirtes, Ricardo; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
RP Neto, MG (corresponding author), Univ Fed Bahia UFBA, Rua Joao das Botas SN,6 Andar, BR-40110160 Salvador, BA, Brazil.
EM netofisio@gmail.com
RI Gomes-NETO, Mansueto MGN/I-5235-2014; Brites, Carlos/D-1353-2013
OI Gomes-NETO, Mansueto MGN/0000-0002-0717-9694; Brites,
   Carlos/0000-0002-4673-6991
CR Alvarez C, 2010, BRAZ J INFECT DIS, V14, P256, DOI 10.1590/S1413-86702010000300010
   Baker JV, 2009, CURR OPIN HIV AIDS, V4, P176, DOI 10.1097/COH.0b013e328329c62f
   Barbaro G, 2001, AM J EMERG MED, V19, P566, DOI 10.1053/ajem.2001.28323
   Barbaro G, 2009, REV ASSOC MED BRAS, V55, P621, DOI 10.1590/S0104-42302009000500031
   Brothers CH, 2009, JAIDS-J ACQ IMM DEF, V51, P20, DOI 10.1097/QAI.0b013e31819ff0e6
   Cahn P, 2010, BRAZ J INFECT DIS, V14, P158, DOI 10.1590/S1413-86702010000200008
   Cecchi Enrico, 2005, Ital Heart J, V6, P972
   Choi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16
   Ciccolo JT, 2004, SPORTS MED, V34, P487, DOI 10.2165/00007256-200434080-00001
   Coplan PM, 2003, AIDS RES HUM RETROV, V19, P449, DOI 10.1089/088922203766774487
   D'Agostino RB, 2012, J INFECT DIS, V205, pS362, DOI 10.1093/infdis/jis196
   Das S, 2010, J ANTIMICROB CHEMOTH, V65, P386, DOI 10.1093/jac/dkp460
   de Saint-Martin L, 2010, AIDS, V24, P2797, DOI 10.1097/QAD.0b013e328340a21f
   Ding X, 2012, J ACQUIR IMMUNE DEFI, V28
   Durand M, 2011, JAIDS-J ACQ IMM DEF, V57, P245, DOI 10.1097/QAI.0b013e31821d33a5
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
   Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010
   Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x
   Hulten E, 2009, HEART, V95, P1826, DOI 10.1136/hrt.2009.177774
   Iloeje UH, 2005, HIV MED, V6, P37, DOI 10.1111/j.1468-1293.2005.00265.x
   Kwiatkowska W, 2011, POSTEP HIG MED DOSW, V65, P770, DOI 10.5604/17322693.967075
   Lang S, 2010, ARCH INTERN MED, V170, P1228, DOI 10.1001/archinternmed.2010.197
   Llibre JM, 2006, AIDS, V20, P1407, DOI 10.1097/01.aids.0000233574.49220.de
   Lundgren JD, 2008, HIV MED, V9, P72, DOI 10.1111/j.1468-1293.2007.00534.x
   Lundgren JD, 2008, AIDS, V22, pF17, DOI 10.1097/QAD.0b013e32830fe35e
   Maggi P, 2009, AIDS PATIENT CARE ST, V23, P809, DOI 10.1089/apc.2009.0102
   Manfredi R, 2009, REV LATINOAM HIPERTE, V4, P86
   Martinez E, 2010, AIDS, V24, pF1, DOI 10.1097/QAD.0b013e32833562c5
   Masia M, 2007, CLIN THER, V29, P1448, DOI 10.1016/j.clinthera.2007.07.025
   McDonald CL, 2009, J AM COLL CARDIOL, V54, P1185, DOI 10.1016/j.jacc.2009.05.055
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   MORANO L, 2007, REV PANAM INFECTOL, V9, P39
   Murphy RL, 2010, AIDS, V24, P885, DOI 10.1097/QAD.0b013e3283352ed5
   Obel N, 2010, HIV MED, V11, P130, DOI 10.1111/j.1468-1293.2009.00751.x
   Obel N, 2007, CLIN INFECT DIS, V44, P1625, DOI 10.1086/518285
   da Silva EFR, 2009, ARQ BRAS CARDIOL, V93, P107
   Reinsch N, 2010, HIV CLIN TRIALS, V11, P156, DOI 10.1310/hct1103-156
   Rerkpattanapipat P, 2000, ARCH INTERN MED, V160, P602, DOI 10.1001/archinte.160.5.602
   Ribaudo HJ, 2011, CLIN INFECT DIS, V52, P929, DOI 10.1093/cid/ciq244
   Sabin CA, 2008, LANCET, V371, P1417, DOI 10.1016/S0140-6736(08)60423-7
   Saumoy M, 2011, ANTIVIR THER, V16, P459, DOI 10.3851/IMP1785
   Scevola D, 2003, AIDS, V17, pS123, DOI 10.1097/00002030-200304001-00015
   Stein JH, 2007, NEW ENGL J MED, V356, P1773, DOI 10.1056/NEJMe078037
   Stein JH, 2008, CIRCULATION, V118, pS1088
   Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5
   Stradling C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038121
   Subramanian S, 2012, JAMA-J AM MED ASSOC, V308, P379, DOI 10.1001/jama.2012.6698
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   van Vonderen MGA, 2009, J INFECT DIS, V199, P1186, DOI 10.1086/597475
   van Vonderen MGA, 2009, JAIDS-J ACQ IMM DEF, V50, P153, DOI 10.1097/QAI.0b013e31819367cd
   Velenzuela GR, 2007, REV MED HERED, V18, P10
   Wand H, 2007, AIDS, V21, P2445, DOI 10.1097/QAD.0b013e3282efad32
   Wierzbicki AS, 2008, CURR MED RES OPIN, V24, P609, DOI 10.1185/030079908X272742
   Wooten JS, 2013, MED SCI SPORTS EXERC
   Worm SW, 2011, AIDS, V25, P1497, DOI 10.1097/QAD.0b013e32834917c6
   Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897
NR 57
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2013
VL 17
IS 6
BP 691
EP 700
DI 10.1016/j.bjid.2013.05.004
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 280QJ
UT WOS:000329045500011
PM 23916459
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Torres, AJL
   Angelo, ALD
   Silva, MO
   Bastos, MD
   de Souza, DF
   Inocencio, LA
   de Lemos, JAR
   Junior, RS
   de Castro, AC
   Palma, PVB
   Ceci, L
   Netto, EM
   Brites, C
AF Leite Torres, Alex Jose
   Dias Angelo, Ana Luiza
   Silva, Marcio Oliveira
   Bastos, Milena de Carvalho
   de Souza, Denise Ferreira
   Inocencio, Lilian Amaral
   Rodrigues de Lemos, Jose Alexandre
   Junior, Ruy S.
   de Castro, Andrea Cauduro
   Bonnini Palma, Patricia Vianna
   Ceci, Loredana
   Netto, Eduardo Martins
   Brites, Carlos
TI ESTABLISHING THE REFERENCE RANGE FOR T LYMPHOCYTES SUBPOPULATIONS IN
   ADULTS AND CHILDREN FROM BRAZIL
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE CD4; CD8; Blood donors; Reference values; Brazil
ID PERIPHERAL-BLOOD; ANTIRETROVIRAL THERAPY; SUBSETS; COUNTS; VALUES;
   POPULATION; NUTRITION; INFECTION; IMMUNITY; CD4
AB In Brazil, the existing reference values for T-lymphocytes subsets are based on data originated in other countries. There is no local information on normal variation for these parameters in Brazilian adults and children. We evaluated the normal variation found in blood donors from five large Brazilian cities, in different regions, and in children living in Salvador, and Rio de Janeiro. All samples were processed by flow cytometry. The results were analyzed according to region, gender, and lifestyle of blood donors. A total of 641 adults (63% males), and 280 children (58% males) were involved in the study. The absolute CD3+, and CD4+ cells count were significantly higher for females (adults and children). Higher CD4+ cell count in adults was associated with smoking, while higher CD8+ count was found among female children. Higher counts, for all T-cells subsets, were detected in blood donors from southeast / south regions while those living in the northern region had the lowest values. Individuals from midwestern and northeastern regions had an intermediate count for all these cells subsets. However, these differences did not reach statistical significance. In Brazil, gender and smoking, were the main determinants of differences in T-lymphocytes reference values.
C1 [Leite Torres, Alex Jose; Dias Angelo, Ana Luiza; Silva, Marcio Oliveira; Bastos, Milena de Carvalho; Netto, Eduardo Martins; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
   [Rodrigues de Lemos, Jose Alexandre] Fed Univ Para, HEMOPA Fdn, Hematol & Hemotherapy Ctr State Para, BR-66059 Belem, Para, Brazil.
   [Ceci, Loredana] HSE Rio de Janeiro, Infect Dis Lab, Rio De Janeiro, RJ, Brazil.
RP Torres, AJL (corresponding author), Univ Fed Bahia, Salvador, BA, Brazil.
EM ajltorres@gmail.com
RI Brites, Carlos/D-1353-2013; Lemos, Jose Alexandre R/M-8753-2016; Netto,
   Eduardo/D-1432-2013; Torres, Alex JL/Q-6186-2018
OI Brites, Carlos/0000-0002-4673-6991; Lemos, Jose Alexandre
   R/0000-0002-7595-2597; Netto, Eduardo/0000-0003-1691-6761; 
FU AIDS and STD National Program from Brazilian Ministry of Healthy
FX AIDS and STD National Program from Brazilian Ministry of Healthy.
CR Anglaret X, 1997, J ACQ IMMUN DEF SYND, V14, P361, DOI 10.1097/00042560-199704010-00009
   Antoine T, 2005, ANGEW CHEM INT EDIT, V44, P1350, DOI 10.1002/anie.200461507
   Audu RA, 2007, EJSR, V16, P168
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Becton Dickinson Industrias Cirurgicas Ltda, 2006, MAN QUANT LINF T CD4, P88
   Bisset LR, 2004, EUR J HAEMATOL, V72, P203, DOI 10.1046/j.0902-4441.2003.00199.x
   BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x
   CEPAL. Comissao Economica para America Latina, 2008, EMPR DES HUM TRAB DE
   CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087
   DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P1484, DOI 10.1001/jama.267.11.1484
   Embree J, 2001, PEDIATR INFECT DIS J, V20, P397, DOI 10.1097/00006454-200104000-00006
   Fahey JL, 2000, MECH AGEING DEV, V115, P1, DOI 10.1016/S0047-6374(00)00094-4
   Feki S, 1998, DIS MARKERS, V14, P161, DOI 10.1155/1998/153450
   GILL GV, 1979, T ROY SOC TROP MED H, V73, P111, DOI 10.1016/0035-9203(79)90142-1
   Gray L, 2003, JAIDS-J ACQ IMM DEF, V33, P635
   Hussain Tajammal, 2004, Food and Nutrition Bulletin, V25, P114
   Instituto Brasileiro de Geografia e Estatistica, 2000, BRAS 500 AN POV
   Lee BW, 1996, CYTOMETRY, V26, P8, DOI 10.1002/(SICI)1097-0320(19960315)26:1<8::AID-CYTO2>3.0.CO;2-E
   Levin A, 1996, INT J STD AIDS, V7, P288, DOI 10.1258/0956462961917825
   Libamba E, 2005, INT J TUBERC LUNG D, V9, P1062
   Lisse IM, 1997, J PEDIATR-US, V130, P77, DOI 10.1016/S0022-3476(97)70313-5
   Maini MK, 1996, GENITOURIN MED, V72, P27
   Ndhlovua Z, 2004, J TROP PEDIATRICS, V50, P94, DOI 10.1093/tropej/50.2.94
   Njoku M O, 2003, Niger Postgrad Med J, V10, P135
   Roller M, 2004, J NUTR, V134, P153
   Santagostino A, 1999, HAEMATOLOGICA, V84, P499
   Saxena RK, 2004, CURR SCI INDIA, V86, P969
   Scrimshaw NS, 1997, AM J CLIN NUTR, V66, P464
   Siegel PD, 2004, J TOXICOL ENV HEAL A, V67, P221, DOI 10.1080/15287390490266891
   Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803
   TELLES Edward Eric, 2003, RACISMO BRASILEIRA N
   Torres AJL, 2009, BRAZ J INFECT DIS, V13, P221, DOI 10.1590/S1413-86702009000300013
   *UNAIDS, 2006, 2006 REP GLOB AIDS E
   World Health Organization, 2005, SCAL ANT THER RES LT
NR 34
TC 9
Z9 9
U1 0
U2 8
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD SEP-OCT
PY 2013
VL 55
IS 5
BP 323
EP 328
DI 10.1590/S0036-46652013000500005
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 219XN
UT WOS:000324545100005
PM 24037286
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cahn, P
   Pozniak, AL
   Mingrone, H
   Shuldyakov, A
   Brites, C
   Andrade-Villanueva, JF
   Richmond, G
   Buendia, CB
   Fourie, J
   Ramgopal, M
   Hagins, D
   Felizarta, F
   Madruga, J
   Reuter, T
   Newman, T
   Small, CB
   Lombaard, J
   Grinsztejn, B
   Dorey, D
   Underwood, M
   Griffith, S
   Min, S
AF Cahn, Pedro
   Pozniak, Anton L.
   Mingrone, Horacio
   Shuldyakov, Andrey
   Brites, Carlos
   Andrade-Villanueva, Jaime F.
   Richmond, Gary
   Beltran Buendia, Carlos
   Fourie, Jan
   Ramgopal, Moti
   Hagins, Debbie
   Felizarta, Franco
   Madruga, Jose
   Reuter, Tania
   Newman, Tamara
   Small, Catherine B.
   Lombaard, John
   Grinsztejn, Beatriz
   Dorey, David
   Underwood, Mark
   Griffith, Sandy
   Min, Sherene
CA Extended SAILING Study Team
TI Dolutegravir versus raltegravir in antiretroviral-experienced,
   integrase-inhibitor-naive adults with HIV: week 48 results from the
   randomised, double-blind, non-inferiority SAILING study
SO LANCET
LA English
DT Article
ID CO-FORMULATED ELVITEGRAVIR; INITIAL TREATMENT; CROSS-RESISTANCE;
   PHASE-II; INFECTION; TRIAL; PHARMACOKINETICS; EMTRICITABINE; COBICISTAT;
   EFAVIRENZ
AB Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance.
   Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1: 1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516.
   Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7.4%, 95% CI 0.7 to 14.2); superiority of dolutegravir versus raltegravir was then concluded (p=0.03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference -3.7%, 95% CI -6.1 to -1.2; p=0.003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir).
   Interpretation Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group.
C1 [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Pozniak, Anton L.] Chelsea & Westminster Hosp NHS Fdn Trust, London, England.
   [Mingrone, Horacio] Fdn IDEAA, Buenos Aires, DF, Argentina.
   [Shuldyakov, Andrey] Saratov Reg Ctr Prophylact AIDS, Saratov, Russia.
   [Brites, Carlos] Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Salvador, BA, Brazil.
   [Andrade-Villanueva, Jaime F.] Univ Guadalajara, Fray Antonio Alcalde CUCS, Hosp Civil Guadalajara, Guadalajara 44430, Jalisco, Mexico.
   [Richmond, Gary] Broward Hlth Med Ctr, Ft Lauderdale, FL USA.
   [Beltran Buendia, Carlos] Hosp Barros Luco, Santiago, Chile.
   [Fourie, Jan] Fourie Med Ctr, Dundee, South Africa.
   [Ramgopal, Moti] Midway Immunol & Res Ctr, Ft Pierce, FL USA.
   [Hagins, Debbie] Chatham CARE Ctr, Savannah, GA USA.
   [Madruga, Jose] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Reuter, Tania] Univ Fed Espirito Santo, Vitoria, Brazil.
   [Newman, Tamara] Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   [Small, Catherine B.] New York Med Coll, Valhalla, NY 10595 USA.
   [Lombaard, John] JOSHA Res, Bloemfontein, South Africa.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Dorey, David] GlaxoSmithKline, Mississauga, ON, Canada.
   [Underwood, Mark; Griffith, Sandy; Min, Sherene] GlaxoSmithKline, Res Triangle Pk, NC USA.
RP Cahn, P (corresponding author), Fdn Huesped, C1202ABB, Buenos Aires, DF, Argentina.
EM pcahn@huesped.org.ar
RI Rugina, Sorin/U-5168-2019; Streinu-Cercel, Adrian/M-5835-2017; Brites,
   Carlos/D-1353-2013; Shuldyakov, Andrey/U-5598-2017
OI Streinu-Cercel, Adrian/0000-0001-6382-5067; Brites,
   Carlos/0000-0002-4673-6991; Shuldyakov, Andrey/0000-0002-3009-9262;
   Ribera, Esteban/0000-0002-3752-8808; Griffith,
   Sandy/0000-0002-3430-5131; Kozal, Michael/0000-0002-3100-8254;
   Moutschen, Michel/0000-0002-6405-1785
FU ViiV Healthcare
FX ViiV Healthcare.
CR Centres for disease control and prevention. National centre for infectious diseases division of HIV/ AIDS, 1993 REV CLASS SYST
   Committee for Medicinal Products for Human Use (CHMP), 2007, GUID CLIN D IN PRESS
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   DeJesus E, 2012, LANCET, V379, P2429, DOI 10.1016/S0140-6736(12)60918-0
   Eron JJ, 2011, LANCET INFECT DIS, V11, P907, DOI 10.1016/S1473-3099(11)70196-7
   Garrido C, 2012, ANTIMICROB AGENTS CH, V56, P2873, DOI 10.1128/AAC.06170-11
   German P, 2010, JAIDS-J ACQ IMM DEF, V55, P323, DOI 10.1097/QAI.0b013e3181eb376b
   Hazuda DJ, 2007, ANTIVIR THER, V12, pS10
   Hightower KE, 2011, ANTIMICROB AGENTS CH, V55, P4552, DOI 10.1128/AAC.00157-11
   KASTRUP J, 1985, BRIT J UROL, V57, P265, DOI 10.1111/j.1464-410X.1985.tb06340.x
   Koteff J, 2013, BRIT J CLIN PHARMACO, V75, P990, DOI 10.1111/j.1365-2125.2012.04440.x
   Lennox JL, 2010, JAIDS-J ACQ IMM DEF, V55, P39, DOI 10.1097/QAI.0b013e3181da1287
   Lepist E-I, 2011, 51 INT C ANT AG CHEM
   Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914
   Margot NA, 2012, ANTIVIR RES, V93, P288, DOI 10.1016/j.antiviral.2011.12.008
   McColl DJ, 2007, ANTIVIR THER, V12, pS11
   Mesplede T, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-22
   Min S, 2010, ANTIMICROB AGENTS CH, V54, P254, DOI 10.1128/AAC.00842-09
   Molina JM, 2012, LANCET INFECT DIS, V12, P27, DOI 10.1016/S1473-3099(11)70249-3
   Nichols G, 2012, 11 INT C DRUG THER H
   Raffi F, 2013, LANCET, V381, P735, DOI 10.1016/S0140-6736(12)61853-4
   Sax PE, 2012, LANCET, V379, P2439, DOI 10.1016/S0140-6736(12)60917-9
   Smith F, 2011, DRUG INF J, V45, P291, DOI 10.1177/009286151104500309
   Song I, 2012, REV ANTIVIR THER INF, V3, P9
   Song I, 2011, ANTIMICROB AGENTS CH, V55, P3517, DOI 10.1128/AAC.00073-11
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   [US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)], 2001, ICH GUID IND E 10 CH
   Walmsley S, 2012, 52 INT C ANT AG CHEM
NR 28
TC 324
Z9 330
U1 1
U2 59
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 24
PY 2013
VL 382
IS 9893
BP 700
EP 708
DI 10.1016/S0140-6736(13)61221-0
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 206SI
UT WOS:000323542400028
PM 23830355
DA 2020-12-01
ER

PT J
AU Pereira, CAP
   Marra, AR
   Camargo, LFA
   Pignatari, ACC
   Sukiennik, T
   Behar, PRP
   Medeiros, EAS
   Ribeiro, J
   Girao, E
   Correa, L
   Guerra, C
   Carneiro, I
   Brites, C
   Reis, M
   de Souza, MA
   Tranchesi, R
   Barata, CU
   Edmond, MB
AF Pires Pereira, Carlos Alberto
   Marra, Alexandre R.
   Aranha Camargo, Luis Fernando
   Campos Pignatari, Antonio Carlos
   Sukiennik, Teresa
   Petersen Behar, Paulo Renato
   Servolo Medeiros, Eduardo Alexandrino
   Ribeiro, Julival
   Girao, Evelyne
   Correa, Luci
   Guerra, Carla
   Carneiro, Irna
   Brites, Carlos
   Reis, Marise
   de Souza, Marta Antunes
   Tranchesi, Regina
   Barata, Cristina U.
   Edmond, Michael B.
CA Brazilian SCOPE Study Grp
TI Nosocomial Bloodstream Infections in Brazilian Pediatric Patients:
   Microbiology, Epidemiology, and Clinical Features
SO PLOS ONE
LA English
DT Article
ID INTENSIVE-CARE-UNIT; PCR ASSAY; HOSPITALS; SURVEILLANCE; COLISTIN;
   UPDATE
AB Background: Nosocomial bloodstream infections (nBSIs) are an important cause of morbidity and mortality and are the most frequent type of nosocomial infection in pediatric patients.
   Methods: We identified the predominant pathogens and antimicrobial susceptibilities of nosocomial bloodstream isolates in pediatric patients (<= 16 years of age) in the Brazilian Prospective Surveillance for nBSIs at 16 hospitals from 12 June 2007 to 31 March 2010 (Br SCOPE project).
   Results: In our study a total of 2,563 cases of nBSI were reported by hospitals participating in the Br SCOPE project. Among these, 342 clinically significant episodes of BSI were identified in pediatric patients (<= 16 years of age). Ninety-six percent of BSIs were monomicrobial. Gram-negative organisms caused 49.0% of these BSIs, Gram-positive organisms caused 42.6%, and fungi caused 8.4%. The most common pathogens were Coagulase-negative staphylococci (CoNS) (21.3%), Klebsiella spp. (15.7%), Staphylococcus aureus (10.6%), and Acinetobacter spp. (9.2%). The crude mortality was 21.6% (74 of 342). Forty-five percent of nBSIs occurred in a pediatric or neonatal intensive-care unit (ICU). The most frequent underlying conditions were malignancy, in 95 patients (27.8%). Among the potential factors predisposing patients to BSI, central venous catheters were the most frequent (66.4%). Methicillin resistance was detected in 37 S. aureus isolates (27.1%). Of the Klebsiella spp. isolates, 43.2% were resistant to ceftriaxone. Of the Acinetobacter spp. and Pseudomonas aeruginosa isolates, 42.9% and 21.4%, respectively, were resistant to imipenem.
   Conclusions: In our multicenter study, we found a high mortality and a large proportion of gram-negative bacilli with elevated levels of resistance in pediatric patients.
C1 [Pires Pereira, Carlos Alberto] Inst Oncol Pediat IOP GRAAC, Sao Paulo, Brazil.
   [Marra, Alexandre R.; Aranha Camargo, Luis Fernando; Correa, Luci] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Marra, Alexandre R.; Aranha Camargo, Luis Fernando; Campos Pignatari, Antonio Carlos; Servolo Medeiros, Eduardo Alexandrino] Univ Fed Sao Paulo UNIFESP, Sao Paulo, Brazil.
   [Campos Pignatari, Antonio Carlos; Tranchesi, Regina] Hosp 9 Julho, Sao Paulo, Brazil.
   [Sukiennik, Teresa] Santa Casa Porto Alegre, Porto Alegre, RS, Brazil.
   [Petersen Behar, Paulo Renato] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Ribeiro, Julival] Hosp Base, Brasilia, DF, Brazil.
   [Girao, Evelyne] Hosp Walter Cantidio, Fortaleza, Ceara, Brazil.
   [Guerra, Carla] Hosp Diadema, Sao Paulo, Brazil.
   [Brites, Carlos] Hosp Espanhol, Salvador, BA, Brazil.
   [Reis, Marise] Hosp Coracao, Natal, RN, Brazil.
   [Reis, Marise] Hosp UNIMED, Natal, RN, Brazil.
   [de Souza, Marta Antunes] Hosp Clin Goiania, Goiania, Go, Brazil.
   [Correa, Luci] Hosp Rim & Hipertensao, Sao Paulo, Brazil.
   [Barata, Cristina U.] Univ Fed Triangulo Mineiro, Uberaba, MG, Brazil.
   [Edmond, Michael B.] Virginia Commonwealth Univ, Richmond, VA USA.
RP Marra, AR (corresponding author), Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
EM alexandre.marra@einstein.br
RI Pignatari, Antonio CC/C-8427-2012; Brites, Carlos/D-1353-2013; Medeiros,
   Eduardo A/B-9825-2012
OI Brites, Carlos/0000-0002-4673-6991; Medeiros, Eduardo
   A/0000-0002-6205-259X; Edmond, Michael/0000-0002-4144-8974; Pignatari,
   Antonio/0000-0002-2146-8476; Camargo, Luis Fernando
   Aranha/0000-0002-3888-8661
FU Pfizer, Inc.Pfizer; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP), BrasilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2006/57700-0]
FX The study was funded in part by an independent medical grant provided by
   Pfizer, Inc. We also thank the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP), Brasil (grant 2006/57700-0). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ariffin N, 2012, AM J INFECT CONTROL, V40, P572, DOI 10.1016/j.ajic.2012.02.032
   Becerra MR, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-66
   Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011
   Clinical and Laboratory Standards Institute Wayne PA, 2010, M100S20 CLSI
   Deshpande LM, 2006, MICROB DRUG RESIST, V12, P223, DOI 10.1089/mdr.2006.12.223
   Elward AM, 2005, PEDIATRICS, V115, P868, DOI 10.1542/peds.2004-0256
   Grisaru-Soen G, 2007, MED SCI MONITOR, V13, pCR251
   Isaacs D, 2003, ARCH DIS CHILD-FETAL, V88, pF89, DOI 10.1136/fn.88.2.F89
   Jean-Baptiste N, 2011, INFECT CONT HOSP EP, V32, P679, DOI 10.1086/660361
   Joram N, 2012, EUR J CLIN MICROBIOL
   Levin AS, 1999, CLIN INFECT DIS, V28, P1008, DOI 10.1086/514732
   Marra AR, 2011, J CLIN MICROBIOL, V49, P1866, DOI 10.1128/JCM.00376-11
   Mendes RE, 2007, J CLIN MICROBIOL, V45, P544, DOI 10.1128/JCM.01728-06
   Milheirico C, 2007, ANTIMICROB AGENTS CH, V51, P3374, DOI 10.1128/AAC.00275-07
   Monteiro J, 2009, ANTIMICROB AGENTS CH, V53, P333, DOI 10.1128/AAC.00736-08
   Paul M, 2010, J ANTIMICROB CHEMOTH, V65, P1019, DOI 10.1093/jac/dkq069
   Slonim Anthony D., 2001, Pediatr Crit Care Med, V2, P170, DOI 10.1097/00130478-200104000-00012
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754
   Wisplinghoff H, 2003, PEDIATR INFECT DIS J, V22, P686, DOI 10.1097/01.inf.0000078159.53132.40
   Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946
   Zhang KY, 2005, J CLIN MICROBIOL, V43, P5026, DOI 10.1128/JCM.43.10.5026-5033.2005
NR 21
TC 30
Z9 33
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 4
PY 2013
VL 8
IS 7
AR e68144
DI 10.1371/journal.pone.0068144
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 204FO
UT WOS:000323350700072
PM 23861860
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Travassos, AGA
   Nobrega, I
   Netto, E
   Timbo, M
   Adami, K
   Fernandes, S
   Silva, P
   Pires, M
   Queiroz, C
   Brites, C
AF Travassos, A. G. A.
   Nobrega, I.
   Netto, E.
   Timbo, M.
   Adami, K.
   Fernandes, S.
   Silva, P.
   Pires, M.
   Queiroz, C.
   Brites, C.
TI CHLAMYDIA TRACHOMATIS IN THE GENITAL TRACT OF HIV-INFECTED WOMEN,
   PREGNANT AND NON-PREGNANT, FOLLOWED IN A REFERENCE CENTRE IN BAHIA,
   NORTHEAST BRAZIL
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Meeting Abstract
C1 [Travassos, A. G. A.; Nobrega, I.; Adami, K.; Fernandes, S.; Silva, P.; Pires, M.] Ctr Estadual Especializado Diagnost Assistencia &, Salvador, BA, Brazil.
   [Netto, E.; Timbo, M.; Queiroz, C.; Brites, C.] Univ Fed Bahia, Salvador, BA, Brazil.
RI Netto, Eduardo/D-1432-2013; Travassos, Ana Gabriela A/E-6809-2016
OI Netto, Eduardo/0000-0003-1691-6761; Travassos, Ana Gabriela
   A/0000-0001-9242-828X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
EI 1472-3263
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD JUL
PY 2013
VL 89
SU 1
MA P3.185
BP A205
EP A206
DI 10.1136/sextrans-2013-051184.0642
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA V40VR
UT WOS:000209506600034
OA Bronze
DA 2020-12-01
ER

PT J
AU Ferraro, GA
   Monteiro-Cunha, JP
   Fernandes, FMC
   Mota-Miranda, ACA
   Brites, C
   Alcantara, LCJ
   Galvao-Castro, B
   Morgado, MG
AF Ferraro, Geraldo A.
   Monteiro-Cunha, Joana P.
   Fernandes, Flora M. C.
   Mota-Miranda, Aline C. A.
   Brites, Carlos
   Alcantara, Luiz C. J.
   Galvao-Castro, Bernardo
   Morgado, Mariza G.
TI Molecular Characterization of Long Terminal Repeat Sequences from
   Brazilian Human Immunodeficiency Virus Type 1 Isolates
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SUBTYPE-C; HIV-1
AB HIV-1 provirus activation is under control of the long terminal repeat (LTR)-5' viral promoter region, which presents remarkable genetic variation among HIV-1 subtypes. It is possible that molecular features of the LTR contribute to the unusual profile of the subtype C epidemic in the Brazilian Southern region. To characterize the LTR of Brazilian HIV isolates, we analyzed sequences from 21 infected individuals from Porto Alegre and Salvador cities. Sequences were compared with subtype B and C reference strains from different countries. Phylogenetic analysis showed that 17 (81%) samples were subtype B and four (19%) were subtype C. Common patterns of transcription factor binding sites (TFBS) in subtypes B and C sequences were confirmed and other potential TFBS specific for subtype C were found. Brazilian subtype C sequences contained an additional NF-kappa B biding site, as previously described for the majority of subtype C isolates. The high level of LTR polymorphisms identified in this study might be important for viral fitness.
C1 [Ferraro, Geraldo A.; Monteiro-Cunha, Joana P.; Fernandes, Flora M. C.; Mota-Miranda, Aline C. A.; Alcantara, Luiz C. J.; Galvao-Castro, Bernardo] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisa Goncalo Moniz CPqGM, Lab Avancado Saude Publ, Salvador, BA, Brazil.
   [Ferraro, Geraldo A.; Monteiro-Cunha, Joana P.; Fernandes, Flora M. C.; Mota-Miranda, Aline C. A.; Alcantara, Luiz C. J.; Galvao-Castro, Bernardo] Fundacao Bahiana Desenvolvimento Ciencias, Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   [Monteiro-Cunha, Joana P.; Fernandes, Flora M. C.; Mota-Miranda, Aline C. A.; Brites, Carlos] Univ Fed Bahia, BR-40110100 Salvador, BA, Brazil.
   [Morgado, Mariza G.] Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
RP Monteiro-Cunha, JP (corresponding author), Univ Fed Bahia, Inst Ciencias Saude, Dept Biofuncao, Av Reitor Miguel Calmon S-N Vale Canela, BR-40110100 Salvador, BA, Brazil.
EM joanapmonteiro@hotmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Alcantara, Luiz/0000-0002-6769-9931
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB); Brazilian
   Ministry of Health STD/AIDS Program; CNPqNational Council for Scientific
   and Technological Development (CNPq); FIOCRUZ
FX The authors are grateful to Luciano Zulbaran Goldane for the selection
   of samples from Porto Alegre and David Watkins, visiting professor
   (CAPES-FIOCRUZ), for revising this manuscript. This work was supported
   by grants from the Fundacao de Amparo a Pesquisa do Estado da Bahia
   (FAPESB), the Brazilian Ministry of Health STD/AIDS Program, CNPq, and
   FIOCRUZ.
CR Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   de Arellano ER, 2007, VIRUS GENES, V34, P111, DOI 10.1007/s11262-006-0054-z
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   ElKharroubi A, 1996, MOL CELL BIOL, V16, P2958
   Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7
   Nicholas K. B., 1997, EMBNET NEWS, V4, P1
   PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924
   Ranjbar S, 2006, PLOS PATHOG, V2, P1176, DOI 10.1371/journal.ppat.0020130
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Silveira J, 2012, J CLIN VIROL, V54, P36, DOI 10.1016/j.jcv.2012.01.017
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   van Opijnen T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000271
   VARAS F, 1991, BIOTECHNIQUES, V11, P384
   Varas F, 1991, BIOTECHNIQUES, V11, P388
   Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200
NR 16
TC 1
Z9 1
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2013
VL 29
IS 5
BP 837
EP 841
DI 10.1089/aid.2012.0326
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 132NA
UT WOS:000318074200014
PM 23153102
OA Green Published
DA 2020-12-01
ER

PT J
AU Teixeira, C
   Dourado, MD
   Santos, MP
   Brites, C
AF Teixeira, Celia
   Dourado, Maria De Lourdes
   Santos, Marcio P.
   Brites, Carlos
TI Impact of Use of Alcohol and Illicit Drugs by AIDS Patients on Adherence
   to Antiretroviral Therapy in Bahia, Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID MEDICATION ADHERENCE; NONADHERENCE; OUTCOMES
AB Use of alcohol and illicit drugs is a common finding among HIV-infected individuals, but there are many open questions about its impact on adherence to antiretroviral therapy and virological outcomes. Our study aimed to evaluate the impact of the use of alcohol and illicit drugs on the adherence to antiretroviral therapy (ART) among patients starting ART in Salvador, Brazil. We followed up 144 AIDS patients initiating ART for a 6-month period. At baseline, they were interviewed about demographics, behavior, and use of illicit drugs and alcohol. All of them had HIV-1 RNA plasma viral load and CD4(+) /CD8(+) cells count measured before starting therapy. After 60 days of treatment they were asked to answer a new questionnaire on adherence to ART. All patients were monitored during the following months, and new CD4(+) cell count/HIV-1 RNA plasma viral load determinations were performed after 6 months of therapy. Optimal adherence to therapy was defined by self-reported questionnaire, by 95% use of prescribed drug doses, and by using plasma HIV-1 RNA viral load as a biological marker. A total of 61 (42.4%) patients reported alcohol use, 7 (4.9%) used illicit drugs, and 17 (11.8%) used both alcohol and illicit drugs. Being in a steady relationship was protective to nonadherence (95% CI: 0.18-0.84). Missing more than two medical visits was also associated with a 68% higher likelihood of nonadherence (95% CI: 0.10-1.02). After logistic regression we detected a higher risk of nonadherence for patients declaring use of alcohol plus illicit drugs (odds ratio = 6.0; 95% CI: 1.78-20.28) or high-intensity use of alcohol (odds ratio = 3.29; 95% CI: 1.83-5.92). AIDS patients using alcohol and/or illicit drugs are socially vulnerable, and need specific and flexible programs, combining mental health care, harm reduction strategies, and assisted drug therapy to maximize the chances of successful use of ART.
C1 [Teixeira, Celia; Dourado, Maria De Lourdes; Santos, Marcio P.] CEDAP Ctr Especializado Diagnost Assistencia & Pe, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Lab Pesquisa Virol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), LAPI, Rua Joao das Botas,60 Andar, BR-40110160 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
FU Brazilian National AIDS Program, Ministry of Health
FX This work was supported by a grant from Brazilian National AIDS Program,
   Ministry of Health.
CR Abbey A, 2002, ALCOHOL CLIN EXP RES, V26, P575, DOI 10.1097/00000374-200204000-00019
   Bangsberg DR, 2006, CLIN INFECT DIS, V43, P939, DOI 10.1086/507526
   Bonolo PD, 2008, CAD SAUDE PUBLICA, V24, P2603, DOI 10.1590/S0102-311X2008001100015
   Braithwaite RS, 2005, ALCOHOL CLIN EXP RES, V29, P1190, DOI 10.1097/01.ALC.0000171937.87731.28
   CARLINI EA, 2002, LEVANTAMENTO DOMICIL
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Ernesto AS, 2012, BRAZ J INFECT DIS, V16, P315, DOI 10.1016/j.bjid.2012.06.006
   Esser S, 2011, EUR J MED RES, V16, P427, DOI 10.1186/2047-783X-16-10-427
   Fatch R, 2013, AIDS BEHAV, V17, P1713, DOI 10.1007/s10461-012-0282-2
   Silva MCF, 2009, REV INST MED TROP SP, V51, P135, DOI 10.1590/S0036-46652009000300003
   Grodensky CA, 2012, J STUD ALCOHOL DRUGS, V73, P899, DOI 10.15288/jsad.2012.73.899
   Ickovics JR, 1997, J CLIN EPIDEMIOL, V50, P385, DOI 10.1016/S0895-4356(97)00041-3
   Kenya S, 2013, AIDS BEHAV, V17, P61, DOI 10.1007/s10461-012-0307-x
   Laranjeiras R, 2007, LEVANTAMENTO NACL PA
   Maggiolo F, 2005, CLIN INFECT DIS, V40, P158, DOI 10.1086/426595
   Moore RD, 2005, JAIDS-J ACQ IMM DEF, V39, P195
   Organizacao Pan-Americana da Saude, 2006, GUIA AT MAN INT US D, V1
   Parsons JT, 2007, J HEALTH PSYCHOL, V12, P357, DOI 10.1177/1359105307074298
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Sampaio-Sa M, 2008, AIDS BEHAV, V12, pS54, DOI 10.1007/s10461-008-9414-0
   Wong T, 2000, J URBAN HEALTH, V77, P492, DOI 10.1007/BF02386756
NR 21
TC 13
Z9 13
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2013
VL 29
IS 5
BP 799
EP 804
DI 10.1089/aid.2012.0296
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 132NA
UT WOS:000318074200010
PM 23294471
DA 2020-12-01
ER

PT J
AU Nobrega, I
   Dantas, P
   Rocha, P
   Rios, I
   Abraao, M
   Netto, EM
   Brites, C
AF Nobrega, Isabella
   Dantas, Paula
   Rocha, Priscila
   Rios, Isabela
   Abraao, Marcos
   Netto, Eduardo M.
   Brites, Carlos
TI Syphilis and HIV-1 among parturient women in Salvador, Brazil: low
   prevalence of syphilis and high rate of loss to follow-up in
   HIV-infected women
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Human immunodeficiency virus; Syphilis; Seroprevalence; Risk factors;
   Parturient; Pregnant; Mother-to-child transmission; Brazil
ID PREGNANT-WOMEN; TRANSMISSION
AB Background: The occurrence of syphilis and HIV-1 infections during pregnancy are major risks to the fetus due to mother-to-child transmission (MTCT).
   Objectives: To determine peripartum seroprevalence and risk factors of syphilis and HIV-1 infection among pregnant women in Salvador, Brazil, and the rate of HIV-1 MTCT.
   Methods: Cross-sectional study of pregnant women who were admitted for delivery in a reference maternity hospital between May 2008 and March 2009 was conducted. Women were screened for HIV-1 infection and syphilis, and interviewed regarding demographic, behavioral and obstetric data. Newborns to HIV-infected mothers were tested by b-DNA and DNA-PCR to detect HIV-1.
   Results: A total 3300/8516 women were evaluated. Mean age was 25.8 +/- 7.3 years. HIV-1 and syphilis seroprevalence rates were 0.84% (28/3300) and 0.51% (17/3300), respectively. HIV-1 infection was associated with: low education (p = 0.04), having a partner with known HIV infection (p < 0.0001) or with previous sexually transmitted infection (p < 0.0001), blood transfusion (p = 0.003), or accidental exposure to blood (p = 0.003). Syphilis was associated with being Caucasian (p = 0.02), having no steady partner (p = 0.02), being a housewife (p = 0.01), having an intravenous drug user (IVDU) sexual partner (p = 0.04) or a sexual partner with previous STI (p < 0.001). Higher education (p = 0.04) was protective against HIV-infection. Attending a prenatal care program was protective against syphilis (p = 0.008) and HIV-1 (p = 0.02). No case of HIV-1 MTCT was detected, but 25% of children born to HIV-infected mothers were lost to follow up.
   Conclusions: In Salvador, peripartum prevalence of syphilis and HIV-1 infection among pregnant women were low, and associated with classic risk factors for both infections. The great proportion of very late diagnosis of HIV infection, and the high rate of loss of follow-up among positive mothers and their infants are of high concern. (C) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Nobrega, Isabella] Ctr Especializado Diagnost Assistencia & Pesquisa, Salvador, BA, Brazil.
   [Dantas, Paula; Rocha, Priscila; Rios, Isabela] Univ Fed Bahia UFBA, BR-40110060 Salvador, BA, Brazil.
   [Abraao, Marcos; Netto, Eduardo M.; Brites, Carlos] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia UFBA, Complexo Hosp Univ Prof Edgard Santos Com HUPES, Rua Augusto Viana SN,6O Andar, BR-40110060 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
CR Barsanti C, 1999, Rev Soc Bras Med Trop, V32, P605, DOI 10.1590/S0037-86821999000600001
   Berman SM, 2004, B WORLD HEALTH ORGAN, V82, P433
   Centers for Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P63
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   De Loranzi DRS, 2001, REV BRAS GINECOL OBS, V23, P647
   de Macedo VC, 2009, CAD SAUDE PUBLICA, V25, P1679, DOI 10.1590/S0102-311X2009000800004
   Inagaki ADD, 2009, REV SOC BRAS MED TRO, V42, P532, DOI 10.1590/S0037-86822009000500010
   de Souza PRB, 2004, REV SAUDE PUBL, V38, P764, DOI 10.1590/S0034-89102004000600003
   Gardella C, 2003, CURRENT TREATMENT OP, V5, P53
   Griemberg G, 2000, MEDICINA-BUENOS AIRE, V60, P343
   Joint United Nations Program on HIV/AIDS and World Health Organization, 2000, GUID 2 GEN HIV SURV
   de Lima LHM, 2009, CAD SAUDE PUBLICA, V25, P668, DOI 10.1590/S0102-311X2009000300021
   *MIN SAUD, 1993, BAS TECN EL SIF CONG
   Ministerio da Saude, 2002, COORD NAC DST AIDS
   Ministerio da Saude, 1997, PROGR NAC DST AIDS S
   Miranda AE, 2009, REV SOC BRAS MED TRO, V42, P386, DOI 10.1590/S0037-86822009000400006
   Mobley JA, 1998, AM J PUBLIC HEALTH, V88, P597, DOI 10.2105/AJPH.88.4.597
   Mofenson LM, 2002, J ACQ IMMUN DEF SYND, V30, P200, DOI [10.1097/01.QAI.0000018366.28828.86, 10.1097/00042560-200206010-00010]
   Peeling RW, 2004, LANCET, V364, P1561, DOI 10.1016/S0140-6736(04)17327-3
   Ray J G, 1995, Obstet Gynecol Surv, V50, P845, DOI 10.1097/00006254-199512000-00003
   Rodrigues CS, 2004, REV PANAM SALUD PUBL, V16, P168, DOI 10.1590/S1020-49892004000900003
   Sa RAM, 2001, J BRAS DOENCAS SEX T, V13, P6
   Secretaria de Vigilancia em Saude, 2006, 68 MIN SAUD SECR VIG, V68
   Secretaria de Vigilancia em Saude, 2007, B EP EL, V07
   Secretaria de Vigilancia em Saude Departamento de DST Aids e Hepatites Virais, 2010, REC PROF TRANSM VERT
   Secretaria de Vigilancia em Saude- Departamento de DST, 2009, B EP AIDS DST 2009
   Temmerman M, 2000, SEX TRANSM INFECT, V76, P117, DOI 10.1136/sti.76.2.117
NR 27
TC 7
Z9 7
U1 0
U2 5
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2013
VL 17
IS 2
BP 184
EP 193
DI 10.1016/j.bjid.2012.10.018
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 141RD
UT WOS:000318743300012
PM 23453946
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Gomes-Neto, M
   Conceicao, CS
   Carvalho, VO
   Brites, C
AF Gomes-Neto, Mansueto
   Conceicao, Cristiano Sena
   Carvalho, Vitor Oliveira
   Brites, Carlos
TI A systematic review of the effects of different types of therapeutic
   exercise on physiologic and functional measurements in patients with
   HIV/AIDS
SO CLINICS
LA English
DT Review
DE AIDS; HIV Infection; Exercise; Therapeutics
ID QUALITY-OF-LIFE; HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRESSIVE RESISTIVE
   EXERCISE; RESISTANCE EXERCISE; BODY-COMPOSITION; EUGONADAL MEN;
   NANDROLONE DECANOATE; METABOLIC INDEXES; AEROBIC EXERCISE; WEIGHT-LOSS
AB Several studies have reported the benefits of exercise training for adults with HIV, although there is no consensus regarding the most efficient modalities. The aim of this study was to determine the effects of different types of exercise on physiologic and functional measurements in patients with HIV using a systematic strategy for searching randomized controlled trials. The sources used in this review were the Cochrane Library, EMBASE, MEDLINE, and PEDro from 1950 to August 2012. We selected randomized controlled trials examining the effects of exercise on body composition, muscle strength, aerobic capacity, and/or quality of life in adults with HIV. Two independent reviewers screened the abstracts using the Cochrane Collaboration's protocol. The PEDro score was used to evaluate methodological quality. In total, 29 studies fulfilled the inclusion criteria. Individual studies suggested that exercise training contributed to improvement of physiologic and functional parameters, but that the gains were specific to the type of exercise performed. Resistance exercise training improved outcomes related to body composition and muscle strength, with little impact on quality of life. Aerobic exercise training improved body composition and aerobic capacity. Concurrent training produced significant gains in all outcomes evaluated, although moderate intensity and a long duration were necessary. We concluded that exercise training was shown to be a safe and beneficial intervention in the treatment of patients with HIV.
C1 [Gomes-Neto, Mansueto; Conceicao, Cristiano Sena] Univ Fed Bahia UFBA, Dept Biofuncao, Curso Fisioterapia, Salvador, BA, Brazil.
   [Gomes-Neto, Mansueto; Brites, Carlos] Univ Fed Bahia UFBA, Programa Posgrad Med & Saude, Salvador, BA, Brazil.
   [Carvalho, Vitor Oliveira] Univ Fed Sergipe, Dept Fisioterapia, Aracaju, SE, Brazil.
   [Gomes-Neto, Mansueto; Conceicao, Cristiano Sena; Brites, Carlos] Univ Fed Bahia UFBA, Salvador, BA, Brazil.
RP Gomes-Neto, M (corresponding author), Univ Fed Bahia UFBA, Dept Biofuncao, Curso Fisioterapia, Salvador, BA, Brazil.
EM netofisio@gmail.com
RI Gomes-NETO, Mansueto MGN/I-5235-2014; Brites, Carlos/D-1353-2013
OI Gomes-NETO, Mansueto MGN/0000-0002-0717-9694; Brites,
   Carlos/0000-0002-4673-6991
CR Agin D, 2001, AIDS, V15, P2431, DOI 10.1097/00002030-200112070-00011
   American college of sports Medicine, 2006, ACSMS GUID EX TEST P
   Anderson SL, 2006, CARDIOPULMONARY PHYS, V17, P103, DOI DOI 10.1097/01823246-200617030-00002
   Baar K, 2006, MED SCI SPORT EXER, V38, P1939, DOI 10.1249/01.mss.0000233799.62153.19
   Baigis Judith, 2002, J Assoc Nurses AIDS Care, V13, P33, DOI 10.1016/S1055-3290(06)60199-4
   Bhasin S, 2000, JAMA-J AM MED ASSOC, V283, P763, DOI 10.1001/jama.283.6.763
   Campos GER, 2002, EUR J APPL PHYSIOL, V88, P50, DOI 10.1007/s00421-002-0681-6
   Ciccolo JT, 2004, SPORTS MED, V34, P487, DOI 10.2165/00007256-200434080-00001
   Crystal S, 2000, MED CARE, V38, P1210, DOI 10.1097/00005650-200012000-00008
   Currier Judith S, 2008, Circulation, V118, pe29, DOI 10.1161/CIRCULATIONAHA.107.189624
   Dolan SE, 2006, ARCH INTERN MED, V166, P1225, DOI 10.1001/archinte.166.11.1225
   Driscoll SD, 2004, AIDS, V18, P465, DOI 10.1097/00002030-200402200-00013
   Driscoll SD, 2004, J CLIN ENDOCR METAB, V89, P2171, DOI 10.1210/jc.2003-031858
   Dudgeon WD, 2004, AIDS PATIENT CARE ST, V18, P81, DOI 10.1089/108729104322802515
   Fairfield WP, 2001, J APPL PHYSIOL, V90, P2166
   Fillipas S, 2006, AUST J PHYSIOTHER, V52, P185, DOI 10.1016/S0004-9514(06)70027-7
   Fletcher GF, 2001, CIRCULATION, V104, P1694, DOI 10.1161/hc3901.095960
   Galantino ML, 2005, J ALTERN COMPLEM MED, V11, P1085, DOI 10.1089/acm.2005.11.1085
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Grinspoon S, 2000, ANN INTERN MED, V133, P348, DOI 10.7326/0003-4819-133-5-200009050-00010
   Hakkinen K, 2003, EUR J APPL PHYSIOL, V89, P42, DOI 10.1007/s00421-002-0751-9
   Hand GA, 2008, AIDS CARE, V20, P1066, DOI 10.1080/09540120701796900
   Haskell WL, 2007, CIRCULATION, V116, P1081, DOI 10.1161/CIRCULATIONAHA.107.185649
   Jones AM, 2000, SPORTS MED, V29, P373, DOI 10.2165/00007256-200029060-00001
   LAPERRIERE AR, 1990, BIOFEEDBACK SELF-REG, V15, P229, DOI 10.1007/BF01011107
   Lindegaard B, 2008, J CLIN ENDOCR METAB, V93, P3860, DOI 10.1210/jc.2007-2733
   Lox CL, 1996, INT J BEHAV MED, V3, P55, DOI 10.1207/s15327558ijbm0301_5
   LOX CL, 1995, J SPORT EXERCISE PSY, V17, P345, DOI 10.1123/jsep.17.4.345
   MACARTHUR RD, 1993, MED SCI SPORT EXER, V25, P684
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713
   Mazzetti SA, 2000, MED SCI SPORT EXER, V32, P1175, DOI 10.1097/00005768-200006000-00023
   Mutimura E, 2008, QUAL LIFE RES, V17, P377, DOI 10.1007/s11136-008-9319-4
   Mutimura E, 2008, AIDS RES HUM RETROV, V24, P15, DOI 10.1089/aid.2007.0023
   Neidig Judith L, 2003, J Assoc Nurses AIDS Care, V14, P30, DOI 10.1177/1055329002250992
   Nieman D, 2003, EXERCISE TESTING PRE, P79
   O'Brien K, 2008, AIDS CARE, V20, P631, DOI 10.1080/09540120701661708
   O'Brien K, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004248.PUB2
   ODell MW, 1996, AIDS, V10, P667, DOI 10.1097/00002030-199606000-00013
   Olivo SA, 2008, PHYS THER, V88, P156, DOI 10.2522/ptj.20070147
   Perez-Moreno F, 2007, INT J SPORTS MED, V28, P1046, DOI 10.1055/s-2007-965129
   Perna FM, 1999, MED SCI SPORT EXER, V31, P973, DOI 10.1097/00005768-199907000-00009
   PERRY AC, 2003, ACSMS EXERCISE MANAG, P173
   Rhea MR, 2003, MED SCI SPORT EXER, V35, P456, DOI 10.1249/01.MSS.0000053727.63505.D4
   RIGSBY LW, 1992, MED SCI SPORT EXER, V24, P6
   Rojas R, 2003, J SPORT EXERCISE PSY, V25, P440, DOI 10.1123/jsep.25.4.440
   Roubenoff R, 2001, MED SCI SPORT EXER, V33, P1811, DOI 10.1097/00005768-200111000-00003
   Sakkas GK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004605
   Sattler FR, 1999, J CLIN ENDOCR METAB, V84, P1268, DOI 10.1210/jc.84.4.1268
   Sattler FR, 2002, AM J PHYSIOL-ENDOC M, V283, pE1214, DOI 10.1152/ajpendo.00189.2002
   Shevitz AH, 2005, JAIDS-J ACQ IMM DEF, V38, P399, DOI 10.1097/01.qai.0000152647.89008.2b
   Smith BA, 2001, AIDS, V15, P693, DOI 10.1097/00002030-200104130-00004
   SPENCE DW, 1990, ARCH PHYS MED REHAB, V71, P644
   Strawford A, 1999, JAMA-J AM MED ASSOC, V281, P1282, DOI 10.1001/jama.281.14.1282
   Stringer WW, 1998, MED SCI SPORT EXER, V30, P11, DOI 10.1097/00005768-199801000-00003
   Terry L, 1999, INT J SPORTS MED, V20, P142, DOI 10.1055/s-2007-971108
   Terry L, 2006, MED SCI SPORT EXER, V38, P411, DOI 10.1249/01.mss.0000191347.73848.80
   Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0
   Wilson JM, 2012, J STRENGTH COND RES, V26, P2293, DOI 10.1519/JSC.0b013e31823a3e2d
   Wood RH, 2001, MED SCI SPORT EXER, V33, P1751, DOI 10.1097/00005768-200110000-00021
   Yarasheski KE, 2011, AM J PHYSIOL-ENDOC M, V300, pE243, DOI 10.1152/ajpendo.00468.2010
NR 61
TC 39
Z9 41
U1 0
U2 14
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2013
VL 68
IS 8
BP 1157
EP 1167
DI 10.6061/clinics/2013(08)16
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 219HJ
UT WOS:000324496600016
PM 24037014
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Neto, MG
   Ogalha, C
   Andrade, AM
   Brites, C
AF Gomes Neto, Mansueto
   Ogalha, Cecilia
   Andrade, Antonio Marcos
   Brites, Carlos
TI A Systematic Review of Effects of Concurrent Strength and Endurance
   Training on the Health-Related Quality of Life and Cardiopulmonary
   Status in Patients with HIV/AIDS
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRESSIVE RESISTIVE EXERCISE; INFECTED
   PATIENTS; AEROBIC EXERCISE; UPDATED RECOMMENDATION; RESISTANCE EXERCISE;
   PHYSICAL-ACTIVITY; AMERICAN-COLLEGE; BODY-COMPOSITION; SPORTS-MEDICINE
AB Purpose. To determine the effects of concurrent strength and endurance training (concurrent training) on the Health-Related Quality of Life (HRQOL) and cardiopulmonary status among HIV-infected patients, using a systematic search strategy of randomized, controlled trials (RCTs). Methods. A systematic review was performed by two independent reviewers using Cochrane Collaboration protocol. The sources used in this review were Cochrane Library, EMBASE, LILACS, MEDLINE, PEDro and Web of Science from 1950 toAugust 2012. The PEDro score was used to evaluate methodological quality. Result. Individual studies suggested that concurrent training contributed to improved HRQOL and cardiovascular status. Concurrent training appears to be safe and may be beneficial for medically stable adults living with HIV. The rates of nonadherence were of 16%. Conclusion. Concurrent training improves the HRQOL and cardiopulmonary status. It may be an important intervention in the care and treatment of adults living with HIV. Further research is needed to determine the minimal and optimal duration, frequency, and intensity of exercise needed to produce beneficial changes in the HIV-infected population subgroups.
C1 [Gomes Neto, Mansueto] Univ Fed Bahia UFBA, Dept Biofuncao, Curso Fisioterapia, BR-40110160 Salvador, BA, Brazil.
   [Gomes Neto, Mansueto; Ogalha, Cecilia; Andrade, Antonio Marcos; Brites, Carlos] Univ Fed Bahia UFBA, Programa Posgrad Med & Saude, BR-40110160 Salvador, BA, Brazil.
RP Neto, MG (corresponding author), Univ Fed Bahia UFBA, Dept Biofuncao, Curso Fisioterapia, BR-40110160 Salvador, BA, Brazil.
EM netofisio@gmail.com
RI Brites, Carlos/D-1353-2013; Gomes-NETO, Mansueto MGN/I-5235-2014
OI Brites, Carlos/0000-0002-4673-6991; Gomes-NETO, Mansueto
   MGN/0000-0002-0717-9694
CR American College Sports Medicine, 2006, ACSMS GUID EX TEST P
   Bopp Christopher M, 2003, J Assoc Nurses AIDS Care, V14, P73, DOI 10.1177/1055329002239192
   Brandt C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/520258
   Cade WT, 2004, PHYS THER, V84, P655, DOI 10.1093/ptj/84.7.655
   Cahn P, 2010, BRAZ J INFECT DIS, V14, P158, DOI 10.1590/S1413-86702010000200008
   Ciccolo JT, 2004, SPORTS MED, V34, P487, DOI 10.2165/00007256-200434080-00001
   Dolan SE, 2006, ARCH INTERN MED, V166, P1225, DOI 10.1001/archinte.166.11.1225
   Driscoll SD, 2004, AIDS, V18, P465, DOI 10.1097/00002030-200402200-00013
   Fillipas S, 2010, HIV CLIN TRIALS, V11, P270, DOI 10.1310/hct1105-270
   Fillipas S, 2006, AUST J PHYSIOTHER, V52, P185, DOI 10.1016/S0004-9514(06)70027-7
   Forkan R, 2006, PHYS THER, V86, P401, DOI 10.1093/ptj/86.3.401
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Grinspoon S, 2000, ANN INTERN MED, V133, P348, DOI 10.7326/0003-4819-133-5-200009050-00010
   Hakkinen K, 2003, EUR J APPL PHYSIOL, V89, P42, DOI 10.1007/s00421-002-0751-9
   Hand GA, 2008, AIDS CARE, V20, P1066, DOI 10.1080/09540120701796900
   Haskell WL, 2007, CIRCULATION, V116, P1081, DOI 10.1161/CIRCULATIONAHA.107.185649
   Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1249/mss.0b013e3180616b27
   Leveritt M, 1999, SPORTS MED, V28, P413, DOI 10.2165/00007256-199928060-00004
   Lima ALLM, 2007, BRAZ J INFECT DIS, V11, P426, DOI 10.1590/S1413-86702007000400012
   Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003
   Lox CL, 1996, INT J BEHAV MED, V3, P55, DOI 10.1207/s15327558ijbm0301_5
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713
   Mutimura E, 2008, QUAL LIFE RES, V17, P377, DOI 10.1007/s11136-008-9319-4
   O'Brien K, 2008, AIDS CARE, V20, P631, DOI 10.1080/09540120701661708
   O'Brien K, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004248.PUB2
   O'Brien K., 2006, PHYSIOTHER CAN, V58, P114, DOI [DOI 10.3138/PTC.58.2.114, 10.3138/ptc.58.2.114]
   Olivo SA, 2008, PHYS THER, V88, P156, DOI 10.2522/ptj.20070147
   Pavone RM, 1998, INT J BEHAV MED, V5, P245, DOI 10.1207/s15327558ijbm0503_5
   Perez-Moreno F, 2007, INT J SPORTS MED, V28, P1046, DOI 10.1055/s-2007-965129
   Petroczi Andrea, 2010, Open AIDS J, V4, P148, DOI 10.2174/1874613601004010148
   RIGSBY LW, 1992, MED SCI SPORT EXER, V24, P6
   Robinson FP, 2007, BIOL RES NURS, V8, P177, DOI 10.1177/1099800406295520
   Rojas R, 2003, J SPORT EXERCISE PSY, V25, P440, DOI 10.1123/jsep.25.4.440
   Roubenoff R, 1999, AIDS, V13, P231, DOI 10.1097/00002030-199902040-00011
   Scevola D, 2003, AIDS, V17, pS123, DOI 10.1097/00002030-200304001-00015
   Smith BA, 2001, AIDS, V15, P693, DOI 10.1097/00002030-200104130-00004
   Spierer DK, 2007, CLIN AUTON RES, V17, P341, DOI 10.1007/s10286-007-0441-0
   Stringer WW, 1999, SPORTS MED, V28, P389, DOI 10.2165/00007256-199928060-00002
   Stringer WW, 1998, MED SCI SPORT EXER, V30, P11, DOI 10.1097/00005768-199801000-00003
   Thoni GJ, 2002, DIABETES METAB, V28, P397
   Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0
NR 42
TC 21
Z9 21
U1 0
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2013
VL 2013
AR 319524
DI 10.1155/2013/319524
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 124VN
UT WOS:000317496200001
PM 23691497
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Nobrega, I
   Travassos, A
   Haguihara, T
   Brites, C
AF Nobrega, I
   Travassos, A.
   Haguihara, T.
   Brites, C.
TI Efficacy of raltegravir in late-presenting HIV-infected pregnant women:
   a case series presentation
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Nobrega, I; Travassos, A.; Haguihara, T.] Ctr Especializado Diag Assistencia & Pesquisa, Salvador, BA, Brazil.
   [Brites, C.] Univ Fed Bahia, Salvador, BA, Brazil.
RI Travassos, Ana Gabriela A/E-6809-2016
OI Travassos, Ana Gabriela A/0000-0001-9242-828X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD NOV
PY 2012
VL 15
SU 4
BP 116
EP 116
DI 10.7448/IAS.15.6.18237
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 167SH
UT WOS:000320654200239
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Travassos, AGA
   Brites, C
   Netto, EM
   Fernandes, SD
   Rutherford, GW
   Queiroz, CM
AF Alvares Travassos, Ana Gabriela
   Brites, Carlos
   Netto, Eduardo M.
   Fernandes, Sheyla de Almeida
   Rutherford, George W.
   Queiroz, Conceicao Maria
TI Prevalence of sexually transmitted infections among HIV-infected women
   in Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Sexually transmitted infections; Pregnancy; Prevalence
ID HIV-1-INFECTED PREGNANT-WOMEN; GENITAL-TRACT INFECTIONS; SOUTHERN
   BRAZIL; TRANSMISSION; HEALTH
AB This study aimed to evaluate the prevalence of sexually transmitted infections (STIs) and associated risk factors in HIV-infected pregnant women followed for prenatal care in Salvador, Bahia. This was a cross-sectional study of 63 women seeking prenatal care at a reference center. Participants were interviewed regarding socio-epidemiological and clinical history, and were tested for HBsAg, anti-HCV, anti HTLV I/II, VDRL, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma hominis, Ureaplasma urealyticum, CD4 count, and HIV plasma viral load. The main outcome variable was the presence of any STI. The mean age of patients was 28.2 years (16-40 years). 23 (36.5%) were diagnosed with at least one STI. The frequency of diagnoses was: HBV, 3.2%; HCV, 8.1%; HTLV I/II, 3.4%; syphilis, 9.5%; Chlamydia trachomatis, 11.1%; HPV, 15.0%; Mycoplasma hominis, 2.1%, and Ureaplasma urealyticum, 2.1%. No case of Neisseria gonorrhoeae was identified. No association was found between socio-epidemiological variables and the presence of an STI. CD4 T lymphocyte <500 cells/mu L (p = 0.047) and plasma viral load >1,000 copies (p = 0.027) were associated with the presence of STI. STIs are frequent in pregnant women infected with HIV, and all HIV-infected pregnant women should be screened to decrease transmission of these pathogens and to protect their own health. (C) 2012 Elsevier Editora Ltda. All rights reserved.
C1 [Alvares Travassos, Ana Gabriela; Fernandes, Sheyla de Almeida] CEDAP, BR-40100160 Salvador, BA, Brazil.
   [Brites, Carlos; Netto, Eduardo M.; Queiroz, Conceicao Maria] Univ Fed Bahia UFBA, Salvador, BA, Brazil.
   [Rutherford, George W.] Univ Calif San Francisco, Dept Epidemiol & Biostat & Global Hlth Sci, San Francisco, CA 94143 USA.
RP Travassos, AGA (corresponding author), CEDAP, Rua Comendador Jose Alves Ferreira 240, BR-40100160 Salvador, BA, Brazil.
EM ana.gabriela@saude.ba.gov.br
RI Travassos, Ana Gabriela A/E-6809-2016; Netto, Eduardo/D-1432-2013;
   Brites, Carlos/D-1353-2013
OI Travassos, Ana Gabriela A/0000-0001-9242-828X; Netto,
   Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
FU US National Institute of Mental Health (NIMH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [P30 MH062246]; International
   Traineeships in AIDS Prevention Studies, US NIMH [R25MH064712]; Fogarty
   International Center's International, Operational and Health Services
   Research Training Award, Brazilian Scientists Program [D43 TW005799];
   FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW005799, D43TW005799, D43TW005799,
   D43TW005799, D43TW005799, D43TW005799, D43TW005799, D43TW005799,
   D43TW005799, D43TW005799, D43TW005799] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, R25MH064712, P30MH062246,
   R25MH064712, R25MH064712, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, R25MH064712, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, R25MH064712,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, R25MH064712, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, R25MH064712, P30MH062246,
   P30MH062246, P30MH062246, R25MH064712, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, R25MH064712, R25MH064712, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, R25MH064712, P30MH062246, R25MH064712, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, R25MH064712,
   P30MH062246, R25MH064712, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   R25MH064712, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246] Funding Source: NIH RePORTER
FX The authors thank the University of California, San Francisco, Center
   for AIDS Prevention Studies, US National Institute of Mental Health
   (NIMH), P30 MH062246, the International Traineeships in AIDS Prevention
   Studies, US NIMH, R25MH064712; and the Fogarty International Center's
   International, Operational and Health Services Research Training Award,
   Brazilian Scientists Program (D43 TW005799).
CR Aboud S, 2008, INT J STD AIDS, V19, P824, DOI 10.1258/ijsa.2008.008067
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de DST Aids e Hepatites Virais, REC PROF TRANSM VERT
   *CDC, 1992, 1993 REV CLASS SYST
   Goncalves MAD, 2010, BRAZ J INFECT DIS, V14, P601, DOI 10.1590/S1413-86702010000600009
   Jalil EM, 2008, REV BRAS GINECOL OBS, V30, P614, DOI 10.1590/S0100-72032008001200005
   Johnson HL, 2011, SEX TRANSM DIS, V38, P167, DOI 10.1097/OLQ.0b013e3181f2e85f
   Kreitchmann R, 2004, BJOG-INT J OBSTET GY, V111, P579, DOI 10.1111/j.1471-0528.2004.00147.x
   Landes M, 2007, EUR J EPIDEMIOL, V22, P925, DOI 10.1007/s10654-007-9188-0
   Majeroni BA, 2007, AM FAM PHYSICIAN, V76, P265
   Marx G, 2010, INT J STD AIDS, V21, P549, DOI 10.1258/ijsa.2010.010005
   de Lima LHM, 2009, CAD SAUDE PUBLICA, V25, P668, DOI 10.1590/S0102-311X2009000300021
   Msuya Sia E, 2009, Reprod Health, V6, P4, DOI 10.1186/1742-4755-6-4
   Mugo NR, 2011, AIDS, V25, P1887, DOI 10.1097/QAD.0b013e32834a9338
   Pinto VM, 2011, SEX TRANSM DIS, V38, P957, DOI 10.1097/OLQ.0b013e31822037fc
   Santos Jairo Vvo Dos, 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P343
   Schwebke JR, 2005, J INFECT DIS, V192, P1315, DOI 10.1086/462430
   Taha TE, 2000, ANN NY ACAD SCI, V918, P84
   Tanton C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017480
   Tornatore M, 2012, MEM I OSWALDO CRUZ, V107, P205, DOI 10.1590/S0074-02762012000200009
   WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001
NR 20
TC 14
Z9 15
U1 0
U2 6
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2012
VL 16
IS 6
BP 581
EP 585
DI 10.1016/j.bjid.2012.08.016
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 059BW
UT WOS:000312680400014
PM 23168304
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Grinsztejn, B
   De Castro, N
   Arnold, V
   Veloso, V
   Morgado, M
   Pilotto, JH
   Brites, C
   Madruga, JV
   Barcellos, N
   Santos, BR
   Vorsatz, C
   Grondin, C
   Santini-Oliveira, M
   Patey, O
   Delaugerre, C
   Chene, G
   Molina, JM
AF Grinsztejn, B.
   De Castro, N.
   Arnold, V.
   Veloso, V.
   Morgado, M.
   Pilotto, J. H.
   Brites, C.
   Madruga, J. V.
   Barcellos, N.
   Riegel Santos, B.
   Vorsatz, C.
   Grondin, C.
   Santini-Oliveira, M.
   Patey, O.
   Delaugerre, C.
   Chene, G.
   Molina, J-M.
CA ANRS 12 180 Reflate TB Study Grp
TI A randomized multicentre open-label trial to estimate the efficacy and
   safety of two doses of raltegravir (RAL) to efavirenz (EFV) for the
   treatment of HIV-TB co-infected patients: results of the ANRS 12 180
   Reflate TB trial
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Grinsztejn, B.; Veloso, V.; Vorsatz, C.; Santini-Oliveira, M.] Inst Pesquisa Clin Evandro Chagas, FIOCRUZ, Lab Pesquisa Clin DST AIDS, Rio De Janeiro, Brazil.
   [De Castro, N.; Delaugerre, C.; Molina, J-M.] Univ Paris Diderot, INSERM, U941, Paris, France.
   [De Castro, N.; Delaugerre, C.; Molina, J-M.] Hosp St Louis, AP HP, Paris, France.
   [Arnold, V.; Grondin, C.; Chene, G.] Univ Bordeaux, INSERM, U897, Bordeaux, France.
   [Morgado, M.] Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, FIOCRUZ, BR-20001 Rio De Janeiro, Brazil.
   [Pilotto, J. H.] Hosp Geral Nova Iguac, Dept DST AIDS, Nova Iguac, Brazil.
   [Brites, C.] Hosp Univ Prof Edgar Santos, Lab Pesquisa Doencas Infecciosas, Salvador, BA, Brazil.
   [Madruga, J. V.] Ctr Referencia & Treinamento DST AIDS, Unidade Pesquisa, Sao Paulo, Brazil.
   [Barcellos, N.] Hlth State Secretariat Hosp Sanatorio Partenon, Porto Alegre, RS, Brazil.
   [Riegel Santos, B.] Hosp Nossa Senhora da Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Patey, O.] CHG Villeneuve St George, Dept Internal & Trop Med, Villeneuve St Georges, France.
RI Pilotto, Jose Henrique/AAD-9773-2019; Brites, Carlos/D-1353-2013
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Brites,
   Carlos/0000-0002-4673-6991
NR 0
TC 0
Z9 0
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 57
EP 57
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200122
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Abrahao, MHN
   Lima, RG
   Netto, E
   Brites, C
AF Abrahao, Marcos H. N.
   Lima, Rosangela G.
   Netto, Eduardo
   Brites, Carlos
TI Short Communication Human Lymphotropic Virus Type 1 Coinfection
   Modulates the Synthesis of Cytokines by Peripheral Blood Mononuclear
   Cells from HIV Type 1-Infected Individuals
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID I HTLV-I; SURVIVAL-TIME; AIDS; PATHOGENESIS; INFECTION; COUNT
AB HIV-1 and HTLV-1 infect CD4(+) T lymphocyte but little is known about the impact of coinfection on patient's immune response. In this study we have evaluated the spontaneous production of interleukin (IL)-2, IL-4, IL-6, and IL-10 and interferon (IFN)-gamma by unstimulated peripheral blood mononuclear cell (PBMC) cultures obtained from patients infected by HTLV-1, HIV-1, or both viruses. We have observed that HIV/HTLV-coinfected individuals presented significantly higher production of IL-2 and IFN-gamma compared to both HIV single-infected and HTLV single-infected individuals. IL-6 and IL-10 synthesis was similar in all infected groups, but HTLV single-infected individuals presented a lower production of IL-4. These results show that HIV/HTLV-coinfected individuals presented a profile of higher production of Th-1 cytokines, suggesting a predominant stimulus of HTLV-1 in detriment to HIV-1 infection.
C1 [Abrahao, Marcos H. N.; Lima, Rosangela G.; Netto, Eduardo; Brites, Carlos] Univ Fed Bahia, Lab Pesquisa Infectol, HUPES, BR-40110160 Salvador, BA, Brazil.
   [Lima, Rosangela G.] Univ Fed Bahia, Inst Ciencias Saude, BR-40110160 Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Lab Pesquisa Infectol, HUPES, 6 Andar,Rua Augusto Viana S-N, BR-40110160 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
FU Conselho Nacional de Pesquisa [Edital Universal 476504/2006-6]
FX This work was supported by Conselho Nacional de Pesquisa [Edital
   Universal 476504/2006-6]. We thank Alex Torres for performing the T
   lymphocytes count and Andre Ramos for performing viral load
   determinations.
CR Brites C, 2011, BRAZ J INFECT DIS, V15, P6, DOI 10.1590/S1413-86702011000100002
   Brites C, 2001, AIDS, V15, P2053, DOI 10.1097/00002030-200110190-00023
   BRITES C, 1997, BRAZ J INFECT DIS, V1, P42
   Carvalho EM, 2001, J ACQ IMMUN DEF SYND, V27, P1, DOI 10.1097/00126334-200105010-00001
   Casseb Jorge, 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P213, DOI 10.1590/S0036-46651997000400006
   Chinen J, 2002, J ALLERGY CLIN IMMUN, V110, P189, DOI 10.1067/mai.2002.126226
   Cohen OJ, 2000, FIELDS VIROLOGY, V2, P2043
   Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0
   Gudo ES, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-211
   Li JCB, 2010, AIDS, V24, P1609, DOI 10.1097/QAD.0b013e32833ac6a0
   Montanheiro PA, 2009, SCAND J IMMUNOL, V70, P403, DOI 10.1111/j.1365-3083.2009.02291.x
   Pedroso C, 2011, JAIDS-J ACQ IMM DEF, V57, pS208, DOI 10.1097/QAI.0b013e31821e9baf
   Regis C, 2009, BRAZ J INFECT DIS, V13, P311, DOI 10.1590/S1413-86702009000400014
   Scapellato PG, 2003, JAIDS-J ACQ IMM DEF, V33, P279, DOI 10.1097/00126334-200306010-00028
   Schechter M, 1997, J ACQ IMMUN DEF SYND, V15, P308, DOI 10.1097/00042560-199708010-00010
   TAJIMA K, 1987, INT J CANCER, V40, P741, DOI 10.1002/ijc.2910400605
   Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15
NR 17
TC 9
Z9 9
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 2012
VL 28
IS 8
BP 806
EP 808
DI 10.1089/aid.2011.0192
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 977SA
UT WOS:000306683600011
PM 22050450
DA 2020-12-01
ER

PT J
AU Nobrega, I
   Netto, EM
   Brites, C
AF Nobrega, Isabella
   Netto, Eduardo M.
   Brites, Carlos
TI Barriers to Prevention of HIV Type 1 Mother-to-Child-Transmission in
   Bahia, Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Letter
C1 [Nobrega, Isabella] Ctr Especializado Diagnost Assistencia & Pesquisa, CEDAP, Salvador, BA, Brazil.
   [Netto, Eduardo M.; Brites, Carlos] Univ Fed Bahia, Lab Pesquisas Infectol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Rua Joao Botas SN,6 Andar, BR-40140480 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
CR [Anonymous], 2010, B EP AIDS DST
   de Macedo VC, 2009, CAD SAUDE PUBLICA, V25, P1679, DOI 10.1590/S0102-311X2009000800004
   de Souza PRB, 2004, REV SAUDE PUBL, V38, P764, DOI 10.1590/S0034-89102004000600003
   Nobrega I, 2010, 18 INT AIDS C JUL 18
NR 4
TC 4
Z9 4
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAR
PY 2012
VL 28
IS 3
BP 233
EP 234
DI 10.1089/aid.2011.0165
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 904VK
UT WOS:000301226100001
PM 21848423
OA Green Published
DA 2020-12-01
ER

PT J
AU Santos, LA
   Monteiro-Cunha, JP
   Araujo, AF
   Brites, C
   Galvao-Castro, B
   Alcantara, LCJ
AF Santos, Luciane Amorim
   Monteiro-Cunha, Joana Paixao
   Araujo, Adriano Fernando
   Brites, Carlos
   Galvao-Castro, Bernardo
   Junior Alcantara, Luiz Carlos
TI Detection of Distinct Human Immunodeficiency Virus Type 1 Circulating
   Recombinant Forms in Northeast Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HIV-1; CRF; resistance
ID DYNAMICS IN-VIVO; HIV TYPE-1; RESISTANCE MUTATIONS; DIVERSITY; SUBTYPE
AB The extraordinary genetic diversity and immune evasion of human immunodeficiency virus (HIV) pose significant challenges for vaccine development and antiretroviral therapy efficacy. The objective of this study was to characterize the molecular profile of HIV-1 epidemic in Salvador, Bahia, Brazil, determining the genetic subtypes and the presence of antiretroviral resistance mutations. HIV-1 pol DNA sequences from 57 individuals infected with HIV were obtained by PCR, followed by sequencing. The subtypes were determined by phylogenetic analyses and the intersubtype recombination was investigated by bootscanning. The pol subtypes were compared with gag and env subtypes. Antiretroviral susceptibility was evaluated through the Stanford HIV resistance Database. The subtypes frequencies were: 77.2% of subtype B, 1.8% of subtype F1, and 21.0% of BF recombinant forms. Two intergenic and three intragenic BF recombinant patterns were observed. Six (10.5%) viruses were related to CRF28/CRF29, two were related to CRF12 (3.5%), and one (1.8%) was CRF39. Fourteen (24.6%) strains carried one or more mutations associated with at least intermediate resistance: 24.6% had resistance to nucleoside reverse transcriptase inhibitors, 21.0% to non-nucleoside reverse transcriptase inhibitors, and 7% to protease inhibitors. The substitutions I54V (7.0%), M184V (14.0%), and K103N (10.5%) were the most frequent within each class of drugs. The results show a high diversity of BF genotypes and a lower prevalence of major reverse transcriptase and protease drug resistance mutations in Salvador, compared with other regions of Brazil. These findings may contribute to improve treatment strategies of patients infected with HIV-1 from this Brazilian region. J. Med. Virol. 83: 2066-2072, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Santos, Luciane Amorim; Monteiro-Cunha, Joana Paixao; Araujo, Adriano Fernando; Galvao-Castro, Bernardo; Junior Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Lab Avancado Saude Publ, BR-40296610 Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
   [Galvao-Castro, Bernardo; Junior Alcantara, Luiz Carlos] Bahia Fdn Sci Dev, Bahia Sch Med & Publ Hlth, HTLV Ctr, Salvador, BA, Brazil.
   [Junior Alcantara, Luiz Carlos] NCI, NIH, Bethesda, MD 20892 USA.
RP Monteiro-Cunha, JP (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Lab Avancado Saude Publ, Rua Waldemar Falca,121 Candeal, BR-40296610 Salvador, BA, Brazil.
EM jmonteiro@bahia.fiocruz.br
OI Alcantara, Luiz/0000-0002-6769-9931
FU FAPESB [303/03]; Brazilian Ministry of Health [306/04, 307/04];
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX Grant sponsor: FAPESB; Grant number: 303/03; Grant sponsor: Brazilian
   Ministry of Health; Grant numbers: 306/04; 307/04; Grant sponsor: CNPq.
CR [Anonymous], 2010, B EPIDEMIOLOGICO AID
   Araujo AF, 2010, AIDS RES HUM RETROV, V26, P1249, DOI 10.1089/aid.2010.0068
   Brennan CA, 2007, AIDS RES HUM RETROV, V23, P1434, DOI 10.1089/aid.2007.0121
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Sa DJ, 2008, AIDS RES HUM RETROV, V24, P347, DOI 10.1089/aid.2007.0203
   Alcantara LCJ, 2009, NUCLEIC ACIDS RES, V37, pW634, DOI 10.1093/nar/gkp455
   McCutchan FE, 2000, AIDS, V14, pS31
   Toledo PV, 2010, BRAZ J INFECT DIS, V14, P360, DOI 10.1590/S1413-86702010000400009
   Monteiro JP, 2009, J MED VIROL, V81, P391, DOI 10.1002/jmv.21414
   Monteiro-Cunha JP, 2011, AIDS RES HUM RETROV, V27, P623, DOI [10.1089/AID.2010.0126, 10.1089/aid.2010.0126]
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   NICHOLAS KB, 1997, EMB NEWS, V14, P30
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Rios M, 2005, AIDS RES HUM RETROV, V21, P835, DOI 10.1089/aid.2005.21.835
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   SWOFFORD DL, 1997, PAUP PHYLOGENETIC AN
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   *UNAIDS, AIDS EP UPD 2007
   LOS ALAMOS HIV DATAB
NR 24
TC 13
Z9 13
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2011
VL 83
IS 12
BP 2066
EP 2072
DI 10.1002/jmv.22170
PG 7
WC Virology
SC Virology
GA 838AM
UT WOS:000296257900002
PM 22012712
OA Green Published
DA 2020-12-01
ER

PT J
AU Bahia, F
   Novais, V
   Evans, J
   Le Marchand, C
   Netto, E
   Page, K
   Brites, C
AF Bahia, Fabianna
   Novais, Vinicius
   Evans, Jennifer
   Le Marchand, Chloe
   Netto, Eduardo
   Page, Kimberly
   Brites, Carlos
TI The Impact of Human T-Cell Lymphotropic Virus I Infection on Clinical
   and Immunologic Outcomes in Patients Coinfected With HIV and Hepatitis C
   Virus
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1 and HCV coinfection; HIV-1; HCV; HTLV-1 triple infection
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTION-DRUG USERS; OPPORTUNISTIC
   DISEASE; HTLV-I; PROGRESSION; MORTALITY; BRAZIL; SEROPREVALENCE;
   EPIDEMIOLOGY; POPULATION
AB Background: HIV, hepatitis C (HCV), and human T-cell lymphotropic virus I (HTLV-1) are associated with high global burdens of disease, notably in resource-poor locales. They share similar routes of transmission and cause chronic infections with associated morbidity. We performed a cross-sectional study to assess the impact of HTLV-1 infection on clinical outcomes in HIV/HCV-coinfected patients.
   Methods: We enrolled 102 (72.3%) with HIV/HCV coinfection (Group 1) and 39 (27.7%) triply infected with HIV, HCV, and HTLV-1 (Group 2). We reviewed medical records of two groups of patients followed in two outpatients services in Salvador, Brazil. We collected and compared demographic, behavioral-related information, immunologic, virologic, and histologic parameters for HIV-1 and HCV infection.
   Results: Demographics, virologic, and immunologic characteristics were similar in the two groups; a higher proportion of triply infected patients (Group 2) reported any history of injection drug use compared with dually infected (Group 1) patients (75% vs 45.8%; P = 0.003). No differences were seen between groups in HIV clinical outcomes (CD4 count and viral load). Alanine aminotransferase levels were significantly higher in HIV/HCV-coinfected patients (P = 0.045). Liver fibrosis damage based on Metavir scores was similar between groups (0.97) but was worse with lower CD4 cell count (under 200 cells/mm(3)) (P = 0.01).
   Conclusions: HIV/HTLV-1 and HIV/HCV coinfections may worsen clinical related outcomes, but virologic and immunologic outcomes were similar in both groups. Hepatic measures were worse in patients with more severe immunosuppression.
C1 Ctr Estadual Diagnost Assistencia & Pesquisa HIV, Salvador, BA, Brazil.
   [Bahia, Fabianna; Novais, Vinicius; Netto, Eduardo; Brites, Carlos] Univ Fed Bahia HUPES UFBA, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Evans, Jennifer; Le Marchand, Chloe; Page, Kimberly] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Bahia, F (corresponding author), Univ Fed Bahia, LAPI, Rua Augusto Viana S-N,Complexo Hosp Prof Edgard S, BR-40110060 Salvador, BA, Brazil.
EM fabianna.bahia@gmail.com
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761;
   Page, Kimberly/0000-0002-7120-1673
FU Fogarty International CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43 TW005799]; NATIONAL INSTITUTE ON DRUG
   ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017, R01DA016017] Funding Source: NIH RePORTER
FX The authors thank the University of California, San Francisco, Center
   for Aids Prevention Studies, US National Institute of Mental Health
   (NIMH), P30 MH062246; the International Traineeships in AIDS Prevention
   Studies, US NIMH, R25MH064712; and the Fogarty International Center's
   International, Operational and Health Services Research Training Award,
   Brazilian Scientists Program (D43 TW005799).
CR Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004
   Bangham CRM, 2000, J CLIN PATHOL, V53, P581, DOI 10.1136/jcp.53.8.581
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409
   Boschi-Pinto C, 2000, J INFECT DIS, V181, P35, DOI 10.1086/315177
   Brites C, 2009, AIDS REV, V11, P8
   Di Martino V, 2001, HEPATOLOGY, V34, P1193, DOI 10.1053/jhep.2001.29201
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0
   Gallo RC, 2002, IMMUNOL REV, V185, P236, DOI 10.1034/j.1600-065X.2002.18520.x
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909
   Hisada M, 2003, J INFECT DIS, V188, P891, DOI 10.1086/377585
   Kim AY, 2009, GASTROENTEROLOGY, V137, P795, DOI 10.1053/j.gastro.2009.06.040
   Kishihara Y, 2001, J INFECT DIS, V184, P1114, DOI 10.1086/323890
   Maida I, 2007, AIDS RES HUM RETROV, V23, P801, DOI 10.1089/aid.2006.0085
   Martin-Carbonero L, 2009, J VIRAL HEPATITIS, V16, P790, DOI 10.1111/j.1365-2893.2009.01133.x
   Morimoto HK, 2005, AIDS RES HUM RETROV, V21, P256, DOI 10.1089/aid.2005.21.256
   Milagres FAP, 2009, REV SOC BRAS MED TRO, V42, P363, DOI 10.1590/S0037-86822009000400001
   Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806
   Segurado AC, 2004, AIDS PATIENT CARE ST, V18, P135, DOI 10.1089/108729104322994829
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Sulkowski MS, 2000, CLIN INFECT DIS, V30, pS77, DOI 10.1086/313842
   Sulkowski MS, 2004, JAIDS-J ACQ IMM DEF, V35, P464, DOI 10.1097/00126334-200404150-00004
   Sulkowski MS, 2003, ANN INTERN MED, V138, P197, DOI 10.7326/0003-4819-138-3-200302040-00012
   Tedaldi E, 2008, CLIN INFECT DIS, V47, P1468, DOI 10.1086/593102
   Reiche EMV, 2008, INT J MOL MED, V21, P387
   Wise M, 2008, HEPATOLOGY, V47, P1128, DOI 10.1002/hep.22165
   Zunt JR, 2006, SCAND J INFECT DIS, V38, P654, DOI 10.1080/00365540600617009
NR 29
TC 14
Z9 14
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2011
VL 57
SU 3
BP S202
EP S207
DI 10.1097/QAI.0b013e31821e9a1e
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 798TU
UT WOS:000293235900013
PM 21857319
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Ogalha, C
   Luz, E
   Sampaio, E
   Souza, R
   Zarife, A
   Neto, MG
   Netto, E
   Brites, C
AF Ogalha, Cecilia
   Luz, Estela
   Sampaio, Ethiane
   Souza, Rodrigo
   Zarife, Andre
   Gomes Neto, Mansueto
   Netto, Eduardo
   Brites, Carlos
TI A Randomized, Clinical Trial to Evaluate the Impact of Regular Physical
   Activity on the Quality of Life, Body Morphology and Metabolic
   Parameters of Patients With AIDS in Salvador, Brazil
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE AIDS; physical activity; lipodystrophy; metabolics disorders; quality of
   life
ID HUMAN-IMMUNODEFICIENCY-VIRUS; EXERCISE; LIPODYSTROPHY; INDIVIDUALS
AB Patients with AIDS under antiretroviral therapy often present with metabolic problems associated with HIV infection and its therapy, which can affect their quality of life. The knowledge on the potential benefits of regular physical exercises for HIV-infected patients is limited.
   Objective: We conducted a clinical trial to evaluate the impact of regular physical activity on quality of life, anatomic disturbances, and/or metabolic changes in patients with AIDS in the city of Salvador, Brazil.
   Methods: Patients were randomly assigned in monthly workshops (1-hour duration) to discuss the importance of physical activity and receive nutritional counseling (control group) or to receive a 1-hour supervised gym class three times a week plus monthly nutritional counseling (intervention group). Before and after intervention, body composition, maximum oxygen consumption, metabolic equivalent, blood count, fasting total cholesterol, high-density lipoprotein, triglycerides, glucose, HIV viral load and CD4/CD8 counts, and resting heart rate were measured. Quality of life was evaluated at baseline and after 24 weeks.
   Results: The domains of quality of life, general health, vitality and mental health increased in the exercise group (P < 0.05) compared with the control group. In the exercise group, fat mass (P = 0.04), the resting heart rate (P = 0.001), waist circumference (P = 0.002), and glucose (P = 0.003) decreased. Muscle mass (P = 0.002), CD4(+) T cells (P = 0.002), metabolic equivalent (P = 0.014), and maximum oxygen consumption (P = 0.05) increased.
   Conclusion: The practice of regular exercise, coupled with nutritional guidance, in individuals with HIV/AIDS significantly improves the quality of life.
C1 [Ogalha, Cecilia; Luz, Estela; Sampaio, Ethiane; Souza, Rodrigo; Zarife, Andre; Gomes Neto, Mansueto; Netto, Eduardo; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Rua Joao das Botas SN,6 Andar, BR-40110160 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Brites, Carlos/D-1353-2013; Gomes-NETO, Mansueto MGN/I-5235-2014; Netto,
   Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Gomes-NETO, Mansueto
   MGN/0000-0002-0717-9694; Netto, Eduardo/0000-0003-1691-6761; Luz,
   Estela/0000-0002-1062-7179
FU Ministry of Health/Secretariat of Health Surveillance/Department of STD,
   AIDS and Viral Hepatitis through Brazilian Government [AD/BRA/03/H34];
   Ministry of Health/Secretariat of Health Surveillance/Department of STD,
   AIDS and Viral Hepatitis through United Nations Office on Drugs and
   Crime-UNODC [AD/BRA/03/H34]
FX This work was carried out by the Hospital Universitario professor Edgard
   Santos with technical and financial support of the Ministry of
   Health/Secretariat of Health Surveillance/Department of STD, AIDS and
   Viral Hepatitis through the Project of International Technical
   Cooperation AD/BRA/03/H34 between the Brazilian Government and the
   United Nations Office on Drugs and Crime-UNODC.
CR *AM COLL SPORTS ME, 2003, ACSMS GUID STRESS TE
   American College Sports Medicine, 2006, ACSMS GUID EX TEST P
   Cade WT, 2004, PHYS THER, V84, P655, DOI 10.1093/ptj/84.7.655
   Carter V M, 2001, HIV Med, V2, P174, DOI 10.1046/j.1468-1293.2001.00073.x
   Ciconelli R. M., 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005
   Collins E, 2000, AIDS Read, V10, P546
   DEROSE EH, 1984, CINEANTROPOMETRY PHY, P80
   Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0
   Aparicio AMG, 2006, CLIN RHEUMATOL, V25, P537, DOI 10.1007/s10067-005-0028-x
   JACKSON AS, 1978, BRIT J NUTR, V40, P497, DOI 10.1079/BJN19780152
   LIRA VA, 1996, EFFECTS SUPERVISED A
   Miller WC, 1997, INT J OBESITY, V21, P941, DOI 10.1038/sj.ijo.0800499
   Mustafa T, 1999, ANN EPIDEMIOL, V9, P127, DOI 10.1016/S1047-2797(98)00043-X
   NOVITSKY S, 1995, EUR J APPL PHYSIOL O, V70, P462, DOI 10.1007/BF00618499
   Palermo PCG, 1997, P 2 BRAZ C SPORTS ME
   PALERMO PCG, 2003, J EXERCISE PHYSL, V2, P218
   POLLOCK ML, 1993, EXERCISE HLTH DIS AS
   Saves M, 2002, CLIN INFECT DIS, V34, P1396, DOI 10.1086/339866
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005
   Terry L, 1999, INT J SPORTS MED, V20, P142, DOI 10.1055/s-2007-971108
   Terry L, 2006, MED SCI SPORT EXER, V38, P411, DOI 10.1249/01.mss.0000191347.73848.80
   TERRY L, 1997, P 2 BRAZ C SPORTS ME
   TERRY L, 2006, REV SOC CARDIOLOGIA, V9, P1
   Thoni GJ, 2002, DIABETES METAB, V28, P397
   ULLUM H, 1994, J ACQ IMMUN DEF SYND, V7, P1122
   Valente Angélica M.M., 2005, Arq Bras Endocrinol Metab, V49, P871, DOI 10.1590/S0004-27302005000600004
   Yarasheski KE, 2001, J APPL PHYSIOL, V90, P133
NR 27
TC 31
Z9 32
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2011
VL 57
SU 3
BP S179
EP S185
DI 10.1097/QAI.0b013e31821e9bca
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 798TU
UT WOS:000293235900009
PM 21857315
DA 2020-12-01
ER

PT J
AU Pedroso, C
   Netto, EM
   Weyll, N
   Brites, C
AF Pedroso, Celia
   Netto, Eduardo M.
   Weyll, Neide
   Brites, Carlos
TI Coinfection by HIV-1 and Human Lymphotropic Virus Type 1 in Brazilian
   Children Is Strongly Associated With a Shorter Survival Time
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; HTLV-1; coinfection; survival; children
ID IN-VIVO COINFECTION; HTLV-I; NEW-ORLEANS; DRUG-USERS; DISEASE;
   REPLICATION; EXPRESSION; INFECTION; INCREASE; CLINICS
AB Coinfection by HIV-1 and human lymphotropic virus type 1 is a frequent finding in South America, the Caribbean and Africa, and its prevalence varies from 4% to 16% according to the available reports. Although the impact of coinfection on HIV disease is still controversial, there is evidence supporting the contention that it can affect the natural history of both infections. No information is available on coinfection in children. In a nested case-control study, we evaluated 35 coinfected children matched by age, gender, and time of diagnosis to HIV monoinfected control subjects. At the first evaluation, coinfected children were more likely to present any signs and symptoms of disease (P < 0.001) than monoinfected ones despite having significantly higher CD4(+) cells count (1429 +/- 608 vs 928 +/- 768 cells/mm(3); P = 0.003). The proportion of deaths was higher (80%) for coinfected children than for HIV-1-infected ones (20%; relative risk, 2.1; 95% confidence interval, 1.4-3.1; P = 0.01). Survival was also significantly shorter for coinfected children (P = 0.001). Coinfection by HIV-1 and human lymphotropic virus type 1 in Brazilian children was strongly associated with higher mortality and shorter survival time despite coinfected patients having a higher baseline CD4(+) cells count.
C1 [Pedroso, Celia; Netto, Eduardo M.; Brites, Carlos] Univ Fed Bahia Hosp, Lab Pesquisa Virol, Salvador, BA, Brazil.
   [Weyll, Neide] CEDAP, Salvador, BA, Brazil.
RP Brites, C (corresponding author), LAPI HUPES, Rua Augusto Viana SN,60 Andar, Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
FU Ministry of Health/Secretariat of Health Surveillance/Department of STD,
   AIDS and Viral Hepatitis through Brazilian Government [914/BRA/1101];
   Ministry of Health/Secretariat of Health Surveillance/Department of STD,
   AIDS and Viral Hepatitis through United Nations Educational, Scientific
   and Cultural Organization-UNESCO [914/BRA/1101]
FX This work was carried out by the Centro Especializado em Diagnostico,
   Assistencia e Pesquisa, Salvador-CEDAP with technical and financial
   support of the Ministry of Health/Secretariat of Health
   Surveillance/Department of STD, AIDS and Viral Hepatitis through the
   Project of International Technical Cooperation 914/BRA/1101 between the
   Brazilian Government and the United Nations Educational, Scientific and
   Cultural Organization-UNESCO.
CR ABRAO M, 2010, 18 INT AIDS C VIENN
   Beilke MA, 1998, J ACQ IMMUN DEF SYND, V17, P391, DOI 10.1097/00042560-199804150-00002
   Bessinger R, 1997, J ACQ IMMUN DEF SYND, V14, P67, DOI 10.1097/00042560-199701010-00011
   BLATTNER WA, 1994, TXB AIDS MED, P887
   *BRAZ MIN HLTH, 2010, B EP AIDS DST
   Brites C, 2005, CLIN INFECT DIS, V40, P329, DOI 10.1086/426690
   Brites C, 2002, AIDS, V16, P1292, DOI 10.1097/00002030-200206140-00015
   Brites C, 2001, AIDS, V15, P2053, DOI 10.1097/00002030-200110190-00023
   BRITES C, 2004, 11 C RETR OPP INF CR
   Casoli C, 2000, BLOOD, V95, P2760, DOI 10.1182/blood.V95.9.2760.009k04_2760_2769
   Dourado I, 1999, MEM I OSWALDO CRUZ, V94, P13, DOI 10.1590/S0074-02761999000100006
   GESSAIN A, 1985, LANCET, V2, P407
   Harrison LH, 1998, AIDS PATIENT CARE ST, V12, P619, DOI 10.1089/apc.1998.12.619
   KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Moriuchi H, 1998, J EXP MED, V187, P1689, DOI 10.1084/jem.187.10.1689
   OSAME M, 1986, LANCET, V1, P1031
   PEDROSO C, 2010, 18 INT AIDS C VIENN
   Schechter M, 1997, J ACQ IMMUN DEF SYND, V15, P308, DOI 10.1097/00042560-199708010-00010
   Sobesky M, 2000, PRESSE MED, V29, P413
   Szabo J, 1999, AIDS RES HUM RETROV, V15, P1653, DOI 10.1089/088922299309694
   WEISS SH, 1987, 3 INT C AIDS WASH DC
   WIKTOR SZ, 1992, J INFECT DIS, V165, P920, DOI 10.1093/infdis/165.5.920
NR 23
TC 13
Z9 15
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2011
VL 57
SU 3
BP S208
EP S211
DI 10.1097/QAI.0b013e31821e9baf
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 798TU
UT WOS:000293235900014
PM 21857320
DA 2020-12-01
ER

PT J
AU Marra, AR
   Camargo, LFA
   Pignatari, ACC
   Sukiennik, T
   Behar, PRP
   Medeiros, EAS
   Ribeiro, J
   Girao, E
   Correa, L
   Guerra, C
   Brites, C
   Pereira, CAP
   Carneiro, I
   Reis, M
   de Souza, MA
   Tranchesi, R
   Barata, CU
   Edmond, MB
AF Marra, Alexandre R.
   Aranha Camargo, Luis Fernando
   Campos Pignatari, Antonio Carlos
   Sukiennik, Teresa
   Petersen Behar, Paulo Renato
   Servolo Medeiros, Eduardo Alexandrino
   Ribeiro, Julival
   Girao, Evelyne
   Correa, Luci
   Guerra, Carla
   Brites, Carlos
   Pires Pereira, Carlos Alberto
   Carneiro, Irna
   Reis, Marise
   de Souza, Marta Antunes
   Tranchesi, Regina
   Barata, Cristina U.
   Edmond, Michael B.
CA Brazilian SCOPE Study Grp
TI Nosocomial Bloodstream Infections in Brazilian Hospitals: Analysis of
   2,563 Cases from a Prospective Nationwide Surveillance Study
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID RESISTANT PSEUDOMONAS-AERUGINOSA; CRITICALLY-ILL PATIENTS; RAPID
   DETECTION; RISK-FACTORS; PCR ASSAY; OUTCOMES; THERAPY; BACTEREMIA;
   CANDIDEMIA; COLISTIN
AB Nosocomial bloodstream infections (nBSIs) are an important cause of morbidity and mortality. Data from a nationwide, concurrent surveillance study, Brazilian SCOPE (Surveillance and Control of Pathogens of Epidemiological Importance), were used to examine the epidemiology and microbiology of nBSIs at 16 Brazilian hospitals. In our study 2,563 patients with nBSIs were included from 12 June 2007 to 31 March 2010. Ninety-five percent of BSIs were monomicrobial. Gram-negative organisms caused 58.5% of these BSIs, Gram-positive organisms caused 35.4%, and fungi caused 6.1%. The most common pathogens (monomicrobial) were Staphylococcus aureus (14.0%), coagulase-negative staphylococci (CoNS) (12.6%), Klebsiella spp. (12.0%), and Acinetobacter spp. (11.4%). The crude mortality was 40.0%. Forty-nine percent of nBSIs occurred in the intensive-care unit (ICU). The most frequent underlying conditions were malignancy, in 622 patients (24.3%). Among the potential factors predisposing patients to BSI, central venous catheters were the most frequent (70.3%). Methicillin resistance was detected in 157 S. aureus isolates (43.7%). Of the Klebsiella sp. isolates, 54.9% were resistant to third-generation cephalosporins. Of the Acinetobacter spp. and Pseudomonas aeruginosa isolates, 55.9% and 36.8%, respectively, were resistant to imipenem. In our multicenter study, we found high crude mortality and a high proportion of nBSIs due to antibiotic-resistant organisms.
C1 [Marra, Alexandre R.] Hosp Israelita Albert Einstein, Intens Care Unit, BR-05651901 Sao Paulo, Brazil.
   [Marra, Alexandre R.; Aranha Camargo, Luis Fernando; Campos Pignatari, Antonio Carlos; Servolo Medeiros, Eduardo Alexandrino] Univ Fed Sao Paulo UNIFESP, Sao Paulo, Brazil.
   [Campos Pignatari, Antonio Carlos; Tranchesi, Regina] Hosp 9 Julho, Sao Paulo, Brazil.
   [Petersen Behar, Paulo Renato] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Ribeiro, Julival] Hosp Base, Brasilia, DF, Brazil.
   [Girao, Evelyne] Hosp Walter Cantidio, Fortaleza, Ceara, Brazil.
   [Guerra, Carla] Hosp Diadema, Sao Paulo, Brazil.
   [Pires Pereira, Carlos Alberto] Inst Oncol Pediat IOP GRAAC, Sao Paulo, Brazil.
   [Brites, Carlos] Hosp Espanhol, Salvador, BA, Brazil.
   [Reis, Marise] Hosp Coracao, Natal, RN, Brazil.
   [Reis, Marise] Hosp UNIMED, Natal, RN, Brazil.
   [de Souza, Marta Antunes] Hosp Clin Goiania, Goiania, Go, Brazil.
   [Correa, Luci] Hosp Rim & Hypertensao, Sao Paulo, Brazil.
   [Barata, Cristina U.] Univ Fed Triangulo Mineiro, Uberaba, MG, Brazil.
   [Edmond, Michael B.] Virginia Commonwealth Univ, Richmond, VA USA.
RP Marra, AR (corresponding author), Hosp Israelita Albert Einstein, Intens Care Unit, Av Albert Einstein 627-701,5th Floor, BR-05651901 Sao Paulo, Brazil.
EM alexmarra@einstein.br
RI Brites, Carlos/D-1353-2013; Medeiros, Eduardo A/B-9825-2012; Pignatari,
   Antonio CC/C-8427-2012
OI Brites, Carlos/0000-0002-4673-6991; Medeiros, Eduardo
   A/0000-0002-6205-259X; Camargo, Luis Fernando
   Aranha/0000-0002-3888-8661; Colombo, Arnaldo Lopes/0000-0003-0793-8491;
   Edmond, Michael/0000-0002-4144-8974; Bispo, Paulo/0000-0002-2867-1450;
   Pignatari, Antonio/0000-0002-2146-8476
FU Pfizer, Inc.Pfizer; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP), BrasilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2006/57700-0]
FX The study was funded in part by an independent medical grant provided by
   Pfizer, Inc. We also thank the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP), Brasil (grant 2006/57700-0).
CR [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST
   Blot S, 2002, CLIN INFECT DIS, V34, P1600, DOI 10.1086/340616
   Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011
   Brito LR, 2006, MED MYCOL, V44, P261, DOI 10.1080/13693780500421476
   Cao B, 2004, J HOSP INFECT, V57, P112, DOI 10.1016/j.jhin.2004.03.021
   Cergole-Novella MC, 2010, MICROB DRUG RESIST, V16, P177, DOI 10.1089/mdr.2010.0008
   Clinical and Laboratory Standards Institute, 2010, M100S20 CLIN LAB STA
   Collin BA, 2001, CLIN INFECT DIS, V33, P947, DOI 10.1086/322604
   Colombo AL, 2006, J CLIN MICROBIOL, V44, P2816, DOI 10.1128/JCM.00773-06
   d'Azevedo PA, 2009, BRAZ J INFECT DIS, V13, P289, DOI 10.1590/S1413-86702009000400010
   Dent LL, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-196
   Deresinski S, 2007, CLIN INFECT DIS, V45, pS177, DOI 10.1086/519472
   Deshpande LM, 2006, MICROB DRUG RESIST, V12, P223, DOI 10.1089/mdr.2006.12.223
   Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146
   Kang CI, 2003, CLIN INFECT DIS, V37, P745, DOI 10.1086/377200
   Levin AS, 1999, CLIN INFECT DIS, V28, P1008, DOI 10.1086/514732
   McDonald LC, 1999, CLIN INFECT DIS, V29, P1133, DOI 10.1086/313441
   Mendes RE, 2007, J CLIN MICROBIOL, V45, P544, DOI 10.1128/JCM.01728-06
   Milheirico C, 2007, ANTIMICROB AGENTS CH, V51, P3374, DOI 10.1128/AAC.00275-07
   Monteiro J, 2009, ANTIMICROB AGENTS CH, V53, P333, DOI 10.1128/AAC.00736-08
   Paul M, 2010, J ANTIMICROB CHEMOTH, V65, P1019, DOI 10.1093/jac/dkq069
   Perencevich EN, 2008, INFECT CONT HOSP EP, V29, P1124, DOI 10.1086/592698
   PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598
   RETAILLIAU HF, 1979, J INFECT DIS, V139, P371, DOI 10.1093/infdis/139.3.371
   Schimith KE, 2010, AM J INFECT CONTROL, V38, P308, DOI 10.1016/j.ajic.2009.09.012
   Sengstock DM, 2010, CLIN INFECT DIS, V50, P1611, DOI 10.1086/652759
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754
   Warren DK, 2001, CLIN INFECT DIS, V33, P1329, DOI 10.1086/322483
   Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946
   Zhang KY, 2005, J CLIN MICROBIOL, V43, P5026, DOI 10.1128/JCM.43.10.5026-5033.2005
NR 30
TC 118
Z9 136
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2011
VL 49
IS 5
BP 1866
EP 1871
DI 10.1128/JCM.00376-11
PG 6
WC Microbiology
SC Microbiology
GA 755OA
UT WOS:000289941000025
PM 21411591
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Netto, EC
   Brites, C
AF Netto, Elaine Coutinho
   Brites, Carlos
TI Characteristics of Chronic Pain and Its Impact on Quality of Life of
   Patients With HTLV-1-associated Myelopathy/Tropical Spastic Paraparesis
   (HAM/TSP)
SO CLINICAL JOURNAL OF PAIN
LA English
DT Article
DE HTLV-1; HAM/TSP; chronic pain; quality of life; Brazil
ID SPINAL-CORD-INJURY; HTLV-I; NEUROPATHIC PAIN; QUESTIONNAIRE
AB Objectives: We describe the prevalence of chronic pain and their characteristics in 43 consecutive patients presenting with human T-lymphotropic virus Type I (HTLV-1) associated myelopathy (HAM)/tropical spastic paraparesis in Salvador, Brazil.
   Methods: In this cross-sectional study, we included 43 consecutive patients with HAM/TSP from Sarah Salvador Unit of the Rehabilitation, in Bahia, Brazil. They were evaluated from September 2007 to July 2008. We used the following scales: Functional disability scales (EDSS, OSAME e HOFFER); visual analogue scale; Hospital Anxiety and Depression Scale; McGill Pain Questionnaire; DN4 Questionnaire and SF-36 Quality-of-Life Questionnaire.
   Results: Chronic pain was highly prevalent (38 patients-88.4%) in this population. We detected an inverse correlation between duration of the disease and the likelihood of patients to present with chronic pain (P<0.05). Individuals with greater neurologic deficits had much more neuropathic, whereas those with lower motor deficit had mainly the characteristics of nociceptive pain (P<0.05). A positive correlation was observed between the score of the dominant pain or the additional pain, and the number of pain descriptors (P<0.05 for both evaluations). The patients with chronic pain had worst Quality-of-Life scores (P<0.05).
   Conclusion: Chronic pain was significantly associated with a higher likelihood of signs/symptoms of anxiety and depression, reflecting a negative impact of pain on patients quality of life.
C1 [Brites, Carlos] Univ Fed Bahia, BR-40110160 Salvador, BA, Brazil.
   [Netto, Elaine Coutinho] Rede Sarah Hosp Reabilitacao, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Rua Joao Botas,SN,6O Andar, BR-40110160 Salvador, BA, Brazil.
EM crbrites@gmail.com
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Beiske AG, 2004, EUR J NEUROL, V11, P479, DOI 10.1111/j.1468-1331.2004.00815.x
   Benrud-Larson LM, 2000, NEUROREHABILITATION, V14, P127
   Botega NJ, 1995, REV SAUDE PUBL, V29, P355, DOI 10.1590/S0034-89101995000500004
   Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010
   Ciconelli R. M., 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005
   De Castro-Costa CM, 2006, AIDS RES HUM RETROV, V22, P931, DOI 10.1089/aid.2006.22.931
   Demirel G, 1998, SPINAL CORD, V36, P25, DOI 10.1038/sj.sc.3100523
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Felix ER, 2007, J REHABIL RES DEV, V44, P703, DOI 10.1682/JRRD.2006.12.0162
   GESSAIN A, 1985, LANCET, V2, P407
   Gotuzzo E, 1996, J NEUROL SCI, V143, P114, DOI 10.1016/S0022-510X(96)00186-4
   Jensen MP, 2007, NEUROLOGY, V68, P1178, DOI 10.1212/01.wnl.0000259085.61898.9e
   Jensen MP, 2005, SPINAL CORD, V43, P704, DOI 10.1038/sj.sc.3101777
   MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5
   Nakazone S, 2005, REV DOR, V2, P553
   NEPOMUCENO C, 1979, ARCH PHYS MED REHAB, V60, P605
   O'Connor AB, 2008, PAIN, V137, P96, DOI 10.1016/j.pain.2007.08.024
   OSAME M, 1986, LANCET, V1, P1031
   Putzke JD, 2002, PAIN, V100, P231, DOI 10.1016/S0304-3959(02)00069-6
   Ravenscroft A, 2001, ARCH PHYS MED REHAB, V38, P611
   ROMAN GC, 1988, LANCET, V1, P651
   Siddall PJ, 2006, SPINAL CORD, V44, P67, DOI 10.1038/sj.sc.3101824
   Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116
   Turner J A, 1999, Semin Clin Neuropsychiatry, V4, P186
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   World Health Organisation, 1989, WHO WKLY EPIDEMIOL R, V49, P382
NR 26
TC 20
Z9 20
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0749-8047
EI 1536-5409
J9 CLIN J PAIN
JI Clin. J. Pain
PD FEB
PY 2011
VL 27
IS 2
BP 131
EP 135
DI 10.1097/AJP.0b013e3181f195d3
PG 5
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA 703QD
UT WOS:000285993200006
PM 20842011
DA 2020-12-01
ER

PT J
AU Soares, CMPD
   Vergara, TRC
   Sucupira, MCA
   Brites, C
   Brito, JDU
   Grinberg, G
   Caseiro, MM
   Correa, C
   Suffert, TA
   Pereira, FR
   Komninakis, S
   Diaz, RS
AF Soares, C. M. P. De Moraes
   Vergara, T. R. C.
   Sucupira, M. C. A.
   Brites, C.
   Brito, J. D. U.
   Grinberg, G.
   Caseiro, M. M.
   Correa, C.
   Suffert, T. A.
   Pereira, F. R.
   Komninakis, S.
   Diaz, R. S.
TI Prevalence of transmitted HIV-1 antiretroviral resistance (TDR) among
   Brazilian individuals initiating antiretroviral therapy using dried
   blood spots (DBS)
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT International Workshop on HIV and Hepatitis Virus Drug Resistance and
   Curative Strategies
CY JUN 07-11, 2011
CL Los Cabos, MEXICO
C1 [Soares, C. M. P. De Moraes; Vergara, T. R. C.; Sucupira, M. C. A.; Grinberg, G.; Caseiro, M. M.; Komninakis, S.; Diaz, R. S.] Univ Fed Sao Paulo, Retrovirol Lab, Sao Paulo, Brazil.
   [Brites, C.] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   [Brito, J. D. U.] Fed Dist Hosp Fdn, Brasilia, DF, Brazil.
   [Caseiro, M. M.] Lusiada Univ, Sao Paulo, Brazil.
   [Suffert, T. A.] Municipal Porto Alegre, Porto Alegre, RS, Brazil.
RI Diaz, Ricardo/K-3978-2012; Komninakis, Shirley V/B-2915-2010
OI Komninakis, Shirley V/0000-0001-7784-3418
NR 0
TC 0
Z9 0
U1 0
U2 2
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2011
VL 16
IS 4
BP A135
EP A135
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 813OB
UT WOS:000294375700130
DA 2020-12-01
ER

PT J
AU Brites, C
   Goyanna, F
   Franca, LG
   Pedroso, C
   Netto, EM
   Adriano, S
   Sampaio, J
   Harrington, W
AF Brites, C.
   Goyanna, F.
   Franca, L. G.
   Pedroso, C.
   Netto, E. M.
   Adriano, S.
   Sampaio, J.
   Harrington, Jr W.
TI Coinfection by HTLV-I/II is associated with an increased risk of
   strongyloidiasis and delay in starting antiretroviral therapy for AIDS
   patients
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; HTLV-I/II; coinfection Strongyloidiasis; CD4/CD8
ID VIRUS TYPE-I; INFECTION; HIV; CARRIERS; TRANSMISSION; CONFIRMATION;
   MYELOPATHY; REACTIVITY; SURVIVAL; ANTIBODY
AB Objective: To compare the clinical characteristics and outcomes of HIV-1-HTLV-1 coinfected patients, in Bahia, Brazil. Methods: Retrospective, comparative study. Results: Among a total of 123 consecutive HIV infected patients, 20 men (20.6%) and 6 women (23.1%) had detectable antibodies against HTLV-I/II. The major risk factor associated with coinfection by HTLV was intravenous drug use (57.7% of coinfected patient versus 9.2% of HTLV seronegative patients, p < 0.0001). Coinfected patients had higher absolute lymphocyte counts (1,921 + 762 versus 1,587 + 951, p = 0.03). Both groups of patients had similar means of CD4+ and CD8+ cell counts. However, among patients with AIDS CD4+ cell counts were significantly higher among those coinfected with HTLV-I/II (292 +/- 92 cells/mm(3), versus 140 +/- 177 cells/mm(3), p = 0.36). The frequency and type of opportunistic infections were similar for both groups, but strongyloidiasis and encephalopathy were more frequently diagnosed in coinfected patients (p < 0.05). On the other hand, patients coinfected with HTLV-I/II received significantly less antiretroviral therapy than singly infected by HIV-1. Conclusion: Coinfection by HTLV-I/II is associated with an increased risk of strongyloidiasis for HIV patients. Higher CD4 count may lead to underestimation of immunodeficiency, and delay to initiate antiretroviral therapy.
C1 [Brites, C.; Goyanna, F.; Franca, L. G.; Pedroso, C.; Netto, E. M.; Adriano, S.; Sampaio, J.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Harrington, Jr W.] Univ Miami, Sch Med, Coral Gables, FL 33124 USA.
RP Brites, C (corresponding author), Lab Pesquisa Infectol Virol, Rua Joao das Botas SN, BR-40110160 Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
CR ANDO Y, 1987, JPN J CANCER RES, V78, P322
   BARTHOLOMEW C, 1986, LANCET, V2, P99
   BARTHOLOMEW C, 1987, LANCET, V2, P1469
   BARTHOLOMEW C, 1987, JAMA-J AM MED ASSOC, V257, P2605
   BLATTNER WA, 1990, HUMAN RETROVIROLOGY : HTLV, P251
   Brites C, 2002, AIDS, V16, P1292, DOI 10.1097/00002030-200206140-00015
   Brites C, 2001, AIDS, V15, P2053, DOI 10.1097/00002030-200110190-00023
   BRITES C, 1997, BRAZ J INFECT DIS, P43
   BRITES C, 1993, 1 NAT C HUM RETR REL
   DELAPORTE E, 1993, J ACQ IMMUN DEF SYND, V6, P424
   DEROSSI A, J ACQ IMMUNE DEF SYN, V4, P380
   DIXON AC, 1989, WESTERN J MED, V151, P410
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   FEITOSA G, 2001, BRAZ J INFECT DIS, V6, P339
   GESSAIN A, 1986, LANCET, V2, P698
   GOTUZZO E, 1992, ARCH INTERN MED, V152, P1429, DOI 10.1001/archinte.152.7.1429
   HATTORI T, 1989, J ACQ IMMUN DEF SYND, V2, P272
   KAJIYAMA W, 1986, J INFECT DIS, V154, P851, DOI 10.1093/infdis/154.5.851
   KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653
   LAL RB, 1992, J CLIN MICROBIOL, V30, P296, DOI 10.1128/JCM.30.2.296-299.1992
   LIPKA JJ, 1991, J INFECT DIS, V164, P400, DOI 10.1093/infdis/164.2.400
   LIPKA JJ, 1992, J INFECT DIS, V165, P268, DOI 10.1093/infdis/165.2.268
   LUSSO P, 1990, J VIROL, V64, P6341, DOI 10.1128/JVI.64.12.6341-6344.1990
   MILLER DH, 1987, LANCET, V2, P514
   *MIN SAUD, AIDS B EP 2002
   NAKADA K, 1984, LANCET, V1, P633
   OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x
   OSAME M, 1986, LANCET, V1, P1031
   Puccioni-Sohler M, 2003, J NEUROL SCI, V207, P87, DOI 10.1016/S0022-510X(02)00413-6
   ROBERTGUROFF M, 1983, BLUT, V47, P1, DOI 10.1007/BF00321045
   ROBINSON RD, 1990, W INDIAN MED J, V169, P692
   SATO Y, 1990, Japanese Journal of Parasitology, V39, P376
   SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353
   Schechter M, 1997, J ACQ IMMUN DEF SYND, V15, P308, DOI 10.1097/00042560-199708010-00010
   SHIBASAKI H, 1988, J NEUROL SCI, V87, P15, DOI 10.1016/0022-510X(88)90050-0
   Sobesky M, 2000, PRESSE MED, V29, P413
   TOURNIERLASSERVE E, 1987, LANCET, V2, P49
   WELLES SL, 1994, INT J CANCER, V56, P337, DOI 10.1002/ijc.2910560307
   ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813
NR 39
TC 9
Z9 10
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2011
VL 15
IS 1
BP 6
EP 11
DI 10.1016/S1413-8670(11)70132-5
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 735AG
UT WOS:000288385100002
PM 21412582
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Araujo, AF
   Brites, C
   Monteiro-Cunha, J
   Santos, LA
   Galvao-Castro, B
   Alcantara, LCJ
AF Araujo, Adriano Fernando
   Brites, Carlos
   Monteiro-Cunha, Joana
   Santos, Luciane Amorim
   Galvao-Castro, Bernardo
   Junior Alcantara, Luiz Carlos
TI Lower Prevalence of Human Immunodeficiency Virus Type 1 Brazilian
   Subtype B Found in Northeastern Brazil with Slower Progression to AIDS
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID V3 REGION; HIV-1
AB Besides being extremely useful in measuring the level of HIV-1 diversity and prevalence in populations, the molecular analysis of genomic sequences provides crucial surveillance support and aids in the development of new therapies and effective vaccines. The present study focused on gag and env DNA and amino acid sequences that were generated from samples taken from 61 infected patients in the City of Salvador, Bahia, located in northeastern Brazil. In order to determine selective pressure and predict coreceptor usage, Bioinformatics tools were employed in phylogeny reconstruction. Fifty-six (91.8%) viruses were classified as belonging to subtype B, three (4.9%) from F1, and two (3.3%) from BF1 recombinants. Based on the characterization of the V3 region, the subtype B strains were represented by eight (18.2%) Brazilian variants (B'-GWGR), 20 (46.5%) European/EUA B variants (GPGR), and 15 (34.9%) GXGX variants. The mean time elapsed since diagnosis was 13 years among subtype B' and 9 years in subtype B. The mean dN/dS ratios from the GWGR, GPGR, and GXGX groups, when compared to an HXB2 reference, were 0.72, 0.77, and 0.67, respectively. Seventy-six percent of the viruses studied were predicted to use the CCR5 coreceptor for cell entry (R5 viruses), while 24% were predicted to use the CXCR4 or were classified as dual tropic viruses. The prevalence of subtypes B' and recombinant B/F1 was shown to be lower than findings from previous studies performed both in Brazil (B') and in Bahia (B/F1). The association between subtype B' and a lengthy period of time since diagnosis can be correlated with a slower disease progression in infected patients, when compared with those infected with subtype B.
C1 [Junior Alcantara, Luiz Carlos] NCI, Anim Models & Retroviral Vaccines Sect, NIH, Bethesda, MD 20892 USA.
   [Araujo, Adriano Fernando; Monteiro-Cunha, Joana; Santos, Luciane Amorim; Galvao-Castro, Bernardo; Junior Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Adv Publ Hlth Lab, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
   [Galvao-Castro, Bernardo; Junior Alcantara, Luiz Carlos] Fdn Dev Sci, Bahia Sch Med & Publ Hlth, Salvador, BA, Brazil.
RP Alcantara, LCJ (corresponding author), NCI, Anim Models & Retroviral Vaccines Sect, NIH, Bldg 41,Room C-303, Bethesda, MD 20892 USA.
EM alcantaralc@mail.nih.gov
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Alcantara, Luiz/0000-0002-6769-9931
CR Bastos FI, 2008, INT J EPIDEMIOL, V37, P729, DOI 10.1093/ije/dyn127
   Brennan CA, 2007, AIDS RES HUM RETROV, V23, P1434, DOI 10.1089/aid.2007.0121
   de Brito A, 2006, CLIN INFECT DIS, V43, P1476, DOI 10.1086/508875
   Diaz RS, 2008, VIROLOGY, V381, P184, DOI 10.1016/j.virol.2008.08.014
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Korber B, 2000, COMPUTATIONAL ANAL H, P55, DOI DOI 10.1007/B112102
   Mindell DP, 1996, P NATL ACAD SCI USA, V93, P3284, DOI 10.1073/pnas.93.8.3284
   Monteiro JP, 2009, J MED VIROL, V81, P391, DOI 10.1002/jmv.21414
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   Nicholas K. B., 1997, EMBNET NEWS, V4, P1
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   POTTS KE, 1993, AIDS, V7, P1191, DOI 10.1097/00002030-199309000-00007
   SALMINEN M, 1995, AIDS RES HUM RETROV, V11, pS119
   Sing T, 2007, ANTIVIR THER, V12, P1097
   Swofford DL, 1999, PAUP 4 0 PHYLOGENETI
NR 16
TC 13
Z9 13
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2010
VL 26
IS 11
BP 1249
EP 1254
DI 10.1089/aid.2010.0068
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 681KL
UT WOS:000284311900014
PM 20854208
DA 2020-12-01
ER

PT J
AU da Silva, EM
   Acosta, AX
   Santos, EJM
   Netto, EM
   Lemaire, DC
   Oliveira, AS
   Barbosa, CM
   Bendicho, MT
   Galvao-Castro, B
   Brites, C
AF da Silva, Edinete Melo
   Acosta, Angelina Xavier
   Melo Santos, Eduardo Jose
   Netto, Eduardo Martins
   Lemaire, Denise Carneiro
   Oliveira, Adriano Silva
   Barbosa, Carolina Matos
   Bendicho, Maria Teresita
   Galvao-Castro, Bernardo
   Brites, Carlos
TI HLA-Bw4-B*57 and Cw*18 alleles are associated with plasma viral load
   modulation in HIV-1 infected individuals in Salvador, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; AIDS; MHC; HLA; polymorphism
ID CYTOTOXIC T-LYMPHOCYTES; NATURAL-KILLER-CELLS; HLA-B; Y-CHROMOSOME;
   TYPE-1 INFECTION; HIV-1 INFECTION; DIRECT BINDING; PROGRESSION; VIREMIA;
   HETEROGENEITY
AB Host genetic factors play an important role in mediating resistance to HIV-1 infection and may modify the course of infection. HLA-B alleles (Bw4 epitope; B*27 and B*57) as well as killer cell immunoglobulin-like receptors have been associated with slow progression of HIV-1 infection. Objective: To evaluate the association between serological epitopes HLA-Bw4 and HLA-Bw6 and prognostic markers in AIDS. Methods: 147 HIV-infected individuals in Bahia, Northeast Brazil, were genotyped for HLA class I locus. HLA class I genotyping was performed by hybridization with sequence-specific oligonucleotide probes following amplification of the corresponding HLA-A, HLA-B and HLA-C genes. Statistical analysis was performed using Fisher's exact and ANOVA tests for categorical and continuous variables, respectively. Results: We detected a significant association (chi(2) = 4.856; p = 0.018) between the presence of HLA-Bw4 and low levels of viremia. Eighteen out of the 147 HIV-infected individuals presented viremia <= 1,800 copies/mL and 129 presented viremia > 2,000 copies/mL. Ninety and four percent (17/18) of all individuals with viremia. 1,800 copies/mL carried HLA-Bw4, compared to 67.4% (87/129) of individuals with viremia > 2,000 copies/mL. Additionally, we found a significantly higher frequency of B*57 (OR = 13.94; 95% CI = 4.19-46.38; p < 0.0001) and Cw*18 (OR = 16.15; 95% CI = 3.46-75.43; p <= 0.0001) alleles, favoring the group with lower viremia levels, in comparison with those with higher viral load. Conclusion: HLA-Bw4-B*57 and Cw*18 alleles are associated with lower level of viral load in HIV-infected Brazilian patients. These findings may help us in understanding the determinants of HIV evolution in Brazilian patients, as well as in providing important information on immune response correlates of protection for such population.
C1 [da Silva, Edinete Melo; Netto, Eduardo Martins; Oliveira, Adriano Silva; Brites, Carlos] Univ Fed Bahia, Lab Pesquisa Infectol, Hosp Univ Prof Edgard Santos, HUPES, BR-40110060 Salvador, BA, Brazil.
   [Acosta, Angelina Xavier; Melo Santos, Eduardo Jose] Univ Fed Bahia, Sch Med, Dept Pediat, BR-40110060 Salvador, BA, Brazil.
   [Lemaire, Denise Carneiro; Bendicho, Maria Teresita] Univ Fed Bahia, Immunol Lab, Inst Ciencias & Saude, ICS, BR-40110060 Salvador, BA, Brazil.
   [Barbosa, Carolina Matos] UFPA, Ctr Biol Sci, Lab Humam & Med Genet, Belem, Para, Brazil.
RP da Silva, EM (corresponding author), Univ Fed Bahia, Lab Pesquisa Infectol, Hosp Univ Prof Edgard Santos, HUPES, Rua Augusto Viana S-N Canela,6 Andar, BR-40110060 Salvador, BA, Brazil.
EM edinete@yahoo.com
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB), Salvador,
   Bahia; Conselho Nacional de Desenvolvimento Cientfico e Tecnologico
   (CNPq/PAPES), BrazilNational Council for Scientific and Technological
   Development (CNPq)
FX This study was financially supported by Fundacao de Amparo a Pesquisa do
   Estado da Bahia (FAPESB), Salvador, Bahia, and Conselho Nacional de
   Desenvolvimento Cientfico e Tecnologico (CNPq/PAPES), Brazil.
CR Abbas K, 1995, BIOL CELULAR MOL
   Abe-Sandes K, 2004, HUM BIOL, V76, P77, DOI 10.1353/hub.2004.0014
   Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005
   Alves-Silva J, 2000, AM J HUM GENET, V67, P444, DOI 10.1086/303004
   [Anonymous], HLA CLASS 1 SEQ AL
   Barbosa AAL, 2006, GENET MOL BIOL, V29, P23, DOI 10.1590/S1415-47572006000100004
   Bashirova AA, 2006, ANNU REV GENOM HUM G, V7, P277, DOI 10.1146/annurev.genom.7.080505.115726
   Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205
   Bruunsgaard H, 1997, SCAND J IMMUNOL, V46, P91, DOI 10.1046/j.1365-3083.1997.d01-98.x
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Carvalho-Silva DR, 2006, GENETICA, V126, P251, DOI 10.1007/s10709-005-1454-z
   Carvalho-Silva DR, 2001, AM J HUM GENET, V68, P281, DOI 10.1086/316931
   CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235
   Chen Y, 1997, CLIN DIAGN LAB IMMUN, V4, P4, DOI 10.1128/CDLI.4.1.4-10.1997
   Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198
   GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133
   Harrer T, 1996, J IMMUNOL, V156, P2616
   Hultstrom AL, 2004, IMMUNOL LETT, V91, P155, DOI 10.1016/j.imlet.2003.11.012
   Kaslow RA, 2001, J VIROL, V75, P8681, DOI 10.1128/JVI.75.18.8681-8689.2001
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Lazaryan A, 2006, J VIROL, V80, P6056, DOI 10.1128/JVI.02119-05
   Lopez-Vazquez A, 2005, HUM IMMUNOL, V66, P285, DOI 10.1016/j.humimm.2005.01.001
   Magierowska M, 1999, BLOOD, V93, P936, DOI 10.1182/blood.V93.3.936.403k08_936_941
   Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035
   Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   MULLER CA, 1989, IMMUNOGENETICS, V30, P200, DOI 10.1007/BF02421207
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.iy.13.040195.002415
   Qi Y, 2006, PLOS PATHOG, V2, P741, DOI 10.1371/journal.ppat.0020079
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Wagtmann N, 1995, IMMUNITY, V3, P801, DOI 10.1016/1074-7613(95)90069-1
   Walker BD, 2007, TOP HIV MED, V15, P134
   Welzel TM, 2007, AIDS, V21, P225, DOI 10.1097/QAD.0b013e3280123840
   Winter CC, 1998, J IMMUNOL, V161, P571
NR 37
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2010
VL 14
IS 5
BP 468
EP 475
DI 10.1016/S1413-8670(10)70095-7
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 705CU
UT WOS:000286107300008
PM 21221475
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Diaz, RS
   Sucupira, MCA
   Vergara, TRC
   Brites, C
   Del Bianco, R
   Bonasser, F
   Colares, GKB
   Portela, E
   Cherman, LA
   Barcelos, NT
   Tupinambas, U
   Turcato, G
   Allamasey, L
   Bacheler, L
   Tuohy, M
AF Diaz, Ricardo Sobhie
   Sucupira, Maria Cecilia A.
   Vergara, Tania R. C.
   Brites, Carlos
   Del Bianco, Rosana
   Bonasser Filho, Francisco
   Colares, Geova Keny B.
   Portela, Estevao
   Cherman, Lia Adler
   Barcelos, Nemora Tregnago
   Tupinambas, Unai
   Turcato, Gilberto, Jr.
   Allamasey, Lisa
   Bacheler, Lee
   Tuohy, Martin
CA Brazilian Network Reference Phys W
TI HIV-1 resistance testing influences treatment decision-making
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE genotype; virtual phenotype; antiretroviral resistance; Brazil
ID ANTIRETROVIRAL THERAPY; GENOTYPIC RESISTANCE; VIRTUAL PHENOTYPE;
   INFECTED PATIENTS; TREATMENT FAILURE; FOLLOW-UP; TRIAL; IMPACT
AB Objective: To investigates how the use of HIV-1 resistance tests influences physician decision-making. Methods: Ten experienced reference physicians from the Brazilian Network for Drug Resistance each received ten patients' case histories. The selected patients had experienced at least two virological failures. First, reference physicians were asked to empirically select a new regimen for each patient. Second, after genotype report (ViroSeq 2.6) was provided, and physicians were again asked to select a new regimen considering this additional information. Finally, they were asked to select a regimen after receiving a virtual phenotype result (vircoTYPE 3.9.00). Results: In 79% of the cases, physicians changed their empirical choice of regimen after receiving the genotype report, resulting in an increase in the mean number of active drugs from 1.8 to 2.2 (p = 0.0003), while the average number of drugs/regimen remained at 4.0. After receipt of the virtual phenotype report, additional changes were made in 75% of the patient cases, resulting in an increase in the number of active drugs to 2.8 (p < 0.0001), while the average number of drugs/regimen remained at 4.0. After receipt of the genotype report, 48% of the changes were in NRTIs, 29% were in NNRTIs and 60% were in PIs; after consideration of the virtual phenotype, 61%, 10% and 49% of the changes, respectively, were in these categories of drugs. Fourteen percent of the physicians rated the genotype report as "extremely useful", whereas 34% rated the subsequent virtual phenotype report as "extremely useful" (p = 0.0003). Conclusions: Resistance testing has a significant impact on physicians' choices of antiretroviral salvage therapies, and it promotes the selection of more active drugs.
C1 [Diaz, Ricardo Sobhie] Univ Fed Sao Paulo, Retrovirol Lab, EPM, BR-04039 Sao Paulo, Brazil.
   [Brites, Carlos] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   [Del Bianco, Rosana; Bonasser Filho, Francisco] Hosp Emilio Ribas, Sao Paulo, Brazil.
   [Colares, Geova Keny B.] Univ Fortaleza, Fortaleza, Ceara, Brazil.
   [Portela, Estevao] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Barcelos, Nemora Tregnago] Secretaria Estadual Saude Rio Grande Sul, Porto Alegre, RS, Brazil.
   [Tupinambas, Unai] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Allamasey, Lisa; Tuohy, Martin] Virco BVBA, Mechelen, Belgium.
   [Bacheler, Lee] VircoLab Inc, Durham, NC USA.
RP Diaz, RS (corresponding author), Univ Fed Sao Paulo, Retrovirol Lab, EPM, R Pedro de Toledo 781, BR-04039 Sao Paulo, Brazil.
EM rsdiaz@catg.com.br
RI Araripe Sucupira, Maria Cecilia/K-1931-2012; Colares, Jeova Keny
   Baima/C-5257-2014; Brites, Carlos/D-1353-2013; Diaz, Ricardo/K-3978-2012
OI Araripe Sucupira, Maria Cecilia/0000-0002-1114-5382; Colares, Jeova Keny
   Baima/0000-0003-1367-6272; Brites, Carlos/0000-0002-4673-6991; 
CR Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001
   Cohen CJ, 2002, AIDS, V16, P579, DOI 10.1097/00002030-200203080-00009
   Deeks SG, 2005, J INFECT DIS, V192, P1537, DOI 10.1086/496892
   Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2
   Lohse N, 2006, CLIN INFECT DIS, V42, P136, DOI 10.1086/498515
   Mazzotta F, 2003, JAIDS-J ACQ IMM DEF, V32, P268, DOI 10.1097/00126334-200303010-00005
   Medeiros Roseane, 2002, Braz J Infect Dis, V6, P298, DOI 10.1590/S1413-86702002000600005
   Napravnik S, 2005, JAIDS-J ACQ IMM DEF, V40, P34, DOI 10.1097/01.qai.0000174929.87015.d6
   Palella F, 2006, 13 C RETR OPP INF DE
   Perez-Elias MJ, 2003, ANTIVIR THER, V8, P577
   Sucupira MCA, 2001, ANTIVIR THER, V6, P263
   Swanstrom R, 2004, J INFECT DIS, V190, P886, DOI 10.1086/422692
   Tural C, 2002, AIDS, V16, P209, DOI 10.1097/00002030-200201250-00010
   Vray M, 2003, ANTIVIR THER, V8, P427
   Weinstein MC, 2001, ANN INTERN MED, V134, P440, DOI 10.7326/0003-4819-134-6-200103200-00008
   Zaccarelli M, 2005, AIDS, V19, P1081, DOI 10.1097/01.aids.0000174455.01369.ad
NR 16
TC 2
Z9 2
U1 0
U2 0
PU CONTEXTO
PI SALVADOR
PA RUA ALFREDO MAGALHAES, 04-BARRA, SALVADOR, BAHIA 40140-140, BRAZIL
SN 1413-8670
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2010
VL 14
IS 5
BP 489
EP 494
DI 10.1590/S1413-86702010000500011
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 705CU
UT WOS:000286107300011
PM 21221478
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Andriolo, A
   Barbosa, AJA
   Hernandez, AJ
   Camargos, AF
   Barraviera, B
   Kadunc, BV
   Caramelli, B
   Brites, C
   do Nascimento, DC
   Braile, DM
   Goldenberg, DC
   Baracat, EC
   Marchiori, E
   Vieira, ED
   de Almeida, EA
   Machado, F
   Jotz, GP
   Kirsztajn, GM
   Camanho, G
   Gusso, G
   Duarte, IC
   Costa, IMC
   de Mello, JF
   Faintuch, J
   Martinez, JAB
   Livramento, JA
   Manson, JEF
   Cabral, JE
   Montal, JHD
   do Amaral, JLG
   Martins, JL
   de Andrade, JM
   Savassi, LCM
   Machado, LD
   Casulari, LA
   Leme, LEG
   Moreira, LFP
   Gebrim, LH
   Madeira, M
   Riberto, M
   Bastos, M
   Falcao, MC
   da Conceicao, MJ
   Silva, MRE
   Ruiz, MA
   Shibata, MK
   Santiago, MB
   Andreollo, NA
   Alonso, N
   Malafaia, O
   de Camargo, OP
   Fernandes, PMP
   Martins, RHG
   Procianoy, RS
   Antunes, RCP
   Fuller, R
   Viebig, RG
   Nitrini, R
   Dedivitis, R
   Damiao, R
   Monteiro, R
   Lianza, S
   Rode, SD
   Barros, TEP
   Chamon, W
   Yoshida, WB
   Handar, Z
AF Andriolo, Adagmar
   Afonso Barbosa, Alfredo Jose
   Hernandez, Arnaldo Jose
   Camargos, Aroldo F.
   Barraviera, Benedito
   Kadunc, Bogdana Victoria
   Caramelli, Bruno
   Brites, Carlos
   do Nascimento, Dejair Caitano
   Braile, Domingo M.
   Goldenberg, Dov Charles
   Baracat, Edmund Chada
   Marchiori, Edson
   Vieira, Eduardo de Paula
   de Almeida, Eros Antonio
   Machado, Flavia
   Jotz, Geraldo Pereira
   Kirsztajn, Gianna Mastroianni
   Camanho, Gilberto
   Gusso, Gustavo
   Duarte, Ivomar Comes
   Carvalho Costa, Izelda Maria
   de Mello Junior, Joao Ferreira
   Faintuch, Joel
   Baddini Martinez, Jose Antonio
   Livramento, Jose Antonio
   Ferreira Manson, Jose Eduardo
   Cabral Filho, Jose Eulalio
   da Costa Montal, Jose Heverardo
   Gomes do Amaral, Jose Luiz
   Martins, Jose Luiz
   de Andrade, Jurandyr Moreira
   Monteiro Savassi, Leonardo Cancado
   Machado, Luis dos Ramos
   Casulari, Luiz Augusto
   Garcez Leme, Luiz Eugenio
   Moreira, Luiz Felipe P.
   Gebrim, Luiz Henrique
   Madeira, Marcelo
   Riberto, Marcelo
   Bastos, Marcus
   Falcao, Mario Cicero
   da Conceicao, Mario J.
   Rocha e Silva, Mauricio
   Ruiz, Milton Artur
   Shibata, Milton K.
   Santiago, Mittermayer Barreto
   Andreollo, Nelson Adami
   Alonso, Nivaldo
   Malafaia, Osvaldo
   de Camargo, Olavo Pires
   Pego Fernandes, Paulo Manuel
   Garcia Martins, Regina Helena
   Procianoy, Renato Soibelmann
   Pinto Antunes, Ricardo Cesar
   Fuller, Ricardo
   Viebig, Ricardo Guilherme
   Nitrini, Ricardo
   Dedivitis, Rogerio
   Damiao, Ronaldo
   Monteiro, Rosangela
   Lianza, Sergio
   Rode, Sigmar de Mello
   Barros Filho, Tarcisio E. P.
   Chamon, Wallace
   Yoshida, Winston Bonetti
   Handar, Zuher
TI Change the Qualis Criteria!
SO ARQUIVOS BRASILEIROS DE CARDIOLOGIA
LA Portuguese
DT Editorial Material
C1 [Brites, Carlos] Brazilian Journal Infect Dis, Salvador, BA, Brazil.
   [Baracat, Edmund Chada; Gomes do Amaral, Jose Luiz] Revista Assoc Med Brasileira, Sao Paulo, Brazil.
   [Ruiz, Milton Artur] Revista Brasileira Hematol & Hemoterapia, Sao Jose Do Rio Preto, SP, Brazil.
   [Pego Fernandes, Paulo Manuel] Sao Paulo Med Journal, Sao Paulo, Brazil.
RP Caramelli, B (corresponding author), Rua Sao Carlos Pinhal,324 Bela Vista, BR-01333903 Sao Paulo, Brazil.
EM ramb@amb.org.br
RI Martins, Regina/AAP-5536-2020; de Mello Rode, Sigmar/G-6411-2012; JOTZ,
   GERALDO P/G-2664-2014; Viebig, Ricardo/AAD-5226-2020; Garcez Leme,
   Luiz/C-6759-2009; Kirsztajn, Gianna Mastroianni/D-9596-2013; Savassi,
   Leonardo CM/I-4733-2013; Hernandez, Jose Arnaldo/I-7939-2016; CAMARGO,
   OLAVO/P-8336-2015; Yoshida, Winston Bonetti/B-8136-2012; Dedivitis,
   Rogerio/J-2992-2014; Moreira, Luiz Felipe P./F-9882-2012; Chamon,
   Wallace/A-5400-2010; Riberto, Marcelo/C-3141-2012; BRAILE, DOMINGO
   MARCOLINO/B-8228-2008
OI de Mello Rode, Sigmar/0000-0002-4261-4217; JOTZ, GERALDO
   P/0000-0001-6289-7827; Viebig, Ricardo/0000-0002-6541-0401; Garcez Leme,
   Luiz/0000-0002-9738-5466; Kirsztajn, Gianna
   Mastroianni/0000-0003-1317-4109; Savassi, Leonardo
   CM/0000-0001-6780-0377; Hernandez, Jose Arnaldo/0000-0001-8645-3956;
   CAMARGO, OLAVO/0000-0002-1128-7292; Yoshida, Winston
   Bonetti/0000-0002-2921-3777; LUIS CAMANHO, GILBERTO/0000-0001-8656-5552;
   Dedivitis, Rogerio/0000-0002-6267-1147; Ferreira Manso, Jose
   Eduardo/0000-0001-9694-7415; Moreira, Luiz Felipe
   P./0000-0003-0179-4976; Eloy Pessoa de Barros Filho,
   Tarcisio/0000-0002-7969-7845; Goldenberg, Dov
   Charles/0000-0001-5953-2448; Chamon, Wallace/0000-0002-2528-0526;
   Barraviera, Benedito/0000-0002-9855-5594; Riberto,
   Marcelo/0000-0001-9549-8830; BRAILE, DOMINGO
   MARCOLINO/0000-0001-7704-2258; Marchiori, Edson/0000-0001-8797-7380
CR [Anonymous], 2010, REV ASS MED BRAS, V56, P127
   de Lucena AF, 2009, REV ASSOC MED BRAS, V55, P247, DOI 10.1590/S0104-42302009000300011
   Rocha-e-Silva M, 2009, CLINICS, V64, P1, DOI 10.1590/S1807-59322009000100001
NR 3
TC 0
Z9 0
U1 0
U2 2
PU ARQUIVOS BRASILEIROS CARDIOLOGIA
PI RIO DE JANEIRO
PA AVENIDA MARECHAL CAMARA 160-330 CENTRO, RIO DE JANEIRO, RJ 20 020-907,
   BRAZIL
SN 0066-782X
J9 ARQ BRAS CARDIOL
JI Arq. Bras. Cardiol.
PD AUG
PY 2010
VL 95
IS 2
BP 142
EP 143
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 651YD
UT WOS:000281962700001
PM 20857051
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Andriolo, A
   Barbosa, AJA
   Hernandez, AJ
   Camargos, AE
   Barraviera, B
   Kadunc, BV
   Caramelli, B
   Brites, C
   do Nascimento, DC
   Brale, DM
   Goldenberg, DC
   Baracat, EC
   Marchiori, E
   Vieira, ED
   de Almeida, EA
   Machado, F
   Jotz, GP
   Kirsztajn, GM
   Camanho, G
   Gusso, G
   Duarte, IG
   Costa, IMC
   de Mello, JF
   Faintuch, J
   Martinez, JAB
   Manso, JEF
   Cabral, JE
   Montal, JHD
   do Amaral, JLG
   Martins, JL
   de Andrade, JM
   Savassi, L
   Casulari, LA
   Leme, LEG
   Moreira, LFP
   Gebrim, LH
   Madeira, M
   Riberto, M
   Bastos, M
   Falcao, MC
   da Conceicao, MI
   Silva, MRE
   Ruiz, MA
   Shibata, MK
   Santiago, MB
   Andreollo, NA
   Alonso, N
   Malafaia, O
   de Camargo, OP
   Fernandes, PMP
   Martins, RHG
   Procianoy, RS
   Antunes, RCP
   Fuller, R
   Viebig, RG
   Nitrini, R
   Dedivitis, R
   Damiao, R
   Monteiro, R
   Lianza, S
   Rode, SD
   Barros, TEP
   Chamon, W
   Yoshida, WB
   Handar, Z
AF Andriolo, Adagmar
   Afonso Barbosa, Alfredo Jose
   Hernandez, Arnaldo Jose
   Camargos, Aroldo E.
   Barraviera, Benedito
   Kadunc, Bogdana Victoria
   Caramelli, Bruno
   Brites, Carlos
   do Nascimento, Dejair Caitano
   Brale, Domingo M.
   Goldenberg, Dov Charles
   Baracat, Edmund Chada
   Marchiori, Edson
   Vieira, Eduardo de Paula
   de Almeida, Eros Antonio
   Machado, Flavia
   Jotz, Gerald Pereira
   Kirsztajn, Gianna Mastroianni
   Camanho, Gilberto
   Gusso, Gustavo
   Duarte, Ivomar Gomes
   Carvalho Costa, Izelda Maria
   de Mello Junior, Joao Ferreira
   Faintuch, Joel
   Baddini Martinez, Jose Antonio
   Ferreira Manso, Jose Eduardo
   Cabral Filho, Jose Eulalio
   da Costa Montal, Jose Heverardo
   Gomes do Amaral, Jose Luiz
   Martins, Jose Luiz
   de Andrade, Jurandyr Moreira
   Savassi, Leonardo
   Casulari, Luiz Augusta
   Garcez Leme, Luiz Eugenio
   Moreira, Luiz Felipe P.
   Gebrim, Luiz Henrique
   Madeira, Marcelo
   Riberto, Marcelo
   Bastos, Marcus
   Falcao, Mario Cicero
   da Conceicao, Mario I.
   Silva, Mauricio Rocha E.
   Ruiz, Milton Artur
   Shibata, Milton K.
   Santiago, Mittermayer Barreto
   Andreollo, Nelson Adami
   Alonso, Nivaldo
   Malafaia, Osvaldo
   de Camargo, Olavo Pires
   Pego Fernandes, Paulo Manuel
   Garcia Martins, Regina Helena
   Procianoy, Renato Soibehnann
   Pinto Antunes, Ricardo Cesar
   Fuller, Ricardo
   Viebig, Ricardo Guilherme
   Nitrini, Ricardo
   Dedivitis, Rogerio
   Damiao, Ronaldo
   Monteiro, Rosangela
   Lianza, Sergio
   Rode, Sigmar de Mello
   Barros Filho, Tarcisio E. P.
   Chamon, Wallace
   Yoshida, Winston Bonetti
   Handar, Zuher
TI Change the Qualis Criteria!
SO JORNAL BRASILEIRO DE PNEUMOLOGIA
LA Portuguese
DT Editorial Material
RI Martins, Regina/AAP-5536-2020; de Mello Rode, Sigmar/G-6411-2012;
   Riberto, Marcelo/C-3141-2012; Viebig, Ricardo/AAD-5226-2020; Malafaia,
   Osvaldo/C-9080-2013; Garcez Leme, Luiz/C-6759-2009; Andrade, Jurandyr
   M/B-2025-2013; Baracat, Edmund C/H-3800-2012; Savassi, Leonardo
   CM/I-4733-2013; CAMARGO, OLAVO/P-8336-2015; BRAILE, DOMINGO
   MARCOLINO/B-8228-2008; Dedivitis, Rogerio/J-2992-2014; Mastroianni
   Kirsztajn, Gianna/D-9596-2013; Hernandez, Jose Arnaldo/I-7939-2016;
   Yoshida, Winston Bonetti/B-8136-2012; Chamon, Wallace/A-5400-2010
OI de Mello Rode, Sigmar/0000-0002-4261-4217; Riberto,
   Marcelo/0000-0001-9549-8830; Viebig, Ricardo/0000-0002-6541-0401;
   Malafaia, Osvaldo/0000-0002-1829-7071; Garcez Leme,
   Luiz/0000-0002-9738-5466; Andrade, Jurandyr M/0000-0003-3619-0582;
   Baracat, Edmund C/0000-0003-0111-9030; Savassi, Leonardo
   CM/0000-0001-6780-0377; CAMARGO, OLAVO/0000-0002-1128-7292; BRAILE,
   DOMINGO MARCOLINO/0000-0001-7704-2258; Goldenberg, Dov
   Charles/0000-0001-5953-2448; Dedivitis, Rogerio/0000-0002-6267-1147;
   Mastroianni Kirsztajn, Gianna/0000-0003-1317-4109; Hernandez, Jose
   Arnaldo/0000-0001-8645-3956; Yoshida, Winston
   Bonetti/0000-0002-2921-3777; Barraviera, Benedito/0000-0002-9855-5594;
   Chamon, Wallace/0000-0002-2528-0526; Ferreira Manso, Jose
   Eduardo/0000-0001-9694-7415; LUIS CAMANHO, GILBERTO/0000-0001-8656-5552;
   Marchiori, Edson/0000-0001-8797-7380; Eloy Pessoa de Barros Filho,
   Tarcisio/0000-0002-7969-7845
CR [Anonymous], 2010, REV ASS MED BRAS, V56, P127
   de Lucena AF, 2009, REV ASSOC MED BRAS, V55, P247, DOI 10.1590/S0104-42302009000300011
   Rocha-e-Silva M, 2009, CLINICS, V64, P1, DOI 10.1590/S1807-59322009000100001
NR 3
TC 0
Z9 0
U1 0
U2 2
PU SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA
PI BRASILIA DF
PA SEPS 714-719, BLOCO E ASA SUL, SALAS 220-223, BRASILIA DF, CEP70390-145,
   BRAZIL
SN 1806-3713
J9 J BRAS PNEUMOL
JI J. Bras. Pneumol.
PD JUL-AUG
PY 2010
VL 36
IS 4
BP 399
EP 401
PG 3
WC Respiratory System
SC Respiratory System
GA 642PD
UT WOS:000281227400002
PM 20835584
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Drexler, JF
   Baumgarte, S
   Luna, LKD
   Stocker, A
   Almeida, PS
   Ribeiro, TCM
   Petersen, N
   Herzog, P
   Pedroso, C
   Brites, C
   Ribeiro, HD
   Gmyl, A
   Drosten, C
   Lukashev, A
AF Drexler, Jan Felix
   Baumgarte, Sigrid
   Luna, Luciano Kleber de Souza
   Stocker, Andreas
   Almeida, Patricia Silva
   Medrado Ribeiro, Tereza Cristina
   Petersen, Nadine
   Herzog, Petra
   Pedroso, Celia
   Brites, Carlos
   Ribeiro, Hugo da Costa, Jr.
   Gmyl, Anatoly
   Drosten, Christian
   Lukashev, Alexander
TI Genomic features and evolutionary constraints in Saffold-like
   cardioviruses
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID MURINE ENCEPHALOMYELITIS VIRUS; COMPLETE NUCLEOTIDE-SEQUENCE; ORDERED
   RNA STRUCTURE; HUMAN-ENTEROVIRUS-B; ENCEPHALOMYOCARDITIS VIRUS;
   CEREBROSPINAL-FLUID; VIRAL PERSISTENCE; THEILERS VIRUS; RECOMBINATION;
   TRANSLATION
AB This study identified the complete genomic sequence of four type 2 and type 3 human Saffold-like cardioviruses (SLCVs) isolated in Germany and Brazil The secondary structures of the SLCV internal ribosome entry sites (IRESs) were deduced based on RNA base-pairing conservation and co-variation, using an established Theiler's murine encephalomyelitis virus (TMEV) IRES structure as a reference The SLCV IRES was highly similar to that of TMEV, but motifs critical in TMEV for binding of the polypyrimidine tract-binding protein (PTB) were disrupted In TMEV, corresponding alterations have been associated with reduced neurovirulence in mice. In the non-structural genome region, there was evidence of multiple intertypic recombination events between different SLCV types. Between viruses of the same type, recombination also occurred in the capsid-encoding genome region. There were apparently no recombination events between mouse TMEV and human SLCV. In another genus of the family Picornaviridae. Enterovirus, natural recombination occurs strictly within species and can serve as an additional criterion for delimiting species Accordingly, the results of this study suggest that SLCV and TMEV may represent distinct species within the genus Cardiovirus.
C1 [Drexler, Jan Felix; Drosten, Christian] Univ Bonn, Med Ctr, Inst Virol, D-5300 Bonn, Germany.
   [Drexler, Jan Felix; Stocker, Andreas; Brites, Carlos] Univ Fed Bahia, Hosp Prof Edgar Santos, Res Lab Infect Dis, Salvador, BA, Brazil.
   [Baumgarte, Sigrid] Inst Hyg & Environm, Dept Microbiol Consumer Protect, Virol Lab, Hamburg, Germany.
   [Luna, Luciano Kleber de Souza; Petersen, Nadine; Herzog, Petra] Bernhard Nocht Inst Trop Med, Clin Virol Grp, Hamburg, Germany.
   [Almeida, Patricia Silva; Medrado Ribeiro, Tereza Cristina; Ribeiro, Hugo da Costa, Jr.] Univ Fed Bahia, Hosp Prof Edgar Santos, Dept Paediat, Salvador, BA, Brazil.
   [Gmyl, Anatoly; Lukashev, Alexander] Chumakov Inst Poliomyelitis & Viral Encephalitide, Moscow, Russia.
RP Drosten, C (corresponding author), Univ Bonn, Med Ctr, Inst Virol, D-5300 Bonn, Germany.
RI Lukashev, Alexander/G-2777-2013; Brites, Carlos/D-1353-2013; de Souza
   Luna, Luciano Kleber/AAG-6418-2019; de Souza Luna, Luciano
   Kleber/L-1213-2013; Gmyl, Anatoly/J-8367-2012; Drexler, Jan
   Felix/C-1004-2014
OI Lukashev, Alexander/0000-0001-7365-0352; Brites,
   Carlos/0000-0002-4673-6991; de Souza Luna, Luciano
   Kleber/0000-0002-3552-5507; de Souza Luna, Luciano
   Kleber/0000-0002-3552-5507; Drexler, Jan Felix/0000-0002-3509-0232
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG)
   [DR772/2-1]; Russian Foundation for Basic ResearchRussian Foundation for
   Basic Research (RFBR); European UnionEuropean Union (EU)
FX This work was supported by the Deutsche Forschungsgemeinschaft (grant no
   DR772/2-1) and the Russian Foundation for Basic Research. Additional
   support was obtained from European Union projects RiViGene, EVA and
   EMPERIE
CR Abed Y, 2008, EMERG INFECT DIS, V14, P834, DOI 10.3201/eid1405.071675
   Blinkova O, 2009, J VIROL, V83, P4631, DOI 10.1128/JVI.02085-08
   CHEN HH, 1995, NAT MED, V1, P927, DOI 10.1038/nm0995-927
   Chiu CY, 2008, P NATL ACAD SCI USA, V105, P14124, DOI 10.1073/pnas.0805968105
   Davis M, 2008, J VIROL, V82, P11824, DOI 10.1128/JVI.01078-08
   DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171
   Drake MT, 2008, COMPARATIVE MED, V58, P458
   Drexler JF, 2008, EMERG INFECT DIS, V14, P1398, DOI 10.3201/eid1409.080570
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   DUKE GM, 1992, J VIROL, V66, P1602, DOI 10.1128/JVI.66.3.1602-1609.1992
   GAJDUSEK DC, 1970, AM J TROP MED HYG, V19, P146
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Harvala H, 2009, J INFECT DIS, V199, P1753, DOI 10.1086/599094
   Jones MS, 2007, J CLIN MICROBIOL, V45, P2144, DOI 10.1128/JCM.00174-07
   KIRKLAND PD, 1989, MED J AUSTRALIA, V151, P176, DOI 10.5694/j.1326-5377.1989.tb139618.x
   LAW KM, 1990, NUCLEIC ACIDS RES, V18, P6707, DOI 10.1093/nar/18.22.6707
   Leitch ECM, 2009, J CLIN VIROL, V44, P119, DOI 10.1016/j.jcv.2008.11.015
   Liang Z, 2008, J VIROL, V82, P11545, DOI 10.1128/JVI.01160-08
   Librado P, 2009, BIOINFORMATICS, V25, P1451, DOI 10.1093/bioinformatics/btp187
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Lu CY, 2002, J MED VIROL, V67, P217, DOI 10.1002/jmv.2210
   Lukashev AN, 2005, J GEN VIROL, V86, P3281, DOI 10.1099/vir.0.81264-0
   Lukashev AN, 2005, REV MED VIROL, V15, P157, DOI 10.1002/rmv.457
   Lukashev AN, 2003, J VIROL, V77, P10423, DOI 10.1128/JVI.77.19.10423-10431.2003
   Michiels T, 1995, VIROLOGY, V214, P550, DOI 10.1006/viro.1995.0066
   Myoung J, 2007, VIROLOGY, V360, P159, DOI 10.1016/j.virol.2006.09.045
   Oberste MS, 2004, J VIROL, V78, P855, DOI 10.1128/JVI.78.2.855-867.2004
   OHARA Y, 1988, VIROLOGY, V164, P245, DOI 10.1016/0042-6822(88)90642-3
   Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798
   PEVEAR DC, 1987, J VIROL, V61, P1507, DOI 10.1128/JVI.61.5.1507-1516.1987
   PILIPENKO EV, 1989, VIROLOGY, V168, P201, DOI 10.1016/0042-6822(89)90259-6
   Pilipenko EV, 2001, EMBO J, V20, P6899, DOI 10.1093/emboj/20.23.6899
   PILIPENKO EV, 1995, J VIROL, V69, P864, DOI 10.1128/JVI.69.2.864-870.1995
   PILIPENKO EV, 1994, J MOL BIOL, V241, P398, DOI 10.1006/jmbi.1994.1516
   PRITCHARD AE, 1992, J VIROL, V66, P1951, DOI 10.1128/JVI.66.4.1951-1958.1992
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   SARMANOVA ES, 1960, CURRENT PROBLEMS MED, V1, P216
   Simmonds P, 1999, J VIROL, V73, P5787, DOI 10.1128/JVI.73.7.5787-5794.1999
   Simmonds P, 2006, J VIROL, V80, P483, DOI 10.1128/JVI.80.1.483-493.2006
   Simmonds P, 2004, RNA, V10, P1337, DOI 10.1261/rna.7640104
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tauriainen S, 2007, J MED VIROL, V79, P457, DOI 10.1002/jmv.20831
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   van Eyll O, 2000, J VIROL, V74, P9071, DOI 10.1128/JVI.74.19.9071-9077.2000
   Vladimirtsev VA, 2007, EMERG INFECT DIS, V13, P1321, DOI 10.3201/eid1309.061585
   WARD CD, 1992, J VIROL, V66, P3784, DOI 10.1128/JVI.66.6.3784-3793.1992
   Witso E, 2006, J CLIN MICROBIOL, V44, P4095, DOI 10.1128/JCM.00653-06
   Wolthers KC, 2008, CLIN INFECT DIS, V47, P358, DOI 10.1086/589752
   Zoll J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000416
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P1
NR 50
TC 25
Z9 25
U1 0
U2 0
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD JUN
PY 2010
VL 91
BP 1418
EP 1427
DI 10.1099/vir.0.018887-0
PN 6
PG 10
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 610AX
UT WOS:000278702400005
PM 20130131
OA Bronze
DA 2020-12-01
ER

PT J
AU Silva, MD
   Bastos, M
   Netto, EM
   Gouvea, NAD
   Torres, AJL
   Kallas, E
   Watkins, DI
   Altfeld, M
   Brites, C
AF Silva, Marcio de Oliveira
   Bastos, Milena
   Netto, Eduardo Martins
   de Lima Gouvea, Nancy Alves
   Leite Torres, Alex Jose
   Kallas, Esper
   Watkins, David I.
   Altfeld, Marcus
   Brites, Carlos
TI Acute HIV infection with rapid progression to AIDS
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; acute infection; progression; AIDS
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HLA
AB Acute HIV infection is rarely recognized as the signs and symptoms are normally unspecific and can persist for days or weeks. The normal HIV course is characterized by a progressive loss of CD4+ cells, which normally leads to severe immunodeficiency after a variable time interval. The mean time from initial infection to development of clinical AIDS is approximately 8-10 years, but it is variable among individuals and depends on a complex interaction between virus and host. Here we describe an extraordinary case of a man who developed Pneumocisits jiroveci pneumonia within one month after sexual exposure to HIV-1, and then presented with 3 consecutive CD4 counts bellow 200 cells/mm(3) within 3 months, with no other opportunistic disease. Although antiretroviral therapy (AZT+3TC+ATZ/r) was started, with full adherence of the patient, and genotyping indicating no primary antiretroviral resistance mutations, he required more than six months to have a CD4 restoration to levels above 200 cells/mm(3) and 10 months to HIV-RNA to become undetectable.
C1 [Silva, Marcio de Oliveira; Bastos, Milena; Netto, Eduardo Martins; Leite Torres, Alex Jose; Brites, Carlos] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   [de Lima Gouvea, Nancy Alves; Kallas, Esper] Fac Med, Sao Paulo, Brazil.
   [Altfeld, Marcus] Massachusetts Gen Hosp, Infect Dis Unit, Partners AIDS Res Ctr, Boston, MA 02114 USA.
RP Silva, MD (corresponding author), Rua Jorge Simoes 156 Ed San Juan,Apt 302, BR-40415720 Salvador, BA, Brazil.
EM oliveiras_m@yahoo.com.br
RI Netto, Eduardo/D-1432-2013; Torres, Alex JL/Q-6186-2018; Kallas, Esper
   G/C-9539-2012; Altfeld, Marcus/AAE-7306-2019
OI Netto, Eduardo/0000-0003-1691-6761; Altfeld, Marcus/0000-0001-5972-2997;
   Kallas, Esper/0000-0003-2026-6925
CR BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198
   GANGE S, 2005, S CAS RAP PROGR MULT
   Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203
   HARRIGAN R, 16 C RETR OPP INF CR
   ITESCU S, 1992, J ACQ IMMUN DEF SYND, V5, P37
   Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107
   LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360
   Magierowska M, 1999, BLOOD, V93, P936, DOI 10.1182/blood.V93.3.936.403k08_936_941
   Markowitz M, 2005, LANCET, V365, P1031, DOI 10.1016/S0140-6736(05)74227-6
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367
   PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183
   SAHMOUD T, 1993, AIDS, V7, P497, DOI 10.1097/00002030-199304000-00007
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737
   VENTO S, 1993, LANCET, V342, P24, DOI 10.1016/0140-6736(93)91884-O
NR 20
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2010
VL 14
IS 3
BP 291
EP 293
DI 10.1590/S1413-86702010000300016
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 648KU
UT WOS:000281693400016
PM 20835515
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Andriolo, A
   Souza, AFM
   Farias, AQ
   Barbosa, AJA
   Netto, ASF
   Hernandez, AJ
   Camargos, AF
   Barraviera, B
   Kadunc, BV
   Caramelli, B
   Campos, CEA
   Brites, C
   do Nascimento, DC
   Braile, DM
   Goldenberg, DC
   Kimura, ET
   Marchiori, E
   Vieira, ED
   de Almeida, EA
   Jotz, GP
   Camanho, G
   Friedman, G
   Cerri, GG
   Duarte, IG
   Costa, IMC
   de Mello, JF
   Faintuch, J
   Martinez, JAB
   Livramento, JA
   Manso, JEF
   Battistella, LR
   Machado, LD
   Moreira, LFP
   Gebrim, LH
   Madeira, M
   Riberto, M
   Bastos, M
   Falcao, MC
   da Conceicao, MJ
   Silva, MRE
   Ruiz, MA
   Shibata, MK
   Santiago, MB
   Andreollo, NA
   Malafaia, O
   Martins, RHG
   Procianoy, RS
   Baroudi, R
   Fuller, R
   Viebig, RG
   Nitrini, R
   de Moura, RCMR
   Dedivitis, R
   Damiao, R
   Lianza, S
   Rode, SD
   Yoshida, WB
   Handar, Z
AF Andriolo, Adagmar
   Meireles Souza, Aecio Flavio
   Farias, Alberto Queiroz
   Afonso Barbosa, Alfredo Jose
   Franca Netto, Antonio Spina
   Hernandez, Arnaldo Jose
   Camargos, Aroldo F.
   Barraviera, Benedito
   Kadunc, Bogdana Victoria
   Caramelli, Bruno
   Aguilera Campos, Carlos Eduardo
   Brites, Carlos
   do Nascimento, Dejair Caitano
   Braile, Domingo M.
   Goldenberg, Dov Charles
   Kimura, Edna T.
   Marchiori, Edson
   Vieira, Eduardo de Paula
   de Almeida, Eros Antonio
   Jotz, Geraldo Pereira
   Camanho, Gilberto
   Friedman, Gilberto
   Cerri, Giovanni Guido
   Duarte, Ivomar Gomes
   Carvalho Costa, Izelda Maria
   de Mello Junior, Joao Ferreira
   Faintuch, Joel
   Baddini Martinez, Jose Antonio
   Livramento, Jose Antonio
   Ferreira Manso, Jose Eduardo
   Battistella, Linamara Rizzo
   Machado, Luis dos Ramos
   Moreira, Luiz Felipe P.
   Gebrim, Luiz Henrique
   Madeira, Marcelo
   Riberto, Marcelo
   Bastos, Marcus
   Falcao, Mario Cicero
   da Conceicao, Mario J.
   Rocha e Silva, Mauricio
   Ruiz, Milton Artur
   Shibata, Milton K.
   Santiago, Mittermayer Barreto
   Andreollo, Nelson Adami
   Malafaia, Osvaldo
   Garcia Martins, Regina Helena
   Procianoy, Renato Soibelmann
   Baroudi, Ricardo
   Fuller, Ricardo
   Viebig, Ricardo Guilherme
   Nitrini, Ricardo
   de Moura, Rita Cristina Mainieri R.
   Dedivitis, Rogerio
   Damiao, Ronaldo
   Lianza, Sergio
   Rode, Sigmar de Mello
   Yoshida, Winston Bonetti
   Handar, Zuher
TI Classification of Journals in the QUALIS System of CAPES - URGENT Need
   of Changing the Criteria!
SO ARQUIVOS BRASILEIROS DE CARDIOLOGIA
LA Portuguese
DT Editorial Material
RP Caramelli, B (corresponding author), Rua Sao Carlos Pinhal,324 Bela Vista, BR-01333903 Sao Paulo, Brazil.
EM ramb@amb.org.br
RI Martins, Regina/AAP-5536-2020; Riberto, Marcelo/C-3141-2012; JOTZ,
   GERALDO P/G-2664-2014; Viebig, Ricardo/AAD-5226-2020; Battistella,
   Linamara Rizzo/E-5131-2013; Friedman, Gilberto/F-7212-2015; Farias,
   Alberto/ABB-1291-2020; Malafaia, Osvaldo/C-9080-2013; de Mello Rode,
   Sigmar/G-6411-2012; Kimura, Edna T./D-7334-2012; Yoshida, Winston
   Bonetti/B-8136-2012; Hernandez, Jose Arnaldo/I-7939-2016; BRAILE,
   DOMINGO MARCOLINO/B-8228-2008; Dedivitis, Rogerio/J-2992-2014
OI Riberto, Marcelo/0000-0001-9549-8830; JOTZ, GERALDO
   P/0000-0001-6289-7827; Viebig, Ricardo/0000-0002-6541-0401; Battistella,
   Linamara Rizzo/0000-0001-5275-0733; Farias, Alberto/0000-0002-5572-663X;
   Malafaia, Osvaldo/0000-0002-1829-7071; de Mello Rode,
   Sigmar/0000-0002-4261-4217; Ferreira Manso, Jose
   Eduardo/0000-0001-9694-7415; Kimura, Edna T./0000-0001-8403-4459; LUIS
   CAMANHO, GILBERTO/0000-0001-8656-5552; Yoshida, Winston
   Bonetti/0000-0002-2921-3777; Hernandez, Jose
   Arnaldo/0000-0001-8645-3956; Goldenberg, Dov
   Charles/0000-0001-5953-2448; Marchiori, Edson/0000-0001-8797-7380;
   BRAILE, DOMINGO MARCOLINO/0000-0001-7704-2258; Martins, Regina Helena
   Garcia/0000-0003-0772-1962; Dedivitis, Rogerio/0000-0002-6267-1147;
   Barraviera, Benedito/0000-0002-9855-5594
NR 0
TC 1
Z9 2
U1 0
U2 7
PU ARQUIVOS BRASILEIROS CARDIOLOGIA
PI RIO DE JANEIRO
PA AVENIDA MARECHAL CAMARA 160-330 CENTRO, RIO DE JANEIRO, RJ 20 020-907,
   BRAZIL
SN 0066-782X
J9 ARQ BRAS CARDIOL
JI Arq. Bras. Cardiol.
PD MAR
PY 2010
VL 94
IS 3
BP 290
EP 291
DI 10.1590/S0066-782X2010000300001
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 577QN
UT WOS:000276239200001
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Brites, C
AF Brites, Carlos
TI Classification of journals in the QUALIS System of CAPES: the urgent
   need for changing the criteria
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
NR 0
TC 0
Z9 0
U1 0
U2 1
PU CONTEXTO
PI SALVADOR
PA RUA ALFREDO MAGALHAES, 04-BARRA, SALVADOR, BAHIA 40140-140, BRAZIL
SN 1413-8670
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2010
VL 14
IS 2
BP 121
EP 123
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 613DY
UT WOS:000278959300001
PM 20563435
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Brites, C
AF Brites, Carlos
TI A new face to BJID: perspective for the near future
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
NR 0
TC 0
Z9 0
U1 0
U2 1
PU CONTEXTO
PI SALVADOR
PA RUA ALFREDO MAGALHAES, 04-BARRA, SALVADOR, BAHIA 40140-140, BRAZIL
SN 1413-8670
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2010
VL 14
IS 1
BP 1
EP 1
DI 10.1016/S1413-8670(10)70001-5
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 615DR
UT WOS:000279113600001
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Lima, RG
   Brites, C
   Hedges, D
   Luz, E
   Barber, G
   Ramos, JC
   Alonso, L
   Manrique, M
   Ruiz, P
   Harrington, W
AF Lima, R. G.
   Brites, C.
   Hedges, D.
   Luz, E.
   Barber, G.
   Ramos, J. C.
   Alonso, L.
   Manrique, M.
   Ruiz, P.
   Harrington, Jr W.
TI A Comprehensive Analysis of Adult T-Cell Leukemia-Lymphoma of Western
   African Descent by High Resolution Comparative Genomic Hybridization
   Array
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
C1 [Lima, R. G.; Brites, C.; Hedges, D.; Luz, E.; Barber, G.; Ramos, J. C.; Alonso, L.; Manrique, M.; Ruiz, P.; Harrington, Jr W.] Univ Miami, Coral Gables, FL 33124 USA.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1244
EP 1244
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200128
DA 2020-12-01
ER

PT J
AU Ramos, JC
   Guettouche, T
   Brites, C
   Luz, E
   Barber, G
   Clarke, J
   Diaz, L
   Manrique, M
   Harrington, W
AF Ramos, J. C.
   Guettouche, T.
   Brites, C.
   Luz, E.
   Barber, G.
   Clarke, J.
   Diaz, L.
   Manrique, M.
   Harrington, W.
TI Subclassification of Adult T-Cell Leukemia-Lymphoma (ATLL) Using the
   Novel nCounter Gene Expression Detection System
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
C1 [Ramos, J. C.; Guettouche, T.; Brites, C.; Luz, E.; Barber, G.; Clarke, J.; Diaz, L.; Manrique, M.; Harrington, W.] Univ Miami, Coral Gables, FL 33124 USA.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1292
EP 1292
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200244
DA 2020-12-01
ER

PT J
AU Regis, C
   Oliveira, A
   Brites, C
AF Regis, Catarina
   Oliveira, Adriano
   Brites, Carlos
TI Onset of Opportunistic Infections in Patients Co-Infected by HTLV-1 and
   HIV-1, With High CD4+Cells Count
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1/HTLV-1 co-infection; Opportunistic infections; CD4
ID VIRUS TYPE-I; DISEASE PROGRESSION; COINFECTION; TYPE-1; BRAZIL;
   TUBERCULOSIS; INCREASE; LOAD
AB We reported two cases of patients with coinfection by human immunodeficiency virus (HIV) type 1 and human T-cell lymphotropic virus (HTLV) type I who developed opportunistic infections despite of relatively high CD4(+) cells count. These cases showed clinical evidence to consider an earlier antiretroviral treatment for coinfected patientes regardless CD4(+) cells counts.
C1 [Regis, Catarina; Oliveira, Adriano; Brites, Carlos] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Virol Res Lab, BR-40110160 Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Virol Res Lab, Rua Joao das Botas SN,6 Andar, BR-40110160 Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Beilke MA, 2004, CLIN INFECT DIS, V39, P256, DOI 10.1086/422146
   Beilke MA, 1998, J ACQ IMMUN DEF SYND, V17, P391, DOI 10.1097/00042560-199804150-00002
   Brites C, 2002, AIDS, V16, P1292, DOI 10.1097/00002030-200206140-00015
   BRITES C, 2004, 11 C RETR OPP INF CR
   Cesaire R, 2001, AIDS RES HUM RETROV, V17, P799, DOI 10.1089/088922201750251990
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   FANTRY L, 1995, CLIN INFECT DIS, V21, P1446
   Harrison LH, 1997, J INFECT DIS, V175, P438, DOI 10.1093/infdis/175.2.438
   Hershow RC, 1996, J INFECT DIS, V174, P309, DOI 10.1093/infdis/174.2.309
   Marinho J, 2005, JAIDS-J ACQ IMM DEF, V40, P625, DOI 10.1097/01.qai.0000174252.73516.7a
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Norrgren HR, 2008, JAIDS-J ACQ IMM DEF, V48, P607, DOI 10.1097/QAI.0b013e31817efb83
   Pedral-Sampaio DB, 1997, BRAZ J INFECT DIS, V1, P31
   SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353
NR 14
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD AUG
PY 2009
VL 13
IS 4
BP 311
EP 313
DI 10.1590/S1413-86702009000400014
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 569JQ
UT WOS:000275592800014
PM 20231997
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Torres, AJL
   Angelo, ALD
   Netto, EM
   Sampaio, GP
   Souza, DFC
   Inocencio, LA
   Lemos, JAR
   Brites, C
AF Torres, A. J. L.
   Angelo, A. L. D.
   Netto, E. M.
   Sampaio, G. P.
   Souza, D. F. C.
   Inocencio, L. A.
   Lemos, J. A. R.
   Brites, C.
TI Reference Range for T Lymphocytes Populations in Blood Donors from Two
   Different Regions in Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE CD4; CD8; blood donors; reference values; Brazil
ID PERIPHERAL-BLOOD; ANTIRETROVIRAL THERAPY; GENOMIC ANCESTRY; ADULTS;
   VALUES; INDIVIDUALS; SUBSETS; COLOR
AB This study defined the normal variation range for different subsets of T-lymphocyte cells count in two different Brazilian regions. We analysed the T-lymphocytes subpopulations (CD3+, CD4+, CD8+) in blood donors of two Brazilian cities, located in North (Belem, capital state of Para, indian background) and Northeast (Salvador, capital state od Bahia, African background) regions of Brazil. Results were compared according to gender, stress level (sleep time lower than 8 hours/day), smoking, and alcohol intake. Lymphocytes subpopulations were measured by flow cytometry. Five hundred twenty-six blood donors from two Brazilians cities participated in the study: 450 samples from Bahia and 76 samples from Para. Most (60%) were men, 59% reported alcohol intake, 12% were smokers, and 80% slept at least 8 h/day. Donors from Bahia presented with significantly higher counts for all parameters, compared with Para. Women had higher lymphocytes levels, in both states, but only CD4+ cells count was significantly higher than men's values. Smokers had higher CD4+ counts, but sleep time had effect on lymphocytes levels only for Para's donors (higher CD3+ and CD4+ counts). That state had also, a higher proportion of donors reporting sleep time < 8 h/day. The values for CD3, CD4 and CD8+ cells count were significantly higher in blood donors from Bahia than among those from Para. Female gender, alcohol intake, stress level, and smoking were associated with higher lymphocyte counts. The use of a single reference range for normal lymphocytes count is not appropriate for a country with such diversity, like Brazil is.
C1 [Torres, A. J. L.; Angelo, A. L. D.; Netto, E. M.; Sampaio, G. P.; Brites, C.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Lemos, J. A. R.] Fed Univ Para, HEMOPA Fdn, Hematol & Hemotherapy Ctr State Para, BR-66059 Belem, Para, Brazil.
RP Brites, C (corresponding author), Rua Joao das Botas SN,60 Andar, BR-40110160 Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Lemos, Jose Alexandre R/M-8753-2016; Torres, Alex JL/Q-6186-2018;
   Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Lemos, Jose Alexandre R/0000-0002-7595-2597; Brites,
   Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
FU Brazilian Ministry of Healthy and Hematology and Hemotherapy Centers
FX AIDS and SDT National Program from Brazilian Ministry of Healthy and
   Hematology and Hemotherapy Centers from states of Bahia (HEMOBA) and
   Para (HEMOPA).
CR Abe-Sandes K, 2004, HUM BIOL, V76, P77, DOI 10.1353/hub.2004.0014
   Albers R, 2005, BRIT J NUTR, V94, P452, DOI 10.1079/BJN20051469
   Arpini-Sampaio Z, 1999, HUM BIOL, V71, P69
   *B DICK IND CIR LT, 2006, MAN QUANT LINF T CD4, P88
   Bisset LR, 2004, EUR J HAEMATOL, V72, P203, DOI 10.1046/j.0902-4441.2003.00199.x
   BODGEN J, 2004, J AM COLL NUTR, P214
   Bower JE, 1998, J CONSULT CLIN PSYCH, V66, P979, DOI 10.1037/0022-006X.66.6.979
   CHOONG ML, 1995, ANN CLIN BIOCHEM, V32, P532, DOI 10.1177/000456329503200603
   de Siqueira MEPB, 1997, REV SAUDE PUBL, V31, P618, DOI 10.1590/S0034-89101997000700010
   Gill Harsharnjit S., 2002, P251, DOI 10.1079/9780851995830.0251
   IBGE. Instituto Brasileiro de Geografia e Estatistica, 2000, BRAS 500 AN POV
   Ikinciogullari A, 2004, TURKISH J PEDIATR, V46, P125
   Kam KM, 1996, CLIN DIAGN LAB IMMUN, V3, P326, DOI 10.1128/CDLI.3.3.326-330.1996
   Lee Michele Y., 1996, Journal of Nutrition for the Elderly, V15, P1, DOI 10.1300/J052v15n03_01
   Menard D, 2003, CLIN DIAGN LAB IMMUN, V10, P443, DOI 10.1128/CDLI.10.3.443-445.2003
   Nakata A, 2006, IND HEALTH, V44, P592, DOI 10.2486/indhealth.44.592
   Orfao A, 1999, CLIN CHEM, V45, P1708
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   Phillips AN, 2002, AIDS, V16, P1073, DOI 10.1097/00002030-200205030-00016
   Pimenta JR, 2006, HUM HERED, V62, P190, DOI 10.1159/000096872
   Sabioncello A, 2004, PERIOD BIOL, V106, P317
   Santagostino A, 1999, HAEMATOLOGICA, V84, P499
   SAXENA R, 2004, CURRENT SCI, V7, P969
   Smith CJ, 2003, AIDS, V17, P963, DOI 10.1097/00002030-200305020-00004
   Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803
   Zekeng L, 1997, J ACQ IMMUN DEF SYND, V14, P82, DOI 10.1097/00042560-199701010-00016
NR 26
TC 17
Z9 17
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUN
PY 2009
VL 13
IS 3
BP 221
EP 225
DI 10.1590/S1413-86702009000300013
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 563CZ
UT WOS:000275105600013
PM 20191201
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Monteiro, JP
   Alcantara, LC
   de Oliveira, T
   Oliveira, AM
   Melo, MAG
   Brites, C
   Galvao-Castro, B
AF Monteiro, Joana Paixao
   Junior Alcantara, Luiz Carlos
   de Oliveira, Tulio
   Oliveira, Antonio Marcos
   Gomes Melo, Marco Antonio
   Brites, Carlos
   Galvao-Castro, Bernardo
TI Genetic Variability of Human Immunodeficiency Virus-1 in Bahia State,
   Northeast, Brazil: High Diversity of HIV Genotypes
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HIV-1; epidemiology; phylogeny; Brazil; Bahia
ID HETERODUPLEX MOBILITY ASSAY; RIO-DE-JANEIRO; MOLECULAR EPIDEMIOLOGY;
   SAO-PAULO; DRUG-RESISTANCE; BF RECOMBINANT; TYPE-1 HIV-1; SUBTYPE-B;
   IDENTIFICATION; TRANSMISSION
AB The HIV-1 genetic variability in Bahia state, Brazil, was investigated. DNA samples from 229 and 213 HIV-1-infected individuals were analyzed using the heteroduplex mobility assay (HMA) in gag and env fragments, respectively. One hundred seventy-five samples were characterized in both genes. Thirty-two subtype F and BF recombinant viruses were sequenced and analyzed by phylogenetic methods. The combination of HMA and sequencing results showed that seven different HIV-1 genotypes comprised this sample: 147 (84%) B/B, 4 (2.3%) F/F, 3 (1.7%) B/F, 1 (0.6%) F/B, 1 (0.6%) F/D, 1 (0.6%) BF/F, and 18 (10.3%) BF/B. A significant divergence was observed between these two techniques results (84.4%). This is explained by the low accuracy of the HMA for detecting recombinant viruses. These recombinants were unrelated to CRF12, while two sequences were related to CRF28 and CRF29. Nineteen BF mosaics shared the same gag breakpoint. In conclusion, the use of HMA may be inappropriate in regions where different subtypes are co-circulating. Subtype B is the most common genotype, however, an increased prevalence (13.1%) of different BF variants and a potentially new CRF suggest that recombination is occurring frequently in Bahia. These viruses were associated with women infected heterosexually. Finally, this study identified the presence of an F/D recombinant HIV-1 in Brazil. J. Med. Virol. 81:391-399, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Galvao-Castro, Bernardo] Fundacao Oswaldo Cruz, FIOCRUZ, CPqGM, Lab Avancado Saude Publ, BR-40296610 Salvador, BA, Brazil.
   [Junior Alcantara, Luiz Carlos; Gomes Melo, Marco Antonio; Galvao-Castro, Bernardo] EBMSP, Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   [de Oliveira, Tulio] S African Natl Bioinformat Inst, Cape Town, South Africa.
   [Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
RP Galvao-Castro, B (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, CPqGM, Lab Avancado Saude Publ, Falcao 121, BR-40296610 Salvador, BA, Brazil.
EM bgalvao@bahia.fiocruz.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Alcantara, Luiz/0000-0002-6769-9931
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB); Brazilian
   Ministry of Health STD/AIDS Program; CNPqNational Council for Scientific
   and Technological Development (CNPq)
FX Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB); Grant
   sponsor: Brazilian Ministry of Health STD/AIDS Program; Grant sponsor:
   CNPq.
CR Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Buonaguro L, 2005, J VIROL METHODS, V124, P123, DOI 10.1016/j.jviromet.2004.11.014
   BURKE DS, 1996, AIDS BIOL DIAGNOSTIC, P119
   Cabral VP, 2006, MEM I OSWALDO CRUZ, V101, P881, DOI 10.1590/S0074-02762006000800010
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Casado G, 2005, JAIDS-J ACQ IMM DEF, V40, P532, DOI 10.1097/01.qai.0000186363.27587.c0
   Couto-Fernandez JC, 2006, AIDS RES HUM RETROV, V22, P207, DOI 10.1089/aid.2006.22.207
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   Couto-Fernandez JC, 1999, J ACQ IMMUN DEF SYND, V22, P288
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Dourado I, 2007, CAD SAUDE PUBLICA, V23, P25, DOI 10.1590/S0102-311X2007000100004
   Eyer-Silva WA, 2007, AIDS RES HUM RETROV, V23, P303, DOI 10.1089/aid.2006.0199
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Heyndrickx L, 2000, J VIROL, V74, P363, DOI 10.1128/JVI.74.1.363-370.2000
   KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8
   McCutchan FE, 2000, AIDS RES HUM RETROV, V16, P801, DOI 10.1089/088922200308792
   Monteiro JP, 2007, AIDS RES HUM RETROV, V23, P135, DOI 10.1089/aid.2006.0064
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   Nicholas K. B., 1997, EMBNET NEWS, V4, P1
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
   Pereira GAS, 2004, AM J TROP MED HYG, V71, P679, DOI 10.4269/ajtmh.2004.71.679
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Quarleri JF, 2004, AIDS RES HUM RETROV, V20, P1100, DOI 10.1089/aid.2004.20.1100
   Rios M, 2005, AIDS RES HUM RETROV, V21, P835, DOI 10.1089/aid.2005.21.835
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   SWOFFORD D, 1999, PAUP 4 0 1999 PHYLOG
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MA, 2005, AIDS, V19, P1155, DOI 10.1097/01.aids.0000176215.95119.1d
   Thomson MM, 2002, J GEN VIROL, V83, P107, DOI 10.1099/0022-1317-83-1-107
   WENIGER BG, 1994, AIDS, V8, pS13
   Weniger BG, 2001, AIDS, V15, P545
   B EPIDEMIOLOGICO AID
NR 37
TC 16
Z9 16
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2009
VL 81
IS 3
BP 391
EP 399
DI 10.1002/jmv.21414
PG 9
WC Virology
SC Virology
GA 399JC
UT WOS:000262795200001
PM 19152417
OA Green Published
DA 2020-12-01
ER

PT J
AU Brites, C
   Sampaio, J
   Oliveira, A
AF Brites, Carlos
   Sampaio, Julio
   Oliveira, Adriano
TI HIV/Human T-cell Lymphotropic Virus Coinfection Revisited: Impact on
   AIDS Progression
SO AIDS REVIEWS
LA English
DT Review
DE HIV-1; HTLV-1; HTLV-2; Coinfection
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTING DRUG-USERS; I-ASSOCIATED
   MYELOPATHY; HTLV-I; LEUKEMIA-VIRUS; DISEASE PROGRESSION; PROVIRUS LOAD;
   TYPE-1 HTLV-1; HIV-INFECTION; MOLECULAR EPIDEMIOLOGY
AB Human T-cell lymphotropic viruses type 1 and 2 are retroviruses that share the same routes of transmission as HIM. Since these agents are prevalent simultaneously in different parts of the world, coinfection is a frequently reported event. However, prevalence rates of coinfection differ for distinct populations and regions of the world or for each virus, with human T-cell lymphotropic virus type 1 being more prevalent among HIM-infected individuals in the Southern hemisphere, while type 2 is more frequently found in the Northern hemisphere. In common, they share the tropism for T-lymphocytes, although human T-cell lymphotropic virus type 1 and HIM are predominantly CD4(+) T-cell tropic and human T-cell lymphotropic virus type 2 preferentially infects CD8(+) cells.
   The biological properties of HIM are distinct of those found in human T-cell lymphotropic virus 1/2. This fact makes possible an in vivo interaction between these agents, when coinfecting the same patients, with potentially relevant clinical implications.
   The available evidence suggests a protective role for coinfection by human T-cell lymphotropic virus type 2 on AIDS progression. This hypothesis is supported by several laboratory evidences, as well as by a number of clinical studies that found no significant interaction between human T-cell lymphotropic virus type 2 and HIM, or even detected a protective effect on HIM disease.
   On the other hand, human T-cell lymphotropic virus type 1 seems to be a significant cofactor, with a potentially important role in HIM infection. Although the clinical evidence is still controversial with regard to the real impact that coinfection exerts on clinical evolution, the majority of studies suggest it is associated with a modification of the natural history of HIM infection, with a faster clinical progression and a shorter survival time. The main limitation of the available data is due to methodological problems in the majority of studies, which weaken the validity of their conclusions. A common finding in coinfection by both human T-cell lymphotropic virus type 1 and 2 is the increase in CD4(+) cell count, but without any additional immune benefit for patients.
   Due to the limited available data, we need more, larger studies, designed to respond to the pending questions on the real significance of coinfection by these retroviruses. (AIDS Rev. 2009;11:8-16)
C1 [Brites, Carlos; Sampaio, Julio; Oliveira, Adriano] Fed Univ Bahia Hosp, Virol Res Lab, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Hosp Univ Prof Edgar Santos 60 Andar, LAPI, Rua Joao Botas SN, BR-40110160 Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
FU Brazilian Ministry of Health and CNPQ (Conselho Nacional de Pesquisa,
   Brasil)National Council for Scientific and Technological Development
   (CNPq)
FX Dr. Carlos Brites has research support from the Brazilian Ministry of
   Health and CNPQ (Conselho Nacional de Pesquisa, Brasil).
CR Andrade TM, 1998, J ACQ IMMUN DEF SYND, V18, P186, DOI 10.1097/00042560-199806010-00011
   Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452
   BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985
   Bangham CRM, 2003, INT J HEMATOL, V78, P297, DOI 10.1007/BF02983553
   BARTHOLOMEW C, 1987, JAMA-J AM MED ASSOC, V257, P2604, DOI 10.1001/jama.257.19.2604
   Bassani S, 2007, CLIN INFECT DIS, V44, P105, DOI 10.1086/510076
   Beilke MA, 2004, CLIN INFECT DIS, V39, P256, DOI 10.1086/422146
   BEILKE MA, 1994, J MED VIROL, V44, P132, DOI 10.1002/jmv.1890440205
   Bessinger R, 1997, J ACQ IMMUN DEF SYND, V14, P67, DOI 10.1097/00042560-199701010-00011
   Bovolenta C, 2002, J IMMUNOL, V169, P4443, DOI 10.4049/jimmunol.169.8.4443
   Brites C, 2005, CLIN INFECT DIS, V40, P329, DOI 10.1086/426690
   Brites C, 2002, AIDS, V16, P1292, DOI 10.1097/00002030-200206140-00015
   Brites C, 2001, AIDS, V15, P2053, DOI 10.1097/00002030-200110190-00023
   BRITES C, 1997, BRAZ J INFECT DIS, V1, P43
   BRITES C, 11 CROI SAN FRANC 20
   BRITES C, 2004, 11 CROI SAN FRANC
   Casoli C, 2007, AIDS REV, V9, P140
   Casseb J, 1997, CLIN INFECT DIS, V25, P1259, DOI 10.1086/516969
   CATALANSOARES B, 2004, VOX SANG, V87, P105
   Cavrois M, 2000, J INFECT DIS, V182, P1044, DOI 10.1086/315844
   Centlivre M, 2007, AIDS, V21, P1, DOI 10.1097/QAD.0b013e3280117f7f
   CHAVANCE M, 1995, J ACQ IMMUN DEF SYND, V8, P91
   Coskun AK, 2005, J VIROL, V79, P4150, DOI 10.1128/JVI.79.7.4150-4158.2005
   CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0
   Rego FFD, 2008, AIDS RES HUM RETROV, V24, P673, DOI 10.1089/aid.2007.0290
   de Oliveira MDFSP, 2005, CLIN INFECT DIS, V40, pE90, DOI 10.1086/430064
   DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381
   Dourado I, 1999, MEM I OSWALDO CRUZ, V94, P13, DOI 10.1590/S0074-02761999000100006
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0
   Etoh K, 1999, INT J CANCER, V81, P859, DOI 10.1002/(SICI)1097-0215(19990611)81:6<859::AID-IJC4>3.0.CO;2-K
   ETZEL A, 2004, 15 INT AIDS C BANGK
   Feitosa G, 2001, Braz J Infect Dis, V5, P339
   Franchini G, 2003, INT J HEMATOL, V78, P280, DOI 10.1007/BF02983552
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   GESSAIN A, 1985, LANCET, V2, P407
   Ghez D, 2006, J VIROL, V80, P6844, DOI 10.1128/JVI.02719-05
   GIACOMO M, 1995, EUR J EPIDEMIOL, V11, P527, DOI 10.1007/BF01719304
   Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004
   Goedert JI, 2001, AIDS, V15, P1295, DOI 10.1097/00002030-200107060-00012
   Gotuzzo E, 2000, INFECT DIS CLIN N AM, V14, P211, DOI 10.1016/S0891-5520(05)70225-7
   GOTUZZO E, 1992, ARCH INTERN MED, V152, P1429, DOI 10.1001/archinte.152.7.1429
   Guenthner PC, 2001, ARCH VIROL, V146, P1617, DOI 10.1007/s007050170083
   Harrison LH, 1998, AIDS PATIENT CARE ST, V12, P619, DOI 10.1089/apc.1998.12.619
   Hershow RC, 1996, J INFECT DIS, V174, P309, DOI 10.1093/infdis/174.2.309
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Hisada M, 2002, CLIN INFECT DIS, V34, P1551, DOI 10.1086/340537
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   Hogan CM, 2001, ANN INTERN MED, V134, P978, DOI 10.7326/0003-4819-134-10-200105150-00012
   Iga M, 2002, J INFECT DIS, V185, P691, DOI 10.1086/339002
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293
   JACOBSON S, 1991, J IMMUNOL, V146, P1155
   Kakuda K, 2002, AM J TROP MED HYG, V66, P404, DOI 10.4269/ajtmh.2002.66.404
   KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847
   Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193, DOI 10.1097/00042560-199606010-00014
   KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
   LAGRENADE L, 1990, LANCET, V336, P1345
   LAL RB, 1995, VIROLOGY, V210, P441, DOI 10.1006/viro.1995.1360
   Lawson VA, 2000, J BIOMED SCI, V7, P71
   Lee SM, 2005, CURR TOP MICROBIOL, V296, P125
   LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0
   Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509
   Li HC, 2004, J INFECT DIS, V190, P1275, DOI 10.1086/423941
   Maloney EM, 2003, PEDIATRICS, V112, pE136, DOI 10.1542/peds.112.2.e136
   Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X
   MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609
   Marinho J, 2005, JAIDS-J ACQ IMM DEF, V40, P625, DOI 10.1097/01.qai.0000174252.73516.7a
   MILLER GJ, 1994, J INFECT DIS, V170, P44, DOI 10.1093/infdis/170.1.44
   MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x
   Moir S, 2001, P NATL ACAD SCI USA, V98, P10362, DOI 10.1073/pnas.181347898
   MONTEFIORI DC, 1987, VIROLOGY, V160, P372, DOI 10.1016/0042-6822(87)90008-0
   Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Moriuchi H, 1998, J EXP MED, V187, P1689, DOI 10.1084/jem.187.10.1689
   Moriuchi H, 2000, VIROLOGY, V278, P514, DOI 10.1006/viro.2000.0684
   Mosley AJ, 2005, VIRAL IMMUNOL, V18, P293, DOI 10.1089/vim.2005.18.293
   MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555
   Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803
   Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858
   OKUBO S, 1990, CANCER DETECT PREV, V14, P343
   Orland Jennie R, 2004, Retrovirology, V1, P4, DOI 10.1186/1742-4690-1-4
   OSAME M, 1986, LANCET, V1, P1031
   OZEL M, 1988, ARCH VIROL, V100, P255, DOI 10.1007/BF01487688
   PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K
   Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254
   Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Porto AF, 2005, J INFECT DIS, V191, P612, DOI 10.1086/427560
   PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0
   RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990
   Roucoux DF, 2004, AIDS REV, V6, P144
   Safaeian M, 2000, J ACQ IMMUN DEF SYND, V24, P483, DOI 10.1097/00126334-200008150-00014
   SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353
   Schechter M, 1997, J ACQ IMMUN DEF SYND, V15, P308, DOI 10.1097/00042560-199708010-00010
   Shindo N, 2002, AIDS RES HUM RETROV, V18, P71, DOI 10.1089/088922202753394736
   Sobesky M, 2000, PRESSE MED, V29, P413
   STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352
   STUVER SO, 1993, J INFECT DIS, V167, P57, DOI 10.1093/infdis/167.1.57
   Suzuki M, 1999, CLIN DIAGN LAB IMMUN, V6, P713, DOI 10.1128/CDLI.6.5.713-717.1999
   Takenouchi N, 2007, J VIROL, V81, P1506, DOI 10.1128/JVI.01522-06
   Turci M, 2006, JAIDS-J ACQ IMM DEF, V41, P100, DOI 10.1097/01.qai.0000179426.04166.12
   UNAIDS, 2008, REP GLOB AIDS EP
   Vine AM, 2002, J INFECT DIS, V186, P932, DOI 10.1086/342953
   VISCONTI A, 1993, J ACQ IMMUN DEF SYND, V6, P1228
   WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   WIGNALL FS, 1992, J MED VIROL, V38, P44, DOI 10.1002/jmv.1890380110
   Willy RJ, 1999, DIAGN MICR INFEC DIS, V35, P269, DOI 10.1016/S0732-8893(99)00082-6
   Wodarz D, 2001, P ROY SOC B-BIOL SCI, V268, P1215, DOI 10.1098/rspb.2001.1608
   WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0
   YAMAGUCHI K, 1994, LEUKEMIA, V8, pS88
   YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Zehender G, 2002, JAIDS, V31, P440, DOI 10.1097/00126334-200212010-00011
NR 119
TC 51
Z9 52
U1 0
U2 2
PU PERMANYER PUBL
PI BARCELONA
PA MALLORCA, 310, BARCELONA, 08037, SPAIN
SN 1139-6121
EI 1698-6997
J9 AIDS REV
JI Aids Rev.
PD JAN-MAR
PY 2009
VL 11
IS 1
BP 8
EP 16
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 435OU
UT WOS:000265354000002
PM 19290030
DA 2020-12-01
ER

PT J
AU Ramos, JC
   Diaz, LM
   Manrique, M
   Lima, R
   Toomey, NL
   Xia, T
   Cabral, L
   Guettouche, T
   Brites, C
   Harrington, WJ
AF Ramos, Juan Carlos
   Diaz, Luis M.
   Manrique, Michele
   Lima, Rosangela
   Toomey, Ngoc L.
   Xia, Tianli
   Cabral, Lisa
   Guettouche, Toumy
   Brites, Carlos
   Harrington, William J.
TI Zidovudine Blocks NF-kappa B activity in Vivo in Adult T-Cell Leukemia.
SO BLOOD
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
C1 [Ramos, Juan Carlos] Univ Miami, Div Hematol Oncol, Miami, FL USA.
   [Diaz, Luis M.; Manrique, Michele; Toomey, Ngoc L.; Xia, Tianli; Cabral, Lisa; Guettouche, Toumy; Harrington, William J.] Sylvester Canc Ctr, Div Hematol & Oncol, Miami, FL USA.
   [Lima, Rosangela; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2008
VL 112
IS 11
BP 876
EP 876
PG 1
WC Hematology
SC Hematology
GA 389OP
UT WOS:000262104702856
DA 2020-12-01
ER

PT J
AU Cunha-Neto, E
   Felgueiras, C
   Manuel, ME
   Samri, A
   Coutinho, R
   Cortes, FH
   Coutinho-Silva, A
   Fonseca, SG
   Giacoia-Gripp, CB
   Ferreira, JL
   Rodrigues, R
   Chequer-Fernandez, S
   Brites, C
   Segurado, A
   Fonseca, LA
   Nunes, C
   Kalil, J
   Grassi, F
   Brigido, LF
   Morgado, MG
   Autran, B
AF Cunha-Neto, E.
   Felgueiras, C.
   Manuel, M. E.
   Samri, A.
   Coutinho, R.
   Cortes, F. H.
   Coutinho-Silva, A.
   Fonseca, S. G.
   Giacoia-Gripp, C. B.
   Ferreira, J. L.
   Rodrigues, R.
   Chequer-Fernandez, S.
   Brites, C.
   Segurado, A.
   Fonseca, L. A.
   Nunes, C.
   Kalil, J.
   Grassi, F.
   Brigido, L. F.
   Morgado, M. G.
   Autran, B.
TI T Cell Crossreactivity of Gag and Nef Epitopes Derived from Brazilian
   and European HIV-1 Strains among Brazilian and French HIV-1-Infected
   Patients
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Cunha-Neto, E.; Felgueiras, C.; Coutinho-Silva, A.; Fonseca, S. G.; Segurado, A.; Fonseca, L. A.; Kalil, J.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Manuel, M. E.; Samri, A.; Autran, B.] Hop La Pitie Salpetriere, Paris, Ile de France, France.
   [Coutinho, R.; Cortes, F. H.; Giacoia-Gripp, C. B.; Chequer-Fernandez, S.; Brites, C.; Nunes, C.; Grassi, F.; Morgado, M. G.] Fiocruz MS, Salvador, BA, Brazil.
   [Ferreira, J. L.; Rodrigues, R.; Brigido, L. F.] Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Fonseca, Luiz Augusto M/F-9344-2012;
   FONSECA, SIMONE GONCALVES/U-9278-2019; KALIL, JORGE/C-8029-2012; Cortes,
   Fernanda/AAF-9254-2020; Brites, Carlos/D-1353-2013; Segurado, Aluisio
   C/K-2229-2012; Brigido, Luis F M/C-2155-2011
OI Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Brites, Carlos/0000-0002-4673-6991; Segurado,
   Aluisio C/0000-0002-6311-8036; Brigido, Luis F M/0000-0002-1022-7837
NR 0
TC 1
Z9 1
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 124
EP 124
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800317
DA 2020-12-01
ER

PT J
AU Alves, C
   Oliveira, AC
   Brites, C
AF Alves, Cresio
   Oliveira, Ana Claudia
   Brites, Carlos
TI Lipodystrophic Syndrome in Children and Adolescents Infected With the
   Human Immunodeficiency Virus
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Review
DE HIV; lipodystrophy; highly active antiretroviral treatment; children and
   adolescents
ID ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITORS; CARDIOVASCULAR RISK;
   FAT REDISTRIBUTION; GROWTH-HORMONE; METABOLIC COMPLICATIONS; MEDICAL
   PROGRESS; HIV; METFORMIN; EXERCISE
AB The introduction of highly active antiretroviral therapy (HAART) for the treatment of acquired immunodeficiency syndrome (AIDS) has resulted in greater survival of patients infected with the human immunodeficiency virus (HIV). However, the use of these drugs has been associated with lipodystrophic syndrome (LS), which is characterized by metabolic alterations (dyslipidemia, insulin resistance, diabetes, and lactic acidosis) and abnormal corporal fat distribution. Clinically, LS may manifest as three different forms: lipohipertrophy (accumulation of fat in the central part of the body), lipoatrophy (loss of fat in the extremities, face and buttocks) and mixed (lipohipertrophy + lipoatrophy). Although its physiopathology has not been elucidated, some mechanisms have been described, including leptin and adiponectin deficiency, mitochondrial dysfunction and use of antiretroviral drugs. The type, dose and duration of the antiretroviral treatment, as well as age and puberty are the main risk factors. LS is also associated with increased incidence of cardiovascular illnesses, atherosclerosis and diabetes mellitus. Treatment includes physical activity, cautious restriction of caloric intake, changes in antiretroviral therapy, and use of insulin-sensitizing and lipid-lowering agents. Follow up must be periodic, consisting of measurement of body fat distribution, evaluation of the lipid profile and insulin resistance.
C1 [Alves, Cresio; Oliveira, Ana Claudia; Brites, Carlos] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
RP Alves, C (corresponding author), Rua Plinio Moscoso 222,Apto 601, BR-40157190 Salvador, BA, Brazil.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Amaya RA, 2002, PEDIATR INFECT DIS J, V21, P405, DOI 10.1097/00006454-200205000-00011
   Beregszaszi M, 2005, JAIDS-J ACQ IMM DEF, V40, P161, DOI 10.1097/01.qai.0000178930.93033.f2
   Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302
   Bitnun A, 2005, J CLIN ENDOCR METAB, V90, P168, DOI 10.1210/jc.2004-0125
   Bitnun A, 2003, AIDS, V17, P1319, DOI 10.1097/00002030-200306130-00006
   Bockhorst JL, 2003, PEDIATR INFECT DIS J, V22, P463, DOI 10.1097/00006454-200305000-00017
   Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048
   Brambilla P, 2001, AIDS, V15, P2415, DOI 10.1097/00002030-200112070-00009
   Brandão Ayrton Pires, 2005, Arq. Bras. Cardiol., V85, P79, DOI 10.1590/S0066-782X2005001500001
   Caron M, 2003, AIDS, V17, P2437, DOI 10.1097/00002030-200311210-00005
   Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003
   Castelo A, 2007, ARQ BRAS ENDOCRINOL, V51, P5, DOI 10.1590/S0004-27302007000100003
   Charakida M, 2005, CIRCULATION, V112, P103, DOI 10.1161/CIRCULATIONAHA.104.517144
   Chen DL, 2002, J CLIN ENDOCR METAB, V87, P4845, DOI 10.1210/jc.2002-020794
   Cheseaux JJ, 2002, J ACQ IMMUN DEF SYND, V30, P288, DOI 10.1097/00126334-200207010-00004
   *CONS BRAS DISL, 2005, ARQ BRAS CARDIOL S6, V85, P1
   Cossarizza A, 2004, AIDS, V18, P137, DOI 10.1097/00002030-200401230-00002
   Cossarizza A, 2002, J INFECT DIS, V185, P299, DOI 10.1086/338564
   de Brito AM, 2006, REV SAUDE PUBL, V40, P18, DOI 10.1590/S0034-89102006000800004
   Desai N, 2003, AIDS, V17, P1565, DOI 10.1097/00002030-200307040-00020
   Driscoll SD, 2004, AIDS, V18, P465, DOI 10.1097/00002030-200402200-00013
   Driscoll SD, 2004, J CLIN ENDOCR METAB, V89, P2171, DOI 10.1210/jc.2003-031858
   Falutz J, 2005, AIDS, V19, P1279, DOI 10.1097/01.aids.0000180099.35146.30
   Farley J, 2005, JAIDS-J ACQ IMM DEF, V38, P480, DOI 10.1097/01.qai.0000139397.30612.96
   Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
   Garg A, 2004, NEW ENGL J MED, V350, P1220, DOI 10.1056/NEJMra025261
   Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Hadigan C, 2002, J CLIN ENDOCR METAB, V87, P4611, DOI 10.1210/jc.2002-020709
   Haerter G, 2004, AIDS, V18, P952, DOI 10.1097/00002030-200404090-00016
   Hartman K, 2006, PEDIATR INFECT DIS J, V25, P427, DOI 10.1097/01.inf.0000215003.32256.aa
   Hoschele D, 2006, TOXICOL IN VITRO, V20, P535, DOI 10.1016/j.tiv.2005.11.007
   Jaquet D, 2000, AIDS, V14, P2123, DOI 10.1097/00002030-200009290-00008
   Krause Jens C, 2005, Pediatr Endocrinol Rev, V3, P45
   La Rovere, 2004, AIDS, V18, P1443, DOI 10.1097/01.aids.0000131334.38172.01
   Lipshultz SE, 2000, NEW ENGL J MED, V343, P759, DOI 10.1056/NEJM200009143431102
   Gmaraes MMM, 2007, ARQ BRAS ENDOCRINOL, V51, P42, DOI 10.1590/S0004-27302007000100008
   Manfredi R, 2004, JAIDS-J ACQ IMM DEF, V35, P99, DOI 10.1097/00126334-200401010-00017
   Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3
   Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010
   McComsey G, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e275
   McComsey GA, 2004, AIDS, V18, P1753, DOI 10.1097/00002030-200409030-00004
   Monforte AD, 2004, AIDS, V18, P1811
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437
   Ortigao M B, 1995, Cad Saude Publica, V11, P142, DOI 10.1590/S0102-311X1995000100021
   Roubenoff R, 2002, CLIN INFECT DIS, V34, P390, DOI 10.1086/338402
   Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001
   SZWARCWALD CL, 2001, B EPIDEMIOLOGICO AID
   Taylor P, 2004, PEDIATRICS, V114, P235
   Temple ME, 2003, ANN PHARMACOTHER, V37, P1214, DOI 10.1345/aph.1A444
   Torres AS, 2005, EUR J PEDIATR, V164, P271, DOI 10.1007/s00431-004-1610-y
   Treacy PJ, 2006, DERMATOL SURG, V32, P804, DOI 10.1111/j.1524-4725.2006.32164.x
   Valente Angélica M.M., 2005, Arq Bras Endocrinol Metab, V49, P871, DOI 10.1590/S0004-27302005000600004
   Valente O, 2007, ARQ BRAS ENDOCRINOL, V51, P3, DOI 10.1590/S0004-27302007000100002
   van Wijk JPH, 2005, ANN INTERN MED, V143, P337, DOI 10.7326/0003-4819-143-5-200509060-00009
   Vigano A, 2005, J CLIN ENDOCR METAB, V90, P4075, DOI 10.1210/jc.2004-2431
   Vigano A, 2003, AIDS, V17, P1435, DOI 10.1097/00002030-200307040-00003
   Vigano A, 2003, JAIDS-J ACQ IMM DEF, V32, P482, DOI 10.1097/00126334-200304150-00003
   VIGANO A, 2005, P 1 M MITH TOX HIV I
   WERNER ML, 2005, THESIS I FERNANDES F
   Yu Pai Ching, 2005, Arq. Bras. Cardiol., V85, P58, DOI 10.1590/S0066-782X2005002400014
NR 62
TC 15
Z9 16
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD AUG
PY 2008
VL 12
IS 4
BP 342
EP 348
DI 10.1590/S1413-86702008000400018
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 376GD
UT WOS:000261171200018
PM 19030739
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Fialho, M
   Messias, M
   Page-Shafer, K
   Farre, L
   Schmalb, M
   Pedral-Sampaio, D
   Ramos, M
   Brites, C
AF Fialho, Margaret
   Messias, Marcia
   Page-Shafer, Kimberly
   Farre, Lourdes
   Schmalb, Marcia
   Pedral-Sampaio, Diana
   Ramos, Mauro
   Brites, Carlos
TI Prevalence and risk of blood-borne and sexually transmitted viral
   infections in incarcerated youth in Salvador, Brazil: Opportunity and
   obligation for intervention
SO AIDS AND BEHAVIOR
LA English
DT Article
DE sexually transmitted infections; HIV; STI; incarcerated youth; Brazil;
   blood-borne infections
ID STREET YOUTH; SOCIAL DISTRIBUTION; BELO-HORIZONTE; HBV INFECTION;
   HIV-INFECTION; SAO-PAULO; CHILDREN; ADOLESCENTS; PREVENTION; SYPHILIS
AB To determine the prevalence of sexually transmitted and blood-borne infections among incarcerated adolescents in Salvador, Brazil, we interviewed 300 incarcerated youth aged 11-18 years to participate in a physical examination and to provide a blood sample to test for HIV-1, hepatitis B and C viruses exposure, human T-cells lymphotrophic virus, and syphilis. Overall prevalence was anti-HIV, 0.34%; anti-HBc, 11.1%; HBsAg, 2.4%; anti-HCV, 6.4%; HTLV, 1.09%; and syphilis, 3.4%. The majority (86.3%) reported a history of sexual activity; 27% had never used condoms. Girls also reported previous pregnancy (35%), abortion (26%) and sexual abuse (74%). Many youth reported a family history of alcohol abuse (56%), illicit drug use (24.7%), or legal problems (38%). Serological results show that youth in Salvador are at high risk for blood-borne and sexually transmitted infections. Policies to reduce the risk and impact of these infections should be a requisite part of health care for incarcerated youth.
C1 [Pedral-Sampaio, Diana; Brites, Carlos] Univ Fed Bahia Hosp, Infect Dis Serv, BR-40110160 Salvador, BA, Brazil.
   [Fialho, Margaret; Messias, Marcia; Schmalb, Marcia] CREAIDS, Salvador, BA, Brazil.
   [Page-Shafer, Kimberly] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
   [Farre, Lourdes] Fiocruz MS, Salvador, BA, Brazil.
   [Ramos, Mauro] Ctr Estudos AIDS Rio Grande do Sul CEARGS, Porto Alegre, RS, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia Hosp, Infect Dis Serv, Rua Joao Botas,SN,6 Andar, BR-40110160 Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Brasil Pedral Sampaio,
   Diana/0000-0002-2446-5828; Farre, Lourdes/0000-0002-3168-1940; Page,
   Kimberly/0000-0002-7120-1673
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW005799, D43TW005799, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW005799, D43TW000003, D43TW000003,
   D43TW005799, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW005799, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW005799, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW005799, D43TW000003, D43TW000003, D43TW000003, D43TW005799,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW005799, D43TW000003, D43TW000003,
   D43TW000003, D43TW005799, D43TW000003, D43TW000003, D43TW005799] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246] Funding Source: NIH RePORTER; FIC NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW005799, D43 TW005799, D43TW00003] Funding Source: Medline; NIMH
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [P30 MH062246] Funding Source: Medline
CR Abdelgalil S, 2004, ARCH DIS CHILD, V89, P817, DOI 10.1136/adc.2003.032078
   Alves K, 2003, JAIDS-J ACQ IMM DEF, V32, P551, DOI 10.1097/00126334-200304150-00014
   CARVALHO FT, 2006, AIDS BEHAV, V10, pS57, DOI DOI 10.1007/S10461-006-9124-4
   CELIA S, 1993, INF MENTAL HLTH J, V14, P96, DOI 10.1002/1097-0355(199322)14:2<96::AID-IMHJ2280140203>3.0.CO;2-E
   de Codes Jose Santiago, 2006, Cad Saude Publica, V22, P325
   de Moura SL, 2004, HEALTH EDUC RES, V19, P175, DOI 10.1093/her/cyg023
   De Moura SL, 2003, J ADOLESCENCE, V26, P459, DOI 10.1016/S0140-1971(03)00030-7
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   FILGUEIRAS A, 1993, PLANNED PARENTHOOD C, V2, P22
   Goodwin R, 2004, J HEALTH PSYCHOL, V9, P381, DOI 10.1177/1359105304042348
   Gurgel RQ, 2004, ARCH DIS CHILD, V89, P222, DOI 10.1136/adc.2002.023481
   Inciardi JA, 1998, SUBST USE MISUSE, V33, P1461, DOI 10.3109/10826089809069809
   LARSEN SA, 1995, CLIN MICROBIOL REV, V8, P1
   Lejeune G, 1993, Child Worldw, V20, P3
   LIBONATTI O, 1994, J ACQ IMMUN DEF SYND, V7, P98
   Lockhart C, 2002, MED ANTHROPOL Q, V16, P294, DOI 10.1525/maq.2002.16.3.294
   Marins JR, 2000, AIDS BEHAV, V4
   Martins RMB, 1995, AM J TROP MED HYG, V53, P654, DOI 10.4269/ajtmh.1995.53.654
   Massad E, 1999, EUR J EPIDEMIOL, V15, P439, DOI 10.1023/A:1007523027876
   *MIN JUST BRAS, 1990, EST CRIANC AD
   Ministry of Higher Education, 2000, DOENC SEX TRANSM MAN, P13
   MIRANDA AE, 2001, J BRASILEIRO DOENCAS, V13, P35
   Noto A. R., 2003, LEVANTAMENTO NACL US
   Peres CA, 2002, AIDS EDUC PREV, V14, P36, DOI 10.1521/aeap.14.7.36.23858
   PINTO JA, 1994, J ADOLESCENT HEALTH, V15, P179, DOI 10.1016/1054-139X(94)90547-9
   PORTO SOB, 1994, J ADOLESCENT HEALTH, V15, P577, DOI 10.1016/1054-139X(94)90142-P
   RAFFAELLI M, 1993, SOC SCI MED, V37, P661, DOI 10.1016/0277-9536(93)90105-D
   Ribeiro Moneda Oliveira, 2003, Rev. Latino-Am. Enfermagem, V11, P622, DOI 10.1590/S0104-11692003000500009
   Roy E, 2001, CAN MED ASSOC J, V165, P557
   SIMINI E, 1995, ADOLESCENT INFORM SY
   Tantoco F G, 1993, Child Worldw, V20, P35
   TAPPARELLI G, 2003, PERFIL ADOLESCENTES
   Toledo Jr. Antonio C., 2005, Braz J Infect Dis, V9, P374, DOI 10.1590/S1413-86702005000500004
NR 33
TC 14
Z9 16
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
J9 AIDS BEHAV
JI AIDS behav.
PD JUL
PY 2008
VL 12
IS 4
SU 1
BP S17
EP S24
DI 10.1007/s10461-008-9409-x
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 327GZ
UT WOS:000257718900004
PM 18500658
OA Green Published
DA 2020-12-01
ER

PT J
AU Sampaio-Sa, M
   Page-Shafer, K
   Bangsberg, DR
   Evans, J
   Dourado, MD
   Teixeira, C
   Netto, EM
   Brites, C
AF Sampaio-Sa, Marcia
   Page-Shafer, Kimberly
   Bangsberg, David R.
   Evans, Jennifer
   Dourado, Maria de Lourdes
   Teixeira, Celia
   Netto, Eduardo M.
   Brites, Carlos
TI 100% adherence study: Educational workshops vs. video sessions to
   improve adherence among ART-Naive patients in Salvador, Brazil
SO AIDS AND BEHAVIOR
LA English
DT Article
DE adherence; AIDS; HIV infection; highly active antiretroviral therapy
   (HAART); ART; Brazil
ID ANTIRETROVIRAL THERAPY ADHERENCE; DRUG-RESISTANCE; INTERVENTION; AIDS;
   MEDICATIONS; EFFICACY; CLIENTS; TRIALS
AB We conducted a randomized trial to test an intervention aimed at increasing adherence to antiretroviral therapy (ART) among HIV-positive, ART-naive patients in Salvador, Brazil. Participants (N = 107) were randomized to either educational workshops based on the information-motivation-behavioral skills model (n=52) or a control video session (n=55). Changes in self-reported ART adherence, viral load, CD4 cell counts and ART pharmacy records were measured periodically over 12 months. After 3-6 months, ART adherence (>= 95%) was 77.8% in the workshop group and 85.7% in video group (as treated) and 53.8% and 65.5%, respectively, using intention-to-treat (ITT) analysis (both P > 0.05) At 9-12 months, ART adherence decreased to 73.7% in the workshop group and 79.1% in the video group (as treated) and 53.8% and 61.8% using ITT, respectively. No differences were found in self-reported adherence, viral load or pharmacy records between groups. We found that the educational workshop intervention does not increase adherence to ART.
C1 [Sampaio-Sa, Marcia; Netto, Eduardo M.; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
   [Sampaio-Sa, Marcia; Dourado, Maria de Lourdes; Teixeira, Celia] Secretariat Hlth State Bahia, Salvador, BA, Brazil.
   [Page-Shafer, Kimberly; Evans, Jennifer] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Bangsberg, David R.] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA.
RP Sampaio-Sa, M (corresponding author), Univ Fed Bahia, Salvador, BA, Brazil.
EM sampaiomarcia@uol.com.br
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991;
   Page, Kimberly/0000-0002-7120-1673
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW005799] Funding Source: Medline; NIAAA NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
   [AA015287] Funding Source: Medline; NIMH NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [P30 MH062246] Funding
   Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43TW005799, D43TW005799,
   D43TW005799, D43TW005799, D43TW005799, D43TW005799, D43TW005799,
   D43TW005799, D43TW005799, D43TW005799, D43TW005799] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL
   ABUSE AND ALCOHOLISMUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Alcohol Abuse & Alcoholism (NIAAA) [K24AA015287, K24AA015287,
   K24AA015287, K24AA015287, K24AA015287, K24AA015287] Funding Source: NIH
   RePORTER
CR Altice FL, 1998, ANN INTERN MED, V129, P503, DOI 10.7326/0003-4819-129-6-199809150-00015
   Amico KR, 2006, JAIDS-J ACQ IMM DEF, V41, P285
   Amico KR, 2005, AIDS CARE, V17, P661, DOI 10.1080/09540120500038058
   Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008
   Bartlett JA, 2002, J ACQ IMMUN DEF SYND, V29, pS2, DOI 10.1097/00126334-200202011-00002
   BASTOS FI, 2001, AIDSCIENCE SCI KNOWL
   *BRAZ MIN HLTH, 2001, IMPL MON REP AIDS
   *BRAZ MIN HLTH, 2006, REC ANT THER HIV INF
   Brigido LFM, 2001, AIDS PATIENT CARE ST, V15, P587, DOI 10.1089/108729101753287685
   Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Fairley CK, 2003, INT J STD AIDS, V14, P805, DOI 10.1258/095646203322556129
   Fisher W. A., 2003, SOCIAL PSYCHOL FDN H, P127, DOI [10.1002/9780470753552.ch4, DOI 10.1002/9780470753552.CH4]
   Garcia Rosa, 2003, Braz J Infect Dis, V7, P307, DOI 10.1590/S1413-86702003000500005
   Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984
   Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001
   Lyon ME, 2003, AIDS PATIENT CARE ST, V17, P299, DOI 10.1089/108729103322108175
   Mannheimer SB, 2006, JAIDS-J ACQ IMM DEF, V43, pS41, DOI 10.1097/01.qai.0000245887.58886.ac
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   Murphy Debra A, 2002, J Assoc Nurses AIDS Care, V13, P57, DOI 10.1177/1055329002238026
   Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Perno CF, 2002, JAIDS-J ACQ IMM DEF, V31, pS118, DOI 10.1097/00126334-200212153-00006
   Pinheiro CAT, 2002, BRAZ J MED BIOL RES, V35, P1173, DOI 10.1590/S0100-879X2002001000010
   Remien RH, 2006, JAIDS-J ACQ IMM DEF, V43, pS69, DOI 10.1097/01.qai.0000248340.20685.7d
   Safren SA, 2001, BEHAV RES THER, V39, P1151, DOI 10.1016/S0005-7967(00)00091-7
   Simoni Jane M, 2003, Top HIV Med, V11, P185
   Tesoriero J, 2003, JAIDS-J ACQ IMM DEF, V33, P484, DOI 10.1097/00126334-200308010-00009
   Tuldra A, 2000, J ACQ IMMUN DEF SYND, V25, P221, DOI 10.1097/00126334-200011010-00003
   Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977
NR 32
TC 19
Z9 19
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JUL
PY 2008
VL 12
IS 4
SU 1
BP S54
EP S62
DI 10.1007/s10461-008-9414-0
PG 9
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 327GZ
UT WOS:000257718900009
PM 18512141
DA 2020-12-01
ER

PT J
AU Xia, T
   O'Hara, A
   Araujo, I
   Barreto, J
   Carvalho, E
   Sapucaia, JB
   Ramos, JC
   Luz, E
   Pedroso, C
   Manrique, M
   Toomey, NL
   Brites, C
   Dittmer, DP
   Harrington, WJ
AF Xia, Tianli
   O'Hara, Andrea
   Araujo, Iguaracyra
   Barreto, Jose
   Carvalho, Eny
   Sapucaia, Jose Bahia
   Ramos, Juan Carlos
   Luz, Estela
   Pedroso, Celia
   Manrique, Michele
   Toomey, Ngoc L.
   Brites, Carlos
   Dittmer, Dirk P.
   Harrington, William J., Jr.
TI EBV MicroRNAs in primary lymphomas and targeting of CXCL-11 by
   ebv-mir-BHRF1-3
SO CANCER RESEARCH
LA English
DT Article
ID BARR-VIRUS BAMHI; BURKITTS-LYMPHOMA; GENE-EXPRESSION; T-LYMPHOCYTES;
   TRANSCRIPTS; INHIBITION; CHEMOKINE; MIRNAS; CXCL11; CXCR3
AB EBV-encoded microRNAs (miRNAs) have been identified and their functions are being studied. The expression pattern of these miRNAs in clinical samples of EBV-associated non-Hodgkin's lymphomas is unknown. We analyzed five primary "endemic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency BL lines, a type III latency line, three EBV+ primary effusion lymphomas (PEL), and three AIDS-related diffuse large B-cell lymphomas (DLBCL) for expression of EBV-encoded miRNAs. A markedly elevated expression of miRNA BHRF1-3 in type III relative to its parental type I BL line was found. Primary unmanipulated type I BLs and EBV+ PELs expressed high levels of BART2 miRNA, whereas DLBCLs expressed both BART2 and BHRF1-3 species. BHRF1-3 miRNA expression inversely correlated with levels of a putative cellular target, the IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC, and suppression of this factor was reversed by transfection of an antisense oligo to the EBV miRNA BHRF1-3. EBV-encoded miRNAs are expressed in primary lymphomas classically linked to the virus and are associated with the viral latency status. Targeted suppression of CXCL-11/I-TAC by a viral-encoded miRNA may serve as an immunomodulatory mechanism in these tumors.
C1 [Xia, Tianli; Ramos, Juan Carlos; Manrique, Michele; Toomey, Ngoc L.; Harrington, William J., Jr.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Viral Oncol Program, Miami, FL 33136 USA.
   [O'Hara, Andrea; Dittmer, Dirk P.] Univ N Carolina, Curriculum Genet & Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC USA.
   [Carvalho, Eny; Sapucaia, Jose Bahia] Hosp Martagao Gesteira, Salvador, BA, Brazil.
   [Araujo, Iguaracyra; Barreto, Jose; Pedroso, Celia; Brites, Carlos] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   [Araujo, Iguaracyra] Hosp Aristides Maltez, Salvador, BA, Brazil.
RP Harrington, WJ (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Viral Oncol Program, Room 3400,1275 NW 12th Ave D8-4, Miami, FL 33136 USA.
EM wharring@med.miami.edu
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Luz, Estela/0000-0002-1062-7179;
   dittmer, dirk/0000-0003-4968-5656
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA082274, R01CA109232, R01CA121935, U01CA070058,
   R01CA109232, R01CA082274, R01CA121935, R01CA109232, U01CA070058,
   U01CA070058, U01CA070058, R01CA082274, R01CA109232, R01CA109232,
   R01CA109232, R01CA121935, R01CA082274, U01CA070058, R01CA082274,
   R01CA109232, R01CA109232, R01CA082274, U01CA070058, R01CA121935,
   R01CA109232, U01CA070058, R01CA109232, R01CA109232, R01CA082274,
   U01CA070058, U01CA070058, R01CA082274, R01CA121935, U01CA070058,
   R01CA082274, U01CA070058, R01CA109232, U01CA070058, U01CA070058] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL
   RESEARCHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR) [R01DE018304, R01DE018304, R01DE018304,
   R01DE018304, R01DE018304, R01DE018304] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR)
   [R01DE018304, R01DE018304, R01DE018304, R01DE018304, R01DE018304]
   Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [CA109232, R01 CA121935, R01 CA082274,
   R01 CA109232, CA082274, R01 CA112217, U01 CA070058, CA121935, CA70058]
   Funding Source: Medline; NIDCR NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR) [R01 DE018304-03,
   R01 DE018304-01, R01 DE018304-02, R01 DE018304, DE018304] Funding
   Source: Medline
CR Araujo I, 1996, BLOOD, V87, P5279, DOI 10.1182/blood.V87.12.5279.bloodjournal87125279
   BROOKS LA, 1993, J VIROL, V67, P3182, DOI 10.1128/JVI.67.6.3182-3190.1993
   Cai XZ, 2006, PLOS PATHOG, V2, P236, DOI 10.1371/journal.ppat.0020023
   Carthew RW, 2006, CURR OPIN GENET DEV, V16, P203, DOI 10.1016/j.gde.2006.02.012
   CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708
   Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200
   Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009
   Colvin RA, 2004, J BIOL CHEM, V279, P30219, DOI 10.1074/jbc.M403595200
   Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070
   FRISAN T, 1995, BLOOD, V86, P1493, DOI 10.1182/blood.V86.4.1493.bloodjournal8641493
   Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106
   Hayashi K, 1997, HUM PATHOL, V28, P1408, DOI 10.1016/S0046-8177(97)90231-8
   He ZY, 2004, RNA, V10, P1165, DOI 10.1261/rna.7900204
   Hensbergen PJ, 2005, J IMMUNOTHER, V28, P343, DOI 10.1097/01.cji.0000165355.26795.27
   Hilscher C, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni181
   KARRAN L, 1992, P NATL ACAD SCI USA, V89, P8058, DOI 10.1073/pnas.89.17.8058
   Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758
   Khanna R, 2000, ANNU REV MICROBIOL, V54, P19, DOI 10.1146/annurev.micro.54.1.19
   Kurokawa M, 2005, BLOOD, V106, P235, DOI 10.1182/blood-2004-09-3748
   Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784
   Lo AKF, 2007, P NATL ACAD SCI USA, V104, P16164, DOI 10.1073/pnas.0702896104
   Navarro WH, 2006, BLOOD, V107, P13, DOI 10.1182/blood-2004-11-4278
   NIEDOBITEK G, 1995, BLOOD, V86, P659, DOI 10.1182/blood.V86.2.659.bloodjournal862659
   Papin James, 2005, Methods Mol Biol, V292, P449
   Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781
   Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248
   SADLER RH, 1995, J VIROL, V69, P1132, DOI 10.1128/JVI.69.2.1132-1141.1995
   Samols MA, 2007, PLOS PATHOG, V3, P611, DOI 10.1371/journal.ppat.0030065
   Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040
   Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3
   Sullivan CS, 2005, NATURE, V435, P682, DOI 10.1038/nature03576
   Touitou R, 2003, J GEN VIROL, V84, P949, DOI 10.1099/vir.0.18687-0
   WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990
   Xing L, 2007, J VIROL, V81, P9967, DOI 10.1128/JVI.02244-06
   Xue SA, 2002, INT J CANCER, V99, P635, DOI 10.1002/ijc.10372
   Yang XL, 2006, VACCINE, V24, P2966, DOI 10.1016/j.vaccine.2005.12.004
   Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444
   Zhang LW, 2004, VIROLOGY, V323, P141, DOI 10.1016/j.virol.2004.03.007
NR 38
TC 223
Z9 241
U1 1
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2008
VL 68
IS 5
BP 1436
EP 1442
DI 10.1158/0008-5472.CAN-07-5126
PG 7
WC Oncology
SC Oncology
GA 271PW
UT WOS:000253802200024
PM 18316607
OA Bronze, Green Accepted
DA 2020-12-01
ER

PT J
AU Brennan, CA
   Brites, C
   Bodelle, P
   Golden, A
   Hackett, J
   Holzmayer, V
   Swanson, P
   Vallari, A
   Yamaguchi, J
   Devare, S
   Pedroso, C
   Ramos, A
   Badaro, R
AF Brennan, Catherine A.
   Brites, Carlos
   Bodelle, Pierre
   Golden, Alan
   Hackett, John, Jr.
   Holzmayer, Vera
   Swanson, Priscilla
   Vallari, Ana
   Yamaguchi, Julie
   Devare, Sushil
   Pedroso, Celia
   Ramos, Andre
   Badaro, Roberto
TI HIV-1 strains identified in Brazilian blood donors: Significant
   prevalence of B/F1 recombinants
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SAO-PAULO; DRUG-RESISTANCE; INDIVIDUALS; GENE
AB In the Brazilian HIV-1 epidemic subtypes B, C, and F1 are cocirculating in the high risk population groups, and there is a high prevalence of intersubtype recombinant forms. The dynamic nature of the HIV epidemic in Brazil led us to study HIV-1 subtypes present in HIV-infected blood donations collected from 2001 to 2003. Donations from 91 seropositive donors were evaluated. Genetic subtype was obtained for 88 specimens based on sequence analysis of gag p24, pol IN, and env gp41 IDR. HIV-1 subtype B was the predominant strain present in the donor population (73.9%). A significant prevalence of intersubtype recombinants of subtypes B and F1 was found (22.7%). Subtype C (1.1%) and F1 (2.3%) were rare. None of the B/F1 recombinants is CRF28_BF or CRF29_BF. The high level of unique B/F1 recombinant strains in this population demonstrates the dynamic and complex nature of the HIV epidemic in Brazil.
C1 Abbott Diagnost, Abbott Pk, IL 60064 USA.
   Univ Fed Bahia, Fundacao Bahiana Infectol, BR-41170290 Salvador, BA, Brazil.
   Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Brennan, CA (corresponding author), Abbott Diagnost, D-09NG,Bldg AP20,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.
EM catherine.brennan@abbott.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Couto-Fernandez JC, 1999, J ACQ IMMUN DEF SYND, V22, P288
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   FILHO DJD, 2005, AIDS RES HUM RETROV, V21, P145
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Magiorkinis G, 2003, J GEN VIROL, V84, P2715, DOI 10.1099/vir.0.19180-0
   Quarleri JF, 2004, AIDS RES HUM RETROV, V20, P1100, DOI 10.1089/aid.2004.20.1100
   Rodrigues R, 2006, VIRUS RES, V116, P201, DOI 10.1016/j.virusres.2005.10.004
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Swanson P, 2003, AIDS RES HUM RETROV, V19, P625, DOI 10.1089/088922203322231003
   Swanson P, 2006, J VIROL METHODS, V134, P237, DOI 10.1016/j.jviromet.2006.01.012
   Thomson MM, 2004, AIDS RES HUM RETROV, V20, P1126, DOI 10.1089/aid.2004.20.1126
   Turchi MD, 2002, J ACQ IMMUN DEF SYND, V30, P527, DOI 10.1097/00126334-200208150-00009
   VINCENTE ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
NR 17
TC 27
Z9 28
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2007
VL 23
IS 11
BP 1434
EP 1441
DI 10.1089/aid.2007.0121
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 239SU
UT WOS:000251538800017
PM 18184087
DA 2020-12-01
ER

PT J
AU Bittencourt, AL
   Vieira, MD
   Brites, CR
   Farre, L
   Barbosa, HS
AF Bittencourt, Achilea L.
   Vieira, Maria da Gracas
   Brites, Carlos R.
   Farre, Lourdes
   Barbosa, Helenemarie S.
TI Adult T-Cell Leukemia/Lymphoma in Bahia, Brazil
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE adult T-cell leukemia/lymphoma; mature T-cell leukemia/lymphoma;
   cutaneous T-cell lymphoma; HTLV-I infection; myelopathy associated with
   HTLV-I/tropical spastic paraparesis; HAM/TSP
ID VIRUS TYPE-I; HTLV-I; MYCOSIS-FUNGOIDES; LEUKEMIA; LYMPHOMA;
   CLASSIFICATION; LEUKAEMIA/LYMPHOMA; INTEGRATION; PROGNOSIS; PATIENT
AB The purpose of this study was to evaluate whether subdivision of adult T-cell leukemial/lymphoma (ATL) on the basis of clinical types, skin involvement, histologic features, cell size, and proliferative index (PI) was clinically relevant. Skin lesions were present in 47 cases (67%). Five cases were classified as primary cutaneous tumoral (PCT) type not included in the Shimoyama classification and characterized by skin tumors and absence of systemic involvement, lymphocytosis, and hypercalcemia. Mortality was high (61170 [87%]). The overall median survival time (MST) was 12 months. The following variables were adversely related to survival: acute, lymphoma, and PCT types; absence of skin lesions; large cells; and PI more than 18%. The longer MST observed in cases with skin lesions was probably due to prolonged survival of the smoldering type (58 months). The MST of the PCT type (21 months) was shorter than that of the smoldering type, confirming the importance of clearly defining these 2 types of ATL.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Dept Pathol, Serv Anat Patol, BR-40110160 Salvador, BA, Brazil.
   Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Dept Internal Med, Serv Anat Patol, BR-40110160 Salvador, BA, Brazil.
RP Bittencourt, AL (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Dept Pathol, Serv Anat Patol, Rua Augusto viana S-N, BR-40110160 Salvador, BA, Brazil.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Farre, Lourdes/0000-0002-3168-1940
CR Barbosa HS, 1999, J ACQ IMMUN DEF SYND, V21, P65, DOI 10.1097/00126334-199905010-00009
   Bittencourt AL, 2007, J CLIN ONCOL, V25, P2480, DOI 10.1200/JCO.2007.11.3043
   Bittencourt AL, 1997, EUR J DERMATOL, V7, P283
   BOENISH T, 1989, IMMUNOCHEMICAL STAIN
   Burg G, 2005, J CUTAN PATHOL, V32, P647, DOI 10.1111/j.0303-6987.2005.00495.x
   Ciminale V, 2000, LEUKEMIA RES, V24, P353, DOI 10.1016/S0145-2126(99)00193-9
   DEOLIVEIRA MSP, 1995, INT J CANCER, V60, P823, DOI 10.1002/ijc.2910600617
   DETMAR M, 1991, BRIT J DERMATOL, V124, P198, DOI 10.1111/j.1365-2133.1991.tb00434.x
   DINCAN M, 1995, BRIT J DERMATOL, V132, P983
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Etoh K, 1997, CANCER RES, V57, P4862
   Ishida T, 2003, CLIN CANCER RES, V9, P3625
   Jaffe ES, 2001, WHO CLASSIFICATION T, P189
   JOHNO M, 1992, GANN MONOGRAPH CANC, V39, P33
   KAMIHIRA S, 1992, LEUKEMIA RES, V16, P435, DOI 10.1016/0145-2126(92)90168-7
   Kikuchi M., 2001, WHO CLASSIFICATION T, P200
   Matutes E, 1994, ADULT T CELL LEUKAEM, P113
   Ohshima K, 1999, VIRCHOWS ARCH, V435, P101, DOI 10.1007/s004280050405
   Pombo De Oliveira MS, 1999, INT J CANCER, V81, P1
   Pombo-de-Oliveira MS, 2002, LEUKEMIA RES, V26, P155, DOI 10.1016/S0145-2126(01)00108-4
   RALFKIAER E, 2001, WHO CLASSIFICATION T, P227
   Setoyama Mitsuru, 1999, Journal of Dermatology (Tokyo), V26, P785
   SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x
   SHIRONO K, 1994, LEUKEMIA, V8, P1834
   TAJIMA K, 1994, ADULT T CELL LEUKAEM, P91
   TAKEMOTO S, 1994, BLOOD, V84, P3080
   TAKIMOTO Y, 1994, LEUKEMIA, V8, P507
   TAMIYA S, 1995, LEUKEMIA, V9, P1768
   Yamaguchi T, 2005, BRIT J DERMATOL, V152, P76, DOI 10.1111/J.1365-2133.2004.06274.X
NR 29
TC 59
Z9 61
U1 0
U2 3
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0002-9173
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD NOV
PY 2007
VL 128
IS 5
BP 875
EP 882
DI 10.1309/2YGD1P0QCVCWBLDX
PG 8
WC Pathology
SC Pathology
GA 222PS
UT WOS:000250310000022
PM 17951212
OA Bronze
DA 2020-12-01
ER

PT J
AU Galrao, L
   Brites, C
   Atta, ML
   Atta, A
   Lima, I
   Gonzalez, F
   Magalhaes, F
   Santiago, M
AF Galrao, Liliana
   Brites, Carlos
   Atta, Maria Luiza
   Atta, Ajax
   Lima, Isabella
   Gonzalez, Fernanda
   Magalhaes, Fernanda
   Santiago, Mittermayer
TI Antiphospholipid antibodies in HIV-positive patients
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE antiphospholipid antibodies; antiphospholipid syndrome; HIV; IgA
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TROPICAL SPASTIC PARAPARESIS; PARVOVIRUS
   B19 INFECTION; HEPATITIS-C VIRUS; INTERNATIONAL CONSENSUS STATEMENT;
   SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-BETA-2 GLYCOPROTEIN-I;
   ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; SEROPOSITIVE
   PATIENTS
AB Antiphospholipid (aPL) antibodies classically have been associated with thrombotic phenomena and abortion in patients with autoimmune diseases. The objective of the present work was to evaluate the frequency of such antibodies in patients infected with HIV and study its association with the presence of clinical manifestations of antiphospholipid syndrome (APS). Using a transversal study, a population of patients diagnosed with HIV, identified through an enzyme-linked immunosorbent assay (ELISA) test and confirmed by Western blotting, aged above 17 years old, was investigated. Through a standard questionnaire, the presence of APS manifestations was investigated, as well as the frequency of rheumatic manifestations. Antibodies against beta 2 glycoprotein I (anti-beta 2 GPI) and anticardiolipin (aCL) IgA, IgG, and IgM were investigated by the ELISA method using commercial kits (QUANTA Lite, INOVA Diagnostics). Ninety patients were studied, 47 (52.2%) male and 43 (47.8%) female. Clinical manifestations of APS were detected in 12 patients (13.3%) of the studied population, whereas arthralgia was the most common rheumatic manifestation (38.9%). Of the 90 patients, 40 (44.4%) were reactive for at least one type of aPL antibody (aCL and/or anti-beta 2 GPI). The frequency of aCL was 17.8%, from which 15 (16.7%) had aCL IgG, 3 (3.3%) IgM, and 1 (1.1%) IgA. The frequency of the anti-beta 2 GPI antibody was 33.3%, from which 29 (32.2%) were positive for isotype IgA, 4 (4.4%) isotype IgM, and 1 (1.1%) isotype IgG. No association was observed between immunoreactivity for aPL antibodies in general or each isotype in particular and the presence of APS manifestation. In the present study, it was possible to observe a relatively high frequency of aPL antibodies, particularly for isotype IgA anti-beta 2 GPI in HIV. However, there was no association to APS manifestations, suggesting that such antibodies had no etiopathogenic role in these complications in patients with such retroviral infection.
C1 Hosp Univ Prof Edgard Santos, Serv Infectol, Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Pharm, Immunol Lab, Salvador, BA, Brazil.
   EBMSP, Salvador, BA, Brazil.
   Hosp Santa Izabel, Serv Rheumatol, Salvador, BA, Brazil.
RP Santiago, M (corresponding author), Praca Conselheiro Almeida Couto 500, BR-40000000 Salvador, BA, Brazil.
EM mitter@svn.com.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR BARTON EN, 1993, J TROP MED HYG, V96, P172
   Biron C, 1998, J LAB CLIN MED, V131, P243, DOI 10.1016/S0022-2143(98)90096-8
   Cacoub P, 2000, MEDICINE, V79, P47, DOI 10.1097/00005792-200001000-00005
   CARRENO L, 1994, J RHEUMATOL, V21, P1344
   Constans J, 1998, EUR J CLIN INVEST, V28, P115, DOI 10.1046/j.1365-2362.1998.00254.x
   Cucurull E, 1999, AM J MED SCI, V318, P55, DOI 10.1097/00000441-199907000-00009
   Dalekos GN, 2000, EUR J GASTROEN HEPAT, V12, P67, DOI 10.1097/00042737-200012010-00013
   DAROCA JC, 1992, INFECTION, V20, P140, DOI 10.1007/BF01704601
   Faghiri Z, 1999, LUPUS, V8, P210, DOI 10.1191/096120399678847731
   Falco M, 1993, Ann Ital Med Int, V8, P171
   Gorczyca I, 2005, FOLIA NEUROPATHOL, V43, P45
   Gratacos E, 1995, PRENATAL DIAG, V15, P1109, DOI 10.1002/pd.1970151205
   Harada M, 2000, J GASTROENTEROL, V35, P272, DOI 10.1007/s005350050345
   Hassoun A, 2004, AIDS PATIENT CARE ST, V18, P333, DOI 10.1089/1087291041444032
   Kulthanan K, 2002, INT J DERMATOL, V41, P417, DOI 10.1046/j.1365-4362.2002.01529.x
   Leder AN, 2001, LUPUS, V10, P370, DOI 10.1191/096120301669209574
   Loizou S, 2003, ANN RHEUM DIS, V62, P1106, DOI 10.1136/ard.62.11.1106
   Loizou S, 1997, ARTHRITIS RHEUM-US, V40, P103, DOI 10.1002/art.1780400115
   Malta J.B.N.S., 2002, Braz J Infect Dis, V6, P40, DOI 10.1590/S1413-86702002000100006
   Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
   Njobvu P, 2000, J RHEUMATOL, V27, P1699
   Palomo I, 2003, J CLIN LAB ANAL, V17, P209, DOI 10.1002/jcla.10093
   Panayiotakopoulos GD, 2003, RHEUMATOLOGY, V42, P1164, DOI 10.1093/rheumatology/keg316
   Petrovas C, 1999, J AUTOIMMUN, V13, P347, DOI 10.1006/jaut.1999.0324
   Ramos-Casals M, 2004, CLIN INFECT DIS, V38, P1009, DOI 10.1086/382537
   Sanchez AN, 2004, NEFROLOGIA, V24, P97
   Santiago M, 2004, CLIN RHEUMATOL, V23, P485, DOI 10.1007/s10067-004-0924-5
   Santiago M, 2001, CLIN EXP RHEUMATOL, V19, P425
   SANTIAGO M, 2000, REV BRAS REUMATOL, V40, P285
   SANTIAGO MB, 1989, CLIN RHEUMATOL, V8, P23, DOI 10.1007/BF02031064
   SANTIAGO MB, 1990, BRAZ J MED BIOL RES, V23, P397
   Santos JL, 2004, REV ESP CARDIOL, V57, P997, DOI 10.1157/13066462
   Shah I, 2006, PEDIATR INFECT DIS J, V25, P185, DOI 10.1097/01.inf.0000200140.04406.d0
   Shahnaz S, 2004, AM J MED SCI, V327, P231, DOI 10.1097/00000441-200404000-00010
   Shen YMP, 2004, CLIN APPL THROMB-HEM, V10, P277, DOI 10.1177/107602960401000311
   STIMMLER MM, 1989, ARCH INTERN MED, V149, P1833, DOI 10.1001/archinte.149.8.1833
   Sued O, 2006, ENFERM INFEC MICR CL, V24, P238, DOI 10.1016/S0213-005X(06)73769-7
   TAILLAN B, 1989, ANN MED INTERNE, V140, P405
   von Landenberg P, 2003, ARTHRITIS RHEUM-US, V48, P1939, DOI 10.1002/art.11038
   WILSON WA, 1995, LUPUS, V4, P138, DOI 10.1177/096120339500400210
   Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
   Yuste JR, 2003, EUR J GASTROEN HEPAT, V15, P717, DOI 10.1097/01.meg.0000059144.68845.61
NR 42
TC 21
Z9 22
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD NOV
PY 2007
VL 26
IS 11
BP 1825
EP 1830
DI 10.1007/s10067-007-0581-6
PG 6
WC Rheumatology
SC Rheumatology
GA 215MU
UT WOS:000249813700005
PM 17332976
DA 2020-12-01
ER

PT J
AU Angelo, ALD
   Angelo, CD
   Torres, AJL
   Ramos, AMC
   Lima, M
   Netto, EM
   Brites, C
AF Dias Angelo, Ana Luiza
   Angelo, Camila Dias
   Leite Torres, Alex Jose
   Costa Ramos, Andre Mauricio
   Lima, Marcia
   Netto, Eduardo Martins
   Brites, Carlos
TI Evaluating total lymphocyte counts as a substitute for CD4 counts in the
   follow up of AIDS patients
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE lymphocyte counts; CD4 counts; AIDS
ID HIV-INFECTION; ABSOLUTE; PERCENTAGE; INDIVIDUALS; PROGRESSION; PREDICTOR
AB This study evaluated total lymphocyte count (TLC) as a substitute marker for CD4(+) cell counts to identify patients who need prophylaxis against opportunistic infection (CD4 < 200 cells/mm(3)) and patients with CD4 < 350 cells/mm' (Brazilian threshold value of CD4 count to define AIDS). We evaluated TLC and CD4 cells count of 1,174 HIV-infected patients, in Salvador, Brazil, from May 2003 to September 2004. CD4(+) cell counts were performed by now cytometry, and TLC was measured with an automated hematological counter. The mean CD4 count was 430 cells/mm(3) (range: 4 to 2,531 cells/mm(3)). Mean TLC was 1,900 cells/mm(range: 300 to 6,200 cells/mm(3)). Using a threshold value of 1,000 cells/mm(3) for TLC, the positive predictive value (PPV) was 77% for CD4 < 200 cells/mm', but the sensitivity was only 29 %, while the negative predictive value (NPV) was 88 %, with 98 % specificity. Similar findings were observed for CD4 count < 350. Using the same threshold value of 1,000 cells/mm(3) for TLC, sensitivity was 14%, and specificity 99 % (PPV= 94 %; NPV=62 %). In 70/1,510 (5 %) of the samples the sum of CD4 and CD8 cell counts was greater than the TLC and in 27 % (419/1,510) this sum was below 65 % of the TLC. TLC has a high specificity to identify patients for prophylaxis, but a quite low sensitivity. It is not useful as an alternative to CD4(+) T-cell counts as a marker in HIV-infected patients.
C1 [Dias Angelo, Ana Luiza; Angelo, Camila Dias; Leite Torres, Alex Jose; Costa Ramos, Andre Mauricio; Netto, Eduardo Martins; Brites, Carlos] Univ Fed Bahia, Prof Edgard Santos Hosp, Salvador, BA, Brazil.
   Univ Fed Bahia, Prof Edgard Santos Hosp, Salvador, BA, Brazil.
   [Netto, Eduardo Martins; Brites, Carlos] Infect Dis Fdn Bahia, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Hosp Univ Prof Edgard Santos 6, Andar Rua Joa Botas SN Canela, BR-40110160 Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013; Torres, Alex
   JL/Q-6186-2018
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991; 
CR Akinola NO, 2004, CLIN INFECT DIS, V39, P579, DOI 10.1086/422722
   Badri M, 2003, AIDS, V17, P541, DOI 10.1097/00002030-200303070-00009
   Beck EJ, 1996, INT J STD AIDS, V7, P422, DOI 10.1258/0956462961918392
   BLATT SP, 1993, JAMA-J AM MED ASSOC, V269, P622, DOI 10.1001/jama.269.5.622
   FOURNIER AM, 1992, AM J MED SCI, V304, P79, DOI 10.1097/00000441-199208000-00002
   Gange SJ, 2003, AIDS, V17, P119, DOI 10.1097/00002030-200301030-00016
   Gebo KA, 2004, JAIDS-J ACQ IMM DEF, V36, P1028, DOI 10.1097/00126334-200408150-00005
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Jacobson MA, 2003, AIDS, V17, P917, DOI 10.1097/00002030-200304110-00019
   Kumarasamy N, 2002, JAIDS-J ACQ IMM DEF, V31, P378, DOI 10.1097/00126334-200212010-00002
   MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144
   Pascale JM, 1997, CLIN DIAGN LAB IMMUN, V4, P474, DOI 10.1128/CDLI.4.4.474-477.1997
   Post FA, 1996, QJM-MON J ASSOC PHYS, V89, P505
   SCHECHTER M, 1994, J ACQ IMMUN DEF SYND, V7, P163
   van der Ryst E, 1998, J ACQ IMMUN DEF SYND, V19, P238, DOI 10.1097/00042560-199811010-00005
   Willy RJ, 1999, DIAGN MICR INFEC DIS, V35, P269, DOI 10.1016/S0732-8893(99)00082-6
   World Health Organization, 2003, SCAL ANT THER RES LI, DOI 10.1097/COH.0b013e32835b8123
NR 17
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD OCT
PY 2007
VL 11
IS 5
BP 466
EP 470
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 279XM
UT WOS:000254388700005
PM 17962871
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Sampaio, J
   Brites, C
   Araujo, I
   Bacchi, CE
   Dittmer, DP
   Tanaka, PY
   Harrington, W
   Netto, EM
AF Sampaio, Julio
   Brites, Carlos
   Araujo, Iguaracyra
   Bacchi, Carlos E.
   Dittmer, Dirk P.
   Tanaka, Paula Y.
   Harrington, William, Jr.
   Netto, Eduardo M.
TI AIDS related malignancies in Brazil
SO CURRENT OPINION IN ONCOLOGY
LA English
DT Review
DE Brazil; HAART; HIV; HTLV-I; Kaposi's sarcoma; lymphoma
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS;
   NON-HODGKIN-LYMPHOMA; EPSTEIN-BARR-VIRUS; KAPOSIS-SARCOMA; NORTHEASTERN
   BRAZIL; HEPATITIS-C; HUMAN-HERPESVIRUS-8; SEROPREVALENCE; AMERINDIANS
AB Purpose of review
   There have been relatively few studies,of HIV-related malignancies in Brazil. Universal,access to antiretroviral drugs in Brazil has changed both the mortality and morbidity rates of AIDS. Nevertheless, there is also extreme poverty in both urban and rural areas and complications of prolonged immune suppression such as mycobacterial and malignant diseases have put a significant strain on the country's healthcare system. This brief review outlines the existing data regarding AIDS related malignancies in the largest Latin American country.
   Recent findings
   Currently, there are almost 600000 people infected with HIV in Brazil and 170 000 patients are receiving highly active antiretroviral therapy. In the studies done of HIV malignancies in Brazil, it appears that these tumors are histologically similar to those that occur in other equatorial countries and differ somewhat from those seen in Europe and the US. Another unique distinction is the high association with oncogenic herpes viruses.
   Summary
   The existence of federally sponsored highly active antiretroviral therapy, clinicians and healthcare providers experienced in the care of HIV patients and high incidence of malignancies associated with oncogenic viruses make Brazil an important site for clinical and basic research in AIDS and immunodeficiency related malignancies.
C1 Univ Miami, Miller Sch Med, Div Hematol Oncol,Sylvester Comprehens Canc Ctr, Dept Med,Fogarty Int Ctr,AIDS & TB Program, Miami, FL 33136 USA.
   Univ Fed Bahia, Edgard Santos Univ Hosp, Salvador, BA, Brazil.
   Univ N Carolina, Chapel Hill, NC USA.
   Emilio Ribas Infectol Inst, Sect Hematol, Sao Paulo, Brazil.
RP Harrington, W (corresponding author), Univ Miami, Miller Sch Med, Div Hematol Oncol,Sylvester Comprehens Canc Ctr, Dept Med,Fogarty Int Ctr,AIDS & TB Program, Room 3400 D8-4, Miami, FL 33136 USA.
EM wharring@med.miami.edu
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; dittmer, dirk/0000-0003-4968-5656
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000017, D43TW000017, D43TW000017,
   D43TW000017, D43TW000017, D43TW000017, D43TW000017, D43TW000017,
   D43TW000017, D43TW000017, D43TW000017, D43TW000017, D43TW000017,
   D43TW000017, D43TW000017, D43TW000017, D43TW000017, D43TW000017,
   D43TW000017, D43TW000017, D43TW000017, D43TW000017, D43TW000017,
   D43TW000017, D43TW000017, D43TW000017, D43TW000017, D43TW000017,
   D43TW000017, D43TW000017, D43TW000017] Funding Source: NIH RePORTER;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U01CA070058, U01CA070058, U01CA070058, R01CA163217,
   R01CA109232, R01CA163217, R01CA163217, R01CA109232, R01CA109232,
   U01CA070058, U01CA070058, R01CA109232, R01CA109232, R01CA109232,
   U01CA070058, U01CA070058, R01CA109232, U01CA070058, R01CA109232,
   U01CA070058, R01CA163217, R01CA163217, R01CA163217, R01CA163217,
   U01CA070058, U01CA070058, U01CA070058, R01CA109232, R01CA109232,
   R01CA109232, R01CA163217, R01CA109232, U01CA070058, R01CA163217] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL
   RESEARCHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR) [R01DE018304, R01DE018304, R01DE018304,
   R01DE018304, R01DE018304, R01DE018304] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR)
   [R01DE018304, R01DE018304, R01DE018304, R01DE018304, R01DE018304]
   Funding Source: NIH RePORTER; FIC NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [5D43 TW00017-18, D43 TW000017]
   Funding Source: Medline; NCI NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01 CA109232-04, R01 CA109232-05, R01
   CA109232-02, U01 CA070058, CA70058, R01 CA109232-01, R01 CA109232-03S1,
   R01 CA109232-03, R01 CA109232, R01 CA163217] Funding Source: Medline;
   NIDCR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR) [R01 DE018304-01, R01 DE018304-02, R01
   DE018304, R01 DE018304-03] Funding Source: Medline
CR Araujo I, 1996, BLOOD, V87, P5279, DOI 10.1182/blood.V87.12.5279.bloodjournal87125279
   Araujo Iguaracyra, 2005, Braz J Infect Dis, V9, P444, DOI 10.1590/S1413-86702005000500028
   Bacchi CE, 1996, AM J CLIN PATHOL, V105, P230
   Biggar RJ, 2000, J INFECT DIS, V181, P1562, DOI 10.1086/315456
   BRITES C, 1997, BRAZ J INFECT DIS, V1, P42
   Cunha AMG, 2005, J GEN VIROL, V86, P2433, DOI 10.1099/vir.0.81087-0
   Harrison LH, 1998, AIDS PATIENT CARE ST, V12, P619, DOI 10.1089/apc.1998.12.619
   Ishak R., 2005, Braz J Infect Dis, V9, P436, DOI 10.1590/S1413-86702005000500018
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   Marins JRP, 2005, AIDS, V19, pS27, DOI 10.1097/01.aids.0000191487.69414.88
   *MIN SAUD, 2006, B EP AIDS DST 2006
   Mohanna S, 2005, INT J INFECT DIS, V9, P239, DOI 10.1016/j.ijid.2005.02.004
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Mwanda W O, 2005, East Afr Med J, V82, pS133
   Parkin DM, 2000, AIDS, V14, P2929, DOI 10.1097/00002030-200012220-00015
   Pereira GAS, 2006, J MED VIROL, V78, P719, DOI 10.1002/jmv.20613
   Ramos-Da-Silva S, 2006, BRAZ J MED BIOL RES, V39, P573, DOI 10.1590/S0100-879X2006000500002
   Sandlund JT, 1997, LEUKEMIA, V11, P743, DOI 10.1038/sj.leu.2400609
   Tanaka PY, 2006, INT J HEMATOL, V84, P337, DOI 10.1532/IJH97.06116
   Tanaka PY, 2007, PATHOL RES PRACT, V203, P1, DOI 10.1016/j.prp.2006.09.004
   Yoshioka MCN, 2004, INT J DERMATOL, V43, P643, DOI 10.1111/j.1365-4632.2004.02170.x
   Zhang XQ, 1998, J INFECT DIS, V178, P1488, DOI 10.1086/314457
NR 22
TC 5
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8746
EI 1531-703X
J9 CURR OPIN ONCOL
JI Curr. Opin. Oncol.
PD SEP
PY 2007
VL 19
IS 5
BP 476
EP 478
DI 10.1097/CCO.0b013e3282c8c8eb
PG 3
WC Oncology
SC Oncology
GA 201NA
UT WOS:000248837400010
PM 17762574
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Sa, MS
   Sampaio, J
   Haguihara, T
   Ventin, FO
   Brites, C
AF Sa, Marcia Sampaio
   Sampaio, Julio
   Haguihara, Thiago
   Ventin, Fernando Oak
   Brites, Carlos
TI Clinical and laboratory profile of HIV-positive patients at the moment
   of diagnosis in Bahia, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE AIDS; HIV infection; stage of disease; Brazil
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; AIDS
AB In Brazil, current trends of the AIDS epidemic include an increase in transmission through heterosexual contact, predominantly from men to women, with more cases of AIDS in women and more children contaminated by vertical transmission. There is also a high proportion of cases in poor people or people living in small towns. HIV-infected patients with high levels of immunodeficiency are frequently hospitalized after their first visit to the clinic due to opportunistic infections, characteristic of advanced disease. This study characterized the clinical and laboratory pattern of AIDS in a sample of patients attended for the first time in the AIDS clinic of the Federal University of Bahia Hospital (HUPES) in Salvador, Brazil. We revised medical charts of cases of subjects registered at the outpatient AIDS clinic from January 1997 to December 2003. The demographics, clinical data, and laboratory characteristics were analyzed to determine the degree of immunodeficiency at the time of admission. A total of 377 patients were evaluated (58.6% were male, with a mean sample age of 33.4 years). The most frequent clinical manifestations were asthenia, weight loss, fever, anemia, dermatitis, oral thrush and diarrhea. CDC criteria were not adequate to define the initial cases. After admission to the outpatient clinic, nearly 25% of the patients were hospitalized immediately, indicating delay in the diagnosis. In Bahia, the initial presentation of HIV-infected patients to health care assistance is occurring at a late stage of the disease, when signs and symptoms of immunodeficiency are already established. Efforts are necessary to construct strategies to make an early diagnosis of these patients, improve the quality of care, and guarantee the benefits of antiretroviral therapy, when it is indicated.
C1 [Sa, Marcia Sampaio] Secretaria Hlth State Bahia, Bahia Blanca, Buenos Aires, Argentina.
   [Sa, Marcia Sampaio; Sampaio, Julio; Haguihara, Thiago; Ventin, Fernando Oak; Brites, Carlos] Univ Fed Bahia, Salvador, BA, Brazil.
RP Sa, MS (corresponding author), Hosp Univ Prof Edgard Santos, Unidad Docente Assistencial Infectol, Rua Joao Das Botas,S-N,6 Andar Canela, Salvador, BA, Brazil.
EM sampaiomarcia@uol.com.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR *CDC, 1981, MMWR-MORBID MORTAL W, V30, P250
   *CN DST AIDS MS CO, 1998, AIDS BRAS ESF CONJ G, P11
   *CN DST AIDS MS CO, 2000, PROGR BRAS DST AIDS, P6
   FOX R, 1987, AIDS, V1, P35
   Gottlieb MS, 2001, NEW ENGL J MED, V344, P1788, DOI 10.1056/NEJM200106073442312
   KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236
   LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q
   LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360
   *MIN SAUD, 2004, DEF NACL CAS AIDS IN
   *MIN SAUD, 2006, B EP AIDST
   MOREIRA ED, 1993, AM J TROP MED HYG, V48, P687, DOI 10.4269/ajtmh.1993.48.687
   SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Steinbrook R, 2001, NEW ENGL J MED, V344, P1781, DOI 10.1056/NEJM200106073442308
   UNAIDS/WHO, 2006, JOINT UN PROGR HIV A
NR 15
TC 8
Z9 10
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD AUG
PY 2007
VL 11
IS 4
BP 395
EP 398
DI 10.1590/S1413-86702007000400004
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA 279XL
UT WOS:000254388600004
PM 17873991
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Pedroso, C
   Queiroz, ATL
   Alcantara, LC
   Drexler, JF
   Diaz, RS
   Weyll, N
   Brites, C
AF Pedroso, Celia
   Queiroz, Artur T. L.
   Alcantara, Luis C.
   Drexler, Jan F.
   Diaz, Ricardo S.
   Weyll, Neide
   Brites, Carlos
TI High prevalence of primary antiretroviral resistance among
   HIV-1-infected adults and children in Bahia, a Northeast State of Brazil
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID HIV-1 DRUG-RESISTANCE; THERAPY
C1 Univ Fed Bahia Hosp, Infect Dis Serv, Salvador, BA, Brazil.
   Fiocruz MS, Goncalo Moniz Res Ctr, Adv Publ Hlth Lab, Salvador, BA, Brazil.
   Univ Fed Sao Paulo, BR-04023062 Sao Paulo, Brazil.
RP Pedroso, C (corresponding author), Univ Fed Bahia Hosp, Infect Dis Serv, Salvador, BA, Brazil.
RI Diaz, Ricardo/K-3978-2012; Drexler, Jan Felix/C-1004-2014; Queiroz,
   Artur/F-6083-2014; Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; de Queiroz, Artur Trancoso
   Lopo/0000-0003-4908-9993; Drexler, Jan Felix/0000-0002-3509-0232
CR Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015
   Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135
   Brites C, 2001, Braz J Infect Dis, V5, P177
   DEMENDOZA C, 2002, PHARMACOTHERAPY, V22, P659
   IDEMYOR V, 2002, AIDS REV, V4, P64
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007
   ROSS LL, 2003, 44 INTERSCIENCE C AN
   Soares MA, 2004, AIDS, V18, pS9, DOI 10.1097/00002030-200406003-00003
   Spira S, 2003, J ANTIMICROB CHEMOTH, V51, P229, DOI 10.1093/jac/dkg079
   WRIN T, 2000, 40 INTERSCIENCE C AN
NR 11
TC 37
Z9 38
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2007
VL 45
IS 2
BP 251
EP 253
DI 10.1097/QAI.0b013e318050d8b0
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 173SD
UT WOS:000246891900020
PM 17527096
OA Green Published
DA 2020-12-01
ER

PT J
AU Drexler, JF
   Luna, LKD
   Pedroso, C
   Pedral-Sampaio, DB
   Queiroz, ATL
   Brites, C
   Netto, EM
   Drosten, C
AF Drexler, Jan Felix
   de Souza Luna, Luciano Kleber
   Pedroso, Celia
   Pedral-Sampaio, Diana Brasil
   Queiroz, Artur T. L.
   Brites, Carlos
   Netto, Eduardo M.
   Drosten, Christian
TI Rates of and reasons for failure of commercial human immunodeficiency
   virus type 1 viral load assays in Brazil
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID GROUP M SUBTYPES; HIV-1; PERFORMANCE; DIVERSITY; STANDARDS; PCR
AB We examined failures of commercial human immunodeficiency virus type 1 (HIV-1) viral load assays of 1,195 plasma samples from Brazilian patients. Assay failure was assumed for samples in which the virus was undetectable by commercial assay but which tested positive by real-time reverse transcription-PCR of the HIV-1 long terminal repeat (LTR) region or if the viral load differed by > 2 log(10) from that determined by LTR assay. Failure rates for Bayer Versant bDNA 3.0, Roche Amplicor Monitor v1.5, and bioMerieux NucliSens QT were 0.68, 0.47, and 4.33%, respectively. NucliSens may be inadequate for use in Brazil.
C1 Bernhard Nocht Inst Trop Med, Clin Virol Sect, D-20359 Hamburg, Germany.
   Hosp Univ Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
   Fiocruz MS, Lab Saude Avancada, Salvador, BA, Brazil.
RP Drosten, C (corresponding author), Bernhard Nocht Inst Trop Med, Clin Virol Sect, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
EM drosten@bni-hamburg.de
RI de Souza Luna, Luciano Kleber/AAG-6418-2019; Netto, Eduardo/D-1432-2013;
   Drexler, Jan Felix/C-1004-2014; Brites, Carlos/D-1353-2013; de Souza
   Luna, Luciano Kleber/L-1213-2013; Queiroz, Artur/F-6083-2014
OI de Souza Luna, Luciano Kleber/0000-0002-3552-5507; Netto,
   Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991; de
   Souza Luna, Luciano Kleber/0000-0002-3552-5507; Drexler, Jan
   Felix/0000-0002-3509-0232; de Queiroz, Artur Trancoso
   Lopo/0000-0003-4908-9993; Brasil Pedral Sampaio,
   Diana/0000-0002-2446-5828
CR [Anonymous], 2006, REP GLOB AIDS EP
   Antunes R, 2003, J CLIN MICROBIOL, V41, P3361, DOI 10.1128/JCM.41.7.3361-3367.2003
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Burgisser P, 2000, J ACQ IMMUN DEF SYND, V23, P138
   Christopherson C, 1997, NUCLEIC ACIDS RES, V25, P654, DOI 10.1093/nar/25.3.654
   Drosten C, 2006, CLIN CHEM, V52, P1258, DOI 10.1373/clinchem.2006.066498
   Jagodzinski LL, 2000, J CLIN MICROBIOL, V38, P1247, DOI 10.1128/JCM.38.3.1247-1249.2000
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Michael NL, 1999, J CLIN MICROBIOL, V37, P2557, DOI 10.1128/JCM.37.8.2557-2563.1999
   *MIN SAUD COORD NA, 2002, EXP PROGR BRAS AIDS
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Swanson P, 2005, J CLIN MICROBIOL, V43, P3860, DOI 10.1128/JCM.43.8.3860-3868.2005
   Swanson P, 2001, J CLIN MICROBIOL, V39, P862, DOI 10.1128/JCM.39.3.862-870.2001
   Takebe Y, 2004, PEDIATR INT, V46, P236, DOI 10.1046/j.1442-200x.2004.01869.x
   VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
   von Truchsess I, 2006, J MED VIROL, V78, P311, DOI 10.1002/jmv.20541
NR 18
TC 23
Z9 23
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2007
VL 45
IS 6
BP 2061
EP 2063
DI 10.1128/JCM.00136-07
PG 3
WC Microbiology
SC Microbiology
GA 179JT
UT WOS:000247286500074
PM 17392448
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Ramos, JC
   Lossos, IS
   Brites, CS
   Ratner, LS
   Dittmer, DP
   Feuer, GP
   Harrington, WJ
AF Ramos, Juan Carlos
   Lossos, Izidore S.
   Brites, Carlos S.
   Ratner, Lee S.
   Dittmer, Dirk P.
   Feuer, Gerold P.
   Harrington, William J., Jr.
TI IRF-4 and interferon resistance in adult T cell leukemia
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 13th International Conference on Human Retrovirology - HTLV and Related
   Viruses
CY MAY 21-25, 2007
CL Hakone, JAPAN
C1 Univ Miami, Miller Sch Med, Miami, FL 33152 USA.
   Washington Univ, St Louis, MO USA.
   Univ N Carolina, Chapel Hill, NC USA.
   SUNY Syracuse, Syracuse, NY USA.
EM jramos2@med.miami.edu
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR
PY 2007
VL 23
IS 4
BP 593
EP 594
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 160AN
UT WOS:000245909300050
DA 2020-12-01
ER

PT J
AU Moreira, MCS
   Ramos, AM
   Porto, A
   Brites, C
AF Moreira, Marcia C. S.
   Ramos, Andre M.
   Porto, Aurelia
   Brites, Carlos
TI Prevalence of hepatitis B (HBV) and C (HCV) infections is higher and
   routes of infection differ for patients coinfected with HIV and HTLV
   compared to individuals infected by a single retrovirus
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 13th International Conference on Human Retrovirology - HTLV and Related
   Viruses
CY MAY 21-25, 2007
CL Hakone, JAPAN
C1 Univ Fed Bahia, Infect Dis Serv, Salvador, BA, Brazil.
   Univ Fed Bahia, Serv Immunol, Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR
PY 2007
VL 23
IS 4
BP 609
EP 610
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 160AN
UT WOS:000245909300095
DA 2020-12-01
ER

PT J
AU Ramos, JC
   Ruiz, P
   Ratner, L
   Reis, IM
   Brites, C
   Pedroso, C
   Byrne, GE
   Toomey, NL
   Andela, V
   Harhaj, EW
   Lossos, IS
   Harrington, WJ
AF Ramos, Juan Carlos
   Ruiz, Phillip, Jr.
   Ratner, Lee
   Reis, Isildinha M.
   Brites, Carlos
   Pedroso, Celia
   Byrne, Gerald E., Jr.
   Toomey, Ngoc L.
   Andela, Valentine
   Harhaj, Edward W.
   Lossos, Izidore S.
   Harrington, William J., Jr.
TI IRF-4 and c-Rel expression in antiviral-resistant adult T-cell
   leukemia/lymphoma
SO BLOOD
LA English
DT Article
ID NF-KAPPA-B; INTERFERON REGULATORY FACTOR-4; LEUKEMIA-LYMPHOMA;
   TRANSCRIPTION FACTOR; HTLV-I; GENE-EXPRESSION; IMPORTANT DETERMINANT;
   INDUCED APOPTOSIS; ALPHA-INTERFERON; ACTIVATION
AB Adult T-cell leukemia/lymphoma (ATLL) is a generally fatal malignancy. Most ATLL patients fare poorly with conventional chemotherapy; however, antiviral therapy with zidovudine (AZT) and interferon alpha (IFN-alpha) has produced long-term clinical remissions. We studied primary ATLL tumors and identified molecular features linked to sensitivity and resistance to antiviral therapy. Enhanced expression of the proto-oncogene c-Rel was noted in 9 of 27 tumors. Resistant tumors exhibited c-Rel (6 of 10; 60%) more often than did sensitive variants (1 of 9; 11%). This finding was independent of the disease form. Elevated expression of the putative c-Rel target, interferon regulatory factor-4 (IRF4), was observed in 10 (91%) of 11 nonresponders and in all tested patients with c-Rel(+) tumors and occurred in the absence of the HTLV-1 oncoprotein Tax. In contrast, tumors in complete responders did not express c-Rel or IRF-4. Gene rearrangement studies demonstrated the persistence of circulating T-cell clones in long-term survivors maintained on antiviral therapy. The expression of nuclear c-Rel and IRF-4 occurs in the absence of Tax in primary ATLL and is associated with antiviral resistance. These molecular features may help guide treatment. AZT and IFN-alpha is a suppressive rather than a curative regimen, and patients in clinical remission should remain on maintenance therapy indefinitely.
C1 Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Div Biostat, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   Washington Univ, Dept Med, Div Oncol, St Louis, MO 63130 USA.
   Univ Fed Bahia, Dept Med, Div Infect Dis, BR-41170290 Salvador, BA, Brazil.
RP Harrington, WJ (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, Rm 3400,D8-4,1475 NW 12th Ave, Miami, FL 33136 USA.
EM wharring@med.miami.edu
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Ratner, Lee/0000-0003-2744-7294
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U01CA070058, R01CA082274, U01CA070058, R01CA082274,
   U01CA070058, U01CA070058, U01CA070058, U01CA070058, R01CA082274,
   R01CA082274, U01CA070058, U01CA070058, R01CA082274, U01CA070058,
   R01CA082274, U01CA070058, U01CA070058, R01CA082274, R01CA082274,
   U01CA070058, U01CA070058, R01CA082274] Funding Source: NIH RePORTER; NCI
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01
   CA070058, CA-10521, R01 CA082274, CA-082274, U01-CA-070058] Funding
   Source: Medline
CR Arima N, 1999, EXP HEMATOL, V27, P1168, DOI 10.1016/S0301-472X(99)00053-3
   Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577
   Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016/S1470-2045(04)01608-0
   Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497
   Carbone A, 2001, BLOOD, V97, P744, DOI 10.1182/blood.V97.3.744
   Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x
   Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182/blood-2006-01-0067
   Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861
   Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128/JVI.77.9.5286-5294.2003
   Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084
   Gallo R C, 1981, Haematol Blood Transfus, V26, P502
   GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603
   Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898
   Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281
   Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545
   Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389
   Hasegawa H, 2005, BRIT J HAEMATOL, V128, P253, DOI 10.1111/j.1365-2141.2004.05289.x
   Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458
   Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038/sj.thj.6200374
   HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604
   Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038/sj.thj.6200195
   Hisada M, 1998, BLOOD, V92, P3557, DOI 10.1182/blood.V92.10.3557.422k09_3557_3561
   Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369
   Imaizumi Y, 2001, JPN J CANCER RES, V92, P1284, DOI 10.1111/j.1349-7006.2001.tb02151.x
   Ito M, 2002, JPN J CANCER RES, V93, P685, DOI 10.1111/j.1349-7006.2002.tb01307.x
   Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34
   Kamihira S, 2001, BRIT J HAEMATOL, V114, P63, DOI 10.1046/j.1365-2141.2001.02902.x
   Keller SA, 2000, BLOOD, V96, P2537
   KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965
   Kurokawa M, 2005, BLOOD, V106, P235, DOI 10.1182/blood-2004-09-3748
   Lairmore MD, 2005, ONCOGENE, V24, P6005, DOI 10.1038/sj.onc.1208974
   Leclercq I, 1999, BRIT J HAEMATOL, V105, P743, DOI 10.1046/j.1365-2141.1999.01389.x
   LIDA S, 1997, NAT GENET, V17, P226
   Lohoff M, 2004, J EXP MED, V200, P247, DOI 10.1084/jem.20040182
   MAEDA M, 1987, BLOOD, V70, P1407
   MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169
   Mamane Y, 2002, ONCOGENE, V21, P6751, DOI 10.1038/sj.onc.1205843
   Marecki S, 1999, J IMMUNOL, V163, P2713
   Matutes E, 2001, BRIT J HAEMATOL, V113, P779, DOI 10.1046/j.1365-2141.2001.02794.x
   Miller JE, 1999, MOL DIAGN, V4, P101, DOI 10.1016/S1084-8592(99)80035-6
   Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 1999, BLOOD, V93, P2360
   Muris JJF, 2006, J PATHOL, V208, P714, DOI 10.1002/path.1924
   Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588
   Nakase K, 2006, BONE MARROW TRANSPL, V37, P41, DOI 10.1038/sj.bmt.1705197
   Nakayama K, 2002, LEUKEMIA LYMPHOMA, V43, P2249, DOI 10.1080/1042819021000039956
   Negishi H, 2005, P NATL ACAD SCI USA, V102, P15989, DOI 10.1073/pnas.0508327102
   Ohshima K, 2000, CANCER LETT, V160, P89, DOI 10.1016/S0304-3835(00)00567-X
   Ohsugi T, 2005, CARCINOGENESIS, V26, P1382, DOI 10.1093/carcin/bgi095
   Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O
   Pernis AB, 2002, J INTERF CYTOK RES, V22, P111, DOI 10.1089/107999002753452728
   Pileri SA, 2003, LEUKEMIA LYMPHOMA, V44, pS21, DOI 10.1080/10428190310001623810
   Rosenwald A, 2003, LEUKEMIA LYMPHOMA, V44, pS41, DOI 10.1080/10428190310001623775
   Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400
   Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120
   Sharma S, 2000, AIDS RES HUM RETROV, V16, P1613, DOI 10.1089/08892220050193047
   SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x
   Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576
   Sundram U, 2005, J CUTAN PATHOL, V32, P227, DOI 10.1111/j.0303-6987.2005.00298.x
   Taguchi H, 1996, J ACQ IMMUN DEF SYND, V12, P182, DOI 10.1097/00042560-199606010-00012
   Tajima K, 1995, INTERVIROLOGY, V38, P238, DOI 10.1159/000150438
   Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179
   Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731
   van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202
   WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063
   Waldmann TA, 1996, J ACQ IMMUN DEF SYND, V13, pS179, DOI 10.1097/00042560-199600001-00027
   WEIH F, 1994, ONCOGENE, V9, P3289
   XU B, 1994, BLOOD, V84, P1942
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   Yamagata T, 1996, MOL CELL BIOL, V16, P1283
   Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475
   Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382
NR 73
TC 52
Z9 53
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD APR 1
PY 2007
VL 109
IS 7
BP 3060
EP 3068
DI 10.1182/blood-2006-07-036368
PG 9
WC Hematology
SC Hematology
GA 156HP
UT WOS:000245639000062
PM 17138822
OA Green Published
DA 2020-12-01
ER

PT J
AU Garcia, R
   Badaro, R
   Netto, EM
   Silva, M
   Amorin, FS
   Ramos, A
   Vaida, F
   Brites, C
   Schooley, RT
AF Garcia, Rosa
   Badaro, Roberto
   Netto, Eduardo M.
   Silva, Marcio
   Amorin, Fabio S.
   Ramos, Andre
   Vaida, Florin
   Brites, Carlos
   Schooley, Robert T.
TI Cross-sectional study to evaluate factors associated with adherence to
   antiretroviral therapy by Brazilian HIV-infected patients
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SELF-REPORTED ADHERENCE; BARRIERS; REGIMENS; ADULTS; HAART; NAIVE
AB Antiretroviral therapy success is highly dependent on the ability of the patient to fully adhere to the prescribed treatment regimen. We present the results of a cross-sectional study that evaluates the predictive value of a self-administered questionnaire of adherence to antiretroviral (ARV) therapy. Study participants were interviewed using a 36-item Patient Medication Adherence Questionnaire (PMAQ) designed to assess knowledge about ARV therapy, motivation to adhere to treatment, and behavioral skills. Plasma HIV-1 RNA levels were correlated with the results obtained from the PMAQ. Of the 182 study participants, 82 (45%) were receiving their initial ARV regimen. Of the remaining patients, 39 (21%) and 61 (34%) were on a second or additional ARV regimen, respectively. An undetectable viral load was documented in 47/62 (76%) patients on their first regimen who reported missing medication on less than 4 days in the last 3 months. The PMAQ had a higher predictive value of plasma viral suppression for patients in the initial regimen than for patients in salvage therapy. The overall predictive value of the PMAQ to identify adherence was 74%, and 59% for nonadherence, with an overall efficacy of 64%. Of the 74 patients (45%) who did not understand the concept of antiretroviral therapy, 80% were failing or had previously failed the ARV treatment. Of 35 patients with doubts about their HIV status or skeptical of the benefits of ARV therapy, 29 (84%) were nonadherent. Despite the positive predictive value of PMAQ in identifying adherence, self-reported adherence is not a sufficiently precise predictor of treatment success to substitute for viral load monitoring. On the other hand, the use of such an instrument to identify factors associated with nonadherence provides an excellent opportunity to apply early intervention designed to specifically address factors that might be contributing to the lack of adherence prior to regimen failure.
C1 Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Schooley, RT (corresponding author), Stein Clin Res Bldg,9500 Gilman Dr, La Jolla, CA 92093 USA.
EM rschooley@ucsd.edu
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201
   Catz SL, 2002, BEHAV MED, V28, P53, DOI 10.1080/08964280209596398
   Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Duong M, 2004, HIV CLIN TRIALS, V5, P216, DOI 10.1310/NXJU-9ERQ-ADWW-UC5X
   Duong M, 2001, HIV Clin Trials, V2, P128
   Duong M, 2001, CLIN INFECT DIS, V33, P386, DOI 10.1086/321876
   Ferguson TF, 2002, AIDS CARE, V14, P607, DOI 10.1080/0954012021000005434
   Garcia Rosa, 2003, Braz J Infect Dis, V7, P307, DOI 10.1590/S1413-86702003000500005
   Gifford AL, 2000, J ACQ IMMUN DEF SYND, V23, P386
   Haubrich RH, 1999, AIDS, V13, P1099, DOI 10.1097/00002030-199906180-00014
   Kirkland LR, 2002, CLIN INFECT DIS, V34, P511, DOI 10.1086/338400
   Laniece I, 2003, AIDS, V17, pS103, DOI 10.1097/00002030-200317003-00014
   Loo VS, 2004, AIDS CARE, V16, P834, DOI 10.1080/09540120412331290121
   Moatti JP, 2000, REV EPIDEMIOL SANTE, V48, P182
   Nachega JB, 2004, AIDS RES HUM RETROV, V20, P1053, DOI 10.1089/aid.2004.20.1053
   Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Rabkin J G, 1998, GMHC Treat Issues, V12, P8
   Reynolds NR, 2004, AIDS BEHAV, V8, P141, DOI 10.1023/B:AIBE.0000030245.52406.bb
   Smith SR, 2003, PATIENT EDUC COUNS, V50, P187
   Spire B, 2002, SOC SCI MED, V54, P1481, DOI 10.1016/S0277-9536(01)00125-3
   Stout BD, 2004, AIDS PATIENT CARE ST, V18, P297, DOI 10.1089/108729104323076034
   Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004
NR 25
TC 14
Z9 16
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC
PY 2006
VL 22
IS 12
BP 1248
EP 1252
DI 10.1089/aid.2006.22.1248
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 124VO
UT WOS:000243398800007
PM 17209767
DA 2020-12-01
ER

PT J
AU Drosten, C
   Panning, M
   Drexler, JF
   Hansel, F
   Pedroso, C
   Yeats, J
   Luna, LKD
   Samuel, M
   Liedigk, B
   Lippert, U
   Sturmer, M
   Doerr, HW
   Brites, C
   Preiser, W
AF Drosten, Christian
   Panning, Marcus
   Drexler, Jan Felix
   Haensel, Florian
   Pedroso, Celia
   Yeats, Jane
   Kleber de Souza Luna, Luciano
   Samuel, Matthew
   Liedigk, Britta
   Lippert, Ute
   Stuermer, Martin
   Doerr, Hans Wilhelm
   Brites, Carlos
   Preiser, Wolfgang
TI Ultrasensitive monitoring of HIV-I viral load by a low-cost real-time
   reverse transcription-PCR assay with internal control for the 5 ' long
   terminal repeat domain
SO CLINICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
   RESOURCE-POOR SETTINGS; RAPID DETECTION; RNA; QUANTIFICATION; TYPE-1;
   MULTICENTER; QUANTITATION; PLASMA
AB Background: Current HIV-1 viral-load assays are too expensive for resource-limited settings. In some countries, monitoring of antiretroviral therapy is now more expensive than treatment itself. In addition, some commercial assays have shown shortcomings in quantifying rare genotypes.
   Methods: We evaluated real-time reverse transcription-PCR with internal control targeting the-conserved long terminal repeat (LTR) domain of HIV-1 on reference panels. and patient samples from Brazil (n = 1186), South Africa (n = 130), India (n = 44), and Germany (n = 127).
   Results: The detection limit was 31.9 IU of HIV-1 RNA/mL of plasma (> 95% probability of detection, Probit analysis). The internal control showed inhibition in 3.7% of samples (95% confidence interval, 2.32%-5.9%; n = 454; 40 different runs). Comparative qualitative testing yielded the following: Roche Amplicor vs LTR assay (n = 431 samples), 51.7% vs 65% positives; Amplicor Ultrasensitive vs LTR (n = 133), 81.2% vs 82.7%; BioMerieux NucliSens HIV-1 QT (n = 453), 60.5% vs 65.1%; Bayer Versant 3.0 (n = 433), 57.7% vs 55.4%a; total (n = 1450), 59.0% vs 63.8% positives. Intra-/interassay variability at medium and near-negative concentrations was 18%-51%. The quantification range was 50-10 000 000 IU/mL. Viral loads for subtypes A-D, F-J, AE, and AG yielded mean differences of 0.31 log(10) compared with Amplicor in the 103-104 IU/mL range. HIV-1 N and O were not detected by Amplicor, but yielded-up to 180 180.00 IU/mL in the LTR assay. Viral loads in stored samples from all countries, compared with Amplicor, NucliSens, or Versant, yielded regression line slopes (SD) of 0.9 (0.13) (P < 0.001 for all).
   Conclusions: This method offers all features of commercial assays and covers all relevant genotypes. It could allow general monitoring of antiretroviral therapy in resource-limited settings. (c) 2006 American Association for Clinical Chemistry.
C1 Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany.
   Hosp Univ Prof Edgard Santos, Serv Infectol, Salvador, BA, Brazil.
   Univ Cape Town, Dept Med Virol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
   Tamil Nadu Med Univ, Dept Expt Med, Madras, Tamil Nadu, India.
   Goethe Univ Frankfurt, Inst Med Virol, D-6000 Frankfurt, Germany.
RP Drosten, C (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
EM drosten@bni-hamburg.de
RI de Souza Luna, Luciano Kleber/L-1213-2013; Drexler, Jan
   Felix/C-1004-2014; Preiser, Wolfgang/J-4875-2016; de Souza Luna, Luciano
   Kleber/AAG-6418-2019; Panning, Marcus/I-7889-2016; Brites,
   Carlos/D-1353-2013
OI de Souza Luna, Luciano Kleber/0000-0002-3552-5507; Preiser,
   Wolfgang/0000-0002-0254-7910; de Souza Luna, Luciano
   Kleber/0000-0002-3552-5507; Brites, Carlos/0000-0002-4673-6991; Drexler,
   Jan Felix/0000-0002-3509-0232; Sturmer, Martin/0000-0003-4300-9315
CR Back DJ, 2000, THER DRUG MONIT, V22, P122, DOI 10.1097/00007691-200002000-00026
   Balakrishnan P, 2005, INDIAN J MED RES, V121, P345
   Berger A, 1998, INTERVIROLOGY, V41, P24, DOI 10.1159/000024912
   Berndt C, 2000, J VIROL METHODS, V89, P177, DOI 10.1016/S0166-0934(00)00225-1
   Bogard M, 2001, EUR J CLIN MICROBIOL, V20, P724, DOI 10.1007/s100960100565
   Calmy A, 2004, NEW ENGL J MED, V350, P2720, DOI 10.1056/NEJM200406243502621
   Clarke John R, 2002, Expert Rev Mol Diagn, V2, P233, DOI 10.1586/14737159.2.3.233
   Dax EM, 2004, PATHOLOGY, V36, P551, DOI 10.1080/00313020400010922
   Debyser Z, 1998, AIDS RES HUM RETROV, V14, P453, DOI 10.1089/aid.1998.14.453
   Drosten C, 2000, TRANSFUSION, V40, P718, DOI 10.1046/j.1537-2995.2000.40060718.x
   Drosten C, 2004, J CLIN MICROBIOL, V42, P2043, DOI 10.1128/JCM.42.5.2043-2047.2004
   Drosten C, 2004, EMERG INFECT DIS, V10, P2200, DOI 10.3201/eid1012.040416
   Drosten C, 2002, J CLIN MICROBIOL, V40, P2323, DOI 10.1128/JCM.40.7.2323-2330.2002
   Drosten C, 2001, J CLIN MICROBIOL, V39, P4302, DOI 10.1128/JCM.39.12.4302-4308.2001
   Elbeik T, 2002, J ACQ IMMUN DEF SYND, V29, P330
   Ghosh MK, 2003, J CLIN MICROBIOL, V41, P2465, DOI 10.1128/JCM.41.6.2465-2470.2003
   Gottesman BS, 2004, J MED VIROL, V73, P167, DOI 10.1002/jmv.20071
   Hodinka RL, 1998, CLIN DIAGN VIROL, V10, P25, DOI 10.1016/S0928-0197(98)00016-6
   Holmes H, 2001, J VIROL METHODS, V92, P141, DOI 10.1016/S0166-0934(00)00283-4
   Hymas W, 2005, J VIROL METHODS, V128, P143, DOI 10.1016/j.jviromet.2005.05.003
   Ivers LC, 2005, CLIN INFECT DIS, V41, P217, DOI 10.1086/431199
   JACOB JT, 2004, INDIAN J MED RES, V119, pR3
   Kaplan JE, 2001, AIDS, V15, P1831, DOI 10.1097/00002030-200109280-00012
   Katz S, 2003, J AGING STUD, V17, P3, DOI 10.1016/S0890-4065(02)00086-5
   Morgado MG, 2000, MEM I OSWALDO CRUZ, V95, P145, DOI 10.1590/S0074-02762000000700024
   Muller Z, 2004, J CLIN MICROBIOL, V42, P1439, DOI 10.1128/JCM.42.4.1439-1443.2004
   Muyldermans G, 2000, CLIN MICROBIOL INFEC, V6, P213, DOI 10.1046/j.1469-0691.2000.00048.x
   Niedrig M, 2004, J CLIN MICROBIOL, V42, P1753, DOI 10.1128/JCM.42.4.1753-1755.2004
   Nolte FS, 2004, CLIN CHEM, V50, P801, DOI 10.1373/clinchem.2004.032672
   Nolte FS, 2001, J CLIN MICROBIOL, V39, P4005, DOI 10.1128/JCM.39.11.4005-4012.2001
   Nolte FS, 1999, ADV CLIN CHEM, V33, P201
   O'Shea S, 2000, J MED VIROL, V61, P187, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;187::AID-JMV3&gt;3.0.CO;2-8
   Romano JW, 1996, CLIN LAB MED, V16, P89, DOI 10.1016/S0272-2712(18)30289-0
   Rosenstraus M, 1998, J CLIN MICROBIOL, V36, P191, DOI 10.1128/JCM.36.1.191-197.1998
   Saldanha J, 1999, VOX SANG, V76, P149, DOI 10.1159/000031040
   Saraceni Valéria, 2005, Braz J Infect Dis, V9, P209, DOI 10.1590/S1413-86702005000300003
   Simonetti SRR, 2003, MEM I OSWALDO CRUZ, V98, P831, DOI 10.1590/S0074-02762003000600021
   Skidmore SJ, 2000, J MED VIROL, V61, P417, DOI 10.1002/1096-9071(200008)61:4&lt;417::AID-JMV2&gt;3.0.CO;2-1
   Tassie JM, 2003, AIDS, V17, P1995, DOI 10.1097/00002030-200309050-00023
   Treadwell TL, 2003, ARCH INTERN MED, V163, P1613, DOI 10.1001/archinte.163.13.1613
   Valdiserri RO, 2003, NAT MED, V9, P881, DOI 10.1038/nm0703-881
   Venturi G, 2000, J VIROL METHODS, V87, P91, DOI 10.1016/S0166-0934(00)00151-8
NR 42
TC 80
Z9 83
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD JUL
PY 2006
VL 52
IS 7
BP 1258
EP 1266
DI 10.1373/clinchem.2006.066498
PG 9
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 059IF
UT WOS:000238725800008
PM 16627558
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Swanson, P
   Huang, SH
   Holzmayer, V
   Bodelle, P
   Yamaguchi, J
   Brennan, C
   Badaro, R
   Brites, C
   Abravaya, K
   Devare, SG
   Hackett, J
AF Swanson, Priscilla
   Huang, Shihai
   Holzmayer, Vera
   Bodelle, Pierre
   Yamaguchi, Julie
   Brennan, Catherine
   Badaro, Roberto
   Brites, Carlos
   Abravaya, Klara
   Devare, Sushil G.
   Hackett, John, Jr.
TI Performance of the automated Abbott RealTime (TM) HIV-1 assay on a
   genetically diverse panel of specimens from Brazil
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE real-time PCR; HIV quantitation; genetic diversity
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL LOAD ASSAYS; REAL-TIME PCR;
   SUBTYPES A-G; GROUP-O; MOLECULAR CHARACTERIZATION; QUANTITATIVE
   DETECTION; SAO-PAULO; RNA; QUANTIFICATION
AB The combination of automated sample preparation and real-time RT-PCR for measurement of HIV-1 viral load has the potential to significantly enhance throughput, reduce operator-associated error, and increase assay sensitivity and dynamic range. In this study, RNA was extracted from the plasma of 91 HIV-1 seropositive Brazilian blood donors using the Abbott m2000sp (TM) automated sample preparation system. Viral loads measured using the RealTime (TM) HIV-1 (RealTime HIV-1) assay and the Abbott m2000rt (TM) instrument were compared to values obtained in the LCx((R)) HIV RNA quantitative assay. Subtype was determined for 89 of 91 specimens by sequence/phylogenetic analysis of three genomic regions: gag p24, pol integrase, and env gp41. The panel included 69 subtype B, I C, 2 F, and 17 recombinant strains. Eighty-seven specimens were quantified by both assays. Two specimens were quantified only in RealTime HIV-1. Two additional specimens below the detection limit of both assays were also negative on PCR amplification. Viral load results were highly correlated, and good agreement was observed between assays with 90% of values within 0.5 log(10) copies/ml. The RealTime HIV-1 assay and m2000 system offer the advantages of automation while providing reliable quantification of diverse HIV strains. (c) 2006 Elsevier B.V. All rights reserved.
C1 Abbott Labs, AIDS Res & Retrovirus Discovery, Abbott Pk, IL 60064 USA.
   Abbott Mol Inc, Des Plaines, IL USA.
   Univ Fed Bahia, Fdn Bahiana Infectol, BR-41170290 Salvador, BA, Brazil.
   Univ Calif San Diego, San Diego, CA 92103 USA.
RP Hackett, J (corresponding author), Abbott Labs, AIDS Res & Retrovirus Discovery, D-9NG,Bldg AP20,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.
EM john.hackett@abbott.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Akouamba BS, 2005, EMERG INFECT DIS, V11, P1230, DOI 10.3201/eid1108.040877
   Barlow KL, 1997, J CLIN MICROBIOL, V35, P2846, DOI 10.1128/JCM.35.11.2846-2853.1997
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169
   Collins ML, 1997, NUCLEIC ACIDS RES, V25, P2979, DOI 10.1093/nar/25.15.2979
   de Mendoza C, 2005, J VIROL METHODS, V127, P54, DOI 10.1016/j.jviromet.2005.03.013
   de Mendoza C, 2002, J CLIN MICROBIOL, V40, P1518, DOI 10.1128/JCM.40.4.1518-1521.2002
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   Dyer JR, 1999, J CLIN MICROBIOL, V37, P447, DOI 10.1128/JCM.37.2.447-449.1999
   Gardner SN, 2003, J CLIN MICROBIOL, V41, P2417, DOI 10.1128/JCM.41.6.2417-2427.2003
   Geelen S, 2003, AIDS, V17, P781, DOI 10.1097/00002030-200303280-00027
   GOTTESMAN B, 2005, C RETR OPP INF, P335
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Hirigoyen DL, 2005, J CLIN MICROBIOL, V43, P5263, DOI 10.1128/JCM.43.10.5263-5271.2005
   Johanson J, 2001, J VIROL METHODS, V95, P81, DOI 10.1016/S0166-0934(01)00297-X
   Lot F, 2004, Euro Surveill, V9, P34
   Nye MB, 2005, J CLIN MICROBIOL, V43, P4968, DOI 10.1128/JCM.43.10.4968-4971.2005
   Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184, DOI 10.1097/00042560-200202010-00013
   Plantier JC, 2003, JAIDS-J ACQ IMM DEF, V33, P1, DOI 10.1097/00126334-200305010-00001
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Stevens W, 2005, J VIROL METHODS, V124, P105, DOI 10.1016/j.jviromet.2004.11.009
   Sun R, 1998, J CLIN MICROBIOL, V36, P2964, DOI 10.1128/JCM.36.10.2964-2969.1998
   Swanson P, 2000, J VIROL METHODS, V89, P97, DOI 10.1016/S0166-0934(00)00205-6
   Swanson P, 2005, J CLIN MICROBIOL, V43, P3860, DOI 10.1128/JCM.43.8.3860-3868.2005
   Swanson P, 2003, AIDS RES HUM RETROV, V19, P625, DOI 10.1089/088922203322231003
   Swanson P, 2001, J CLIN MICROBIOL, V39, P862, DOI 10.1128/JCM.39.3.862-870.2001
   Troonen H, 2002, CLIN CHEM LAB MED, V40, P698, DOI 10.1515/CCLM.2002.120
   Whiley DA, 2005, J CLIN VIROL, V34, P104, DOI 10.1016/j.jcv.2005.02.010
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   Yao J, 2005, J VIROL METHODS, V129, P40, DOI 10.1016/j.jviromet.2005.04.017
NR 34
TC 37
Z9 38
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUN
PY 2006
VL 134
IS 1-2
BP 237
EP 243
DI 10.1016/j.jviromet.2006.01.012
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 049GZ
UT WOS:000238005500033
PM 16510195
DA 2020-12-01
ER

PT J
AU Bittencourt, AL
   Oliveira, MD
   Ferraz, N
   Vieira, MD
   Muniz, A
   Brites, C
AF Bittencourt, AL
   Oliveira, MD
   Ferraz, N
   Vieira, MD
   Muniz, A
   Brites, C
TI Adult-onset infective dermatitis associated with HTLV-I. Clinical and
   immunopathological aspects of two cases
SO EUROPEAN JOURNAL OF DERMATOLOGY
LA English
DT Article
DE HTLV-I infection; infective dermatitis; inflammatory simulators of
   mycosis fungoides; adult-onset infective dermatitis
ID VIRUS TYPE-I; ATOPIC-DERMATITIS; MYCOSIS-FUNGOIDES; T-CELLS; LYMPHOMA
AB Infective dermatitis associated with HTLV-I (IDH) is a chronic, infected childhood eczema. Two adult-onset cases of IDH were studied, one of which was associated with HAM/TSP. The patients were submitted to dermatological, neurological and pathological examination. Immunohistochemical studies were made using CD3, CD4, CD8, CD20, CD79a, and CD57 antibodies. Cytotoxic granules were investigated using granzyme B, perforin, and TIA. The patients presented infected erythematous, scaly lesions with mild itching and a good response to sulfamethoxazole/ trimethoprim. A differential diagnosis with atopic dermatitis (AD) and seborrheic dermatitis (SD) was made, based on: the distinctive morphology and distribution of the lesions, presence of exudative and infected lesions, and mild pruritus. The inflammatory infiltrate was composed predominantly of CD8+ lymphocytes that did not present cytotoxic granules. We concluded that IDH can begin in adulthood and may be associated with HAM/TSP. The immunohistochemical findings were different from those observed in AD and SD.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Dept Pathol, Salvador, BA, Brazil.
   Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Lab Retrovirol, Salvador, BA, Brazil.
RP Bittencourt, AL (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Dept Pathol, Salvador, BA, Brazil.
EM achilea@uol.com.br
CR Bittencourt AL, 2005, EUR J DERMATOL, V15, P26
   Burton JL, 1998, TXB DERMATOLOGY, P629
   de Oliveira MDFSP, 2005, CLIN INFECT DIS, V40, pE90, DOI 10.1086/430064
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   HANIFIN JM, 1980, ACTA DERM-VENEREOL, V92, P44, DOI DOI 10.2340/00015555924447
   HOLDEN CA, 1998, ROOK WILKINSON EBLIN, P681
   Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016
   IZUMO S, 1992, ACTA PAEDIATR JAPON, V34, P354
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439
   Lugovic L, 2001, INT J DERMATOL, V40, P489, DOI 10.1046/j.1365-4362.2001.01203.x
   Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4
   MOBINI N, 2004, LEVERS HISTOPATHOLOG, P179
   Ohkawa T, 2001, IMMUNOLOGY, V103, P281, DOI 10.1046/j.1365-2567.2001.01248.x
   ORANJE AP, 1986, DERMATOLOGICA, V172, P191, DOI 10.1159/000249333
   Primo JRL, 2005, CLIN INFECT DIS, V41, P535, DOI 10.1086/432058
   Santucci M, 2000, AM J SURG PATHOL, V24, P40, DOI 10.1097/00000478-200001000-00005
   SMOLLER BR, 1995, AM J SURG PATHOL, V19, P1423, DOI 10.1097/00000478-199512000-00009
   SUITE M, 1994, AIDS RES HUM RETROV, V10, P447
   Tok J, 1998, J AM ACAD DERMATOL, V38, P453, DOI 10.1016/S0190-9622(98)70505-5
   Van den Hove LE, 1998, LEUKEMIA, V12, P1573, DOI 10.1038/sj.leu.2401146
   WATANABE K, 1994, ANN ALLERGY, V72, P39
   Yawalkar N, 2001, BRIT J DERMATOL, V144, P1133, DOI 10.1046/j.1365-2133.2001.04222.x
NR 23
TC 17
Z9 17
U1 0
U2 1
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 1167-1122
EI 1952-4013
J9 EUR J DERMATOL
JI Eur. J. Dermatol.
PD JAN-FEB
PY 2006
VL 16
IS 1
BP 62
EP 66
PG 5
WC Dermatology
SC Dermatology
GA 018XE
UT WOS:000235797300011
PM 16436345
DA 2020-12-01
ER

PT J
AU Primo, JRL
   Brites, C
   de Fatima, M
   de Oliveira, SP
   Moreno-Carvalho, O
   Machado, M
   Bittencourt, AL
AF Primo, JRL
   Brites, C
   de Fatima, M
   de Oliveira, SP
   Moreno-Carvalho, O
   Machado, M
   Bittencourt, AL
TI Infective dermatitis and human T cell lymphotropic virus type
   1-associated myelopathy/tropical spastic paraparesis in childhood and
   adolescence
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID I-ASSOCIATED MYELOPATHY; HTLV-I; MULTIPLE-SCLEROSIS; JAMAICAN CHILDREN;
   HAPLOTYPE; FEATURES; CLUSTER
AB Background. Human T cell lymphotropic virus type 1 (HTLV-1)-associated infective dermatitis (IDH) is a chronic and recurrent eczema occurring during childhood and adolescence. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic myelopathy of adulthood, presenting with slowly progressive spastic paraparesis and sphincter dysfunction with mild sensory involvement. There are few reports describing an association between IDH and HAM/TSP. The objective of this study was to evaluate the occurrence of HAM/TSP in patients with IDH and in seropositive members of their families and to determine the blood levels of antibodies against HTLV-1 in patients with HAM/TSP.
   Methods. Twenty patients with IDH and their seropositive mothers and siblings underwent clinical, neurological, and laboratory evaluations. The diagnosis of HAM/TSP was made in accordance with the World Health Organization criteria.
   Results. Nine individuals had HAM/TSP ( 6 of the patients with IDH, 2 mothers, and 1 seropositive brother). In 3 families, 11 individual had HAM/TSP. The serum antibody titers of the patients with HAM/TSP varied from 1:3.125 to 1:78.125.
   Conclusions. A strong association was observed between IDH and HAM/TSP. The familial clustering of both diseases suggests a genetic background. Serological screening for HTLV-1 in children with symptoms of myelopathy is essential in areas where HTLV-1 is endemic.
C1 Univ Fed Bahia, Fac Med Bahia, Curso Posgrad Med & Saude, Dept Med, BR-40110170 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med Bahia, Curso Posgrad Med & Saude, Dept Pathol, BR-40110170 Salvador, BA, Brazil.
   Sao Rafael Hosp, Dept Bioimage, Salvador, BA, Brazil.
RP Primo, JRL (corresponding author), Univ Fed Bahia, Fac Med Bahia, Curso Posgrad Med & Saude, Dept Med, Rua Padre Feijo 240,Ambulatorio Magalhaes Neto 3o, BR-40110170 Salvador, BA, Brazil.
EM janeusa.primo@cpunet.com.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Araujo A. Q.-C., 1993, Acta Neurologica Scandinavica, V88, P59
   Araujo APQC, 2002, CLIN INFECT DIS, V35, P201, DOI 10.1086/341251
   Biglione MM, 2003, JAIDS-J ACQ IMM DEF, V32, P441, DOI 10.1097/00126334-200304010-00015
   Bittencourt AL, 2001, J ACQ IMMUN DEF SYND, V26, P490, DOI 10.1097/00126334-200104150-00016
   CAN AJ, 1996, HUMAN TCELL LEUKEMIA, P1849
   de Oliveira MDFSP, 2005, CLIN INFECT DIS, V40, pE90, DOI 10.1086/430064
   de Oliveira MDSP, 2004, J NEUROL SCI, V222, P35, DOI 10.1016/j.jns.2004.04.006
   DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Fishman R., 1992, CEREBROSPINAL FLUID, P183
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   IMAMURA A, 1991, UROL INT, V46, P149, DOI 10.1159/000282121
   Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016
   KAYEMBE K, 1990, J NEUROL NEUROSUR PS, V53, P4, DOI 10.1136/jnnp.53.1.4
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   KURTZKE JF, 1965, NEUROLOGY, V15, P654, DOI 10.1212/WNL.15.7.654
   La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439
   LAGRENADE L, 1990, LANCET, V336, P1345
   LaGrenade L, 1996, AM J MED GENET, V61, P37, DOI 10.1002/(SICI)1096-8628(19960102)61:1<37::AID-AJMG7>3.0.CO;2-U
   LAGRENADE L, 1995, W INDIAN MED J, V44, P34
   Maloney EM, 2004, J INFECT DIS, V189, P41, DOI 10.1086/380567
   Maloney EM, 2000, PEDIATR INFECT DIS J, V19, P560, DOI 10.1097/00006454-200006000-00014
   Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4
   MCKHANN G, 1989, J INFECT DIS, V160, P371, DOI 10.1093/infdis/160.3.371
   Moreno-Carvalho O A, 1992, Arq Neuropsiquiatr, V50, P183
   NAKAGAWA M, 1995, J NEUROVIROL, V1, P50, DOI 10.3109/13550289509111010
   OSAME M, 1990, ANN NEUROL, V28, P50, DOI 10.1002/ana.410280110
   OSAME M, 1989, JPN J MED, V28, P412, DOI 10.2169/internalmedicine1962.28.412
   OSAME M, 1986, LANCET, V1, P1031
   OSAME M, 1987, LANCET, V1, P106
   OSAME M, 1989, HTLV I NERVOUS SYSTE, P213
   Osame M, 1990, HEMATOLOGY REV, V3, P271
   Quintas S, 2004, REV NEUROLOGIA, V39, P1133, DOI 10.33588/rn.3912.2003611
   SAITO M, 1991, BRIT J UROL, V68, P365, DOI 10.1111/j.1464-410X.1991.tb15351.x
   SHINZATO O, 1993, INT J CANCER, V54, P208, DOI 10.1002/ijc.2910540208
   USUKU K, 1988, ANN NEUROL, V23, pS143, DOI 10.1002/ana.410230733
   YOSHIDA Y, 1993, J NEUROL SCI, V118, P145, DOI 10.1016/0022-510X(93)90103-6
NR 37
TC 52
Z9 55
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2005
VL 41
IS 4
BP 535
EP 541
DI 10.1086/432058
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 946ZE
UT WOS:000230611000019
PM 16028164
OA Bronze
DA 2020-12-01
ER

PT J
AU de Oliveira, MDFSP
   Brites, C
   Ferraz, N
   Magalhaes, P
   Almeida, F
   Bittencourt, AL
AF de Oliveira, MDFSP
   Brites, C
   Ferraz, N
   Magalhaes, P
   Almeida, F
   Bittencourt, AL
TI Infective dermatitis associated with the human T cell lymphotropic virus
   type I in Salvador, Bahia, Brazil
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID HTLV-I; SEBORRHEIC DERMATITIS; JAMAICAN CHILDREN; BLOOD-DONORS; MARKER
AB Background. Infective dermatitis associated with human T cell lymphotropic virus type I (HTLV-I) infection is a chronic, relapsing eczema of childhood.
   Methods. Children, their mothers, and their siblings underwent serological testing for HTLV-I. Epidemiological data were collected from all seropositive children and their family members, and clinical and dermatological examinations were performed. Laboratory studies, including skin culture, and histopathological analyses were also performed. The diagnosis of infective dermatitis associated with HTLV-I (IDH) was made according to previously established criteria.
   Results. All of the patients with cases that demonstrated clinical aspects of IDH were positive for HTLV-I. The median age of the children at the time of the first visit was 8.0 years (range, 2-14 years). The median duration of breastfeeding for 19 children was 22.5 months (range, 1-48 months). The lesions were erythematous, scaly, exudative, and crusted in all cases. The scalp, retroauricular areas, neck, and groin were the regions that were commonly affected. Cultures were positive for Staphylococcus aureus for 95% of the patients. The children were followed-up for a median of 3.0 years (range, 0.1-7 years), and 5 children developed HTLV-I-associated myelopathy/tropical spastic paraparesis. All of the children except 1 were treated with sulfamethoxazole-trimethoprim, and their lesions either improved greatly or completely disappeared.
   Conclusions. The present study demonstrates the severity of IDH in Bahia and confirms that its diagnosis is based almost exclusively on clinical aspects of the disease. Serological testing for HTLV-I and careful follow-up is recommended for all children with chronic, relapsing, severe eczema in regions where HTLV-I is endemic.
C1 Univ Fed Bahia, Dept Med, Salvador, BA, Brazil.
   Univ Fed Bahia, Dept Pathol, Salvador, BA, Brazil.
   CNR, Brasilia, DF, Brazil.
RP de Oliveira, MDFSP (corresponding author), Univ Fed Bahia, Fac Med Bahia, Rua Padre Feijo 240,3 Andar Canela, BR-40110170 Salvador, BA, Brazil.
EM fatimapaim@ibest.com.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Aquije M, 2002, FOLIA DERMATOL, V13, P1
   Araujo APQC, 2002, CLIN INFECT DIS, V35, P201, DOI 10.1086/341251
   Bittencourt A L, 1998, Rev Inst Med Trop Sao Paulo, V40, P245, DOI 10.1590/S0036-46651998000400008
   Bittencourt AL, 2001, J ACQ IMMUN DEF SYND, V26, P490, DOI 10.1097/00126334-200104150-00016
   BITTENCOURT AL, 2005, IN PRESS EUR J DERMA
   BLANK A, 1995, LANCET, V346, P710, DOI 10.1016/S0140-6736(95)92326-8
   Brites C, 2002, AIDS, V16, P1292, DOI 10.1097/00002030-200206140-00015
   Burton JL, 1998, TXB DERMATOLOGY, P629
   Clyti E, 2004, ANN DERMATOL VENER, V131, P191, DOI 10.1016/S0151-9638(04)93569-7
   de Oliveira MDSP, 2004, J NEUROL SCI, V222, P35, DOI 10.1016/j.jns.2004.04.006
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Goncalves DU, 2003, AM J TROP MED HYG, V68, P562, DOI 10.4269/ajtmh.2003.68.562
   HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763
   HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44
   HENG MCY, 1990, J AM ACAD DERMATOL, V23, P82, DOI 10.1016/0190-9622(90)70191-J
   HOLDEN CA, 1998, ROOK WILKINSON EBLIN, P681
   Hurwitz S, 1993, CLIN PEDIAT DERMATOL, P45
   La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439
   LAGRENADE L, 1990, LANCET, V336, P1345
   LaGrenade L, 1996, CUTIS, V58, P115
   LENZI MER, 1996, AN BRAS DERMATOL, V71, P115
   Mahe A, 2004, BRIT J DERMATOL, V150, P958, DOI 10.1111/j.1365-2133.2004.05834.x
   Mahe A, 1999, LANCET, V354, P1386, DOI 10.1016/S0140-6736(05)76239-5
   Maloney EM, 2003, PEDIATRICS, V112, pE136, DOI 10.1542/peds.112.2.e136
   Maloney EM, 2004, J INFECT DIS, V189, P41, DOI 10.1086/380567
   Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4
   Marsh BJ, 1996, CLIN INFECT DIS, V23, P138, DOI 10.1093/clinids/23.1.138
   RUEDA R, 1996, HTLV TRUTHS QUESTION, P212
   SUITE M, 1994, AIDS RES HUM RETROV, V10, P447
   SWEET RD, 1966, BRIT J DERMATOL, V78, P93, DOI 10.1111/j.1365-2133.1966.tb12181.x
   TSUKASAKI K, 1994, INT J CANCER, V57, P293, DOI 10.1002/ijc.2910570227
   WALSHE MM, 1967, BRIT J DERMATOL, V79, P229, DOI 10.1111/j.1365-2133.1967.tb11479.x
   Zaidi Z, 2002, J Pak Med Assoc, V52, P504
NR 34
TC 24
Z9 25
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2005
VL 40
IS 11
BP E90
EP E96
DI 10.1086/430064
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 923AD
UT WOS:000228880100035
PM 15889351
OA Bronze
DA 2020-12-01
ER

PT J
AU Grimaldi, R
   Acosta, AX
   Cabral-Oliveira, FC
   Brites, C
   Galvao-Castro, B
AF Grimaldi, R
   Acosta, AX
   Cabral-Oliveira, FC
   Brites, C
   Galvao-Castro, B
TI Study of the CCR5-m303 mutation in three different ethnic groups from
   Brazil
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE CCR5 gene; m303 frequency; Brazilian populations; HIV-1
ID CHEMOKINE RECEPTORS; HIV-1 INFECTION; CCR5; ALLELES; FREQUENCIES; ENTRY;
   SUSCEPTIBILITY; INDIVIDUALS; POPULATIONS; CORECEPTOR
AB The main coreceptor gene involved in HIV-1 infection is CCR5 beta chemokine receptor gene for which several mutations have been described, some of which have correlated with HIV-1 infection, acquired immune deficiency syndrome (AIDS), or both. Deletion of 32bp in the CCR5 gene (Delta 32) has been shown to confer resistance to infection by HIV-1 P5 strains. Another mutation, characterized by a thymine to adenine (T to A) nucleotide substitution at position 303 (m303), has shown the same effects as the Delta 32 mutation, with previous studies having shown that the allele frequency of the CCR5-m303 mutation is 0.014 in African-American and 0.007 in French populations. The Brazilian population is known to be genetically diverse, because of which we investigated the allele frequency of the CCR5-m303 mutation in three different Brazilian ethnic groups containing individuals who were not infected with HIV-1 and also in a cohort of HIV-1 long-term non-progressors. We used the polymerase chain reaction (PCR) and Hind I restriction fragment length polymorphisms (RFLP) to investigate these populations and found that none of the 566 individuals examined the mutant CCR5-m303 allele. These results are in accordance with the previously reported allelic frequencies for African-American and Caucasian populations and may reflect the real prevalence of the m303 mutation in Brazil.
C1 Fdn Inst Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Avancado Saude Publ, BR-40296710 Salvador, BA, Brazil.
   Escola Bahiana Med & Saude Publ, Fdn Bahiana Desenvolvimento Ciencias, Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Dept Pediat, Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Dept Virol, Salvador, BA, Brazil.
RP Galvao-Castro, B (corresponding author), Fdn Inst Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Avancado Saude Publ, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM bgalvao@cpqgm.fiocruz.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   AZEVEDO ES, 1982, HUM BIOL, V54, P329
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657
   Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645
   Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Grimaldi R, 2002, HUM GENET, V111, P102, DOI 10.1007/s00439-002-0747-x
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Ometto L, 1999, AIDS, V13, P871, DOI 10.1097/00002030-199905070-00026
   Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X
   Shieh B, 1999, AIDS, V13, P421, DOI 10.1097/00002030-199902250-00018
   Teixeira Maria da Glória, 2002, Cad. Saúde Pública, V18, P1189, DOI 10.1590/S0102-311X2002000500011
   Voevodin A, 1999, J MED VIROL, V58, P54, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;54::AID-JMV8&gt;3.0.CO;2-N
   Wang FS, 2003, JAIDS-J ACQ IMM DEF, V32, P124, DOI 10.1097/00126334-200302010-00002
   Williamson C, 2000, AIDS, V14, P449, DOI 10.1097/00002030-200003100-00020
   Winkler C, 2004, HUM MOL GENET, V13, pR9, DOI 10.1093/hmg/ddh075
   ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453
NR 23
TC 1
Z9 1
U1 1
U2 1
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
EI 1678-4685
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PD JUN
PY 2005
VL 28
IS 2
BP 214
EP 217
DI 10.1590/S1415-47572005000200006
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 951KN
UT WOS:000230929200006
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Bittencourt, ALB
   Oliveira, MF
   Brites, C
   Vieira, MG
AF Bittencourt, ALB
   Oliveira, MF
   Brites, C
   Vieira, MG
TI Infective dermatitis associated to HTLV-I in adulthood. Clinical and
   immunopathological aspects of two cases
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 12th International Conference on Human Retrovirology - HTLV and Related
   Viruses
CY JUN 22-25, 2005
CL Montego Bay, JAMAICA
SP Int Retrovirol Assoc, Natl Inst Hlth, Univ W Indies, Natl Inst Allergy & Infect Dis, Natl Canc Inst, Natl Inst Neurol Dis & Stroke, BD Biosci, Bristol-Myers Squibb, Ohio State Univ, Ctr Retrovirus Res, Dept Vet Biosci, Genome Sci Lab Ltd, Horai Chem Co Ltd, Natl Inst Drug Abuse, Sci Supplies & Technol, Jamaica Med Fdn, J Wray & Nephew Ltd, Red Stripe, UCSF AIDS & Canc Specimen Resource
C1 Univ Fed Bahia, Salvador, BA, Brazil.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2005
VL 21
IS 5
MA P22
BP 469
EP 469
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 936AV
UT WOS:000229825700103
DA 2020-12-01
ER

PT J
AU Brites, C
   Oliveira, AS
   Netto, EM
AF Brites, C
   Oliveira, AS
   Netto, EM
TI Coinfection with HIV and human T lymphotropic virus type 1: What is the
   real impact on HIV disease?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID PROGRESSION; BRAZIL
C1 Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
EM crbrites@ufba.br
RI Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013
OI Brites, Carlos/0000-0002-4673-6991; Netto, Eduardo/0000-0003-1691-6761
CR Beilke MA, 2004, CLIN INFECT DIS, V39, P256, DOI 10.1086/422146
   Brites C, 2001, AIDS, V15, P2053, DOI 10.1097/00002030-200110190-00023
   GIACOMO M, 1995, EUR J EPIDEMIOL, V11, P527, DOI 10.1007/BF01719304
   Hershow RC, 1996, J INFECT DIS, V174, P309, DOI 10.1093/infdis/174.2.309
   SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353
NR 5
TC 12
Z9 12
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 15
PY 2005
VL 40
IS 2
BP 329
EP 330
DI 10.1086/426690
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 904JL
UT WOS:000227492400029
PM 15655763
OA Bronze
DA 2020-12-01
ER

PT J
AU Bittencourt, AL
   Oliveira, MDF
   Brites, C
   Van Weyenbergh, J
   Vieira, MDDS
   Araujo, I
AF Bittencourt, AL
   Oliveira, MDF
   Brites, C
   Van Weyenbergh, J
   Vieira, MDDS
   Araujo, I
TI Histopathological and immunohistochemical studies of infective
   dermatitis associated with HTLV-1
SO EUROPEAN JOURNAL OF DERMATOLOGY
LA English
DT Article
DE HTLV-I infection; infective dermatitis; inflammatory simulators of
   mycosis fungoides; pediatric HTLV-I-associated myelopathy/tropical
   spastic paraparesis
ID T-CELL LYMPHOMA; MYCOSIS-FUNGOIDES; ATOPIC-DERMATITIS; CHILDHOOD; BRAZIL
AB Infective dermatitis associated with HTLV-I (IDH) is a chronic, recurrent, exudative eczema occurring in childhood which is considered to be a risk factor for the development of lymphoma and HTLV-I-associated myelopathy/tropical spastic paraparesis. Skin biopsies from 19 patients with IDH were studied histologically and immunohistochemically using the following antibodies: anti-CD3, CD45RO, CD20, CD79a, CD4, CD8, CD56, CD57, TIA-1, granzyme-B, and perform. A chronic dermatitis similar to atopic and seborrheic dermatitis was observed in 15 cases, whereas architectural aspects mimicking mycosis fungoides were observed in the remaining four. The infiltrate consisted predominantly of CD8+ lymphocytes and of CD57+ cells in the dermis and epidermis. TIA-1 and granzyme-B were expressed in 15/18 cases and 5/19 cases at the proportion of less than or equal to 15% and less than or equal to 3%, respectively. All cases were negative for perform and CD56. Like other dermatites, histologically IDH may represent a benign simulator of mycosis fungoides. IDH shows a predominance of CD8+ cells and a low percentage of cells with cytotoxic granules, indicating that most CD8+ lymphocytes are not activated. These findings differ from the immunohistochemical pattern of atopic and seborrheic dermatitis, possibly representing additional means of differentiation between IDH and these dermatites. The distribution of CD57+ cells suggests that they play a role in the inflammatory process.
C1 Univ Fed Bahia, Dept Pathol, Salvador, BA, Brazil.
   Univ Fed Bahia, Dept Dermatol, Salvador, BA, Brazil.
   Univ Fed Bahia, Lab Retrovirol, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   Fiocruz MS, CPqGM, Lab Immunoregulat & Microbiol, Salvador, BA, Brazil.
   Univ Fed Bahia, Dept Pathol, Hosp Univ Prof Edgard Santos, BR-40110060 Salvador, BA, Brazil.
RP Bittencourt, AL (corresponding author), Univ Fed Bahia, Dept Pathol, Salvador, BA, Brazil.
EM achilea@uol.com.br
RI Brites, Carlos/D-1353-2013; Van Weyenbergh, Johan/Q-3829-2019; Van
   Weyenbergh, Johan/B-4187-2009
OI Brites, Carlos/0000-0002-4673-6991; Van Weyenbergh,
   Johan/0000-0003-3234-8426; Van Weyenbergh, Johan/0000-0003-3234-8426
CR ACKERMAN AB, 1997, ALGORITHMIC METHOD B
   ANDERSON P, 1990, J IMMUNOL, V144, P574
   Barbosa HS, 1999, J ACQ IMMUN DEF SYND, V21, P65, DOI 10.1097/00126334-199905010-00009
   BERGBRANT IM, 1991, CLIN EXP DERMATOL, V16, P331, DOI 10.1111/j.1365-2230.1991.tb00395.x
   BLANK A, 1995, LANCET, V346, P710, DOI 10.1016/S0140-6736(95)92326-8
   BOENISH T, 1989, IMMUNOCHEMICAL STAIN
   Cohen Lisa M., 1997, P209
   de Oliveira MDSP, 2004, J NEUROL SCI, V222, P35, DOI 10.1016/j.jns.2004.04.006
   DETMAR M, 1991, BRIT J DERMATOL, V124, P198, DOI 10.1111/j.1365-2133.1991.tb00434.x
   Dourado I, 2003, JAIDS-J ACQ IMM DEF, V34, P527, DOI 10.1097/00126334-200312150-00013
   Goncalves D U, 2000, Braz J Infect Dis, V4, P100
   HANCHARD B, 1991, LANCET, V338, P1593, DOI 10.1016/0140-6736(91)92413-V
   HOLDEN PWE, 1998, TXB DERMATOLOGY, P681
   La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439
   LAGRENADE L, 1990, LANCET, V336, P1345
   LaGrenade L, 1996, AM J MED GENET, V61, P37, DOI 10.1002/(SICI)1096-8628(19960102)61:1<37::AID-AJMG7>3.0.CO;2-U
   LaGrenade L, 1996, J ACQ IMMUN DEF SYND, V13, pS46, DOI 10.1097/00042560-199600001-00009
   Leboit Philip E., 1997, P805
   LENZI MER, 1996, AN BRAS DERMATOL, V71, P115
   LEVER R, 1987, J INVEST DERMATOL, V89, P4, DOI 10.1111/1523-1747.ep12579727
   Lugovic L, 2001, INT J DERMATOL, V40, P489, DOI 10.1046/j.1365-4362.2001.01203.x
   Mahe A, 1999, LANCET, V354, P1386, DOI 10.1016/S0140-6736(05)76239-5
   Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4
   Neuhaus IM, 2000, PEDIATR DERMATOL, V17, P403, DOI 10.1046/j.1525-1470.2000.017005403.x
   Ohkawa T, 2001, IMMUNOLOGY, V103, P281, DOI 10.1046/j.1365-2567.2001.01248.x
   ORANJE AP, 1986, DERMATOLOGICA, V172, P191, DOI 10.1159/000249333
   PARISH WE, 1998, TXB DERMATOLOGY, P635
   Santucci M, 2000, AM J SURG PATHOL, V24, P40, DOI 10.1097/00000478-200001000-00005
   SHAPIRO PE, 1994, AM J SURG PATHOL, V18, P645, DOI 10.1097/00000478-199407000-00001
   SMITT JHS, 1986, CLIN EXP DERMATOL, V11, P159, DOI 10.1111/j.1365-2230.1986.tb00441.x
   SUITE M, 1994, AIDS RES HUM RETROV, V10, P447
   SWEET RD, 1966, BRIT J DERMATOL, V78, P93, DOI 10.1111/j.1365-2133.1966.tb12181.x
   TAKAHASHI K, 1994, INT J CANCER, V57, P293
   Tok J, 1998, J AM ACAD DERMATOL, V38, P453, DOI 10.1016/S0190-9622(98)70505-5
   Van den Hove LE, 1998, LEUKEMIA, V12, P1573, DOI 10.1038/sj.leu.2401146
   WATANABE K, 1994, ANN ALLERGY, V72, P39
   Whittam LR, 2000, BRIT J DERMATOL, V143, P1199, DOI 10.1046/j.1365-2133.2000.03888.x
   Yawalkar N, 2001, BRIT J DERMATOL, V144, P1133, DOI 10.1046/j.1365-2133.2001.04222.x
NR 38
TC 23
Z9 24
U1 1
U2 2
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 1167-1122
EI 1952-4013
J9 EUR J DERMATOL
JI Eur. J. Dermatol.
PD JAN-FEB
PY 2005
VL 15
IS 1
BP 26
EP 30
PG 5
WC Dermatology
SC Dermatology
GA 901UM
UT WOS:000227307400004
PM 15701589
DA 2020-12-01
ER

PT J
AU de Oliveira, MDSP
   Bittencourt, AL
   Brites, C
   Soares, G
   Hermes, C
   Almeida, FO
AF de Oliveira, MDSP
   Bittencourt, AL
   Brites, C
   Soares, G
   Hermes, C
   Almeida, FO
TI HTLV-I associated myelopathy/tropical spastic paraparesis in a
   7-year-old boy associated with infective dermatitis
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE HTLV-I; HAM/TSP; infective dermatitis; vertical transmission
ID CELL LYMPHOTROPIC VIRUS; NATIONWIDE SURVEY; FEATURES; JAPAN
AB HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic myelopathy characterized by a slowly progressive spastic paraparesis and sphincter disturbances beginning in adulthood. Only eight well-documented cases occurring in childhood and adolescence have been described. Infective dermatitis associated to the HTLV-I (IDH) is a chronic eczema of childhood occurring in vertically infected carriers.
   Here we describe a 7-year-old boy with HAM/TSP and IDH. The neurological manifestations were spastic gait, hyperreflexia of lower limbs, clonus and bilateral Babinski's sign. High levels of HTLV-I antibodies in the serum and in the cerebrospinal fluid were observed. The association of these two diseases and the early onset of HAM/TSP are probably related to a strong humoral anti-HTLV-I response. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Fed Bahia, Curso Posgraduacao Med & Saude, Fac Med, Dept Internal Med,Sch Med, BR-40110170 Salvador, BA, Brazil.
   Univ Fed Bahia, Dept Pathol, Sch Med, BR-40110170 Salvador, BA, Brazil.
   Fiocruz MS, LIMI, CPqGM, Oswaldo Cruz Fdn, Salvador, BA, Brazil.
RP de Oliveira, MDSP (corresponding author), Univ Fed Bahia, Curso Posgraduacao Med & Saude, Fac Med, Dept Internal Med,Sch Med, Rua Padre Feijo 240,Ambulatorio Magalhaes Neto 3, BR-40110170 Salvador, BA, Brazil.
EM fatimaoliv@bol.com.br
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Araujo APQC, 2002, CLIN INFECT DIS, V35, P201, DOI 10.1086/341251
   Araujo AQC, 1998, J ACQ IMMUN DEF SYND, V19, P536, DOI 10.1097/00042560-199812150-00014
   BHIGJEE AI, 1995, S AFR MED J, V85, P687
   BOENISH T, 1989, IMMUNOCHEMICAL STAIN, P16
   Carod-Artal FJ, 1999, REV NEUROLOGIA, V29, P932, DOI 10.33588/rn.2910.99290
   HANCHARD B, 1991, LANCET, V338, P1593, DOI 10.1016/0140-6736(91)92413-V
   La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439
   LaGrenade L, 1996, AM J MED GENET, V61, P37, DOI 10.1002/(SICI)1096-8628(19960102)61:1<37::AID-AJMG7>3.0.CO;2-U
   LAGRENADE L, 1995, W INDIAN MED J, V44, P34
   Levin MC, 1997, NEW ENGL J MED, V336, P839, DOI 10.1056/NEJM199703203361205
   Lugovic L, 2001, INT J DERMATOL, V40, P489, DOI 10.1046/j.1365-4362.2001.01203.x
   Maloney EM, 2000, PEDIATR INFECT DIS J, V19, P560, DOI 10.1097/00006454-200006000-00014
   MCKHANN G, 1989, J INFECT DIS, V160, P371, DOI 10.1093/infdis/160.3.371
   NAKAGAWA M, 1995, J NEUROVIROL, V1, P50, DOI 10.3109/13550289509111010
   OSAME M, 1990, ANN NEUROL, V28, P50, DOI 10.1002/ana.410280110
   OSAME M, 1990, HUMAN RETROVIROLOGY : HTLV, P191
   TSUKASAKI K, 1994, INT J CANCER, V57, P293, DOI 10.1002/ijc.2910570227
NR 17
TC 13
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JUL 15
PY 2004
VL 222
IS 1-2
BP 35
EP 38
DI 10.1016/j.jns.2004.04.006
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 841UL
UT WOS:000222957000007
PM 15240193
DA 2020-12-01
ER

PT J
AU Santos, ACS
   Crisostomo, LML
   Olavarria, V
   Brites, C
   Galvao-Castro, B
AF Santos, ACS
   Crisostomo, LML
   Olavarria, V
   Brites, C
   Galvao-Castro, B
TI Alterations in bone mineral metabolism in Brazilian HIV-infected
   patients
SO AIDS
LA English
DT Letter
ID OSTEOPENIA
C1 CEPARH, Salvador, BA, Brazil.
   Fundacao Desenvolvimento Ciencia, Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   Fund Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Lab Avancado Saude Publ, Salvador, BA, Brazil.
   Univ Fed Bahia, Univ Hosp, BR-41170290 Salvador, BA, Brazil.
RP Santos, ACS (corresponding author), CEPARH, Salvador, BA, Brazil.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR *BRAZ MIN HLTH, 2001, B EP AIDS, P1
   *BRAZ MIN HLTH, 2002, B EP AIDS, P2
   Carr A, 2001, AIDS, V15, P703, DOI 10.1097/00002030-200104130-00005
   Knobel H, 2001, AIDS, V15, P807, DOI 10.1097/00002030-200104130-00022
   Kong YY, 2000, EXP GERONTOL, V35, P947, DOI 10.1016/S0531-5565(00)00178-9
   Kuhne CA, 2001, J BONE MINER RES, V16, P2, DOI 10.1359/jbmr.2001.16.1.2
   Nacher M, 2001, AIDS, V15, P2239, DOI 10.1097/00002030-200111230-00004
   SERRANO S, 1995, BONE, V16, P185, DOI 10.1016/8756-3282(94)00028-X
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005
NR 9
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUL 4
PY 2003
VL 17
IS 10
BP 1578
EP +
DI 10.1097/01.aids.0000072674.21517.18
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 705XB
UT WOS:000184420900027
PM 12824805
DA 2020-12-01
ER

PT J
AU Pedral-Sampaio, DB
   Netto, EM
   Brites, C
   Badaro, R
AF Pedral-Sampaio, DB
   Netto, EM
   Brites, C
   Badaro, R
TI Treating tuberculosis in AIDS patients: when to start and how long to
   keep giving drugs?
SO AIDS
LA English
DT Letter
C1 Univ Fed Bahia, Fdn Bahiana Infectol, Salvador, BA, Brazil.
RP Pedral-Sampaio, DB (corresponding author), Univ Fed Bahia, Fdn Bahiana Infectol, Salvador, BA, Brazil.
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Chaisson RE, 1996, AM J RESP CRIT CARE, V154, P1034, DOI 10.1164/ajrccm.154.4.8887603
   Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010
   Driver CR, 2001, CLIN INFECT DIS, V33, P1762, DOI 10.1086/323784
   Pedral-Sampaio DB, 1997, BRAZ J INFECT DIS, V1, P123
   PEDRALSAMPAIO DB, 2001, 1 IAS C HIV PATH TRE
NR 5
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD SEP 6
PY 2002
VL 16
IS 13
BP 1845
EP 1845
DI 10.1097/00002030-200209060-00026
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 594AZ
UT WOS:000178027800025
PM 12218406
DA 2020-12-01
ER

PT J
AU Grimaldi, R
   Shindo, N
   Acosta, AX
   Dourado, I
   Brites, C
   Carvalho, OD
   Brito, I
   Bou-Habib, DC
   Galvao-Castro, B
AF Grimaldi, R
   Shindo, N
   Acosta, AX
   Dourado, I
   Brites, C
   Carvalho, OD
   Brito, I
   Bou-Habib, DC
   Galvao-Castro, B
TI Prevalence of the CCR5 Delta 32 mutation in Brazilian populations and
   cell susceptibility to HIV-1 infection
SO HUMAN GENETICS
LA English
DT Article
ID DELETION
AB We investigated the occurrence of the CCR5Delta32 mutation in various regional ethnic groups in Brazil and tested the resistance of mutant peripheral blood mononuclear cells (PBMCs) to infection by HIV-1 in vitro. The heterozygous prevalence was 5.3% in uninfected African descendents and 8.8% in HIV-1-positive individuals (neither population had Delta32/Delta32). German descendents were 11% heterozygous and 1% Delta32/Delta32. Amerindians were exclusively CCR5/CCR5. Heterozygous uninfected PBMCs showed partial resistance to R5-HIV-1 strains in vitro, but no resistance to X4 virus. HIV-1-positive CCR5/CCR5 had higher viral loads than did heterozygous cells.
C1 Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Lab Avancado Saude Publ, BR-40295001 Salvador, BA, Brazil.
   Escola Bahiana Med & Saude Publ, Fdn Desenvolvimento Ciencias, Salvador, BA, Brazil.
   Univ Fed Bahia, Inst Saude Coletiva, Salvador, BA, Brazil.
   Univ Fed Bahia, Hosp Univ Prof Edgar Santos, Salvador, BA, Brazil.
   Secretaria Estado Saude Sao Paulo, Hemoctr Reg Joinville, Santa Catarina, Brazil.
   Minist Saude, Programa Nacl Controle DST AIDS, Brasilia, DF, Brazil.
RP Galvao-Castro, B (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Lab Avancado Saude Publ, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
EM bgalvao@cpqgm.fiocruz.br
RI Brites, Carlos/D-1353-2013; Dourado, Ines/Q-6535-2016
OI Brites, Carlos/0000-0002-4673-6991; Dourado, Ines/0000-0003-1675-2146
CR Accetturi CA, 2000, J ACQ IMMUN DEF SYND, V24, P399, DOI 10.1097/00126334-200008010-00016
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657
   Ferraro GA, 2001, AIDS RES HUM RETROV, V17, P1241, DOI 10.1089/088922201750461294
   Leboute APM, 1999, HUM GENET, V105, P442, DOI 10.1007/s004390051128
   Lucotte G, 1998, J ACQ IMMUN DEF SYND, V19, P174, DOI 10.1097/00042560-199810010-00011
   Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100
   Passos GAS, 1998, IMMUNOL LETT, V61, P205, DOI 10.1016/S0165-2478(98)00015-7
   Walli R, 1998, J ACQ IMMUN DEF SYND, V18, P229, DOI 10.1097/00042560-199807010-00005
NR 8
TC 22
Z9 24
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD JUL
PY 2002
VL 111
IS 1
BP 102
EP 104
DI 10.1007/s00439-002-0747-x
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA 580CX
UT WOS:000177218000014
PM 12136242
DA 2020-12-01
ER

PT J
AU Brites, C
   Weyll, M
   Pedroso, C
   Badaro, R
AF Brites, C
   Weyll, M
   Pedroso, C
   Badaro, R
TI Severe and Norwegian scabies are strongly associated with retroviral
   (HIV-1/HTLV-1) infection in Bahia, Brazil
SO AIDS
LA English
DT Article
AB Severe scabies has been associated with HTLV infection. To evaluate the impact of HTLV-I/ HIV-1 co-infection on the clinical presentation of scabies, we reviewed 91 cases of scabies in Bahia, Brazil, during a 3 year period. Infections by HIV-1 (50%), HTLV-1 (32%), and both (20%) were highly prevalent. Crusted or severe scabies were strongly associated with HTLV-I and, to a lesser degree, with HIV-1 infection. Co-infected patients had a higher risk of death (P = 0.01). Severe forms of scabies were highly predictive of double retroviral infection.
C1 Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   Fundacao Baiana Infectol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991; Mayoral P. Weyll,
   Monica/0000-0003-1663-2072
CR BRITES C, 1997, 4 C RETR OPP INF WAS
   Chosidow O, 2000, LANCET, V355, P819, DOI 10.1016/S0140-6736(99)09458-1
   delGiudice P, 1997, J INFECT DIS, V176, P1090, DOI 10.1086/516518
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
NR 4
TC 54
Z9 57
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUN 14
PY 2002
VL 16
IS 9
BP 1292
EP 1293
DI 10.1097/00002030-200206140-00015
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 565KR
UT WOS:000176369600017
PM 12045498
DA 2020-12-01
ER

PT J
AU Branco, BC
   Chamon, W
   Belfort, R
   Carneiro, NF
   Brites, C
AF Branco, BC
   Chamon, W
   Belfort, R
   Carneiro, NF
   Brites, C
TI New corneal findings in human T-cell lymphotropic virus type 1 infection
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Letter
RI Chamon, Wallace/A-5400-2010; Belfort, Rubens/E-2252-2012; Brites,
   Carlos/D-1353-2013
OI Chamon, Wallace/0000-0002-2528-0526; Belfort,
   Rubens/0000-0002-8422-3898; Brites, Carlos/0000-0002-4673-6991
CR CARNEIRO NF, 1999, REV INST MED TROP SP, V41, P15
   Goto Kaori, 1995, Nippon Ganka Gakkai Zasshi, V99, P959
   KAWAMOTO K, 1994, JPN J OPHTHALMOL, V38, P62
   Merle H, 2001, AM J OPHTHALMOL, V131, P305, DOI 10.1016/S0002-9394(00)00645-0
NR 4
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2001
VL 132
IS 6
BP 950
EP 950
DI 10.1016/S0002-9394(01)01155-2
PG 1
WC Ophthalmology
SC Ophthalmology
GA 498JT
UT WOS:000172506900036
PM 11730678
DA 2020-12-01
ER

PT J
AU Brites, C
   Alencar, R
   Gusmao, R
   Pedroso, C
   Netto, EM
   Pedral-Sampaio, D
   Badaro, R
AF Brites, C
   Alencar, R
   Gusmao, R
   Pedroso, C
   Netto, EM
   Pedral-Sampaio, D
   Badaro, R
TI Co-infection with HTLV-1 is associated with a shorter survival time for
   HIV-1-infected patients in Bahia, Brazil
SO AIDS
LA English
DT Article
AB Co-infection with HTLV-1 reaches 20% among patients infected by HIV-1 in Bahia, Brazil. To evaluate its impact on survival, we conducted a retrospective, case-control study involving 198 patients (63 cases). Co-infection was associated with parenteral exposure (P = 0.0001) and female sex (P = 0.02). Co-infected patients had a shorter mean survival (1849 days) than controls (2430 days, P = 0.001), regardless of sex or baseline CD4 cell count. In Bahia, Brazil, co-infection with HIV-1 and HTLV-1 is associated with a shorter survival time.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   Fundacao Baina Infectol, Salvador, BA, Brazil.
RP Brites, C (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Beilke MA, 1998, J ACQ IMMUN DEF SYND, V17, P391, DOI 10.1097/00042560-199804150-00002
   BRITES C, 1997, BRAZ J INFECT DIS, V1, P43
   DHALIA C, 2000, SEMANA EPIDEMIOLOGIC, P3
   LUSSO P, 1990, J VIROL, V64, P6341, DOI 10.1128/JVI.64.12.6341-6344.1990
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Moriuchi H, 1998, J EXP MED, V187, P1689, DOI 10.1084/jem.187.10.1689
   Moriuchi H, 2000, VIROLOGY, V278, P514, DOI 10.1006/viro.2000.0684
   Schechter M, 1997, J ACQ IMMUN DEF SYND, V15, P308, DOI 10.1097/00042560-199708010-00010
   Szabo J, 1999, AIDS RES HUM RETROV, V15, P1653, DOI 10.1089/088922299309694
NR 9
TC 47
Z9 49
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD OCT 19
PY 2001
VL 15
IS 15
BP 2053
EP 2055
DI 10.1097/00002030-200110190-00023
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 485TJ
UT WOS:000171779700023
PM 11600839
DA 2020-12-01
ER

PT J
AU Brites, C
   Gilbert, MJ
   Pedral-Sampaio, D
   Bahia, F
   Pedroso, C
   Alcantara, AP
   Sasaki, MD
   Matos, J
   Renjifo, B
   Essex, M
   Whitmore, JB
   Agosti, JM
   Badaro, R
AF Brites, C
   Gilbert, MJ
   Pedral-Sampaio, D
   Bahia, F
   Pedroso, C
   Alcantara, AP
   Sasaki, MD
   Matos, J
   Renjifo, B
   Essex, M
   Whitmore, JB
   Agosti, JM
   Badaro, R
TI A randomized, placebo-controlled trial of granulocyte-macrophage
   colony-stimulating factor and nucleoside analogue therapy in AIDS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 38th Interscience Conference on Antimicrobial Agents and Chemotherapy
CY SEP 24-28, 1998
CL SAN DIEGO, CALIFORNIA
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCYTE-MACROPHAGES; ZIDOVUDINE;
   REPLICATION; COMBINATION; INFECTION; INDINAVIR
AB Preliminary preclinical and clinical data suggest that granulocyte-macrophage colony-stimulating factor (GM-CSF) may decrease viral replication. Therefore, 105 individuals with AIDS who were receiving nucleoside analogue therapy were enrolled in a placebo-controlled, double-blind study and were randomized to receive either 125 mug/m(2) of yeast-derived, GM-CSF (sargramostim) or placebo subcutaneously twice weekly for 6 months. Subjects were evaluated for toxicity and disease progression. A significant decrease in mean virus load (VL) was observed for the GM-CSF treatment group at 6 months (-0,07 log,, vs. -0.60 log(10); P = .02), More subjects achieved human immunodeficiency virus (HIV)-RNA levels <500 copies/mt at <greater than or equal to>2 evaluations (2% on placebo vs. 11% on GM-CSF; P = .04), Genotypic analysis of 46 subjects demonstrated a lower frequency of zidovudine-resistant mutations among those receiving GM-CSF (80% vs. 50%; P = .04), No difference was observed in the incidence of opportunistic infections (OIs) through 6 months or survival, despite a higher risk for OI among GM-CSF recipients. GM-CSF reduced VL and limited the evolution of zidovudine-resistant genotypes, potentially providing adjunctive therapy in HIV disease.
C1 Univ Fed Bahia, Salvador, BA, Brazil.
   Hosp Sao Rafael, Salvador, BA, Brazil.
   Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil.
   Immunex Corp, Seattle, WA USA.
   Harvard Sch Publ Hlth, Cambridge, MA USA.
RP Badaro, R (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Rua Joao das Botas 40, BR-40110160 Salvador, BA, Brazil.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Barbaro G, 1997, AIDS, V11, P1453, DOI 10.1097/00002030-199712000-00009
   Bernstein Z. P., 1997, Blood, V90, p133A
   Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511
   COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502
   Di Marzio P, 1998, AIDS RES HUM RETROV, V14, P129, DOI 10.1089/aid.1998.14.129
   DIMARZIO P, 1998, 5 C RETR OPP INF CHI, P86
   Esser R, 1998, BLOOD, V91, P4752, DOI 10.1182/blood.V91.12.4752.412k06_4752_4760
   FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501
   Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35
   HEWITT RG, 1993, ANTIMICROB AGENTS CH, V37, P512, DOI 10.1128/AAC.37.3.512
   Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502
   MATSUDA S, 1995, AIDS RES HUM RETROV, V11, P1031, DOI 10.1089/aid.1995.11.1031
   PERNO CF, 1992, BLOOD, V80, P995
   PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933
   Schooley RT, 1996, J INFECT DIS, V173, P1354, DOI 10.1093/infdis/173.6.1354
   Skowron G, 1999, J INFECT DIS, V180, P1064, DOI 10.1086/314981
   1998, ANN INTERN MED, V128, P1057
NR 17
TC 22
Z9 23
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV
PY 2000
VL 182
IS 5
BP 1531
EP 1535
DI 10.1086/315901
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 368FA
UT WOS:000090106000034
PM 11023477
OA Bronze
DA 2020-12-01
ER

PT J
AU Straatmann, A
   Vidal, A
   Pedral-Sampaio, DB
   Bahia, F
   Brites, C
AF Straatmann, A
   Vidal, A
   Pedral-Sampaio, DB
   Bahia, F
   Brites, C
TI Preliminary results of randomized, pilot trial using escalating versus
   full-dose regimens for desensitization of AIDS patients allergic to
   sulfonamides
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 Univ Fed Bahia, Salvador, BA, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL
PY 2000
VL 31
IS 1
MA 367
BP 276
EP 276
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 347VY
UT WOS:000088950900417
DA 2020-12-01
ER

PT J
AU Badaro, R
   Nakatani, M
   Houghton, R
   Skeiky, Y
   Bhatia, A
   Ghalib, H
   Brites, C
   Reed, S
AF Badaro, R
   Nakatani, M
   Houghton, R
   Skeiky, Y
   Bhatia, A
   Ghalib, H
   Brites, C
   Reed, S
TI A novel protein K26 of L-chagasi in combination with K39 upgrading the
   sensitivity of the serodiagnosis of Visceral Leishmaniasis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 Corixa Corp, Seattle, WA USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL
PY 2000
VL 31
IS 1
MA 471
BP 293
EP 293
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 347VY
UT WOS:000088950900521
DA 2020-12-01
ER

PT J
AU Yamashita, M
   Veronesi, R
   Menna-Barreto, M
   Harrington, WJ
   Sampio, C
   Brites, C
   Badaro, R
   Andrade, AD
   Ohkura, S
   Igarashi, T
   Takehisa, J
   Miura, T
   Chamone, D
   Bianchini, O
   Jardim, C
   Sonoda, S
   Hayami, M
AF Yamashita, M
   Veronesi, R
   Menna-Barreto, M
   Harrington, WJ
   Sampio, C
   Brites, C
   Badaro, R
   Andrade, AD
   Ohkura, S
   Igarashi, T
   Takehisa, J
   Miura, T
   Chamone, D
   Bianchini, O
   Jardim, C
   Sonoda, S
   Hayami, M
TI Molecular epidemiology of human T-cell leukemia virus type I (HTLV-I) in
   Brazil: The predominant HTLV-Is in South America differ from HTLV-Is of
   Japan and Africa, as well as those of Japanese immigrants and their
   relatives in Brazil
SO VIROLOGY
LA English
DT Article
ID COMPLETE NUCLEOTIDE-SEQUENCE; TROPICAL SPASTIC PARAPARESIS; LYMPHOTROPIC
   VIRUS; PHYLOGENETIC ANALYSES; HUMAN-POPULATIONS; LYMPHOMA VIRUS;
   MASHHADI JEWS; LTR SEQUENCE; STLV-I; STRAINS
AB To better understand the origin of human T-cell leukemia virus type I (HTLV-I) in South America, we conducted a phylogenetic study on 27 new HTLV-Is in Brazil. These were obtained from Brazilians of various ethnic origins, such as Japanese immigrants, whites, blacks, and mulattos. We amplified and sequenced proviral DNAs of a part of the long terminal repeats. Phylogenetic trees revealed that all but 6 of the new isolates were not only similar to each other but also similar to HTLV-Is of other South American countries, including those from Amerindians. However, the isolates differed from the HTLV-Is of Africa and Japan. The other six isolates were from Japanese immigrants and were phylogenetically almost identical to HTLV-Is in Japan but different from the majority of South American HTLV-Is, including the other new Brazilian HTLV-Is. These findings indicate that the recent introduction of HTLV-I from Japan is limited to Japanese immigrants. In addition, the results do not support the prevailing hypothesis that HTLV-Is in South America were introduced by blacks who were brought from Africa as slaves. Rather, these results suggest that the majority of HTLV-Is prevailing in South America have spread from Amerindians, some of whom are likely to have possessed this human retrovirus from the beginning of their settlement in South America. (C) 1999 Academic Press.
C1 Kyoto Univ, Inst Virus Res, Lab Virol Pathogenesis, Kyoto 6068507, Japan.
   Univ Mogi das Cruzes, Ctr Med Invest, Mogi Das Cruzes, SP, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Dept Neurol, Porto Alegre, RS, Brazil.
   Univ Miami, Sch Med, Dept Internal Med, Miami, FL USA.
   Univ Fed Bahia, Sch Med, Dept Hematol, BR-41170290 Salvador, BA, Brazil.
   Univ Fed Bahia, Sch Med, Dept Internal Med, BR-41170290 Salvador, BA, Brazil.
   Univ Fed Bahia, Sch Med, Dept Virus Epidemiol, BR-41170290 Salvador, BA, Brazil.
   Univ Fed Bahia, Sch Med, Dept Neurol, BR-41170290 Salvador, BA, Brazil.
   Univ Sao Paulo, Hemoctr, Sao Paulo, Brazil.
   VIRION HTLV Working Grp, Porto Alegre, RS, Brazil.
   Kagoshima Univ, Fac Med, Kagoshima 8908520, Japan.
RP Yamashita, M (corresponding author), Kyoto Univ, Inst Virus Res, Lab Virol Pathogenesis, Kyoto 6068507, Japan.
EM myamashi@virus.kyoto-u.ac.jp
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Andrade AS, 1996, BRAZ J MED BIOL RES, V29, P757
   Araujo ADC, 1996, J ACQ IMMUN DEF SYND, V13, pS33
   BOUZAS MB, 1990, J ACQ IMMUN DEF SYND, V3, P741
   DETHE G, 1985, CANCER RES, V45, P4633
   DUENASBARAJAS E, 1992, AIDS RES HUM RETROV, V8, P1851, DOI 10.1089/aid.1992.8.1851
   Engelbrecht S, 1996, J ACQ IMMUN DEF SYND, V12, P298, DOI 10.1097/00042560-199607000-00011
   EVANGELISTA A, 1990, MICROB PATHOGENESIS, V8, P259, DOI 10.1016/0882-4010(90)90052-R
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Felsenstein J., 1993, PHYLIP PHYLOGENETIC
   FLANCHINI G, 1994, AIDS RES HUM RETROV, V9, P1047
   FUJIYOSHI F, 1995, INT J CANCER, V63, P510, DOI 10.1002/ijc.2910630409
   GALLO RC, 1983, LANCET, V2, P962
   GASMI M, 1994, AIDS RES HUM RETROV, V10, P1313, DOI 10.1089/aid.1994.10.1313
   GESSAIN A, 1993, J VIROL, V67, P1015, DOI 10.1128/JVI.67.2.1015-1023.1993
   GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992
   Gessain A, 1996, J ACQ IMMUN DEF SYND, V13, pS228, DOI 10.1097/00042560-199600001-00034
   GESSAIN A, 1985, LANCET, V2, P407
   Gessain A, 1996, ADV VIRUS RES, V47, P377, DOI 10.1016/S0065-3527(08)60740-X
   Gessain A, 1996, J ACQ IMMUN DEF SYND, V13, pS132, DOI 10.1097/00042560-199600001-00022
   HALL WW, 1994, AIDS RES HUM RETROV, V10, P443
   Hall WW, 1996, J ACQ IMMUN DEF SYND, V13, pS204, DOI 10.1097/00042560-199600001-00031
   HASHIMOTO K, 1993, AIDS RES HUM RETROV, V9, P495, DOI 10.1089/aid.1993.9.495
   HAYAMI M, 1983, LANCET, V2, P620
   Heneine W, 1996, J ACQ IMMUN DEF SYND, V13, pS236, DOI 10.1097/00042560-199600001-00035
   HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   ISHAK R, 1995, AIDS RES HUM RETROV, V11, P813, DOI 10.1089/aid.1995.11.813
   ISHIDA T, 1986, NATURE, V322, P504, DOI 10.1038/322504a0
   JOSEPHS SF, 1984, VIROLOGY, V139, P340, DOI 10.1016/0042-6822(84)90379-9
   KOMURIAN F, 1991, J VIROL, V65, P3770, DOI 10.1128/JVI.65.7.3770-3778.1991
   KORALNIK IJ, 1994, J VIROL, V68, P2693, DOI 10.1128/JVI.68.4.2693-2707.1994
   Liu HF, 1996, J GEN VIROL, V77, P359, DOI 10.1099/0022-1317-77-2-359
   Mahieux R, 1997, J VIROL, V71, P1317, DOI 10.1128/JVI.71.2.1317-1333.1997
   MALIK KTA, 1988, J GEN VIROL, V69, P1695, DOI 10.1099/0022-1317-69-7-1695
   MENNABARRETO M, 1995, ARQ NEURO-PSIQUIAT, V53, P771, DOI 10.1590/S0004-282X1995000500010
   Miura T, 1997, J MOL EVOL, V44, pS76, DOI 10.1007/PL00000053
   MIURA T, 1994, P NATL ACAD SCI USA, V91, P1124, DOI 10.1073/pnas.91.3.1124
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   ONO A, 1994, JPN J CANCER RES, V85, P767, DOI 10.1111/j.1349-7006.1994.tb02945.x
   OSAME M, 1986, LANCET, V1, P1031
   PICARD FJ, 1995, J VIROL, V69, P7248, DOI 10.1128/JVI.69.11.7248-7256.1995
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   RATNER L, 1991, AIDS RES HUM RETROV, V7, P923, DOI 10.1089/aid.1991.7.923
   SAKSENA NK, 1992, VIROLOGY, V189, P1, DOI 10.1016/0042-6822(92)90675-F
   SAKSENA NK, 1994, VIROLOGY, V198, P297, DOI 10.1006/viro.1994.1033
   SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618
   SHIMOTOHNO K, 1985, P NATL ACAD SCI USA, V82, P3101, DOI 10.1073/pnas.82.10.3101
   SONG KJ, 1994, VIROLOGY, V199, P56, DOI 10.1006/viro.1994.1097
   SONG KJ, 1995, AM J TROP MED HYG, V52, P101, DOI 10.4269/ajtmh.1995.52.101
   Tajima K, 1992, GANN MONOGR CANCER R, P129
   UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481
   URETAVIDAL A, 1994, J GEN VIROL, V75, P3655
   Van Dooren S, 1998, J GEN VIROL, V79, P2695, DOI 10.1099/0022-1317-79-11-2695
   VANDAMME AM, 1994, VIROLOGY, V202, P212, DOI 10.1006/viro.1994.1337
   Veronesi R., 1995, Revista Brasileira de Medicina, V52, P1281
   VOEVODIN A, 1995, AIDS RES HUM RETROV, V11, P1255, DOI 10.1089/aid.1995.11.1255
   WATANABE T, 1985, VIROLOGY, V144, P59, DOI 10.1016/0042-6822(85)90304-6
   WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995
   YAMASHITA M, 1995, VIRUS GENES, V10, P85, DOI 10.1007/BF01724300
   YAMASHITA M, 1995, AIDS RES HUM RETROV, V11, P645, DOI 10.1089/aid.1995.11.645
   Yamashita M, 1995, AIDS RES HUM RETROV, V11, P1533, DOI 10.1089/aid.1995.11.1533
   Yamashita M, 1995, MOL BIOL+, V29, P697
   Yamashita M, 1996, J ACQ IMMUN DEF SYND, V13, pS124, DOI 10.1097/00042560-199600001-00021
   Yamashita M, 1998, J MED VIROL, V55, P152, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;152::AID-JMV12&gt;3.0.CO;2-K
   YANAGIHARA R, 1994, ADV VIRUS RES, V43, P147, DOI 10.1016/S0065-3527(08)60048-2
   ZAMORA T, 1990, JPN J CANCER RES, V81, P715, DOI 10.1111/j.1349-7006.1990.tb02633.x
NR 66
TC 23
Z9 25
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD AUG 15
PY 1999
VL 261
IS 1
BP 59
EP 69
PG 11
WC Virology
SC Virology
GA 230LA
UT WOS:000082251600008
PM 10484750
DA 2020-12-01
ER

PT J
AU Zhang, XQ
   Fitzpatrick, L
   Campbell, TB
   Badaro, R
   Schechter, M
   Meio, MD
   Brites, C
   Sampaio, DP
   Schooley, RT
AF Zhang, XQ
   Fitzpatrick, L
   Campbell, TB
   Badaro, R
   Schechter, M
   Meio, MD
   Brites, C
   Sampaio, DP
   Schooley, RT
TI Comparison of the prevalence of antibodies to human herpesvirus 8
   (Kaposi's sarcoma-associated herpesvirus) in Brazil and Colorado
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT National AIDS Malignancy Conference
CY APR 28-30, 1997
CL BETHESDA, MARYLAND
ID DNA-SEQUENCES; INFECTION; ANTIGENS; VIRUS; KSHV
AB The prevalence of human herpesvirus 8 (HHV-8; Kaposi's sarcoma [KS] herpesvirus) infection was determined by IFA in 297 persons living in Brazil and Colorado. The prevalence of antibody to HHV-8 in human immunodeficiency virus (HIV) type 1-seropositive gay men with and without KS was similar in Brazil and Colorado. In Brazil, the prevalence of HHV-8 antibody was significantly greater in HIV-1-seronegative gay men than in HIV-1-seronegative male intravenous drug users. HHV-8-seropositive Brazilian gay men who had a clinical diagnosis of KS or who were infected with HIV-1 had significantly higher titers of HHV-8 antibody than did HHV-8-seropositive, HIV-1-seronegative Brazilian gay men. These findings provide further support for the association between HHV-8 infection and KS and suggest that, as in the United States, HHV-8 infection is transmitted sexually in Brazil.
C1 Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
   Univ Fed Rio de Janeiro, BR-21941 Rio De Janeiro, Brazil.
RP Schooley, RT (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Box B-168,4200 E 9th Ave, Denver, CO 80262 USA.
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA-46934] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934, P30CA046934, P30CA046934, P30CA046934,
   P30CA046934, P30CA046934] Funding Source: NIH RePORTER
CR AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108
   CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879
   Gaidano G, 1996, LEUKEMIA, V10, P1237
   Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925
   Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403
   Harrington W, 1997, LANCET, V349, P774
   Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918
   Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0
   Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403
   Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003
   Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996
   MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801
   Purvis SF, 1997, J INFECT DIS, V175, P947, DOI 10.1086/513997
   SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707
NR 14
TC 18
Z9 19
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV
PY 1998
VL 178
IS 5
BP 1488
EP 1491
DI 10.1086/314457
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 138TQ
UT WOS:000076989500032
PM 9780272
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Machado, P
   David, Y
   Pedroso, C
   Brites, C
   Barral, A
   Barral-Netto, M
AF Machado, P
   David, Y
   Pedroso, C
   Brites, C
   Barral, A
   Barral-Netto, M
TI Leprosy and HIV infection in Bahia, Brazil
SO INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES
LA English
DT Letter
ID HUMAN IMMUNODEFICIENCY VIRUS-1; RISK FACTOR
C1 Univ Fed Bahai, HUPES, Serv Imunol, BR-40110040 SSA Bahia, Brazil.
   FIOCRUZ, Ctr Pesquisas Goncalo Muniz, SSA Bahia, Brazil.
RP Machado, P (corresponding author), Univ Fed Bahai, HUPES, Serv Imunol, Rua Joao Botas S-N, BR-40110040 SSA Bahia, Brazil.
RI Barral, Aldina/B-4191-2009; Barral-Netto, Manoel/B-3904-2009; Brites,
   Carlos/D-1353-2013; MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020
OI Barral, Aldina/0000-0002-7177-464X; Barral-Netto,
   Manoel/0000-0002-5823-7903; Brites, Carlos/0000-0002-4673-6991; MACHADO,
   PAULO ROBERTO LIMA/0000-0003-1894-6171
CR BORGDORFF MW, 1993, INT J LEPROSY, V61, P556
   JAYASHEELA M, 1994, INDIAN J LEPR, V66, P428
   KAWUMA HJS, 1994, INT J LEPROSY, V62, P521
   Lienhardt C, 1996, INT J LEPROSY, V64, P383
   MUNYAO TM, 1994, E AFR MED J, V71, P490
   OREGE PA, 1993, TUBERCLE LUNG DIS, V74, P377, DOI 10.1016/0962-8479(93)90080-H
   SEKAR B, 1994, INT J LEPROSY, V62, P527
   STERNE JAC, 1995, J INFECT DIS, V172, P543, DOI 10.1093/infdis/172.2.543
NR 8
TC 8
Z9 8
U1 0
U2 0
PU INT JOURNAL LEPROSY
PI GREENVILLE
PA BUSINESS & CIRCULATION OFFICE, 1 ALM WAY, GREENVILLE, SC 29601-9999 USA
SN 0148-916X
J9 INT J LEPROSY
JI Int. J. Lepr. Other Mycobact. Dis.
PD JUN
PY 1998
VL 66
IS 2
BP 227
EP 229
PG 3
WC Microbiology; Pathology; Tropical Medicine
SC Microbiology; Pathology; Tropical Medicine
GA 112WY
UT WOS:000075518700016
PM 9728459
DA 2020-12-01
ER

PT J
AU Bittencourt, AL
   Barbosa, HS
   Brites, C
   Ferraz, N
   Freitas, V
   Pereira, CS
   Harrington, W
AF Bittencourt, AL
   Barbosa, HS
   Brites, C
   Ferraz, N
   Freitas, V
   Pereira, CS
   Harrington, W
TI Clinicopathological aspects of HTLV-1 positive and negative cutaneous
   T-cell lymphoma
SO EUROPEAN JOURNAL OF DERMATOLOGY
LA English
DT Article
DE cutaneous lymphoma; cutaneous T-cell lymphoma; HTLV-1 infection;
   HTLV-1(+) lymphoma; mycosis fungoides; pleomorphic lymphoma
ID VIRUS TYPE-I; LEUKEMIA-LYMPHOMA; LYMPHOTROPIC VIRUS; MYCOSIS-FUNGOIDES;
   INTERFERON-ALFA; BRAZIL; CLASSIFICATION; ZIDOVUDINE; FEATURES; SUBTYPES
AB The clinico-pathological and immunohistochemical features of 17 cases of HTLV-1(+) cutaneous T-cell lymphoma (CTCL) are compared with 17 cases of HTLV-1(-) CTCL. All patients were from the same geographical area in Northeastern Brazil, an area endemic for HTLV-1(+) infection. In all patients, cutaneous lesions were the first clinical manifestation of disease. In both the HTLV-1(+) and the HTLV-1(-) groups, 12 patients had pleomorphic lymphoma and 5 had mycosis fungoides (MF). Clinical subtypes in the HTLV-1(+) group included five cases of acute, two cases of chronic, nine cases of smoldering and one case of lymphoma type adult T-cell leukemia/lymphoma (ATL). A few clinical differences were noticed between the two groups: a marked predominance of black, mulatto and male subjects, a more aggressive course and a higher frequency of erythroderma and disseminated skin lesions in the HTLV-1(+) patients. However, around 40% of the HTLV-1(+) patients had an indolent course of disease with an evolution of up to 20 years. No specific histopathological features that could allow a distinction between HTLV-1(+) and HTLV-1(-) lymphomas were found. No significant differences were observed between the two groups concerning the intensity of cellular pleomorphism, cellular size, epidermotropism, frequency and size of Pautrier's abscesses, fibrosis of the papillary derma, and eosinophilic infiltrate. In two HTLV-1(+) lymphomas, atypical multinucleated giant cells were present. Considering the present knowledge concerning ATL and CTCL, it seems more appropriate to designate CTCL as HTLV-1(+) or HTLV-1(-) and morphologically as pleomorphic, MF, large cell anaplastic lymphoma or other histological types. The use of the terminology, cutaneous type of ATL, is confusing since there are HTLV-1(+) cutaneous lymphomas with clinical and histological features distinctly different from ATL.
C1 UNIV MIAMI, JACKSON MEM MED CTR, DEPT HEMATOL & ONCOL, CORAL GABLES, FL 33124 USA.
RP Bittencourt, AL (corresponding author), UNIV FED BAHIA, SCH MED, DEPT PATHOL & INTERNAL MED, BR-41170290 SALVADOR, BA, BRAZIL.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR ABEL EA, 1988, J AM ACAD DERMATOL, V19, P1089, DOI 10.1016/S0190-9622(88)70277-7
   ACKERMAN B, 1993, DIFFERENTIAL DIAGNOS, P42
   AGNARSSON BA, 1990, J AM ACAD DERMATOL, V22, P569, DOI 10.1016/0190-9622(90)70074-R
   ANAGNOSTOPOULOS I, 1990, AM J PATHOL, V137, P1317
   BELJAARDS RC, 1994, J PATHOL, V172, P53, DOI 10.1002/path.1711720110
   BITTENCOURT AL, 1994, MEM I OSWALDO CRUZ, V89, P59, DOI 10.1590/S0074-02761994000100011
   BOENISH T, 1989, IMMUNOCHEMICAL STAIN, P16
   BUKER CB, 1990, LANCET          0217, P426
   BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501
   CATOVSKY D, 1982, LANCET, V1, P639
   CRUZ DJS, 1994, DIAGNOSTIC SURG PATH, P57
   DEOLIVEIRA MSP, 1995, INT J CANCER, V60, P823, DOI 10.1002/ijc.2910600617
   DEOLIVEIRA MSP, 1990, LANCET, V336, P987, DOI 10.1016/0140-6736(90)92432-H
   DETMAR M, 1991, BRIT J DERMATOL, V124, P198, DOI 10.1111/j.1365-2133.1991.tb00434.x
   Diamandidou E, 1996, BLOOD, V88, P2385, DOI 10.1182/blood.V88.7.2385.bloodjournal8872385
   GIBBS WN, 1987, ANN INTERN MED, V106, P361, DOI 10.7326/0003-4819-106-3-361
   GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603
   Hashimoto K, 1992, Rinsho Ketsueki, V33, P1725
   HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   HOOD AF, 1990, PATHOLOGY SKIN
   HOPPE RT, 1995, J AM ACAD DERMATOL, V32, P448, DOI 10.1016/0190-9622(95)90067-5
   LENNERT K, 1992, HISTOPATHOLOGY NONHO, P16
   LIPKA JJ, 1991, J INFECT DIS, V164, P400, DOI 10.1093/infdis/164.2.400
   LIPKA JJ, 1992, J INFECT DIS, V165, P268, DOI 10.1093/infdis/165.2.268
   MAEDA K, 1989, BRIT J DERMATOL, V121, P603, DOI 10.1111/j.1365-2133.1989.tb08192.x
   MATSUSHIMA M, 1987, EUR J HAEMATOL, V39, P282
   Matutes E, 1994, ADULT T CELL LEUKAEM, P113
   MCNUTT NS, 1990, ARCH PATHOL LAB MED, V114, P170
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   Murphy GF, 1991, ATLAS TUMOR PATHOLOG
   NAGATANI T, 1990, CANCER-AM CANCER SOC, V66, P2380, DOI 10.1002/1097-0142(19901201)66:11<2380::AID-CNCR2820661122>3.0.CO;2-H
   PANCAKE BA, 1995, J CLIN INVEST, V95, P547, DOI 10.1172/JCI117697
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   RAPPAPORT H, 1974, CANCER-AM CANCER SOC, V34, P1198, DOI 10.1002/1097-0142(197410)34:4<1198::AID-CNCR2820340431>3.0.CO;2-E
   SERENO A, 1994, ABSTR INT C AIDS YOK, P304
   SHAPIRO PE, 1994, AM J SURG PATHOL, V18, P645, DOI 10.1097/00000478-199407000-00001
   SHIMOKAWA I, 1991, HUM PATHOL, V22, P200, DOI 10.1016/0046-8177(91)90044-P
   SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x
   STERRY W, 1992, BRIT J DERMATOL, V126, P456
   SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995
   TAJIMA K, 1991, ADULT CELL LEUKEMIA, P90
   TAKIMOTO Y, 1994, LEUKEMIA, V8, P507
   Tonkin K S, 1990, Clin Oncol (R Coll Radiol), V2, P354, DOI 10.1016/S0936-6555(05)81000-3
   UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481
   URRUTIA S, 1990, AM J DERMATOPATH, V12, P603, DOI 10.1097/00000372-199012000-00012
   WHITTAKER SJ, 1993, BRIT J DERMATOL, V128, P483, DOI 10.1111/j.1365-2133.1993.tb00223.x
   WILLEMZE R, 1993, DERMATOLOGY, P615
   WILLIAMS CKO, 1993, BRIT J CANCER, V67, P783, DOI 10.1038/bjc.1993.142
   YAMAGUCHI K, 1987, LANCET, V2, P94, DOI 10.1016/S0140-6736(87)92752-8
NR 50
TC 7
Z9 7
U1 0
U2 0
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 1167-1122
EI 1952-4013
J9 EUR J DERMATOL
JI Eur. J. Dermatol.
PD JUN
PY 1997
VL 7
IS 4
BP 283
EP 289
PG 7
WC Dermatology
SC Dermatology
GA XD838
UT WOS:A1997XD83800009
DA 2020-12-01
ER

PT J
AU Andrade, AS
   Brites, C
   dosSantos, SRS
   Harrington, W
   Reinhardt, ICB
   Freitas, FMS
   Silva, MC
   Badaro, R
AF Andrade, AS
   Brites, C
   dosSantos, SRS
   Harrington, W
   Reinhardt, ICB
   Freitas, FMS
   Silva, MC
   Badaro, R
TI HTLV-I/II as a common etiology of myelopathies in Bahia, Brazil
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE HTLV-I/II; TSP; myelopathy; Brazil
ID I-ASSOCIATED MYELOPATHY; TROPICAL SPASTIC PARAPARESIS; C RETROVIRUS;
   VIRUS; LYMPHOMA
AB Infection by human T-cell lymphotrophic virus type I (HTLV-I) is associated with a myelopathy known as tropical spastic paraparesis (TSP). The prevalence of HTLV-I infection was found to be high in a pilot study in Bahia, Brazil. In the present study, among patients with myelopathy of unclear etiology, 27% (17/62) were immunoblot reactive to HTLV-I/II (serum and CSF), but none of 40 consecutive patients seen at the neurological clinic and having a well-established neurological diagnosis had detectable antibodies against those viruses (discrimination between HTLV-I and HTLV-II was not possible with the tests we used), The clinical syndrome of typical TSP with upper limb hyperreflexia was found to be a significant feature among the HTLV-I/II-seropositive patients compared to seronegative individuals. The 17 HTLV-I/II-reactive individuals had negative tests for syphilis, toxoplasmosis and schistosomiasis. TSP was also associated with female gender (P = 0.001). We conclude that TSP is strongly associated with HTLV-I/II infection in women in Bahia.
C1 UNIV FED BAHIA,DEPT MED,BR-40110160 SALVADOR,BA,BRAZIL.
   ESCOLA BAHIANA MED & SAUDE PUBL,DEPT MED,BR-40050420 SALVADOR,BA,BRAZIL.
   UNIV MIAMI,SCH MED,DIV HEMATOL ONCOL,MIAMI,FL 33136.
   CORNELL UNIV,COLL MED,DEPT INTERNAL MED,NEW YORK,NY 10021.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW00018] Funding Source: Medline; NIAID NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [AI26506]
   Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01AI026506, P01AI026506, P01AI026506,
   P01AI026506, P01AI026506] Funding Source: NIH RePORTER
CR BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302
   CARVALHO OAM, 1992, ARQUIVOS NEUROPSIQUI, V2, P183
   CASTRO L H M, 1989, Arquivos de Neuro-Psiquiatria, V47, P501
   GESSAIN A, 1985, LANCET, V2, P407
   KAJIYAMA W, 1986, J INFECT DIS, V154, P851, DOI 10.1093/infdis/154.5.851
   KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
   MIYAI I, 1987, ANN NEUROL, V22, P601, DOI 10.1002/ana.410220507
   MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959
   MORI M, 1988, ANN NEUROL, V23, P98
   OSAME M, 1987, ANN NEUROL, V22, P116
   OSAME M, 1986, LANCET, V1, P1031
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   SONODA S, 1991, CURR OPIN NEUROL NEU, V4, P209
NR 13
TC 8
Z9 10
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JUN
PY 1996
VL 29
IS 6
BP 757
EP 761
PG 5
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA UU922
UT WOS:A1996UU92200008
PM 9070387
DA 2020-12-01
ER

PT J
AU FERREIRA, OC
   SULEIMAN, G
   BRITES, C
   NOVOA, P
   PIOVESANA, M
   SULEIMAN, J
   KANAYAMA, RH
   RUSSEL, TR
   ZWERNER, R
   HARRINGTON, W
   HO, JL
AF FERREIRA, OC
   SULEIMAN, G
   BRITES, C
   NOVOA, P
   PIOVESANA, M
   SULEIMAN, J
   KANAYAMA, RH
   RUSSEL, TR
   ZWERNER, R
   HARRINGTON, W
   HO, JL
TI A RAPID AND RELIABLE ASSAY TO ENUMERATE CD4(+) T-LYMPHOCYTES IN
   WHOLE-BLOOD
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
LA English
DT Article
DE CD4(+) T CELLS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASSAY METHODS; FLOW
   CYTOMETRY
ID IMMUNODEFICIENCY-VIRUS-INFECTION; COUNTS
AB We compared the performance of a rapid and simple anti-CD4 antibody-coated microsphere assay with flow cytometry and immunofluorescence for quantitation of absolute count of CD4(+) T lymphocytes. A longitudinal evaluation of CD4(+) T lymphocytes by flow cytometry and microsphere assay in 10 human immunodeficiency virus (HIV)-seronegative and 59 HIV-seropositive individuals was conducted over a period of 9 months. Standard flow cytometry analysis was performed to establish the absolute CD4(+) T-lymphocyte count. The microsphere assay uses whole blood; CD14(+) and CD4(+) cells are first blocked by small latex beads coated with anti-CD14 antibody, and remaining cells are stained with larger anti-CD4 antibody-coated beads. Cells rosetted with only anti-CD4 antibody-coated beads are counted with use of a hemacytometer. Immunofluorescence microscopy was performed by standard techniques with use of peripheral blood mononuclear cells. The predictive value for stratification of HIV-seropositive patients by CD4(+) T-lymphocyte values of <200/mu l was 95% when the microsphere method was compared with flow cytometry. A correlation coefficient of 0.91 between the two assay methods was demonstrated in 281 CD4(+) T-lymphocyte tests for absolute count. Finally, the flow cytometry method yielded better results than did the microsphere assay and immunofluorescence microscopy, in descending order of accuracy. The microsphere method should be effective in determining absolute CD4(+) T-lymphocyte count in developing countries where, for a variety of reasons, no other method can be reliably performed.
C1 HOSP ISRAELITA ALBERT EINSTEIN,SAO PAULO,BRAZIL.
   UNIV FED BAHIA,SALVADOR,BA,BRAZIL.
   COULTER CORP,HIALEAH,FL.
   UNIV MIAMI,WILLIAM J HARRINGTON CTR BLOOD RES,MIAMI,FL.
   CORNELL UNIV,COLL MED,NEW YORK,NY.
RP FERREIRA, OC (corresponding author), INST INFECT EMILIO RIBAS,AV DR ARNALDO 165,CERQUEIRA CESAR,BR-01246 SAO PAULO,BRAZIL.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI026506, P01AI026506, P01AI026506, P01AI026506, P01AI026506]
   Funding Source: NIH RePORTER; FIC NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [TW 00018] Funding Source: Medline;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01 AI 26506] Funding Source: Medline
CR DEAN AG, 1990, EPIINFO VERSION 5 WO
   LANDAY A, 1993, AIDS, V7, P1565, DOI 10.1097/00002030-199312000-00004
   LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360
   LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631
   MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13
   PHILLIPS AN, 1991, LANCET, V337, P389
   STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352
   1989, MMWR-MORBID M      S, V36, P15
   1992, MMWR-MORBID MORTAL W, V41, P1
NR 9
TC 11
Z9 11
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 1077-9450
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
PD DEC
PY 1994
VL 7
IS 12
BP 1224
EP 1227
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA PV290
UT WOS:A1994PV29000002
PM 7965632
DA 2020-12-01
ER

PT J
AU MOREIRA, ED
   RIBEIRO, TT
   SWANSON, P
   SAMPAIO, C
   MELO, A
   BRITES, C
   BADARO, R
   TOEDTER, G
   LEE, H
   HARRINGTON, W
AF MOREIRA, ED
   RIBEIRO, TT
   SWANSON, P
   SAMPAIO, C
   MELO, A
   BRITES, C
   BADARO, R
   TOEDTER, G
   LEE, H
   HARRINGTON, W
TI SEROEPIDEMIOLOGY OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I/II IN
   NORTHEASTERN BRAZIL
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HTLV-I/II; EPIDEMIOLOGY; MYELOPATHY; ADULT T-CELL LEUKEMIA LYMPHOMA
   (ATL); BRAZIL
ID HTLV-I INFECTION; LEUKEMIA-VIRUS; WEST-AFRICA; IVORY-COAST; HIV-1;
   ANTIBODIES; PREVALENCE; SEROPREVALENCE; EPIDEMIOLOGY; POPULATIONS
AB We investigated the prevalence of human T-lymphotropic virus I/II (HTLV-I/II) infection in Bahia, a state in Northeastern Brazil. Healthy individuals (n = 327) and patients (n = 337) with a variety of diseases were screened for antibodies to HTLV-I/II using an enzyme immunoassay and Western blot. The overall prevalence among healthy subjects was 1.8% (six of 327); among patients it was 18.4% (62 of 337). Patients with AIDS had the highest prevalence of HTLV-I/II infection, 22.7% (20/88), followed by randomly selected patients from an infectious disease hospital, 19.4% (25 of 129), and tuberculosis patients, 11.1 % (10 of 90). Four of 14 patients with myelopathy and three of 16 patients with lymphoid leukemia or lymphoma were seropositive for HTLV-I\II. Sixty-three of 68 HTLV-I/II-positive specimens were then typed: 53 patients were HTLV-I positive, three patients were HTLV-II positive, and in seven patients the assay could not distinguish infection by HTLV-I or II. The finding among HIV-seropositive intravenous drug users in Bahia of coinfection with HTLV-I is contrasted with reports from other areas in which dual infection occurs with HTLV-II. Although high prevalence of HTLV-I infection was found in Bahia, the extent and clinical manifestations of HTLV-II/I infection in Brazil remains imprecisely defined, and further studies are needed.
C1 UNIV FED BAHIA, DEPT MED, SALVADOR, BA, BRAZIL.
   CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA.
   COULTER IMMUNOL, HIALEAH, FL USA.
   ABBOTT LABS, CHICAGO, IL USA.
   UNIV MIAMI, DIV HEMATOL ONCOL, MIAMI, FL 33152 USA.
RI Brites, Carlos/D-1353-2013; Moreira, Edson/W-7437-2019; Moreira, Edson
   D/J-1758-2012
OI Brites, Carlos/0000-0002-4673-6991; Moreira, Edson/0000-0002-7081-8348;
   Moreira, Edson D/0000-0002-7081-8348; Melo, Ailton/0000-0001-7457-0573
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW 00018] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI
   26506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P01AI026506, P01AI026506,
   P01AI026506, P01AI026506, P01AI026506] Funding Source: NIH RePORTER
CR ABOULAFIA DM, 1991, AIDS RES HUM RETROV, V7, P333, DOI 10.1089/aid.1991.7.333
   BARTHOLOMEW C, 1987, LANCET, V2, P1469
   BIGGAR RJ, 1984, INT J CANCER, V34, P215, DOI 10.1002/ijc.2910340212
   BLATTNER WA, 1983, J INFECT DIS, V147, P406, DOI 10.1093/infdis/147.3.406
   CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501
   Costa C M, 1989, Arq Neuropsiquiatr, V47, P134
   DELAPORTE E, 1988, INT J CANCER, V42, P687, DOI 10.1002/ijc.2910420509
   DELAPORTE E, 1989, J ACQ IMMUN DEF SYND, V2, P410
   DEOLIVEIRA MSP, 1990, LANCET, V336, P987, DOI 10.1016/0140-6736(90)92432-H
   DEROSSI A, 1991, J ACQ IMMUN DEF SYND, V4, P380
   DUMAS M, 1991, AIDS RES HUM RETROV, V7, P447, DOI 10.1089/aid.1991.7.447
   GESSAIN A, 1985, LANCET, V2, P407
   HUNSMANN G, 1984, MED MICROBIOL IMMUN, V173, P167, DOI 10.1007/BF02123765
   KAJIYAMA W, 1986, J INFECT DIS, V154, P851, DOI 10.1093/infdis/154.5.851
   KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847
   LAIRMORE MD, 1990, P NATL ACAD SCI USA, V87, P8840, DOI 10.1073/pnas.87.22.8840
   MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824
   OUATTARA SA, 1989, J ACQ IMMUN DEF SYND, V2, P481
   ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133
   TEDDER RS, 1984, LANCET, V2, P125
   VERDIER M, 1989, J INFECT DIS, V160, P363, DOI 10.1093/infdis/160.3.363
   WEBER J, 1990, BRIT MED J, V301, P71, DOI 10.1136/bmj.301.6743.71
   WILLIAMS AE, 1988, SCIENCE, V240, P643, DOI 10.1126/science.2896386
   WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0
   ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813
   1988, MMWR, V37, P736
NR 26
TC 63
Z9 67
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr.
PD AUG
PY 1993
VL 6
IS 8
BP 959
EP 963
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA LM633
UT WOS:A1993LM63300014
PM 8315579
DA 2020-12-01
ER

PT J
AU MOREIRA, ED
   SILVA, N
   BRITES, C
   CARVALHO, EM
   BINA, JC
   BADARO, R
   JOHNSON, WD
AF MOREIRA, ED
   SILVA, N
   BRITES, C
   CARVALHO, EM
   BINA, JC
   BADARO, R
   JOHNSON, WD
TI CHARACTERISTICS OF THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME IN BRAZIL
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID TROPICAL DISEASES; HIV INFECTION; AIDS; LEISHMANIASIS
AB The clinical and epidemiologic characteristics of the acquired immunodeficiency syndrome (AIDS) were studied in a tropical area of Brazil. During an 18-month period (July 1989-January 1991), 111 consecutive AIDS patients (102 men and nine women) were evaluated. Patients reported homosexual/bisexual activities (60%), intravenous drug use (19%), or both (6%), heterosexual activities (11%), blood transfusions (2%), and 2% belonged to an undetermined category. Weight loss, fever, oral thrush, and diarrhea were present in greater-than-or-equal-to 70% of the patients at presentation. An unexpected high frequency of hepatomegaly (49%) was detected, and found to be significantly associated with tuberculosis (P < 0.0001). Although the epidemiologic features of human immunodeficiency virus transmission were comparable to the United States/European pattern, the clinical spectrum of opportunistic infections more closely resembled that reported in Africa and Haiti, with a greater frequency of fungal and mycobacterial infections than Pneumocystis carinii pneumonia and viral infections.
C1 FED UNIV BAHIA,SALVADOR,BRAZIL.
   HOSP CENT ROBERTO SANTOS,SALVADOR,BRAZIL.
   CORNELL UNIV,MED CTR,DIV INT MED,NEW YORK,NY 10021.
RI Moreira, Edson/W-7437-2019; Moreira, Edson D/J-1758-2012; Brites,
   Carlos/D-1353-2013
OI Moreira, Edson/0000-0002-7081-8348; Moreira, Edson
   D/0000-0002-7081-8348; Brites, Carlos/0000-0002-4673-6991
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW-00018] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI-26506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P01AI026506, P01AI026506,
   P01AI026506, P01AI026506, P01AI026506] Funding Source: NIH RePORTER
CR BADARO R, 1986, AM J TROP MED HYG, V35, P79
   BERENGUER J, 1989, ANN INTERN MED, V111, P129, DOI 10.7326/0003-4819-111-2-129
   CHAISSON RE, 1990, PRINCIPLES PRACTICE, P1059
   CHAMBERLAND ME, 1990, PRINCIPLES PRACTICES, P1029
   COLTON T, 1974, STATISTICS MED
   DEHOVITZ JA, 1986, NEW YORK STATE J MED, V86, P117
   GARRIS I, 1991, J ACQ IMMUN DEF SYND, V4, P1173
   GLUCKSTEIN D, 1992, AM J MED, V92, P429, DOI 10.1016/0002-9343(92)90275-G
   Ho M, 1990, PRINCIPLES PRACTICES, P1159
   JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585
   KOSHIBA L, 1987, HIST BRASIL, P28
   LENNETTE E, 1980, MANUAL CLIN MICROBIO
   MAAYAN S, 1987, AM J MED, V83, P945, DOI 10.1016/0002-9343(87)90656-5
   Pape JW, 1988, BAILLIERE CLIN TROP, V3, P31
   QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379
   SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043
   SCAGLIA M, 1989, T ROY SOC TROP MED H, V83, P338, DOI 10.1016/0035-9203(89)90494-X
   SMITH PG, 1988, INT J EPIDEMIOL, V17, P705, DOI 10.1093/ije/17.4.705
   SMITH PG, 1988, T ROY SOC TROP MED H, V82, P753, DOI 10.1016/0035-9203(88)90226-X
   1981, MMWR MORBID MORTAL W, V30, P250
   1987, 1987 INF CONS HELD K
   1990, B EPIDEMIOLOGICO AID
   1991, B EPIDEMIOLOGICO DOE
   1987, MMWR MORBID MORTAL W, V36, pS3
   1991, UPDATE AIDS CASES
NR 25
TC 15
Z9 15
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 1993
VL 48
IS 5
BP 687
EP 692
DI 10.4269/ajtmh.1993.48.687
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA LJ653
UT WOS:A1993LJ65300014
PM 8517487
DA 2020-12-01
ER

PT J
AU RIBEIRO, TT
   BRITES, C
   MOREIRA, ED
   SILLER, K
   SILVA, N
   JOHNSON, WD
   BADARO, R
AF RIBEIRO, TT
   BRITES, C
   MOREIRA, ED
   SILLER, K
   SILVA, N
   JOHNSON, WD
   BADARO, R
TI SEROLOGIC VALIDATION OF HIV-INFECTION IN A TROPICAL AREA
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
LA English
DT Article
DE ELISA; WESTERN BLOT; HIV-1; TROPICAL AREA
ID IMMUNODEFICIENCY-VIRUS INFECTION; WESTERN-BLOT TESTS; TYPE-1; DONORS;
   RISK
AB We have defined human immunodeficiency virus type 1 (HIV-1) serologic reactivity in Brazilians living in an area endemic for tropical diseases. Enzyme-linked immunosorbent assay (ELISA) and Western blot (WB) analyses were performed on 342 patients with diseases including Chagas' disease, schistosomiasis, typhoid fever, helminthiasis, and cutaneous and visceral leishmaniasis. Nine percent of the visceral leishmaniasis patients' sera reacted in the HIV-1 ELISA but all were WB negative. All other sera from these patients were HIV negative. A total of 224 HIV-1 ELISA repeatedly positive sera also were HIV-1 WB tested. They were drawn from a total population of 19,230 individuals, including AIDS patients, blood donors, homosexual men, intravenous drug users, pregnant women, individuals with hemophiliac, and tuberculosis and sexually transmitted disease patients. The WB results were analyzed using five different interpretive criteria for WB positivity. The Centers for Disease Control (CDC) and the World Health Organization (WHO) criteria were the most sensitive and specific for identifying HIV-1-infected individuals. The WB pattern was similar to that seen in the United States. Envelope (ENV) protein antibodies were highly predictive of HIV-1 infection; none of the AIDS patients lacked ENV protein reactivity. We conclude that among the tropical diseases studied, only visceral leishmaniasis is associated with false-positive HIV-1 ELISA tests. Current CDC and WHO criteria for interpretation of HIV-1 WB tests are appropriate for Brazil.
C1 CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV INT MED,1300 YORK AVE,NEW YORK,NY 10021.
   FED UNIV BAHIA,RETROVIRUS LAB,SALVADOR,BRAZIL.
   CENT HOSP ROBERTO SANTOS,SALVADOR,BRAZIL.
RI Brites, Carlos/D-1353-2013; Moreira, Edson D/J-1758-2012; Moreira,
   Edson/W-7437-2019
OI Brites, Carlos/0000-0002-4673-6991; Moreira, Edson
   D/0000-0002-7081-8348; Moreira, Edson/0000-0002-7081-8348
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018, D43TW000018, D43TW000018, D43TW000018,
   D43TW000018, D43TW000018] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI026506, P01AI026506, P01AI026506, P01AI026506, P01AI026506]
   Funding Source: NIH RePORTER; FIC NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43 TW00018] Funding Source:
   Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI 26506] Funding Source:
   Medline
CR BURKHARDT U, 1987, J MED VIROL, V23, P217, DOI 10.1002/jmv.1890230303
   CARLSON JR, 1985, JAMA-J AM MED ASSOC, V253, P3405, DOI 10.1001/jama.253.23.3405
   CELUM CL, 1991, J INFECT DIS, V164, P656, DOI 10.1093/infdis/164.4.656
   DOCK NL, 1991, ARCH INTERN MED, V151, P525, DOI 10.1001/archinte.151.3.525
   FLEMING AF, 1990, T ROY SOC TROP MED H, V84, P1, DOI 10.1016/0035-9203(90)90446-L
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402
   LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401
   MIDTHUN K, 1990, J INFECT DIS, V162, P1379, DOI 10.1093/infdis/162.6.1379
   Sandler SG, 1988, AIDS ETIOLOGY DIAGNO, P121
   1991, MMWR, V40, P692
   1987, MMWR, V36, pS3
   1990, WEEK EPIDEMIOL REC, V65, P281
   1987, HUMAN IMMUNODEFICIEN
   1989, MMWR S7, V38, P1
   1988, JAMA-J AM MED ASSOC, V260, P674
NR 16
TC 13
Z9 14
U1 0
U2 6
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 1077-9450
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
PD MAR
PY 1993
VL 6
IS 3
BP 319
EP 322
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA KN542
UT WOS:A1993KN54200018
PM 8450408
DA 2020-12-01
ER

PT J
AU PATRICIO, MB
   BRITES, CF
   GUIMARAES, MF
   DEJESUS, EB
   CATITA, JI
   VILHENA, M
AF PATRICIO, MB
   BRITES, CF
   GUIMARAES, MF
   DEJESUS, EB
   CATITA, JI
   VILHENA, M
TI PALLIATIVE TELECOBALT-60 WITH CONCENTRATED DOSE IN TNM CLASSIFICATION T4
   OF THE BREAST
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
RP PATRICIO, MB (corresponding author), INST PORTUGUES ONCOL FRANCISCO GENTIL,RUA PROFESSOR LIMA BASTO,PALHAVA,P-1000 LISBON,PORTUGAL.
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR ATKINS HL, 1964, AMER J ROENTGENOL RA, V91, P50
   COCHRAN DQ, 1959, AMER J ROENTGENOL RA, V81, P479
   DUTREIX J, 1971, ANN CLIN RES, V3, P9
   EDELMAN AH, 1965, AMER J ROENTGENOL RA, V93, P585
   FLOIRAS JL, 1976, J RADIOL ELEC MED N, V57, P838
   GREENBERG M, 1976, AM J ROENTGENOL, V126, P268, DOI 10.2214/ajr.126.2.268
   HORRIGAN WD, 1962, RADIOLOGY, V78, P439, DOI 10.1148/78.3.439
   MIKURIYA S, 1983, 4TH AOCR BANGK, P368
   OLIVIER JP, 1975, GAZ MED FR, V82, P3803
   PATRICIO MB, UNPUB CONCENTRATED D
   PATRICIO MB, 1983, MEDICO, V106, P542
   SCHLIENGER M, 1976, J RADIOL ELEC MED N, V57, P831
   SIMOES MJ, B SOC PORT GINEC, V3, P56
NR 13
TC 0
Z9 0
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0022-4790
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD NOV
PY 1986
VL 33
IS 3
BP 198
EP 202
DI 10.1002/jso.2930330311
PG 5
WC Oncology; Surgery
SC Oncology; Surgery
GA E9759
UT WOS:A1986E975900010
PM 2430143
DA 2020-12-01
ER

EF